



(51) International Patent Classification:

C07D 401/14 (2006.01) **C07D 491/048** (2006.01)
C07D 405/14 (2006.01) **A61P 31/18** (2006.01)
C07D 401/04 (2006.01) **A61K 31/4545** (2006.01)

(21) International Application Number:

PCT/IB2018/050021

(22) International Filing Date:

02 January 2018 (02.01.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/441,612 03 January 2017 (03.01.2017) US
 62/588,628 20 November 2017 (20.11.2017) US

(71) **Applicant: VIIV HEALTHCARE UK (NO.5) LIMITED** [GB/GB]; 980 Great West Road, Brentford Middlesex TW89GS (GB).

(72) **Inventors: BELEMA, Makonen**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **BOWSHER, Michael S.**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **DESKUS, Jeffrey A.**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **EASTMAN, Kyle J.**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **GILLIS, Eric P.**; 36 E Industrial Rd, Branford, Connecticut 06405 (US). **FRENNESSON, David B.**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **IWUAGWU, Christiana**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **KADOW, John F.**; 36 E Industrial Rd, Branford, Connecticut 06405 (US). **NAIDU, B. Narasimhulu**; 36 E Industrial Rd, Branford, Connecticut 06405 (US). **PARCELLA, Kyle E.**; 36 E Industrial Rd, Branford, Connecticut 06405 (US). **PEESE, Kevin M.**; 36 E Industrial Rd, Branford, Connecticut 06405 (US). **SAULNIER, Mark G.**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **SIVAPRAKASAM, Prasanna**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) **Title:** PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION



(57) **Abstract:** Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. (I)



PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN
IMMUNODEFICIENCY VIRUS REPLICATION

FIELD OF THE INVENTION

5 The invention relates to compounds, compositions, and methods for the treatment of human immunodeficiency virus (HIV) infection. More particularly, the invention provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. The invention also relates to methods for making the compounds hereinafter described.

10

BACKGROUND OF THE INVENTION

Human immunodeficiency virus (HIV) has been identified as the etiological agent responsible for acquired immune deficiency syndrome (AIDS), a fatal disease characterized by destruction of the immune system and the inability to fight off life threatening
15 opportunistic infections. Recent statistics indicate that an estimated 35.3 million people worldwide are infected with the virus (UNAIDS: Report on the Global HIV/AIDS Epidemic, 2013). In addition to the large number of individuals already infected, the virus continues to spread. Estimates from 2013 point to close to 3.4 million new infections in that year alone. In the same year there were approximately 1.6 million deaths associated with HIV and AIDS.

20 Current therapy for HIV-infected individuals consists of a combination of approved anti-retroviral agents. Over two dozen drugs are currently approved for HIV infection, either as single agents or as fixed dose combinations or single tablet regimens, the latter two containing 2-4 approved agents. These agents belong to a number of different classes, targeting either a viral enzyme or the function of a viral protein during
25 the virus replication cycle. Thus, agents are classified as either nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleotide reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs), or entry inhibitors (one, maraviroc, targets the host CCR5 protein, while the other, enfuvirtide, is a peptide that targets the gp41 region of the viral gp160 protein). In addition, a pharmacokinetic
30 enhancer with no antiviral activity, i.e., cobicistat, available from Gilead Sciences, Inc. under the tradename TYBOST™ (cobicistat) tablets, has recently been approved for use in combinations with certain antiretroviral agents (ARVs) that may benefit from boosting.

In the US, where combination therapy is widely available, the number of HIV-related deaths has dramatically declined (Palella, F. J.; Delany, K. M.; Moorman, A. C.; Loveless, M. O.; Furher, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. *N. Engl. J. Med.* 1998, 338, 853-860).


5 Unfortunately, not all patients are responsive and a large number fail this therapy. In fact, initial studies suggest that approximately 30-50% of patients ultimately fail at least one drug in the suppressive combination. Treatment failure in most cases is caused by the emergence of viral resistance. Viral resistance in turn is caused by the replication rate of HIV-1 during the course of infection combined with the relatively high viral mutation rate
10 associated with the viral polymerase and the lack of adherence of HIV-infected individuals in taking their prescribed medications. Clearly, there is a need for new antiviral agents, preferably with activity against viruses already resistant to currently approved drugs. Other important factors include improved safety and a more convenient dosing regimen than many of the currently approved drugs.

15 Compounds which inhibit HIV replication have been disclosed. See, for example, the following patent applications: WO2007131350, WO2009062285, WO2009062288, WO2009062289, WO2009062308, WO2010130034, WO2010130842, WO2011015641, WO2011076765, WO2012033735, WO2013123148, WO2013134113, WO2014164467, WO2014159959, WO2015126726, and WO2017025915.

20 What is now needed in the art are additional compounds which are novel and useful in the treatment of HIV. Additionally, these compounds may desirably provide advantages for pharmaceutical uses, for example, with regard to one or more of their mechanisms of action, binding, inhibition efficacy, target selectivity, solubility, safety profiles, or bioavailability. Also needed are new formulations and methods of treatment
25 which utilize these compounds.

BRIEF DESCRIPTION OF THE INVENTION

Briefly, in one aspect, the present invention discloses compounds of Formula I,



and pharmaceutically acceptable salts thereof, wherein:

- R^1 is hydrogen, halo, cyano, C_{1-10} alkyl, C_{1-10} haloalkyl, $-C_{1-10}$ alkyl-OH, HO- C_{1-10} alkyl-O-,
 5 Ar^1 , $-N(R^5)(R^6)$, $-C(O)N(R^7)(R^8)$, or $(R^9)(R^{10})NC_{1-10}$ alkyl-;
 provided R^1 and R^4 are not both alkyl;
 R^2 is benzodioxolyl, naphthalenyl, phenyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl,
 quinolinyl, isoquinolinyl, tetrazinyl, or triazinyl, and is optionally substituted with 1-4
 substituents independently selected from cyano, carbamoyl, carboxyl, halo, hydroxy, C_{1-10}
 10 C_{1-10} alkyl, C_{1-10} haloalkyl, $-N(R^5)(R^7)$, C_{1-10} alkyl-O-, Ar^4 , Ar^4-C_{1-10} alkyl-O-, $(R^5)(Ar^4-C_{1-10}$
 C_{1-10} alkyl)N-, Ar^4-O-C_{1-10} alkyl-, or $(Ar^4)(R^5)N-C_{1-10}$ alkyl-;
 R^3 is C_{1-10} alkyl;
 R^4 is hydrogen, cyano, halo, C_{1-10} haloalkyl, C_{1-10} alkyl, C_{1-10} alkyl-O-, C_{1-10} alkenyl, NH_2 ,
 hydroxy, $-C_{1-10}$ alkyl-OH, carbamoyl, azetidiny, pyrrolidinyl, piperidinyl, morpholinyl, or
 15 piperazinyl; provided R^1 and R^4 are not both alkyl;
 R^5 is hydrogen, or C_{1-10} alkyl;
 R^6 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl-O- C_{1-10} alkyl-, C_{1-10} alkyl-O-C(O)-, C_{3-9} cycloalkyl,
 (C_{3-9} cycloalkyl) C_{1-10} alkyl-, 1-(C_{1-10} alkyl)piperidinyl-, tetrahydropyranyl,
 (tetrahydropyranyl) C_{1-10} alkyl-, morpholino C_{1-10} alkyl-, $(C_{1-10}$ alkyl) $_2$ N- C_{1-10} alkyl-,
 20 piperidinyl C_{1-10} alkyl-, 1-(C_{1-10} alkyl)piperidinyl C_{1-10} alkyl-, 1-(C_{1-10} alkyl)piperazinyl C_{1-10}
 C_{1-10} alkyl-, Ar^2-C_{1-10} alkyl-, Ar^3 , 1-(C_{1-10} alkylsulfonyl)piperidinyl-, or
 1-(C_{1-10} alkylcarbonyl)piperidinyl-;
 R^7 is hydrogen, or C_{1-10} alkyl;
 R^8 is hydrogen, C_{1-10} alkyl, C_{3-9} cycloalkyl, $(C_{1-10}$ alkyl) C_{3-9} cycloalkyl-, $-SO_2(C_{1-10}$ alkyl), or
 25 $-SO_2(C_{3-9}$ cycloalkyl);
 R^9 is hydrogen, or C_{1-10} alkyl;
 R^{10} is hydrogen, C_{1-10} alkyl, (tetrahydropyranyl) C_{1-10} alkyl-, or C_{1-10} alkyl-O-C(O)-;
 or $N(R^7)(R^8)$ taken together form an azetidiny, pyrrolidinyl, piperidinyl, 1,1-
 dioxidothiomorpholinyl, or morpholinyl ring;

or N(R⁹)(R¹⁰) taken together form an azetidiny, azocanyl, pyrrolidinyl, piperidinyl, or azaspirononanyl ring, and is optionally substituted with 1-3 C₁₋₁₀alkyl substituents;

Ar¹ is imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, or

dihydrocyclopentapyrazolyl and is optionally substituted with 1-3 substituents

5 independently selected from amino, C₁₋₁₀alkyl, or C₃₋₉cycloalkyl;

Ar² is imidazolyl, pyrazolyl, or pyridinyl, and is optionally substituted with 1-3

substituents independently selected from C₁₋₁₀alkyl and halo substituents;

Ar³ is phenyl, pyridinyl, pyrazolyl, pyridazinyl, or pyrimidinyl, and is optionally

substituted with 1-3 substituents independently selected from C₁₋₁₀alkyl, halo, carboxy,

10 and cyano; and

Ar⁴ is phenyl, benzofuopyrimidinyl, or pyridofuopyrimidinyl and is optionally

substituted with 1-3 substituents independently selected from cyano, halo, C₁₋₁₀alkyl, and

C₁₋₁₀alkyl-O-;

and wherein each reference to "haloalkyl" includes all halogenated isomers from

15 monohalo to perhalo.

The invention also provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in therapy.

The invention also provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of HIV infection

20 The invention also provides the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of HIV infection.

The invention also provides a pharmaceutical composition comprising a compound or salt of the invention.

25 In addition, the invention provides a method of treating HIV infection comprising administering a compound or salt of the invention to a patient.

In addition, the invention provides a method for inhibiting HIV integrase.

Also provided in accordance with the invention are methods for making the compounds and salts of the invention.

30

DETAILED DESCRIPTION OF THE INVENTION

Preferably, R¹ is hydrogen, halo, cyano, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, -C₁₋₁₀alkyl-OH, Ar¹, -N(R⁵)(R⁶), or (R⁹)(R¹⁰)NC₁₋₁₀alkyl-; provided R¹ and R⁴ are not both alkyl; and


wherein R^5 , R^6 , R^9 , and R^{10} are as defined above. More preferably, R^1 is hydrogen or $(R^9)(R^{10})NC_{1-10}alkyl-$; provided R^1 and R^4 are not both alkyl; and wherein R^9 and R^{10} are as defined above. Most preferably R^1 is hydrogen.

Preferably, R^2 is phenyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl,
 5 quinolinyl, or isoquinolinyl, and is optionally substituted with 1-4 substituents independently selected from cyano, carbamoyl, carboxyl, halo, hydroxy, $C_{1-10}alkyl$, $C_{1-10}haloalkyl$, $-N(R^5)(R^7)$, $C_{1-10}alkyl-O-$, Ar^4 , $Ar^4-C_{1-10}alkyl-O-$, $(R^5)(Ar^4-C_{1-10}alkyl)N-$, $Ar^4-O-C_{1-10}alkyl-$, or $(Ar^4)(R^5)N-C_{1-10}alkyl-$; and wherein R^5 and Ar^4 are defined as above. More Preferably, R^2 is phenyl, pyrazinyl, pyridazinyl, pyridinyl, or pyrimidinyl,
 10 and is optionally substituted with 1-4 substituents independently selected from cyano, carbamoyl, carboxyl, halo, $C_{1-10}alkyl$, $C_{1-10}haloalkyl$, $-N(C_{1-10}alkyl)_2$, $C_{1-10}alkyl-O-$, Ar^4 , $Ar^4-C_{1-10}alkyl-O-$, $(R^5)(Ar^4-C_{1-10}alkyl)N-$, $Ar^4-O-C_{1-10}alkyl-$, or $(Ar^4)(R^5)N-C_{1-10}alkyl-$; and wherein R^5 and Ar^4 are defined as above. Most preferably, R^2 is pyridinyl substituted with one $C_{1-10}alkyl-O-$. Preferably, the $C_{1-10}alkyl-O-$ is a C_4alkyl .

15 Preferably, the R^3 is a C_4alkyl .

Preferably, R^4 is hydrogen, cyano, halo, $C_{1-10}haloalkyl$, $C_{1-10}alkyl$, $C_{1-10}alkyl-O-$, $C_{1-10}alkenyl$, hydroxy, or $-C_{1-10}alkyl-OH$; provided R^1 and R^4 are not both alkyl. More preferably, R^4 is $C_{1-10}alkyl$, cyano, halo, or $C_{1-10}haloalkyl$; provided R^1 and R^4 are not both alkyl. Most preferably R^4 is methyl and R^1 is hydrogen.

20 In one embodiment, there is provided compounds of Formula IA,



IA

and pharmaceutically acceptable salts thereof, wherein:

R^1 is hydrogen, halo, cyano, $C_{1-6}alkyl$, $C_{1-6}haloalkyl$, $-C_{1-6}alkyl-OH$, $HO-C_{1-6}alkyl-O-$,
 25 Ar^1 , $-N(R^5)(R^6)$, $-C(O)N(R^7)(R^8)$, or $(R^9)(R^{10})NC_{1-6}alkyl-$;
 provided R^1 and R^4 are not both alkyl;
 R^2 is benzodioxolyl, naphthalenyl, phenyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, tetrazinyl, or triazinyl, and is optionally substituted with 1-4 substituents independently selected from cyano, carbamoyl, carboxyl, halo, $C_{1-6}alkyl$, $C_{1-6}haloalkyl$, $-N(R^5)(R^7)$, $C_{1-6}alkyl-O-$, Ar^4 , $Ar^4-C_{1-6}alkyl-O-$, $(R^5)(Ar^4-C_{1-6}alkyl)N-$, $Ar^4-O-C_{1-6}alkyl-$, or $(Ar^4)(R^5)N-C_{1-6}alkyl-$; and wherein R^5 and Ar^4 are defined as above. Most preferably, R^2 is pyridinyl substituted with one $C_{1-6}alkyl-O-$. Preferably, the $C_{1-6}alkyl-O-$ is a C_4alkyl .

6haloalkyl, -N(C₁₋₆alkyl)₂, C₁₋₆alkyl-O-, Ar⁴, Ar⁴-C₁₋₆alkyl-O-, (R⁵)(Ar⁴-C₁₋₆alkyl)N-, Ar⁴-O-C₁₋₆alkyl-, or (Ar⁴)(R⁵)N-C₁₋₆alkyl-;

R³ is C₁₋₆alkyl;

R⁴ is hydrogen, cyano, halo, C₁₋₆haloalkyl, C₁₋₆alkyl, C₁₋₆alkyl-O-, C₁₋₆alkenyl, NH₂,

- 5 hydroxy, -C₁₋₆alkyl-OH, carbamoyl, azetidiny, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl; provided R¹ and R⁴ are not both alkyl;

R⁵ is hydrogen, or C₁₋₆alkyl;

R⁶ is hydrogen, C₁₋₆alkyl, C₁₋₆alkyl-O-C₁₋₆alkyl-, C₁₋₆alkyl-O-C(O)-, C₃₋₆cycloalkyl, (C₃₋₆cycloalkyl)C₁₋₆alkyl-, 1-(C₁₋₆alkyl)piperidinyl-, tetrahydropyranyl,

- 10 (tetrahydropyranyl)C₁₋₆alkyl-, morpholinoC₁₋₆alkyl-, (C₁₋₆alkyl)₂N-C₁₋₆alkyl-, piperidinylC₁₋₆alkyl-, 1-(C₁₋₆alkyl)piperidinylC₁₋₆alkyl-, 1-(C₁₋₆alkyl)piperazinylC₁₋₆alkyl-, Ar²-C₁₋₆alkyl-, Ar³, 1-(C₁₋₆alkylsulfonyl)piperidinyl-, or 1-(C₁₋₆alkylcarbonyl)piperidinyl-;

R⁷ is hydrogen, or C₁₋₆alkyl;

- 15 R⁸ is hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, (C₁₋₆alkyl)C₃₋₆cycloalkyl-, -SO₂(C₁₋₆alkyl), or -SO₂(C₃₋₆cycloalkyl);

R⁹ is hydrogen, or C₁₋₆alkyl;

R¹⁰ is hydrogen, C₁₋₆alkyl, (tetrahydropyranyl)C₁₋₆alkyl-, or C₁₋₆alkyl-O-C(O)-;

(R⁷)(R⁸)N taken together form an azetidiny, pyrrolidinyl, piperidinyl, 1,1-

- 20 dioxidothiomorpholinyl, or morpholinyl ring;

(R⁹)(R¹⁰)N taken together form an azetidiny, azocanyl, pyrrolidinyl, piperidinyl, or azaspirononanyl ring, and is optionally substituted with 1-3 C₁₋₆alkyl substituents;

Ar¹ is imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, or

dihydrocyclopentapyrazolyl and is optionally substituted with 1-3 substituents

- 25 independently selected from amino, C₁₋₆alkyl, or C₃₋₆cycloalkyl;

Ar² is imidazolyl, pyrazolyl, or pyridinyl, and is optionally substituted with 1-3 substituents independently selected from C₁₋₆alkyl and halo substituents;

Ar³ is phenyl, pyridinyl, pyrazolyl, pyridazinyl, or pyrimidinyl, and is optionally substituted with 1-3 substituents independently selected from C₁₋₆alkyl, halo, carboxy,

- 30 and cyano; and

Ar⁴ is phenyl, benzofuopyrimidinyl, or pyridofuopyrimidinyl and is optionally substituted with 1-3 substituents independently selected from cyano, halo, C₁₋₆alkyl, and C₁₋₆alkyl-O-;


and wherein each reference to “haloalkyl” includes all halogenated isomers from monohalo to perhalo.

Preferably, R^1 is hydrogen, halo, cyano, C_{1-6} alkyl, C_{1-6} haloalkyl, $-C_{1-6}$ alkyl-OH, Ar^1 , $-N(R^5)(R^6)$, or $(R^9)(R^{10})NC_{1-6}$ alkyl-; provided R^1 and R^4 are not both alkyl; and
 5 wherein R^5 , R^6 , R^9 , and R^{10} are as defined above for the compounds of formula (IA).
 More preferably, R^1 is hydrogen or $(R^9)(R^{10})NC_{1-6}$ alkyl-; provided R^1 and R^4 are not both alkyl; and wherein R^9 and R^{10} are as defined above for the compounds of formula (IA).

Preferably, R^2 is phenyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, quinolinyl, or isoquinolinyl, and is optionally substituted with 1-4 substituents
 10 independently selected from cyano, carbamoyl, carboxyl, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, $-N(C_{1-6}$ alkyl) $_2$, C_{1-6} alkyl-O-, Ar^4 , Ar^4-C_{1-6} alkyl-O-, $(R^5)(Ar^4-C_{1-6}$ alkyl)N-, Ar^4-O-C_{1-6} alkyl-, or $(Ar^4)(R^5)N-C_{1-6}$ alkyl-; and wherein R^5 and Ar^4 are defined as above for the compounds of formula (IA).
 More Preferably, R^2 is phenyl, pyrazinyl, pyridazinyl, pyridinyl, or pyrimidinyl, and is optionally substituted with 1-4 substituents independently
 15 selected from cyano, carbamoyl, carboxyl, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, $-N(C_{1-6}$ alkyl) $_2$, C_{1-6} alkyl-O-, Ar^4 , Ar^4-C_{1-6} alkyl-O-, $(R^5)(Ar^4-C_{1-6}$ alkyl)N-, Ar^4-O-C_{1-6} alkyl-, or $(Ar^4)(R^5)N-C_{1-6}$ alkyl-; and wherein R^5 and Ar^4 are defined as above for the compounds of formula (IA).

Preferably, R^4 is hydrogen, cyano, halo, C_{1-6} haloalkyl, C_{1-6} alkyl, C_{1-6} alkyl-O-, C_{1-6} alkenyl, hydroxy, or $-C_{1-6}$ alkyl-OH; provided R^1 and R^4 are not both alkyl. More
 20 preferably, R^4 is C_{1-6} alkyl, cyano, halo, or C_{1-6} haloalkyl; provided R^1 and R^4 are not both alkyl.


In one embodiment there is provided (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(2-methylpropoxy)-[2,3'-bipyridine]-5'-yl]acetic



25 acid of formula or a pharmaceutically acceptable salt thereof.

In one embodiment there is provided (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(2-methylpropoxy)-[2,3'-bipyridine]-5'-yl]acetic
 acid.

In one embodiment there is provided (2S)-2-(tert-butoxy)-2-[5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid of formula



or a pharmaceutically acceptable salt thereof.

In one embodiment there is provided (2S)-2-(tert-butoxy)-2-[5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid

In one embodiment there is provided a compound or pharmaceutically acceptable salt thereof selected from the group consisting of Examples 1-442 or pharmaceutically acceptable salts thereof.

The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucuronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.

Some of the compounds of the invention exist in stereoisomeric forms. The invention includes all stereoisomeric forms of the compounds including enantiomers and diastereomers. Methods of making and separating stereoisomers are known in the art. The invention includes all tautomeric forms of the compounds. The invention includes atropisomers and rotational isomers.

The invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include ^{13}C and ^{14}C . Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein,

using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for example as standards and reagents in determining biological activity. In the case of stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.

In one embodiment, a method for treating or preventing an HIV infection in a patient having or at risk of having the infection is provided, comprising administering to the patient a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents.

In one embodiment, a method for treating or preventing an HIV infection in a human having or at risk of having the infection is provided, comprising administering to the human a therapeutically effective amount of (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(2-methylpropoxy)-[2,3'-bipyridine]-5'-yl]acetic acid or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents.

In one embodiment, a method for treating or preventing an HIV infection in a human having or at risk of having the infection is provided, comprising administering to the human a therapeutically effective amount of (2S)-2-(tert-butoxy)-2-[5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents.

In one embodiment there is provided of (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(2-methylpropoxy)-[2,3'-bipyridine]-5'-yl]acetic acid or a pharmaceutically acceptable salt thereof for use in the treatment of HIV infection.

In one embodiment there is provided (2S)-2-(tert-butoxy)-2-[5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid or a pharmaceutically acceptable salt thereof for use in the treatment of HIV infection.

In one embodiment there is provided the use of (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(2-methylpropoxy)-[2,3'-bipyridine]-5'-yl]acetic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of HIV infection.

In one embodiment there is provided the use of (2S)-2-(tert-butoxy)-2-[5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of HIV infection.

5 In one embodiment, pharmaceutical compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more additional therapeutic agents, and a pharmaceutically acceptable carrier, diluent or excipient are provided.

10 In one embodiment, pharmaceutical compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more additional therapeutic agents, and a pharmaceutically acceptable carrier, diluent or excipient are provided.

15 In one embodiment, combination pharmaceutical agents comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more additional therapeutic agents are provided.

20 In the above embodiments, the additional therapeutic agent may be an anti-HIV agent. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, entry inhibitors (e.g., CCR5 inhibitors, gp41 inhibitors (i.e., fusion inhibitors) and CD4 attachment inhibitors), CXCR4 inhibitors, gp120 inhibitors, G6PD and NADH-oxidase inhibitors, compounds that target the HIV capsid ("capsid inhibitors"; e.g., capsid polymerization inhibitors or capsid disrupting compounds such as those disclosed in WO 2013/006738 (Gilead Sciences), US 2013/0165489 (University of Pennsylvania), and WO 2013/006792 (Pharma Resources), pharmacokinetic enhancers, and other drugs for treating HIV, and combinations thereof.

 In further embodiments, the additional therapeutic agent is selected from one or more of:

30 (1) HIV protease inhibitors selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brexanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, PPL-100,

DG35, and AG 1859;

(2) HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase selected from the group consisting of capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV-150, TMC-
5 120, rilpivirene, BILR 355 BS, VRX 840773, lersivirine (UK-453061), RDEA806, KM023 and MK-1439;

(3) HIV nucleoside inhibitors of reverse transcriptase selected from the group consisting of zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, .+.-FTC, D-d4FC, emtricitabine,
10 phosphazide, fozivudine tidoxil, apricitibine (AVX754), KP-1461, GS-9131 (Gilead Sciences) and fosavudine tidoxil (formerly HDP 99.0003);

(4) HIV nucleotide inhibitors of reverse transcriptase selected from the group consisting of tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate (Gilead Sciences), GS-7340 (Gilead Sciences), GS-9148 (Gilead Sciences), adefovir, adefovir
15 dipivoxil, CMX-001 (Chimerix) or CMX-157 (Chimerix);

(5) HIV integrase inhibitors selected from the group consisting of curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl
20 ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, AR-177, L-870812, and L-870810, raltegravir, BMS-538158, GSK364735C, BMS-707035, NMK-2048, BA 011, elvitegravir, dolutegravir and GSK-744;

(6) HIV non-catalytic site, or allosteric, integrase inhibitors (NCINI) including, but not limited to, BI-224436, CX0516, CX05045, CX14442, compounds disclosed in WO
25 2009/062285 (Boehringer Ingelheim), WO 2010/130034 (Boehringer Ingelheim), WO 2013/159064 (Gilead Sciences), WO 2012/145728 (Gilead Sciences), WO 2012/003497 (Gilead Sciences), WO 2012/003498 (Gilead Sciences) each of which is incorporated by references in its entirety herein;

(7) gp41 inhibitors selected from the group consisting of enfuvirtide, sifuvirtide,
30 albuvirtide, FB006M, and TRI-1144;

(8) the CXCR4 inhibitor AMD-070;

(9) the entry inhibitor SP01A;

(10) the gp120 inhibitor BMS-488043;

(11) the G6PD and NADH-oxidase inhibitor immunitin;

(12) CCR5 inhibitors selected from the group consisting of aplaviroc, vicriviroc, maraviroc, cenicriviroc, PRO-140, INCB115050, PF-232798 (Pfizer), and CCR5 mAb004;

5 (13) CD4 attachment inhibitors selected from the group consisting of ibalizumab (TMB-355) and BMS-068 (BMS-663068);

(14) pharmacokinetic enhancers selected from the group consisting of cobicistat and SPI-452; and

(15) other drugs for treating HIV selected from the group consisting of BAS-100, SPI-452, REP 9, SP-01A, TNX-355, DES6, ODN-93, ODN-112, VGV-1, PA-457
10 (bevirimat), HRG214, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS119, ALG 889, and PA-1050040 (PA-040),
and combinations thereof.

15 Unless specified otherwise, these terms have the following meanings.

“Combination,” “coadministration,” “concurrent” and similar terms referring to the administration of a compound of Formula I with at least one anti-HIV agent mean that the components are part of a combination antiretroviral therapy or highly active antiretroviral therapy (“HAART”) as understood by practitioners in the field of AIDS and HIV
20 infection.

“Therapeutically effective” means the amount of agent required to provide a benefit to a patient as understood by practitioners in the field of AIDS and HIV infection. In general, the goals of treatment are suppression of viral load, restoration and preservation of immunologic function, improved quality of life, and reduction of HIV-related
25 morbidity and mortality.

“Patient” means a person infected with the HIV virus.

“Treatment,” “therapy,” “regimen,” “HIV infection,” “ARC,” “AIDS” and related terms are used as understood by practitioners in the field of AIDS and HIV infection.

Those terms not specifically set forth herein shall have the meaning which is
30 commonly understood and accepted in the art.

Solid compositions which are normally formulated in dosage units and compositions providing from about 1 to 1000 milligram (“mg”) of the active ingredient per dose are typical. Some examples of dosages are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000

mg. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is about 0.25-1000 mg/unit.

Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of about 1-100 milligram per milliliter
5 ("mg/mL"). Some examples of dosages are 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is about 1-100 mg/mL.

The invention encompasses all conventional modes of administration; oral and parenteral methods are preferred. Generally, the dosing regimen will be similar to other
10 antiretroviral agents used clinically. Typically, the daily dose will be about 1-100 milligram per kilogram ("mg/kg") body weight daily. Generally, more compound is required orally and less parenterally. The specific dosing regimen, however, will be determined by a physician using sound medical judgment.

15 *Methods of Synthesis*

The compounds of this invention can be made by various methods known in the art including those of the following schemes and in the specific embodiments section. The structure numbering and variable numbering shown in the synthetic schemes are distinct from, and should not be confused with, the structure or variable numbering in the claims
20 or the rest of the specification. The variables in the schemes are meant only to illustrate how to make some of the compounds of this invention. The disclosure is not limited to the foregoing illustrative examples and the examples should be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and
25 range of equivalency of the claims are therefore intended to be embraced.

Abbreviations used in the schemes and examples generally follow conventions used in the art. Chemical abbreviations used in the specification and examples are defined as follows: "KHMDs" for potassium bis(trimethylsilyl)amide; "DMF" for N,N-dimethylformamide; "HATU" for O-(t-Azabenzotriazol-1-yl)-N,N,N',N'-
30 tetramethyluronium hexafluorophosphate, "MeOH" for methanol; "Ar" for aryl; "TFA" for trifluoroacetic acid, "DMSO" for dimethylsulfoxide; "h" for hours; "rt" for room temperature or retention time (context will dictate); "min" for minutes; "EtOAc" for ethyl acetate; "THF" for tetrahydrofuran; "Et₂O" for diethyl ether; "DMAP" for 4-

dimethylaminopyridine; "DCE" for 1,2-dichloroethane; "ACN" for acetonitrile; "DME" for 1,2-dimethoxyethane; "HOBt" for 1-hydroxybenzotriazole hydrate; and "DIEA" for diisopropylethylamine.


Certain other abbreviations as used herein, are defined as follows: "1 x" for once,
5 "2 x" for twice, "3 x" for thrice, "°C" for degrees Celsius, "eq" for equivalent or equivalents, "g" for gram or grams, "mg" for milligram or milligrams, "L" for liter or liters, "mL" for milliliter or milliliters, "μL" for microliter or microliters, "N" for normal, "M" for molar, "mmol" for millimole or millimoles, "atm" for atmosphere, "psi" for pounds per square inch, "conc." for concentrate, "sat" or "sat'd" for saturated, "MW" for
10 molecular weight, "mp" for melting point, "ee" for enantiomeric excess, "MS" or "Mass Spec" for mass spectrometry, "ESI" for electrospray ionization mass spectroscopy, "HR" for high resolution, "HRMS" for high resolution mass spectrometry, "LCMS" for liquid chromatography mass spectrometry, "HPLC" for high pressure liquid chromatography, "RP HPLC" for reverse phase HPLC, "TLC" or "tlc" for thin layer chromatography,
15 "NMR" for nuclear magnetic resonance spectroscopy, "¹H" for proton, "δ" for delta, "s" for singlet, "d" for doublet, "t" for triplet, "q" for quartet, "m" for multiplet, "br" for broad, "Hz" for hertz, and "α", "β", "R", "S", "E", and "Z" are stereochemical designations familiar to one skilled in the art.

Some compounds can be synthesized from an appropriately substituted
20 heterocycle **I-1** according to Scheme I. Compounds **I-1** and **I-6** are commercially available or synthesized by reactions well known in the art. Treatment of compound **I-1** with bromine provided the dibromo intermediates **I-2** which was converted to the chloropyridine **I-3** by reacting with POCl₃. Intermediate **I-3** conveniently transformed to ketoester **I-5** using conditions well-known to those skilled in the art, including reacting **I-3** with Grignard reagent in the presence of catalytic copper(I) bromide dimethylsulfide
25 complex followed by alkyl 2-chloro-2-oxoacetate. Coupling of amines **1-5** with intermediate **1-6** in the presence of an organic base such as Hunig's base provided intermediate **I-7**. Chiral Lewis acid such as **I-8** mediated reduction of ketoester **I-7** with catecholborane furnished the chiral alcohol **I-9**. Tertiary butylation of alcohol **I-9** by well-
30 known conditions, including but not limited to tertiary-butyl acetate and perchloric acid, gave intermediate **I-10**. Intermediates **I-10** are conveniently transformed to intermediates **I-11** using conditions well-known in the art, including but not limited to the Suzuki

coupling between intermediates **I-10** and $R^6B(OR)_2$. The boronate or boronic acid coupling reagents, well-known in the art, are commercially available or are prepared by reactions well-known to those skilled in the art. Hydrolysis of intermediate **I-11** by using conditions well-known to those skilled in the art furnished the carboxylic acid **I-12**.


5

Scheme I



Intermediates **I-10** are conveniently transformed to intermediates **II-2** using conditions well-known in the art, including but not limited to the Suzuki coupling between intermediates **I-10** and **II-1**. Cleavage of protecting group in **II-2** provided phenol **II-3**. Alkylation of the phenol **II-3** was achieved by using conditions well known to those skilled in the art, including but not limited to Mitsunobu reaction to provide the intermediate **II-4**. Hydrolysis of intermediate **II-4** by using conditions well-known in the literature furnished carboxylic acid **II-5**.


Scheme II



In yet another method, some compounds of this invention can be synthesized according to Scheme III. Pyridine **III-1**, can be produced using methods similar to those described in the previous schemes. This intermediate can be carried on to the final products by a variety of paths. In one, the C2 and C6 alkyl groups can be oxidized to furnish intermediates **III-3** and/or **III-4** which can be further transformed to final compounds **III-9** or **III-10** by methods well known in the art.

10

Scheme III




In yet another process, some compounds of this invention can be synthesized according to Scheme IV. Pyridine **III-5** can be transformed to the final products by several paths. In one path, the C6 hydroxymethyl is oxidized to furnish carboxylic acid **IV-1** which upon heating in the presence of acid provided C6-desmethyl analog **IV-2**.

- 5 The “Pd” mediated coupling of boronate **IV-2** with appropriate aryl halides or aryl triflate followed by hydrolysis furnished the target compounds. Alternatively, the target compounds could be synthesized by coupling intermediate **IV-2** with aryl halides under Negishi coupling conditions followed by ester hydrolysis.

10

Scheme IV




The compounds described herein were purified by the methods well known to those skilled in art by normal phase column chromatography on silica gel column using appropriate solvent system described. Preparative HPLC or preparative LC/MS

- 15 purifications mentioned in this experimentation section were carried out gradient elution either on Sunfire Prep C18 ODB column (5 μ m; 19 or 30 X 100 mm) or Waters Xbridge C18 column (5 μ m; 19 X 200 or 30 X 100 mm) or Water Atlantis (5 μ m; 19 or 30 X 100 mm) or Waters XBridge C18, 2.1 mm x 50 mm, 1.7 μ m particles using the following mobile phases. Mobile phase A: 9:1 H₂O/acetonitrile with 10 mM NH₄OAc and mobile
- 20 phase B: A: 9:1 acetonitrile/H₂O with 10 mM NH₄OAc; or mobile phase A: 9:1 H₂O/acetonitrile with 0.1% TFA and mobile phase B: A: 9:1 acetonitrile/H₂O with 0.1% TFA; or mobile phase A: water/MeOH (9:1) with 20 mM NH₄OAc and mobile phase B:

95:5 MeOH/H₂O with 20 mM NH₄OAc or mobile phase A: water/MeOH (9:1) with 0.1% TFA and mobile phase B: 95:5 MeOH/H₂O with 0.1% TFA or mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate.


- 5 Compounds purified by preparative HPLC were diluted in methanol (1.2 mL) or DMF and purified using a Shimadzu LC-8A or LC-10A automated preparative HPLC system.

Intermediate 1



- 10 *(S)*-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2,6-dimethylpyridin-3-yl)-2-(*tert*-butoxy)acetate: was prepared according to the procedure described in WO2015126726.


Intermediate 2



- 15 *(S)*-3-Bromo-5-(1-(*tert*-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-2,6-dimethylpyridine 1-oxide:

- 20 To a stirred solution of *(S)*-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2,6-dimethylpyridin-3-yl)-2-(*tert*-butoxy)acetate (15 g, 32.0 mmol) in DCM (150 mL) was added 77% mCPBA (10.74 g, 47.9 mmol) at rt over 5 min. After 4 h, the reaction mixture was washed with 1M NaOH (2 X 100 mL), dried (MgSO₄), filtered and concentrated to give *(S)*-3-bromo-5-(1-(*tert*-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-2,6-dimethylpyridine 1-oxide (15.3 g, 31.5 mmol, 99 % yield) which was used in the next step without purification. LCMS (M+1) = 485.1 and 487.1.

Intermediate 3 and 4



(*S*)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (intermediate 3) and (*S*)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(hydroxymethyl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (intermediate 4):

To a stirred solution of (*S*)-3-bromo-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-2,6-dimethylpyridine 1-oxide (5.24 g, 10.79 mmol) anhydrous DCM (50 ml) was added trifluoroacetic anhydride (3.05 ml, 21.59 mmol) at RT. After 3 h, sat NaHCO₃ (50 mL) was added and stirred vigorously for 10 minutes. The solution phases were separated and organic phase collected and volatiles evaporated. The residue was taken up in EtOAc and washed with 50 mL of 1 M HCl followed by a wash with sat. sodium bicarbonate. The organic layer was then washed with brine, dried over MgSO₄, filtered and volatiles evaporated to afford the crude as an orange oil. The crude product was purified via silica gel (120 g column, 5-20% EtOAc:Hex) to give two products:

(*S*)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (intermediate 3):


Clear oil that later crystallized, 4.0 g (76%). ¹H NMR (500MHz, CDCl₃) δ 6.25 (br. s., 1H), 5.06 (spt, *J*=6.3 Hz, 1H), 4.75-4.79 (m, 1H), 4.74 - 4.62 (m, 2H), 4.02-4.12 (br. s., 1H), 3.54 - 3.46 (m, 1H), 2.93 (d, *J*=11.5 Hz, 1H), 2.70 - 2.63 (m, 1H), 2.61 (s, 3H), 1.65 - 1.56 (m, 2H), 1.50 - 1.43 (m, 1H), 1.35-1.40 (m, 1H), 1.23 (d, *J*=6.2 Hz, 3H), 1.22 (s, 9H), 1.16 (d, *J*=6.3 Hz, 3H), 1.09 (s, 3H), 1.05 (s, 3H). LCMS (M+H) = 485.35 and 487.2.

(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(hydroxymethyl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (intermediate 4):

Clear oil, 0.430 g (8.2%). ¹H NMR (500MHz, CDCl₃) δ 6.21 (br. s., 1H), 5.03 (spt, *J*=6.3 Hz, 1H), 4.95 (d, *J*=15.1 Hz, 1H), 4.64 (dd, *J*=15.3, 5.0 Hz, 1H), 4.50 (br. s., 1H), 4.05 - 3.97 (m, 1H), 3.57 (td, *J*=12.1, 2.5 Hz, 1H), 2.84 (d, *J*=11.8 Hz, 1H), 2.69 (s, 3H), 2.62 (d, *J*=11.8 Hz, 1H), 1.66 - 1.55 (m, 2H), 1.47 (dd, *J*=13.2, 2.0 Hz, 1H), 1.40 - 1.34 (m, 1H), 1.23 (d, *J*=6.3 Hz, 3H), 1.22 (s, 9H), 1.16 (d, *J*=6.1 Hz, 3H), 1.09 (s, 3H), 1.05 (s, 3H). LCMS (M+H) = 485.2 and 487.05.

10

Intermediate 5




(S)-Isopropyl 2-(5-bromo-6-(bromomethyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

To a solution of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (500 mg, 1.030 mmol) in CH₂Cl₂ (10 mL) was added CBr₄ (376 mg, 1.133 mmol) followed by Ph₃P (297 mg, 1.133 mmol) and the resulting mixture was stirred at room temperature for 16 h. Water (2 mL) was then added and the mixture was extracted with dichloromethane (10 mL), dried (Na₂SO₄), filtered and concentrated. The residue was then purified by Biotage (5-30%

EtOAc/hexane) to afford (S)-isopropyl 2-(5-bromo-6-(bromomethyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (350 mg, 0.638 mmol, 62.0 % yield) as white solid. ¹H NMR (500MHz, CDCl₃) δ 6.25 (br. s., 1H), 5.14 - 4.94 (m, 1H), 4.76 (d, *J*=9.6 Hz, 1H), 4.69 (d, *J*=9.6 Hz, 1H), 4.04 (br. s., 1H), 3.51 (t, *J*=11.9 Hz, 1H), 2.91 (d, *J*=11.5 Hz, 1H), 2.66 (d, *J*=12.1 Hz, 1H), 2.58 (s, 3H), 1.68 - 1.55 (m, 2H), 1.47 (d, *J*=12.5 Hz, 1H), 1.37 (d, *J*=12.8 Hz, 1H), 1.26 - 1.23 (m, 3H), 1.22 (s, 9H), 1.16 (d, *J*=6.1 Hz, 3H), 1.09 (s, 3H), 1.04 (s, 3H). LCMS (M+2H) = 549.2.


Intermediate 6



(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-formyl-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

- 5 To a stirred solution of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (15.4 g, 31.7 mmol) in DCM (288 ml) and acetonitrile (28.8 ml) was added Dess-Martin Periodinane (16.15 g, 38.1 mmol) at once at rt. After 5 h, the reaction mixture was diluted with ether (250 mL), washed with 1M NaOH (2 x 100 ml), brine (200 mL), dried (MgSO₄), filtered and
- 10 concentrated to afford (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-formyl-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (15.3 g, 31.6 mmol, 99% yield) as yellow solid. ¹H NMR (500 MHz, CDCl₃) δ 10.30 (s, 1H), 6.27 (br s, 1H), 5.13 - 5.03 (m, 1H), 4.12 (br s, 1H), 3.61 - 3.52 (m, 1H), 2.96 (br d, *J*=9.8 Hz, 1H), 2.76 - 2.70 (m, 1H), 2.66 (s, 3H), 1.66 - 1.54 (m, 4H), 1.23 - 1.21 (m, 12H), 1.17 (d, *J*=6.1 Hz, 3H), 1.11 (s, 3H),
- 15 1.06 (s, 3H). LCMS (M+1) = 483.1 and 485.1.

Intermediate 7




- (S)-3-Bromo-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpicolinic acid:*
- 20

- To a solution of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-formyl-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (15.3 g, 31.6 mmol) in acetonitrile (127 ml) and water (31.6 ml) was added oxone (14.79 g, 24.05 mmol) and the mixture was stirred at RT for 1 hr. The reaction was diluted with water and EtOAc. The organic
- 25 layer was washed with water (2X) and brine, dried (MgSO₄), filtered and concentrated to afford the product (S)-3-bromo-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-

dimethylpiperidin-1-yl)-6-methylpicolinic acid (15.6 g, 31.2 mmol, 99 % yield) as a yellow crispy foam. ¹H NMR (500 MHz, CDCl₃) δ 6.33 - 6.17 (m, 1H), 5.09 (dt, *J*=12.5, 6.3 Hz, 1H), 4.26 - 4.14 (m, 1H), 3.67 - 3.49 (m, 1H), 3.03 - 2.83 (m, 1H), 2.77 - 2.65 (m, 1H), 2.62 (s, 3H), 1.64 - 1.35 (m, 4H), 1.24 (d, *J*=6.3 Hz, 3H), 1.22 (s, 9H), 1.18 (d, *J*=6.1 Hz, 3H), 1.10 - 1.06 (m, 6H). LCMS (M+1) = 499.1 and 501.1.


Intermediate 8



Isopropyl (S)-2-(6-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

To a solution of ((S)-3-bromo-5-(1-(*tert*-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpicolinic acid (6.5 g, 13.01 mmol) and triethylamine (3.63 ml, 26.0 mmol) in toluene (130 mL) was added water (1.172 ml, 65.1 mmol) followed by diphenyl phosphorazidate (5.78 ml, 26.0 mmol). The resulting mixture was heated at 90 °C for 2 h. The reaction mixture was then cooled to ambient temperature, diluted with EtOAc (200 mL), and washed with saturated aqueous NaHCO₃, water, and brine. The organic layer was dried (Na₂SO₄), filtered, and concentrated *in vacuo*. The residue was then purified on silica gel (220 g column) using 5-80% EtOAc/hexane. The desired fractions were concentrated *in vacuo* to afford (S)-isopropyl 2-(6-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (5.6 g, 91%) as an off white solid. ¹H NMR (500 MHz, CDCl₃) δ 5.57 (s, 1H), 4.90 (spt, *J* = 6.2 Hz, 1H), 3.04 (dd, *J* = 12.9, 3.0 Hz, 1H), 3.04 (dd, *J* = 12.9, 3.0 Hz, 1H), 3.04 (ddd, *J* = 12.9, 11.7, 3.0 Hz, 1H), 3.04 (ddd, *J* = 12.9, 11.7, 3.0 Hz, 1H), 2.57 (s, 3H), 1.45 (ddd, *J* = 14.2, 3.0, 2.7 Hz, 1H), 1.45 (ddd, *J* = 14.2, 3.0, 2.7 Hz, 1H), 1.45 (ddd, *J* = 14.2, 11.7, 3.0 Hz, 1H), 1.45 (ddd, *J* = 14.2, 11.7, 3.0 Hz, 1H), 1.10 (s, 9H), 1.09 (d, *J* = 6.2 Hz, 6H), 0.98 (s, 3H), 0.91 (s, 3H). LCMS (M+1) = 470.10.


Intermediate 9



(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

- 5 Water (2.81 ml, 156 mmol) followed by acetic acid (4.65 ml, 81 mmol) was added to a stirring solution of (S)-3-bromo-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpicolinic acid (15.6 g, 31.2 mmol) in toluene (156 ml) at rt. The reaction was stirred at 90 °C for 7 hrs. The reaction volatiles were evaporated and the crude material purified via silica gel (330g column, 5-20% EtOAc:Hex) to afford the
- 10 product (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (12.8 g, 28.1 mmol, 90 % yield) as a clear oil that later crystallized. ¹H NMR (500 MHz, CDCl₃) δ 8.46 (s, 1H), 6.35 - 6.17 (m, 1H), 5.06 (dt, *J*=12.5, 6.2 Hz, 1H), 4.10 - 3.96 (m, 1H), 3.45 (br s, 1H), 2.92 (br s, 1H), 2.72 - 2.62 (m, 1H), 2.57 (s, 3H), 1.58 - 1.28 (m, 4H), 1.22 (s, 12H), 1.15 (d, *J*=6.3 Hz, 3H), 1.07 (br s, 6H). LCMS
- 15 (M+1) = 455.3 and 457.3.

Intermediate 10




(S)-2-(5-Bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

- 20 To a solution of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (2 g, 4.39 mmol) in EtOH (13.17 ml) and water (1.464 ml) was added lithium hydroxide monohydrate (0.590 g, 14.05 mmol) and heated at 75 °C for 18 hrs. The reaction was cooled to RT, neutralized and made slightly
- 25 acidic with the addition of HCl (15.37 ml, 15.37 mmol). The mixture was extracted with EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered

and the volatiles evaporated to afford the product (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid (1.82 g, 4.40 mmol, 100 % yield) as a white solid. LCMS (M+1) = 413.1 and 415.0.

5

Intermediate 11




(S)-Benzyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

To a stirred suspension of (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid (1.83 g, 4.43 mmol) and cesium carbonate (1.442 g, 4.43 mmol) in anhydrous acetonitrile (14.76 ml) and DMF (7.38 ml) was added benzy bromide (0.553 ml, 4.65 mmol). The reaction was stirred for 1 hr. After 1 hr, the LCMS indicated the reaction was complete. The reaction was diluted with water and EtOAc. The organic layer was washed with water (2X), followed by brine, collected, dried over MgSO₄, filtered and the volatiles evaporated to afford the crude product. The crude product was purified on silica gel (40 g column, 5-20% EtOAc:Hex) to afford the product (S)-benzyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (2.19 g, 4.35 mmol, 98 % yield) as a clear oil that solidified upon sitting. ¹H NMR (500 MHz, CDCl₃) δ 8.46 (s, 1H), 7.38 - 7.31 (m, 3H), 7.27 - 7.22 (m, 2H), 6.25 (br s, 1H), 5.24 - 5.04 (m, 2H), 4.07 - 3.90 (m, 1H), 3.34 (br d, J=2.7 Hz, 1H), 2.76 (br d, J=2.8 Hz, 1H), 2.69 - 2.57 (m, 1H), 2.52 (s, 3H), 1.60 - 1.39 (m, 4H), 1.22 (s, 9H), 1.02 (br s, 6H). LCMS (M+1) = 503.2 and 505.2.

25


Intermediate 12



(S)-3-(2-(Benzyloxy)-1-(tert-butoxy)-2-oxoethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridine 1-oxide:

To a stirred solution of (S)-benzyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (2.19 g, 4.35 mmol) in DCM (40 mL) was
 5 added 77% mCPBA (1.462 g, 6.52 mmol) at rt over 5 min. After 4 h, the reaction mixture was washed with 1M NaOH (2 X 25 mL), dried (MgSO₄), filtered and concentrated to afford the product (S)-3-(2-(benzyloxy)-1-(tert-butoxy)-2-oxoethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridine 1-oxide (2.12 g, 4.08 mmol, 94 % yield). ¹H
 NMR (500 MHz, CDCl₃) δ 8.39 (s, 1H), 7.36 - 7.33 (m, 3H), 7.28 - 7.25 (m, 2H), 6.26 (br
 10 s, 1H), 5.25 - 5.05 (m, 2H), 3.97 - 3.88 (m, 1H), 3.33 (br t, *J*=11.7 Hz, 1H), 2.69 (br d, *J*=12.9 Hz, 1H), 2.60 (br d, *J*=9.9 Hz, 1H), 2.48 (s, 3H), 1.58 - 1.38 (m, 4H), 1.21 (s, 9H), 1.05 - 0.98 (m, 6H). LCMS (M+1) = 519.1 and 521.1.

Intermediate 13




15 (S)-Benzyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(hydroxymethyl)pyridin-3-yl)-2-(tert-butoxy)acetate:

To a stirred solution of (S)-3-(2-(benzyloxy)-1-(tert-butoxy)-2-oxoethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridine 1-oxide (2.12 g, 4.08 mmol) in
 20 anhydrous DCM (18.55 ml) was added trifluoroacetic anhydride (0.865 ml, 6.12 mmol) at RT. After 3 h, sat Na₂CO₃ (100 mL) was added and stirred vigorously for 60 minutes. The solution phases were separated and organic phase collected and volatiles evaporated. The residue was taken up in EtOAc and washed with 50 mL of 1 M HCl followed by a wash with sat. sodium carbonate. The organic layer was then washed with brine, collected
 25 and volatiles evaporated to give the crude orange oil. The crude product was purified via silica gel (40g column, 5-20% EtOAc:Hex) to afford the product (S)-benzyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(hydroxymethyl)pyridin-3-yl)-2-(tert-butoxy)acetate (1.67 g, 3.21 mmol, 79 % yield) as a yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 8.55 (s, 1H), 7.35 - 7.31 (m, 3H), 7.27 - 7.23 (m, 2H), 6.27 (s, 1H), 5.23 - 5.03 (m, 2H), 4.98 -

4.61 (m, 2H), 4.00 - 3.86 (m, 1H), 3.45 - 3.32 (m, 1H), 2.75 - 2.52 (m, 2H), 1.55 - 1.36 (m, 4H), 1.22 (s, 9H), 1.01 (br s, 6H). LCMS (M+1) = 519.1 and 521.1.


Intermediate 14



(S)-Benzyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(fluoromethyl)pyridin-3-yl)-2-(tert-butoxy)acetate:

To a stirred solution of (S)-benzyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(hydroxymethyl)pyridin-3-yl)-2-(tert-butoxy)acetate (.2 g, 0.385 mmol) in DCM (3.85 ml) was added Deoxofluor (0.284 ml, 1.540 mmol) dropwise at 0 °C and allowed to stir at 0 °C for 1.5 hr. After 1.5 h, the reaction mixture was diluted with ether (25 mL), washed with 1M potassium phosphate buffer (50 ml), brine (20 mL), dried (MgSO₄), filtered and concentrated to give a purple oil. The crude material was purified via silica gel (24 g column, 5-50% EtOAc:Hex) to afford the product (S)-benzyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(fluoromethyl)pyridin-3-yl)-2-(tert-butoxy)acetate (84 mg, 0.161 mmol, 41.8 % yield) as a clear thick oil. ¹H NMR (500 MHz, CDCl₃) δ 8.64 (s, 1H), 7.38 - 7.31 (m, 3H), 7.28 - 7.25 (m, 2H), 6.25 (s, 1H), 5.77 - 5.51 (m, 2H), 5.23 - 5.06 (m, 2H), 4.00 - 3.89 (m, 1H), 3.41 - 3.30 (m, 1H), 2.74 - 2.56 (m, 2H), 1.55 - 1.40 (m, 4H), 1.20 (s, 9H), 1.05 - 0.97 (m, 6H). LCMS (M+1) = 521.1 and 523.1.


Intermediate 15



(S)-5-Bromo-3-(1-(*tert*-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridine 1-oxide:

To a stirred solution of (*S*)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (0.9 g, 1.976 mmol) in DCM (19.76 ml) was added 77% *m*CPBA (0.664 g, 2.96 mmol) at rt over 5 min. After 1 h, the reaction mixture was diluted with DCM and washed with sat. Na₂CO₃ (3 x 25 mL), dried (MgSO₄), filtered and concentrated to afford (*S*)-5-bromo-3-(1-(*tert*-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridine 1-oxide (873 mg, 1.852 mmol, 94 % yield) which was used in the next step without purification. LCMS (M+1) = 471.1 and 473.1.


Intermediate 16



(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(hydroxymethyl)pyridin-3-yl)-2-(*tert*-butoxy)acetate:

To a stirred solution of (*S*)-5-bromo-3-(1-(*tert*-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridine 1-oxide (.873 g, 1.852 mmol) anhydrous DCM (18.52 ml) was added trifluoroacetic anhydride (0.785 ml, 5.56 mmol) at RT. After 3 h, sat. sodium carbonate (50 mL) was added and stirred vigorously for 10 minutes. The solution phases were separated and organic phase collected and volatiles evaporated. The residue was taken up in EtOAc and washed with 50 mL of 1 M HCl followed by a wash with sat. sodium carbonate. The organic layer was then washed with 2 M aq. sodium carbonate (50 mL) for 18 hrs. The crude product was purified via silica gel (40 g column, 5-30% EtOAc:Hex) to afford the product (*S*)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(hydroxymethyl)pyridin-3-yl)-2-(*tert*-butoxy)acetate (720 mg, 1.527 mmol, 82 % yield). ¹H NMR (500 MHz, CDCl₃) δ 8.56 (s, 1H), 6.30 - 6.17 (m, 1H), 5.04 (dt, *J*=12.5, 6.3 Hz, 1H), 4.97 (d, *J*=15.3 Hz, 1H), 4.66 (d, *J*=15.3 Hz, 1H), 4.04 - 3.94 (m, 1H), 3.58 - 3.45 (m, 1H), 2.88 (br d, *J*=3.6 Hz, 1H), 2.71 - 2.59 (m, 1H), 1.57 - 1.36 (m, 4H), 1.25 - 1.22 (m, 12H), 1.16 (d, *J*=6.3 Hz, 3H), 1.07 (br d, *J*=12.0 Hz, 6H). LCMS (M+1) = 471.1 and 473.1.


Intermediate 17



(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-hydroxyacetate:

(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (500 mg, 0.621 mmol) was taken up in a 2:1 solution of TFA/DCE (0.15 M). The reaction was stirred for 2 days and then the mixture was diluted with EtOAc and washed with sat Na₂CO₃. The organic phase was dried over Na₂SO₄, filtered and concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs) to give the expected product (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-hydroxyacetate (450 mg, quant yield). LCMS (M+H) = 399 and 401.

Intermediate 18




(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetate:

In a 20 mL microwave vial, (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-hydroxyacetate (440 mg, 1.10 mmol), CH₂Cl₂ (9.1 ml), and 2-methylbut-2-ene (3.7 ml, 44 mmol) were combined. Then, the vial was capped and perchloric acid (.284 ml, 3.31 mmol) was added at once to the reaction (see ppt form and then go back into a clear solution). The reaction was stirred for 4 hrs. The mixture was diluted with EtOAc and washed with sat Na₂CO₃. The organic phase was dried over Na₂SO₄, filtered and concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs) to give 112 mg of (S)-isopropyl

2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetate (21% yield). LCMS (M+H) = 469, and 471. Also 297 mg of starting material was recovered.

Intermediate 19




5

(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-hydroxyphenyl)-2-methylpyridin-3-yl)acetate:

(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (100 mg, 0.220 mmol), (4-hydroxyphenyl)boronic acid (36 mg, 0.26 mmol), chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (16 mg, 0.022 mmol), potassium phosphate tribasic (140 mg, 0.659 mmol) were combined under N₂ (g). 1,4-Dioxane (3.7 ml) and water (0.7 ml) was added under N₂ (g). The reaction was stirred at 80 °C. for 1 hr. The reaction was concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs) to give the expected product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-hydroxyphenyl)-2-methylpyridin-3-yl)acetate (75 mg, 0.160 mmol, 72.9 % yield). LCMS (M+H) = 469.25.

15

Intermediate 20



20


(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-hydroxyphenyl)-2-methylpyridin-3-yl)acetic acid:

5N NaOH (0.2 ml, 1 mmol) was added to a stirring solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-hydroxyphenyl)-2-methylpyridin-3-yl)acetate (50 mg, 0.11 mmol) in EtOH (2 ml) at 80 °C. The reaction was stirred overnight and then purified by preparative reverse phase HPLC to afford (S)-2-(tert-

25

butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-hydroxyphenyl)-2-methylpyridin-3-yl)acetic acid (20 mg, 0.047 mmol, 43.9 % yield). LCMS (M+H) = 427.15.

Intermediate 21




5

(*S*)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-ethynyl-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

Dimethyl (2-diazo-3-oxobutanoyl)phosphonite (507 mg, 2.48 mmol) was added to a stirring solution of (*S*)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-formyl-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (1.0 g, 2.1 mmol) and K₂CO₃ (1.3 g, 9.3 mmol) in MeOH (21 ml) at rt. The reaction was stirred for 1 hr. The reaction was then concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient) to afford (*S*)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-ethynyl-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (923 mg, 1.925 mmol, 93 % yield) was isolated. LCMS (M+H) = 479.10 and 481.05.

15

Intermediate 22



(*S*)-Isopropyl 2-(5-bromo-6-cyano-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

20


Under N₂, tert-butyl nitrite (25 μ l, 0.21 mmol) was added to a stirring solution of (*S*)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-ethynyl-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (50 mg, 0.10 mmol) and 2-methylpyridine 1-oxide (23 mg, 0.209 mmol) in THF (1 ml) at 70 °C under N₂. The reaction was stirred overnight at 70 °C. LCMS showed ~1:1 mixture of sm and product. The reaction was concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient) to

25

afford (S)-isopropyl 2-(5-bromo-6-cyano-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (18 mg, 0.037 mmol, 35.9 % yield). LCMS (M+H) = 480.05 and 482.10.

5

Intermediate 23




(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-formyl-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

To a stirred solution of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-
 10 2-(hydroxymethyl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (300 mg, 0.618 mmol) in
 DCM (5618 μ l) and acetonitrile (562 μ l) was added Dess-Martin Periodinane (393 mg,
 0.927 mmol) at once at rt. After 5 h, the reaction mixture was diluted with ether (25 mL),
 washed with 1M NaOH (2 x 20 ml), brine (5 mL), dried (MgSO₄), filtered and
 concentrated to afford the product (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-
 15 yl)-2-formyl-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (285 mg, 0.590 mmol, 95 %
 yield). ¹H NMR (500 MHz, CDCl₃) δ 10.57 - 10.25 (m, 1H), 6.39 - 6.19 (m, 1H), 5.10 -
 5.02 (m, 1H), 3.96 - 3.84 (m, 1H), 3.51 (br t, J =10.2 Hz, 1H), 2.91 (br s, 1H), 2.78 (s,
 3H), 2.68 - 2.63 (m, 1H), 1.49 - 1.37 (m, 2H), 1.36 - 1.27 (m, 2H), 1.26 (d, J =6.3 Hz, 3H),
 1.20 - 1.18 (m, 12H), 1.07 (br d, J =14.3 Hz, 6H). LCMS (M+1) = 483.1 and 485.1.

20


Intermediate 24



(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-2-vinylpyridin-3-yl)-2-(tert-butoxy)acetate:

To a suspension of methyltriphenylphosphonium bromide (111 mg, 0.310 mmol) in THF (1 ml) at 0 °C was added sodium hydride (12.41 mg, 0.310 mmol) and the resulting mixture was stirred at rt for 45 min. (S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-formyl-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (50 mg, 0.103 mmol) dissolved in THF (1 ml) was added dropwise and the mixture was stirred at 0 °C for 1 h then warmed to rt and stirred 18 h. The reaction was quenched with water and the product was extracted with EtOAc. The organic phase was washed with brine, dried (MgSO₄), filtered and concentrated. The residue was purified by silica gel chromatography (12 g column; 5-20% EtOAc/hexane) to afford (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-2-vinylpyridin-3-yl)-2-(tert-butoxy)acetate (25 mg, 0.052 mmol, 50.2 % yield). ¹H NMR (500 MHz, CDCl₃) δ 7.43 - 7.33 (m, 1H), 6.34 (br dd, *J*=16.8, 2.3 Hz, 2H), 5.46 - 5.38 (m, 1H), 5.07 - 4.98 (m, 1H), 4.07 (br s, 1H), 3.58 - 3.49 (m, 1H), 2.91 (br d, *J*=11.2 Hz, 1H), 2.69 (s, 3H), 2.63 (br d, *J*=12.6 Hz, 1H), 1.67 - 1.53 (m, 4H), 1.22 (s, 9H), 1.20 (d, *J*=6.3 Hz, 3H), 1.11 - 1.09 (m, 6H), 1.04 (s, 3H). LCMS (M+1) = 481.2 and 483.1.

Intermediate 25




(S)-5-Bromo-3-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpicolinic acid:

To a solution of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-formyl-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (.350 g, 0.724 mmol) in DMSO (10 ml) was added potassium phosphate monobasic (0.296 g, 2.172 mmol) in water (0.5 mL) followed by sodium chlorite (0.196 g, 2.172 mmol) in water (1.0 mL) and the mixture was stirred for 3 hr. The reaction was diluted with water and EtOAc. The organic layer was washed with water (2X). The organic layer was then washed with brine dried (MgSO₄), filtered and concentrated to afford the product (S)-5-bromo-3-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpicolinic acid (319 mg,

0.639 mmol, 88 % yield) as a sticky oil. ¹H NMR (500 MHz, CDCl₃) δ 7.18 - 6.63 (m, 1H), 5.12 - 4.99 (m, 1H), 3.58 - 3.48 (m, 1H), 2.99 - 2.91 (m, 1H), 2.74 (s, 3H), 2.64 (s, 1H), 1.48 - 1.33 (m, 4H), 1.25 (d, *J*=6.3 Hz, 3H), 1.21 (s, 9H), 1.18 (d, *J*=6.3 Hz, 3H), 1.03 (s, 6H). LCMS (M+1) = 500.0 and 501.0.

5


Intermediate 26



Water (57.5 μl, 3.19 mmol) followed by diphenylphosphoryl azide (276 μl, 1.277 mmol) was added to a stirring solution of (S)-5-bromo-3-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpicolinic acid (319 mg, 0.639 mmol) and TEA (178 μl, 1.277 mmol) in Toluene (6387 μl) at rt. The reaction was stirred at 90 °C for 2 hrs. The mixture was then cooled to room temp, diluted with EtOAc (100 mL) and washed with sat. NaHCO₃ solution,. The organic layer was then washed with brine, collected, dried (MgSO₄), filtered and concentrated. The residue was then purified by silica gel (40 g column, 5-50% EtOAc:hexane) to afford (S)-isopropyl 2-(2-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (150 mg, 0.319 mmol, 49.9 % yield) as a yellow solid. ¹H NMR (500 MHz, CDCl₃) δ 6.21 (s, 1H), 5.36 - 5.19 (m, 2H), 5.02 (dt, *J*=12.6, 6.2 Hz, 1H), 3.98 (td, *J*=12.1, 2.6 Hz, 1H), 3.60 (td, *J*=12.0, 2.4 Hz, 1H), 2.85 - 2.82 (m, 1H), 2.62 - 2.56 (m, 1H), 2.49 (s, 3H), 1.66 - 1.58 (m, 2H), 1.44 (br dd, *J*=12.8, 2.4 Hz, 1H), 1.39 - 1.35 (m, 1H), 1.25 (s, 9H), 1.23 (d, *J*=6.3 Hz, 3H), 1.14 (d, *J*=6.3 Hz, 3H), 1.09 (s, 3H), 1.04 (s, 3H). LCMS (M+1) = 470.1 and 472.1.

25

Intermediate 27




3,5-Dibromo-2-methylpyridin-4-ol:

To a stirred solution of 2-methylpyridin-4-ol (5 g, 45.8 mmol) in DCM (56.4 ml) and MeOH (6.80 ml) was added tert-butylamine (9.81 ml, 93 mmol) and cooled to 0 °C.

Bromine (4.72 ml, 92 mmol) was added dropwise over 60 minutes. The reaction mixture was stirred at RT for 3 hours. The reaction mixture was filtered through a fine frit filter and the solid white material dried under vacuum for 18 hrs. ¹H NMR (500 MHz, DMSO-d₆) δ 12.32 (br. s., 1H), 8.21 (s, 1H), 2.40 (s, 3H). LCMS (M+1) = 267.7.

5


Intermediate 28



3,5-Dibromo-4-chloro-2-methylpyridine: To a solution of 3,5-dibromo-2-methylpyridin-4-ol (13.12 g, 49.2 mmol) in POCl₃ (13.74 ml, 147 mmol) was added triethylamine (6.85 ml, 49.2 mmol) at 0 °C slowly over 80 min. After addition ice bath was removed, and the reaction was heated to 80 °C and stirred for 3h. The reaction mixture was then cooled to rt and slowly quenched by adding it to crushed ice. The resulting suspension was extracted with DCM (250ml). The organic layer was washed with saturated NaHCO₃ solution (250 mL) followed by water (250 mL) and brine (250mL). The organic layer was dried (MgSO₄), filtered and concentrated to get 3,5-dibromo-4-chloro-2-methylpyridine (14.7 g, 51.5 mmol, 105 % yield) as a off white solid. ¹H NMR (500 MHz, CDCl₃) δ 8.55 (s, 1H), 2.72 (s, 3H). LCMS (M+1) = 285.7.

15

Intermediate 29



20


Isopropyl 2-(5-bromo-4-chloro-6-methylpyridin-3-yl)-2-oxoacetate:

To a -78 °C solution of 3,5-dibromo-4-chloro-2-methylpyridine (9.42 g, 33.0 mmol) and copper(I) bromide-dimethyl sulfide complex (0.339 g, 1.651 mmol) in THF (75 mL) was added dropwise isopropylmagnesium chloride (17.33 mL, 34.7 mmol) over 20 min. The reaction was allowed to warm to -10 °C for 60 min. The reaction mixture was then transferred via cannula to another flask containing a solution of isopropyl 2-chloro-2-oxoacetate (4.97 g, 33.0 mmol) in THF(75 ml) at -60 °C and allowed to warm to -10 °C for 2.5 hr. The reaction was then quenched with 10% solution of ammonium chloride and diethyl ether. The organic layer was washed with brine, collected, dried

25

(MgSO₄), filtered and volatiles evaporated to give the crude material. The crude material was purified via silica gel (330g column, 10-40% EtOAc:Hex) to give the product isopropyl 2-(5-bromo-4-chloro-6-methylpyridin-3-yl)-2-oxoacetate (3.45 g, 9.15 mmol, 27.7 % yield) as a yellow oil that later solidified. ¹H NMR (500 MHz, methanol-d₄) δ 8.79 (s, 1H), 5.09 (dt, *J*=12.6, 6.2 Hz, 1H), 2.76 (s, 3H), 1.24 - 1.22 (m, 3H), 1.20 (d, *J*=6.3 Hz, 3H). LCMS (M+1) = 321.8.

Intermediate 30




10 *Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)-2-oxoacetate:*

To a 40 mL vial equipped with a stir bar was added isopropyl 2-(5-bromo-4-chloro-6-methylpyridin-3-yl)-2-oxoacetate (5 g, 15.60 mmol), DIPEA (3.00 mL, 17.16 mmol) and acetonitrile (10.40 mL), then 4,4-dimethylpiperidine (1.942 g, 17.16 mmol). The vial was capped and then placed in a heating block at 85 °C with stirring. After 18 hrs the reaction mixture was dissolved in Et₂O (100 mL) and water (100 mL) and transferred to a 500 mL separatory funnel. The mixture was agitated; the phases were separated. The aq. phase was back extracted with Et₂O (100 mL). The combined organics were washed with brine (50 mL). The solution was dried over MgSO₄; filtered; then concentrated in vacuo. The crude product was purified via silica gel purification (120 g column, 0-30% EtOAc:Hex) to give the product isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)-2-oxoacetate (4.56 g, 11.48 mmol, 73.6 % yield) as a yellow oil that partially solidified. ¹H NMR (500 MHz, CDCl₃) δ 8.45 (s, 1H), 5.26 (dt, *J*=12.5, 6.3 Hz, 1H), 3.20 - 3.14 (m, 4H), 2.76 (s, 3H), 1.52 - 1.48 (m, 4H), 1.42 (d, *J*=6.3 Hz, 6H), 1.04 (s, 6H). LCMS (M+1) = 399.0.

25


Intermediate 31



(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)-2-hydroxyacetate:

- To a 100 mL R B-flask equipped with a stir bar was added isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)-2-oxoacetate (2.5 g, 6.29 mmol).
- 5 The flask was fitted with a rubber septum and then placed under N₂ atm (vac/fill x 3). To the flask was added toluene (17.98 ml). The flask was placed in a -35 °C bath (dichloroethane/dry ice). A thermometer was used to monitor the internal temperature. When the internal temp was -30 °C, to the flask was added (R)-1-methyl-3,3-diphenylhexahydropyrrolo[1,2-c][1,3,2]oxazaborole (0.944 ml, 0.944 mmol). To the
- 10 stirred solution was added 50% catecholborane/toluene (1.886 ml, 8.81 mmol) over 2 minutes. Within 5 minutes following the addition the temperature rose to -25 °C before falling to -30 °C. The solution was stirred at -30 °C for 3 h. The flask was transferred to a -15 to -12 °C cold bath (chiller/circulator). The yellow solution was stirred for 1 day at -15 to -12 °C. The reaction was quenched with 5 mL of 2M aq. sodium carbonate. The
- 15 reaction was then diluted with 100 mL EtOAc and 100 mL 2M aq sodium carbonate and stirred vigorously for 2 hrs. The layers were separated and the organic layer collected and stirred vigorously for an additional 1 hr. The organic layer was washed with brine, dried over MgSO₄, filtered and evaporated to give the crude product. The crude product was purified on silica gel chromatography (80 g column, 10-40% EtOAc:Hex) to afford the
- 20 product *(S)*-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)-2-hydroxyacetate (2 g, 5.01 mmol, 80 % yield) as a yellow oil that solidified at RT. ¹H NMR (500 MHz, CDCl₃) δ 8.33 (s, 1H), 5.31 (d, *J*=6.9 Hz, 1H), 5.13 - 5.03 (m, 2H), 3.80 (br. s., 2H), 2.87 - 2.75 (m, 1H), 2.71 (s, 3H), 2.69 - 2.60 (m, 1H), 1.71 - 1.59 (m, 2H), 1.43 (d, *J*=14.8 Hz, 2H), 1.28 (d, *J*=6.1 Hz, 3H), 1.16 (d, *J*=6.3 Hz, 3H), 1.04 (s, 3H),
- 25 1.08 (s, 3H). LCMS (M+1) = 399.0.


Intermediate 32



(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

In a 250 ml round bottom flask fitted with a shlenk adaptor with rubber septum (with empty balloon attached), isobutylene gas was vigorously bubbled for 30 minutes into a 0 °C solution of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)-2-hydroxyacetate (2 g, 5.01 mmol) and perchloric acid (0.861 mL, 10.02 mmol) in DCM (100 mL) until the volume doubled and the balloon filled to firmness. After 2 hrs, the isobutylene line was disconnected and needle pulled to just above the solution line then connected to a bubbler to monitor isobutylene gas exit. The ice bath was removed and warmed up to RT while monitoring for conversion. After 2 hrs the reaction appeared to go to full conversion according to LCMS. The reaction mixture was poured into a 1L Erlenmeyer flask and made basic with 2M sodium carbonate while vigorously stirring. The organic layer was separated and washed with water, followed by brine, collected, dried (MgSO₄), filtered and volatiles evaporated to afford the crude product. The crude product was purified on silica gel (40 g column, 5-40% EtOAc:Hex) to afford the product (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (1.95 g, 4.28 mmol, 85 % yield) as a clear oil that later crystallized to a white solid. ¹H NMR (500 MHz, CDCl₃) δ 8.61 (s, 1H), 5.61 (s, 1H), 5.01 (dt, *J*=12.5, 6.3 Hz, 1H), 3.81 (t, *J*=10.9 Hz, 1H), 3.60 (t, *J*=11.0 Hz, 1H), 2.76 (d, *J*=11.5 Hz, 1H), 2.69 (s, 3H), 2.64 (d, *J*=12.1 Hz, 1H), 1.63 - 1.51 (m, 2H), 1.46 (d, *J*=11.2 Hz, 1H), 1.38 (d, *J*=14.2 Hz, 1H), 1.26 - 1.22 (m, 12H), 1.20 (d, *J*=6.1 Hz, 3H), 1.09 - 1.03 (m, 6H). LCMS (M+1) = 457.1.

Intermediate 33




3-Bromo-2-chloro-4-fluoropyridine:

To a dry 1000 mL round bottom flask under nitrogen was added 2-chloro-4-fluoropyridine (13 g, 99 mmol) and THF (250 mL). The reaction was flushed with argon, securely capped, cooled to -78 °C and slowly (over 20-25 min) treated with LDA, 1 M in THF:hexanes (100 ml, 100 mmol). After the addition was complete, the reaction was stirred at -78 °C for 85 min. The reaction was then treated (over 10 min) with a solution

of 1,2-dibromo-1,1,2,2-tetrachloroethane (35 g, 107 mmol) in THF (150 mL). After the addition was complete, the reaction was stirred at -78 °C for 30 min, then the bath was removed and the reaction was allowed to warm to room temp. The reaction was diluted with dichloromethane (500 mL), extracted with water (1 x 150 mL), brine (1 x 100 mL), dried over Na₂SO₄, and concentrated. The crude material was purified via silica gel chromatography (330g SiO₂ column, hexane:dichloromethane 100:0 -> 65:35) to afford 3-bromo-2-chloro-4-fluoropyridine, 12 g (58%). ¹H NMR (500 MHz, CDCl₃) δ 8.33 (dd, *J*=7.4, 5.4 Hz, 1H), 7.07 (dd, *J*=7.1, 5.4 Hz, 1H).


10

Intermediate 34

*5-Bromo-2-chloro-4-fluoro-3-iodopyridine:*

To a flame dried 500 mL conical flask under nitrogen was added 2,2,6,6-tetramethylpiperidine (12.7 mL, 75 mmol) and THF (225 mL). The reaction was flushed with argon, cooled to -78 °C and treated with n-butyllithium, 1.6M in hexanes (39 mL, 62.4 mmol). The reaction was stirred at -78 °C, then the bath was removed and the reaction was allowed to warm to 0 °C over 20 min. The reaction was recooled to -78 °C and transferred to a solution of 3-bromo-2-chloro-4-fluoropyridine (13.55 g, 64.4 mmol) in THF (225 mL) at -78 °C over 10 min. After the addition was complete, the reaction was stirred at -78 °C for 50 min, then treated with a solution of iodine (18.8 g, 74.1 mmol) in THF (225 mL) at -50 °C. The reaction was packed in dry ice and allowed to stir while slowly warming to room temp over 18 h. The reaction was diluted with ethyl acetate (600 mL), extracted with aq Na₂S₂O₃ (5 g dissolved in water (250 mL)), water (1 x 60 mL), brine (1 x 60 mL), dried over Na₂SO₄, and concentrated. The crude material was purified via silica gel chromatography (330g SiO₂ column, hexane:dichloromethane: 100:0 -> 65:35) to afford 5-bromo-2-chloro-4-fluoro-3-iodopyridine, 15.7 g (72%). ¹H NMR (500 MHz, CDCl₃) δ 8.42 (d, *J*=8.4 Hz, 1H)


Intermediate 35



Ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-oxoacetate:

To a dry 500 mL conical flask under nitrogen was added 5-bromo-2-chloro-4-fluoro-3-iodopyridine (11.34 g, 33.7 mmol), copper(I) bromide-dimethyl sulfide (1.36 g, 6.62 mmol) and THF (400 mL). The resulting suspension was flushed very well with argon, cooled to -78 °C and treated with isopropylmagnesium chloride, 1.92 M in THF (17.56 mL, 33.7 mmol). After the addition was complete, the reaction was stirred at -78 °C for 33 min, then allowed to warm to -10 °C over 2 h. The reaction was recooled to -60 °C and transferred via cannulae to a solution of ethyl oxalyl chloride (6.34 mL, 56.8 mmol) in THF (100 mL) at -78 °C. The reaction was stirred at -78 °C for 5 min, slowly allowed to warm to -12 °C over 85 min then held at -12 °C for 2.5 h. The reaction was cooled to -35 °C and treated (via cannulae) with a solution of 4,4-dimethylpiperidine (16 g, 141 mmol) in N,N-diisopropylethylamine (19.2 mL, 110 mmol), followed by acetonitrile (100 mL) and allowed to stir while slowly warming to room temp over 18 h. The reaction was treated with diethanol amine (805 mg, 7.66 mmol), diluted with ethyl acetate (1100 mL), extracted with water (1 x 150 mL), dried over Na₂SO₄ and concentrated. The crude material was purified via silica gel chromatography (330g SiO₂ column, hexane:dichloromethane: 100:0 -> 0:100) to afford ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-oxoacetate, 10.81 g (79%). LCMS (M+1) = 403.1 and 405.0.


Intermediate 36



Ethyl (S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-hydroxyacetate:

To a solution of ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-oxoacetate (11.6 g, 28.7 mmol) in anhydrous Toluene (500 mL) was added (R)-2-methyl-CBS-oxazaborolidine, 1.0M in toluene (35.5 mL, 35.5 mmol). The reaction was cooled to -78 °C and treated (over 33 min) with catecholborane, 50 wt% in toluene (29 mL, 135 mmol). After the addition was complete, the dry ice was removed from the bath and the reaction was allowed to warm to -5 °C over 5 h, then held at -5 °C for 40 min. The reaction was cooled to -55 °C and transferred (via cannulae) to an ice cold solution of aqueous saturated K₂CO₃ (200 mL) and EtOAc (400 mL) and the resulting two phase mixture was stirred at room temp for 18 h. The reaction was further diluted with ethyl acetate, extracted with water (1 x 30 mL), brine (1 x 30 mL), dried over Na₂SO₄ and concentrated. The crude material was purified via silica gel chromatography (330g SiO₂ column, dichloromethane:EtOAc 100:0 -> 50:50) to afford ethyl (S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-hydroxyacetate, 11.5 g (99%). LCMS (M+1) = 405.0 and 407.0.

Intermediate 37




Ethyl-(S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(tert-butoxy)acetate:

To a dry 1000 mL pressure bottle under nitrogen was added (S)-ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-hydroxyacetate (5.23 g, 12.89 mmol), CH₂Cl₂ (300 mL) and 4A mol sieves. The reaction was allowed to stir at room temp for 2h, then cooled to -78 °C. The reaction was then treated with perchloric acid (2.33 mL, 38.7 mmol), and isobutylene was bubbled into the reaction until the reaction volume roughly doubled. The flask was securely capped, removed from the bath and allowed to stir for 18 h while slowly warming to room temp. The reaction was cooled to -60 °C and quenched into an erlenmeyer flask containing a mixture of CH₂Cl₂ (200 mL)

and NaHCO₃ (12.8 g, 152 mmol) dissolved in water (250 mL). The reaction was further diluted with dichloromethane (300 mL), extracted with water (1 x 75 mL), brine (1 x 75 mL), dried over Na₂SO₄ and concentrated. The crude material was purified via silica gel chromatography (330g SiO₂ column, dichloromethane:EtOAc 100:0 -> 55:45) to afford ethyl-(S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate, 4.62 g (78%). LCMS (M+1) = 461.1, 463.1. ¹H NMR (500 MHz, CDCl₃) δ 8.37 (s, 1H), 5.60 (br s, 1H), 4.28 - 4.11 (m, 2H), 3.91 - 3.63 (m, 1H), 3.33 (br s, 1H), 3.07 (br d, *J*=2.3 Hz, 1H), 2.58 (br d, *J*=1.5 Hz, 1H), 1.81 - 1.63 (m, 1H), 1.49 - 1.35 (m, 2H), 1.27 (br d, *J*=5.0 Hz, 1H), 1.25 (s, 9H), 1.02 (s, 6H).


Intermediate 38



Ethyl-(S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)-2-(tert-butoxy)acetate:

To a dry 100 mL round bottom flask under argon was added ethyl-(S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate (1.05 g, 2.274 mmol) and THF (48 mL). The resulting solution was cooled to -25 °C and then treated slowly (over 2 min) 2,2,6,6-tetramethylpiperidinylmagnesium chloride lithium chloride complex 1.0 M in THF/toluene (4.65 mL, 4.65 mmol). The reaction was stirred at -21 °C (+/- 4 °C) for 33 min, then recooled to -20 °C and treated with anhydrous DMF (1.00 mL, 12.91 mmol). The reaction was allowed to warm to -8 °C over 70 min, then recooled to -20 °C and quenched with aqueous saturated NH₄Cl. The crude reaction was diluted with ethyl acetate (150 mL), extracted with water (1 x 15 mL, brine (1 x 15 mL), dried over Na₂SO₄, and concentrated. The crude material was purified via silica gel chromatography (80g SiO₂ column, dichloromethane:EtOAc 100:0 -> 80:20) to afford ethyl (S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)-2-(*tert*-butoxy)acetate, 1.04 g (93%). LCMS (M+1) = 489.1, 491.1.

Intermediate 39




Ethyl (S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)pyridin-3-yl)-2-(tert-butoxy)acetate:

- 5 To a dry reaction vial under nitrogen was added (S)-ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)-2-(tert-butoxy)acetate (20 mg, 0.041 mmol) and EtOH (1.5 mL). The resulting solution was treated with sodium borohydride (8.5 mg, 0.225 mmol), capped and stirred at room temp for 2 h. The reaction was diluted with ethyl acetate (75 mL), extracted with aq sat'd NH₄Cl (1 x 10 mL), water (1 x 10 mL),
10 brine (1 x 10 mL), dried over Na₂SO₄ and concentrated to afford ethyl (S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)pyridin-3-yl)-2-(tert-butoxy)acetate (12 mg, 60%) was used "as is" without further purification. LCMS (M+1) = 491.2, 493.1.

15

Intermediate 40




Ethyl (S)-2-(6-amino-5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(tert-butoxy)acetate:

- To a reaction vial under nitrogen was added (S)-ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)-2-(tert-butoxy)acetate (149 mg, 0.304 mmol) and acetonitrile (4 mL). The reaction was stirred at room temp, treated with a solution of oxone (380 mg, 0.618 mmol) in water (1.75 mL) and stirred at room temp for 20h. The reaction was diluted with ethyl acetate (100 mL), extracted with water (1 x 8 mL) and evaporated to dryness. The crude residue was dissolved in toluene (4 mL) and
25 treated with triethylamine (100.4 μL, 0.720 mmol), water (32.45 μL, 1.801 mmol), and diphenylphosphoryl azide (198 mg, 0.719 mmol). The reaction was flushed very briefly


with nitrogen, capped and heated at 90 °C oil bath for 90 min. The reaction was diluted with ethyl acetate (100 mL), extracted with aq sat'd NaHCO₃ (1 x 10 mL), water (1 x 10 mL), brine (1 x 10 mL) dried over Na₂SO₄ and concentrated. The crude residue was purified via silica gel chromatography (40g SiO₂ column, hexane:EtOAc 100:0 -> 70:30) to afford ethyl (S)-2-(6-amino-5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate, 100 mg (58%). LCMS (M+1) = 476.1, 478.1.

Intermediate 41

10 *2-Chloro-5-(4-fluorophenethoxy)pyrimidine:*

To a 50 mL round bottom flask equipped with a stir bar was added 2-chloropyrimidin-5-ol (250 mg, 1.915 mmol), 2-(4-fluorophenyl)ethanol (268 mg, 1.915 mmol), triphenylphosphine (603 mg, 2.298 mmol) and THF (10 mL). To the stirred solution was added DIAD (0.447 mL, 2.298 mmol). The solution warmed to a mild exotherm, then cooled within 5 minutes. The solution was stirred at r.t. for 2 hrs. The reaction solution was concentrated in vacuo and the resulting oil was purified via silica gel chromatography (40 g column, 5-40% EtOAc:Hex) to afford the product 2-chloro-5-(4-fluorophenethoxy)pyrimidine (310 mg, 1.227 mmol, 64.1 % yield) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ 8.28 (s, 2H), 7.25 (dd, *J*=8.7, 5.4 Hz, 2H), 7.08 - 7.02 (m, 2H), 4.26 (t, *J*=6.7 Hz, 2H), 3.13 (t, *J*=6.7 Hz, 2H). LCMS (M+1) = 252.9.

Intermediate 42


*2-Chloro-5-(4-fluorophenethoxy)pyrazine:*

To a 50 mL round bottom flask equipped with a stir bar was added 5-chloropyrazin-2-ol (250 mg, 1.915 mmol), 2-(4-fluorophenyl)ethanol (268 mg, 1.915 mmol), triphenylphosphine (603 mg, 2.298 mmol) and THF (10 mL). To the stirred solution was added DIAD (0.447 mL, 2.298 mmol). The solution had a mild exotherm, then cooled within 5 minutes. The solution was stirred at RT for 2 hrs. The reaction solution was concentrated in vacuo and the resulting oil was purified via silica gel chromatography (40 g column, 5-40% EtOAc:Hex) to afford the product 2-chloro-5-(4-

fluorophenethoxy)pyridazine (330 mg, 1.306 mmol, 68.2 % yield) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ 8.10 (d, *J*=1.3 Hz, 1H), 8.01 (d, *J*=1.3 Hz, 1H), 7.25 (dd, *J*=8.6, 5.4 Hz, 2H), 7.03 (t, *J*=8.7 Hz, 2H), 4.52 (t, *J*=6.9 Hz, 2H), 3.09 (t, *J*=6.9 Hz, 2H). LCMS (M+1) = 253.0.

5

Intermediate 43




3-Chloro-6-(4-fluorophenethoxy)pyridazine:

To a 50 mL round bottom flask equipped with a stir bar was added 6-chloropyridazin-3-ol (250 mg, 1.915 mmol), 2-(4-fluorophenyl)ethanol (268 mg, 1.915 mmol), triphenylphosphine (603 mg, 2.298 mmol) and THF (10 mL). To the stirred solution was added DIAD (0.447 mL, 2.298 mmol). The solution had a mild exotherm, then cooled within 5 minutes. The solution was stirred at RT for 2 hrs. The reaction solution was concentrated in vacuo and purified via silica gel chromatography (40 g column, 5-40% EtOAc:Hex) to afford the semi pure product. The material was further purified via reverse phase C18 chromatography (55 g column, 20-100% CH₃CN:Water with 0.1% TFA buffer). The desired fractions were isolated, diluted with sat. sodium bicarbonate solution (25 mL) and EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, and volatiles evaporated to afford the pure product 3-chloro-6-(4-fluorophenethoxy)pyridazine (450 mg, 1.781 mmol, 93 % yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.22 (dd, *J*=8.3, 5.4 Hz, 2H), 7.18 (d, *J*=9.8 Hz, 1H), 7.04 - 6.97 (m, 2H), 6.91 (d, *J*=9.5 Hz, 1H), 4.37 - 4.30 (m, 2H), 3.13 - 3.06 (m, 2H). LCMS (M+1) = 253.0.

25

Intermediate 44




4-Vinylbenzofuro[3,2-d]pyrimidine:

4-Chlorobenzofuro[3,2-d]pyrimidine (500 mg, 2.44 mmol), 6-methyl-2-vinyl-1,3,6,2-dioxazaborocane-4,8-dione (492 mg, 2.69 mmol), chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-

30

- biphenyl)]palladium(II) (176 mg, 0.244 mmol), potassium phosphate tribasic (3.89 g, 18.3 mmol) were combined under N₂ (g). 1,4-Dioxane (20 ml) and water (4.0 ml) was added under N₂ (g). The reaction was stirred at 80 °C for 1 hr. The reaction was concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs) to give the expected product 4-vinylbenzofuro[3,2-d]pyrimidine (254 mg, 1.30 mmol, 53.0 % yield) LCMS (M+H) = 196.80.

Intermediate 45




10

Benzofuro[3,2-d]pyrimidine-4-carbaldehyde:

- To a clear solution of 4-vinylbenzofuro[3,2-d]pyrimidine (254 mg, 1.30 mmol) in THF (5 ml) were sequentially added NMO (50% wt in H₂O) (607 mg, 2.59 mmol) and osmium tetroxide (4% in water) (198 µl, 0.032 mmol) at RT under nitrogen. The solution was vigorously stirred at 65 °C for 2 h. The reaction was cooled to room temperature and sodium periodate (1.1 g, 5.2 mmol) in H₂O (4mL) was added [precipitate formed]. The mixture was stirred vigorously at RT under nitrogen for 1 hr. The mixture was diluted with EtOAc and washed with H₂O. The organic phase was concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient) to give the expected product benzofuro[3,2-d]pyrimidine-4-carbaldehyde (84 mg, 0.424 mmol, 32.7 % yield). LCMS (M+H) = 198.93.

20

Intermediate 46




- Benzofuro[3,2-d]pyrimidin-4-ylmethanol:*

- The above crude benzofuro[3,2-d]pyrimidine-4-carbaldehyde (84 mg, 0.424 mmol) was taken up in MeOH and treated with 16 mg of NaBH₄ at rt. and stirred for 1 hr. The mixture was diluted with ethyl acetate and washed with sat NaHCO₃, and sat NaCl.

The organic phase was dried over Na₂SO₄, filtered and concentrated, adsorbed onto celite and was purified on silica gel (Biotage, MeOH/DCM gradient, 0-100% over 10 CVs followed by 10 CVs of 10% MeOH/DCM) to give the expected product benzofuro[3,2-d]pyrimidin-4-ylmethanol (64 mg, 0.320 mmol, 24.69 % yield). LCMS (M+H) = 200.95.

5


Intermediate 47

*4-(Chloromethyl)benzofuro[3,2-d]pyrimidine:*

Ms-Cl (20 μ L, 0.25 mmol) was added to a stirring solution of Hunig's base (44 μ L, 0.25 mmol) and benzofuro[3,2-d]pyrimidin-4-ylmethanol (50 mg, 0.25 mmol) in DCM (2.5 ml) at 0 °C, then stir at rt for 2 hrs. LCMS showed two peaks. The reaction was concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs). One of the products that was isolated was consistent with 4-(chloromethyl)benzofuro[3,2-d]pyrimidine (15 mg, 0.069 mmol, 27.5 % yield). LCMS (M+H) = 218.90.

15


Intermediate 48

*N-(4-Bromobenzyl)-N-methylbenzofuro[3,2-d]pyrimidin-4-amine:*

4-chlorobenzofuro[3,2-d]pyrimidine (102 mg, 0.500 mmol) was added to a stirring solution of 1-(4-bromophenyl)-N-methylmethanamine (100 mg, 0.500 mmol) in ACN (2.5 ml) at rt. The reaction was stirred at 90 °C overnight. The reaction was concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs) to give the expected product N-(4-bromobenzyl)-N-methylbenzofuro[3,2-d]pyrimidin-4-amine (174 mg, 0.473 mmol, 95 % yield). LCMS (M+H) = 367.90 and 369.90.

25


Intermediate 49



N-Methyl-*N*-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-
d]pyrimidin-4-amine:

- 5 *N*-(4-Bromobenzyl)-*N*-methylbenzofuro[3,2-*d*]pyrimidin-4-amine (174 mg, 0.473 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (180 mg, 0.709 mmol), PdCl₂dppf (35 mg, 0.047 mmol) and potassium acetate (139 mg, 1.42 mmol) were combined in dioxane (9.5 ml) in a sealed bottle. The mixture was degassed and heated at 85 °C for 2 hrs. The mixture was concentrated and the residue was purified by silica gel
 10 column (EtOAc/hexanes gradient 0-100% over 10 CVs) to give *N*-methyl-*N*-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-*d*]pyrimidin-4-amine (quant yield). LCMS (M+H) = 416.05.


Intermediate 50



- 15 *N*-(4-Bromobenzyl)benzofuro[3,2-*d*]pyrimidin-4-amine:

- 4-Chlorobenzofuro[3,2-*d*]pyrimidine (110 mg, 0.537 mmol) was added to a stirring solution of (4-bromophenyl)methanamine (100 mg, 0.537 mmol) in ACN (2.7 ml) at rt. The reaction was stirred at 90 °C overnight. The reaction was concentrated,
 20 adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs) to afford *N*-(4-bromobenzyl)benzofuro[3,2-*d*]pyrimidin-4-amine (130 mg, 0.367 mmol, 68.3 % yield). LCMS (M+H) = 353.85 and 355.85.

Intermediate 51




- 25

N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-*d*]pyrimidin-4-amine:

- N-(4-Bromobenzyl)benzofuro[3,2-*d*]pyrimidin-4-amine (65 mg, 0.18 mmol),
 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (70 mg, 0.28 mmol),
 5 PdCl₂(dppf) (13 mg, 0.018 mmol) and potassium acetate (54 mg, 0.55 mmol) were
 combined in dioxane (3.7 ml) in a sealed MW vial. The mixture was degassed and heated
 at 95 °C for 2 hrs. The mixture was concentrated and the residue was purified by silica gel
 column (EtOAc/hexanes gradient 0-100% over 10 CVs) to give N-(4-(4,4,5,5-
 tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-*d*]pyrimidin-4-amine (quant
 10 yield). LCMS (M+H) = 402.05.


Intermediate 52



N-(4-Bromo-2-fluorobenzyl)benzofuro[3,2-*d*]pyrimidin-4-amine:

- A mixture of 4-chlorobenzofuro[3,2-*d*]pyrimidine (1.01 g, 4.94 mmol) and (4-
 15 bromo-2-fluorophenyl)methanamine (1.04 g, 5.10 mmol) in acetonitrile (50 mL) in a
 pressure bottle was treated with Hunig's base (1.6 mL, 9.16 mmol) and the resulting
 suspension stirred at RT for 10 min, then heated to 120 °C in an oil bath. After 5 hours
 the mixture went into solution and was then stirred for 16 hours overnight. A pale yellow
 solid had formed while at 120 °C, then the reaction mixture was cooled to RT. The
 20 mixture was filtered and washed with CH₃CN, and was dried under vacuum to give 1.43
 g (78%) of *N*-(4-bromo-2-fluorobenzyl)benzofuro[3,2-*d*]pyrimidin-4-amine as a pale
 yellow solid. LCMS (M+1) = 371.6/373.6.

Intermediate 53




- N*-(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-
 25 *d*]pyrimidin-4-amine:

In a pressure vessel equipped with a magnetic stirring bar was added *N*-(4-bromo-
 2-fluorobenzyl)benzofuro[3,2-*d*]pyrimidin-4-amine (1 g, 2.69 mmol), PdCl₂(dppf)-

CH₂Cl₂ adduct (0.219 g, 0.269 mmol), potassium acetate (0.791 g, 8.06 mmol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.023 g, 4.03 mmol). The solids were suspended in dioxane (15 mL). Argon was bubbled through the mixture for 5 minutes while sonicating. The vial was capped and heated to 80 °C within a preheated oil bath and allowed to continue for 16 hours. After 16 hours at 80 °C, LC/MS showed the desired product as major. The reaction mixture was filtered, then concentrated down. The residue was purified by flash column chromatography to give 1.35g (quant.) of *N*-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-*d*]pyrimidin-4-amine as an off-white sticky solid. LCMS (M+1, boronic acid fragment) = 337.7.

10

Intermediate 54




N-(4-Bromo-2,6-difluorobenzyl)benzofuro[3,2-*d*]pyrimidin-4-amine:

In a pressure vessel equipped with a magnetic stirring bar was added (4-bromo-2,6-difluorophenyl)methanamine•HCl (1 g, 3.87 mmol), and 4-chlorobenzofuro[3,2-*d*]pyrimidine (0.792 g, 3.87 mmol) in acetonitrile (20 mL). Hunig's base (2.70 mL, 15.47 mmol) was added and the mixture was heated to 80 °C in a preheated oil bath and allowed to stir for 48 hours overnight. Cool to RT and filter formed solids, wash with excess acetonitrile, filter and dry under vacuum to give 863 mg (57%) of *N*-(4-bromo-2,6-difluorobenzyl)benzofuro[3,2-*d*]pyrimidin-4-amine as a fluffy white solid. LCMS (M+1) = 389.6 and 391.6.

20

Intermediate 55



N-(2,6-Bisfluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-*d*]pyrimidin-4-amine:


25

In a pressure vessel equipped with a magnetic stirring bar was added recrystallized *N*-(4-bromo-2,6-difluorobenzyl)benzofuro[3,2-*d*]pyrimidin-4-amine (860 mg, 2.204 mmol), PdCl₂(dppf)•CH₂Cl₂ adduct (180 mg, 0.220 mmol), potassium acetate (649 mg,

6.61 mmol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (840 mg, 3.31 mmol). The solids were suspended in dioxane (15 mL). Argon was bubbled through the mixture for 5 minutes while sonicating. The flask was capped and heated to 80 °C within a preheated oil bath and allowed to continue for 16 hours. LC/MS showed the desired product (as the boronic acid) as major. The reaction mixture was filtered, then concentrated down. The residue was purified by flask column chromatography to give 1.28g (quant.) of *N*-(2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-d]pyrimidin-4-amine as an off-white solid. LCMS (M+1, boronic acid fragment) = 355.8.

10


Intermediate 56

*1-Bromo-4-(4-fluorophenethoxy)benzene:*

To a stirred solution of 4-bromophenol (81.7 g, 472 mmol), 2-(4-fluorophenyl)ethanol (79 g, 567 mmol) and Ph_3P (149 g, 567 mmol) in THF (100 mL) cooled in an ice-water bath was added drop wise DEAD (93 ml, 590 mmol) over 20 min. Note: The reaction is exothermic and efficient cooling is highly recommended before initiating large scale reaction. After 1 h, cold bath was removed and stirred overnight (17 h) at rt. Then, the reaction mixture was concentrated, the resulting residue triturated with hexanes, filtered and the filter cake washed with 10% ether/hexanes (2-lit). The filtrate was concentrated and purified by flash chromatography (silica gel column 3" x 11") using 4-lit hexanes and 2-lit 2% EtOAc/Hex to afford 1-bromo-4-(4-fluorophenethoxy)benzene (142 g, 469 mmol, 99 % yield) as colorless liquid (contaminated with ~2.5% Ph_3P by ^1H NMR). ^1H NMR (500MHz, CDCl_3) δ 7.41 - 7.36 (m, 2H), 7.28 - 7.22 (m, 2H), 7.05 - 6.99 (m, 2H), 6.82 - 6.76 (m, 2H), 4.14 (t, $J=6.9$ Hz, 2H), 3.08 (t, $J=6.9$ Hz, 2H).

25


Intermediate 57



(4-(4-Fluorophenethoxy)phenyl)boronic acid:

To a stirred solution of 1-bromo-4-(4-fluorophenethoxy)benzene (142 g, 469 mmol) in THF (1000 mL) was added 2M n-BuLi/cyclohexane (293 ml, 586 mmol) over 15 min at -78 °C. After 1.5 h, triisopropyl borate (131 ml, 563 mmol) was added to the light pink reaction mixture over 5 min and stirred for 2 h at -78 °C. Then, the reaction was quenched by careful addition of 3M HCl (375 mL), cold bath was replaced with water bath, stirred for 1 h, diluted with ether (500 mL), aq. layer separated and organic layer washed with water (2 x 200 mL). The combined aq. layers extracted with ether (200 mL) and combined ether layers washed with brine (100 mL), dried (MgSO₄), filtered and concentrated to 200 mL. To this was added 250 mL hexanes and concentrated to about 300 mL and allowed to stand at rt. The precipitated solid was triturated with hexanes and filtered to give white solid which was used in next step without purification. ¹H NMR (500MHz, CDCl₃) δ 8.18 - 8.15 (m, 2H), 7.32 - 7.28 (m, 2H), 7.07 - 7.00 (m, 4H), 4.26 (t, *J*=6.9 Hz, 2H), 3.14 (t, *J*=6.9 Hz, 2H).


Intermediate 58



2-(4-(4-Fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione:


A slurry of (4-(4-fluorophenethoxy)phenyl)boronic acid (122 g, 469 mmol) and 2,2'-(methylazanediyl)diacetic acid (76 g, 516 mmol) in anhydrous toluene (500 mL) and DMSO (200 mL) was refluxed for 4 h. Then, cooled, diluted with EtOAc (500 mL), washed with water (5 x 200 mL), brine (2 x 100 mL), dried (MgSO₄), filtered and concentrated to give light orange foam which was purified by flash chromatography using 5-40% acetone/CH₂Cl₂ (5% increment per 2-lit) to afford 2-(4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (131.38 g, 354 mmol, 75 % yield) as white solid. ¹H NMR (500MHz, CDCl₃) δ 7.43 (d, *J*=8.4 Hz, 2H), 7.28 - 7.24 (m, 2H), 7.04 - 6.99 (m, 2H), 6.92 (d, *J*=8.5 Hz, 2H), 4.17 (t, *J*=6.9 Hz, 2H), 4.00 (d, *J*=16.6 Hz, 2H), 3.76 (d, *J*=16.6 Hz, 2H), 3.08 (t, *J*=6.8 Hz, 2H), 2.54 (s, 3H). LCMS (M+H) = 372.3.

Intermediate 59

*4-Bromo-2-fluoro-1-(4-fluorophenethoxy)benzene:*


To a 40 mL vial equipped with a stir bar was added 4-bromo-2-fluorophenol (954
 5 mg, 5.00 mmol), 2-(4-fluorophenyl)ethanol (700 mg, 5.00 mmol), triphenylphosphine
 (2.62 g, 10 mmol) and THF (25 mL). To the stirred solution was added diisopropyl
 azodicarboxylate ("DIAD", 1.9 mL, 10 mmol) upon which the resulting exotherm heated
 the solution to a mild reflux. The solution cooled to r.t. within 5 minutes, then was stirred
 at r.t. for 18 h. The solution was concentrated in vacuo and the resulting residue was
 10 diluted with a small amount of acetone, then was concentrated onto Celite in vacuo. The
 resulting powder was subjected to SiO₂ purification (80 g SiO₂ column, hexanes:EtOAc
 100:0→90:10) to afford 4-bromo-2-fluoro-1-(4-fluorophenethoxy)benzene as a colorless
 oil, 1.31 g (84%). ¹H NMR (500 MHz, CDCl₃) δ 7.26 - 7.20 (m, 3H), 7.17 - 7.12 (m, 1H),
 7.00 (t, *J*=8.7 Hz, 2H), 6.79 (t, *J*=8.7 Hz, 1H), 4.17 (t, *J*=6.9 Hz, 2H), 3.08 (t, *J*=6.9 Hz,
 15 2H).

Intermediate 60

*(3-Fluoro-4-(4-fluorophenethoxy)phenyl)boronic acid:*

To a dry 25 mL Schlenk flask equipped with a stir bar was added a degassed (5
 20 min N₂ bubbling) solution of 4-bromo-2-fluoro-1-(4-fluorophenethoxy)benzene (760 mg,
 2.43 mmol) in THF (10 mL). The flask was cooled in a -78 °C bath. To the solution was
 added n-butyllithium (1.00 mL, 2.50 mmol). The solution was stirred for 5 minutes. A
 pale yellow color was noted. To the solution was added triisopropyl borate (0.845 mL,
 25 3.64 mmol). The solution was stirred for 15 minutes. The cold bath was removed and the
 solution was allowed to warm to r.t. over 1 h. The turbid white solution was transferred to
 a 125 mL separatory funnel charged with aq HCl (1M, 10 mL). The mixture was
 extracted with Et₂O (30 mL). The organic phase was washed with brine (10 mL); dried
 over MgSO₄; filtered; then concentrated in vacuo to afford (3-fluoro-4-(4-
 30 fluorophenethoxy)phenyl)boronic acid as a golden oil.


Intermediate 61



2-(3-Fluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione:

- 5 To a 100 mL r.b. flask charged with the entirety of (3-fluoro-4-(4-fluorophenethoxy)phenyl)boronic acid prepared above was added N-methyliminodiacetic acid (500 mg, 3.40 mmol), DMSO (2 mL) and benzene (10 mL). The flask was fitted with a Dean-Stark trap pre-filled with benzene. The Dean-Stark trap was fitted with an air-cooled reflux condensor. The reaction flask was placed in a 125 °C oil bath with stirring.
- 10 An active azeotrope was observed within 10 minutes. Heating and stirring was maintained for 30 min, then the mixture was cooled to r.t. The volatiles were removed in vacuo, then the reaction mixture was transferred to a 125 mL separatory funnel and was diluted with water (50 mL). The mixture was extracted with EtOAc (2 x 50 mL). The combined organics were washed with brine (15 mL); dried over MgSO₄; filtered; then
- 15 concentrated in vacuo. The resulting residue was dissolved in a min. of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (24 g SiO₂ column, hexanes:EtOAc 50:50→0:100, then 100% EtOAc) to 2-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione as a colorless solid foam, 777 mg (82% over two steps). ¹H NMR (500 MHz, acetone-d₆) δ
- 20 7.40 (dd, *J*=8.7, 5.5 Hz, 2H), 7.28 - 7.19 (m, 2H), 7.13 (t, *J*=8.3 Hz, 1H), 7.10 - 7.03 (m, 2H), 4.33 (d, *J*=17.0 Hz, 2H), 4.29 (t, *J*=6.8 Hz, 2H), 4.14 (d, *J*=17.0 Hz, 2H), 3.12 (t, *J*=6.7 Hz, 2H), 2.76 (s, 3H).

Intermediate 62




25

2-(3-Fluoro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane:

To a dry 500 mL pressure bottle under nitrogen was added 4-bromo-2-fluoro-1-(4-fluorophenethoxy)benzene (6.3 g, 20.12 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-

bi(1,3,2-dioxaborolane) (7.8 g, 30.7 mmol), potassium acetate (8 g, 82 mmol) and dioxane (175 mL). The reaction was flushed wll with argon, treated with [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (800 mg, 1.093 mmol), capped and heated at 100 °C oil bath for 18 h. The crude reaction was diluted with ethyl acetate (450 mL), filtered through a pad of celite, extracted with water (1 x 150 mL), brine, dried over Na₂SO₄ and concentrated. The crude material was purified via silica gel chromatography (330g SiO₂ column, hexane:dichloromethane 100:0 -> 0:100) to afford 2-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 3.95 g (55%). ¹H NMR (500 MHz, CDCl₃) δ 7.54 - 7.48 (m, 2H), 7.30 - 7.25 (m, 3H), 7.05 - 6.99 (m, 2H), 6.93 (t, *J*=8.0 Hz, 1H), 4.24 (t, *J*=6.9 Hz, 2H), 3.13 (t, *J*=6.9 Hz, 2H), 1.35 (s, 12H).


Intermediate 63



1-Bromo-2-fluoro-4-(4-fluorophenethoxy)benzene:

To a 40 mL vial equipped with a stir bar was added 4-bromo-3-fluorophenol (954 mg, 5.00 mmol), 2-(4-fluorophenyl)ethanol (700 mg, 5.00 mmol), triphenylphosphine (1.57 g, 6.00 mmol) and THF (25 mL). To the stirred solution was added DIAD (1.17 mL, 6.00 mmol) upon which the resulting exotherm heated the solution to a mild reflux. The solution cooled to r.t. within 5 minutes. The solution was stirred at r.t. for 18h. The solution was concentrated in vacuo and the residue was diluted with a small amount of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (80 g SiO₂ column, hexanes:EtOAc 100:0→90:10) to afford 1-bromo-2-fluoro-4-(4-fluorophenethoxy)benzene as a yellow liquid, 1.28 g (82%). ¹H NMR (500 MHz, CDCl₃) δ 7.40 (dd, *J*=8.8, 8.0 Hz, 1H), 7.26 - 7.19 (m, 2H), 7.01 (t, *J*=8.7 Hz, 2H), 6.68 (dd, *J*=10.4, 2.8 Hz, 1H), 6.60 (ddd, *J*=8.8, 2.8, 1.0 Hz, 1H), 4.12 (t, *J*=6.8 Hz, 2H), 3.07 (t, *J*=6.8 Hz, 2H).

Intermediate 64




(2-Fluoro-4-(4-fluorophenethoxy)phenyl)boronic acid:

To a dry 25 mL Schlenk flask equipped with a stir bar was added a degassed (5 min N₂ bubbling) solution of 1-bromo-2-fluoro-4-(4-fluorophenethoxy)benzene (0.709 g, 2.27 mmol) in THF (10 mL). The flask was cooled in a -78 °C bath. To the solution was added n-butyllithium (1.00 mL, 2.50 mmol). The solution was stirred for 5 minutes. No color change was observed. To the solution was added triisopropyl borate (0.789 mL, 3.40 mmol). The solution was stirred for 15 minutes. The cold bath was removed and the solution was allowed to slowly warm to r.t. over 30 min., then the solution was stirred at r.t. for 18h. The turbid white solution was transferred to a 125 mL separatory funnel charged with aq HCl (1M, 10 mL). The mixture was extracted with Et₂O (30 mL). The organic phase was washed with brine (10 mL); dried over MgSO₄; filtered; then concentrated in vacuo to afford (2-fluoro-4-(4-fluorophenethoxy)phenyl)boronic acid as a white solid.

15

Intermediate 65




2-(2-Fluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione:

To a 100 mL r.b. flask charged with the entirety of (2-fluoro-4-(4-fluorophenethoxy)phenyl)boronic acid prepared above was added N-methyliminodiacetic acid (500 mg, 3.40 mmol), DMSO (2 mL) and benzene (10 mL). The flask was fitted with a Dean-Stark trap pre-filled with benzene. The Dean-Stark trap was fitted with an air-cooled reflux condenser. The reaction flask was placed in a 125 °C oil bath with stirring. An active azeotrope was observed within 10 minutes. Heating and stirring was maintained for 30 min. The reaction mixture was cooled to r.t., then was transferred to a 125 mL separatory funnel and was diluted with water (50 mL). The mixture was extracted with EtOAc (2 x 50 mL). The combined organics were washed with brine (15 mL); dried over MgSO₄; filtered; then concentrated in vacuo. The resulting residue was dissolved in a min. of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (80 g SiO₂ column, hexanes:EtOAc 100:0→90:10) to afford 2-(2-fluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione as a colorless solid foam, 665 mg (75% over two steps). ¹H NMR (500 MHz,

acetone-d₆) δ 7.50 - 7.44 (m, 1H), 7.42 - 7.36 (m, 2H), 7.10 - 7.03 (m, 2H), 6.79 (dd, $J=8.4, 2.2$ Hz, 1H), 6.67 (dd, $J=12.2, 2.3$ Hz, 1H), 4.36 (dd, $J=17.0, 1.1$ Hz, 2H), 4.24 (t, $J=6.7$ Hz, 2H), 4.12 (d, $J=17.0$ Hz, 2H), 3.09 (t, $J=6.7$ Hz, 2H), 2.78 (s, 3H).


5

Intermediate 66



To a 40 mL vial equipped with a stir bar was added 4-bromo-2,3-difluorophenol (1.04 g, 5.00 mmol), 2-(4-fluorophenyl)ethanol (700 mg, 5.00 mmol), triphenylphosphine (1.57 g, 6.00 mmol) and THF (25 mL). To the stirred solution was added DIAD (1.17
10 mL, 6.00 mmol) upon which the resulting exotherm heated the solution to a mild reflux. The solution cooled to r.t. within 5 minutes. The solution was stirred at r.t. for 18h. The solution was concentrated in vacuo and the resulting oil was diluted with a min. of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (80 g SiO₂ column, hexanes:EtOAc 100:0→90:10) to afford 1-bromo-
15 2,3-difluoro-4-(4-fluorophenethoxy)benzene as a colorless oil, 1.611 g (97%). ¹H NMR (500MHz, CDCl₃) δ 7.26 - 7.21 (m, 2H), 7.18 (ddd, $J=9.2, 7.0, 2.5$ Hz, 1H), 7.04 - 6.97 (m, 2H), 6.62 (ddd, $J=9.3, 7.4, 2.0$ Hz, 1H), 4.19 (t, $J=6.9$ Hz, 2H), 3.09 (t, $J=6.9$ Hz, 2H).

Intermediate 67




20

To a dry 25 mL Schlenk flask equipped with a stir bar was added a degassed (5 min N₂ bubbling) solution of 1-bromo-2,3-difluoro-4-(4-fluorophenethoxy)benzene (750 mg, 2.27 mmol) in THF (10 mL). The flask was cooled in a -78 °C bath. To the solution was added n-butyllithium (1.00 mL, 2.50 mmol). The solution was stirred for 5 minutes.
25 No color change was observed. To the solution was added triisopropyl borate (0.789 mL, 3.40 mmol). The solution was stirred for 15 minutes. The cold bath was removed and the solution was allowed to slowly warm to r.t. over 30 min, then the mixture was stirred at r.t. for 18h. The turbid white solution was transferred to a 125 mL separatory funnel charged with aq. HCl (1M, 10 mL). The mixture was extracted with Et₂O (30 mL). The

organic phase was washed with brine (10 mL); dried over MgSO_4 ; filtered; then concentrated in vacuo to afford (2,3-difluoro-4-(4-fluorophenethoxy)phenyl)boronic acid as a white solid.

5


Intermediate 68



To a 100 mL r.b. flask charged with the entirety of (2,3-difluoro-4-(4-fluorophenethoxy)phenyl)boronic acid prepared above was added N-methyliminodiacetic acid (500 mg, 3.40 mmol), DMSO (2 mL) and Benzene (10 mL). The flask was fitted with a Dean-Stark trap pre-filled with benzene. The Dean-Stark trap was fitted with an air-cooled reflux condensor. The reaction flask was placed in a 125 °C oil bath with stirring. An active azeotrope was observed within 10 minutes. Heating and stirring was maintained for 30 min. The reaction mixture was cooled to r.t., then was transferred to a 125 mL separatory funnel and was diluted with water (50 mL). The mixture was extracted with EtOAc (2 x 50 mL). The combined organics were washed with brine (15 mL); dried over MgSO_4 ; filtered; then concentrated in vacuo. The resulting residue was dissolved in a min. of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO_2 purification (24g SiO_2 column, hexanes:EtOAc 50:50 $\rightarrow$ 0:100, then 100% EtOAc) to afford 2-(2,3-difluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione as a white crystalline solid, 732 mg (79% over two steps). ^1H NMR (500 MHz, acetone- d_6) δ 2.88 (s, 3 H) 3.13 (t, $J=6.70$ Hz, 2 H) 4.16 (d, $J=17.02$ Hz, 2 H) 4.33 (t, $J=6.70$ Hz, 2 H) 4.37 - 4.43 (m, 2 H) 6.99 (ddd, $J=8.47, 7.05, 1.50$ Hz, 1 H) 7.04 - 7.11 (m, 2 H) 7.24 (ddd, $J=8.63, 6.82, 2.21$ Hz, 1 H) 7.37 - 7.43 (m, 1 H).

25

Intermediate 69




1-Bromo-2,5-difluoro-4-(4-fluorophenethoxy)benzene:

To a 40 mL vial equipped with a stir bar was added 4-bromo-2,5-difluorophenol (1.04 g, 5.00 mmol), 2-(4-fluorophenyl)ethanol (700 mg, 5.00 mmol), triphenylphosphine

(1.57 g, 6.00 mmol) and THF (25 mL). To the stirred solution was added DIAD (1.17 mL, 6.00 mmol). The solution warmed to a mild reflux, then cooled within 5 minutes. The solution was stirred at r.t. for 18h. The reaction solution was concentrated in vacuo and the resulting oil was diluted with a min. of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (80g column, hexanes:EtOAc 100:0→90:10) to afford 1-bromo-2,5-difluoro-4-(4-fluorophenethoxy)benzene as a colorless oil (1.562 g, 94%). ¹H NMR (500MHz, CDCl₃) δ 7.28 - 7.21 (m, 3H), 7.04 - 6.96 (m, 2H), 6.73 (dd, *J*=9.5, 7.2 Hz, 1H), 4.16 (t, *J*=6.9 Hz, 2H), 3.09 (t, *J*=6.9 Hz, 2H).


Intermediate 70



(2,5-Difluoro-4-(4-fluorophenethoxy)phenyl)boronic acid:

To a dry 25 mL Schlenk flask equipped with a stir bar was added a degassed (5 min. N₂ bubbling) solution of 1-bromo-2,5-difluoro-4-(4-fluorophenethoxy)benzene (0.750 g, 2.27 mmol) in THF (10 mL). The flask was cooled in a -78 °C bath. To the solution was added n-butyllithium (1.00 mL, 2.50 mmol). The solution was stirred for 5 minutes. To the solution was added triisopropyl borate (0.789 mL, 3.40 mmol). The solution was stirred for 15 minutes. The cold bath was removed and the solution was allowed to slowly warm to r.t. After 18h, the turbid, pale yellow reaction solution was transferred to a 125 mL separatory funnel charged with aq. HCl (1M, 10 mL). The mixture was extracted with Et₂O (30 mL). The organic phase was washed with brine (10 mL), then dried over MgSO₄, then filtered, then concentrated in vacuo to afford crude (2,5-difluoro-4-(4-fluorophenethoxy)phenyl)boronic acid as a pale yellow oil residue.


Intermediate 71



2-(2,5-Difluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxaborocane-4,8-dione:

To a 100 mL r.b. flask charged with (2,5-difluoro-4-(4-fluorophenethoxy)phenyl)boronic acid prepared above was added N-methyliminodiacetic acid (500 mg, 3.40 mmol), DMSO (2 mL) and Benzene (10 mL). The flask was fitted with a Dean-Stark trap pre-filled with benzene. The Dean-Stark trap was fitted with an air-cooled reflux condensor. The reaction flask was placed in a 125 °C oil bath with stirring. An active azeotrope was observed within 10 minutes. Heating and stirring was maintained for 30 min. The reaction mixture was cooled to r.t., then was transferred to a 125 mL separatory funnel and was diluted with water (50 mL). The mixture was extracted with EtOAc (2 x 50 mL). The combined organics were washed with brine (15 mL); dried over MgSO₄; filtered; then concentrated in vacuo. The resulting residue was dissolved in a min. of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (24g SiO₂ column, hexanes:EtOAc 50:50 → 0:100, then 100% EtOAc) to afford 2-(2,5-difluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxaborocane-4,8-dione as a white solid (681 mg, 74 % yield over two steps). ¹H NMR (500 MHz, acetone-d₆) δ 7.43 - 7.37 (m, 2H), 7.22 (dd, *J*=11.7, 6.0 Hz, 1H), 7.11 - 7.03 (m, 2H), 6.93 - 6.92 (m, 1H), 6.93 (dd, *J*=11.0, 6.6 Hz, 1H), 4.39 (dd, *J*=17.0, 1.1 Hz, 2H), 4.31 (t, *J*=6.7 Hz, 2H), 4.14 (d, *J*=17.3 Hz, 2H), 3.13 (t, *J*=6.7 Hz, 2H), 2.89 (s, 3H), 2.80 (d, *J*=17.0 Hz, 2H).

Intermediate 72




4-Bromo-2-fluoro-1-(2-fluorophenethoxy)benzene:

To a 100 mL r.b. flask equipped with a stir bar was added 2-(2-fluorophenyl)ethanol (2.00g, 14.3 mmol), 4-bromo-2-fluorophenol (3.27g, 17.1 mmol), triphenylphosphine (5.24g, 20.0 mmol), and THF (28 mL). To the stirred solution was added dropwise DIAD (3.88 mL, 20.0 mmol). After stirring 1h, the reaction solution was diluted with Et₂O and then washed with 10% K₂CO₃ in water. The organic phase was washed brine, then dried over MgSO₄, then filtered, then concentrated in vacuo. The resulting residue was subjected to SiO₂ purification (hexane:EtOAc 100:0 → 50:50) to afford 4-bromo-2-fluoro-1-(2-fluorophenethoxy)benzene as a colorless oil (4.16 g, 93%).

^1H NMR (500 MHz, CDCl_3) δ 7.33 (td, $J = 7.5, 1.8$ Hz, 1H), 7.29 - 7.23 (m, 2H), 7.18 (dt, $J = 8.4, 2.1$ Hz, 1H), 7.12 (td, $J = 7.5, 1.1$ Hz, 1H), 7.07 (ddd, $J = 9.9, 8.4, 1.1$ Hz, 1H), 6.85 (t, $J = 8.7$ Hz, 1H), 4.24 (t, $J = 7.1$ Hz, 2H), 3.19 (t, $J = 7.1$ Hz, 2H).

5

Intermediate 73




(3-Fluoro-4-(2-fluorophenethoxy)phenyl)boronic acid:

To a dry 50 mL Schlenk flask equipped with a stir bar was added a degassed (5 min N_2 bubbling) solution of 4-bromo-2-fluoro-1-(2-fluorophenethoxy)benzene (1.57 g, 5.00 mmol) in THF (20 mL). The flask was cooled in a -78°C bath. To the solution was added n-butyllithium (2.5M in hexane, 2.20 mL, 5.50 mmol). The solution was stirred for 5 minutes. To the solution was added triisopropyl borate (1.74 mL, 7.50 mmol). The solution was stirred for 15 minutes. The cold bath was removed and the solution was allowed to slowly warm to r.t. with stirring for 7d (reaction time not optimized). The reaction mixture was transferred to a 125 mL separatory funnel charged with aq HCl (1M, 20 mL). The mixture was extracted with Et_2O (60 mL). The organic phase was washed with brine (20 mL), then dried over MgSO_4 , then filtered, then concentrated in vacuo to afford (3-fluoro-4-(2-fluorophenethoxy)phenyl)boronic acid as an off-white solid (1.3463 g, 97%). ^1H NMR (500 MHz, methanol- d_4) δ 7.49 (br d, $J = 8.0$ Hz, 1H), 7.43 (br d, $J = 12.5$ Hz, 1H), 7.38 (td, $J = 7.6, 1.6$ Hz, 1H), 7.34 (br d, $J = 12.3$ Hz, 1H), 7.27 (tdd, $J = 7.8, 5.4, 1.9$ Hz, 1H), 7.13 (td, $J = 7.5, 1.2$ Hz, 1H), 7.10 - 7.05 (m, 1H), 4.28 (br t, $J = 6.6$ Hz, 2H), 3.16 (t, $J = 6.8$ Hz, 2H)

25

Intermediate 74




5-Bromo-1,3-difluoro-2-(4-fluorophenethoxy)benzene:

To a 40 mL vial equipped with a stir bar was added 4-bromo-2,6-difluorophenol (1.04 g, 5.00 mmol), 2-(4-fluorophenyl)ethanol (700 mg, 5.00 mmol), triphenylphosphine (1.57 g, 6.00 mmol) and THF (25 mL). To the stirred solution was added DIAD (1.17 mL, 6.00 mmol). The solution warmed to a mild reflux, then cooled within 5 minutes.

The solution was stirred at r.t. for 18h. The reaction solution was concentrated in vacuo. The resulting residue was dissolved in a min. of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (80g column, hexanes:EtOAc 100:0→80:20) to afford 5-bromo-1,3-difluoro-2-(4-

- 5 fluorophenethoxy)benzene (1.552 g, 94%). ¹H NMR (500MHz, CDCl₃) δ 7.26 - 7.21 (m, 2H), 7.11 - 7.04 (m, 2H), 7.03 - 6.97 (m, 2H), 4.30 (t, *J*=6.9 Hz, 2H), 3.06 (t, *J*=6.9 Hz, 2H).

Intermediate 75



10


2-(3,5-Difluoro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane:

To a dry 10 mL Schlenk flask equipped with a stir bar was added potassium acetate (445 mg, 4.53 mmol), Pd(dppf)Cl₂·DCM complex (123 mg, 0.151 mmol), and bis(pinacolato)diboron (575 mg, 2.27 mmol). The flask was sealed with a rubber septum, then placed under N₂ atmosphere. To the flask was added a degassed (N₂ bubbling for 5 min) solution of 5-bromo-1,3-difluoro-2-(4-fluorophenethoxy)benzene (500 mg, 1.51 mmol) in dioxane (10 mL). The flask was placed in a 80 °C oil bath with stirring for 1d. The reaction mixture was cooled to r.t., then was transferred to a 125 mL separatory funnel. The mixture was diluted with aq. NaOH (1M, 25 mL), then was extracted with Et₂O (50 mL). The organic phase was washed with brine (25 mL), then dried over MgSO₄, then filtered, then concentrated in vacuo. The resulting residue was dissolved in a min. of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ chromatography (40g column, hexanes:EtOAc 100:0→90:10) to afford a mixture of 2-(3,5-difluoro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and (3,5-difluoro-4-(4-fluorophenethoxy)phenyl)boronic acid as a solid (115 mg, 20%). ¹H NMR (500 MHz, CDCl₃, spectrum for pinacol ester reported) δ 7.32 (d, *J*=9.0 Hz, 2H), 7.28 - 7.24 (m, 2H), 7.08 - 6.98 (m, 2H), 4.38 (t, *J*=7.0 Hz, 2H), 3.08 (t, *J*=5.0 Hz, 2H), 1.35 (s, 12H).

20

25


Intermediate 76



2-Bromo-5-(4-fluorophenethoxy)pyridine:

To a 40 mL vial equipped with a stir bar was added 1-(2-bromoethyl)-4-fluorobenzene (2.334 g, 11.49 mmol) and 6-bromopyridin-3-ol (1.00 g, 5.75 mmol), then DMSO (30 ml) and potassium carbonate (1.589 g, 11.49 mmol). The vial was vented to a N₂ stream (bubbler), then placed in a 50 °C oil bath with stirring for 18h. (t=0). To the reaction solution was added 1-(2-bromoethyl)-4-fluorobenzene (2.334 g, 11.49 mmol). The mixture was stirred at 50 °C for 3h. To the reaction mixture was added potassium carbonate (1.589 g, 11.49 mmol). The reaction mixture was stirred for 18h. The reaction mixture was cooled to r.t., then was transferred to a 500 mL separatory funnel and was diluted with water (150 mL). The mixture was extracted with Et₂O (100 mL). The organic phase was washed with brine (50 mL), then dried over MgSO₄, filtered, then concentrated in vacuo. The resulting residue was dissolved in a min. of acetone and then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (80g SiO₂, hexanes:EtOAc 100:0→80:20) to afford a colorless oil that crystallized upon standing to afford 2-bromo-5-(4-fluorophenethoxy)pyridine (1.5337 g, 90 %) as a colorless, crystalline solid. ¹H NMR (500MHz, CDCl₃) δ 8.04 (d, *J*=3.0 Hz, 1H), 7.36 (dd, *J*=8.7, 0.5 Hz, 1H), 7.26 - 7.21 (m, 2H), 7.08 (dd, *J*=8.8, 3.2 Hz, 1H), 7.05 - 6.99 (m, 2H), 4.18 (t, *J*=6.8 Hz, 2H), 3.08 (t, *J*=6.8 Hz, 2H).

Intermediate 77




2-(5-(4-Fluorophenethoxy)pyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione:

To a dry 50 mL Schlenk flask equipped with a large stir bar was added 2-bromo-5-(4-fluorophenethoxy)pyridine (6.103 g, 20.61 mmol). The flask was placed under nitrogen atmosphere. To the flask was added THF (36 ml) and triisopropyl borate (4.83 ml, 20.8 mmol). The flask was sealed with a septum, then the solution was sparged with N₂ for 5 minutes. The flask was cooled in a -78 °C bath. To the solution was added dropwise n-butyllithium in hexanes (8.33 ml, 20.8 mmol) at a rate necessary to avoid

build-up of any localized dark discoloration. The rate was approximately 0.25-0.50 mL/min. At the completion of the addition the solution slowly began to turn a deep amber color. The mixture was stirred for 1h up which the solution was observed to be a deep amber color. The bath was removed and the solution was allowed to warm to r.t. with stirring for 3h. Separately, a distillation apparatus was assembled as follows: a 3-neck 250 mL flask equipped with a large stir bar was charged with methyliminodiacetic acid (6.06 g, 41.2 mmol) and DMSO (36.2 ml); the center neck was fitted with a pressure-equalizing addition funnel vented to positive N₂ pressure; another neck was fitted with a rubber septum through which a thermocouple was inserted to monitor internal temperature; and the final neck was fitted with a short-path distillation apparatus collecting into a 250 mL r.b. flask and vented to a bubbler. The reaction solution containing the boronate was transferred to the addition funnel. The 3-neck flask was heated with an oil bath (160 °C). Once the internal temperature had reached 115-120 °C, the boronate solution was added dropwise at a rate necessary to maintain an internal temp of 115-120 °C. The addition took approximately 20 min. The receiver flask containing the THF was exchanged for an empty 200 mL r.b. flask. The bubbler line connected to the vacuum arm of the distillation apparatus was exchanged for a tube running vacuum. The N₂ source was closed. The system was placed under vacuum, slowly ramping to 30 Torr upon which the DMSO distilled. The distillation was maintained at 30 Torr until only trace DMSO remained. The resulting residue, a solid, was dissolved in MeCN upon which only a white powder did not dissolve. The mixture was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (120g SiO₂ column, EtOAc:MeCN 100:0→0:100) on the Biotage to afford 2-(5-(4-fluorophenoxy)pyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (2.067 g, 27.0 %) as a colorless solid foam. ¹H NMR (500 MHz, acetone-d₆) δ 8.40 - 8.36 (m, 1H), 7.57 - 7.52 (m, 1H), 7.44 - 7.35 (m, 2H), 7.29 (dd, J=8.4, 2.8 Hz, 1H), 7.12 - 7.02 (m, 2H), 4.31 (d, J=16.6 Hz, 2H), 4.30 (t, J=6.7 Hz, 2H), 4.14 (d, J=16.6 Hz, 2H), 3.11 (t, J=6.7 Hz, 2H), 2.75 (s, 3H).

Intermediate 78




30

5-Bromo-2-(4-fluorophenethoxy)-1,3-dimethylbenzene.


To a solution of 4-bromo-2,6-dimethylphenol (1.0 g, 4.99 mmol), 2-(4-fluorophenyl)ethanol (0.70 g, 4.99 mmol), and triphenylphosphine (2.6 g, 9.99 mmol) in THF (25 mL) was added DIAD (1.94 mL, 9.99 mmol). The solution warmed to a mild reflux, then cooled to r.t. within 5 min. After stirring 18 h, the reaction solution was concentrated *in vacuo*. The resulting residue was purified by silica gel flash column chromatography (0-10% EtOAc/hexane) to provide the product as a colorless oil (1.50 g, 93%). ¹H NMR (500 MHz, CDCl₃) δ 7.28 - 7.22 (m, 2H), 7.12 (s, 2H), 7.04 - 6.98 (m, 2H), 3.91 (t, *J*=6.7 Hz, 2H), 3.06 (t, *J*= 6.7 Hz, 2H), 2.13 (s, 6H).

Intermediate 79

*2-(4-(4-Fluorophenethoxy)-3,5-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.*

A solution of potassium acetate (455 mg, 4.64 mmol), Pd(dppf)Cl₂ DCM complex (126 mg, 0.155 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (589 mg, 2.321 mmol), 5-bromo-2-(4-fluorophenethoxy)-1,3-dimethylbenzene (500 mg, 1.547 mmol) in dioxane (10 mL) was heated at 80 °C for 18 h. The reaction mixture was diluted with 1 M NaOH and extracted with ether. The organic phase was washed with brine (25 mL), dried (MgSO₄), and concentrated *in vacuo*. The resulting residue was purified by silica gel column chromatography (0-10% EtOAc/hexane) to give a white solid (0.44 g, 77%). ¹H NMR (500 MHz, CDCl₃) δ 7.48 (s, 2H), 7.31 - 7.26 (m, 2H), 7.02 (t, *J*= 8.7 Hz, 2H), 3.97 (t, *J*= 6.9 Hz, 2H), 3.09 (t, *J*= 6.8 Hz, 2H), 2.19 (s, 6H), 1.35 (s, 12H).


Intermediate 80

*1-(2-(4-Bromophenoxy)ethyl)-2-fluorobenzene:*

To a solution of 2-(2-fluorophenyl)ethanol (2.85 g, 20.3 mmol, 1 equiv), 4-bromophenol (4.22 g, 24.4 mmol, 1.2 equiv), and triphenylphosphine (7.5 g, 28.5 mmol, 1.4 equiv) in THF (41 mL) was added DIAD (5.5 mL, 28.5 mmol, 1.4 equiv) slowly with

a syringe. After stirring 1 h, the reaction was diluted with ether and washed with 10% aqueous potassium carbonate and brine. The ether layer was dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography to provide the product (4.80 g, 80%) as a colorless oil. ¹H NMR (500 MHz, CDCl₃) δ 7.40 - 7.36 (m, 2H), 7.33 - 7.30 (m, 1H), 7.27 - 7.23 (m, 1H), 7.11 (br td, *J* = 7.5, 1.1 Hz, 1H), 7.07 (br ddd, *J* = 9.9, 8.4, 1.0 Hz, 1H), 6.82 - 6.77 (m, 2H), 4.17 (t, *J* = 7.0 Hz, 2H), 3.15 (t, *J* = 6.9 Hz, 2H).


Intermediate 81



2-(4-(2-Fluorophenoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane:

A solution of 1-(2-(4-bromophenoxy)ethyl)-3-fluorobenzene (0.82 g, 2.78 mmol, 1 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.06 g, 4.17 mmol, 1.5 equiv), Pd(dppf)Cl₂ (0.20 g, 0.278 mmol, 0.1 equiv), and KOAc (0.82 g, 8.33 mmol, 3 equiv) in dioxane (14 mL) was heated at 80 °C for 18 h. After cooling to ambient temperature, the reaction was diluted with EtOAc and washed with brine. The organic layer was dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography (0-60% EtOAc in hexane) to provide the product (0.63 g, 66%) as a waxy yellow solid. ¹H NMR (500 MHz, CDCl₃) δ 7.76 (d, *J* = 8.5 Hz, 2H), 7.33 - 7.29 (m, 1H), 7.08 (d, *J* = 7.6 Hz, 1H), 7.02 (dd, *J* = 9.9, 2.0 Hz, 1H), 6.95 (td, *J* = 8.6, 2.5 Hz, 1H), 6.91 (d, *J* = 8.7 Hz, 2H), 4.22 (t, *J* = 6.9 Hz, 2H), 3.12 (t, *J* = 6.9 Hz, 2H), 1.36 (s, 12H). LCMS (M+1): 343.30.

Intermediate 82




4-Bromo-2-fluoro-1-(3-fluorophenoxy)benzene:

To a solution of 2-(3-fluorophenyl)ethanol (2.5 g, 17.8 mmol, 1 equiv), 4-bromo-2-fluorophenol (4.09 g, 21.4 mmol, 1.2 equiv), and triphenylphosphine (6.55 g, 25.0 mmol, 1.4 equiv) in THF (36 mL) was added DIAD (4.9 mL, 25.0 mmol, 1.4 equiv) slowly with a syringe. After stirring 1 h, the reaction was diluted with ether and washed

with 10% aqueous potassium carbonate and brine. The ether layer was dried (MgSO_4) and concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography to provide the product (5.1 g, 92%) as a colorless oil. ^1H NMR (500 MHz, CDCl_3) δ 7.34 - 7.28 (m, 1H), 7.26 (dd, J = 10.6, 2.4 Hz, 1H), 7.20 - 7.15 (m, 1H), 7.08 (d, J = 7.6 Hz, 1H), 7.03 (dt, J = 9.9, 1.9 Hz, 1H), 6.99 - 6.93 (m, 1H), 6.83 (t, J = 8.7 Hz, 1H), 4.23 (t, J = 6.9 Hz, 2H), 3.14 (t, J = 6.9 Hz, 2H).


Intermediate 83



10 2-(3-Fluoro-4-(3-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

A solution of 4-bromo-2-fluoro-1-(3-fluorophenethoxy)benzene (1.28 g, 4.09 mmol, 1 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.56 g, 6.13 mmol, 1.5 equiv), $\text{Pd}(\text{dppf})\text{Cl}_2$ (0.30 g, 0.409 mmol, 0.1 equiv), and KOAc (1.20 g, 12.3 mmol, 3 equiv) in dioxane (14 mL) was heated at 80 °C for 18 h. After cooling to ambient temperature, the reaction was diluted with EtOAc and washed with brine. The organic layer was dried (Na_2SO_4) and concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography (0-60% EtOAc in hexane) to provide the product (0.59 g, 40%) as a waxy yellow solid. ^1H NMR (500 MHz, CDCl_3) δ 7.58 - 7.42 (m, 2H), 7.33 - 7.29 (m, 1H), 7.09 (d, J = 7.6 Hz, 1H), 7.03 (dt, J = 9.8, 2.0 Hz, 1H), 6.98 - 6.91 (m, 2H), 4.27 (t, J = 6.9 Hz, 2H), 3.16 (t, J = 6.9 Hz, 2H), 1.35 (s, 12H). LCMS ($\text{M}+1$): 361.10.

Intermediate 84




4-Bromo-2-fluoro-1-phenethoxybenzene.

25 To a solution of 2-phenylethanol (3.0 g, 24.6 mmol, 1 equiv), 4-bromo-2-fluorophenol (5.6 g, 29.5 mmol, 1.2 equiv), and triphenylphosphine (9.0 g, 34.4 mmol, 1.4 equiv) in THF (49 mL) was added DIAD (6.7 mL, 34.4 mmol, 1.4 equiv) slowly with a syringe. After stirring 1 h, the reaction was diluted with ether and washed with 10% aqueous potassium carbonate and brine. The ether layer was dried (MgSO_4) and

concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography to provide the product (6.2 g, 86%) as a pale orange oil. ¹H NMR (500 MHz, CDCl₃) δ 7.38 - 7.24 (m, 6H), 7.18 (dt, *J* = 8.7, 2.0 Hz, 1H), 6.83 (t, *J* = 8.7 Hz, 1H), 4.23 (t, *J* = 7.1 Hz, 2H), 3.15 (t, *J* = 7.1 Hz, 2H).

5

Intermediate 85




2-(3-Fluoro-4-phenethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane:

A solution of 4-bromo-2-fluoro-1-phenethoxybenzene (1.46 g, 4.95 mmol, 1 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.88 g, 7.42 mmol, 1.5 equiv), Pd(dppf)Cl₂ (0.36 g, 0.495 mmol, 0.1 equiv), and KOAc (1.46 g, 14.8 mmol, 3 equiv) in dioxane (25 mL) was heated at 80 °C for 18 h. After cooling to ambient temperature, the reaction was diluted with EtOAc and washed with brine. The organic layer was dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography (0-60% EtOAc in hexane) to provide the product (1.20 g, 71%) as a viscous yellow solid. ¹H NMR (500 MHz, CDCl₃) δ 7.54 - 7.48 (m, 2H), 7.39 - 7.29 (m, 5H), 6.94 (t, *J* = 8.0 Hz, 1H), 4.28 (t, *J* = 7.3 Hz, 2H), 3.17 (t, *J* = 7.2 Hz, 2H), 1.35 (s, 12H). LCMS (M+1): 343.05.

20

Intermediate 86




4-Bromo-2-chloro-1-(4-fluorophenethoxy)benzene:

To a solution of 2-(4-fluorophenyl)ethanol (1.0 g, 7.13 mmol, 1 equiv) in DMF (24 mL) was added KOtBu (1.12 g, 9.99 mmol, 1.4 equiv) and 4-bromo-2-chloro-1-fluorobenzene (1.04 mL, 8.56 mmol, 1.2 equiv). After stirring 3 h, the reaction was diluted with ether. The ether solution was washed with water, brine, dried (Na₂SO₄), and concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography (0-30% EtOAc in hexane) to provide the product (0.93 g, 40%) as a colorless oil. ¹H

NMR (500 MHz, CDCl₃) δ 7.37 - 7.22 (m, 4H), 7.03 (t, J = 8.7 Hz, 2H), 6.83 - 6.68 (m, 1H), 4.18 (t, J = 6.6 Hz, 2H), 3.13 (t, J = 6.6 Hz, 2H).

Intermediate 87




5

2-(3-Chloro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane:

A solution of 4-bromo-2-chloro-1-(4-fluorophenethoxy)benzene (0.93 g, 2.82 mmol, 1 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.08 g, 4.23 mmol, 1.5 equiv), Pd(dppf)Cl₂ (0.21 g, 0.282 mmol, 0.1 equiv), and KOAc (0.83 g, 8.46 mmol, 3 equiv) in dioxane (14 mL) was heated at 80 °C for 18 h. After cooling to ambient temperature, the reaction was diluted with EtOAc and washed with brine. The organic layer was dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography (0-60% EtOAc in hexane) to provide the product (0.70 g, 66%) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ 7.82 (d, J = 1.3 Hz, 1H), 7.65 (dd, J = 8.2, 1.4 Hz, 1H), 7.32 (dd, J = 8.5, 5.5 Hz, 2H), 7.02 (t, J = 8.7 Hz, 2H), 6.89 (d, J = 8.2 Hz, 1H), 4.24 (t, J = 6.8 Hz, 2H), 3.15 (t, J = 6.8 Hz, 2H), 1.35 (s, 12H). LCMS (M+1): 377.0.

15

Intermediate 88



20


5-Bromo-2-(4-fluorophenethoxy)benzonitrile.

To a solution of 2-(4-fluorophenyl)ethanol (2.57 g, 12.8 mmol, 1 equiv) in DMF (24 mL) was added KOtBu (2.02 g, 18.0 mmol, 1.4 equiv) and 5-bromo-2-fluorobenzonitrile (1.80 g, 12.8 mmol, 1 equiv). After stirring 3 h, the reaction was diluted with ether. The ether solution was washed with water, brine, dried (Na₂SO₄), and concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography (0-30% EtOAc in hexane) to provide the product (2.24 g, 55%) as a pale yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 7.67 (d, J = 2.4 Hz, 1H), 7.61 (dd, J = 9.0, 2.5 Hz, 1H), 7.32 (t,

25

$J = 6.7$ Hz, 2H), 7.04 (t, $J = 8.7$ Hz, 2H), 6.82 (d, $J = 9.0$ Hz, 1H), 4.23 (t, $J = 6.5$ Hz, 2H), 3.15 (t, $J = 6.5$ Hz, 2H), 1.60 - 1.50 (m, 5H).

Intermediate 89




5

2-(4-Fluorophenethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile.

A solution of 5-bromo-2-(4-fluorophenethoxy)benzonitrile (2.0 g, 6.25 mmol, 1 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.4 g, 9.37 mmol, 1.5 equiv), Pd(dppf)Cl₂ (0.48 g, 0.625 mmol, 0.1 equiv), and KOAc (1.84 g, 18.7 mmol, 3 equiv) in dioxane (31 mL) was heated at 80 °C for 18 h. After cooling to ambient temperature, the reaction was diluted with EtOAc and washed with brine. The organic layer was dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography (0-60% EtOAc in hexane) to provide the product (2.1 g, 92%) as a viscous yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 8.02 (d, $J = 1.4$ Hz, 1H), 7.92 (dd, $J = 8.4, 1.7$ Hz, 1H), 7.33 (dd, $J = 8.7, 5.4$ Hz, 2H), 7.04 (t, $J = 8.7$ Hz, 2H), 6.91 (d, $J = 8.5$ Hz, 1H), 4.27 (t, $J = 6.7$ Hz, 2H), 3.16 (t, $J = 6.6$ Hz, 2H), 1.35 (s, 12H). LCMS (M+1): 368.05.

15

Intermediate 90



20


4-Bromo-1-(4-fluorophenethoxy)-2-(trifluoromethyl)benzene:

To a solution of 2-(4-fluorophenyl)ethanol (1.02 g, 7.31 mmol, 1.2 equiv) in DMF (20 mL) was added KOtBu (0.96 g, 5.99 mmol, 1.4 equiv) and 4-bromo-1-fluoro-2-(trifluoromethyl)benzene (1.48 g, 6.09 mmol, 1.2 equiv). After stirring 2 h, the reaction was diluted with ether. The ether solution was washed with water, brine, dried (Na₂SO₄), and concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography (0-30% EtOAc in hexane) to provide the product (1.36 g, 62%) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ 7.69 (d, $J = 2.5$ Hz, 1H), 7.57 (dd, $J = 8.8, 2.5$

25

Hz, 1H), 7.28 - 7.25 (m, 2H), 7.02 (t, $J=8.3$ Hz, 2H), 6.85 (d, $J=8.8$ Hz, 1H), 4.21 (t, $J=6.5$ Hz, 2H), 3.12 (t, $J=6.5$ Hz, 2H).


Intermediate 91



2-(4-(4-Fluorophenethoxy)-3-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane:

A solution of 4-bromo-1-(4-fluorophenethoxy)-2-(trifluoromethyl)benzene (1.36 g, 3.75 mmol, 1 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.43 g, 5.62 mmol, 1.5 equiv), Pd(dppf)Cl₂ (0.274 g, 0.375 mmol, 0.1 equiv), and KOAc (1.10 g, 11.2 mmol, 3 equiv) in dioxane (19 mL) was heated at 80 °C for 18 h. After cooling to ambient temperature, the reaction was diluted with EtOAc and washed with brine. The organic layer was dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by silica gel flash chromatography (0-60% EtOAc in hexane) to provide the product (1.20 g, 78%) as a viscous yellow oil. ¹H NMR (500 MHz, CDCl₃) δ 8.02 (s, 1H), 7.91 (d, $J=8.4$ Hz, 1H), 7.31 - 7.27 (m, 2H), 7.02 (t, $J=8.7$ Hz, 2H), 6.95 (d, $J=8.4$ Hz, 1H), 4.26 (t, $J=6.6$ Hz, 2H), 3.13 (t, $J=6.5$ Hz, 2H), 1.36 (s, 12H). ¹⁹F NMR (471 MHz, CDCl₃) δ -62.17 (s, 3F), -116.70 (br s, 1F). LCMS (M+1): 411.0.

Intermediate 92




1-Bromo-4-phenethoxybenzene:

To a 100 mL round bottom flask equipped with a stir bar was added 4-bromophenol (1.00 g, 5.78 mmol), 2-phenylethan-1-ol (706 mg, 5.78 mmol), triphenylphosphine (1.82 g, 6.94 mmol) and THF (30 ml). To the stirring solution was added diethyl (E)-diazene-1,2-dicarboxylate (1.09 ml, 6.94 mmol) dropwise. The solution was stirred at r.t. for 2 hrs. The reaction solution was concentrated in vacuo and the resulting oil was diluted with a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to silica gel chromatography (80 g column, 0-50%

EtOAc:Hex over 10 CVs) to afford the product 1-bromo-4-phenethoxybenzene (1.05 g, 3.79 mmol, 65.5 % yield) as a clear oil. ¹H NMR (500 MHz, CHLOROFORM-d) δ 7.43 - 7.30 (m, 7H), 6.80 (d, *J*=8.1 Hz, 2H), 4.17 (t, *J*=7.1 Hz, 2H), 3.11 (t, *J*=7.1 Hz, 2H)

5

Intermediate 93




4,4,5,5-Tetramethyl-2-(4-phenethoxyphenyl)-1,3,2-dioxaborolane:

1-Bromo-4-phenethoxybenzene (1.0 g, 3.6 mmol), BISPIN (1.0 g, 3.9 mmol), PdCl₂(dppf) (0.132 g, 0.180 mmol), potassium acetate (1.06 g, 10.8 mmol) were combined in 1,4 dioxane (18 ml) at rt, degassed and backfilled with N₂, and warmed to 90 °C. The reaction was allowed to stir overnight. The reaction was concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs) to afford 4,4,5,5-tetramethyl-2-(4-phenethoxyphenyl)-1,3,2-dioxaborolane (1.0 g, 3.08 mmol, 85 % yield). LCMS Method 4: retention time = 1.78 min.; observed ion = 325.05. ¹H NMR (500 MHz, CHLOROFORM-d) δ 7.76 (d, *J*=7.9 Hz, 2H), 7.41 - 7.30 (m, 4H), 7.28 - 7.24 (m, 1H), 6.91 (d, *J*=7.9 Hz, 2H), 4.23 (t, *J*=7.2 Hz, 2H), 3.13 (t, *J*=7.2 Hz, 2H), 1.35 (s, 12H).

20

Intermediate 94




5-(Benzyloxy)-2-bromopyridine:

To a 1L round bottom flask equipped with a large stir bar was added 6-bromopyridin-3-ol (24.69 g, 142 mmol), benzyl alcohol (15.42 mL, 149 mmol), triphenylphosphine (39.1 g, 149 mmol) and THF (600 mL). The flask was placed in a r.t. water bath. To the stirred solution was added in six portions DIAD (29.0 mL, 149 mmol). The internal temperature increased from 20 deg to 35 deg C, and was 35 deg C at the completion of the addition. After stirring for 18 h the reaction solution was concentrated in vacuo to afford a liquid residue. The material was diluted with hexane:Et₂O (1:1, 850 mL). A precipitate was immediately formed. The mixture was stirred for 5 minutes, then

the liquid was decanted and reserved. The solids were treated with Et₂O (200 mL), and the mixture was stirred for 5 minutes. The solution was diluted with hexanes (200 mL), and the mixture was then stirred for 5 minutes. The mixture and the reserved solution were combined and filtered through a fine-fritted vacuum funnel. The filtrate was concentrated in vacuo. The resulting residue was diluted with a small amount of acetone and then concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ chromatography (330g SiO₂ column, hexanes:EtOAc 100:0 → 80:20) to afford 5-(benzyloxy)-2-bromopyridine as a colorless, crystalline solid (24.84 g, 66%). ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.16 (d, *J*=3.2 Hz, 1H), 7.45 - 7.36 (m, 6H), 7.18 (dd, *J*=8.6, 3.2 Hz, 1H), 5.12 (s, 2H).

Alternative procedure: To a stirred solution of 6-bromopyridin-3-ol (100 g, 575 mmol), K₂CO₃ (119 g, 862 mmol) in acetone (1 L) was added benzyl bromide (0.075 L, 632 mmol). The mixture was stirred for 3 h at 80 °C. LCMS showed completion of reaction. Then, the mixture was cooled to 20 °C and poured into water (250 mL). The precipitate was filtered, taken up in DCM and washed with sat. NaHCO₃ (50 mL), water (50 mL), brine (50 mL) and concentrated to afford 5-(benzyloxy)-2-bromopyridine (120 g, 454 mmol, 79 % yield) as a off-white solid.

Intermediate 95



(5-(Benzyloxy)pyridin-2-yl)boronic acid MIDA ester:

To a dry 250 mL round bottom flask equipped with a large stir bar and charged with 5-(benzyloxy)-2-bromopyridine (21.8527 g, 83 mmol) was added THF (150 ml) and triisopropyl borate (19.40 ml, 84 mmol). The flask was sealed with a rubber septum, then the solution was sparged with N₂ for 5 min. The flask was cooled in a -78 °C bath. To the solution was added dropwise over 30 min n-butyllithium in hexanes (33.4 ml, 84 mmol). The cold bath was removed and the solution was allowed to slowly warm to r.t. with stirring. After 2 h the solution was transferred to a pressure-equalizing addition funnel. The addition funnel was fitted onto the center neck of a 3-neck 250 mL flask equipped with a large stir bar was charged with N-methyliminodiacetic acid (24.35 g, 165 mmol)


and DMSO (150 ml). A side neck was fitted with a thermocouple. The other side neck was fitted with a water-cooled short-path distillation apparatus collecting into a 250 mL round bottom flask and vented to a bubbler. The addition funnel was capped with a gas adapter connected to a low-volume stream of N₂ gas. The 3-neck flask was heated with an oil bath (150 °C). Once the DMSO solution had reached 115-120 °C the boronate solution was added dropwise at a rate necessary to maintain an internal temp of 115-120 °C. The blue boronate solution immediately becomes a red/amber color upon contacting the DMSO solution. The reaction mixture is a deep amber solution. Upon completion of the addition the receiver flask containing THF was exchanged for an empty 200 mL round bottom flask. The bubbler line connected to the vacuum arm of the distillation apparatus was exchanged for a controlled vacuum source. The N₂ source feeding into the addition funnel was closed. The system was placed under vacuum, slowly ramping to 30 Torr. The receiver flask was emptied, then the vacuum was slowly ramped to 2 Torr. The bath temperature was set to 125 °C and the pressure was maintained at 2 Torr. When the majority of DMSO had been removed the flask was opened to ambient atmosphere. To the flask was added MeCN (100 mL). Heating was maintained until the solvent had reached reflux, then heating was stopped. To the hot mixture was added Celite. The mixture was concentrated in vacuo to afford a clumpy solid which was subjected to SiO₂ chromatography (EtOAc:MeCN 100:0 → 0:100) to afford the desired product as a colorless solid. This material was dissolved/suspended in MeCN (100 mL), then was diluted with Et₂O (400 mL). The crystalline solid was collected via vacuum filtration. The solids were dried under high vacuum to afford (5-(benzyloxy)pyridin-2-yl)boronic acid MIDA ester as a colorless, fine crystalline solid (5.81 g, 21%). ¹H NMR (500 MHz, ACETONITRILE-d₃) δ 8.50 - 8.42 (m, 1H), 7.56 (d, *J*=8.4 Hz, 1H), 7.49 - 7.44 (m, 2H), 7.44 - 7.38 (m, 2H), 7.38 - 7.33 (m, 1H), 7.31 (dd, *J*=8.4, 2.9 Hz, 1H), 5.16 (s, 2H), 4.10 - 4.04 (m, 2H), 3.98 - 3.92 (m, 2H), 2.54 (s, 3H).

Simplified procedure: To a solution of 5-(benzyloxy)-2-bromopyridine (98 g, 371 mmol) and triisopropyl borate (77 g, 408 mmol) in THF (800mL) was added n-butyllithium (193 mL, 482 mmol) at -78 °C and stirred for 20 min at -78°C. Then, the reaction mixture was stirred at rt for 3 h. The reaction mixture was added to a solution of 2,2'-(2,2'-(methylazanediyl)diacetic acid (109 g, 742 mmol) in DMSO (800 mL) at 115-120 °C (internal temperature). Then, the THF and DMSO was distilled off over 2 h to remove as much solvent as possible. The reaction flask was cooled, diluted with 3000 mL

of ethyl acetate and washed with water (2000 mL x2), dried and concentrated. The residue was purified by silica gel chromatography to give 2-(5-(benzyloxy)pyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (41 g, 120 mmol, 32.2 % yield) as pale solid.

5


Intermediate 96



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methyl-2-vinylpyridin-3-yl)acetate:

- 10 A mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-2-vinylpyridin-3-yl)-2-(tert-butoxy)acetate (18 mg, 0.037 mmol), (4-(4-fluorophenethoxy)phenyl)boronic acid (14.58 mg, 0.056 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (4.60 mg, 0.011 mmol), and potassium phosphate tribasic (59.5 mg, 0.280 mmol) in 1,4-dioxane (623 μ L) and water (125 μ L) was
- 15 bubbled with N₂ for 10 minutes. Pd(OAc)₂ (1.259 mg, 5.61 μ mol) was then added and the reaction vessel sealed under positive pressure of N₂. The reaction was heated at 80 °C for 2 h. The reaction was diluted with water and extracted with EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified on silica gel (4 g column, 5-25%
- 20 EtOAc:Hex) to afford the product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methyl-2-vinylpyridin-3-yl)acetate (11 mg, 0.018 mmol, 47.7 % yield) as a lightly colored oil. LCMS (M+1) = 617.7.

Intermediate 97




25

(S)-Isopropyl 2-(2-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

A mixture of (S)-isopropyl 2-(2-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (200 mg, 0.425 mmol), (4-(4-fluorophenethoxy)phenyl)boronic acid (166 mg, 0.638 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (34.9 mg, 0.085 mmol) and potassium phosphate tribasic (677 mg, 3.19 mmol) in 1,4-dioxane (7086 µl) and water (1417 µl), then bubbled with nitrogen for 10 minutes. Pd(OAc)₂ (9.54 mg, 0.043 mmol) was added to the reaction and heated at 80°C for 2 h. The reaction was diluted with water and extracted with EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified on silica gel (40 g column, 5-50% EtOAc:Hex) to afford the product (S)-isopropyl 2-(2-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (150 mg, 0.248 mmol, 58.2 % yield) as a yellow solid. ¹H NMR (500 MHz, CDCl₃) δ 7.30 (br d, *J*=2.4 Hz, 2H), 7.13 (dd, *J*=8.7, 2.0 Hz, 1H), 7.10 - 7.06 (m, 1H), 7.04 (t, *J*=8.7 Hz, 2H), 6.97 - 6.91 (m, 2H), 6.02 (s, 1H), 5.19 (br s, 2H), 5.07 (dt, *J*=12.5, 6.3 Hz, 1H), 4.23 (td, *J*=6.9, 3.3 Hz, 2H), 3.12 (t, *J*=6.9 Hz, 1H), 3.17 (br s, 1H), 2.85 (br t, *J*=11.3 Hz, 1H), 2.36 - 2.28 (m, 1H), 2.15 (br t, *J*=11.2 Hz, 1H), 2.04 (s, 3H), 1.40 - 1.28 (m, 2H), 1.26 (d, *J*=6.3 Hz, 3H), 1.25 - 1.25 (m, 1H), 1.24 (s, 9H), 1.21 (d, *J*=6.1 Hz, 3H), 1.19 - 1.09 (m, 2H), 0.90 (s, 3H), 0.64 (s, 3H). LCMS (M+1) = 606.7.

Intermediate 98




(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)acetate:

To a solution of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (1 g, 2.196 mmol), (4-(4-fluorophenethoxy)phenyl)boronic acid (0.857 g, 3.29 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (0.180 g, 0.439 mmol), and potassium phosphate tribasic (3.50 g,

16.47 mmol) in 1,4-dioxane (36.6 ml) and water (7.32 ml) under N₂ was added Pd(OAc)₂ (0.049 g, 0.220 mmol). The reaction was heated at 80 °C for 2 h. The reaction was cooled to RT and diluted with water and extracted with EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified on silica gel (40 g column, 5-50% EtOAc:Hex) to give the product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)acetate (1.15 g, 1.947 mmol, 89 % yield) as a brown oil. ¹H NMR (400MHz, CDCl₃) δ 8.68 (s, 1H), 7.30 (d, *J*=5.4 Hz, 1H), 7.27 (br. s., 1H), 7.18 - 7.11 (m, 1H), 7.09 - 7.01 (m, 3H), 6.98 (d, *J*=8.8 Hz, 2H), 5.52 (s, 1H), 5.04 (dt, *J*=12.6, 6.2 Hz, 1H), 4.24 (t, *J*=7.0 Hz, 2H), 3.13 (t, *J*=7.0 Hz, 2H), 2.93 (br. s., 1H), 2.65 (br. s., 1H), 2.51 (d, *J*=7.1 Hz, 1H), 2.39 (br. s., 1H), 2.23 (s, 3H), 1.41 - 1.31 (m, 1H), 1.27 (d, *J*=6.1 Hz, 4H), 1.25 (s, 9H), 1.23 (d, *J*=6.1 Hz, 4H), 1.16 - 1.02 (m, 1H), 0.86 (br. s., 3H), 0.72 (br. s., 3H). LCMS (M+1) = 591.4.

15

Intermediate 99




(S)-5-(1-(tert-Butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridine 1-oxide:

To a stirred solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)acetate (1.15 g, 1.947 mmol) in DCM (10 ml) was added 77% mCPBA (0.654 g, 2.92 mmol) at rt over 5 min. After 4 h, the reaction mixture was washed with sat. Na₂CO₃ (3 x 25 mL), dried (MgSO₄), filtered and concentrated to give (S)-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridine 1-oxide (1.1 g, 1.813 mmol, 93 % yield) which was used in the next step without purification. ¹H NMR (500 MHz, CDCl₃) δ 8.55 (s, 1H), 7.31 - 7.29 (m, 1H), 7.28 - 7.27 (m, 1H), 7.13 - 6.97 (m, 6H), 5.40 (s, 1H), 5.06 - 4.98 (m, 1H), 4.24 (t, *J*=6.9 Hz, 2H), 3.13 (t, *J*=6.9 Hz, 2H), 2.70 (br. s., 1H), 2.58 - 2.44 (m, 2H), 2.39 - 2.29 (m, 1H), 2.22 (s, 3H), 1.53 - 1.35

(m, 2H), 1.27 (s, 3H), 1.25 (s, 9H), 1.24 (s, 3H), 1.19 - 1.05 (m, 2H), 0.91 (br. s., 3H), 0.64 (br. s., 3H). LCMS (M+1) = 607.4.


Intermediate 100



(S)-Isopropyl 2-(tert-butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)acetate:

To a solution of (S)-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridine 1-oxide (25 mg, 0.041 mmol) and trimethylsilanecarbonitrile (5.67 μ l, 0.045 mmol) in acetonitrile (5 mL) in a 1 dram vial was added dimethylcarbamoyl chloride (4.17 μ l, 0.045 mmol) and allowed to stir at RT for 18 hr. The reaction was monitored via LCMS. The reaction was heated to 40 $^{\circ}$ C for 1 hr then to 55 $^{\circ}$ C for another hr to try to push to full conversion. The reaction material was transferred to a separatory funnel and washed with sat. sodium hydrogen carbonate solution and extracted with EtOAc. The organic layer was washed with brine, collected, dried over MgSO_4 , filtered and evaporated to afford the crude product (S)-isopropyl 2-(tert-butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)acetate (20 mg, 0.032 mmol, 79 % yield). LCMS (M+1) = 616.4.

Intermediate 101




(S)-Benzyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-(fluoromethyl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate:

A mixture of (S)-benzyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(fluoromethyl)pyridin-3-yl)-2-(tert-butoxy)acetate (83 mg, 0.159 mmol), (4-(4-

fluorophenethoxy)phenyl)boronic acid (62.1 mg, 0.239 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (13.07 mg, 0.032 mmol), and potassium phosphate tribasic (253 mg, 1.194 mmol) in 1,4-dioxane (2653 μ l) and water (531 μ l) was bubbled with N₂ for 10 minutes. Pd(OAc)₂ (3.57 mg, 0.016 mmol) was added and the reaction was kept under positive pressure of N₂ for the duration of the reaction. The reaction was heated at 80 °C for 1 h. The reaction was cooled to RT and diluted with water and EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel (24g column, 5-40 % EtOAc:Hex) to afford the product (S)-benzyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-(fluoromethyl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate (43 mg, 0.065 mmol, 41.1 % yield) as a light colored thick oil. LCMS (M+1) = 657.3.

Intermediate 102




(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate:

A mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (1 g, 2.060 mmol), (4-(4-fluorophenethoxy)phenyl)boronic acid (0.804 g, 3.09 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (0.169 g, 0.412 mmol), and potassium phosphate tribasic (3.28 g, 15.45 mmol) in 1,4-dioxane (34.3 ml) and water (6.87 ml) was bubbled with N₂ for 10 minutes. Pd(OAc)₂ (0.046 g, 0.206 mmol) was added and the reaction vessel capped under positive pressure of N₂. The reaction was heated at 80°C for 2 h. The reaction was diluted with water and extracted with EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified on silica gel (40 g column, 5-50% EtOAc:Hex) to afford the product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate (1.15 g,

1.852 mmol, 90 % yield) as a brown oil. ¹H NMR (500 MHz, CDCl₃) δ 7.31 - 7.29 (m, 2H), 7.13 (dd, *J*=8.3, 2.0 Hz, 1H), 7.09 - 7.02 (m, 3H), 7.00 - 6.93 (m, 2H), 6.04 (br s, 1H), 5.11 (dt, *J*=12.5, 6.2 Hz, 1H), 4.42 (d, *J*=15.4 Hz, 1H), 4.26 - 4.20 (m, 2H), 4.08 (d, *J*=15.4 Hz, 1H), 3.30 - 3.18 (m, 1H), 3.14 (t, *J*=6.9 Hz, 2H), 2.95 - 2.83 (m, 1H), 2.65 (s, 3H), 2.31 (br s, 1H), 2.19 - 2.09 (m, 1H), 1.58 (br s, 4H), 1.26 (d, *J*=6.3 Hz, 3H), 1.23 (d, *J*=6.3 Hz, 3H), 1.20 (s, 9H), 0.95 - 0.85 (m, 3H), 0.68 (br s, 3H). LCMS (M+1) = 621.7.


Intermediate 103



10 (S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-formyl-2-methylpyridin-3-yl)acetate:

To a stirred solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate (960 g, 1.546 mmol) in DCM (14.06 ml) and acetonitrile (1.406 ml) was added Dess-
 15 Martin Periodinane (0.984 g, 2.320 mmol) at once at rt. After 4 h, the reaction mixture was diluted with ether (25 mL), washed with 1M NaOH (2 x 25 mL), brine (25 mL), dried (MgSO₄), filtered and concentrated to afford the product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-formyl-2-methylpyridin-3-yl)acetate (829 mg, 1.340 mmol, 87 % yield). ¹H NMR (500 MHz, CDCl₃) δ 9.84 (s, 1H), 7.32 - 7.29 (m, 2H), 7.22 (ddd, *J*=11.0, 8.6, 2.1 Hz, 2H), 7.08 - 7.03 (m, 2H), 7.00 (ddd, *J*=16.3, 8.3, 2.5 Hz, 2H), 6.14 - 6.03 (m, 1H), 5.13 (dt, *J*=12.5, 6.3 Hz, 1H), 4.30 - 4.21 (m, 2H), 3.30 - 3.20 (m, 1H), 3.14 (t, *J*=6.9 Hz, 2H), 2.98 (br t, *J*=11.0 Hz, 1H), 2.72 (s, 3H), 2.31 (br d, *J*=8.7 Hz, 1H), 2.14 (br d, *J*=11.0 Hz, 1H), 1.59 - 1.27 (m, 4H), 1.26 (d, *J*=6.1 Hz, 3H), 1.24 (d, *J*=6.1 Hz, 3H), 1.19 (s, 9H), 0.93 (br s, 3H), 0.71 (br s, 3H). LCMS (M+1) = 619.3.


Intermediate 104



(S)-5-(1-(tert-Butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-6-methylpicolinic acid:

- 5 To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-formyl-2-methylpyridin-3-yl)acetate (529 mg, 0.855 mmol) in DMSO (15 ml) was added potassium phosphate monobasic (349 mg, 2.56 mmol) in water (0.75 mL) followed by sodium chlorite (232 mg, 2.56 mmol) in water (1.5 mL) and the mixture was stirred for 3 hr. The reaction was diluted with water and
- 10 EtOAc. The organic layer was washed with water (2X). The organic layer was then washed with brine dried (MgSO₄), filtered and concentrated to afford the product (S)-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-6-methylpicolinic acid (536 mg, 0.844 mmol, 99 % yield) as a yellow crispy foam. ¹H NMR (500 MHz, CDCl₃) δ 7.30 (br s, 1H), 7.29 - 7.24 (m, 2H),
- 15 7.09 - 7.00 (m, 3H), 6.99 - 6.94 (m, 2H), 6.05 (br s, 1H), 5.17 - 5.08 (m, 1H), 4.24 (td, *J*=7.0, 1.8 Hz, 2H), 3.29 - 2.69 (m, 4H), 2.67 (s, 3H), 2.61 - 2.11 (m, 2H), 1.34 - 1.15 (m, 19H), 1.00 - 0.68 (m, 6H). LCMS (M+1) = 635.3.

Intermediate 105




- 20 *(S)-5-(1-(tert-Butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-ylboronic acid:*

- To a dry 10 mL Schlenk flask equipped with a stir bar and placed under N₂ was added (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.114 g, 0.250 mmol), then placed under vacuum and back filled
- 25 with N₂ (3 times) with finally being left under positive pressure of N₂. THF (3 mL) was

then added followed by pyridine (0.040 mL, 0.501 mmol). The solution was cooled to -78 °C. To the solution was added butyllithium (0.100 mL, 0.250 mmol) dropwise upon which the solution turned a light brown color. The solution was stirred for 5 minutes. To the solution was added trimethyl borate (0.112 mL, 1.001 mmol). Stirring was maintained as the -78 °C for 5 minutes and then the bath was removed and slowly warmed to RT and stirred for 18 hr. The reaction mixture was transferred to a 125 mL separatory funnel and was diluted with water (25 mL), then extracted with EtOAc (50 mL). The organic phase was washed with brine, dried over MgSO₄, filtered and volatiles evaporated to afford the product (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid which was used in the subsequent step without purification. LCMS (M+1) = 421.1.

Intermediate 106




15 *Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)acetate:*

To a 14 mL test tube equipped with a stir and charged with crude (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (113 mg, 0.269 mmol) and SPhos-Pd-G3 (10.47 mg, 0.013 mmol) was added tribasic potassium phosphate (514 mg, 2.419 mmol) and 2-chloro-5-(4-fluorophenethoxy)pyrimidine (67.9 mg, 0.269 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (1 mL) + water (0.4 mL). The test tube was placed in a 60 °C heating block with stirring. The reaction was stirred for 3 hours at this temperature. The reaction was then cooled to RT and then diluted with water and EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude material. The crude material was purified via silica gel chromatography (24 g column, 25-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-

methylpyridin-3-yl)acetate (20 mg, 0.034 mmol, 12.55 % yield over 2 steps) as a brown oil. LCMS (M+1) = 593.4.

Intermediate 107




5

Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

A mixture of isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.15 g, 0.329 mmol, 1 equiv), (6-fluoropyridin-3-yl)boronic acid (0.070 g, 0.494 mmol, 1.5 equiv), SPhos (0.027 g, 0.066 mmol, 0.2 equiv), palladium(II) acetate (7.4 mg, 0.033 mmol, 0.1 equiv) and 2 M K₃PO₄ (0.494 ml, 0.988 mmol, 3 equiv) in dioxane (3 mL) was heated at 90 °C for 4 h. Upon cooling to ambient temperature, the reaction mixture was filtered through celite/Na₂SO₄, diluted with ethyl acetate, concentrated *in vacuo*, and purified by silica gel flash chromatography (0-50% ethyl acetate in hexanes) to afford the product (84 mg, 54%) as a colorless viscous oil. LCMS (M+1): 472.20.

15

Intermediate 108



20 *(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-methoxypyridazin-3-yl)-2-methylpyridin-3-yl)acetate:*


The product was prepared according to procedure for the preparation of isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)acetate by using (S)-2-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (113 mg, 0.269 mmol) and SPhos-Pd-G3 (10.47 mg, 0.013 mmol) was

25

added tribasic potassium phosphate (514 mg, 2.419 mmol) and 3-chloro-6-methoxypyridazine (0.269 mmol) to afford the product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-methoxypyridazin-3-yl)-2-methylpyridin-3-yl)acetate (22 mg, 0.045 mmol, 16.89 % yield over 2 steps). LCMS (M+1) = 485.3.

5


Intermediate 109



(S)-Isopropyl 2-(tert-butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate:

- 10 To a 10 mL Schlenk flask tube equipped with a stir was added tribasic potassium phosphate (590 mg, 2.78 mmol), (3,5-difluoro-4-methoxyphenyl)boronic acid (174 mg, 0.927 mmol), and SPhos-Pd-G3 (24 mg, 0.031 mmol). The flask was sealed with a rubber septum and then placed under N₂ atmosphere. To the flask was added a degassed (N₂ sparging for 5 min) solution of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (300 mg, 0.618 mmol) in
- 15 dioxane (3 mL) and water (1 mL). The flask was placed in a 60 °C oil bath with stirring for 18h. The reaction mixture was diluted with sat. aq. NaCl ("brine", 6 mL) and Et₂O (15 mL) and was transferred to a 24 mL test tube. The organic phase was isolated and then dried over MgSO₄, then filtered, then concentrated in vacuo. The resulting residue was
- 20 dissolved in a min. of acetone and then concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (40g SiO₂ column, hexanes:EtOAc 100:0→60:40) to afford (S)-isopropyl 2-(tert-butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate as a white solid foam (223 mg, 66%). ¹H NMR (500 MHz, CDCl₃) δ 7.30 (dd, J=5.2, 1.7 Hz, 1H), 6.87 - 6.80 (m, 1H), 6.78 - 6.71 (m, 1H), 5.95 (br s, 1H), 5.14 - 5.05 (m, 1H), 4.44 (d, J=15.3 Hz, 1H), 4.12 (d, J=15.3 Hz, 1H), 4.09 (s, 3H), 3.35 - 3.11 (m, 1H), 2.98 - 2.73 (m, 1H), 2.64 (s, 3H), 2.47 - 2.27 (m, 1H), 2.24 - 2.00 (m, 1H), 1.26 - 1.24 (m, 4H), 1.22 (d, J=6.3 Hz, 4H), 1.18 (s, 11H), 0.98 - 0.84 (m, 4H), 0.81 - 0.65 (m, 3H).
- 25

Intermediate 110




(S)-Isopropyl 2-(tert-butoxy)-2-(5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate:

- 5 To a 14 mL test tube equipped with a stir was added tribasic potassium phosphate (197 mg, 0.927 mmol), (3,4-difluorophenyl)boronic acid (48.8 mg, 0.309 mmol), (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (100 mg, 0.206 mmol), and SPhos-Pd-G3 (8 mg, 10 μ mol). The test tube was sealed with a rubber septum and then placed under N₂
- 10 atmosphere. To the test tube was added a degassed (5 min. N₂ sparging) solution of dioxane (0.75 mL) and water (0.25 mL). The test tube was placed in a 60 °C heating block with for 18h. The reaction mixture was cooled to r.t., then was diluted with brine (2 mL) and Et₂O (5 mL). The isolated organic phase was dried over MgSO₄, then filtered, then concentrated in vacuo. The resulting residue was dissolved in a min. of acetone and
- 15 then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (24g SiO₂ column, hexanes:EtOAc 100:0 $\rightarrow$ hexanes:EtOAc 60:40) to afford (S)-isopropyl 2-(tert-butoxy)-2-(5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate as a colorless solid foam (61.5 mg, 58 %).

20

Intermediate 111




(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrazin-2-yl)-2-methylpyridin-3-yl)acetate:

- The product was prepared according to procedure for the preparation of isopropyl
- 25 (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)acetate by using (S)-(1-(tert-

butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (113 mg, 0.269 mmol) and SPhos-Pd-G3 (10.47 mg, 0.013 mmol) was added tribasic potassium phosphate (514 mg, 2.419 mmol) and 3-chloro-6-methoxypyridazine (0.269 mmol) to afford the product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrazin-2-yl)-2-methylpyridin-3-yl)acetate (30 mg, 0.051 mmol, 18.83 % yield). LCMS (M+1) = 593.3.


Intermediate 112



10 (S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)pyridazin-3-yl)-2-methylpyridin-3-yl)acetate:

The product was prepared according to procedure for the preparation of isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)acetate by using (S)-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (113 mg, 0.269 mmol) and SPhos-Pd-G3 (10.47 mg, 0.013 mmol) was added tribasic potassium phosphate (514 mg, 2.419 mmol) and 3-chloro-6-(4-fluorophenethoxy)pyridazine (0.269 mmol) to afford the product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)pyridazin-3-yl)-2-methylpyridin-3-yl)acetate (47 mg, 0.079 mmol, 29.5 % yield). LCMS (M+1) = 593.3.

Intermediate 113




(S)-Isopropyl 2-(6-(bromomethyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate (930 mg, 1.498 mmol) in CH₂Cl₂ (20 mL) was added CBr₄ (546 mg, 1.648 mmol) followed by Ph₃P (432 mg, 1.648 mmol) and the resulting mixture was stirred at room temp for 16 h. Water (10 mL) was then added and the mixture was extracted with dichloromethane (10 mL), dried (Na₂SO₄), filtered and concentrated. The residue was then purified by Biotage (5-30% EtOAc/hexane) to afford (S)-isopropyl 2-(6-(bromomethyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (850 mg, 1.243 mmol, 83 % yield) as white solid. ¹H NMR (500MHz, CDCl₃) δ 7.38 (d, *J*=8.2 Hz, 1H), 7.31 (br. s., 1H), 7.13 (d, *J*=7.7 Hz, 2H), 7.05 (t, *J*=8.4 Hz, 2H), 6.99 (t, *J*=7.2 Hz, 2H), 6.07 (br. s., 1H), 5.11 (dt, *J*=12.5, 6.3 Hz, 1H), 4.34 (d, *J*=9.3 Hz, 1H), 4.25 (br. s., 2H), 4.18 (d, *J*=9.3 Hz, 1H), 3.20 (d, *J*=11.7 Hz, 1H), 3.14 (t, *J*=6.9 Hz, 2H), 2.87 (t, *J*=12.7 Hz, 1H), 2.63 (s, 3H), 2.30 (d, *J*=9.6 Hz, 1H), 2.11 - 1.96 (m, 1H), 1.51 (br. s., 1H), 1.37 (br. s., 1H), 1.24 (d, *J*=6.3 Hz, 3H), 1.26 (d, *J*=6.5 Hz, 3H), 1.20 (s, 9H), 1.09 (d, *J*=14.5 Hz, 1H), 0.91 (br. s., 3H), 0.66 (br. s., 3H). LCMS (M+2H) = 685.4.

20

Intermediate 114




Isopropyl (S)-2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate.

A mixture of (S)-isopropyl 2-(6-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (1.7 g, 3.61 mmol), (4-(4-fluorophenethoxy)phenyl)boronic acid (1.880 g, 7.23 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (0.297 g, 0.723 mmol), palladium(II) acetate (0.081 g, 0.361 mmol) and 2 M K₃PO₄ (5.42 mL, 10.84 mmol) in dioxane (36 mL) was heated at 80 °C for 1 h. After cooling to ambient temperature, the reaction mixture was filtered through celite, diluted with ethyl acetate, washed with brine, dried (Na₂SO₄), and concentrated *in*

30

vacuo. The crude product was purified on silica gel (220 g column) using 5-80% ethyl acetate in hexanes to give a light orange solid (1.55 g, 71%). LCMS (M+1) = 606.35.


Intermediate 115



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate:

(S)-Isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.6 g, 0.842 mmol) and sodium nitrite (0.145 g, 2.105 mmol) were mixed together and added in portions to a mixture of hexanes (2.1 mL), DMSO (0.21 mL) and trifluoromethanesulfonic acid (0.229 mL, 2.53 mmol) at 5 °C. The mixture was stirred for 10 min at 5 °C, then stirred at ambient temperature overnight. Water was added to the reaction mixture and it was extracted with DCM, dried (Na₂SO₄) and concentrated *in vacuo*. The residue was purified on silica gel (80 g column) using 0-40% ethyl acetate in hexanes, then 40-100% ethyl acetate in hexanes. The desired fractions were concentrated *in vacuo* give desired compound as pale yellow glass (0.25 g, 40%). LCMS (M+1) = 739.3.


Intermediate 116



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-hydroxy-2-methylpyridin-3-yl)acetate:

To a solution of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.21 g, 0.350 mmol, 1 equiv) in AcOH (3.5 mL) was added NaNO₂ (0.15 g, 2.10 mmol, 6 equiv) portionwise. After 1 h, the orange solution was concentrated under a stream of nitrogen. The crude intermediate was taken up in MeOH (3.5 mL) and THF (1 mL). Potassium carbonate (0.39 g, 2.80 mmol, 8 equiv) was added. After 1 h, the reaction was added to 10% citric acid solution and extracted with DCM (x3). The combined DCM layers were dried (Na₂SO₄) and concentrated *in vacuo*. The crude product was purified by silica gel flash column chromatography (50-100% EtOAc/hex) to provide the product (0.20 g, 93%) as a yellow foam. ¹H NMR (500 MHz, CDCl₃) δ 7.28 - 7.24 (m, 3H), 7.07 - 6.91 (m, 5H), 5.58 (s, 1H), 5.09 (dt, *J* = 12.5, 6.2 Hz, 1H), 4.21 (td, *J* = 7.0, 1.3 Hz, 2H), 3.34 - 3.20 (m, 1H), 3.11 (t, *J* = 6.9 Hz, 2H), 2.83 (br s, 1H), 2.38 (s, 3H), 2.29 - 2.21 (m, 1H), 2.08 (d, *J* = 8.5 Hz, 1H), 1.42 - 1.28 (m, 3H), 1.28 (d, *J* = 6.3 Hz, 3H), 1.25 (d, *J* = 6.3 Hz, 3H), 1.21 (s, 9H), 1.16 - 1.09 (m, 1H), 0.91 (br d, *J* = 3.8 Hz, 3H), 0.73 (br s, 3H). LCMS (M+1) = 607.3.

Intermediate 117




Isopropyl (S)-2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate.

A mixture of 2-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (0.27 g, 0.701 mmol), (S)-isopropyl 2-(6-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.22 g, 0.468 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (0.058 g, 0.140 mmol), palladium(II) acetate (0.016 g, 0.070 mmol) and 2 M K₃PO₄ (2.81 mL, 5.61 mmol) in dioxane (5 mL) was heated at 80°C for 2 h. The reaction mixture was filtered through celite, diluted with ethyl acetate, washed with brine, dried (Na₂SO₄), and concentrated *in*

vacuo. The crude product was purified on silica gel (80 g column) using 0-70% ethyl acetate in hexanes to give an orange solid (0.29 g, 99%). LCMS (M+1) = 624.45.


Intermediate 118



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-hydroxy-2-methylpyridin-3-yl)acetate:

Sodium nitrite (0.119 g, 1.731 mmol) was added to a solution of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.18 g, 0.289 mmol) in acetic acid (2.9 mL). The mixture was stirred at ambient temperature for 1 h and concentrated. The residue was taken up in methanol (5 mL) and THF (1 mL). K₂CO₃ (0.399 g, 2.89 mmol) was added and the mixture was stirred at ambient temperature for 1 h. 10% citric acid was added and the mixture was extracted with DCM (x3). The combined organic extracts were dried (Na₂SO₄) and concentrated *in vacuo*. The residue was purified on silica (40 g column) using 40-100% ethyl acetate in hexanes to give a brown solid (0.15 g, 83%). LCMS (M+1) = 625.35.

Intermediate 119




Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate.

To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-hydroxy-2-methylpyridin-3-yl)acetate (0.07 g, 0.112 mmol) and pyridine (0.091 mL, 1.120 mmol) in DCM (3 mL) at 0 °C was added

triflic anhydride (0.026 ml, 0.153 mmol). The mixture was stirred at 0 °C for 3 h and then quenched with saturated aqueous NaHCO₃. The mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried (Na₂SO₄), and concentrated *in vacuo*. The residue was purified on silica (40 g column) using 0-40% ethyl acetate in hexanes to give a white foamy solid (55 mg, 65%). LCMS (M+1) = 757.25.


Intermediate 120



(S)-Isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(3,4,5-trifluorophenyl)pyridin-3-yl)-2-(tert-butoxy)acetate:

A mixture of (S)-isopropyl 2-(6-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.2 g, 0.425 mmol), (3,4,5-trifluorophenyl)boronic acid (0.075 g, 0.425 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (0.013 g, 0.033 mmol), palladium(II) acetate (9.54 mg, 0.043 mmol), and 2 M K₃PO₄ (0.850 mL, 1.701 mmol) in dioxane (4.25 mL) was degassed and heated at 100 °C for 2 h in a microwave. The reaction mixture was then diluted with ethyl acetate, washed with brine, dried (Na₂SO₄), and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (10-100% ethyl acetate in hexanes). The desired fractions were concentrated *in vacuo* to give the product as a white solid (0.19 g, 86%). ¹H NMR (500 MHz, CDCl₃) δ 7.12 - 6.99 (m, 1H), 6.95 - 6.85 (m, 1H), 5.82 (br. s., 1H), 5.09 (dt, *J* = 12.5, 6.3 Hz, 1H), 4.18 (s, 2H), 3.32 (d, *J* = 12.0 Hz, 1H), 2.92 - 2.74 (m, 1H), 2.48 (s, 3H), 2.36 (d, *J* = 10.9 Hz, 1H), 2.14 - 1.98 (m, 1H), 1.57 - 1.54 (m, 2H), 1.45 - 1.37 (m, 2H), 1.26 (d, *J* = 6.3 Hz, 3H), 1.24 (d, *J* = 6.3 Hz, 3H), 1.20 (s, 9H), 0.94 (s, 3H), 0.74 (s, 3H). LCMS (M+1) = 522.40.


Intermediate 121



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-hydrazinyl-2-methylpyridin-3-yl)acetate:

- 5 A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.075 g, 0.102 mmol) and hydrazine (0.325 g, 10.15 mmol) in toluene (5.1 mL) was heated at 150 °C for 1 h in the microwave. The reaction mixture was diluted with ethyl acetate, washed with brine, dried (Na₂SO₄), and concentrated *in vacuo* give a
10 pale yellow foam which was used as is for further reactions. LCMS (M+1) = 621.25.

Intermediate 122




Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetate:

- 15 To a 14 mL test tube equipped with a stir was added tribasic potassium phosphate (419 mg, 1.98 mmol), 2-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (103 mg, 0.263 mmol), (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (100 mg, 0.220
20 mmol), and SPhos-Pd-G3 (8.6 mg, 11 µmol). The test tube was sealed with a rubber septum and then placed under nitrogen atmosphere. To the test tube was added a degassed (5 minutes of nitrogen sparging) mixture of dioxane (1.5 mL) and water (0.5 mL). The test tube was placed in a 60 °C heating block with stirring for 18 h. The reaction mixture was transferred to 125 mL separatory funnel and was diluted with Et₂O (25 mL). The
25 mixture was washed with water (25 mL), then dried over MgSO₄; filtered; then concentrated in vacuo. The resulting residue was dissolved in a minimum of acetone, then

was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (25 g SiO₂ column, hexanes:EtOAc 100:0 → 50:50) to afford a solid residue, isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetate. ESI-MS(+) m/z = 609.3 (M+1).

5


Intermediate 123



Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetate:

- 10 To a 14 mL test tube equipped with a stir was added tribasic potassium phosphate (419 mg, 1.98 mmol), 2-(2-fluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (103 mg, 0.263 mmol), (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (100 mg, 0.220 mmol), and SPhos-Pd-G3 (8.6 mg, 11 μmol). The test tube was sealed with a rubber
- 15 septum and then placed under N₂ atm. To the flask was added a degassed (5 min N₂ sparging) mixture of dioxane (1.5 mL) and water (0.5 mL). The test tube was placed in a 60 °C heating block with stirring for 18h. The reaction mixture was transferred to 125 mL separatory funnel and was diluted with Et₂O (25 mL). The mixture was washed with water (25 mL), then dried over MgSO₄; filtered; then concentrated in vacuo. The resulting
- 20 residue was dissolved in a min. of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (24g SiO₂ column, hexanes:EtOAc 100:0→:50:50) to afford isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetate as a solid. ESI-MS(+) m/z = 609.3 (M+1).

Intermediate 124




(S)-Isopropyl 2-(tert-butoxy)-2-(5-(2,3-difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetate:

- 5 To a 14 mL test tube equipped with a stir was added tribasic potassium phosphate (419 mg, 1.97 mmol), 2-(2,3-difluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (107 mg, 0.263 mmol), (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (100 mg, 0.220 mmol), and SPhos-Pd-G3 (8.6 mg, 11 μ mol). The test tube was sealed with a rubber
- 10 septum and then placed under N₂ atm. To the flask was added a degassed (N₂ sparging for 5 min.) solution of dioxane (1.5 mL) and water (0.5 mL). The test tube was placed in a 60 °C heating block with stirring for 18h. The reaction mixture was transferred to 125 mL separatory funnel and was diluted with Et₂O (25 mL). The mixture was washed with water (25 mL), then dried over MgSO₄; filtered; then concentrated in vacuo. The resulting
- 15 residue was dissolved in a min. of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (24g SiO₂ column, hexanes:EtOAc 100:0 $\rightarrow$ 50:50) to afford (S)-isopropyl 2-(tert-butoxy)-2-(5-(2,3-difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetate as a solid. ESI-MS(+) m/z = 627.3 (M+1).

20


Intermediate 125



(S)-Isopropyl 2-(6-(7-azaspiro[3.5]nonan-7-ylmethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

To a 25 mL r.b. flask equipped with a stir bar and charged with (*S*)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-formyl-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (644.7 mg, 1.33 mmol) was added 7-azaspiro[3.5]nonane (334 mg, 2.67 mmol) and DCM (10 mL). To the solution was added acetic acid (0.191 mL, 3.33 mmol). To the solution was added sodium triacetoxymethylborohydride (565 mg, 2.67 mmol) and MeOH (5 mL) to afford a homogeneous orange solution. The solution was stirred at r.t. for 18h. The reaction solution was concentrated in vacuo and the resulting residue was dissolved in EtOAc (25 mL), then transferred to a 125 mL separatory funnel. The solution was washed with aq. NaOH (1M, 25 mL), then brine (15 mL). The organic phase was dried over MgSO₄, filtered and concentrated in vacuo. The resulting residue was dissolved in a min. of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (40g column, hexanes:EtOAc 100:0→70:30) to afford (*S*)-isopropyl 2-(6-(7-azaspiro[3.5]nonan-7-ylmethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as a solid foam (577 mg, 73%). ¹H NMR (500 MHz, CDCl₃) δ 6.25 (br s, 1H), 5.03 (quin, J=6.2 Hz, 1H), 4.04 (br s, 1H), 3.78 - 3.63 (m, 2H), 3.57 - 3.45 (m, 1H), 2.88 (br d, J=11.3 Hz, 1H), 2.62 (br d, J=11.8 Hz, 1H), 2.56 (s, 3H), 2.49 (br s, 4H), 1.90 - 1.80 (m, 2H), 1.76 - 1.70 (m, 4H), 1.70 - 1.66 (m, 1H), 1.62 (br t, J=5.4 Hz, 4H), 1.60 - 1.52 (m, 2H), 1.43 (br d, J=12.1 Hz, 1H), 1.37 - 1.30 (m, 1H), 1.21 - 1.17 (m, 9H), 1.19 (d, J=6.1 Hz, 3H), 1.11 (d, J=6.1 Hz, 3H), 1.07 (s, 3H), 1.02 (s, 3H).

Intermediate 126




(S)-Isopropyl 2-(tert-butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formyl-2-methylpyridin-3-yl)acetate:

To a 25 mL r.b. flask equipped with a stir bar and charged with (*S*)-isopropyl 2-(tert-butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-

(hydroxymethyl)-2-methylpyridin-3-yl)acetate (213 mg, 0.388 mmol) in DCM (3.5 mL) and MeCN (0.5 mL) was added Dess-Martin periodinane (247 mg, 0.582 mmol). The solution was stirred at r.t. for 7h. The reaction mixture was transferred to a 125 mL separatory funnel and was diluted with Et₂O (25 mL). The solution was washed with aq. NaOH (1M, 15 mL). The aq. phase was extracted with Et₂O (25 mL). The combined organics were washed with brine (15 mL), then dried over MgSO₄, then filtered, then concentrated in vacuo. The resulting residue was dissolved in a min. of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (24g column, hexanes:EtOAc 100:0→80:20) to afford (S)-isopropyl 2-(tert-butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formyl-2-methylpyridin-3-yl)acetate as a white solid foam (172.3 mg, 81%). ¹H NMR (500 MHz, CDCl₃) δ 9.90 (s, 1H), 6.89 (br d, J=10.7 Hz, 1H), 6.83 (br d, J=10.7 Hz, 1H), 6.03 (br s, 1H), 5.11 (dt, J=12.5, 6.3 Hz, 1H), 4.10 (s, 3H), 3.26 - 3.18 (m, 1H), 2.99 - 2.89 (m, 1H), 2.71 (s, 3H), 2.43 - 2.33 (m, 1H), 2.17 - 2.09 (m, 1H), 1.46 - 1.26 (m, 4H), 1.25 (d, J=6.3 Hz, 3H), 1.23 (d, J=6.1 Hz, 3H), 1.18 (s, 9H), 0.94 (br s, 3H), 0.74 (br s, 3H).

Intermediate 127




Ethyl-(S)-2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenoxy)phenyl)pyridin-3-yl)acetate:

To a dry reaction vial under nitrogen was added ethyl-(S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(tert-butoxy)acetate (230 mg, 0.498 mmol), (4-(4-fluorophenoxy)phenyl)boronic acid (190 mg, 0.731 mmol) and THF (25 mL). The reaction was flushed with argon, treated with 0.5 M potassium phosphate tribasic (3 mL, 1.500 mmol), followed 2nd generation X-phos precatalyst (30 mg, 0.038 mmol), capped and stirred at room temp for 18 h. The crude reaction was dissolved in EtOAc, extracted and purified via silica gel chromatography (40g SiO₂ column, hexane:EtOAc 100:0 → 0:100) to afford ethyl (S)-2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-

1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate, 260 mg (87%). LCMS (M+1) = 597.3, 599.3.

Intermediate 128




5

Ethyl-(S)-2-(tert-butoxy)-2-(2-chloro-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)acetate:

To a dry pressure vial under nitrogen was added ethyl-(S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)-2-(tert-butoxy)acetate (180 mg, 0.367 mmol), 3,5-difluoro-4-methoxy-phenylboronic acid (105 mg, 0.559 mmol) and THF (17 mL). The reaction was flushed with argon, treated with 0.5 M potassium phosphate tribasic (2.60 mL, 1.300 mmol), followed by 2nd generation X-phos precatalyst (32 mg, 0.041 mmol), capped and stirred at room temp for 18 h. The crude material was dissolved in EtOAc (200 mL), extracted with water (1 x 6 mL), brine (1 x 10 mL), dried over Na₂SO₄, and concentrated. The crude material was purified via silica gel chromatography (40g SiO₂ column, hexane:EtOAc 100:0 -> 70:30) to afford ethyl (S)-2-(tert-butoxy)-2-(2-chloro-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)acetate, 60.2 mg, (30%). LCMS (M+1) = 553.3 and 555.3.

20

Intermediate 129




Ethyl (S)-2-(6-amino-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)-2-(tert-butoxy)acetate:

To a dry pressure vial under nitrogen was added (32.2 mg, 0.068 mmol, (4-(4-fluorophenethoxy)phenyl) ethyl-(S)-2-(6-amino-5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(tert-butoxy)acetate boronic acid (27 mg, 0.104

mmol) and THF (4 mL). The reaction was flushed with argon, treated with 0.5 M potassium phosphate tribasic (500 μ L, 0.250 mmol) followed by 2nd generation X-phos precatalyst (6.6 mg, 8.39 μ mol) and stirred at room temp for 18 h. The reaction was diluted with ethyl acetate (75 mL), extracted with water (1 x 5 mL), brine (1 x 5 mL),
 5 dried over Na₂SO₄, and concentrated. The crude material was purified via silica gel chromatography (12g SiO₂ column, dichloromethane:EtOAc 100:0 -> 0:100) to afford ethyl (S)-2-(6-amino-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)-2-(tert-butoxy)acetate, 34.9 mg (84%). LCMS (M+1) = 612.5.

10

Intermediate 130




Ethyl (S)-2-(tert-butoxy)-2-(2-chloro-5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)acetate:

15 To a reaction vial under nitrogen was added (S)-ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)-2-(tert-butoxy)acetate (97 mg, 0.198 mmol), (3,4-difluorophenyl)boronic acid (60 mg, 0.380 mmol) and THF (8 mL). The reaction was flushed with argon, treated with 0.5 M potassium phosphate tribasic (1.30 mL, 0.650 mmol), followed by 2nd generation X-phos precatalyst (15 mg, 0.019 mmol),
 20 capped and stirred at room temp for 18 h. The crude material was dissolved in EtOAc, extracted with brine and purified via silica gel chromatography (12g SiO₂ column, dichloromethane:EtOAc 100:0 -> 0:100) to afford ethyl (S)-2-(tert-butoxy)-2-(2-chloro-5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)acetate, 60.8 mg, (58%). LCMS (M+1) = 523.2, 525.2.

25


Intermediate 131



Ethyl (S)-2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-formylpyridin-3-yl)acetate:

To a dry reaction vial under nitrogen was added ethyl-(S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)-2-(tert-butoxy)acetate (110.5 mg, 0.226 mmol), 2-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (104.7 mg, 0.291 mmol) and THF (9 mL). The reaction was flushed with argon, treated with 0.5 M potassium phosphate tribasic (1.6 mL, 0.800 mmol), followed by 2nd generation X-phos precatalyst (13.6 mg, 0.017 mmol), capped and stirred at room temp for 18 h. The crude reaction was dissolved in EtOAc (110 mL), extracted with water (1 x 5 mL), brine (1 x 5 mL), dried over Na₂SO₄ and concentrated. The crude material was purified via silica gel chromatography (24g SiO₂ column, dichloromethane:EtOAc 100:0 -> 10:90) to afford ethyl (S)-2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-formylpyridin-3-yl)acetate, 67.8 mg (47%). LCMS (M+1) = 643.3.

Intermediate 132




Ethyl (S)-2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-formylpyridin-3-yl)acetate:

To a dry reaction vial under argon was added ethyl-(S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)-2-(tert-butoxy)acetate (117.5 mg, 0.240 mmol), (4-(4-fluorophenethoxy)phenyl)boronic acid (95 mg, 0.365 mmol) and THF (9 mL). The reaction was flushed with argon, treated with 0.5 M potassium phosphate tribasic (1.65 mL, 0.825 mmol), followed by 2nd generation X-phos precatalyst (15 mg, 0.019 mmol), capped and stirred at room temp for 18 h. The crude material was dissolved in EtOAc, extracted and purified via silica gel chromatography (40g SiO₂ column,

hexane:EtOAc 100:0 -> 0:100) to afford ethyl (S)-2-(*tert*-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-formylpyridin-3-yl)acetate, 80.0 mg (53%). LCMS (M+1) = 625.4.


Intermediate 133



Ethyl (S)-2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate:

To a dry reaction vial under argon was added (S)-ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate (105 mg, 0.227 mmol), 2-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (150 mg, 0.416 mmol) and THF (9 mL). The reaction was flushed with argon, treated with 0.5 M potassium phosphate tribasic (1.70 mL, 0.850 mmol), followed by 2nd generation X-phos precatalyst (9.7 mg, 0.012 mmol), capped and stirred at room temp for 18 h. The reaction was diluted with ethyl acetate, extracted and the crude material was purified via silica gel chromatography (24g SiO₂ column, dichloromethane:EtOAc 100:0 -> 0:100) to afford ethyl (S)-2-(*tert*-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate, 143 mg (82%). LCMS (M+1) = 615.3, 617.3.

Intermediate 134



Ethyl (S)-2-(tert-butoxy)-2-(6-chloro-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-2-formyl-[3,3'-bipyridin]-5-yl)acetate:


To a dry reaction vial under argon was added ethyl(S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)-2-(*tert*-butoxy)acetate (104 mg, 0.212 mmol), (5-fluoropyridin-3-yl)boronic acid (66 mg, 0.468 mmol) and THF (9 mL). The

reaction was flushed with argon, treated with 0.5 M potassium phosphate tribasic (1.80 mL, 0.900 mmol), followed by 2nd generation X-phos precatalyst (18 mg, 0.023 mmol), capped and stirred at room temp for 48h. The reaction was diluted with ethyl acetate, extracted and the crude residue was purified via silica gel chromatography (24g SiO₂ column, dichloromethane:EtOAc 100:0 -> 30:70) to afford ethyl (S)-2-(tert-butoxy)-2-(6-chloro-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-2-formyl-[3,3'-bipyridin]-5-yl)acetate, 14 mg (13%). LCMS (M+1) = 506.3.

Also present within the above intermediate was

10


Intermediate 135



Ethyl (S)-2-(tert-butoxy)-2-(6-chloro-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-[3,3'-bipyridin]-5-yl)acetate: LCMS (M+1) = 478.2 and 480.2.

15

Intermediate 136




Ethyl (S)-2-(tert-butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate:

To a dry microwave vial under nitrogen was added ethyl-(S)-2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate (113.7 mg, 0.185 mmol), zinc (3 mg, 0.046 mmol), zinc cyanide (45 mg, 0.383 mmol) and DMF (1.0 mL). The reaction was flushed with argon, treated with [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (13 mg, 0.018 mmol), capped and heated in a microwave reactor at 145 C for 19h. The reaction was diluted with ethyl acetate (100 mL), extracted with water (3 x 15 mL), brine (1 x 50 mL), dried over Na₂SO₄ and concentrated. The crude material was purified via silica gel chromatography (40g

SiO₂ column, hexane:EtOAc 100:0 -> 60:40) to afford ethyl (S)-2-(*tert*-butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate, 63.1 mg (56%). LCMS (M+1) = 606.4.

5

Intermediate 137




(*S*)-Ethyl 2-(*tert*-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate:

A mixture of (*S*)-ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate (230 mg, 0.498 mmol) and (4-(4-fluorophenethoxy)phenyl)boronic acid in THF (25 mL) is flushed well with argon, then added degassed 0.5 M potassium phosphate tribasic (3 mL, 1.500 mmol) then 2nd generation Xphos precatalyst (30 mg, 0.038 mmol), sealed vial and stirred at RT for 16 hours overnight. LC/MS showed formation of the ester. The organic layer was decanted from the water layer, removed the THF under nitrogen, take up in EtOAc, dry over MgSO₄, filter, and concentrate under vacuum. Purified residue by flash column chromatography to give 260 mg (93%) of (*S*)-ethyl 2-(*tert*-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate as a colorless solid. LCMS (M+1) = 596.7.

20

Intermediate 138




Isopropyl (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

To a 100 mL Schlenk flask equipped with a stir bar was added dioxane (40 ml) and water (10.00 ml). The flask was sealed with a septum, then the solution was degassed via N₂ sparging for 10 min. To the solution was added (5,6-difluoropyridin-3-yl)boronic

acid (2.00 g, 12.6 mmol), isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (3.82 g, 8.39 mmol), tribasic potassium phosphate (8.02 g, 37.8 mmol), and SPhos-Pd-G3 (0.327 g, 0.420 mmol). The flask was placed in a 60 °C heating bath with stirring for 4 h. The reaction mixture was cooled to r.t., then was transferred to a 500 mL separatory funnel and was diluted with water (200 mL), then was extracted with Et₂O (200 mL). The organic phase was dried over MgSO₄; filtered; then concentrated in vacuo. The residue was dissolved in a min of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ chromatography (80g SiO₂ column, hexanes:EtOAc 100:0→60:40) to afford isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate as a solid yellow foam (3.5305 g, 86 %). ¹H NMR (500 MHz, CHLOROFORM-d) δ 8.14 (s, 1H), 7.95 (t, *J*=1.8 Hz, 1H), 7.54 (t, *J*=8.4 Hz, 1H), 5.91 (br s, 1H), 5.12 (spt, *J*=6.3 Hz, 1H), 3.43 (br s, 1H), 2.96 (br s, 1H), 2.64 (s, 3H), 2.43 - 2.22 (m, 2H), 1.26 (d, *J*=6.3 Hz, 3H), 1.24 (d, *J*=6.1 Hz, 3H), 1.18 (s, 9H), 1.50 - 1.12 (m, 4H), 0.94 (br s, 3H), 0.85 (br s, 3H).


Intermediate 139



Isopropyl (S)-2-(tert-butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

A mixture of Isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.100 g, 0.220 mmol, 1 equiv), 3-chloro-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (0.057 g, 0.220 mmol, 1 equiv), Cs₂CO₃ (0.300 g, 0.922 mmol, 4.2 equiv), and Pd(dppf)Cl₂ CH₂Cl₂ adduct (0.018 g, 0.022 mmol, 0.1 equiv) in dioxane was heated at 110 °C for 2 h. After cooling to ambient temperature, the reaction mixture was filtered through celite/Na₂SO₄ eluting with ethyl acetate. The filtrate was concentrated *in vacuo* and purified by silica gel flash chromatography (0-50 % ethyl acetate in hexanes) to give the product (0.069 g, 62%) as a white foamy solid. LCMS (M+1): 506.35.


Intermediate 140



Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-5',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate:


- 5 A solution of isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.030 g, 0.066 mmol, 1 equiv), (6-fluoro-5-methylpyridin-3-yl)boronic acid (10.21 mg, 0.066 mmol, 1 equiv), Cs₂CO₃ (0.090 g, 0.277 mmol, 4.2 equiv), and Pd(dppf)Cl₂ CH₂Cl₂ adduct (5.38 mg, 6.59 μmol, 0.1 equiv) in dioxane was heated at 110 °C for 2 h. After cooling to ambient temperature, the
- 10 reaction was filtered through a plug of celite and concentrated *in vacuo*. The crude product was carried on without further purification. LCMS (M+1): 486.4.

Intermediate 141



- 15 *Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate:*
- A mixture of isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.15 g, 0.329 mmol, 1 equiv), (6-fluoro-2-methylpyridin-3-yl)boronic acid (0.102 g, 0.659 mmol, 2 equiv), Cs₂CO₃ (0.451 g, 1.383
- 20 mmol, 4.2 equiv), and Pd(dppf)Cl₂ CH₂Cl₂ adduct (0.027 g, 0.033 mmol, 0.1 equiv) in dioxane (5 mL) was heated at 110 °C for 2 h. After cooling to ambient temperature, the reaction was concentrated *in vacuo* and purified silica gel flash chromatography (0-100% ethyl acetate/hexanes) to give the product (42 mg, 26%) as a pale yellow viscous oil. LCMS (M+1): 486.40.


Intermediate 142



Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

- 5 A mixture of Isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.15 g, 0.329 mmol, 1 equiv), (2,6-difluoropyridin-3-yl)boronic acid (0.105 g, 0.659 mmol, 2 equiv), Cs₂CO₃ (0.451 g, 1.383 mmol, 4.2 equiv), and Pd(dppf)Cl₂ CH₂Cl₂ adduct (0.027 g, 0.033 mmol, 0.1 equiv) in dioxane (5 mL) was heated at 110 °C for 2 h. After cooling to ambient temperature, the
- 10 reaction was concentrated *in vacuo* and purified by silica gel flash chromatography (0-100% ethyl acetate/hexanes to give the product (22 mg, 14%) as a pale yellow viscous oil. LCMS (M+1): 490.4.

Intermediate 143




- 15 *Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:*

- To a dry 150 mL pressure bottle under nitrogen was added isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (630 mg, 1.298 mmol), 2-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (700 mg, 1.943 mmol) and THF (60 mL). The
- 20 reaction was flushed well with argon, treated with potassium phosphate tribasic, 0.5M in water (9.75 mL, 4.88 mmol), followed by 2nd generation X-phos precatalyst (71.1 mg, 0.090 mmol), capped and stirred at room temp for 18 h. The crude reaction was diluted
- 25 with ethyl acetate (300 mL), extracted with water (1 x 10 mL), brine (1 x 10 mL), dried over Na₂SO₄ and concentrated. The crude material was purified via silica gel

chromatography (80g SiO₂ column, hexane:EtOAc 100:0 → 50:50) to afford isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate, 560 mg (54%). LCMS = 639.4 (M+H).

5


Intermediate 144



Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-formyl-2-methylpyridin-3-yl)acetate:

- 10 To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate (477.3 mg, 0.747 mmol) in a mixture of CH₂Cl₂ (20 mL) and acetonitrile (2.0 mL) was added Dess-Martin periodinane (514 mg, 1.212 mmol). The reaction was flushed briefly with N₂, capped and stirred at room temp for 4.5 h. The crude reaction was
- 15 diluted with Et₂O (400 mL), extracted with 1.0M NaOH (2 x 40 mL), brine (1 x 20 mL), dried over Na₂SO₄, filtered and concentrated. The crude material was purified via silica gel chromatography (40g SiO₂ column, CH₂Cl₂:EtOAc 100:0 → 20:80) to afford isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-formyl-2-methylpyridin-3-yl)acetate, 458 mg (96%). LCMS
- 20 = 668.7 (M+32).

Intermediate 145




Isopropyl (2S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(1-hydroxyethyl)-2-methylpyridin-3-yl)acetate (Atrop Isomer 1):

To a dry reaction vial under N₂ was added isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-formyl-2-methylpyridin-3-yl)acetate (40 mg, 0.063 mmol) and THF (1.5 mL). The reaction was flushed very well with argon, cooled to 0 °C and treated with methylmagnesium chloride, 3.0 M in THF (25 µL, 0.075 mmol) over 30 seconds. The reaction was stirred at 0 °C for 2 min, then the bath was removed and the reaction was allowed to slowly warm to room temp over 10 min. The reaction was recooled to 0 °C and treated with additional methylmagnesium chloride, 3.0 M in THF (25 µL, 0.075 mmol). The cooling bath was removed and the reaction was allowed to warm to room temp over 15 min. The crude material was purified via silica gel chromatography (40g SiO₂ column, CH₂Cl₂:EtOAc 100:0 -> 50:50) to afford isopropyl (2S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(1-hydroxyethyl)-2-methylpyridin-3-yl)acetate (**diastereomer 1**), 15.3 mg (37%). LCMS = 652.7 (M+H).


Also isolated from this reaction was

Intermediate 146



Isopropyl (2S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(1-hydroxyethyl)-2-methylpyridin-3-yl)acetate (**diastereomer 2**), 9.7 mg (24%). LCMS = 652.7 (M+H).


Intermediate 147



Isopropyl (S)-2-(6-acetyl-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

To a dry reaction vial under N₂ was added isopropyl (2S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(1-hydroxyethyl)-2-methylpyridin-3-yl)acetate (111.5 mg, 0.171 mmol), CH₂Cl₂ (4 mL), acetonitrile (0.4 mL) and several pieces of 4 Å molecular sieves. The reaction was then treated with Dess-Martin periodinane (129.3 mg, 0.305 mmol), capped and stirred at room temp for 18 h. The reaction was diluted with EtOAc (150 mL), extracted with aq 1M NaOH (1 x 5 mL), water (1 x 5 mL), brine (1 x 5 mL), dried over Na₂SO₄ and concentrated. The crude material was purified via silica gel chromatography (24g SiO₂ column, CH₂Cl₂:EtOAc 100:0 → 85:15) to afford isopropyl (S)-2-(6-acetyl-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate, 100 mg (90%). LC/MS = 651.4 (M+H).

Intermediate 148




Isopropyl (S)-2-(5-(benzyloxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-butoxy)acetate:

To a 100 mL Schlenk flask equipped with a stir bar was added 2-(5-(benzyloxy)pyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (3.50 g, 10.29 mmol), isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (3.12 g, 6.86 mmol), palladium tetrakis (1.585 g, 1.372 mmol), diacetoxy copper (0.623 g, 3.43 mmol) and anhydrous tribasic potassium phosphate, finely ground (7.28 g, 34.3 mmol). The flask was sealed with a rubber septum, then placed under N₂ atm. To the flask was added a degassed (N₂ sparging for 5 min) solution of diethanolamine (0.721 g, 6.86 mmol) in DMF (60 mL). The flask was placed in a 100 °C oil bath with stirring for 18 h. The reaction mixture was transferred to a 1L separatory funnel. The mixture was diluted with water:brine and extracted with EtOAc. However, an emulsion made this process extremely problematic. The volumes of each solvent were increased incrementally to finally achieve water (175 mL) : brine (175 mL) : EtOAc (250

mL). However, the emulsion persisted. The entire mixture was filtered through Celite. The filtrate was transferred back to the separatory funnel and the mixture was shaken, upon which the emulsion re-formed and persisted. The mixture was filtered through Celite and the mixture was immediately partitioned in the separatory funnel without further mixing. The aq. phase was mixed with EtOAc (250 mL). The emulsion was filtered through the same Celite pad as before, and the mixture was partitioned in the separatory funnel without further mixing. The combined organics were washed with water:brine (175 mL:175 mL) (no problematic emulsion), then brine (150 mL) (no problematic emulsion). The combined organics were dried over MgSO₄; were filtered; then were concentrated in vacuo. The resulting amber solution/solid residue was dissolved in a min. of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ chromatography (220g SiO₂ column, hexanes:EtOAc 100:0 → 40:60) to afford isopropyl (S)-2-(5-(benzyloxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-butoxy)acetate as a colorless solid (1.88 g, 49 %). ¹H NMR (500 MHz, CHLOROFORM-d) δ 8.51 (d, *J*=2.4 Hz, 1H), 8.28 (s, 1H), 7.51 - 7.36 (m, 7H), 7.32 (d, *J*=8.5 Hz, 1H), 6.06 (br s, 1H), 5.24 - 5.18 (m, 2H), 5.16 - 5.09 (m, 1H), 3.31 (br d, *J*=11.3 Hz, 2H), 2.64 (s, 3H), 2.34 - 2.07 (m, 1H), 1.48 - 1.27 (m, 4H), 1.25 (d, *J*=6.3 Hz, 3H), 1.22 (d, *J*=6.1 Hz, 3H), 1.19 (s, 9H), 0.98 - 0.89 (m, 3H), 0.82 (br s, 3H).

20

Intermediate 149




Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

To a 250 mL round bottom flask equipped with a stir bar and charged with isopropyl (S)-2-(5-(benzyloxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-butoxy)acetate (1.8796 g, 3.36 mmol) was added palladium on carbon (Degussa type E101 NE/W, 10% dry basis Pd, 50% wt water, 0.179 g, 0.168 mmol) and MeOH (20 mL). The flask was sealed with a rubber septum, then was sparged with N₂ for 5 min. The mixture was then sparged with H₂ for 3 minutes, then was placed under a

static balloon-pressure H₂ atm. with stirring for 1 h. The mixture was sparged with N₂ for 10 minutes, then the reaction mixture was directly concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ chromatography (DCM:EtOH 100:0→97.5:2.5→90:10) to a colorless solid. The material was co-evaporated twice with PhMe to afford isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate as a colorless solid foam (1.41 g, 80 % yield). ¹H NMR (500 MHz, CHLOROFORM-d) δ 8.40 (d, *J*=2.7 Hz, 1H), 8.22 (s, 1H), 7.31 - 7.26 (m, 1H), 7.22 - 7.16 (m, 1H), 6.03 (br s, 1H), 5.14 (quin, *J*=6.3 Hz, 1H), 3.51 - 3.09 (m, 2H), 2.71 (s, 3H), 2.44 - 2.18 (m, 2H), 1.77 - 1.42 (m, 2H), 1.41 - 1.31 (m, 4H), 1.26 (d, *J*=6.1 Hz, 3H), 1.23 (d, *J*=6.3 Hz, 3H), 1.20 (s, 9H), 0.90 (br s, 6H).

Intermediate 150




Isopropyl (S)-2-(5-(4-(benzyloxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate:

To a 40 mL vial equipped with a stir was added tribasic potassium phosphate (anhydrous, 4.19 g, 19.76 mmol), (4-(benzyloxy)phenyl)boronic acid (0.751 g, 3.29 mmol), isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (1.0 g, 2.196 mmol), and SPhos-Pd-G3 (0.086 g, 0.110 mmol). The vial was sealed with a screw cap rubber septum and then placed under N₂ atm. To the vial was added a degassed (N₂ bubbling for 5 minutes) solution of dioxane:water (15 mL : 5 mL) water (5 mL). The vial was placed in a 65 °C heating block with stirring for 2 h. The reaction mixture was transferred to 500 mL separatory funnel and was diluted with Et₂O (250 mL). The mixture was washed with water (250 mL), then dried over MgSO₄; filtered; then concentrated in vacuo. The resulting residue was dissolved in a min. of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (hexanes:EtOAc 90:10→40:60) to afford a colorless solid foam, isopropyl (S)-2-(5-(4-(benzyloxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (1.0882 g, 89 % yield). ¹H NMR (500 MHz, CHLOROFORM-d) δ 8.18 (s, 1H), 7.49 (d, *J*=7.4 Hz, 2H), 7.43 (t, *J*=7.6 Hz, 2H), 7.40 -

7.35 (m, 1H), 7.23 (d, $J=8.4$ Hz, 2H), 7.06 (d, $J=8.5$ Hz, 2H), 6.02 (br s, 1H), 5.16 (s, 2H), 5.14 - 5.08 (m, 1H), 3.37 (br s, 1H), 3.02 (br s, 1H), 2.63 (s, 3H), 2.31 (br s, 1H), 2.22 (br s, 1H), 1.25 (dd, $J=11.6$, 6.2 Hz, 6H), 1.19 (s, 9H), 0.93 (br s, 3H), 0.77 (br s, 3H); 4 piperidine protons appear as very broad resonances between 0.7 and 1.7 ppm.

5

Intermediate 151




Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-hydroxyphenyl)-2-methylpyridin-3-yl)acetate:

10 To a 100 mL round bottom flask equipped with a stir bar and charged with isopropyl (S)-2-(5-(4-(benzyloxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (1.0882 g, 1.948 mmol) was added 10% Pd-C (0.104 g, 0.097 mmol) and MeOH (20 mL). The flask was sealed with a rubber septum, then the mixture was sparged via N₂ bubbling through the solvent for 5 min. The mixture
15 was then sparged with H₂ for 3 minutes. The mixture was placed under a static balloon-pressure H₂ atm. with stirring for 30 min. The atmosphere was exchanged to N₂ (5 min bubbling). The reaction mixture was filtered through a pad of Celite and the filtrate was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (hexanes:EtOAc 100:0→0:100) to afford a colorless solid, isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-hydroxyphenyl)-2-methylpyridin-3-yl)acetate (784 mg, 85 % yield). ¹H NMR (500 MHz, CHLOROFORM-d) δ 8.15 (s, 1H), 7.15 - 7.11 (m, 2H), 6.96 - 6.91 (m, 2H), 6.00 (br s, 1H), 5.11 (spt, $J=6.3$ Hz, 1H), 3.36 (br s, 1H), 3.01 (br s, 1H), 2.64 (s, 3H), 2.39 (br s, 1H), 2.23 (br s, 1H), 1.62 (br s, 4H), 1.24 (dd, $J=11.1$, 6.2 Hz, 6H), 1.18 (s, 9H), 0.96 - 0.74 (m, 6H).

25

Intermediate 152




6-Bromo-3-(4-fluorophenethoxy)-2-methylpyridine:

To a 50 mL round bottom flask equipped with a stir bar was added 6-bromo-2-methylpyridin-3-ol (250 mg, 1.330 mmol), 2-(4-fluorophenyl)ethan-1-ol (186 mg, 1.330 mmol), triphenylphosphine (418 mg, 1.596 mmol) and THF (10 mL). To the stirred solution was added DIAD (0.310 mL, 1.596 mmol). The solution warmed to a mild reflux, then cooled within 5 minutes. The solution was stirred at r.t. for 2 hrs. The reaction solution was concentrated in vacuo and the resulting oil was diluted with a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to silica gel chromatography (40 g column, 5-40% EtOAc:Hex) to afford the product 6-bromo-3-(4-fluorophenethoxy)-2-methylpyridine (386 mg, 1.244 mmol, 94 % yield) as a white solid. ¹H NMR (500 MHz, chloroform-d) δ 7.29 - 7.21 (m, 3H), 7.03 (t, J=8.7 Hz, 2H), 6.95 (d, J=8.5 Hz, 1H), 4.14 (t, J=6.6 Hz, 2H), 3.11 (t, J=6.5 Hz, 2H), 2.42 (s, 3H). ESI-MS(+) m/z = 309.9 (M+1).

15

Intermediate 153




Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6,6'-dimethyl-[2,3'-bipyridin]-5'-yl)acetate:

To a 14 mL test tube equipped with a stir bar was added (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (100 mg, 0.238 mmol), SPhos-Pd-G3 (9.27 mg, 0.012 mmol), tribasic potassium phosphate (454 mg, 2.141 mmol) and 6-bromo-3-(4-fluorophenethoxy)-2-methylpyridine (73.8 mg, 0.238 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) Dioxane (892 μ l) and Water (297 μ l). The test tube was placed in a 60 °C heating block with stirring (t=0). LCMS analysis at t=3h found a large product mass peak and the disappearance of the starting boronic acid. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford

the product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6,6'-dimethyl-[2,3'-bipyridin]-5'-yl)acetate (20 mg, 0.033 mmol, 13.88 % yield) as a brown oil. ESI-MS(+) m/z = 606.8 (M+1).


5

Intermediate 154

*2-Chloro-5-(4-fluorophenethoxy)-4-methylpyridine:*

To a 40 mL vial equipped with a stir bar was added 6-chloro-4-methylpyridin-3-ol (1.0 g, 6.97 mmol), 2-(4-fluorophenyl)ethan-1-ol (0.976 g, 6.97 mmol),
 10 triphenylphosphine (2.192 g, 8.36 mmol) and THF (25 mL). To the stirred solution was added DIAD (1.625 mL, 8.36 mmol). The solution warmed to a mild reflux, then cooled within 5 minutes. The solution was stirred at r.t. (t=0). LCMS analysis at t=18h found a major peak corresponding to the desired product. The reaction solution (blue color) was transferred to a 100 mL r.b. flask and then concentrated in vacuo. The resulting residue
 15 was dissolved in a min of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (80 g column, 0-20% EtOAc:Hex) to afford the product 2-chloro-5-(4-fluorophenethoxy)-4-methylpyridine (1.404 g, 5.28 mmol, 76 % yield) as a colorless oil. ¹H NMR (500 MHz, chloroform-d) δ 7.85 (s, 1H), 7.25 - 7.21 (m, 2H), 7.07 (s, 1H), 7.04 - 6.98 (m, 2H), 4.21 (t, J=6.5 Hz, 2H), 3.09 (t,
 20 J=6.5 Hz, 2H), 2.16 (s, 3H).

Intermediate 155




Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-
 25 *4,6'-dimethyl-[2,3'-bipyridin]-5'-yl)acetate:*

To a 14 mL test tube equipped with a stir bar and (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (100 mg, 0.238 mmol) was added SPhos-Pd-G3 (9.27 mg, 0.012 mmol), tribasic

potassium phosphate (454 mg, 2.141 mmol) and 2-chloro-5-(4-fluorophenethoxy)-4-methylpyridine (63.2 mg, 0.238 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (892 µl) and water (297 µl). The test tube was placed in a 60 °C heating block with stirring (t=0). LCMS analysis at t=3h found a large product mass peak and the disappearance of the starting boronic acid. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-4,6'-dimethyl-[2,3'-bipyridin]-5'-yl)acetate (12 mg, 0.020 mmol, 8.33 % yield) as a red/brown oil. ESI-MS(+) *m/z* = 606.4 (M+1).


Intermediate 156



2-Chloro-5-(4-fluorophenethoxy)-4-methylpyrimidine:

To a 50 mL round bottom flask equipped with a stir bar was added 2-chloro-4-methylpyrimidin-5-ol (250 mg, 1.729 mmol), 2-(4-fluorophenyl)ethan-1-ol (242 mg, 1.729 mmol), triphenylphosphine (544 mg, 2.075 mmol) and THF (10 mL). To the stirred solution was added DIAD (0.404 mL, 2.075 mmol). The solution warmed to a mild reflux, then cooled within 5 minutes. The solution was stirred at r.t. for 2 hrs. The reaction solution was concentrated in vacuo and the resulting oil was diluted with a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to silica gel chromatography (40 g column, 5-40% EtOAc:Hex) to afford the product 2-chloro-5-(4-fluorophenethoxy)-4-methylpyrimidine (448 mg, 1.680 mmol, 97 % yield) as a white solid. ¹H NMR (500 MHz, chloroform-d) δ 8.04 (s, 1H), 7.26 (dd, *J*=8.7, 5.4 Hz, 2H), 7.07 - 6.97 (m, 2H), 4.25 (t, *J*=6.5 Hz, 2H), 3.14 (t, *J*=6.5 Hz, 2H). ESI-MS(+) *m/z* = 267 (M+1).


Intermediate 157



Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)-4-methylpyrimidin-2-yl)-2-methylpyridin-3-yl)acetate:

- 5 To a 14 mL test tube equipped with a stir bar and added (S)-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (105 mg, 0.250 mmol) and SPhos-Pd-G3 (9.73 mg, 0.012 mmol), tribasic potassium phosphate (477 mg, 2.248 mmol) and 2-chloro-5-(4-fluorophenethoxy)-4-methylpyrimidine (66.6 mg, 0.250 mmol). The flask was sealed with a rubber septum,
- 10 then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (937 µl) and water (312 µl). The test tube was placed in a 60 °C heating block with stirring (t=0). The reaction was stirred for 3 hrs. LCMS analysis at t=3h found a large peak that corresponded to the expected product mass. The LCMS did not show any more boronic acid. The reaction was cooled to RT and diluted with EtOAc
- 15 and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and the volatiles evaporated to afford the crude product. The crude product was purified via silica gel (24 g column, 20-100% EtOAc:Hex), desired fractions collected and the volatiles evaporated to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)-4-methylpyrimidin-2-yl)-2-
- 20 methylpyridin-3-yl)acetate (26 mg, 0.043 mmol, 17.15 % yield) as a brown oil. ESI-MS(+) *m/z* = 607.7 (M+1).

Intermediate 158




- 25 *2-Chloro-3-fluoro-5-(4-fluorophenethoxy)pyridine:*

To a 50 mL round bottom flask equipped with a stir bar was added 6-chloro-5-fluoropyridin-3-ol (250 mg, 1.695 mmol), 2-(4-fluorophenyl)ethan-1-ol (238 mg, 1.695 mmol), triphenylphosphine (533 mg, 2.033 mmol) and THF (10 mL). To the stirred solution was added DIAD (0.395 mL, 2.033 mmol). The solution warmed to a mild

reflux, then cooled within 5 minutes. The solution was stirred at RT for 2 hrs. The reaction solution was concentrated in vacuo and the resulting oil was diluted with a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to silica gel chromatography (40 g column, 5-40% EtOAc:Hex) to afford the product 2-chloro-3-fluoro-5-(4-fluorophenethoxy)pyridine (443 mg, 1.643 mmol, 97 % yield) as a white solid. ¹H NMR (500 MHz, chloroform-d) δ 7.93 (d, J=2.5 Hz, 1H), 7.25 (dd, J=8.5, 5.4 Hz, 2H), 7.08 - 7.01 (m, 3H), 4.21 (t, J=6.7 Hz, 2H), 3.11 (t, J=6.8 Hz, 2H). ESI-MS(+) m/z = 270 (M+1).

10


Intermediate 159



Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-3-fluoro-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

To a 14 mL test tube equipped with a stir bar and (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (100 mg, 0.238 mmol) was added SPhos-Pd-G3 (9.27 mg, 0.012 mmol), tribasic potassium phosphate (454 mg, 2.141 mmol) and 2-chloro-3-fluoro-5-(4-fluorophenethoxy)pyridine (64.2 mg, 0.238 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (892 μ l) and water (297 μ l). The test tube was placed in a 60 °C heating block with stirring (t=0). LCMS analysis at t=3h found a large product mass peak and the disappearance of the starting boronic acid. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-3-fluoro-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (24 mg, 0.039 mmol, 16.55 % yield) as a red/brown oil. ESI-MS(+) m/z = 610.3 (M+1).

Intermediate 160




Isopropyl (S)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetate:

- 5 To a 14 mL test tube equipped with a stir bar and added (S)-4-(4,4-dimethylpiperidin-1-yl)-5-(2-isopropoxy-2-oxo-1-(tert-pentyloxy)ethyl)-6-methylpyridin-3-yl)boronic acid (105 mg, 0.242 mmol) and SPhos-Pd-G3 (9.42 mg, 0.012 mmol), tribasic potassium phosphate (462 mg, 2.175 mmol) and 2-chloro-5-(4-fluorophenethoxy)pyrimidine (61.1 mg, 0.242 mmol). The flask was sealed with a rubber
- 10 septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (906 µl) and water (302 µl). The test tube was placed in a 60 °C heating block with stirring (t=0). The reaction was stirred for 3 hrs. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and the volatiles evaporated to afford the
- 15 crude product. The crude product was purified via silica gel (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetate (21 mg, 0.035 mmol, 14.32 % yield) as a brown oil. ESI-MS(+) *m/z* = 607.7 (M+1).

20

Intermediate 161




6-chloro-3-(4-fluorophenethoxy)-2-methoxypyridine:

- To a 50 mL round bottom flask equipped with a stir bar was added 6-chloro-2-methoxypyridin-3-ol (250 mg, 1.567 mmol), 2-(4-fluorophenyl)ethan-1-ol (220 mg, 1.567
- 25 mmol), triphenylphosphine (493 mg, 1.880 mmol) and THF (10 mL). To the stirred solution was added DIAD (0.366 mL, 1.880 mmol). The solution warmed to a mild reflux, then cooled within 5 minutes. The solution was stirred at r.t. for 2 hrs. The reaction solution was concentrated in vacuo and the resulting oil was diluted with a min of acetone, then concentrated onto Celite in vacuo. The resulting residue was subjected to

silica gel chromatography(40 g column, 5-40% EtOAc:Hex) to afford the product 6-chloro-3-(4-fluorophenethoxy)-2-methoxypyridine (378 mg, 1.342 mmol, 86 % yield) as a white solid. ¹H NMR (500 MHz, chloroform-d) δ 7.26 (dd, J=8.5, 5.5 Hz, 2H), 7.06 - 6.97 (m, 3H), 6.83 (d, J=8.2 Hz, 1H), 4.17 (t, J=7.2 Hz, 2H), 3.13 (t, J=7.2 Hz, 2H). ESI-
 5 MS(+) m/z = 282 (M+1).


Intermediate 162



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6-methoxy-
 10 6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

To a 14 mL test tube equipped with a stir bar was added (S)-2-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (105 mg, 0.250 mmol), SPhos-Pd-G3 (9.73 mg, 0.012 mmol), tribasic potassium phosphate (477 mg, 2.248 mmol) and 6-chloro-3-(4-fluorophenethoxy)-2-
 15 methoxypyridine (70.4 mg, 0.250 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (937 μ l) and water (312 μ l). The test tube was placed in a 60 °C heating block with stirring (t=0). LCMS analysis at t=3h found a large product mass peak and the disappearance of the starting boronic acid. The reaction was cooled to RT
 20 and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6-methoxy-6'-methyl-[2,3'-bipyridin]-5'-
 25 yl)acetate (77 mg, 0.124 mmol, 49.6 % yield) as a brown oil. ESI-MS(+) m/z = 622.3 (M+1).

Intermediate 163




(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-methoxypyrimidin-2-yl)-2-methylpyridin-3-yl)acetate:

- 5 To a 14 mL test tube equipped with a stir bar was added (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (113 mg, 0.269 mmol) and SPhos-Pd-G3 (10.47 mg, 0.013 mmol), tribasic potassium phosphate (514 mg, 2.419 mmol) and 2-chloro-5-methoxypyrimidine (38.9 mg, 0.269 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm
- 10 (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (1008 µl) and water (336 µl). The test tube was placed in a 60 °C heating block with stirring (t=0). The reaction was stirred for 3 hrs. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and the volatiles evaporated to afford the crude product. The crude product was
- 15 purified on silica gel (24 g column, 20-100% EtOAc:Hex) to afford the product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-methoxypyrimidin-2-yl)-2-methylpyridin-3-yl)acetate (26 mg, 0.054 mmol, 19.96 % yield) as a brown oil. ESI-MS(+) *m/z* = 485.3 (M+1).

20

Intermediate 164



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:


- To a 14 mL test tube equipped with a stir bar was added (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid
- 25 (105 mg, 0.250 mmol), SPhos-Pd-G3 (9.73 mg, 0.012 mmol), tribasic potassium phosphate (477 mg, 2.248 mmol) and 2-chloro-5-methoxypyridine (35.9 mg, 0.250

mmol) . The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (937 µl) and water (312 µl) . The test tube was placed in a 60 °C heating block with stirring (t=0). The reaction was stirred for 3 hours. The reaction was cooled to RT and diluted with

5 water and EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and hte volatiles evaporated to afford the crude product. The crude product was purified on silica gel (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (22 mg, 0.045 mmol, 18.21 % yield) as a brown oil. ESI-MS(+)

10 m/z = 484.3 (M+1).

Intermediate 165


*2-Chloro-5-(4-fluorophenoxy)-4-(trifluoromethyl)pyridine:*

15 To a 40 mL vial equipped with a stir bar was added 6-chloro-4-(trifluoromethyl)pyridin-3-ol (1.00 g, 5.06 mmol), 2-(4-fluorophenyl)ethan-1-ol (0.710 g, 5.06 mmol), triphenylphosphine (1.593 g, 6.07 mmol) and THF (25 mL). To the stirred solution was added DIAD (1.181 mL, 6.07 mmol). The solution warmed to a mild reflux, then cooled within 5 minutes. The solution was stirred at r.t. (t=0). LCMS analysis at

20 t=24h found a major peak corresponding to the desired product mass. The reaction solution was concentrated in vacuo. The resulting residue was dissolved in a min of acetone, then was concentrated onto Celite in vacuo. The resutling powder was subjected to SiO₂ purification on the Interchim system using ESI detection. The column conditions were 80g SiO₂ column, hexanes:EtOAc 100:0-->80:20 over 16 CV to afford the product

25 2-chloro-5-(4-fluorophenoxy)-4-(trifluoromethyl)pyridine (1.3675 g, 4.28 mmol, 85 % yield) as a colorless liquid. ¹H NMR (500 MHz, chloroform-d) δ 8.14 (s, 1H), 7.46 (s, 1H), 7.26 - 7.21 (m, 2H), 7.04 - 6.96 (m, 2H), 4.31 (t, *J*=6.4 Hz, 2H).

Intermediate 166




Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-4-(trifluoromethyl)-[2,3'-bipyridin]-5'-yl)acetate:

- 5 To a 14 mL test tube equipped with a stir bar and (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (100 mg, 0.238 mmol) was added SPhos-Pd-G3 (9.27 mg, 0.012 mmol), tribasic potassium phosphate (454 mg, 2.141 mmol) and 2-chloro-5-(4-fluorophenethoxy)-4-(trifluoromethyl)pyridine (76 mg, 0.238 mmol). The flask was sealed with a rubber
- 10 septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (892 µl) and water (297 µl). The test tube was placed in a 60 °C heating block with stirring for t=3h. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was
- 15 purified via silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-4-(trifluoromethyl)-[2,3'-bipyridin]-5'-yl)acetate (36 mg, 0.055 mmol, 22.94 % yield) as a red/brown oil. ESI-MS(+) *m/z* = 660.3 (M+1).

20

Intermediate 167




Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinolin-2-yl)pyridin-3-yl)acetate:

- To a 14 mL test tube equipped with a stir bar and added (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid
- 25 (105 mg, 0.250 mmol) and SPhos-Pd-G3 (9.73 mg, 0.012 mmol), tribasic potassium phosphate (477 mg, 2.248 mmol) and 2-chloroquinoline (40.9 mg, 0.250 mmol). The

flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (937 µl) and water (312 µl). The test tube was placed in a 60 °C heating block with stirring (t=0). The reaction was stirred for 3 hrs. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and the volatiles evaporated to afford the crude product. The crude product was purified silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinolin-2-yl)pyridin-3-yl)acetate (74 mg, 0.147 mmol, 58.8 % yield) as a brown oil. ESI-MS(+) *m/z* = 504.3

(M+1).


Intermediate 168



Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinazolin-2-yl)pyridin-3-yl)acetate:


To a 14 mL test tube equipped with a stir bar and added (S)-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-ylboronic acid (105 mg, 0.250 mmol) and SPhos-Pd-G3 (9.73 mg, 0.012 mmol), tribasic potassium phosphate (477 mg, 2.248 mmol) and 2-chloroquinazoline (41.1 mg, 0.250 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (937 µl) and water (312 µl). The test tube was placed in a 60 °C heating block with stirring (t=0). The reaction was stirred for 3 hrs. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and the volatiles evaporated to afford the crude product. The crude product was purified silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinazolin-2-yl)pyridin-3-yl)acetate (13 mg, 0.026 mmol, 10.31 % yield) as a brown oil. ESI-MS(+) *m/z* = 505.3 (M+1).

Intermediate 169

*6-Chloro-3-(4-fluorophenethoxy)-4-methylpyridazine:*

To a 50 mL round bottom flask equipped with a stir bar was added 6-chloro-4-methylpyridazin-3-ol (250 mg, 1.729 mmol), 2-(4-fluorophenyl)ethan-1-ol (0.216 mL, 1.729 mmol), triphenylphosphine (544 mg, 2.075 mmol) and THF (10 mL). To the stirred solution was added DIAD (0.404 mL, 2.075 mmol). The solution warmed to a mild reflux, then cooled within 5 minutes. The solution was stirred at r.t. for 2 hrs. The reaction solution was concentrated in vacuo and the resulting oil was diluted with a min
 10 of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to silica gel chromatography (40 g column, 5-40% EtOAc:Hex) to afford the product 6-chloro-3-(4-fluorophenethoxy)-4-methylpyridazine (429 mg, 1.609 mmol, 93 % yield) as a white solid. ¹H NMR (500 MHz, chloroform-d) δ 7.25 - 7.20 (m, 2H), 7.08 (d, J=1.3 Hz, 1H), 7.01 (t, J=8.7 Hz, 2H), 4.35 - 4.30 (m, 2H), 3.12 - 3.06 (m, 2H), 2.23 (d, J=1.3
 15 Hz, 3H). ESI-MS(+) *m/z* = 267 (M+1).

Intermediate 170




Isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)-5-methylpyridazin-3-yl)-2-methylpyridin-3-yl)acetate:

To a 14 mL test tube equipped with a stir bar and added (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (105 mg, 0.250 mmol) and SPhos-Pd-G3 (9.73 mg, 0.012 mmol), tribasic potassium phosphate (477 mg, 2.248 mmol) and 6-chloro-3-(4-fluorophenethoxy)-4-methylpyridazine (66.6 mg, 0.250 mmol). The flask was sealed with a rubber septum,
 25 then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (937 μl) and water (312 μl). The test tube was placed in a 60 °C heating block with stirring (t=0). The reaction was stirred for 3 hrs. The reaction was

cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and the volatiles evaporated to afford the crude product. The crude product was purified via silica gel (24 g column, 20-100% EtOAc:Hex), desired fractions collected and the volatiles evaporated to afford the product

5 isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)-5-methylpyridazin-3-yl)-2-methylpyridin-3-yl)acetate (56 mg, 0.092 mmol, 36.9 % yield) as a brown oil. ESI-MS(+) m/z = 607.4 (M+1).

Intermediate 171



10 (S)-5-(tert-Butoxy)-4-(4,4-dimethylpiperidin-1-yl)-3-(5-(4-fluorophenethoxy)pyridin-2-yl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin-6-one:

To a dry 10 mL Schlenk flask equipped with a stir bar was added 2-(5-(4-fluorophenethoxy)pyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (53.7 mg, 0.144 mmol), benzyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(hydroxymethyl)pyridin-3-yl)-2-(tert-butoxy)acetate (50 mg, 0.096 mmol), palladium tetrakis (22.25 mg, 0.019 mmol), diacetylcopper (8.74 mg, 0.048 mmol) and anhydrous tribasic potassium phosphate, finely ground (102 mg, 0.481 mmol). The flask was sealed with a rubber septum, then placed under N₂ atm (vac/fill x 3). To the flask was added a degassed (N₂ sparging for 5 min) solution of DMF + diethanolamine (10.12 mg, 0.096 mmol). The flask was placed in a 100 °C oil bath with stirring for 18 hrs. The reaction mixture was transferred to a 125 mL separatory funnel and was diluted with water:brine (1:1, 50 mL). The mixture was extracted with EtOAc (3 x 50 mL). The combined organics were washed with water:brine (1:1, 50 mL), then brine (50 mL). The organics were dried over MgSO₄, filtered; then concentrated in vacuo to afford an amber oil. This material was dissolved in a min of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (24 g column, 5-100% EtOAc:Hex) to afford the exclusive product (S)-5-(tert-butoxy)-4-(4,4-dimethylpiperidin-1-yl)-3-(5-(4-fluorophenethoxy)pyridin-2-yl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin-6-one


15

20

25

(10.1 mg, 0.018 mmol, 19.16 % yield) as a light yellow oil. ^1H NMR (500 MHz, methanol- d_4) δ 8.13 (d, $J=2.4$ Hz, 1H), 8.04 (s, 1H), 7.37 - 7.31 (m, 1H), 7.29 - 7.23 (m, 1H), 7.16 (dd, $J=8.1, 5.6$ Hz, 2H), 6.85 (t, $J=8.7$ Hz, 2H), 5.70 (d, $J=14.0$ Hz, 1H), 5.17 (s, 1H), 4.94 (d, $J=14.0$ Hz, 1H), 4.15 (t, $J=6.6$ Hz, 2H), 2.94 (t, $J=6.6$ Hz, 2H), 2.74 - 2.66 (m, 2H), 2.61 - 2.50 (m, 2H), 1.20 (br t, $J=5.2$ Hz, 4H), 1.16 (s, 9H), 0.72 (s, 6H). ESI-MS(+) m/z = 548.3 (M+1).


Intermediate 172



10 (S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-formylpyridin-3-yl)-2-(tert-butoxy)acetate:

To a stirred solution of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(hydroxymethyl)pyridin-3-yl)-2-(tert-butoxy)acetate (.443 g, 0.940 mmol) in DCM (8.54 ml) and Acetonitrile (0.854 ml) was added Dess-MartinPeriodinane (0.598 g, 1.410 mmol) at once at rt. After 6 h, the reaction mixture was diluted with ether (25 mL), washed with 1M NaOH (2 x 25 ml), brine (25 mL), dried (MgSO_4), filtered and concentrated to afford the product (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-formylpyridin-3-yl)-2-(tert-butoxy)acetate (425 mg, 0.905 mmol, 96 % yield) as a yellow oil. ESI-MS(+) m/z = 469.1 (M+1).

Intermediate 173




(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-vinylpyridin-3-yl)-2-(tert-butoxy)acetate:

25 To a suspension of methyltriphenylphosphonium bromide (753 mg, 2.109 mmol) in THF (8 ml) at 0 °C was added sodium hydride (84 mg, 2.109 mmol) and the resulting

mixture was stirred at rt for 45 min. (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-formylpyridin-3-yl)-2-(tert-butoxy)acetate (330 mg, 0.703 mmol) dissolved in THF (0.5 mL) THF (8 ml) was added dropwise and the mixture was stirred at 0°C for 1 h then warmed to rt and stirred 18 h. The reaction was quenched with water and the product
 5 was extracted with EtOAc. The organic phase was washed with brine, dried (MgSO₄), filtered and concentrated. The residue was purified by silica gel chromatography (40 g column; 5-20% EtOAc/hexane) to afford (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-vinylpyridin-3-yl)-2-(tert-butoxy)acetate (184 mg, 0.394 mmol, 56.0 % yield). ESI-MS(+) *m/z* = 467.3 (M+1).

10

Intermediate 174




Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-vinyl-[2,3'-bipyridin]-5'-yl)acetate:

15 To a dry 50 mL Schlenk flask equipped with a stir bar was added 2-(5-(4-fluorophenethoxy)pyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (119 mg, 0.321 mmol), isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-vinylpyridin-3-yl)-2-(tert-butoxy)acetate (100 mg, 0.214 mmol), palladium tetrakis (49.4 mg, 0.043 mmol), diacetoxycopper (19.43 mg, 0.107 mmol) and anhydrous tribasic potassium
 20 phosphate, finely ground (227 mg, 1.070 mmol). The flask was sealed with a rubber septum, then placed under N₂ atm (vac/fill x 3). To the flask was added a degassed (N₂ sparging for 5 min) solution of DMF + diethanolamine (22.49 mg, 0.214 mmol). The flask was placed in a 100 °C oil bath with stirring (t=0) and stirred for 18 hrs. The reaction mixture was transferred to a 125 mL separatory funnel and was diluted with
 25 water:brine (1:1, 50 mL). The mixture was extracted with EtOAc (3 x 50 mL). The combined organics were washed with water:brine (1:1, 50 mL), then brine (50 mL). The organics were dried over MgSO₄; filtered; then concentrated in vacuo to afford an amber oil. This material was dissolved in a min of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification to afford the the desired
 30 product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-

fluorophenethoxy)-6'-vinyl-[2,3'-bipyridin]-5'-yl)acetate (63 mg, 0.104 mmol, 48.8 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.36 (d, *J*=2.5 Hz, 1H), 8.26 (s, 1H), 7.58 - 7.53 (m, 1H), 7.51 - 7.46 (m, 1H), 7.41 - 7.29 (m, 3H), 7.10 - 7.02 (m, 2H), 6.20 (dd, *J*=17.0, 2.2 Hz, 1H), 6.11 (br s, 1H), 5.42 (br d, *J*=12.1 Hz, 1H), 5.09 (dt, *J*=12.5, 6.3 Hz, 1H), 4.42 - 4.32 (m, 2H), 3.16 (t, *J*=6.5 Hz, 2H), 2.41 - 2.21 (m, 1H), 2.18 - 2.08 (m, 1H), 1.74 - 1.57 (m, 1H), 1.55 - 1.29 (m, 3H), 1.27 - 1.25 (m, 3H), 1.20 (s, 9H), 1.18 (d, *J*=6.1 Hz, 3H), 0.99 - 0.80 (m, 6H) 2 protons on the piperidine (closest to N) were not observed in HNMR. ESI-MS(+) *m/z* = 604.4 (M+1).

10

Intermediate 175




Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-5-(4-fluorophenethoxy)-[2,3'-bipyridin]-5'-yl)acetate:

To an N₂ sparged solution of isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-vinyl-[2,3'-bipyridin]-5'-yl)acetate (63 mg, 0.104 mmol) in MeOH (2.5 mL) was added Pd/C (11.10 mg, 10.43 μmol) and capped with a rubber septum. H₂ was then bubbled through the solution for 10 minutes. The reaction was left under positive pressure of H₂ for 1 hr. The LCMS indicated the reaction was complete. The reaction was filtered through a 0.45 μ nylon frit filter and the volatiles evaporated to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-5-(4-fluorophenethoxy)-[2,3'-bipyridin]-5'-yl)acetate (63 mg, 0.104 mmol, 100 % yield) as a clear oil. ESI-MS(+) *m/z* = 606.7 (M+1).

25


Intermediate 176



Isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-isopropoxyacetate:

To a solution of isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-hydroxyacetate (50 mg, 0.125 mmol) and 2-iodopropane (0.025 mL, 0.250 mmol) in DMF (1.5 mL) was added sodium hydride (10.02 mg, 0.250 mmol) and stirred at RT. The reaction was cooled to RT and 2-iodopropane (0.025 mL, 0.250 mmol) was added followed by sodium hydride (10.02 mg, 0.250 mmol) and heated to 60 °C. This process was repeated 6 more times over 2 days. At this point the material appeared to show ester hydrolysis. The reaction was quenched with water and diluted with EtOAc. The organic layer was washed with water (2X), followed by brine, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified on silica gel (12 g column, 5-40% EtOAc:Hex) to afford the product isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-isopropoxyacetate (28 mg, 0.063 mmol, 50.7 % yield) as a clear oil. ESI-MS(+) *m/z* = 441.3 and 443.3.

Intermediate 177




Isopropyl (S)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-isopropoxyacetate:

To a dry 10 mL Schlenk flask equipped with a stir bar was added 2-(5-(4-fluorophenethoxy)pyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (35.4 mg, 0.095 mmol), isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-isopropoxyacetate (28 mg, 0.063 mmol), palladium tetrakis (14.66 mg, 0.013 mmol), diacetylcopper (5.76 mg, 0.032 mmol) and anhydrous tribasic potassium phosphate, finely ground (67.3 mg, 0.317 mmol). The flask was sealed with a rubber septum, then placed under N₂ atm (vac/fill x 3). To the flask was added a degassed (N₂ sparging for 5 min) solution of DMF + diethanolamine (6.67 mg, 0.063 mmol). The flask was placed in a 100°C oil bath with stirring for t=18h. The reaction mixture was transferred to a 125 mL separatory funnel and was diluted with water:brine (1:1, 50 mL).

The mixture was extracted with EtOAc (3 x 50 mL). The combined organics were washed with water:brine (1:1, 50 mL), then brine (50 mL). The organics were dried over MgSO₄; filtered; then concentrated in vacuo to afford an amber oil. This material was dissolved in a min of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification. The pure fractions were pooled and concentrated in vacuo to afford the product isopropyl (S)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-isopropoxyacetate (15 mg, 0.026 mmol, 40.9 % yield). ESI-MS(+) m/z = 578.5 (M+1).

10

Intermediate 178




2-Chloro-5-(phenoxymethyl)pyridine:

To a 50 mL round bottom flask equipped with a stir bar was added (6-chloropyridin-3-yl)methanol (250 mg, 1.741 mmol), phenol (164 mg, 1.741 mmol), triphenylphosphine (548 mg, 2.090 mmol) and THF (10 mL). To the stirred solution was added DIAD (0.406 mL, 2.090 mmol). The solution warmed to a mild reflux, then cooled within 5 minutes. The solution was stirred at r.t. for 2 hrs. The reaction solution was concentrated in vacuo and the resulting oil was diluted with a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to silica gel chromatography (40 g column, 5-40% EtOAc:Hex) to afford the product 2-chloro-5-(phenoxymethyl)pyridine (305 mg, 1.388 mmol, 80 % yield) as a white solid. ¹H NMR (500 MHz, chloroform-d) δ 8.48 (d, J =1.9 Hz, 1H), 7.78 (dd, J =8.2, 2.4 Hz, 1H), 7.39 (d, J =8.0 Hz, 1H), 7.36 - 7.31 (m, 2H), 7.29 - 7.24 (m, 1H), 7.03 (t, J =7.3 Hz, 1H), 6.89 - 6.84 (m, 1H), 5.09 (s, 2H).

25


Intermediate 179



Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(phenoxy)methyl)-[2,3'-bipyridin]-5'-yl)acetate:

- To a 14 mL test tube equipped with a stir bar and (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (210 mg, 0.500 mmol) was added 2-chloro-5-(phenoxy)methylpyridine (27.4 mg, 0.125 mmol), potassium phosphate tribasic (954 mg, 4.50 mmol) and SPhos-Pd-G3 (19.46 mg, 0.025 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (1873 µl) and water (624 µl). The test tube was placed in a 60 °C heating block with stirring t=18h.
- The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(phenoxy)methyl)-[2,3'-bipyridin]-5'-yl)acetate (39 mg, 0.070 mmol, 55.8 % yield) as a red/brown oil. ESI-MS(+) *m/z* = 560.5 (M+1).


Intermediate 180



- (Z)-2-Chloro-5-(3-methylbut-1-en-1-yl)pyridine:*

- To a 0 °C solution of isobutyltriphenylphosphonium bromide (705 mg, 1.766 mmol) in THF (10 mL) was added BuLi (0.706 mL, 1.766 mmol) dropwise and allowed to stir at 0 °C for 30 minutes. The reaction was then added 6-chloronicotinaldehyde (250 mg, 1.766 mmol) (in 2 mL THF) dropwise at 0 °C. The reaction was then allowed to warm up to RT and stir for 2 hrs. The reaction was diluted with sat aq. ammonium chloride and extracted with EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified on silica gel (24 g column, 5-20% EtOAc:Hex) to afford the product (Z)-2-chloro-5-(3-methylbut-1-en-1-yl)pyridine (240 mg, 1.321 mmol, 74.8 % yield). ¹H NMR (500 MHz, chloroform-d) δ 8.30 (d, *J*=2.4 Hz, 1H), 7.54 (dd, *J*=8.2, 2.4 Hz, 1H), 7.30 (d, *J*=8.2 Hz, 1H), 6.22 (d, *J*=11.7 Hz, 1H), 5.66 (dd, *J*=11.5, 10.4 Hz, 1H), 2.78 (ddtd, *J*=13.1, 10.4, 6.6, 0.7 Hz, 1H), 1.07 (d, *J*=6.6 Hz, 6H).


Intermediate 181



Isopropyl (S,Z)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(3-methylbut-1-en-1-yl)-[2,3'-bipyridin]-5'-yl)acetate:

To a 14 mL test tube equipped with a stir bar and (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (210 mg, 0.500 mmol) was added (Z)-2-chloro-5-(3-methylbut-1-en-1-yl)pyridine (22.69 mg, 0.125 mmol), potassium phosphate tribasic (954 mg, 4.50 mmol) and SPhos-Pd-G3 (19.46 mg, 0.025 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (1873 µl) and water (624 µl). The test tube was placed in a 60 °C heating block with stirring for t=18h. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the impure product isopropyl (S,Z)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(3-methylbut-1-en-1-yl)-[2,3'-bipyridin]-5'-yl)acetate (164 mg, 0.314 mmol, 62.9 % yield) as a red/brown oil. ESI-MS(+) *m/z* = 522.3 (M+1).

Intermediate 182




6-Chloro-N-methoxy-N-methylnicotinamide:

To a solution of 6-chloronicotinic acid (2 g, 12.69 mmol) and N,O-dimethylhydroxylamine, HCl (1.362 g, 13.96 mmol) in DCM (50 mL) was added HATU (5.31 g, 13.96 mmol) followed by Hunig's Base (7.09 mL, 40.6 mmol) and stirred at RT for 18 hrs. The reaction was monitored via LCMS. After 18 hrs, the LCMS indicated that the reaction was complete. The organic phase was washed with water, followed by brine,


dried over MgSO_4 , filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel (80g column, 10-60% EtOAc:Hex) to afford the product 6-chloro-N-methoxy-N-methylnicotinamide (2.2 g, 10.97 mmol, 86 % yield) as a clear thin oil. ^1H NMR (500 MHz, chloroform- d) δ 8.80 (d, $J=1.9$ Hz, 1H), 8.04 (dd, $J=8.4, 2.4$ Hz, 1H), 7.41 (dd, $J=8.2, 0.6$ Hz, 1H), 3.58 (s, 3H), 3.41 (s, 3H). ESI-MS(+) $m/z = 201.1$ (M+1).

Intermediate 183

10 *1-(6-Chloropyridin-3-yl)-3-methylbutan-1-one:*

To a 0 °C solution of 6-chloro-N-methoxy-N-methylnicotinamide (500 mg, 2.492 mmol) in THF (10 mL) was added dropwise isobutylmagnesium bromide (2.492 mL, 4.98 mmol) and allowed to stir for 15 min at 0 °C before allowing to warm up to RT. The reaction was then stirred for 1 hr. After stirring for 1 hr, the reaction was quenched with sat. aq. ammonium chloride and then extracted with EtOAc (50 mL). The organic layer was washed with brine, collected, dried over MgSO_4 , filtered and volatiles evaporated to afford a yellow solid. The crude material was purified on silica gel (24 g column, 5-40% EtOAc:Hex) to afford the product 1-(6-chloropyridin-3-yl)-3-methylbutan-1-one (386 mg, 1.953 mmol, 78 % yield) as a white solid. ^1H NMR (500 MHz, chloroform- d) δ 8.95 (d, $J=2.4$ Hz, 1H), 8.21 (dd, $J=8.4, 2.5$ Hz, 1H), 7.46 (dd, $J=8.4, 0.6$ Hz, 1H), 2.85 (d, $J=6.9$ Hz, 2H), 2.32 (dquin, $J=13.4, 6.7$ Hz, 1H), 1.03 (d, $J=6.6$ Hz, 6H).


Intermediate 184

25 *2-Chloro-5-(1,1-difluoro-3-methylbutyl)pyridine:*

Deoxofluor (3 mL, 8.14 mmol) (50% in toluene) was added dropwise to a solution of 1-(6-chloropyridin-3-yl)-3-methylbutan-1-one (386 mg, 1.953 mmol) in toluene (0.5 mL). The reaction was then heated to 60 °C and stirred for 18 hrs. The LCMS after 18 hrs, showed some product conversion. The reaction was cooled to RT and reverse added

to an aq. 1.5 M K₃PO₄ solution and extracted with EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified on silica gel (24 g column, 5-20% EtOAc:Hex) to afford the product as a clear oil. ¹H NMR (500 MHz, chloroform-d) δ 8.54 (d, *J*=1.7 Hz, 1H), 7.76 (dd, *J*=8.4, 2.5 Hz, 1H), 7.42 (d, *J*=8.4 Hz, 1H), 2.06 (td, *J*=17.6, 6.5 Hz, 2H), 1.88 (dt, *J*=13.2, 6.6 Hz, 1H), 1.00 (d, *J*=6.6 Hz, 6H).

Intermediate 185




10 *Isopropyl (S)-2-(tert-butoxy)-2-(5-(1,1-difluoro-3-methylbutyl)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:*

To a 14 mL test tube equipped with a stir bar and (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (210 mg, 0.500 mmol) was added 2-chloro-5-(1,1-difluoro-3-methylbutyl)pyridine (27.4 mg, 0.125 mmol), potassium phosphate tribasic (954 mg, 4.50 mmol) and SPhos-Pd-G3 (19.46 mg, 0.025 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (1873 μ l) and water (624 μ l). The test tube was placed in a 60 °C heating block with stirring for t=18h. The reaction was cooled to RT and diluted with EtOAc and water.

20 The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(5-(1,1-difluoro-3-methylbutyl)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (152 mg, 0.272 mmol, 54.4 % yield) as a red/brown

25 oil. ESI-MS(+) *m/z* = 560.6 (M+1).


Intermediate 186



6-Chloro-3-isobutoxy-2-(trifluoromethyl)pyridine:

To a 50 mL round bottom flask equipped with a stir bar was added 6-chloro-2-(trifluoromethyl)pyridin-3-ol (250 mg, 1.266 mmol), 2-methylpropan-1-ol (0.234 mL, 1.266 mmol), triphenylphosphine (398 mg, 1.519 mmol) and THF (10 mL). To the stirred solution was added DIAD (0.295 mL, 1.519 mmol) dropwise. The solution was stirred at r.t. for 18 hrs. The reaction solution was concentrated in vacuo and the resulting oil was diluted with a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to silica gel chromatography (24 g column, 0-20% EtOAc:Hex) to afford the product 6-chloro-3-isobutoxy-2-(trifluoromethyl)pyridine (225 mg, 0.887 mmol, 70.1 % yield) as a clear oil. ¹H NMR (500 MHz, chloroform-d) δ 7.47 (d, $J=8.8$ Hz, 1H), 7.36 (d, $J=8.8$ Hz, 1H), 3.84 (d, $J=6.3$ Hz, 2H), 2.22 - 2.14 (m, 1H), 1.08 (d, $J=6.6$ Hz, 6H). ESI-MS(+) m/z = 254.1 (M+1).


Intermediate 188

*Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-6'-methyl-6-(trifluoromethyl)-[2,3'-bipyridin]-5'-yl)acetate:*

To a 14 mL test tube equipped with a stir bar and (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (210 mg, 0.500 mmol) was added 6-chloro-3-isobutoxy-2-(trifluoromethyl)pyridine (31.7 mg, 0.125 mmol), potassium phosphate tribasic (954 mg, 4.50 mmol) and SPhos-Pd-G3 (19.46 mg, 0.025 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (1873 μ l) and water (624 μ l). The test tube was placed in a 60 °C heating block with stirring for t=18h. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-6'-methyl-6-

(trifluoromethyl)-[2,3'-bipyridin]-5'-yl)acetate (99 mg, 0.167 mmol, 33.4 % yield) as a red/brown oil. ESI-MS(+) m/z = 594.6 (M+1).

Intermediate 189




5

1-(6-Chloropyridin-3-yl)pentan-1-one:

To a 0 °C solution of 6-chloro-N-methoxy-N-methylnicotinamide (500 mg, 2.492 mmol) in THF (10 mL) was added dropwise butylmagnesium bromide (2.492 mL, 4.98 mmol) and allowed to stir for 15 min at 0 °C before allowing to warm up to RT. The reaction was then stirred for 1 hr. After stirring for 1 hr, the reaction was quenched with sat. aq. ammonium chloride and then extracted with EtOAc (50 mL). The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford a yellow solid. The crude material was purified on silica gel (24 g column, 5-40% EtOAc:Hex) to afford the product 1-(6-chloropyridin-3-yl)pentan-1-one (425 mg, 2.150 mmol, 86 % yield) as a white solid. ¹H NMR (500 MHz, chloroform-d) δ 8.96 (dd, J =2.4, 0.6 Hz, 1H), 8.21 (dd, J =8.4, 2.4 Hz, 1H), 7.46 (dd, J =8.4, 0.6 Hz, 1H), 3.03 - 2.92 (m, 2H), 1.80 - 1.68 (m, 2H), 1.49 - 1.38 (m, 2H), 0.99 (t, J =7.4 Hz, 3H).

15

Intermediate 190



20


2-Chloro-5-(1,1-difluoropentyl)pyridine:

Deoxofluor (3 mL, 8.14 mmol) (50% in toluene) was added to a solution of 1-(6-chloropyridin-3-yl)pentan-1-one (425 mg, 2.150 mmol) in toluene (0.5 mL). The reaction was warmed up to 60 °C for 18 hrs. The reaction was cooled to RT and diluted with 1.5 M K₃PO₄ and extracted with EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified on silica gel (24 g column, 0-20% EtOAc:Hex) to afford the product 2-chloro-5-(1,1-difluoropentyl)pyridine (243 mg, 1.106 mmol, 51.5 % yield) as a clear oil. ¹H NMR (500 MHz, chloroform-d) δ 8.56 - 8.49 (m, 1H), 7.76 (dd, J =8.2, 2.5

25

Hz, 1H), 7.42 (dd, $J=8.4, 0.6$ Hz, 1H), 2.22 - 2.07 (m, 2H), 1.48 - 1.34 (m, 4H), 0.95 - 0.90 (m, 3H).

Intermediate 191




5

Isopropyl (S)-2-(tert-butoxy)-2-(5-(1,1-difluoropentyl)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

To a 14 mL test tube equipped with a stir bar and (S)-2-(tert-butoxy)-2-isopropoxy-2-oxoethyl-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid
 10 (210 mg, 0.500 mmol) was added 2-chloro-5-(1,1-difluoropentyl)pyridine (27.4 mg, 0.125 mmol), potassium phosphate tribasic (954 mg, 4.50 mmol) and SPhos-Pd-G3 (19.46 mg, 0.025 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (1873 μ l) and water (624 μ l). The test tube was placed in a 60 °C heating block
 15 with stirring for t=18h. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(5-(1,1-difluoropentyl)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-
 20 [2,3'-bipyridin]-5'-yl)acetate (130 mg, 0.232 mmol, 46.5 % yield) as a red/brown oil. ESI-MS(+) m/z = 560.6 (M+1).

Intermediate 192




25 *2-Bromo-5-isobutoxypyridine:*

To a 500mL r.b. flask equipped with a large stir bar was added 6-bromopyridin-3-ol (10.0 g, 57.5 mmol), 2-methylpropan-1-ol (4.26 g, 57.5 mmol), triphenylphosphine (15.8 g, 60.3 mmol) and THF (192 ml). The flask was placed at r.t. To the stirring

solution was added DIAD (11.73 ml, 60.3 mmol). At t=15min the reaction solution was concentrated in vacuo. To the crude reaction product was added hexanes:Et₂O (1:1, 250 mL). The mixture was stirred. A significant amount of crystalline material (OPPh₃) ppt'd and was removed via filtration. The filtrate was concentrated in vacuo and the residue was dissolved in a minimal of acetone and then concentrated onto Celite. The resulting powder was subjected to SiO₂ purification on the Biotage (120 g column) 0-100% 10 CVs to afford 2-bromo-5-isobutoxypyridine (12.7 g, 96%) as a clear oil. LCMS Method 4: retention time = 1.36 min.; observed ion = 230.0, 232.0. ¹H NMR (500 MHz, CHLOROFORM-d) δ 8.07 (d, J=3.0 Hz, 1H), 7.44 - 7.25 (m, 1H), 7.11 (dd, J=8.8, 3.2 Hz, 1H), 3.76 (d, J=6.5 Hz, 2H), 2.17 - 2.06 (m, 1H), 1.05 (d, J=6.8 Hz, 6H).

Intermediate 193



2-(5-Isobutoxypyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione:

To a dry 250 mL r.b.flask equipped with a large stir bar was added 2-bromo-5-isobutoxypyridine (12.7 g, 55.2 mmol). The flask was placed under N₂ atm (vac/fill x 3), then to the flask was added THF (97 ml) and triisopropyl borate (12.9 ml, 55.7 mmol). The solution was degassed with N₂ 2x. The flask was cooled in a -78 °C bath. To the solution was added dropwise n-butyllithium in hexanes (22.3 ml, 55.7 mmol) at a rate necessary to avoid build-up of any localized dark discoloration (usually visible in the central vortex with fast stirring). The rate was approximately 0.25-0.50 mL/min. At the completion of the addition the solution slowly began to turn dark yellow. Stirring was maintained for 20 min upon which the solution was observed to be a light amber. The bath was removed and the solution was allowed to warm to r.t. with stirring (t=0). As the solution warmed, the color deepened even more significantly. At t=3h the reaction solution was carried forward into the distillation step.

The distillation is setup:


A 3-neck 250 mL flask equipped with a large stir bar was charged with methyliminodiacetic acid (16.24 g, 110 mmol) and DMSO (97 ml). The center neck was fitted with a pressure-equalizing addition funnel vented to positive N₂ pressure. Another

neck was fitted with a rubber septum through which a thermocouple was inserted to monitor internal temperature. The final neck was fitted with a short-path distillation apparatus collecting in a 100 mL r.b. flask and vented to a bubbler. This provides a slow stream of N₂ carrier gas through the setup and out through the bubbler so that THF vapor
 5 does not accumulate.

Distillation:

The reaction solution containing the boronate was transferred to the addition funnel. The 3-neck flask was heated with an oil bath (160 °C). Once the internal temperature had reached 115-120 °C the boronate solution was added dropwise at a rate
 10 necessary to maintain an internal temp of 115-120 °C. The addition took approximately 20 min. The receiver flask containing the THF was exchanged for an empty 100 mL r.b. flask. The bubbler line connected to the vacuum arm of the distillation apparatus was exchanged for a tube running to the rotovap. The N₂ source was closed. The system was placed under vacuum, slowly ramping upon which the DMSO distilled. The distillation
 15 was maintained until only trace DMSO remained. The residue was dissolved in MeCN upon which only the MIDA (white powder) did not dissolve. The mixture was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification on the Biotage (0-100% EtOAc/ACN gradient over 10 CVs). TLC was performed with 1:1 EA/ACN looking at it with both UV and then KMnO₄ staining (to
 20 observe biproduct). The fractions containing the product were collected and concentrated to afford the desired product: 2-(5-isobutoxypyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (7.3 g, 23.85 mmol, 43.2 % yield) as a white solid. LCMS Method 5: retention time = 1.35 min.; observed ion = 307.2. ¹H NMR (500 MHz, Acetone) δ 8.45 - 8.38 (m, 1H), 7.60 - 7.54 (m, 1H), 7.29 (dd, *J*=8.4, 2.9 Hz, 1H), 4.34 (d, *J*=16.6 Hz, 2H), 4.17 (d, *J*=16.6 Hz, 2H), 3.90 - 3.84 (m, 2H), 2.78 (s, 3H), 2.15 - 2.09 (m, 1H), 1.05 (d, *J*=6.8 Hz, 6H).


Intermediate 194



Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-6'-vinyl-[2,3'-bipyridin]-5'-yl)acetate:

To a dry 10 mL Schlenk flask equipped with a stir bar was added 2-(5-isobutoxypyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione compound with 2-butyl-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (41.6 mg, 0.080 mmol), isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-vinylpyridin-3-yl)-2-(tert-butoxy)acetate (25 mg, 0.053 mmol), palladium tetrakis (12.36 mg, 10.70 μ mol), diacetoxycopper (4.86 mg, 0.027 mmol) and anhydrous tribasic potassium phosphate, finely ground (56.8 mg, 0.267 mmol). The flask was sealed with a rubber septum, then placed under N₂ atm (vac/fill x 3). To the flask was added a degassed (N₂ sparging for 5 min) solution of DMF + diethanolamine (5.62 mg, 0.053 mmol). The flask was placed in a 100 °C oil bath with stirring for t=18 hrs. The reaction mixture was transferred to a 125 mL separatory funnel and was diluted with water:brine (1:1, 50 mL). The mixture was extracted with EtOAc (3 x 50 mL). The combined organics were washed with water:brine (1:1, 50 mL), then brine (50 mL). The organics were dried over MgSO₄; filtered; then concentrated in vacuo to afford an amber oil. This material was dissolved in a min of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-6'-vinyl-[2,3'-bipyridin]-5'-yl)acetate (18 mg, 0.033 mmol, 62.6 % yield) as a dark amber oil. ESI-MS(+) m/z = 538.5 (M+1).

Intermediate 195




Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-5-isobutoxy-[2,3'-bipyridin]-5'-yl)acetate:

To an N₂ sparged solution of isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-6'-vinyl-[2,3'-bipyridin]-5'-yl)acetate (18 mg, 0.033 mmol) in MeOH (2 mL) was added Pd-C (3.56 mg, 3.35 μ mol) and capped with a rubber septum. H₂ was then bubbled through the solution for 10 minutes. The reaction was left

under positive pressure of H₂ for 1 hr. The LCMS indicated the reaction was complete. The reaction was filtered through a 0.45 μ nylon frit filter and volatiles evaporated to afford the crude oil. The reaction afforded the expected product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-5-isobutoxy-[2,3'-bipyridin]-5'-yl)acetate (18 mg, 0.033 mmol, 100 % yield). ESI-MS(+) *m/z* = 540.6 (M+1).


Intermediate 196



Benzyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-(fluoromethyl)-5-isobutoxy-[2,3'-bipyridin]-5'-yl)acetate:

To a dry 10 mL Schlenk flask equipped with a stir bar was added 2-(5-isobutoxypyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione compound with 2-butyl-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (87 mg, 0.168 mmol), isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(fluoromethyl)pyridin-3-yl)-2-(tert-butoxy)acetate (53 mg, 0.112 mmol), palladium tetrakis (25.9 mg, 0.022 mmol), diacetoxycopper (10.17 mg, 0.056 mmol) and anhydrous tribasic potassium phosphate, finely ground (119 mg, 0.560 mmol). The flask was sealed with a rubber septum, then placed under N₂ atm (vac/fill x 3). To the flask was added a degassed (N₂ sparging for 5 min) solution of DMF + diethanolamine (11.77 mg, 0.112 mmol). The flask was placed in a 100 °C oil bath with stirring for t=18h. The reaction mixture was transferred to a 125 mL separatory funnel and was diluted with water:brine (1:1, 50 mL). The mixture was extracted with EtOAc (3 x 50 mL). The combined organics were washed with water:brine (1:1, 50 mL), then brine (50 mL). The organics were dried over MgSO₄; filtered; then concentrated in vacuo to afford an amber oil. This material was dissolved in a min of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification to afford the product benzyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-(fluoromethyl)-5-isobutoxy-[2,3'-bipyridin]-5'-yl)acetate (23 mg, 0.039 mmol, 34.7 % yield) as an amber oil. ESI-MS(+) *m/z* = 592.4 (M+1).


Intermediate 197



Isopropyl (S)-2-(5-(benzyloxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-vinyl-[2,3'-bipyridin]-5'-yl)-2-(tert-butoxy)acetate:

- 5 To a dry 10 mL Schlenk flask equipped with a stir bar was added 2-(5-(benzyloxy)pyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (1.091 g, 3.21 mmol), isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-vinylpyridin-3-yl)-2-(tert-butoxy)acetate (1 g, 2.139 mmol), palladium tetrakis (0.494 g, 0.428 mmol), diacetylcopper (0.194 g, 1.070 mmol) and anhydrous tribasic potassium phosphate,
- 10 finely ground (2.270 g, 10.70 mmol). The flask was sealed with a rubber septum, then placed under N₂ atm (vac/fill x 3). To the flask was added a degassed (N₂ sparging for 5 min) solution of DMF + diethanolamine (0.225 g, 2.139 mmol). The flask was placed in a 100 °C oil bath with stirring for t=18h. The reaction mixture was transferred to a 125 mL separatory funnel and was diluted with water:brine (1:1, 50 mL). The mixture was
- 15 extracted with EtOAc (3 x 50 mL). The combined organics were washed with water:brine (1:1, 50 mL), then brine (50 mL). The organics were dried over MgSO₄; filtered; then concentrated in vacuo to afford an amber oil. This material was dissolved in a min of acetone, then was concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification to afford the product isopropyl (S)-2-(5-(benzyloxy)-4'-(4,4-
- 20 dimethylpiperidin-1-yl)-6'-vinyl-[2,3'-bipyridin]-5'-yl)-2-(tert-butoxy)acetate (670 mg, 1.172 mmol, 54.8 % yield). ¹H NMR (400 MHz, chloroform-d) δ 8.52 (d, *J*=2.7 Hz, 1H), 8.37 (s, 1H), 7.53 - 7.48 (m, 2H), 7.45 (t, *J*=7.5 Hz, 2H), 7.42 - 7.32 (m, 4H), 6.33 (dd, *J*=16.8, 2.1 Hz, 1H), 6.10 (br s, 1H), 5.43 (dd, *J*=10.6, 2.1 Hz, 1H), 5.21 (s, 2H), 5.10 (dt, *J*=12.6, 6.2 Hz, 1H), 3.44 - 3.22 (m, 2H), 1.23 (d, *J*=6.1 Hz, 3H), 1.19 (s, 9H), 1.17 (d, *J*=6.4 Hz, 3H), 0.98 - 0.80 (m, 6H). 6 protons of the methylenes on the piperidine were not observed in the HNMR spectrum. ESI-MS(+) *m/z* = 572.6 (M+1).
- 25


Intermediate 198



(S)-2-(*tert*-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-5-hydroxy-[2,3'-bipyridin]-5'-yl)acetate:

- 5 To an N₂ sparged solution of isopropyl (*S*)-2-(5-(benzyloxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-vinyl-[2,3'-bipyridin]-5'-yl)-2-(*tert*-butoxy)acetate (670 mg, 1.172 mmol) in MeOH (15 mL) was added Pd-C (125 mg, 0.117 mmol) and capped with a rubber septum. H₂ was then bubbled through the solution for 10 minutes. The reaction was left under positive pressure of H₂ for 1 hr. The LCMS indicated the reaction was
- 10 complete. The reaction was filtered through a 0.45 μ nylon frit filter and volatiles evaporated to afford the product isopropyl (*S*)-2-(*tert*-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-5-hydroxy-[2,3'-bipyridin]-5'-yl)acetate (447 mg, 0.924 mmol, 79 % yield). ¹H NMR (400 MHz, chloroform-*d*) δ 8.39 (d, *J*=2.4 Hz, 1H), 8.26 (s, 1H), 7.31 (br d, *J*=2.7 Hz, 1H), 7.24 - 7.19 (m, 1H), 6.05 (br s, 1H), 5.17 - 5.08 (m, 1H),
- 15 3.05 (dq, *J*=13.9, 7.1 Hz, 1H), 2.97 - 2.88 (m, 1H), 1.38 - 1.35 (m, 3H), 1.25 (d, *J*=6.4 Hz, 3H), 1.23 - 1.19 (m, 12H), 0.89 (br s, 6H). 8 protons on the methylenes on the piperidine ring were not observed in the HNMR spectrum. ESI-MS(+) *m/z* = 484.5 (M+1).

Intermediate 200




20

2-Chloro-6-(4-fluorophenethoxy)pyridine:

- To a 50 mL round bottom flask equipped with a stir bar was added 6-chloropyridin-2-ol (250 mg, 1.930 mmol), 2-(4-fluorophenyl)ethan-1-ol (0.242 mL, 1.930 mmol), triphenylphosphine (607 mg, 2.316 mmol) and THF (10 mL). To the stirred
- 25 solution was added DIAD (0.450 mL, 2.316 mmol). The solution warmed to a mild reflux, then cooled within 5 minutes. The solution was stirred at r.t. for 2 hrs. The reaction solution was concentrated in vacuo and the resulting oil was diluted with a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to

silica gel chromatography(40 g column, 5-40% EtOAc:Hex) to afford the product 2-chloro-6-(4-fluorophenethoxy)pyridine (443 mg, 1.760 mmol, 91 % yield) as a white solid. ¹H NMR (500 MHz, chloroform-d) δ 7.52 (dd, *J*=8.2, 7.6 Hz, 1H), 7.26 (dd, *J*=8.7, 5.4 Hz, 2H), 7.04 - 6.99 (m, 2H), 6.91 (dd, *J*=7.6, 0.6 Hz, 1H), 6.65 (dd, *J*=8.2, 0.6 Hz, 1H), 4.51 (t, *J*=6.9 Hz, 2H), 3.07 (t, *J*=6.9 Hz, 2H). ESI-MS(+) *m/z* = 252.1 (M+1).


Intermediate 201



Isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

To a 14 mL test tube equipped with a stir bar and (S)-(5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl)boronic acid (210 mg, 0.500 mmol) was added 2-chloro-6-(4-fluorophenethoxy)pyridine (31.4 mg, 0.125 mmol), potassium phosphate tribasic (954 mg, 4.50 mmol) and SPhos-Pd-G3 (19.46 mg, 0.025 mmol). The flask was sealed with a rubber septum, then was placed under N₂ atm (vac/fill x 3). To the flask was added degassed (N₂ bubbling for 5 min) dioxane (1873 μl) and water (624 μl). The test tube was placed in a 60 °C heating block with stirring for t=18h. The reaction was cooled to RT and diluted with EtOAc and water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was purified via silica gel chromatography (24 g column, 20-100% EtOAc:Hex) to afford the product isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (132 mg, 0.223 mmol, 44.6 % yield) as a red/brown oil. ESI-MS(+) *m/z* = 592.4 (M+1).


Intermediate 202



(S)-Isopropyl 2-(tert-butoxy)-2-(5-(2,6-dichlorophenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (300 mg, 0.639 mmol) and sodium carbonate (508 mg, 4.79 mmol) in dichloromethane (15 mL), 2,6-dichlorophenethyl methanesulfonate (860 mg, 3.19 mmol) was added and stirred for 16 hour at 25 °C. Then, the reaction mixture was concentrated under vacuo and the residue was treated with aq. HCl (1N, 0.5ml) and purified by Prep-HPLC to give desired product (S)-isopropyl 2-(tert-butoxy)-2-(5-(2,6-dichlorophenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (300 mg, 0.387 mmol, 60.7 % yield) as white solid. LCMS [M + H] = 642.2.


Intermediate 203



(S)-Isopropyl 2-(tert-butoxy)-2-(5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (250 mg, 0.532 mmol), 1-bromopropane (524 mg, 4.26 mmol) and K₂CO₃ (441 mg, 3.19 mmol) in DMF (4 mL) stirred for 16 h at rt. The suspension was filtered and filtrate was purified by preparative-HPLC to give the desired product (S)-isopropyl 2-(tert-butoxy)-2-(5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (240 mg, 0.457 mmol, 86 % yield) as white solid. LCMS [M + H] = 526.3.


Intermediate 204



(S)-Isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (500 mg, 1.065 mmol) in acetonitrile (20 mL), K₂CO₃ (736 mg, 5.32 mmol) and 1-bromo-2-methylpropane (438 mg, 3.19 mmol) was stirred for 20 hours at 70 °C. The reaction mixture was filtered, concentrated and purified by silica gel chromatography eluting with EtOAc/Pet. ether (from 10:1 to 1:1) to afford (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (500 mg, 0.951 mmol, 89 % yield) as white yellow oil. LCMS [M + H] = 526.3.


Intermediate 205



(S)-Isopropyl 2-(tert-butoxy)-2-(5-(3-chlorophenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

To a stirred mixture of 3-chlorophenethyl methanesulfonate (750 mg, 3.19 mmol), (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (300 mg, 0.639 mmol) in DMF (15 mL) was added K₂CO₃ (662 mg, 4.79 mmol) and heated at 60 °C for 2 hours. Then, reaction mixture was diluted by DCM 20 ml and water (5 ml), organic layer separated and aqueous layer extracted by DCM (20ml). The combined organic layers were dried over Na₂SO₄ and concentrated. The residue was purified by silica gel column (Pet. ether/EtOAc= 10:1) to afford desired product (S)-isopropyl 2-(tert-butoxy)-2-(5-(3-chlorophenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (300 mg, 0.486 mmol, 76 % yield) as a white solid. LCMS [M + H] = 608.3.


Intermediate 206



(S)-Isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(2-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

- 5 To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (300 mg, 0.639 mmol) in acetonitrile (15 mL) was added cesium carbonate (624 mg, 1.916 mmol) and the mixture was stirred overnight at 75 °C. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column (Pet. ether/EtOAc, 8:1) to afford the desired
- 10 product (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(2-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (210 mg, 0.341 mmol, 53.3 % yield) as yellow oil. LCMS [M + H] = 592.3.


Intermediate 207



- 15 *(S)-Isopropyl 2-(tert-butoxy)-2-(5-(3,5-difluorophenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:*

- To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (200 mg, 0.426 mmol) in acetonitrile
- 20 (20 mL) was added potassium carbonate (294 mg, 2.129 mmol) and stirred overnight at 75 °C. The mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column (Pet. ether/EtOAc 1:1) to afford the desired product (S)-isopropyl 2-(tert-butoxy)-2-(5-(3,5-difluorophenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (210 mg, 0.313 mmol, 73.6 % yield) as yellow oil.
- 25 LCMS [M + H] = 610.2.


Intermediate 208



(S)-Isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(isopentyloxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

- 5 A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (240 mg, 0.511 mmol), 1-bromo-3-methylbutane (116 mg, 0.767 mmol) and K₂CO₃ (212 mg, 1.533 mmol) in DMF (8 mL) was heated at 80°C overnight. Then, diluted with EtOAc (20 ml) and water (15 ml), aqueous phase separated and the organic phase was washed with water (10 ml × 2), dried
- 10 with Na₂SO₄ and concentrated. The residue was purified by Prep-TLC (EtOAc:Pet. ether; 1:2) to afford (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(isopentyloxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (240 mg, 0.445 mmol, 87 % yield). LCMS [M + H] = 540.

- 15 Intermediate 209




(S)-Isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(pentyloxy)-[2,3'-bipyridin]-5'-yl)acetate:

- A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (200 mg, 0.426 mmol), 1-bromopentane (96 mg, 0.639 mmol) and K₂CO₃ (294 mg, 2.129 mmol) in DMF (8 mL) was heated at
- 20 80°C overnight. Then, the reaction mixture was diluted with EtOAc (20 ml) and water (15 ml). The aqueous phase separated and organic phase was washed with water (10 ml × 2), dried with Na₂SO₄ and concentrated. The residue was purified by Prep-TLC (EtOAc:Pet.
- 25 ether; 1:2) to afford (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-

methyl-5-(pentyloxy)-[2,3'-bipyridin]-5'-yl)acetate (220 mg, 0.408 mmol, 96 % yield).

LCMS $[M + H] = 540$.

Intermediate 210



5


(S)-Isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-phenethoxy-[2,3'-bipyridin]-5'-yl)acetate:

To a mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (200 mg, 0.426 mmol), (2-

10 bromoethyl)benzene (394 mg, 2.129 mmol) in DMF (2 mL) was added K₂CO₃ (589 mg, 4.26 mmol) and stirred at rt for 16 hr. Then, diluted with water (20 ml) and EtOAc (10 ml), organic phase separated, washed with water (20 ml x2), brine (20 ml), dried with Na₂SO₄ and concentrated. The residue was purified by silica gel column (Pet. ether/EtOAc; 2:1) to afford the desired product (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-phenethoxy-[2,3'-bipyridin]-5'-yl)acetate (200 mg, 0.349 mmol, 82 % yield) as a white solid. LCMS $[M + H] = 574.0$.

15

Intermediate 211



20 *(S)-Isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-methoxyphenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:*


To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (200 mg, 0.426 mmol) in DMF (5 mL) was added 1-(2-bromoethyl)-4-methoxybenzene (733 mg, 3.41 mmol), K₂CO₃ (353 mg, 2.56 mmol). The resulting mixture was stirred at 25 °C for about 8 hours and diluted with Et₂O (100ml). The organic layer was washed with water (40ml), dried over Na₂SO₄,

25

filtered and concentrated to give crude product. The crude product was purified by prep-HPLC to give the desired product (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-methoxyphenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (250 mg, 0.414 mmol, 97 % yield) as a yellow oil. LCMS (M + H) = 604.3.

5

Intermediate 212




(S)-Isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(3-methylphenethoxy)-[2,3'-bipyridin]-5'-yl)acetate:

10 A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (300 mg, 0.639 mmol), 1-(2-bromoethyl)-3-methylbenzene (191 mg, 0.958 mmol) and K₂CO₃ (441 mg, 3.19 mmol) in acetonitrile (8 mL) was heated at 80 °C for 1 h. Then, 1-(2-bromoethyl)-3-methylbenzene (191 mg, 0.958 mmol) was added and the mixture was stirred for 2 h at 80

15 °C. The reaction mixture was diluted with EtOAc (20 ml) and water (15 ml), organic phase separated and washed with water (10 ml × 2), dried over Na₂SO₄, concentrated. The residue was purified by Prep-TLC (EtOAc:Pet. ether; 1:2) to afford (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(3-methylphenethoxy)-[2,3'-bipyridin]-5'-yl)acetate (280 mg, 0.476 mmol, 74.6 % yield). LCMS [M + H] = 589.

20

Intermediate 213




(S)-Isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-6'-(pentyloxy)-[3,3'-bipyridin]-5'-yl)acetate:

25 A mixture of pentan-1-ol (65 mg, 0.737 mmol) and sodium hydride (30 mg, 1.250 mmol) in THF (10 mL) was stirred 30 mins. To the reaction mixture was added (S)-

isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.148 mmol) and stirred at 25 °C. After 4 h, the reaction mixture was diluted with H₂O (100 mL) and extracted with EtOAc (150 mL×3). The organic phase was dried over Na₂SO₄ and concentrated. The residue was purified on silica gel column (Pet. ether/EtOAc 4:1) to afford the desired product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(pentyloxy)-[3,3'-bipyridin]-5-yl)acetate (60 mg, 65.2 % yield). LCMS [M + H] = 540.3.

Intermediate 214




10

(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

A mixture of 2-methylpropan-1-ol (11.00 mg, 0.148 mmol) and sodium hydride (3.56 mg, 0.148 mmol) in THF (15 mL) was stirred 30 mins. Then, (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.148 mmol) was added and stirred at 25 °C. After 4 h, the reaction mixture was diluted with H₂O (100 mL), extracted with EtOAc (150 mL×3) and dried over Na₂SO₄ and concentrated. The residue was purified on silica gel column (Pet. ether/EtOAc 4:1) to afford the desired product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate (75 mg, 79 % yield) as a white solid. LCMS [M + H] = 526.2.

20

Intermediate 215




(6-Fluoro-5-methoxypyridin-3-yl)boronic acid:

To a mixture of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.465 g, 9.71 mmol), potassium acetate (1.429 g, 14.56 mmol) and 5-bromo-2-fluoro-3-

methoxypyridine (1 g, 4.85 mmol) in 1,4-dioxane (15 mL) was added 1,1'-bis(diphenylphosphino)ferrocenedichloro palladium(II) dichloromethane complex (0.355 g, 0.485 mmol). The mixture was stirred overnight at 83 °C under the nitrogen. Then, the reaction mixture was taken up in EtOAc (300 mL) and H₂O (150 mL). Organic layer was separated and washed with H₂O (100 mL × 3), dried with Na₂SO₄ and concentrated. The residue was purified by silica gel column (Pet. ether/EtOAc 3:1) to afford the desired product (6-fluoro-5-methoxypyridin-3-yl)boronic acid (0.67 g, 76 % yield). LCMS [M + H] = 172.1.


Intermediate 216



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-5'-methoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

To a mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (500 mg, 1.098 mmol), sodium carbonate (233 mg, 2.196 mmol), (6-fluoro-5-methoxypyridin-3-yl)boronic acid (281 mg, 1.647 mmol) in 1,4-dioxane (30 mL) and water (5.0 mL) was added (Ph₃P)₄Pd (254 mg, 0.220 mmol). The flask was placed under N₂ atm (vac/fill × 3) and stirred at 84 °C overnight. Then, taken up in EtOAc (400 mL) and H₂O (150 mL), organic layer was separated, washed with H₂O (200 mL × 3), dried with Na₂SO₄ and concentrated. The residue was purified by silica gel column (Pet. ether/EtOAc 3:1) to afford the desired product (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-5'-methoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate (100 mg, 16.52 % yield). LCMS [M + H] = 502.2.

Intermediate 217




1-(5-Bromopyridin-2-yl)-3-methylbutan-1-ol:

To a pre-cooled solution of 5-bromopicolinaldehyde (8 g, 43.0 mmol) in anhydrous THF (100 mL) was added dropwise the isobutylmagnesium bromide (86 mL,


86 mmol). The mixture was stirred at rt. for 3 hours and carefully quenched with ice-water. The solvent was removed and water (100 ml) was added to residue and extracted with EtOAc (100 mL x 3). The combined organic phases were dried over NaSO₄ and concentrated. The crude was purified by column chromatography to give 1-(5-bromopyridin-2-yl)-3-methylbutan-1-ol (4.3 g, 36%). LCMS [M + H] = 244.1.

Intermediate 218

*5-Bromo-2-(1-fluoro-3-methylbutyl) pyridine:*

To a solution of 1-(5-bromopyridin-2-yl)-3-methylbutan-1-ol (800 mg, 3.28 mmol) in dichloromethane (15 mL) was added diethylaminosulfur trifluoride (2113 mg, 13.11 mmol) below 0 °C. The mixture was stirred overnight at 35 °C under nitrogen. Then, solvent was removed, and EtOAc (200 mL) and saturate solution of NaHCO₃ (100 mL) were added. The organic phase was separated and washed with saturate solution of NaHCO₃ (100 mL x 3), dried over Na₂SO₄ and concentrated. The residue was purified by Prep-HPLC to afford the desired product 5-bromo-2-(1-fluoro-3-methylbutyl) pyridine (320 mg, 39.7 % yield). LCMS [M + H] = 242.0.

Intermediate 219


*(6-(1-Fluoro-3-methylbutyl)pyridin-3-yl)boronic acid:*

To a solution of 5-bromo-2-(1-fluoro-3-methylbutyl)pyridine (220 mg, 0.894 mmol), 1,1'-bis(diphenylphosphino)ferrocenedichloro palladium(II) dichloromethane complex (65.4 mg, 0.089 mmol) in 1,4-dioxane (15 mL) was added potassium acetate (263 mg, 2.68 mmol) and stirred overnight at 83 °C under nitrogen. Then, the reaction mixture was diluted with EtOAc (300 mL) and H₂O (150 mL), organic layer was separated, washed with H₂O (100mL x 3), dried over Na₂SO₄ and concentrated. The

residue was purified on silica gel column (Pet. ether/EtOAc 20:1) to afford the desired product (6-(1-fluoro-3-methylbutyl)pyridin-3-yl)boronic acid (300 mg, 135 % yield).
LCMS [M + H] = 212.2.

5

Intermediate 220




(2S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(1-fluoro-3-methylbutyl)-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

To a mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (600 mg, 1.317 mmol), sodium carbonate (279 mg, 2.63 mmol), (6-(1-fluoro-3-methylbutyl)pyridin-3-yl)boronic acid (278 mg, 1.317 mmol) in 1,4-dioxane (30 mL) and water (5.0 mL) was added (Ph₃P)₄Pd (304 mg, 0.263 mmol). The flask was placed under N₂ atm (vac/fill × 3) and stirred at 84 °C overnight. Then, EtOAc (400 mL) and H₂O (150 mL) were added, organic layer was separated and washed with H₂O (200 mL × 3), dried over Na₂SO₄ and concentrated. The residue was purified on silica gel column (Pet. ether/EtOAc 4:1) to afford the desired product (2S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(1-fluoro-3-methylbutyl)-6-methyl-[3,3'-bipyridin]-5-yl)acetate (400 mg, 35.9 % yield). LCMS [M + H] = 542.3.

20

Intermediate 221



2-Chloro-6-isobutoxypyridine:

To a solution of 2-methylpropan-1-ol (3.38 g, 45.6 mmol) in DMF (20 mL) was added sodium hydride (1.976 g, 49.4 mmol) and stirred for 20 min. Then, 2-chloro-6-fluoropyridine (5.0 g, 38.0 mmol) was added and stirred at 60 °C overnight. The solution was cooled to room temperature, diluted with 50 mL of EtOAc and the mixture was washed with water (50 mL x2). The organic layer was dried, filtered and concentrated. The crude product was purified by chromatography on silica gel eluting with Pet.

ether:EtOAc (10:1) to give 2-chloro-6-isobutoxypyridine (3.96 g, 12.12 mmol, 31.9 % yield). LCMS [M + H] = 186.


Intermediate 222



3-Bromo-2-chloro-6-isobutoxypyridine:

A mixture of 2-chloro-6-isobutoxypyridine (2g, 10.77 mmol) and 1-bromopyrrolidine-2, 5-dione (2.88 g, 16.16 mmol) in acetonitrile (20 mL) was heated at 85 °C overnight. The solution was evaporated and the residue dissolved in EtOAc (20 m.), washed with brine and dried over Na₂SO₄, concentrated in vacuum to afford crude product. The crude product was purified by chromatography (Pet. ether:EtOAc; 100:1) to 3-bromo-2-chloro-6-isobutoxypyridine and 5-bromo-2-chloro-6-isobutoxypyridine mixture (2.6 g, 8.78 mmol, 81 % yield). LCMS [M + H] = 264.


Intermediate 223



3-Bromo-6-isobutoxy-2-methoxypyridine:

To a solution of 3-bromo-2-chloro-6-isobutoxypyridine and 5-bromo-2-chloro-6-isobutoxypyridine mixture (2.0 g, 7.56 mmol) in methanol (8 mL) was added sodium methoxide (2.042 g, 37.8 mmol) under an atmosphere of N₂. The mixture was stirred at 100 °C for 4 hr in microwave. The solution was evaporated and the residue dissolved in EtOAc (50 mL), washed with brine solution and dried over Na₂SO₄, concentrated in vacuum to afford crude product. The crude product was purified by silica gel chromatography (Pet. ether:EtOAc; 100:1) to give 3-bromo-6-isobutoxy-2-methoxypyridine (1.1 g, 3.85 mmol, 51 % yield). LCMS [M + H] = 260 and 261.


Intermediate 224



(6-Isobutoxy-2-methoxypyridin-3-yl) boronic acid:

To a solution of 3-bromo-6-isobutoxy-2-methoxypyridine (500 mg, 1.922 mmol) in THF (20 mL) was added n-butyllithium (1.153 mL, 2.88 mmol) at -78 °C and stirred for 20 min. Then, triisopropyl borate (398 mg, 2.114mmol) was added and the reaction mixture was stirred at rt for 1 h. The reaction mixture was then diluted with 20 mL of water and neutralized with aq. HCl to pH = 6-7. Then, the mixture was extracted with EtOAc (20 mL x 2), dried and concentrated. The residue was purified by Prep-TLC (EtOAc:Pet. ether; 1:4) to give (6-isobutoxy-2-methoxypyridin-3-yl) boronic acid (70 mg, 0.229 mmol, 11.91 % yield). LCMS [M + H] = 226.


Intermediate 225



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2'-methoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

A mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (100 mg, 0.220 mmol), (6-isobutoxy-2-methoxypyridin-3-yl) boronic acid (59.3 mg, 0.263 mmol) and sodium carbonate (69.8 mg, 0.659mmol) in 1,4-dioxane (1.5mL) and water (0.500mL) was degassed by N₂. Then, the Pd(PPh₃)₄ (50.7 mg, 0.044 mmol) was added and the mixture was heated for 1 h at 110 °C with microwave. Then, the reaction mixture was diluted with 20 mL of water and extracted with EtOAc (20 mL x 2). The combined organic layers were dried, concentrated and the resulting residue was purified by Prep-TLC (EtOAc:Pet. ether; 1:3) to give (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2'-methoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate (60 mg, 0.108 mmol, 49.2 % yield). LCMS [M + H] = 556.4.


Intermediate 226



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate:


- 5 A mixture of butan-1-amine (1 mL, 10.12 mmol) and (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.143 mmol) was sealed in microwave tube and heated at 100°C for 1 h.. Then, the solvent was removed and the residue was purified by Prep-TLC (Pet. ether:EtOAc; 1:1) to afford (S)-isopropyl 2-(tert-butoxy)-2-(6'-(butylamino)-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.129 mmol, 90 % yield. LCMS = 543 [M+H].

Intermediate 227



- 15 *(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-(isobutylamino)-6-methyl-[3,3'-bipyridin]-5-yl)acetate:*
- A mixture of 2-methylpropan-1-amine (1 mL, 10.12 mmol) and (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (80 mg, 0.163 mmol) was sealed in microwave tube and heated at 100°C for 1 h. The solvent was removed and the residue was purified by Prep-TLC (Pet. ether:EtOAc; 1:1) to afford (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-(isobutylamino)-6-methyl-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.129 mmol, 79 % yield). LCMS m/z = 543 [M+H].


Intermediate 228



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-((4-fluorophenethyl)amino)-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

- 5 A mixture of 2-(4-fluorophenyl)ethanamine (1 mL, 7.62 mmol) and (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (80 mg, 0.163 mmol) was sealed in microwave tube and heated at 100°C for 1 h. Then, the solvent was removed and the residue was purified by Prep-TLC(Pet. ether:EtOAc; 1:1) afford (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-((4-fluorophenethyl)amino)-6-methyl-[3,3'-bipyridin]-5-yl)acetate (80 mg, 0.131 mmol, 80 % yield). LCMS = 609 [M+H].


Intermediate 229



- 15 *5-Bromo-3-chloro-2-isobutoxypyridine:*

A mixture of 2-methylpropan-1-ol (1.240 g, 16.73 mmol), Cs₂CO₃ (5.95 g, 18.25 mmol) and 5-bromo-3-chloro-2-fluoropyridine (3.2 g, 15.21 mmol) in DMSO (20 mL) was heated at 90 °C overnight. Then, the reaction mixture was taken up in 50 mL of EtOAc and washed with water (50 mL x 2). The organic layer was dried, concentrated and the residue was purified by silica gel chromatography to give 5-bromo-3-chloro-2-isobutoxypyridine (3.0 g, 11.34 mmol, 74.6 % yield). LCMS = 264 [M+H].


Intermediate 230



3-Chloro-2-isobutoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine:

A mixture of 1,1'-bis(diphenylphosphino)ferrocenedichloro palladium(II) dichloromethane complex (277 mg, 0.378 mmol), 5-bromo-3-chloro-2-isobutoxypyridine (1000 mg, 3.78 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1152 mg, 4.54 mmol) and potassium acetate (1113 mg, 11.34 mmol) in 1,4-dioxane (20 mL) was heated at 90 °C under N₂ atm (vac/fill ×3). Then, the reaction mixture was diluted with 50 mL of water and extracted with EtOAc (50 mL × 2). The organic layers were dried over Na₂SO₄, concentrated and the residue was purified by Prep-TLC to give 3-chloro-2-isobutoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (630 mg, 1.820 mmol, 48.1 % yield). LCMS = 312 [M+H].


Intermediate 231



(S)-Isopropyl 2-(tert-butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

A mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (250 mg, 0.549 mmol), 3-chloro-2-isobutoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (257 mg, 0.823 mmol), Pd(Ph₃P)₄ (127 mg, 0.110 mmol) and Na₂CO₃ (175 mg, 1.647 mmol), water (3 mL) and 1,4-dioxane (20 mL) was degassed with N₂ (vac/fill ×3) and heated at 90 °C overnight under N₂. Then, cooled, diluted with EtOAc (20 ml) and H₂O (20 ml), organic phase separated and aqueous layer extracted with EtOAc (20 ml × 3). The combined organic layers were dried with Na₂SO₄ and concentrated. The residue was purified by silica gel column (EtOAc:Pet. ether; 1:5) to afford (S)-isopropyl 2-(tert-butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate (65 mg, 0.079 mmol, 14.37 % yield). LCMS = 560 [M+H].


Intermediate 232



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate:

- 5 A mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (300 mg, 0.659 mmol), (6-fluoro-2-methylpyridin-3-yl)boronic acid (153 mg, 0.988 mmol), Pd(Ph₃P)₄ (114 mg, 0.099 mmol) and Na₂CO₃ (209 mg, 1.976 mmol), water (3 mL) and 1,4-dioxane (20 mL) was degassed with N₂, sealed in microwave tube and heated at 110 °C for 40 min. Then,
- 10 cooled, diluted with EtOAc (20 ml) and H₂O (50 ml), the organic phase separated and aqueous phase extracted with EtOAc (20 ml × 3). The combined organic layers were dried with Na₂SO₄ and concentrated. The residue was purified by silica gel column (EtOAc:Pet. ether, 1:5) to afford (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate (240 mg, 0.257 mmol, 39.0 % yield).
- 15 LCMS = 486 [M+H].

Intermediate 233




(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate:

- 20 A mixture of 2-methylpropan-1-ol (145 mg, 1.956 mmol), (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate (190 mg, 0.391 mmol) and Cs₂CO₃ (637 mg, 1.956 mmol) in DMF (5 mL) was sealed in microwave tube and heated at 150 °C for 4 h. Then, cooled, diluted with 20
- 25 mL of EtOAc and the mixture was washed with water. The organic layer was concentrated and the residue was purified by Prep-TLC to give (S)-isopropyl 2-(tert-

butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate (37 mg, 0.065 mmol, 16.65 % yield). LCMS = 540 [M+H].


Intermediate 234



3-Bromo-5-(3-methylbut-1-en-1-yl) pyridine:

To a mixture of bromo (isobutyl) triphenylphosphorane (8.37 g, 20.97 mmol) in toluene (40 mL) was added potassium 2-methylpropan-2-olate (20.97 mL, 20.97 mmol) at -78 °C and stirred at rt for 4 h. Then, 5-bromonicotinaldehyde (3.0 g, 16.13 mmol) in 10 mL of toluene was added and stirred at rt overnight. Then, the reaction mixture was diluted with 50 ml of water and the mixture was extracted with EtOAc. The combined organic layers were dried, filtered and concentrated. The residue was purified by silica gel chromatography to give 3-bromo-5-(3-methylbut-1-en-1-yl) pyridine (2.85 g, 10.34 mmol, 64.1 % yield). LCMS = 226 [M+H].


Intermediate 235



3-(3-Methylbut-1-en-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine:

A mixture of 1,1'-bis(diphenylphosphino)ferrocenedichloro palladium(II) dichloromethane complex (324 mg, 0.442 mmol), 3-bromo-5-(3-methylbut-1-en-1-yl)pyridine (1000 mg, 4.42 mmol), 4,4,4',4'',5,5,5',5''-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1685 mg, 6.63 mmol) and KOAc (1302 mg, 13.27 mmol) in 1,4-dioxane (20 mL) was heated at 90 °C under N₂ overnight. Then, cooled, diluted with 30 ml of water and the mixture was extracted with EtOAc (30 mLx3). The combined organic layers were dried, filtered and concentrated. The residue was purified by Prep-TLC (Pet. ether:EtOAc = 3:1) to give 3-(3-methylbut-1-en-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (950 mg, 2.71 mmol, 61.3 % yield). LCMS = 192 [M-81].


Intermediate 236



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-5'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetate:

- 5 A stirred mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (200 mg, 0.439 mmol), 3-(3-methylbut-1-en-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (180 mg, 0.659 mmol), Pd(Ph₃P)₄ (507 mg, 0.439 mmol) and Na₂CO₃ (140 mg, 1.317 mmol), water (3 mL) and 1,4-dioxane (10 mL) was placed under N₂ atm (vac/fill ×3). The mixture was heated at 10 90°C overnight under N₂ and cooled, diluted with EtOAc (50 ml) and H₂O (50 ml). Organic phase separated and aqueous phase extracted with EtOAc (50 ml × 3). The combined organic layers were dried with Na₂SO₄ and concentrated. The residue was purified by Prep-TLC (EtOAc:Pet. ether; 1:5) to afford (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-5'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetate (160 mg, 0.264 mmol, 60.1 % yield). LCMS = 522 [M+H].


Intermediate 237



- 20 *(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-isopentyl-6-methyl-[3,3'-bipyridin]-5-yl)acetate:*


A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-5'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetate (80 mg, 0.153 mmol) and Pd/C (15 mg) in methanol (5 mL) was stirred at rt for 1 h under H₂. The mixture was filtered and concentrated to give (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-isopentyl-6-methyl-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.116 mmol, 76 % yield). LCMS = 524 [M+H].

Intermediate 238

*5-Bromo-2-(3-methylbut-1-en-1-yl)pyridine:*


- 5 To a mixture of bromo(isobutyl)triphenyl-phosphorane (8.37 g, 20.97 mmol) in toluene (40 mL) was added potassium 2-methylpropan-2-olate (20.97 mL, 20.97 mmol) at -78 °C and stirred at rt for 4 h. Then, 5-bromopicolinaldehyde (3.0 g, 16.13 mmol) in 10 mL of toluene was added and stirred at rt overnight. The reaction mixture was diluted with 50 ml of water and extracted with EtOAc, the organic layer was dried, filtered and
- 10 concentrated. The residue was purified by silica gel chromatography to give 5-bromo-2-(3-methylbut-1-en-1-yl)pyridine (3.0 g, 8.89 mmol, 55.1 % yield. LCMS = 226 [M+H]).

Intermediate 239



- 15 *2-(3-Methylbut-1-en-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine:*
- A mixture of 1,1'-bis(diphenylphosphino)ferrocenedichloro palladium(II) dichloromethane complex (324 mg, 0.442 mmol), (E)-5-bromo-2-(3-methylbut-1-en-1-yl)pyridine (1000 mg, 4.42 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1685 mg, 6.63 mmol) and KOAc (1302 mg, 13.27 mmol) in 1,4-dioxane
- 20 (20 mL) was heated at 90 °C under N₂ overnight. Then, diluted with 30 ml of water and the mixture was extracted with EtOAc (30 mL x3), the combined organic layers were dried, filtered and concentrated. The residue was purified by Prep-TLC (Pet. ether:EtOAc; 3:1) to give 2-(3-methylbut-1-en-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (950 mg, 1.426 mmol, 32.2 % yield). LCMS = 192 [M-81].


Intermediate 240



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetate:

- 5 A stirred mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (500 mg, 1.098 mmol), 2-(3-methylbut-1-en-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (450 mg, 1.647 mmol), Pd(Ph₃P)₄ (127 mg, 0.110 mmol), Na₂CO₃ (349 mg, 3.29 mmol) water (3 mL) and 1,4-dioxane (10 mL) was placed under N₂ atm (vac/fill×3). Then, the mixture was heated at
- 10 90 °C overnight under N₂ and, cooled, diluted with EtOAc (50 ml) and H₂O (50 ml). The organic phase separated and aqueous extracted with EtOAc (50 ml × 3). The combined organic layers were dried with Na₂SO₄, concentrated and the residue was purified by Prep-TLC (EtOAc:Pet. ether; 1:2) to afford (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetate
- 15 (250 mg, 0.457 mmol, 41.6 % yield. LCMS = 522.2 [M+H].


Intermediate 241



(S)-Isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isopentyl-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

- 20 A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetate (80 mg, 0.153 mmol) and Pd/C (30 mg) in methanol (5 mL) was stirred at rt for 1 h under H₂. The mixture was filtered and concentrated to give (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-
- 25 dimethylpiperidin-1-yl)-6'-isopentyl-6-methyl-[3,3'-bipyridin]-5-yl)acetate (75 mg, 0.121 mmol, 79 % yield). LCMS = 524 [M+H].


Intermediate 242



5 *(S)-Isopropyl 2-(tert-butoxy)-2-(6'-((2-chloro-6-methylbenzyl)oxy)-4-(4,4-*
dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetate:

To a pre-cooled solution of (2-chloro-6-methylphenyl)methanol (166 mg, 1.060 mmol) in DMF (1 mL) was added the NaH (42.4 mg, 1.060 mmol) in portions. Then, (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (100 mg, 0.212 mmol) was added and the mixture was stirred at
 10 room temperature for additional 16 h. The reaction mixture was poured into the ice-water (3 ml). The aqueous layer was extracted with EtOAc (30 ml x 3), the combined organic layers were dried over Na₂SO₄ and concentrated to give (S)-isopropyl 2-(tert-butoxy)-2-(6'-((2-chloro-6-methylbenzyl)oxy)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetate as a yellow oil (80 mg, 0.092 mmol, 43.4 % yield) which was used
 15 in the next step without purification. LCMS [M + H] = 609.0.


Intermediate 243



2,3-Dichloro-6-methyl-5-nitropyridine:


20 To a solution of quinoline (1.370 g, 10.61 mmol) was added POCl₃ (1.977 ml, 21.21 mmol) dropwise at 0 °C under N₂ and stirred at 0 °C for 30 min. Then, 3-chloro-6-methyl-5-nitropyridin-2-ol (4 g, 21.21 mmol) was added at 0 °C and the mixture was heated at 120 °C for 2 hr under N₂. Ice water (30 ml) and EtOAc (30 ml) were added to the reaction mixture with stirring. The pH was adjusted to 8 by sat NaHCO₃. The organic
 25 layer was washed with brine, dried over Na₂SO₄, concentrated to give crude product. The product was purified by flash chromatography (Pet. ether:EtOAc; 20:1) to give 2,3-dichloro-6-methyl-5-nitropyridine (1.7 g, 8.21 mmol, 38.7 % yield) as a white solid. LCMS [M + H] = 207.0.

Intermediate 244




To a solution of 2,3-dichloro-6-methyl-5-nitropyridine (1.7 g, 8.21 mmol) and ammonium chloride (4.39 g, 82 mmol) in ethanol (10 mL) was added iron (2.293 g, 41.1 mmol). The mixture was stirred at 90 °C for 6 hr. Ice water and EtOAc (20 ml each) was added to the reaction mixture with stirring. The organic layer was washed with brine, dried by Na₂SO₄, concentrated to give crude product. The product was purified by Prep-TLC (Pet. ether:EtOAc; 6:1) to give aim product 5,6-dichloro-2-methylpyridin-3-amine (800 mg, 4.52 mmol, 55.0 % yield) as a white solid. LCMS [M + H] = 177.

Intermediate 245



To a solution of 5,6-dichloro-2-methylpyridin-3-amine (850 mg, 4.80 mmol) in HBr (48%, 25 ml) was added dropwise a solution of sodium nitrite (358 mg, 5.19 mmol) in water (8 mL) at 0-5 °C. The mixture was stirred at 0-5 °C for 10 min and copper(I) bromide (758 mg, 5.28 mmol) was added at 0 °C. Then, the reaction mixture was stirred at rt for 1 h and ice water and EtOAc (30 ml each) were added to the reaction mixture with stirring. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated to give crude product. The product was purified by Prep-TLC (Pet. ether:EtOAc; 20:1) to give desired product 3-bromo-5,6-dichloro-2-methylpyridine (0.6 g, 2.491 mmol, 51.9 % yield) as a white solid. LCMS [M + H] = 240.0.


Intermediate 246



To a solution of 2-methylpropan-1-ol (0.923 g, 12.45 mmol) in DMF (10 mL) was added NaH (0.548 g, 13.70 mmol) at 0-5 °C and stirred at rt for 10 min. Then, 3-bromo-5,6-dichloro-2-methylpyridine (0.6 g, 2.491 mmol) in DMF (2 mL) was added and the


mixture was stirred at rt for 16 h. Ice water (20 ml) and EtOAc (20 ml) were added the reaction mixture with stirring. The organic layer was washed with water (20 ml x 3), dried over N₂SO₄, concentrated to give crude product. The product was purified by Pre-TLC (Pet. ether:EtOAc; 20:1) to give desired product 3-bromo-5-chloro-6-isobutoxy-2-methylpyridine (0.4 g, 1.350 mmol, 54.2 % yield) as an oil. LCMS [M + H] = 278.

Intermediate 247



To a solution of 3-bromo-5-chloro-6-isobutoxy-2-methylpyridine (200 mg, 0.718 mmol) in THF (3 mL) was added n-butyllithium (0.373 mL, 0.933 mmol) at -78 °C and stirred for 20 min at -78 °C. Then, triisopropyl borate (270 mg, 1.436 mmol) in THF (2 ml) was added and the reaction mixture was stirred at rt for 1 h. 10 mL of water was added and the mixture was neutralized with aq. HCl to pH = 6-7. Then, the mixture was extracted with EtOAc (20 mL x2), dried and concentrated. The residue was purified by Prep TLC (EtOAc:Pet. ether; 1:4) to give (5-chloro-6-isobutoxy-2-methylpyridin-3-yl)boronic acid (80 mg, 0.245 mmol, 34.1 % yield) as a white solid. LCMS [M + H] = 244.


Intermediate 248



A mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (122 mg, 0.267 mmol), (5-chloro-6-isobutoxy-2-methylpyridin-3-yl)boronic acid (65 mg, 0.267 mmol) and Na₂CO₃ (85 mg, 0.801 mmol) in 1,4-dioxane (1.5 mL) and water (0.500 mL) was degassed by N₂. Then, Pd(PPh₃)₄ (61.7 mg, 0.053 mmol) was added and heated for 1 hour at 110 °C with microwave. 20 mL of water was added and the mixture was extracted with EtOAc (20 mL x2), the combined organic layers were dried and concentrated. The residue was purified by Prep-TLC (EtOAc:Pet. ether; 1:3) to give aim product (S)-isopropyl 2-(tert-butoxy)-2-

(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate (20 mg, 0.033 mmol, 12.40 % yield) as a white solid. LCMS $[M + H] = 575$.

Intermediate 248




5

(*S*)-Isopropyl 2-tert-butoxy-2-(6'-butoxy-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetate:

To a ice-cold solution of butan-1-ol (55.0 mg, 0.742 mmol) in anhydrous THF (3 mL) was added the sodium hydride (29.7 mg, 0.742mmol). The mixture was stirred at rt for 20 min. Then, (*S*)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-3,3'-bipyridin-5-yl)acetate (70 mg, 0.148 mmol) was added and stirred at rt for 2 h. The mixture was poured into the ice-water, extracted with the EtOAc (25 ml x 3), the combined organic layers dried over Na₂SO₄, filtered and concentrated. The crude was purified by Prep-TLC (Pet. ether:EtOAc; 4:1) to give (*S*)-isopropyl 2-tert-butoxy-2-(6'-butoxy-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetate (55 mg, 58%). LCMS $[M + H] = 526.4$.

15

Intermediate 250




20 1-(5-Bromopyridin-2-yl)-3-methylbutan-1-one:

To a ice-cold solution of 1-(5-bromopyridin-2-yl)-3-methylbutan-1-ol (3.35 g, 13.72 mmol) in dichloromethane (70 mL) was added Dess-martinperiodinane (11.64 g, 27.4 mmol). The mixture was stirred for 4 h at 25 °C. Then, NaHCO₃ sat. (100 ml) was added, extracted with EA (200 ml x 3). The combined organic phase were dried over Na₂SO₄ and concentrated. The residue was purified on silica gel column (PE/EA 20:1) to afford desired product 1-(5-bromopyridin-2-yl)-3-methylbutan-1-one (3.3 g, 13.49 mmol, 98 % yield) yellow oil. LCMS $[M + H] = 242.1$.

25

Intermediate 251

*5-Bromo-2-(1,1-difluoro-3-methylbutyl)pyridine:*


To a ice-cold 1-(5-bromopyridin-2-yl)-3-methylbutan-1-one (3.3 g, 13.63 mmol)
 5 was added Bast (10.05 ml, 54.5 mmol). The mixture was stirred overnight at 60 °C. Then,
 cooled, diluted with 5 M K₃PO₄ (100 ml) and extracted with EA (150 ml×3). The
 combined organic layers were dried over Na₂SO₄ and concentrated. The residue was
 purified by Prep-HPLC to afford desired product 5-bromo-2-(1,1-difluoro-3-
 methylbutyl)pyridine (600 mg, 2.272 mmol, 16.67 % yield) as yellow oil. LCMS [M + H]
 10 = 264.2.

Intermediate 252

*6-(1,1-Difluoro-3-methylbutyl)pyridin-3-ylboronic acid:*

15 A mixture of 5-bromo-2-(1,1-difluoro-3-methylbutyl)pyridine (300 mg, 1.136
 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (433 mg, 1.704 mmol),
 potassium acetate (334 mg, 3.41 mmol) and PdCl₂(dppf) (166 mg, 0.227 mmol) in 1,4-
 dioxane(10 ml) was heated at 100 °C for 16 h under N₂ atmosphere. The mixture was
 then filtered, concentrated, the residue taken up in water and extracted with the EtOAc
 20 (70 ml x 3). The combined organic layers were dried over NaSO₄, concentrated and
 purified by prep-TLC(Pet. ether:EtOAc; 5:1) to give 6-(1,1-difluoro-3-
 methylbutyl)pyridin-3-ylboronic acid (160 mg, 29%). LCMS [M + H] = 230.1.

Intermediate 253




25

(S)-Isopropyl 2-tert-butoxy-2-(6'-(1,1-difluoro-3-methylbutyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetate:

A mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (100 mg, 0.220 mmol), (6-(1,1-difluoro-3-methylbutyl)pyridin-3-yl)boronic acid (101 mg, 0.439 mmol), Na₂CO₃ (69.8 mg, 0.659 mmol) in 1,4-dioxane (3 ml) and water (1 ml) was degassed with N₂. Then, Pd(PPh₃)₄ (50.7 mg, 0.044 mmol) was added and heated at 110 °C for 16 h under N₂ atmosphere. The mixture was then filtered, concentrated, the residue was taken up into water and extracted with the EA (50 ml x 3). The combined organic layers were dried over NaSO₄, concentrated and purified by prep-TLC (Pet. ether:EtOAc; 6:1) to give (S)-isopropyl 2-tert-butoxy-2-(6'-(1,1-difluoro-3-methylbutyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetate (70 mg, 57%). LCMS [M + H] = 560.3.


Intermediate 254



(2-Chloro-6-isobutoxypyridin-3-yl)boronic acid:

To a solution of 3-bromo-2-chloro-6-isobutoxypyridine (1.4 g, 5.29 mmol) in THF (20 mL) was added n-butyllithium (3.18 mL, 7.94 mmol) at -78°C and stirred for 20 min at -78°. Then, triisopropyl borate (1.095 g, 5.82 mmol) was added and the reaction mixture was stirred at rt for 1 h. The reaction mixture was diluted with water (20 mL), neutralized with aq. HCl to pH = 6-7 and extracted with EtOAc (20 mL x2). The combined organic layers were dried over Na₂SO₄ and concentrated. The residue was purified by Prep_TLC (EtOAc: Pet. Ether = 1:3) to give (2-chloro-6-isobutoxypyridin-3-yl)boronic acid (450 mg, 1.902 mmol, 35.9 % yield) as white solid. LCMS [M + H] = 230.

Intermediate 255




(2S)-Isopropyl 2-tert-butoxy-2-(2'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetate:

- 5 The solution of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-tert-butoxyacetate (200 mg, 0.439 mmol), 2-chloro-6-isobutoxypyridin-3-ylboronic acid (202 mg, 0.878 mmol) and sodium carbonate (140 mg, 1.317 mmol) in 1,4-dioxane (3 ml) and water (1 ml) was degassed by N₂. Then, Pd(PPh₃)₄ (101 mg, 0.088 mmol) was added and heated at 110 °C for 1 h in microwave.
- 10 The mixture was filtered, concentrated, taken up into water and extracted with the EtOAc (50 ml x 3). The combined organic layers were dried over NaSO₄, concentrated and the crude was purified by prep-TLC (Pet. ether:EtOAc; 3:1) to give (2S)-isopropyl 2-tert-butoxy-2-(2'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetate (100 mg, 27%). LCMS [M + H] = 560.3.

15


Intermediate 256



6-(1-Hydroxy-3-methylbutyl)pyridin-3-ylboronic acid:

- 20 A mixture of 1-(5-bromopyridin-2-yl)-3-methylbutan-1-ol (800 mg, 3.28 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1248 mg, 4.92 mmol), potassium acetate (965 mg, 9.83 mmol) and PdCl₂(dppf) (480 mg, 0.655 mmol) in 1,4-dioxane (10 ml) was heated at 100 °C for 16 h under N₂ atmosphere. The mixture was used in the next step without purification. LCMS [M + H] = 210.0.

Intermediate 257




(2S)-Isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(1-hydroxy-3-methylbutyl)-6-methyl-3,3'-bipyridin-5-yl)acetate:

- 5 The mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (600 mg, 1.32 mmol), 6-(1-hydroxy-3-methylbutyl)pyridin-3-ylboronic acid (crude from previous reaction, 3.83 mmol), Na₂CO₃ (1217 mg, 11.48 mmol) in 1,4-dioxane (5 ml) and water (1.5 ml) was degassed with N₂. Then, Pd(Ph₃P)₄ (884 mg, 0.765 mmol) was added and heated at 110 °C for 16
- 10 h under N₂ atmosphere. The mixture filtered, concentrated and the residue was taken up into water and extracted with EtOAc (80 ml x 3). The combined organic layers were dried over NaSO₄, concentrated and purified by prep-TLC (Pet. ether:EtOAc; 1:1) to give (2S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(1-hydroxy-3-methylbutyl)-6-methyl-3,3'-bipyridin-5-yl)acetate (250 mg, 35%). LCMS [M + H] = 540.3.

15


Intermediate 258



- A mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-tert-butoxyacetate (400 mg, 0.878 mmol), 2,6-difluoropyridin-3-ylboronic acid (279 mg, 1.757 mmol) and sodium carbonate (279 mg, 2.63 mmol) in 1,4-dioxane (6 ml) and water (2 ml) was degassed by bubbling N₂ through the reaction mixture.. Then, the Pd(PPh₃)₄ (203 mg, 0.176 mmol) was added and the mixture was heated at 110 °C for 1 h in microwave. Then, the mixture was filtered and the filtrate was concentrate. The residue was suspended in water and extracted with the EtOAc (3 x 50
- 20 mL). The combined organic layers were dried over Na₂SO₄ and concentrated. The crude product was purified by prep-TLC (Pet. ether:EtOAc = 2:1), to give (2S)-isopropyl 2-tert-
- 25

butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-2',6'-difluoro-6-methyl-3,3'-bipyridin-5-yl)acetate (210 mg, 24%). LCMS $[M + H] = 490.2$.

Intermediate 259



5


(2S)-Isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-2'-fluoro-6'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetate:

To a pre-cooled solution of 2-methylpropan-1-ol (32 mg, 0.43 mmol) in anhydrous DMF (3 mL) was added the NaH (17 mg, 0.43 mmol) and the mixture was stirred at this temperature for 30 min. Then, (2S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-2',6'-difluoro-6-methyl-3,3'-bipyridin-5-yl)acetate (210 mg, 0.43 mmol) was added. The mixture was stirred at rt overnight and poured into ice-water, extracted with the EtOAc (50 ml x 3), dried over Na₂SO₄ and concentrated. The crude was purified by prep-HPLC to give (2S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-2'-fluoro-6'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetate (51 mg, 17%). LCMS $[M + H] = 544.4$.

15

Also isolated


Intermediate 260



(2S)-Isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-2'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetate: (30 mg, 38%). LCMS $[M + H] = 544.4$.

20


Intermediate 261



(S)-Isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(isobutylamino)-6-methyl-3,3'-bipyridin-5-yl)acetate:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (100 mg, 0.212 mmol) and 2-methylpropan-1-amine (736 mg, 10.06 mmol) in THF (5 mL) was stirred at 100 °C for 16 hours. Then, the reaction was diluted with water (20 mL) and extracted with EtOAc (2 x 40 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄, concentrated to afford a crude product as an oil. The crude product was purified on silica gel column (Pet. ether:EtOAc = 4:1) to afford (S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(isobutylamino)-6-methyl-3,3'-bipyridin-5-yl)acetate (55 mg, 41.48%). LCMS [M + H] = 525.4.


Intermediate 262



(S)-Isopropyl 2-tert-butoxy-2-(6'-(butylamino)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetate:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.148 mmol) and butan-1-amine (217 mg, 2.97 mmol) in THF (5 mL) was stirred at 100 °C for 16 hours. Then, the mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 40 mL). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄, and concentrated to afford (S)-isopropyl 2-tert-butoxy-2-(6'-(butylamino)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetate (55 mg, 29.3%). LCMS [M + H] = 525.0.


Intermediate 263



(S)-Isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(((trifluoromethyl)sulfonyl)oxy)-[2,3'-bipyridin]-5'-yl)acetate:

To a mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (500 mg, 1.065 mmol) and triethylamine (215 mg, 2.129 mmol) in dichloromethane (8 mL) was added 1,1,1-trifluoro-N-(pyridin-2-yl)-N-((trifluoromethyl)-sulfonyl)methanesulfonamide (496 mg, 1.384 mmol) at 0 °C and stirred at rt for 2 h. Then, the reaction mixture was diluted with water (20 mL) and extracted with DCM (20 mL x2). The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The residue was purified by Prep-TLC (Pet. ether:EtOAc = 5:1) to afford (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(((trifluoromethyl)sulfonyl)-oxy)-[2,3'-bipyridin]-5'-yl)acetate (580 mg, 0.954 mmol, 90 % yield as syrup. LCMS [M + H] = 602.


Intermediate 264



(S)-Isopropyl 2-(tert-butoxy)-2-(5-(butylamino)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

A stirred mixture of tris(dibenzylideneacetone)di-palladium(0) (22.83 mg, 0.025 mmol), (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(((trifluoromethyl)sulfonyl)oxy)-[2,3'-bipyridin]-5'-yl)acetate (150 mg, 0.249 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenyl-phosphine) (28.9 mg, 0.050 mmol), butan-1-amine (36.5 mg, 0.499 mmol) and Cs₂CO₃ (244 mg, 0.748 mmol) in toluene (10 mL) was placed under N₂ atm (wac/fill x3). The mixture was heated at 100 °C overnight under N₂. Then, diluted with EtOAc (50 mL) and H₂O (20 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were dried over Na₂SO₄ and concentrated. The residue was purified by Prep-TLC (Pet. ether:EtOAc = 1:1) to give (S)-isopropyl 2-(tert-butoxy)-2-(5-(butylamino)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (65 mg, 0.105 mmol, 42.2 % yield). LCMS [M + H] = 525.


Intermediate 265



(S)-Isopropyl 2-(tert-butoxy)-2-(5-(butylamino)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate:

- 5 A stirred mixture of tris(dibenzylideneacetone)-dipalladium(0) (22.83 mg, 0.025 mmol), (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethyl-piperidin-1-yl)-6'-methyl-5-(((trifluoromethyl)sulfonyl)oxy)-[2,3'-bipyridin]-5'-yl)acetate (150 mg, 0.249 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (28.9 mg, 0.050 mmol), N-methylbutan-1-amine (43.5 mg, 0.499 mmol) and Cs₂CO₃ (244 mg, 0.748 mmol) in
- 10 toluene (10 mL) was placed under N₂ atm (vac/fill×3). The mixture was heated at 100 °C overnight under N₂. Then, diluted EtOAc (50 ml) and H₂O (20 ml) and extracted with EtOAc (50ml × 3). The combined organic layers were dried with Na₂SO₄ and concentrated. The residue was purified by Prep-TLC (Pet. ether:EtOAc = 1:1) to give (S)-isopropyl 2-(tert-butoxy)-2-(5-(butylamino)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-
- 15 [2,3'-bipyridin]-5'-yl)acetate (50 mg, 0.094 mmol, 37.6 % yield). LCMS [M + H] = 539.

Example 1




- (S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methyl-2-vinylpyridin-3-yl)acetic acid:*
- 20

- To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methyl-2-vinylpyridin-3-yl)acetate (11 mg, 0.018 mmol) in EtOH (1 mL) and water (0.111 mL) was added lithium hydroxide monohydrate (7.48 mg, 0.178 mmol) and heated at 75 °C for 48 hrs. The reaction was cooled to RT,
- 25 filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS to afford the product (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-

fluorophenethoxy)phenyl)-6-methyl-2-vinylpyridin-3-yl)acetic acid (7.3 mg, 0.013 mmol, 71.2 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ 7.38 (dd, *J*=8.2, 5.8 Hz, 2H), 7.27 - 7.20 (m, 2H), 7.18 - 7.12 (m, 2H), 7.08 - 7.01 (m, 2H), 6.26 (dd, *J*=16.9, 2.9 Hz, 1H), 5.92 (br s, 1H), 5.30 (dd, *J*=10.8, 2.6 Hz, 1H), 4.29 - 4.19 (m, 2H), 3.06 (t, *J*=6.7 Hz, 2H), 2.23 - 2.16 (m, 1H), 2.11 (s, 3H), 1.96 (br t, *J*=11.6 Hz, 1H), 1.54 - 1.44 (m, 1H), 1.34 - 1.17 (m, 1H), 1.12 (s, 9H), 1.07 - 0.99 (m, 2H), 0.85 (s, 3H), 0.60 (s, 3H) 3 protons on the piperidine ring and the 2 protons of the methylene on the 4-fluorophenethoxy were not resolved via ¹H NMR due to water in the experiment. LCMS (M+1) = 575.2.

10


Example 2



(S)-2-(2-Amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

To a solution of (S)-isopropyl 2-(2-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (20 mg, 0.033 mmol) in EtOH (1mL) and water (0.111 mL) was added lithium hydroxide monohydrate (13.85 mg, 0.330 mmol) and heated at 75 °C for 2 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS to afford the product (S)-2-(2-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-

fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid (1.8 mg, 2.94 μmol, 8.90 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ 7.37 (dd, *J*=8.4, 5.9 Hz, 2H), 7.19 - 7.11 (m, 3H), 7.08 - 6.96 (m, 3H), 5.81 - 5.70 (m, 1H), 4.27 - 4.15 (m, 2H), 3.50 - 3.34 (m, 1H), 3.04 (t, *J*=7.0 Hz, 2H), 1.96 - 1.87 (m, 3H), 1.29 - 1.18 (m, 2H), 1.16 (s, 9H), 0.90 - 0.54 (m, 6H). 5 protons on the piperidine ring were not resolved via ¹H NMR due to water suppression in the experiment. LCMS (M+1) = 564.2.




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methoxy-6-methylpyridin-3-yl)acetic acid and (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)acetic acid:

(S)-Isopropyl 2-(2-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)-2-(tert-butoxy)acetate (50 mg, 0.083 mmol) and copper(II) chloride (33.3 mg, 0.248 mmol) were combined in 37% HCl (413 μ l) and MeOH (413 μ l) in a 7 ml vial. The mixture was then cooled to 0 °C and a solution of sodium nitrite (17.08 mg, 0.248 mmol) in 0.1 mL H₂O was added. The vial was sealed and the mixture was warmed to room temp and stirred for 5 h. The mixture was diluted with EtOAc and washed with water, brine, dried (MgSO₄), filtered and concentrated. The residue was taken up in EtOH (1 mL) and water (0.1 mL) and added lithium hydroxide monohydrate (34.6 mg, 0.825 mmol). The reaction was heated to 75 °C for 18 hrs. The reaction was cooled to RT and filtered through a 0.45 μ nylon frit filter and purified via preparative LC/MS to afford the products (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methoxy-6-methylpyridin-3-yl)acetic acid (2.6 mg, 4.49 μ mol, 5.44 % yield) and (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)acetic acid (6.8 mg, 0.012 mmol, 14.59 % yield).

(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methoxy-6-methylpyridin-3-yl)acetic acid ¹H NMR (500 MHz, DMSO-d₆) δ 7.36 (dd, J =8.4, 5.5 Hz, 2H), 7.17 - 7.10 (m, 3H), 7.07 - 7.03 (m, 1H), 7.02 - 6.96 (m, 2H), 5.35 (s, 1H), 4.27 - 4.16 (m, 2H), 3.82 (s, 3H), 3.62 - 3.45 (m, 1H), 3.03 (t, J =6.6 Hz, 2H), 2.86 - 2.68 (m, 1H), 2.24 - 2.07 (m, 1H), 2.01 (s, 3H), 1.71 - 1.54 (m, 1H), 1.14 (s, 9H), 0.82 - 0.75 (m, 3H), 0.54 (br s, 3H). 4 protons on the piperidine ring were not resolved via ¹H NMR due to water suppression in the experiment. LCMS (M+1) = 579.1.


(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)acetic acid ¹H NMR (500 MHz, DMSO-d₆) δ 7.35 (dd, *J*=8.3, 5.7 Hz, 1H), 7.19 - 7.15 (m, 1H), 7.12 (t, *J*=8.8 Hz, 2H), 7.07 - 7.01 (m, 1H), 6.97 (br t, *J*=7.3 Hz, 2H), 5.36 - 5.25 (m, 1H), 4.25 - 4.14 (m, 2H), 3.59 - 3.49 (m, 1H), 3.02 (t, *J*=6.6 Hz, 2H), 2.55 (s, 3H), 1.92 - 1.82 (m, 4H), 1.14 (s, 9H), 0.78 - 0.45 (m, 6H). 4 protons on the piperidine ring were not resolved via ¹H NMR due to water suppression in the experiment. LCMS (M+1) = 565.2.



(S)-2-(tert-Butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)acetic acid:

To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)acetate (20 mg, 0.032 mmol) in EtOH (1ml) and water (0.111 ml) was added lithium hydroxide monohydrate (2.73 mg, 0.065 mmol) and heated at 75 °C for 30 min. After 30 minutes, the LCMS indicated the reaction was complete. The reaction was cooled to room temp, filtered through a 0.45 μ frit filter and purified via preparative LC/MS to afford the product (S)-2-(tert-butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)acetic acid (2.4 mg, 4.10 μmol, 12.62 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ 7.36 (dd, *J*=8.4, 5.9 Hz, 2H), 7.27 (br d, *J*=7.3 Hz, 1H), 7.15 - 7.03 (m, 5H), 5.47 (s, 1H), 4.31 - 4.22 (m, 2H), 3.89 (s, 1H), 3.06 (t, *J*=6.6 Hz, 2H), 2.17 (s, 3H), 1.24 (br d, *J*=12.1 Hz, 2H), 1.18 (s, 9H), 0.80 - 0.50 (m, 6H). 6 protons on the piperidine ring were not resolved via ¹H NMR due to water suppression in the experiment. LCMS (M+1) = 574.2.


Example 6



(S)-2-(tert-Butoxy)-2-(2-carbamoyl-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)acetic acid:

- 5 To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)acetate (50 mg, 0.081 mmol) in EtOH (1mL) and water (0.111 mL) was added lithium hydroxide monohydrate (34.1 mg, 0.812 mmol) and heated at 75 °C for 30 min. After 30 minutes, the LCMS indicated the reaction was complete. The reaction was cooled to room temp,
- 10 filtered through a 0.45 μ frit filter and purified via preparative LC/MS to afford the product (S)-2-(tert-butoxy)-2-(2-carbamoyl-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-3-yl)acetic acid (1.5 mg, 2.459 μmol, 3.03 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ 7.38 - 7.33 (m, 2H), 7.26 - 7.16 (m, 1H), 7.15 - 7.05 (m, 5H), 5.64 (s, 1H), 4.27 (q, *J*=6.0 Hz, 2H), 3.06 (br t, *J*=6.4 Hz, 2H), 2.13 (s, 3H),
- 15 1.28 - 1.25 (m, 1H), 1.24 - 1.16 (m, 4H), 1.10 (s, 9H), 0.72 (br s, 6H). 4 protons of methylenes on the 4-fluorophenethoxy were not resolved via ¹H NMR due to water suppression in the experiment. LCMS (M+1) = 592.1.

Example 7




- 20 *(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-(fluoromethyl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetic acid:*

- To an N₂ sparged solution of (S)-benzyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-(fluoromethyl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate (43 mg, 0.065 mmol) in MeOH (2 mL) was added Pd/C (6.97 mg, 6.55 μmol)
- 25 and capped with a rubber septum. Hydrogen was then bubbled through the solution for 10

minutes. The reaction was then left under positive pressure of hydrogen for 1 hr. The LCMS indicated the reaction was complete. The reaction was filtered through a 0.45 μ nylon frit filter and the volatiles evaporated. The crude material was taken up in MeOH and purified via preparative LC/MS to afford the product (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-(fluoromethyl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetic acid (30 mg, 0.052 mmol, 80 % yield) as an off-white fluffy solid. ¹H NMR (500 MHz, methanol-d₄) δ 8.18 (s, 1H), 7.36 (dd, J =8.7, 5.4 Hz, 2H), 7.27 (d, J =8.7 Hz, 2H), 7.08 - 7.03 (m, 4H), 5.84 (s, 1H), 5.70 (s, 1H), 5.61 (s, 1H), 4.27 (t, J =6.7 Hz, 2H), 3.12 (t, J =6.7 Hz, 2H), 1.45 - 1.37 (m, 3H), 1.18 (s, 9H), 0.88 (br s, 6H). 5 protons on the piperidine ring were not resolved via ¹H NMR due to water in the experiment. LCMS (M+1) = 567.3.


Example 8



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-(hydroxymethyl)pyridin-3-yl)acetic acid:


A mixture of (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-(hydroxymethyl)pyridin-3-yl)-2-(tert-butoxy)acetate (50 mg, 0.106 mmol), (4-(4-fluorophenethoxy)phenyl)boronic acid (41.4 mg, 0.159 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (8.71 mg, 0.021 mmol), and potassium phosphate tribasic (169 mg, 0.795 mmol) in 1,4-dioxane (1768 μ l) and water (354 μ l) was bubbled with N₂ for 10 minutes. Pd(OAc)₂ (2.381 mg, 10.61 μ mol) was added and the reaction was kept under positive pressure of N₂ for the duration of the reaction. The reaction was heated at 80 °C for 18 h. The reaction was cooled to RT and diluted with water and EtOAc. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to give the crude product. The crude product was purified via preparative LC/MS to afford the product (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-(hydroxymethyl)pyridin-3-yl)acetic acid (11.3 mg, 0.018 mmol, 17.2% yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.20 - 8.00 (m, 1H), 7.40 - 7.35 (m, 2H), 7.30 (br s, 1H), 7.10 - 6.99 (m, 5H), 5.62 (br s, 1H), 4.30 - 4.24 (m, 2H), 3.12 (t,

$J=6.8$ Hz, 2H), 3.05 - 2.87 (m, 1H), 2.84 - 2.70 (m, 2H), 2.68 (s, 3H), 1.49 - 1.39 (m, 4H), 1.20 (s, 9H), 0.93 - 0.89 (m, 6H). LCMS (M+1) = 565.2.




(S)-2-(tert-Butoxy)-2-(6-((cyclopropylsulfonyl)carbamoyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

To a solution of (S)-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-6-methylpicolinic acid (25 mg, 0.039 mmol) in DCM (1 mL) was added DMAP (0.962 mg, 7.88 μ mol) followed by cyclopropanesulfonamide (5.25 mg, 0.043 mmol) and N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine•HCl salt (9.06 mg, 0.047 mmol). The reaction was stirred at RT for 2 hrs. The reaction volatiles were evaporated under a stream of nitrogen to afford the crude product. The crude residue was taken up in EtOH (1 mL) and water (0.1 mL) and added lithium hydroxide monohydrate (16.53 mg, 0.394 mmol). The reaction was heated at 75 °C and stirred for 18 hrs. The reaction was then cooled to RT, filtered through a 0.45 μ nylon frit filter and purified via preparative LC/MS to afford the product (S)-2-(tert-butoxy)-2-(6-((cyclopropylsulfonyl)carbamoyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid (13.6 mg, 0.020 mmol, 49.6 % yield). ^1H NMR (500 MHz, DMSO- d_6) δ 7.36 (dd, $J=8.4, 5.6$ Hz, 2H), 7.27 (br d, $J=8.2$ Hz, 1H), 7.13 (t, $J=8.9$ Hz, 2H), 7.04 (br d, $J=7.6$ Hz, 1H), 6.94 (br d, $J=7.9$ Hz, 1H), 6.88 (br d, $J=6.1$ Hz, 1H), 5.89 - 5.83 (m, 1H), 4.25 - 4.12 (m, 2H), 3.03 (br t, $J=6.7$ Hz, 2H), 2.94 - 2.84 (m, 1H), 2.44 (s, 3H), 2.41 - 2.35 (m, 1H), 2.16 - 2.06 (m, 1H), 2.03 - 1.92 (m, 1H), 1.56 - 1.45 (m, 1H), 1.34 - 1.19 (m, 2H), 1.14 (s, 9H), 1.08 - 0.97 (m, 1H), 0.88 - 0.59 (m, 6H), 0.55 - 0.32 (m, 2H). 4 protons(piperidine protons) were not resolved via ^1H NMR due to water suppression in the experiment. LCMS (M+1) = 696.2.




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-(1,1-dioxidothiomorpholine-4-carbonyl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

- 5 To a solution of (S)-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-6-methylpicolinic acid (25 mg, 0.039 mmol), Hunig's Base (0.015 mL, 0.087 mmol), and thiomorpholine 1,1-dioxide (5.32 mg, 0.039 mmol) in DCM (1 mL) was added HATU (16.47 mg, 0.043 mmol) and stirred at RT for 1 hr. The reaction volatiles were removed via nitrogen stream to afford
- 10 the crude product. The crude product was taken up in EtOH (1 mL) and water (0.1 mL) and added lithium hydroxide monohydrate (16.53 mg, 0.394 mmol) and heated to 75 °C for 18 hrs. The reaction was cooled to RT and filtered through a 0.45μ nylon frit filter and purified via preparative LC/MS to afford the product (S)-2-(tert-butoxy)-2-(4-(4,4-
- 15 fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid (17.5 mg, 0.025 mmol, 62.6 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 7.35 (dd, *J*=8.5, 5.5 Hz, 2H), 7.32 - 7.29 (m, 1H), 7.23 (dd, *J*=8.5, 2.1 Hz, 1H), 7.09 - 6.99 (m, 4H), 5.84 (s, 1H), 4.26 (t, *J*=6.7 Hz, 2H), 4.04 - 3.92 (m, 1H), 3.87 - 3.62 (m, 2H), 3.48 - 3.36 (m, 1H), 3.21 - 3.13 (m, 1H), 3.11 (t, *J*=6.7 Hz, 2H), 3.07 - 2.99 (m, 2H), 2.83 - 2.73 (m, 1H), 2.61 (s, 3H), 2.58 - 2.49
- 20 (m, 1H), 2.37 - 2.05 (m, 2H), 1.79 - 1.58 (m, 1H), 1.51 - 1.26 (m, 2H), 1.21 (s, 9H), 1.17 - 1.02 (m, 1H), 1.00 - 0.69 (m, 6H). LCMS (M+1) = 710.1.



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-(4,4-dimethylpiperidine-1-carbonyl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:


- 5 To a solution of (S)-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-6-methylpicolinic acid (25 mg, 0.039 mmol), Hunig's Base (0.015 mL, 0.087 mmol), and 4,4-dimethylpiperidine (4.46 mg, 0.039 mmol) in DCM (1 mL) was added HATU (16.47 mg, 0.043 mmol) and stirred at RT for 1 hr. The reaction was then diluted with DCM and washed with water.
- 10 The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was taken up in EtOH (2 mL) and water (0.2 mL) and added lithium hydroxide monohydrate (16.53 mg, 0.394 mmol) and heated to 75 °C. After 18 hrs, the reaction was filtered through a 0.45μ nylon frit filter and purified via preparative LC/MS to afford the product (S)-2-(tert-butoxy)-2-
- 15 (4-(4,4-dimethylpiperidin-1-yl)-6-(4,4-dimethylpiperidine-1-carbonyl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid (11.5 mg, 0.017 mmol, 42.4 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ 7.36 (dd, *J*=8.4, 5.6 Hz, 2H), 7.20 (br d, *J*=7.9 Hz, 1H), 7.13 (t, *J*=8.9 Hz, 2H), 7.07 - 7.00 (m, 2H), 6.97 (dd, *J*=8.4, 2.3 Hz, 1H), 5.60 (s, 1H), 4.25 - 4.16 (m, 2H), 3.03 (br t, *J*=6.6 Hz, 3H), 2.99 - 2.76 (m, 5H), 2.44 (s, 3H), 2.18 - 1.95 (m, 2H), 1.62 - 1.48 (m, 1H), 1.37 - 1.20 (m, 2H), 1.10 (s, 9H), 0.98 (br
- 20 d, *J*=7.9 Hz, 2H), 0.89 - 0.82 (m, 6H), 0.66 (br d, *J*=15.6 Hz, 6H). 4 protons of the piperidine methylene protons were not observed via ¹H NMR due to water in the experiment. LCMS (M+1) = 688.3.



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((1r,4S)-4-methylcyclohexyl)carbamoyl)pyridin-3-yl)acetic acid:

- 5 To a solution of (S)-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-6-methylpicolinic acid (25 mg, 0.039 mmol), Hunig's Base (0.015 mL, 0.087 mmol), and (1r,4r)-4-methylcyclohexanamine (4.46 mg, 0.039 mmol) in DCM (1 mL) was added HATU (16.47 mg, 0.043 mmol) and stirred at RT for 1 hr. The reaction was then diluted with
- 10 DCM and washed with water. The organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was taken up in EtOH (2 mL) and water (0.2 mL) and added lithium hydroxide monohydrate (16.53 mg, 0.394 mmol) and heated to 75 °C for 18 hrs. The reaction was then cooled to RT and filtered through a 0.45 μ nylon frit filter and purified via
- 15 preparative LC/MS to afford the product (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((1r,4S)-4-methylcyclohexyl)carbamoyl)pyridin-3-yl)acetic acid (8.4 mg, 0.012 mmol, 31.0 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ 7.88 (d, *J*=8.2 Hz, 1H), 7.35 (dd, *J*=8.4, 5.6 Hz, 2H), 7.18 - 7.09 (m, 4H), 7.00 - 6.88 (m, 2H), 5.79 (br s, 1H), 4.28 - 4.15 (m, 2H), 3.02 (t, *J*=6.7 Hz, 2H), 2.91 - 2.82 (m, 1H), 2.47 (s, 3H), 2.18 - 2.11 (m, 1H), 2.00 (br t, *J*=11.4 Hz, 1H), 1.59 - 1.39 (m, 4H), 1.37 - 1.19 (m, 3H), 1.13 (s, 9H), 1.08 - 0.97 (m, 2H), 0.88 - 0.71 (m, 8H), 0.63 (s, 3H). 4 protons of the piperidine methylene protons were not
- 20 observed via ¹H NMR due to water in the experiment. LCMS (M+1) = 688.3.


Example 13



(S)-2-(tert-Butoxy)-2-(6-carbamoyl-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

- 5 To a solution of (S)-5-(1-(tert-butoxy)-2-isopropoxy-2-oxoethyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-6-methylpicolinic acid (25 mg, 0.039 mmol), Hunig's Base (0.015 mL, 0.087 mmol), and ammonium chloride (10.53 mg, 0.197 mmol) in DCM (1 mL) was added HATU (16.47 mg, 0.043 mmol) and stirred at RT for 1 hr. The reaction was then diluted with DCM and washed with water. The
- 10 organic layer was washed with brine, collected, dried over MgSO₄, filtered and volatiles evaporated to afford the crude product. The crude product was taken up in EtOH (1 mL) and water (0.1 mL) and added lithium hydroxide monohydrate (16.53 mg, 0.394 mmol) and heated to 75 °C for 18 hrs. The reaction was then cooled to RT and filtered through a 0.45 μ nylon frit filter and purified via preparative LC/MS to afford the product (S)-2-
- 15 (tert-butoxy)-2-(6-carbamoyl-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid (9.7 mg, 0.016 mmol, 41.2 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ 7.55 (s, 1H), 7.37 (dd, *J*=8.5, 5.8 Hz, 2H), 7.20 (br d, *J*=8.5 Hz, 1H), 7.14 (t, *J*=8.9 Hz, 2H), 7.08 (br d, *J*=10.1 Hz, 1H), 7.01 (s, 1H), 6.99 - 6.95 (m, 1H), 6.91 (dd, *J*=8.4, 2.6 Hz, 1H), 5.66 (s, 1H), 4.25 - 4.16 (m, 2H), 3.06 - 3.03 (m, 2H), 2.85 - 2.78 (m, 1H), 2.47 (s, 3H), 2.16 - 2.09 (m, 1H), 1.57 - 1.47 (m, 1H), 1.35 - 1.14 (m, 2H), 1.11 (s, 9H), 1.05 - 0.98 (m, 1H), 0.85 (s, 3H), 0.63 (s, 3H). 3 protons of the piperidine methylene protons were not observed via ¹H NMR due to water in the experiment. LCMS (M+1) = 592.2.
- 20


Example 14



(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)acetic acid:

To a solution of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)acetate (20 mg, 0.034 mmol) in EtOH (1 mL) and water (0.111 mL) was added lithium hydroxide monohydrate (14.16 mg, 0.337 mmol) and heated at 75 °C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS to afford the product (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)acetic acid (8.4 mg, 0.015 mmol, 45.2 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.61 (s, 2H), 8.29 (s, 1H), 7.42 - 7.29 (m, 2H), 7.04 (t, *J*=8.8 Hz, 2H), 5.96 (s, 1H), 4.50 - 4.42 (m, 2H), 3.16 (t, *J*=6.6 Hz, 2H), 2.99 - 2.74 (m, 4H), 2.64 (s, 3H), 1.44 (br d, *J*=4.4 Hz, 4H), 1.21 (s, 9H), 0.92 (s, 6H). LCMS (M+1) = 551.3.


15



(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-methoxypyridazin-3-yl)-2-methylpyridin-3-yl)acetic acid:

To a solution of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-methoxypyridazin-3-yl)-2-methylpyridin-3-yl)acetate (22 mg, 0.045 mmol) in EtOH (1mL) and water (0.111 mL) was added lithium hydroxide monohydrate (19.05 mg, 0.454 mmol) and heated at 75 °C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS to afford the product (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-methoxypyridazin-3-yl)-2-methylpyridin-3-yl)acetic acid (16.1 mg, 0.036 mmol, 80 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.20 (s, 1H), 7.70 (d, *J*=9.2 Hz, 1H), 7.31 (d, *J*=8.8 Hz, 1H), 5.96 (s, 1H), 4.18 (s, 3H), 3.03 - 2.68 (m, 4H), 2.66 (s, 3H), 1.50 - 1.39 (m, 4H), 1.25 - 1.20 (m, 9H), 0.90 (s, 6H). LCMS (M+1) = 443.2.


Example 16



(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrazin-2-yl)-2-methylpyridin-3-yl)acetic acid:

- 5 To a solution of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrazin-2-yl)-2-methylpyridin-3-yl)acetate (30 mg, 0.051 mmol) in EtOH (1 mL) and water (0.111 mL) was added lithium hydroxide monohydrate (21.24 mg, 0.506 mmol) and heated at 75 °C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS to afford the product
- 10 (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrazin-2-yl)-2-methylpyridin-3-yl)acetic acid (7.5 mg, 0.014 mmol, 26.9 % yield). ¹H NMR (500 MHz, methanol-*d*₄) δ 8.29 (d, *J*=1.5 Hz, 1H), 8.24 (d, *J*=1.1 Hz, 1H), 8.14 (s, 1H), 7.35 - 7.30 (m, 2H), 7.05 - 7.00 (m, 2H), 5.88 (s, 1H), 4.66 (t, *J*=6.8 Hz, 2H), 3.14 (t, *J*=6.8 Hz, 2H), 3.07 - 2.89 (m, 2H), 2.83 - 2.74 (m, 2H), 2.65 (s, 3H), 1.43 (br s, 4H), 1.20 (s, 9H),
- 15 0.90 (s, 6H). LCMS (*M*+1) = 551.3.

Example 17




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)pyridazin-3-yl)-2-methylpyridin-3-yl)acetic acid:

- 20 To a solution of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)pyridazin-3-yl)-2-methylpyridin-3-yl)acetate (47 mg, 0.079 mmol) in EtOH (1 mL) and water (0.111 mL) was added lithium hydroxide monohydrate (33.3 mg, 0.793 mmol) and heated at 75°C for 24 hrs. The reaction was cooled to RT,
- 25 filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS to afford the product (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)pyridazin-3-yl)-2-methylpyridin-3-yl)acetic acid (25.6 mg, 0.046

mmol, 58.0 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.08 (s, 1H), 7.55 (d, J=9.5 Hz, 1H), 7.23 (dd, J=8.6, 5.4 Hz, 2H), 7.09 (d, J=9.5 Hz, 1H), 6.98 (t, J=8.8 Hz, 2H), 5.80 (s, 1H), 4.66 (dt, J=13.0, 7.2 Hz, 1H), 4.37 (dt, J=13.0, 7.2 Hz, 1H), 3.18 (t, J=7.2 Hz, 2H), 2.89 - 2.70 (m, 2H), 2.63 (s, 3H), 1.56 - 1.40 (m, 4H), 1.20 (s, 9H), 0.97 (s, 6H).

5 LCMS (M+1) = 551.2.




(2S)-2-[4-(4,4-Dimethylpiperidin-1-yl)-5-{4-[2-(4-fluorophenyl)ethoxy]phenyl}-2-methylpyridin-3-yl]-2-[(2-methylbutan-2-yl)oxy]acetic acid:

(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetate (45 mg, 0.096 mmol), (4-(4-fluorophenethoxy)phenyl)boronic acid (37 mg, 0.14 mmol), (2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl) [2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (7 mg, 10 μmol), potassium phosphate tribasic (61 mg, 0.29 mmol) were combined under N₂ (g). 1,4-Dioxane (1.6 ml) and water (0.32 ml) was added under N₂ (g). The reaction was stirred at 80 °C. for 1 hr.

The reaction was concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs). The major product was isolated and taken up in EtOH and 0.1 mL of 5 N NaOH was added and the reaction was stirred at 100 C for 5 hrs. Then the crude material was purified via preparative LC/MS to afford (2S)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-{4-[2-(4-fluorophenyl)ethoxy]phenyl}-2-methylpyridin-3-yl]-2-[(2-methylbutan-2-yl)oxy]acetic acid (15.3 mg). LCMS (M+H) = 563.24. ¹H NMR (500 MHz, DMSO-d₆) δ 8.02 (s, 1H), 7.36 (t, J=6.6 Hz, 2H), 7.20 (d, J=8.8 Hz, 2H), 7.14 - 7.09 (m, 2H), 7.02 (d, J=7.5 Hz, 2H), 5.83 (s, 1H), 4.28 - 4.20 (m, 2H), 3.05 (t, J=6.8 Hz, 1H), 1.51 - 1.35 (m, 3H), 1.30 (br s, 4H), 1.11 (s, 3H), 1.03 (s, 3H), 0.80 (br s, 7H), 0.71 (t, J=7.3 Hz, 4H). Not all of the piperidine protons were well resolved.


Example 19



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-[4-({8-oxa-3,5-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl}methoxy)phenyl]pyridin-3-yl]acetic acid:

4-(Chloromethyl)benzofuro[3,2-d]pyrimidine (12 mg, 0.056 mmol) was added to a stirring solution of (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-hydroxyphenyl)-2-methylpyridin-3-yl)acetic acid (20 mg, 0.047 mmol) and K₂CO₃ (32 mg, 0.23 mmol) and KI (8 mg, 0.05 mmol) in ACN (1 ml) at rt. The reaction was stirred at 80 °C for 12 hrs and then the crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-[4-({8-oxa-3,5-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl}methoxy)phenyl]pyridin-3-yl]acetic acid (10.0 mg). LCMS (M+H) = 609.28. ¹H NMR (500 MHz, DMSO-d₆) δ 9.14 (s, 1H), 8.28 (d, J=7.7 Hz, 1H), 8.01 (s, 1H), 7.88 - 7.79 (m, 3H), 7.61 (t, J=7.3 Hz, 1H), 7.02 (d, J=8.4 Hz, 3H), 6.80 (d, J=8.4 Hz, 3H), 6.13 (br s, 1H), 5.76 (d, J=13.9 Hz, 1H), 5.56 (d, J=13.9 Hz, 1H), 3.17 (s, 1H), 2.54 - 2.51 (m, 4H), 1.17 (s, 15H), 0.67 (br s, 8H). Not all of the piperidine protons were well resolved.

Example 20




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(4-{[methyl({8-oxa-3,5-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl})amino]methyl}phenyl)pyridin-3-yl]acetic acid:

(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (25 mg, 0.055 mmol), N-methyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-d]pyrimidin-4-amine (27 mg, 0.066 mmol), chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-

biphenyl)]palladium(II) (3.95 mg, 5.49 μ mol), potassium phosphate tribasic (35 mg, 0.17 mmol) were combined under N₂ (g). 1,4-Dioxane (1 ml) and water (0.2 ml) was added under N₂ (g). The reaction was stirred at 80 °C for 1 hr. The reaction was concentrated and subjected to hydrolysis conditions (0.1 mL 5 N NaOH in 1.5 mL of EtOH) stirring at 100 °C for 5 hrs. The sample was then the crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-{4-[(8-oxa-3,5-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl)}amino)methyl]phenyl]pyridin-3-yl]acetic acid (12.0 mg) LCMS (M+H) = 622.13. ¹H NMR (500 MHz, DMSO-d₆) δ 8.54 (s, 1H), 8.11 (d, *J*=8.1 Hz, 1H), 8.03 (s, 1H), 7.78 - 7.74 (m, 1H), 7.68 (t, *J*=7.7 Hz, 1H), 7.50 (t, *J*=7.5 Hz, 1H), 7.41 (br d, *J*=7.3 Hz, 2H), 7.29 (br d, *J*=7.7 Hz, 2H), 5.78 (s, 1H), 5.21 (br s, 2H), 2.55 - 2.52 (m, 1H), 2.48 - 2.44 (m, 3H), 1.91 (s, 1H), 1.21 (br s, 3H), 1.09 (s, 11H), 0.80 (br s, 4H), 0.48 (br s, 3H). Not all of the piperidine protons were well resolved.

15

Example 21




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-{4-[(8-oxa-3,5-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl)}amino)methyl]phenyl]pyridin-3-yl]acetic acid:

(S)-Isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (25 mg, 0.055 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-d]pyrimidin-4-amine (26 mg, 0.066 mmol), chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (4 mg, 5 μ mol), potassium phosphate tribasic (35 mg, 0.17 mmol) were combined under N₂ (g). 1,4-Dioxane (1 ml) and water (0.2 ml) was added under N₂ (g). The reaction was stirred at 80 °C for 1 hr. The reaction was concentrated taken up in 1.5 mL of EtOH and treated with 0.1 mL of 5 N NaOH and stirred at 100 °C for 5 hrs. Then the crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-{4-[(8-oxa-3,5-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaen-6-

yl}amino)methyl]phenyl]pyridin-3-yl]acetic acid (11.3 mg). LCMS (M+H) = 608.25. ¹H NMR (500 MHz, DMSO-d₆) δ 8.78 (br s, 1H), 8.48 (s, 1H), 8.10 (d, *J*=8.1 Hz, 1H), 8.02 (s, 1H), 7.82 (d, *J*=8.4 Hz, 1H), 7.71 (t, *J*=7.7 Hz, 1H), 7.53 - 7.47 (m, 3H), 7.27 (d, *J*=7.7 Hz, 2H), 5.81 (s, 1H), 4.84 (br d, *J*=5.1 Hz, 2H), 2.55 (s, 1H), 2.49 - 2.45 (m, 3H), 1.26 (br s, 2H), 1.11 (s, 10H), 0.84 (br s, 4H), 0.60 (br s, 3H). Not all of the piperidine protons were well resolved.

Example 22




(2*S*)-2-(*tert*-Butoxy)-2-[6-cyano-4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-({[methyl({8-oxa-3,5-diazatricyclo[7.4.0.0²,7]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl})amino]methyl}phenyl)pyridin-3-yl]acetic acid:

(*S*)-Isopropyl 2-(5-bromo-6-cyano-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (30 mg, 0.062 mmol), *N*-methyl-*N*-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-*d*]pyrimidin-4-amine (29 mg, 0.069 mmol), chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (4 mg, 5 μmol) and potassium phosphate tribasic (40 mg, 0.19 mmol) were combined under N₂. 1,4-Dioxane (1 ml) and water (0.2 ml) was added under N₂. The reaction was heated at 80 °C for 1 h. The reaction was concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs) isolated (*S*)-isopropyl 2-(5-(4-((benzofuro[3,2-*d*]pyrimidin-4-yl(methylamino)methyl)phenyl)-6-cyano-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate consistent by LCMS. This material was taken up in 3 mL of EtOH and it was added lithium hydroxide hydrate (5 mg, 0.1 mmol) dissolved in 0.3 mL of H₂O. The reaction was stirred at 70 °C overnight. Additional lithium hydroxide hydrate (5 mg, 0.1 mmol) dissolved in 0.3 mL of H₂O was added and the reaction was stirred at 80 °C for 6 hrs. LCMS showed a mixture of products, one being the expected product. The crude material was purified via preparative LC/MS to afford desired compound (6.2 mg). LCMS (M+H) = 647.28. ¹H NMR (500 MHz, DMSO-

d₆) δ 8.55 (s, 1H), 8.11 (d, *J*=7.7 Hz, 1H), 7.76 (d, *J*=8.4 Hz, 1H), 7.69 (t, *J*=7.7 Hz, 1H), 7.57 - 7.43 (m, 5H), 7.26 (br d, *J*=7.3 Hz, 1H), 5.70 (s, 1H), 5.29 - 5.21 (m, 3H), 3.45 (s, 1H), 2.55 - 2.53 (m, 4H), 1.92 (s, 1H), 1.17 (br s, 3H), 1.11 (s, 12H), 0.58 (br s, 6H).

5


Example 23



(S)-2-(*tert*-Butoxy)-2-(6-(((*tert*-butoxycarbonyl)amino)methyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

NaH (60% dispersion on oil) (2.6 mg, 0.064 mmol) was added to a stirring
 10 solution of (*S*)-isopropyl 2-(6-(bromomethyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (22 mg, 0.032 mmol) and *tert*-butyl carbamate (5.7 mg, 0.048 mmol) in DMF (1 mL) at rt. The mixture was allowed to stir at this temp for 4h. LCMS shows quant conversion to the desired product. The mixture was concentrated to a brown oil. This oil was then taken up in EtOH
 15 (1 mL) and 5M NaOH (0.097 mL, 0.483 mmol) was added. The mixture was heated to 80 °C and stirred at this temp for 2 h. The mixture was filtered and then purified via preparative LC/MS to give (*S*)-2-(*tert*-butoxy)-2-(6-(((*tert*-butoxycarbonyl)amino)methyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid (4.8 mg, 22% yield). LCMS
 20 (M+H) = 678.31.

Example 24




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((tetrahydro-2H-pyran-4-yl)amino)pyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and tetrahydro-2H-pyran-4-amine (0.011 mL, 0.108 mmol) in NMP (0.63 mL) was heated at 180 °C for 3 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 7 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford desired product (9.6 mg, 55%). LCMS (M+1) = 648.35.

10

Example 25




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((1-methylpiperidin-4-yl)amino)pyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.06 g, 0.081 mmol) and 1-methylpiperidin-4-amine (0.041 mL, 0.325 mmol) in NMP (2 mL) was heated at 180 °C for 3 h and cooled to ambient temperature. The reaction mixture was taken up in water and the resultant suspension was filtered. The filter cake was washed with water, suction dried. The solid was taken up in ethyl acetate, dried over (Na₂SO₄), and concentrated. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.162 mL, 0.812 mmol) was added. The mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (15.9 mg, 30%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.37 (dd, *J* = 8.4, 5.5 Hz, 2H), 7.23 - 7.01 (m, 6H), 5.71 (br. s., 1H), 4.33 - 4.18 (m, 2H), 3.96 (d, *J* = 7.7 Hz, 1H), 3.77 (br. s., 1H), 3.05 (t, *J* = 6.6 Hz, 2H), 2.74 (t, *J* = 11.2 Hz, 1H), 2.32 (s, 3H), 2.24 - 1.98 (m, 5H), 1.96 - 1.70 (m, 3H), 1.48 (d, *J* = 14.3

Hz, 1H), 1.37 - 1.09 (m, 16H), 1.00 (d, $J = 11.0$ Hz, 1H), 0.89 - 0.81 (m, 3H), 0.58 (s, 3H). LCMS (M+1) = 661.4.


Example 26



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((2-morpholinoethyl)amino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 2-morpholinoethanamine (0.014 g, 0.108 mmol) in NMP (0.63 mL) was heated at 180 °C for 3 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 7 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (12.3 mg, 67%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.37 (dd, $J = 8.4, 5.9$ Hz, 2H), 7.24 - 7.00 (m, 6H), 5.72 (br. s., 1H), 4.82 (t, $J = 4.6$ Hz, 1H), 4.31 - 4.17 (m, 2H), 3.91 - 3.79 (m, 1H), 3.32 - 3.17 (m, 1H), 3.06 (t, $J = 6.6$ Hz, 2H), 2.84 - 2.71 (m, 1H), 2.42 - 2.11 (m, 10H), 2.08 - 1.96 (m, 1H), 1.54 - 1.39 (m, 1H), 1.33 - 1.22 (m, 4H), 1.21 - 1.09 (m, 10H), 1.01 (d, $J = 11.7$ Hz, 1H), 0.90 - 0.80 (m, 3H), 0.59 (s, 3H). LCMS (M+1) = 677.3.


Example 27



(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-((2-methoxyethyl)amino)-2-methylpyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 2-methoxyethanamine (8.13 mg, 0.108 mmol) in NMP (0.63 mL) was heated at 180 °C for 3 h (LCMS showed the desired product peak as the major peak). Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (8.4 mg, 50%). LCMS (*M*+1) = 622.3.


Example 28



(S)-2-(*tert*-Butoxy)-2-(6-((2-(dimethylamino)ethyl)amino)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and N1,N1-dimethylethane-1,2-diamine (9.54 mg, 0.108 mmol) in NMP (0.63 mL) was heated at 180 °C for 3 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (7.3 mg, 43%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.37 (dd, *J* = 8.4, 5.5 Hz, 2H), 7.20 - 6.97 (m, 6H), 5.71 (br. s., 1H), 4.65 (t, *J* = 5.3 Hz, 1H), 4.31 - 4.15 (m, 2H), 3.26 (br. s., 1H), 3.05 (t, *J* = 6.6 Hz, 2H), 2.75 (t, *J* = 11.9 Hz, 1H), 2.55 (s, 5H), 2.35 - 2.24 (m, 5H), 2.16 (d, *J* = 11.0 Hz, 1H), 2.07 (s, 6H), 1.47 (br. s., 1H), 1.32 - 1.26 (m, 1H), 1.13 (s, 9H), 1.00 (d, *J* = 12.5 Hz, 1H), 0.89 - 0.81 (m, 3H), 0.59 (s, 3H). LCMS (*M*+1) = 635.3.


Example 29



(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((2-(piperidin-1-yl)ethyl)amino)pyridin-3-yl)acetic acid:

- 5 A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 2-(piperidin-1-yl)ethanamine (0.014 g, 0.108 mmol) in NMP (0.63 mL) was heated at 180 °C for 3 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.27 mmol). The crude mixture was purified via preparative HPLC to afford the
- 10 desired product (7.6 mg, 40%). LCMS (*M*+1) = 675.4.


Example 30



(S)-2-(6-(((1*H*-Pyrazol-5-yl)methyl)amino)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetic acid:

- 15 A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and (1*H*-pyrazol-5-yl)methanamine (10.52 mg, 0.108 mmol) in NMP (0.63 mL) was heated at 180 °C for 3 h. Ethanol (0.5 mL) and 5 M NaOH
- 20 (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (2.3 mg, 13%). LCMS (*M*+1) = 675.4.


Example 31



(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((2-(1-methylpiperidin-4-yl)ethyl)amino)pyridin-3-yl)acetic acid:

- 5 A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 2-(1-methylpiperidin-4-yl)ethanamine (0.015 g, 0.108 mmol) in NMP (0.63 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5
- 10 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (3.1 mg, 16%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.37 (dd, *J* = 8.3, 5.7 Hz, 2H), 7.22 - 6.99 (m, 6H), 5.62 (s, 1H), 4.30 - 4.14 (m, 2H), 3.25 - 3.14 (m, 1H), 3.05 (t, *J* = 6.6 Hz, 2H), 2.77 - 2.64 (m, 3H), 2.31 (s, 3H), 2.21 - 2.08 (m, 4H), 1.94 - 1.82 (m, 2H), 1.76 (br. s., 2H), 1.59 - 1.41 (m, 3H), 1.28 (br.
- 15 s., 3H), 1.20 - 0.92 (m, 14H), 0.82 (s, 3H), 0.58 (s, 3H). LCMS (*M*+1) = 689.3.

Example 32




- 20 *(S)*-2-(6-((2-(1*H*-Imidazol-4-yl)ethyl)amino)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetic acid:

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-

yl)acetate (0.02 g, 0.027 mmol) and 2-(1H-imidazol-4-yl)ethanamine (0.012 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via
 5 preparative HPLC to afford the desired product (4.8 mg, 26%). LCMS (M+1) = 658.3.


Example 33



10 *(S)*-2-(6-((2-(1H-Pyrazol-1-yl)ethyl)amino)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 2-(1H-pyrazol-1-yl)ethanamine (0.012 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH
 15 (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (6.7 mg, 38%). LCMS (M+1) = 658.3.

Example 34




20

(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((3-morpholinopropyl)amino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-

yl)acetate (0.02 g, 0.027 mmol) and 3-morpholinopropan-1-amine (0.016 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (4.1 mg, 22%). LCMS (M+1) = 691.4.


Example 35



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((3-(piperidin-1-yl)propyl)amino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 3-(piperidin-1-yl)propan-1-amine (0.015 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (4.2 mg, 21%). LCMS (M+1) = 689.4.

Example 36




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.03 g, 0.041 mmol) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-

yl)-1H-pyrazole (0.017 g, 0.081 mmol), Pd(Ph₃P)₄ (9.38 mg, 8.12 μmol), and 2 M Na₂CO₃ (0.051 mL, 0.102 mmol) in toluene (1 mL) and ethanol (1 mL) was degassed. The reaction was then heated at 90 °C in a sealed tube for 2 h. After cooling to ambient temperature, the reaction mixture was filtered through a pad of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.081 mL, 0.406 mmol). The mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (15.7 mg, 62%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.39 (dd, *J* = 8.3, 5.7 Hz, 2H), 7.28 (s, 1H), 7.22 - 7.07 (m, 5H), 7.00 (dd, *J* = 8.4, 2.6 Hz, 1H), 6.57 (s, 1H), 5.89 (br. s., 1H), 4.33 - 4.22 (m, 2H), 3.69 (s, 2H), 3.08 (t, *J* = 6.8 Hz, 2H), 2.84 (t, *J* = 12.5 Hz, 1H), 2.55 (s, 3H), 2.26 (d, *J* = 11.0 Hz, 1H), 2.03 (t, *J* = 11.4 Hz, 1H), 1.55 - 1.45 (m, 1H), 1.37 - 1.27 (m, 1H), 1.20 - 1.13 (m, 10H), 1.03 (d, *J* = 11.4 Hz, 1H), 0.86 (s, 3H), 0.60 (s, 3H). LCMS (M+1) = 629.3.

15

Example 37




(*S*)-2-(*tert*-Butoxy)-2-(6-(1,3-dimethyl-1H-pyrazol-4-yl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid.

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.025 g, 0.034 mmol), 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.015 g, 0.068 mmol), Pd(Ph₃P)₄ (7.82 mg, 6.77 μmol), and 2 M Na₂CO₃ (0.042 mL, 0.085 mmol) in toluene (1 mL) and ethanol (1 mL) was degassed. The reaction was heated at 90 °C in a sealed tube for 2 h. After cooling to ambient temperature, the reaction mixture was filtered through a pad of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL). 5 M NaOH (0.068 mL, 0.338 mmol) was added and the mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (14.7 mg, 68%). ¹H NMR (500 MHz, DMSO-*d*₆) δ

7.37 (dd, $J = 8.4, 5.5$ Hz, 2H), 7.22 - 7.11 (m, 3H), 7.05 (d, $J = 8.1$ Hz, 1H), 6.99 - 6.94 (m, 1H), 6.92 - 6.87 (m, 1H), 6.47 (s, 1H), 5.88 (br. s., 1H), 4.29 - 4.18 (m, 2H), 3.51 (s, 1H), 3.05 (t, $J = 6.8$ Hz, 2H), 2.86 (t, $J = 12.7$ Hz, 1H), 2.56 (s, 5H), 2.23 - 2.13 (m, 4H), 1.98 - 1.90 (m, 3H), 1.52 (br. s., 1H), 1.37 - 1.26 (m, 1H), 1.16 (s, 10H), 1.02 (d, $J = 11.7$ Hz, 1H), 0.86 (s, 3H), 0.61 (s, 3H). LCMS (M+1) = 643.4.


Example 38



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((3-methyl-1H-pyrazol-4-yl)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.025 g, 0.034 mmol), 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.014 g, 0.068 mmol), Pd(Ph₃P)₄ (7.82 mg, 6.77 μmol), and 2 M Na₂CO₃ (0.042 mL, 0.085 mmol) in toluene (1 mL) and ethanol (1 mL) was degassed. The reaction was heated at 90 °C in a sealed tube for 2 h. The reaction mixture was filtered through a pad of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL). 5 M NaOH (0.068 mL, 0.338 mmol) was added and the mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered. The crude mixture was then purified via preparative HPLC to afford the desired product (3.1 mg, 15%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.37 (dd, $J = 8.4, 5.9$ Hz, 2H), 7.15 (q, $J = 8.9$ Hz, 3H), 7.08 - 7.01 (m, 1H), 6.95 (d, $J = 8.4$ Hz, 1H), 6.90 - 6.84 (m, 1H), 6.32 (s, 1H), 5.79 (br. s., 1H), 4.27 - 4.16 (m, 2H), 3.05 (t, $J = 6.8$ Hz, 2H), 2.88 - 2.79 (m, 1H), 2.55 (s, 6H), 2.28 (s, 3H), 1.91 (s, 2H), 1.53 (br. s., 1H), 1.31 (br. s., 1H), 1.20 - 1.11 (m, 10H), 1.01 (d, $J = 12.5$ Hz, 1H), 0.85 (s, 3H), 0.61 (s, 3H). LCMS (M+1) = 629.3.

Example 39




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(pyrimidin-5-yl)pyridin-3-yl)acetic acid:

- 5 A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.025 g, 0.034 mmol), pyrimidin-5-ylboronic acid (8.39 mg, 0.068 mmol), Pd(Ph₃P)₄ (7.82 mg, 6.77 μmol), and 2 M Na₂CO₃ (0.042 ml, 0.085 mmol) in toluene (1 mL) and ethanol (1 mL) was degassed. The reaction was heated at 90 °C in a sealed tube
- 10 for 2 h. The reaction mixture was filtered through a pad of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL). 5 M NaOH (0.068 ml, 0.338 mmol) was added and the mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (1.2 mg, 5%). LCMS (M+1) = 627.3.

15

Example 40




(S)-2-(*tert*-Butoxy)-2-(6-((3-(dimethylamino)propyl)amino)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

- 20 A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and N1,N1-dimethylpropane-1,3-diamine (0.011 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h,

cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (1.4 mg, 8%). LCMS (M+1) = 649.4.


Example 41



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-6-methyl-[2,3'-bipyridin]-5-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.03 g, 0.041 mmol), pyridin-3-ylboronic acid (9.98 mg, 0.081 mmol), Pd(Ph₃P)₄ (9.38 mg, 8.12 μmol), and 2 M Na₂CO₃ (0.051 ml, 0.102 mmol) in toluene (1 mL) and ethanol (1 mL) was degassed. The reaction tube was heated at 90 °C in a sealed tube for 2 h. The reaction mixture was filtered through a pad of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL). 5 M NaOH (0.081 ml, 0.406 mmol) was added and the mixture was heated at 80 °C for 3 h, cooled to ambient temperature and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (6.4 mg, 25%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.67 - 8.32 (m, 2H), 7.77 (br d, *J* = 7.7 Hz, 1H), 7.51 - 6.66 (m, 10H), 5.80 (br s, 1H), 4.21 - 4.05 (m, 2H), 3.00 (br t, *J* = 6.6 Hz, 2H), 2.64 (s, 3H), 2.55 (s, 3H), 1.19 (s, 12H), 0.78 (br s, 6H). LCMS (M+1) = 626.3.

Example 42




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((1-methylpiperidin-4-yl)methyl)amino)pyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and (1-methylpiperidin-4-yl)methanamine (0.014 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (13.6 mg, 73%). LCMS (M+1) = 649.4.

10

Example 43




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((2-(4-methylpiperazin-1-yl)ethyl)amino)pyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 2-(4-methylpiperazin-1-yl)ethanamine (0.016 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (11.8 mg, 62%). LCMS (M+1) = 690.2.

20


Example 44



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyridin-3-yl)acetic acid:

- 5 A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and (tetrahydro-2H-pyran-4-yl)methanamine (0.012 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5
- 10 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (11.6 mg, 65%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.38 (dd, *J* = 8.4, 5.9 Hz, 2H), 7.23 - 6.98 (m, 6H), 5.73 (br. s., 1H), 4.45 (br. s., 1H), 4.32 - 4.18 (m, 2H), 3.84 - 3.72 (m, 2H), 3.26 - 3.01 (m, 4H), 2.75 (t, *J* = 12.7 Hz, 1H), 2.55 (s, 2H), 2.37 - 2.28 (m, 3H), 2.16 (br. s., 1H), 1.97 - 1.87 (m, 2H), 1.72 (br. s., 1H), 1.56 - 1.24 (m, 4H), 1.23 - 0.95 (m, 12H), 0.88 - 0.79 (m, 3H), 0.59 (s, 3H).
- 15 LCMS (M+1) = 662.4.

Example 45




- 20 *(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-(1H-imidazol-1-yl)-2-methylpyridin-3-yl)acetic acid:*

- A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 1H-imidazole (0.018 g, 0.271 mmol) in NMP (1 mL)
- 25 was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol)

were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (5.7 mg, 34%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.49 (s, 1H), 7.36 (dd, *J* = 8.4, 5.9 Hz, 2H), 7.26 (d, *J* = 8.4 Hz, 1H), 7.14 (t, *J* = 8.8 Hz, 2H), 7.05 - 6.98 (m, 3H), 6.87 - 6.82 (m, 1H), 6.76 (s, 1H), 5.86 (br. s., 1H), 4.25 - 4.12 (m, 2H), 3.03 (t, *J* = 6.8 Hz, 2H), 2.91 (br. s., 1H), 2.55 (s, 2H), 2.21 (br. s., 1H), 1.92 (s, 2H), 1.55 (br. s., 1H), 1.36 - 1.21 (m, 2H), 1.18 (s, 9H), 1.05 (d, *J* = 6.2 Hz, 1H), 0.87 (br. s., 3H), 0.64 (br. s., 3H). LCMS (M+1) = 615.3.

10


Example 46



(*S*)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(1-methyl-1*H*-pyrazol-3-yl)pyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.025 g, 0.034 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole (0.014 g, 0.068 mmol), Pd(Ph₃P)₄ (7.82 mg, 6.77 μmol), and 2 M Na₂CO₃ (0.042 mL, 0.085 mmol) in toluene (1 mL) and ethanol (1 mL) was degassed. The reaction was heated at 90 °C for 2 h. After cooling to ambient temperature, the reaction mixture was filtered through a pad of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL). 5 M NaOH (0.068 mL, 0.338 mmol) was added and the mixture was heated at 80 °C for 3 h, cooled to ambient temperature and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (14.6 mg, 68%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.40 - 7.33 (m, 3H), 7.14 (t, *J* = 8.6 Hz, 3H), 7.01 - 6.94 (m, 2H), 6.83 (dd, *J* = 8.6, 2.4 Hz, 1H), 5.95 (br. s., 1H), 5.51 (d, *J* = 2.2 Hz, 1H), 4.25 - 4.13 (m, 2H), 3.72 (s, 3H), 3.23 (br. s., 1H), 3.03 (t, *J* = 6.6 Hz, 2H), 2.89 (t, *J* = 11.9 Hz, 1H), 2.55 (s, 4H), 2.20 (d, *J* = 11.4 Hz, 1H), 1.99 - 1.90 (m, 2H), 1.51 (br. s., 1H), 1.30 (d, *J* = 16.1 Hz, 1H), 1.24 - 1.13 (m, 11H), 1.03 (d, *J* = 12.1 Hz, 1H), 0.86 (s, 3H), 0.61 (s, 3H). LCMS (M+1) = 629.3.


Example 47



(S)-2-(tert-Butoxy)-2-(6-(1-cyclopropyl-1H-pyrazol-4-yl)-4-(4,4-dimethylpiperidin-1-yl)-
5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

A degassed mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol), 1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.013 g, 0.054 mmol),
10 Pd(Ph₃P)₄ (6.26 mg, 5.41 μmol), and 2 M Na₂CO₃ (0.034 ml, 0.068 mmol) in toluene and ethanol was heated at 90 °C for 2 h. The reaction mixture was allowed to cool to ambient temperature and then filtered through a pad of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL). 5 M NaOH (0.054 ml, 0.271 mmol) was added and the mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered.
15 The crude mixture was purified via preparative HPLC to afford the desired product (9.6 mg, 53%). LCMS (M+1) = 655.3.

Example 48




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(1-methyl-1H-pyrrol-3-yl)pyridin-3-yl)acetic acid:

A degassed mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole (0.011 g, 0.054 mmol),
25

Pd(Ph₃P)₄ (6.26 mg, 5.41 μmol), and 2 M Na₂CO₃ (0.034 ml, 0.068 mmol) in toluene and ethanol was heated at 90 °C for 2 h. The reaction mixture was filtered through a pad of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL), 5 M NaOH (0.054 ml, 0.271 mmol) was added, and the mixture was heated at 80 °C for 3 h. After
 5 cooling to ambient temperature, the reaction was filtered. The crude mixture was purified via preparative HPLC to afford the desired product (7.5 mg, 43%). LCMS (M+1) = 628.2.


Example 49



10 (S)-2-(tert-Butoxy)-2-(6-(1,5-dimethyl-1H-pyrazol-4-yl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

A degassed mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-
 (((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol), 1,5-dimethyl-
 15 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.012 g, 0.054 mmol), Pd(Ph₃P)₄ (6.26 mg, 5.41 μmol), and 2 M Na₂CO₃ (0.034 ml, 0.068 mmol) in toluene (1 mL) and ethanol (1 mL) was heated at 90 °C for 2 h. The reaction mixture was filtered through a pad of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.054 ml, 0.271 mmol) was added. The mixture was heated at 80 °C
 20 for 3 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (6.1 mg, 35%). LCMS (M+1) = 643.3.


Example 50



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(1-methyl-1H-pyrazol-5-yl)pyridin-3-yl)acetic acid:

A degassed mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-
 5 (((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol), 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.011 g, 0.054 mmol), Pd(Ph₃P)₄ (6.26 mg, 5.41 μmol), and 2 M Na₂CO₃ (0.034 ml, 0.068 mmol) in toluene (1 mL) and ethanol (1 mL) was heated at 90 °C for 2 h. The reaction mixture was filtered through a plug of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1
 10 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) was added. The mixture was heated at 80 °C for 3 h, cooled to ambient temperature and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (8.8 mg, 52%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.35 (dd, *J* = 8.4, 5.9 Hz, 1H), 7.21 - 7.10 (m, 2H), 7.01 - 6.90 (m, 1H), 6.80 (dd, *J* = 8.4, 2.6 Hz, 1H), 5.91 (br. s., 1H), 5.57 (d, *J* = 1.8 Hz, 1H), 4.24 - 4.09 (m, 2H),
 15 3.70 (s, 2H), 3.02 (t, *J* = 6.6 Hz, 2H), 2.56 - 2.54 (m, 8H), 2.19 (br. s., 1H), 1.54 (br. s., 1H), 1.38 - 1.20 (m, 2H), 1.17 (s, 9H), 1.05 (d, *J* = 5.9 Hz, 1H), 0.87 (br. s., 3H), 0.63 (br. s., 3H). LCMS (M+1) = 629.3.

Example 51



20

(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(1H-pyrazol-4-yl)pyridin-3-yl)acetic acid:


A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-
 25 yl)acetate (0.025 g, 0.034 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-1H-pyrazole (0.030 g, 0.068 mmol), Pd(Ph₃P)₄ (7.82 mg, 6.77 μmol), and 2 M Na₂CO₃ (0.042 ml, 0.085 mmol) in toluene (1 mL) and ethanol (1 mL) was heated at 90 °C for 2 h. The reaction mixture was filtered through a pad of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.068 ml, 0.338 mmol) was

added. The mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and concentrated *in vacuo*. The residue was taken up in methanol (1 mL) and DCM (1 mL), 2 drops of conc. HCl was added and the mixture was stirred at 40 °C for 3 d. The reaction mixture was concentrated, taken up in ethanol, and filtered. The crude mixture was

5 purified via preparative HPLC to afford the desired product (9.1 mg, 44%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.39 (dd, *J* = 8.4, 5.9 Hz, 1H), 7.22 - 7.07 (m, 2H), 7.03 - 6.95 (m, 1H), 5.90 (br. s., 1H), 4.32 - 4.20 (m, 2H), 3.08 (t, *J* = 6.8 Hz, 2H), 2.84 (t, *J* = 12.1 Hz, 1H), 2.55 (s, 4H), 2.27 (d, *J* = 10.3 Hz, 1H), 2.08 - 2.00 (m, 1H), 1.91 (s, 2H), 1.50 (br. s., 1H), 1.36 - 1.27 (m, 1H), 1.21 - 1.12 (m, 10H), 1.04 (d, *J* = 11.7 Hz, 1H), 0.86 (s, 3H),

10 0.60 (s, 3H). LCMS (M+1) = 615.3.

Example 52



(*S*)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((3-(4-methylpiperazin-1-yl)propyl)amino)pyridin-3-yl)acetic acid:


15

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 3-(4-methylpiperazin-1-yl)propan-1-amine (0.017 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 3 h. Ethanol (1 mL) and 5 M

20 NaOH (0.054 mL, 0.271 mmol) were added. The mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (10.5 mg, 55%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.45 - 7.33 (m, 1H), 7.21 - 7.01 (m, 3H), 5.71 (br. s., 1H), 4.32 - 4.15 (m, 3H), 3.34 - 3.11 (m, 3H), 3.05 (t, *J* = 6.6 Hz, 3H), 2.74 (t, *J* = 11.2 Hz, 1H), 2.39 - 1.82

25 (m, 23H), 1.61 - 1.39 (m, 4H), 1.27 (d, *J* = 16.5 Hz, 1H), 1.19 - 1.10 (m, 9H), 0.99 (d, *J* = 12.5 Hz, 1H), 0.83 (s, 3H), 0.59 (s, 3H). LCMS (M+1) = 704.4.


Example 53



(S)-2-(tert-Butoxy)-2-(6-(2,4-dimethyl-1H-imidazol-1-yl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

- 5 A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 2,4-dimethyl-1H-imidazole (0.026 g, 0.271 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added. The mixture was heated at 80 °C for 3 h, cooled to ambient
10 temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (7.0 mg, 40%). LCMS (M+1) = 643.3.

Example 54




- 15 *(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(2-methyl-1H-imidazol-1-yl)pyridin-3-yl)acetic acid:*


- A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 2-methyl-1H-imidazole (0.022 g, 0.271 mmol) in
20 NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added. The mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (7.2 mg, 42%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.35 (dd, *J* = 8.6, 5.7 Hz, 1H), 7.18 - 7.10 (m, 1H), 6.98 - 6.86 (m, 1H), 6.76 (d, *J* = 6.6 Hz, 1H), 6.56 (s, 1H), 5.74 (br. s., 1H), 4.15 (dt, *J* = 13.5, 6.6 Hz, 3H), 3.01 (t, *J* = 6.8 Hz, 3H), 2.89 (br. s.,
25 1H).

1H), 2.55 (s, 1H), 2.19 (br. s., 1H), 2.01 (s, 5H), 1.92 (s, 3H), 1.56 (br. s., 1H), 1.25 (br. s., 2H), 1.15 (s, 9H), 1.06 (br. s., 1H), 0.87 (br. s., 3H), 0.65 (br. s., 3H). LCMS (M+1) = 629.2.

5 Example 55




Example 56



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(5-methyl-1H-imidazol-1-yl)pyridin-3-yl)acetic acid and (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(4-methyl-1H-imidazol-1-yl)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 4-methyl-1H-imidazole (0.022 g, 0.271 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added. The mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired products (2.7 mg, 16%) and (6.4 mg, 38%). Isomer regiochemistry was not assigned. First eluting isomer, LCMS (M+1) = 629.2. Second eluting isomer, LCMS (M+1) = 629.2.


Example 57



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(1-methyl-1H-imidazol-4-yl)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.03 g, 0.041 mmol), 1-methyl-4-(tributylstannyl)-1H-imidazole (0.022 mL, 0.063 mmol), Pd(Ph₃P)₄ (9.38 mg, 8.12 μmol), and a catalytic amount of lithium chloride in DME (1 mL) was degassed. The reaction was heated at 110 °C for 1 h. Upon cooling to ambient temperature, the reaction mixture was filtered through a pad of celite and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.081 mL, 0.406 mmol) was added. The mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (11.6 mg, 45%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.40 - 7.31 (m, 3H), 7.19 - 6.96 (m, 5H), 6.87 (dd, *J* = 8.4, 2.6 Hz, 1H), 6.41 (s, 1H), 5.91 (br s, 1H), 4.29 - 4.14 (m, 2H), 3.05 (t, *J* = 6.6 Hz, 2H), 2.89 - 2.80 (m, 1H), 2.56 - 2.56 (m, 1H), 2.56 (s, 1H), 2.49 (s, 3H), 2.24 - 2.17 (m, 1H), 1.96 - 1.87 (m, 2H), 1.55 - 1.46 (m, 1H), 1.36 - 1.26 (m, 1H), 1.22 - 1.11 (m, 11H), 1.05 - 0.99 (m, 1H), 0.86 (s, 3H), 0.61 (s, 3H). LCMS (M+1) = 629.4.

Example 58




(S)-2-(6-Amino-4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(3,4,5-trifluorophenyl)pyridin-3-yl)-2-(tert-butoxy)acetic acid:

10 N NaOH (0.1 mL, 1.0 mmol) was added to a solution of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(3,4,5-trifluorophenyl)pyridin-3-yl)-2-(tert-butoxy)acetate (0.02g, 0.038 mmol) in ethanol (1 mL). The mixture was heated at 60 °C for 18 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (10.3 mg, 52%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.38 - 7.25 (m, 1H), 7.21 - 7.12 (m, 1H), 5.67 (br. s., 1H), 5.29 (s, 2H), 3.27 (br. s., 1H), 2.76 (t, *J* = 12.1 Hz, 1H), 2.33 (br. s., 1H), 2.29 (s, 3H), 1.98 - 1.85 (m, 1H),

1.52 - 1.43 (m, 1H), 1.36 - 1.26 (m, 1H), 1.20 (d, $J = 12.8$ Hz, 1H), 1.14 (s, 9H), 1.09 (d, $J = 11.4$ Hz, 1H), 0.87 (s, 3H), 0.66 (s, 3H). LCMS ($M+1$) = 480.1.

Example 59




5

(*S*)-2-(*tert*-Butoxy)-2-(6-(3,5-dimethyl-1*H*-pyrazol-1-yl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

Acetylacetone (0.015 g, 0.150 mmol) was added to a solution of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-hydrazinyl-2-methylpyridin-3-yl)acetate (0.031 g, 0.050 mmol) in AcOH (0.5 mL) and heated at 80 °C for 1 h. The reaction mixture was diluted with ethyl acetate, washed with 10% K₂CO₃, dried (Na₂SO₄), and concentrated *in vacuo*. The residue was taken up in MeOH (1.5 mL) and 10 N NaOH, heated at 70 °C for 18 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (18.2 mg, 57%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.34 (dd, $J = 8.4$, 5.9 Hz, 2H), 7.13 (t, $J = 9.0$ Hz, 2H), 7.07 (d, $J = 9.2$ Hz, 1H), 6.91 (d, $J = 6.6$ Hz, 2H), 6.73 (d, $J = 8.4$ Hz, 1H), 5.78 (br. s., 1H), 5.67 (s, 1H), 4.22 - 4.06 (m, 2H), 3.52 - 3.26 (m, 2H), 3.00 (t, $J = 6.6$ Hz, 2H), 2.91 (br. s., 1H), 2.49 (s, 3H), 2.15 (br. s., 1H), 2.01 (s, 3H), 1.81 (s, 3H), 1.55 (br. s., 1H), 1.34 - 1.21 (m, 2H), 1.14 (s, 9H), 1.05 (br. s., 1H), 0.87 (br. s., 3H), 0.65 (br. s., 3H). LCMS($M+1$) = 643.3

20


Example 60



(S)-2-(6-Amino-5-(3,5-difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.027 g, 0.057 mmol), 2-(3,5-difluoro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.028 g, 0.075 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (4.71 mg, 0.011 mmol), palladium(II) acetate (1.289 mg, 5.74 μ mol) and 2 M K_3PO_4 (0.086 mL, 0.172 mmol) in dioxane (1 mL) was purged with nitrogen. The reaction was heated at 80 °C for 1 h. The reaction mixture was then filtered through celite, diluted with ethyl acetate, washed with brine, dried (Na_2SO_4), concentrated *in vacuo*, and purified on silica gel (220 g column) using 0-70% ethyl acetate in hexanes. The desired fractions were concentrated *in vacuo* give a light orange solid. The solid was taken up in ethanol (1 mL) and 5 M NaOH (0.115 mL, 0.574 mmol) was added. The mixture was heated at 80 °C for 2 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (10.2 mg, 29%). ^1H NMR (500 MHz, $DMSO-d_6$) δ 7.38 - 7.33 (m, 2H), 7.18 - 7.11 (m, 2H), 7.08 (br d, $J=11.4$ Hz, 1H), 6.96 - 6.91 (m, 1H), 5.68 - 5.63 (m, 1H), 5.21 (s, 2H), 4.37 - 4.31 (m, 2H), 3.03 (t, $J=6.8$ Hz, 2H), 2.80 - 2.72 (m, 1H), 2.28 (s, 4H), 1.98 - 1.90 (m, 1H), 1.52 - 1.42 (m, 1H), 1.35 - 1.26 (m, 1H), 1.22 - 1.02 (m, 12H), 0.86 (s, 3H), 0.64 (s, 3H). LCMS ($M+1$) = 600.22.

Example 61




(S)-2-(6-Amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)-3,5-dimethylphenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.035 g, 0.074 mmol), 2-(4-(4-fluorophenethoxy)-3,5-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.036 g, 0.097 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (6.11 mg, 0.015 mmol), palladium(II) acetate (1.670 mg, 7.44 μ mol), and 2 M K_3PO_4 (0.112 mL, 0.223

mmol) in dioxane (1 mL) was purged with nitrogen and then heated at 80 °C for 1 h. The reaction mixture was filtered through a pad of celite, diluted with ethyl acetate, washed with brine, dried (Na₂SO₄), concentrated *in vacuo*, and purified on silica gel (220 g column) using 0-70% ethyl acetate in hexanes. The desired fractions were concentrated *in vacuo* give a light orange solid. The solid was taken up in ethanol (1 mL) and 5 M NaOH (0.115 mL, 0.574 mmol) was added. The mixture was heated at 80 °C for 2 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (14.5 mg, 33%). ¹H NMR (500 MHz, DMSO-d₆) δ 7.47 - 7.32 (m, 2H), 7.23 - 7.09 (m, 2H), 6.93 (s, 1H), 6.81 - 6.80 (m, 1H), 6.79 (s, 1H), 5.80 - 5.64 (m, 1H), 5.02 - 4.86 (m, 2H), 4.07 - 3.91 (m, 2H), 3.06 (br t, *J*=6.4 Hz, 2H), 2.85 - 2.75 (m, 1H), 2.56 (s, 1H), 2.31 - 2.22 (m, 3H), 2.20 - 2.08 (m, 6H), 1.91 - 1.83 (m, 1H), 1.52 - 1.40 (m, 1H), 1.33 - 1.23 (m, 1H), 1.21 - 1.08 (m, 10H), 0.99 (br d, *J*=11.0 Hz, 1H), 0.88 - 0.78 (m, 3H), 0.59 (s, 3H). LCMS (M+1) = 592.29.

15


Example 62



(*S*)-2-(*tert*-Butoxy)-2-(4-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(1*H*-pyrazol-1-yl)pyridin-3-yl)acetic acid:

1,1,3,3-Tetraethoxypropane (0.024 g, 0.100 mmol) was added to a solution of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-hydrazinyl-2-methylpyridin-3-yl)acetate (0.031 g, 0.050 mmol) in AcOH (0.5 mL). The reaction heated to 80 °C for 1 h. The reaction mixture was diluted with ethyl acetate, washed with 10% K₂CO₃, dried (Na₂SO₄), and concentrated *in vacuo*. The residue was taken up in MeOH (1.5 mL) and 10 N NaOH (0.15 mL). The reaction heated at 70 °C for 18 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (1.4 mg, 4%). LCMS (M+1) = 615.1.

Example 63




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(pyridin-2-ylamino)pyridin-3-yl)acetic acid:

- 5 A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.05 g, 0.083 mmol), 2-chloropyridine (0.011 g, 0.099 mmol), Xantphos (2.87 mg, 3 4.95 μ mol), tris(dibenzylideneacetone)dipalladium(0) (1.512 mg, 1.651 μ mol), and cesium carbonate (0.038 g, 0.116 mmol) in dioxane (0.825 mL) was degassed and heated at 100 °C for 18
- 10 h. The reaction mixture was cooled, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in methanol (1 mL) and 5 M NaOH (0.132 mL, 0.660 mmol) was added. The mixture was heated at 60 °C for 18 h, cooled to ambient temperature and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (27.1 mg, 50%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.48 (d, *J* = 8.4
- 15 Hz, 1H), 8.05 (d, *J* = 4.8 Hz, 1H), 7.70 (t, *J* = 7.9 Hz, 1H), 7.44 - 7.34 (m, 3H), 7.23 - 7.13 (m, 5H), 6.91 - 6.83 (m, 2H), 5.80 (br. s., 1H), 4.29 (q, *J* = 6.6 Hz, 2H), 3.34 - 3.27 (m, 1H), 3.18 (br. s., 1H), 3.09 (t, *J* = 6.6 Hz, 2H), 2.81 (t, *J* = 12.1 Hz, 1H), 2.49 (s, 3H), 2.26 (d, *J* = 11.0 Hz, 1H), 1.51 (br. s., 1H), 1.37 - 1.28 (m, 1H), 1.20 (d, *J* = 11.7 Hz, 1H), 1.16 (s, 9H), 1.05 (d, *J* = 12.8 Hz, 1H), 0.86 (s, 3H), 0.62 (s, 3H). LCMS (M+1) = 641.1.

20

Example 64




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(pyridin-3-ylamino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.032 g, 0.053 mmol), 3-bromopyridine (0.012 g, 0.074 mmol), Xantphos (1.834 mg, 3.17 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.967 mg, 1.056 μ mol), and cesium carbonate (0.024 g, 0.074 mmol) in dioxane (0.528 mL) was degassed and heated at 100 °C for 4 h. The reaction mixture was cooled, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in methanol (1 mL) and 5 M NaOH (0.132 mL, 0.660 mmol) was added. The mixture was heated at 60 °C for 18 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (4.2 mg, 12%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.63 (br. s., 1H), 8.09 - 7.98 (m, 2H), 7.44 - 7.37 (m, 2H), 7.33 (d, *J* = 8.4 Hz, 1H), 7.23 - 7.06 (m, 6H), 6.73 (s, 1H), 5.73 (br. s., 1H), 4.27 (d, *J* = 11.0 Hz, 2H), 3.12 - 3.02 (m, 2H), 2.87 - 2.75 (m, 1H), 2.41 (s, 3H), 2.20 (d, *J* = 11.7 Hz, 1H), 1.96 - 1.82 (m, 1H), 1.51 (br. s., 1H), 1.31 (br. s., 1H), 1.20 (br. s., 1H), 1.15 (s, 9H), 1.03 (d, *J* = 10.6 Hz, 1H), 0.86 (br. s., 3H), 0.62 (br. s., 3H) [note: 1H of piperidine does not show likely due to water suppression]. LCMS (M+1) = 641.1.

20

Example 65




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((3-methylpyridin-2-yl)amino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.04 g, 0.066 mmol), 2-bromo-3-methylpyridine (0.014 g, 0.079 mmol), Xantphos (2.292 mg, 3.96 μ mol), tris(dibenzylideneacetone)dipalladium(0) (1.209 mg, 1.321 μ mol), and cesium carbonate (0.030 g, 0.092 mmol) in dioxane (1.1 mL) was degassed and heated at 100 °C

for 5 h. The reaction mixture was cooled, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.132 mL, 0.660 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (17.0 mg, 39%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.97 - 7.91 (m, 1H), 7.43 - 7.27 (m, 4H), 7.16 - 7.08 (m, 3H), 7.04 - 6.96 (m, 2H), 6.85 (br dd, *J*=6.1, 5.3 Hz, 1H), 5.79 (br s, 1H), 4.26 - 4.13 (m, 2H), 3.02 (t, *J*=6.8 Hz, 2H), 2.78 (s, 1H), 2.55 (s, 1H), 2.35 - 2.28 (m, 3H), 2.21 (br d, *J*=11.7 Hz, 1H), 2.01 (s, 4H), 1.59 - 1.47 (m, 1H), 1.38 - 1.28 (m, 1H), 1.24 - 1.09 (m, 10H), 1.03 (br d, *J*=14.3 Hz, 1H), 0.90 - 0.80 (m, 3H), 0.67 - 0.57 (m, 3H). LCMS (*M*+1) = 655.11.

Example 66




(*S*)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(pyrimidin-5-ylamino)pyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (0.03 g, 0.050 mmol), 5-bromopyrimidine (0.011 g, 0.069 mmol, Xantphos (1.719 mg, 2.97 μmol), tris(dibenzylideneacetone)dipalladium(0) (0.907 mg, 0.990 μmol) and cesium carbonate (0.023 g, 0.069 mmol) in dioxane (0.495 mL) was degassed and heated at 100 °C for 3 h. The reaction mixture was cooled, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in methanol (1 mL) and 5 M NaOH (0.132 mL, 0.660 mmol) was added. The mixture was heated at 70 °C for 18 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (19.5 mg, 59%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.98 (s, 1H), 8.97 (br. s., 1H), 8.63 (s, 1H), 7.38 (dd, *J* = 8.6, 5.7 Hz, 2H), 7.30 (d, *J* = 8.1 Hz, 1H), 7.18 - 7.01 (m, 6H), 5.72 (br. s., 1H), 4.33 - 4.15 (m, 2H), 3.49 (br. s., 1H), 3.37 (br. s., 1H), 3.07 (t, *J* = 6.6 Hz, 2H), 2.80 (t, *J* = 11.7 Hz, 1H), 2.41 (s, 3H), 2.18 (d, *J* = 9.2 Hz, 1H),

1.89 - 1.81 (m, 1H), 1.50 (d, $J = 11.0$ Hz, 1H), 1.30 (d, $J = 8.4$ Hz, 1H), 1.14 (s, 9H), 1.01 (d, $J = 11.4$ Hz, 1H), 0.85 (s, 3H), 0.62 (s, 3H). LCMS (M+1) = 642.1.


Example 67



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(phenylamino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.023 g, 0.038 mmol), bromobenzene (8.35 mg, 0.053 mmol), Xantphos (1.318 mg, 2.278 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.695 mg, 0.759 μ mol), and cesium carbonate (0.017 g, 0.053 mmol) in dioxane (0.380 mL) was degassed and heated at 100 °C for 18 h. The reaction mixture was cooled, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in methanol (1 mL) and 5 M NaOH (0.132 mL, 0.660 mmol) was added. The mixture was heated at 70 °C for 18 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (10.0 mg, 41%). ^1H NMR (500 MHz, DMSO- d_6) δ 7.51 - 7.02 (m, 13H), 6.92 (br. s., 1H), 5.74 (br. s., 1H), 4.41 - 4.16 (m, 2H), 3.08 (t, $J = 6.4$ Hz, 2H), 2.43 (s, 3H), 1.32 - 1.22 (m, 3H), 1.16 (s, 9H), 0.92 - 0.60 (m, 6H)[note: piperidine protons are very broad and poorly resolved]. LCMS (M+1) = 640.1.


Example 68



(2*S*)-2-(6-Amino-5-(2,5-difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.036 g, 0.077 mmol), 2-(2,5-difluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (0.047 g, 0.115 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (9.42 mg, 0.023 mmol), palladium(II) acetate (2.58 mg, 0.011 mmol), and 2 M K₃PO₄ (0.459 mL, 0.918 mmol) in dioxane (1.53 mL) was purged with nitrogen and was heated at 80 °C for 2 h. The reaction mixture was diluted with ethyl acetate, washed with brine, dried (Na₂SO₄), and concentrated *in vacuo*. The residue was taken up in methanol (1 mL) and 10 N NaOH (0.1 mL, 1.0 mmol). The reaction was then heated to 70 °C for 6 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (4.4 mg, 9%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.38 (dd, *J* = 8.4, 5.5 Hz, 2H), 7.27 (dd, *J* = 10.6, 7.3 Hz, 1H), 7.15 (t, *J* = 9.0 Hz, 2H), 7.09 (dd, *J* = 11.2, 7.2 Hz, 1H), 5.69 (br. s., 1H), 5.19 (s, 2H), 4.42 - 4.34 (m, 1H), 4.31 - 4.22 (m, 1H), 3.08 (t, *J* = 6.6 Hz, 2H), 2.73 (t, *J* = 12.8 Hz, 1H), 2.32 - 2.30 (m, 1H), 2.29 (s, 3H), 2.06 (t, *J* = 11.9 Hz, 1H), 1.48 (br. s., 1H), 1.39 - 1.30 (m, 1H), 1.20 (br. s., 1H), 1.13 (s, 9H), 1.07 (br. s., 1H), 0.87 (s, 3H), 0.63 (s, 3H) [notes: piperidine protons poorly resolved and not all visible, may be rotamers present]. LCMS (M+1) = 600.1.

Example 69




(*S*)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(pyrimidin-2-ylamino)pyridin-3-yl)-2-(tert-butoxy)acetic acid:


A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.031 g, 0.051 mmol), 2-bromopyrimidine (11 mg, 0.072 mmol), Xantphos (1.8 mg, 3 μmol), tris(dibenzylideneacetone)dipalladium(0) (1 mg, 1.0 μmol), and cesium carbonate

(0.023 g, 0.072 mmol) in dioxane was degassed and heated at 100 °C for 3 h. The reaction mixture was cooled, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in methanol (1 mL) and 10 N NaOH (0.1 mL) was added. The mixture was heated at 70 °C for 18 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (21.4 mg, 81%). LCMS (M+1) = 660.3.

Example 70



Example 71




10 (2S)-2-(6-Amino-5-(2,3-difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid and atropisomer:

A solution of (S)-isopropyl 2-(6-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.036 g, 0.077 mmol, 1 equiv), 2-(2,3-difluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione
 15 (0.047 g, 0.115 mmol, 1.5 equiv), Pd(OAc)₂ (0.003 g, 0.12 mmol, 0.15 equiv), and SPhos (0.009 g, 0.23 mmol, 0.3 equiv) in degassed dioxane (1.5 mL) and 2 M K₃PO₄ (0.5 mL) was heated at 80 °C for 2 h. After cooling to ambient temperature, the reaction mixture was diluted with ethyl acetate, washed with brine, dried (Na₂SO₄), and concentrated *in vacuo*. The residue was taken up in methanol (1 mL) and 10 N NaOH (0.1 mL, 1.0
 20 mmol). The reaction was then heated to 70 °C for 18 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the product (3.6 mg, 8%) and its atropisomer (5.5 mg, 12%). 1st eluting isomer: ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.42 - 7.35 (m, 2H), 7.26 - 7.13 (m, 5H), 7.03 (d, *J* = 8.1 Hz, 1H), 5.43 (br. s., 1H), 4.50 - 4.22 (m, 2H), 3.15 - 2.99 (m, 2H), 2.45 (s, 3H), 1.26 (br. s., 4H), 1.16 (s, 9H), 0.78 (br. s., 6H) [note: piperidine protons are broad, poorly resolved, and not all
 25 visible; appears to be two rotamers]; LCMS (M+1) = 600.1. 2nd eluting isomer: ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.38 (dd, *J* = 8.3, 5.7 Hz, 3H), 7.25 - 7.13 (m, 4H), 7.01 (t, *J* = 7.7 Hz, 1H), 5.45 (br. s., 1H), 4.47 - 4.26 (m, 2H), 3.09 (t, *J* = 6.6 Hz, 2H), 2.43 (s, 3H), 1.47 (br. s., 1H), 1.27 (br. s., 3H), 1.14 (s, 9H), 0.77 (br. s., 6H) [note: piperidine protons

are broad, poorly resolved, and not all visible; appears to be two rotamers]; LCMS (M+1) = 600.3.

Example 72




(2S)-2-(6-Amino-4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

A solution of (S)-isopropyl 2-(6-amino-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.042 g, 0.089 mmol, 1 equiv), 2-(2-fluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (0.052 g, 0.134 mmol, 1.5 equiv), Pd(OAc)₂ (0.003 g, 0.13 mmol, 0.15 equiv), and SPhos (0.011 g, 0.027 mmol, 0.3 equiv) in degassed dioxane (1.8 mL) and 2 M K₃PO₄ (0.5 mL) was heated at 80 °C for 2 h. After cooling to ambient temperature, the reaction mixture was diluted with ethyl acetate, washed with brine, dried (Na₂SO₄), and concentrated *in vacuo*.

The residue was taken up in methanol (1 mL) and 10 N NaOH (0.1 mL). The reaction was then heated to 70 °C for 18 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the product (20.2 mg, 37%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.41 - 7.34 (m, 3H), 7.18 - 7.12 (m, 3H), 7.08 (t, *J* = 8.6 Hz, 1H), 6.92 (br s, 2H), 5.68 (br s, 1H), 5.01 (s, 1H), 4.30 - 4.16 (m, 2H), 3.05 (t, *J* = 6.4 Hz, 2H), 2.76 - 2.66 (m, 1H), 2.28 - 2.21 (m, 1H), 1.51 - 1.41 (m, 1H), 1.31 (br d, *J* = 9.2 Hz, 1H), 1.19 - 1.15 (m, 1H), 1.13 (s, 9H), 1.09 - 1.00 (m, 2H), 0.85 (s, 3H), 0.60 (s, 3H) [note: piperidine protons are poorly resolved and not all visible; appears to be mixture of two rotamers]; LCMS (M+1) = 582.3.

Example 73




(S)-2-(6-Amino-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.033 g, 0.07 mmol), 2-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (0.041 g, 0.105 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (8.64 mg, 0.021 mmol), palladium(II) acetate (2.362 mg, 10.52 μ mol), and 2 M K_3PO_4 (0.421 mL, 0.842 mmol) in dioxane (1.40 mL) was purged with nitrogen. The reaction was heated at 80 °C for 2 h. The reaction mixture was diluted with ethyl acetate, washed with brine, dried (Na_2SO_4), and concentrated *in vacuo*. The residue was taken up in methanol (1 mL) and 10 N NaOH (0.1 mL, 1.0 mmol), heated to 70 °C, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (13.2 mg, 32%). ^1H NMR (500 MHz, DMSO- d_6) δ 7.42 - 7.25 (m, 7H), 7.07 - 6.96 (m, 2H), 6.89 (br d, J = 7.7 Hz, 1H), 7.45 - 6.84 (m, 7H), 5.70 (br s, 1H), 5.03 (br d, J = 18.7 Hz, 2H), 4.44 - 4.19 (m, 2H), 3.53 - 3.19 (m, 1H), 3.14 - 3.01 (m, 2H), 2.85 - 2.70 (m, 1H), 2.28 (s, 3H), 2.25 - 2.17 (m, 1H), 2.01 - 1.83 (m, 1H), 1.53 - 1.40 (m, 1H), 1.35 - 1.25 (m, 1H), 1.23 - 1.15 (m, 1H), 1.13 (s, 9H), 1.10 - 0.96 (m, 1H), 0.85 (br s, 3H), 0.62 (br d, J = 4.8 Hz, 3H) [note: appears to be two rotamers]. LCMS ($M+1$) = 582.3.

20

Example 74




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(pyridazin-4-ylamino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.02 g, 0.043 mmol), 4-bromopyridazine, hydrobromide (0.014 mg, 0.060 mmol), Xantphos (3.73 mg, 6.44 μ mol), tris(dibenzylideneacetone)dipalladium(0) (1.965 mg, 2.146 μ mol), and sodium tert-butoxide (12 mg, 0.129 mmol) in dioxane (0.858 mL) was degassed and

heated at 100 °C for 2 h. The reaction mixture was cooled, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in methanol (1 mL) and 10 N NaOH (0.1 mL, 0.1 mmol) was added. The mixture was heated at 70 °C for 18 h, cooled to ambient temperature and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (14.0 mg, 51%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.28 - 9.07 (m, 1H), 8.75 (br d, *J* = 5.9 Hz, 1H), 7.94 (dd, *J* = 5.3, 3.1 Hz, 1H), 7.53 (s, 1H), 7.40 (br dd, *J* = 8.3, 5.7 Hz, 2H), 7.28 (br d, *J* = 8.4 Hz, 1H), 7.20 - 7.11 (m, 4H), 7.07 (br s, 1H), 5.78 (br s, 1H), 4.40 - 4.15 (m, 2H), 3.37 - 3.23 (m, 1H), 3.14 - 3.02 (m, 2H), 2.87 - 2.76 (m, 1H), 2.48 (s, 3H), 2.23 - 2.08 (m, 1H), 1.91 - 1.76 (m, 1H), 1.58 - 1.43 (m, 1H), 1.37 - 1.26 (m, 1H), 1.23 - 1.18 (m, 1H), 1.16 (s, 9H), 1.02 (br d, *J* = 14.7 Hz, 1H), 0.86 (br s, 3H), 0.63 (br s, 3H). LCMS (M+1) = 642.3.

Example 75




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(3,4,5-trimethyl-1H-pyrazol-1-yl)pyridin-3-yl)acetic acid:

3-Methylpentane-2,4-dione (8.09 mg, 0.071 mmol) and 1 M HCl (0.039 mL, 0.039 mmol) were added to a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-hydrazinyl-2-methylpyridin-3-yl)acetate (0.022 g, 0.035 mmol) in ethanol (0.5 mL) and heated to 80 °C for 2 h. 10 N NaOH (0.1 mL, 1.0 mmol) was then added and heating was continued at 80 °C for 2 h. After cooling to ambient temperature, the reaction was filtered. The crude mixture was purified via preparative HPLC to afford the desired product (12.3 mg, 52%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.33 (dd, *J* = 8.6, 5.7 Hz, 2H), 7.12 (br d, *J* = 18.0 Hz, 2H), 7.06 (br d, *J* = 8.8 Hz, 1H), 6.93 (br t, *J* = 10.1 Hz, 2H), 6.74 (br d, *J* = 7.0 Hz, 1H), 5.76 (br s, 1H), 4.20 - 4.07 (m, 2H), 3.58 - 3.46 (m, 1H), 2.99 (t, *J* = 6.6 Hz, 2H), 2.94 - 2.82 (m, 1H), 2.47 (s, 3H), 2.23 - 2.10 (m, 1H), 1.96 (s, 3H), 1.89 - 1.82 (m, 1H), 1.76 (s, 3H),

1.73 (s, 3H), 1.62 - 1.51 (m, 1H), 1.39 - 1.20 (m, 2H), 1.14 (s, 9H), 1.09 - 0.98 (m, 1H), 0.87 (br s, 3H), 0.65 (br s, 3H). LCMS (M+1) = 657.

Example 76




5

(S)-2-(6-(3-Amino-5,6-dihydrocyclopenta[c]pyrazol-2(4H)-yl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

2-Oxocyclopentanecarbonitrile (0.011 g, 0.103 mmol) and 1 M HCl (0.057 mL, 0.057 mmol) were added to a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-hydrazinyl-2-methylpyridin-3-yl)acetate (0.032 g, 0.052 mmol) in ethanol (0.5 mL) and heated to 80 °C for 2 h. 10 N NaOH (0.1 mL, 1.0 mmol) was added and heating was continued at 80 °C for 2 h. The reaction was then cooled to ambient temperature and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (10.8 mg, 31%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.35 (dd, *J* = 8.4, 5.9 Hz, 2H), 7.22 - 7.16 (m, 1H), 7.13 (br t, *J* = 9.0 Hz, 3H), 7.10 - 7.05 (m, 1H), 6.96 - 6.88 (m, 1H), 6.85 - 6.77 (m, 1H), 5.77 (br s, 1H), 4.24 - 4.12 (m, 2H), 3.55 - 3.42 (m, 1H), 3.01 (t, *J* = 6.6 Hz, 2H), 2.91 - 2.79 (m, 1H), 2.48 (s, 3H), 2.35 - 2.28 (m, 4H), 2.20 - 2.09 (m, 3H), 1.57 - 1.49 (m, 1H), 1.34 - 1.26 (m, 1H), 1.25 - 1.18 (m, 1H), 1.15 (s, 9H), 1.08 - 0.98 (m, 1H), 0.87 (br s, 3H), 0.63 (br s, 3H). LCMS (M+1) = 670.4.

20

Example 77




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(pyridin-4-ylamino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041 mmol), 4-bromopyridine hydrochloride (8.03 mg, 0.041 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and sodium tert-butoxide (9.52 mg, 0.099 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (6.9 mg, 26%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.19 (br d, *J* = 5.9 Hz, 2H), 7.48 (d, *J* = 5.9 Hz, 2H), 7.39 (dd, *J* = 8.3, 5.7 Hz, 2H), 7.32 - 7.27 (m, 1H), 7.20 - 7.03 (m, 6H), 5.79 - 5.73 (m, 1H), 4.33 - 4.21 (m, 2H), 3.11 - 3.04 (m, 2H), 2.85 - 2.78 (m, 1H), 2.47 (s, 3H), 2.19 (br d, *J* = 11.7 Hz, 1H), 1.90 - 1.90 (m, 1H), 1.90 - 1.81 (m, 1H), 1.55 - 1.46 (m, 1H), 1.36 - 1.27 (m, 1H), 1.22 - 1.13 (m, 10H), 1.03 (br d, *J* = 12.1 Hz, 1H), 0.86 (s, 3H), 0.62 (s, 3H). LCMS (M+1) = 641.3.

20

Example 78




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(pyridin-4-ylamino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041 mmol), 2-bromo-5-methylpyridine (8.52 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C

for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via
 5 preparative HPLC to afford the desired product (11.4 mg, 42%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.42 - 8.38 (m, 1H), 7.85 (s, 1H), 7.52 (br d, *J* = 8.4 Hz, 1H), 7.44 - 7.32 (m, 3H), 7.22 - 7.12 (m, 5H), 6.76 (s, 1H), 5.75 (br s, 1H), 4.35 - 4.23 (m, 2H), 3.09 (t, *J* = 6.6 Hz, 2H), 2.79 (br t, *J* = 11.7 Hz, 1H), 2.47 (s, 3H), 2.25 (br d, *J* = 12.5 Hz, 1H), 2.18 (s, 3H), 1.99 - 1.88 (m, 3H), 1.58 - 1.46 (m, 1H), 1.37 - 1.27 (m, 1H), 1.22 - 1.12 (m, 10H),
 10 1.09 - 1.00 (m, 1H), 0.86 (s, 3H), 0.62 (s, 3H). LCMS (*M*+1) = 655.3.

Example 79




(*S*)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((4-methylpyridin-2-yl)amino)pyridin-3-yl)acetic acid:
 15

A mixture of (*S*)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (0.025 g, 0.041 mmol), 2-bromo-4-methylpyridine (8.52 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μmol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μmol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C
 20 for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via
 25 preparative HPLC to afford the desired product (9.8 mg, 36%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.36 - 8.32 (m, 1H), 7.90 (d, *J* = 5.1 Hz, 1H), 7.43 - 7.32 (m, 3H), 7.22 - 7.11 (m, 5H), 6.80 (s, 1H), 6.71 (br d, *J* = 4.8 Hz, 1H), 5.83 - 5.74 (m, 1H), 4.34 - 4.23 (m, 2H), 3.09 (br t, *J* = 6.8 Hz, 2H), 2.84 (br d, *J* = 2.9 Hz, 1H), 2.50 - 2.46 (m, 3H), 2.33

- 2.22 (m, 4H), 2.00 - 1.89 (m, 2H), 1.57 - 1.47 (m, 1H), 1.37 - 1.26 (m, 1H), 1.21 - 1.13 (m, 10H), 1.04 (br d, $J = 13.2$ Hz, 1H), 0.86 (s, 3H), 0.62 (s, 3H). LCMS ($M+1$) = 655.33.

Example 80




5

(*S*)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((6-methylpyridin-2-yl)amino)pyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (0.025 g, 0.041 mmol), 2-bromo-6-methylpyridine (8.52 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 5 h. The reaction mixture was cooled, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (13.9 mg, 51%). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.34 - 8.28 (m, 1H), 7.61 - 7.54 (m, 1H), 7.43 - 7.31 (m, 3H), 7.21 - 7.10 (m, 5H), 6.81 - 6.71 (m, 1H), 5.76 (br s, 1H), 4.34 - 4.21 (m, 2H), 3.35 - 3.27 (m, 1H), 3.11 - 3.04 (m, 2H), 2.23 (s, 4H), 1.95 - 1.85 (m, 2H), 1.54 - 1.46 (m, 1H), 1.34 - 1.25 (m, 1H), 1.21 - 1.10 (m, 11H), 1.05 - 1.00 (m, 1H), 0.85 (s, 3H), 0.60 (s, 3H). LCMS ($M+1$) = 655.28.

20


Example 81



(S)-2-(*tert*-Butoxy)-2-(4-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-((4-fluoropyridin-2-yl)amino)-2-methylpyridin-3-yl)acetic acid:

- 5 A mixture of (*S*)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (0.025 g, 0.041 mmol), 2-bromo-4-fluoropyridine (8.72 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C
- 10 for 5 h. The reaction mixture was cooled, filtered through a pad of celite, and concentrated. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (5.7 mg, 20%) and its estimated purity by LCMS analysis was. ¹H
- 15 NMR (500 MHz, DMSO-*d*₆) δ 8.36 - 8.29 (m, 1H), 8.07 (dd, *J* = 9.2, 5.9 Hz, 1H), 7.44 - 7.33 (m, 3H), 7.21 - 7.11 (m, 5H), 7.05 (s, 1H), 6.82 - 6.76 (m, 1H), 5.76 (br s, 1H), 4.37 - 4.20 (m, 2H), 3.62 - 3.54 (m, 1H), 3.38 - 3.29 (m, 1H), 3.20 - 3.14 (m, 1H), 3.07 (br t, *J* = 6.4 Hz, 2H), 2.79 (br t, *J* = 11.9 Hz, 1H), 2.49 (s, 3H), 2.28 - 2.18 (m, 1H), 1.93 (br t, *J* = 11.6 Hz, 1H), 1.55 - 1.45 (m, 1H), 1.37 - 1.26 (m, 1H), 1.23 - 1.10 (m, 10H), 1.08 - 1.00
- 20 (m, 1H), 0.89 - 0.81 (m, 3H), 0.61 (s, 3H). LCMS (*M*+1) = 659.3.


Example 82



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-((3-fluoropyridin-2-yl)amino)-2-methylpyridin-3-yl)acetic acid:

- 5 A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041 mmol), 2-bromo-3-fluoropyridine (8.72 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C
- 10 for 5 h. The reaction mixture was cooled, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (20.1 mg, 74%). ^1H NMR (500 MHz, DMSO- d_6) δ 7.93 -
- 15 7.88 (m, 1H), 7.47 (dd, J = 10.3, 8.8 Hz, 1H), 7.38 - 7.26 (m, 3H), 7.16 - 7.07 (m, 3H), 7.04 - 6.96 (m, 2H), 6.92 (dt, J = 8.1, 4.0 Hz, 1H), 5.76 (br s, 1H), 4.27 - 4.13 (m, 2H), 3.40 - 3.32 (m, 1H), 3.02 (br t, J = 6.6 Hz, 2H), 2.86 - 2.78 (m, 1H), 2.55 - 2.53 (m, 1H), 2.31 (s, 3H), 2.19 (br d, J = 8.8 Hz, 1H), 1.98 - 1.92 (m, 1H), 1.55 - 1.46 (m, 1H), 1.35 - 1.25 (m, 1H), 1.23 - 1.17 (m, 1H), 1.13 (s, 9H), 1.06 - 1.00 (m, 1H), 0.85 (s, 3H), 0.61 (s,
- 20 3H). LCMS ($M+1$) = 659.26.


Example 83



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-((5-fluoropyridin-2-yl)amino)-2-methylpyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041 mmol), 2-bromo-5-fluoropyridine (8.72 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (10.2 mg, 38%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.55 - 8.47 (m, 1H), 8.06 - 8.01 (m, 1H), 7.70 - 7.61 (m, 1H), 7.44 - 7.31 (m, 3H), 7.22 - 7.09 (m, 5H), 6.87 (s, 1H), 5.83 - 5.73 (m, 1H), 4.32 - 4.22 (m, 2H), 3.30 (br d, *J* = 11.4 Hz, 1H), 3.07 (br t, *J* = 6.6 Hz, 2H), 2.83 - 2.75 (m, 1H), 2.47 (s, 3H), 2.27 - 2.20 (m, 1H), 1.98 - 1.89 (m, 1H), 1.54 - 1.45 (m, 1H), 1.36 - 1.25 (m, 1H), 1.22 - 1.09 (m, 10H), 1.03 (br d, *J* = 11.4 Hz, 1H), 0.85 (s, 3H), 0.60 (s, 3H). LCMS (M+1) = 659.31.

Example 84




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((5-fluoropyridin-2-yl)amino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041 mmol), 5-bromo-2-methylpyridine (8.52 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C

for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (6.5 mg, 24%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.52 - 8.46 (m, 1H), 7.84 (dd, *J* = 8.3, 2.8 Hz, 1H), 7.38 (dd, *J* = 8.3, 5.7 Hz, 2H), 7.33 - 7.27 (m, 1H), 7.19 - 7.03 (m, 6H), 6.61 (s, 1H), 5.76 (br s, 1H), 4.32 - 4.19 (m, 2H), 3.31 - 3.23 (m, 1H), 3.06 (br t, *J* = 6.6 Hz, 2H), 2.83 - 2.75 (m, 1H), 2.36 (d, *J* = 9.9 Hz, 6H), 2.23 - 2.16 (m, 1H), 1.93 - 1.83 (m, 1H), 1.54 - 1.44 (m, 1H), 1.30 (td, *J* = 13.0, 4.4 Hz, 1H), 1.21 - 1.10 (m, 10H), 1.05 - 0.98 (m, 1H), 0.84 (s, 3H), 0.60 (s, 3H). LCMS (M+1) = 655.33.

Example 85




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-((2,6-dimethylpyridin-3-yl)amino)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041 mmol), 3-bromo-2,6-dimethylpyridine (9.21 mg, 0.050 mmol, Xantphos (1.433 mg, 2.476 μmol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μmol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (10.5 mg, 38%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.40 - 8.32 (m, 1H), 7.46 - 7.34 (m, 3H), 7.25 - 7.10 (m, 5H), 7.00 (d, *J* = 8.1 Hz, 1H), 6.17 - 6.10 (m, 1H), 5.77 (br s, 1H), 4.34 - 4.20 (m, 2H), 3.07 (br t, *J* = 6.8

Hz, 2H), 2.81 (br t, $J = 11.6$ Hz, 1H), 2.35 (d, $J = 18.0$ Hz, 7H), 2.04 - 1.92 (m, 4H), 1.56 - 1.45 (m, 1H), 1.36 - 1.27 (m, 1H), 1.23 - 1.10 (m, 10H), 1.08 - 1.01 (m, 1H), 0.86 (s, 3H), 0.62 (s, 3H). LCMS ($M+1$) = 669.3.

5


Example 86



(*S*)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((4-methylpyridin-3-yl)amino)pyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (0.025 g, 0.041 mmol), 3-bromo-4-methylpyridine (8.52 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (7.4 mg, 26%). ^1H NMR (500 MHz, DMSO- d_6) δ 9.26 - 9.16 (m, 1H), 8.06 (d, $J = 4.8$ Hz, 1H), 7.48 - 7.34 (m, 3H), 7.25 - 7.07 (m, 6H), 6.26 (s, 1H), 5.84 - 5.76 (m, 1H), 4.35 - 4.18 (m, 2H), 3.12 - 3.01 (m, 2H), 2.88 - 2.79 (m, 1H), 2.57 (br d, $J = 2.6$ Hz, 2H), 2.37 (s, 3H), 2.31 - 2.23 (m, 1H), 1.87 (s, 3H), 1.57 - 1.46 (m, 1H), 1.37 - 1.28 (m, 1H), 1.25 - 1.12 (m, 11H), 1.10 - 1.02 (m, 1H), 0.86 (s, 3H), 0.65 - 0.59 (m, 3H). LCMS ($M+1$) = 655.33.

Example 87




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

- 5 A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.036 g, 0.06 mmol), 4-bromo-1-methyl-1H-pyrazole (0.012 g, 0.072 mmol), BrettPhos (0.966 mg, 1.800 μ mol), BrettPhos precatalyst (1.438 mg, 1.800 μ mol), and sodium tert-butoxide (5.77 mg, 0.060 mmol) in dioxane (1 mL) heated at 110 $^{\circ}$ C, heated for 23 h, cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.120 mL, 0.600 mmol) was added. The mixture was heated at 80 $^{\circ}$ C for 2 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (3.4 mg, 9%). ^1H NMR (500 MHz, DMSO-*d*₆) δ 8.02 - 7.97 (m, 1H), 7.45 - 7.38 (m, 3H), 7.26 - 7.06 (m, 6H), 6.55 (s, 1H), 5.74 (br s, 1H), 4.32 - 4.21 (m, 2H), 3.75 (s, 3H), 3.08 (t, *J* = 6.8 Hz, 2H), 2.77 (br t, *J* = 12.1 Hz, 1H), 2.43 (s, 3H), 2.18 (br d, *J* = 9.9 Hz, 1H), 1.82 (s, 1H), 1.55 - 1.45 (m, 1H), 1.36 - 1.26 (m, 1H), 1.20 - 1.12 (m, 10H), 1.05 - 0.98 (m, 1H), 0.85 (s, 3H), 0.61 (s, 3H). LCMS (*M*+1) = 644.42.

20


Example 88



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(pyrimidin-4-ylamino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041 mmol), 4-chloropyrimidine (5.67 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (3.1 mg, 12%). LCMS (M+1) = 642.28


Example 89



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-((6-fluoropyridin-2-yl)amino)-2-methylpyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041 mmol), 2-bromo-6-fluoropyridine (8.72 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (10.3 mg, 35%). LCMS (M+1) = 659.31.

Example 90




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-((2-fluoropyridin-3-yl)amino)-2-methylpyridin-3-yl)acetic acid:

- 5 A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041 mmol), 3-bromo-2-fluoropyridine (8.72 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C
- 10 for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a plug of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (9.7 mg, 36%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.07 - 8.77 (m, 1H), 7.65 (br d, *J* = 4.4 Hz, 1H), 7.49 - 6.99 (m, 9H), 6.52 (d, *J* = 3.3 Hz, 1H), 5.69 (s, 1H), 4.37 - 4.15 (m, 2H), 3.12 - 3.03 (m, 2H), 2.86 - 2.74 (m, 1H), 2.55 (s, 3H), 2.45 (s, 3H), 2.31 - 2.21 (m, 1H), 1.56 - 1.47 (m, 1H), 1.38 - 1.27 (m, 1H), 1.23 - 1.09 (m, 10H), 1.08 - 1.00 (m, 1H), 0.86 (s, 3H), 0.65 - 0.57 (m, 3H). LCMS (M+1) = 659.31.

20

Example 91




(S)-2-(*tert*-Butoxy)-2-(6-((3-cyclohexylpropyl)amino)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and 3-cyclohexylpropan-1-amine (0.015 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (5.3 mg, 28%). LCMS (M+1) = 688.41.

10

Example 92




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((pyridin-3-ylmethyl)amino)pyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and pyridin-3-ylmethanamine (0.012 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 2 h. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (2.2 mg, 12%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.52 - 8.43 (m, 1H), 8.36 (br d, *J* = 3.7 Hz, 1H), 7.69 - 7.59 (m, 1H), 7.36 (dd, *J* = 8.4, 5.5 Hz, 2H), 7.29 - 7.24 (m, 1H), 7.21 - 7.16 (m, 1H), 7.14 - 7.02 (m, 6H), 5.74 (s, 1H), 5.15 (t, *J* = 6.2 Hz, 1H), 4.44 (d, *J* = 5.9 Hz, 2H), 4.28 - 4.21 (m, 2H), 3.05 (t, *J* = 6.6 Hz, 2H), 2.55 (s, 2H), 2.32 (s, 3H), 1.53 - 1.44 (m, 1H), 1.36 - 1.25 (m, 1H), 1.19 - 1.09 (m, 11H), 1.04 - 0.97 (m, 1H), 0.87 - 0.79 (m, 3H), 0.63 - 0.54 (m, 3H). LCMS (M+1) = 655.33.

25

Example 93




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-((3-fluoropyridin-4-yl)amino)-2-methylpyridin-3-yl)acetic acid:

- 5 A mixture of (*S*)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (0.025 g, 0.041 mmol), 4-bromo-3-fluoropyridine (8.72 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C
- 10 for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (8.2 mg, 30%). LCMS (*M*+1) = 659.29.

15

Example 94




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((2-methylpyridin-3-yl)amino)pyridin-3-yl)acetic acid:

- 20 A mixture of (*S*)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (0.025 g, 0.041 mmol), 3-bromo-2-methylpyridine (8.52 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C

for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via
 5 preparative HPLC to afford the desired product (18.2 mg, 67%). LCMS (M+1) = 655.4.


Example 95



10 ((S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-((2-fluoropyridin-4-yl)amino)-2-methylpyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041 mmol), 4-bromo-2-fluoropyridine (8.72 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μmol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μmol) and cesium
 15 carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via
 20 preparative HPLC to afford the desired product (9.5 mg, 35%). LCMS (M+1) = 659.29.


Example 96



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-((2-fluoropyridin-4-yl)amino)-2-methylpyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041 mmol), 4-bromo-2-fluoropyridine (8.72 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 100 °C for 1 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (9.5 mg, 35%). LCMS (M+1) = 659.4.


Example 97



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((pyridin-2-ylmethyl)amino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol), and pyridin-2-ylmethanamine (0.012 g, 0.108 mmol) in NMP (1 mL) was heated at 180 °C for 5 h. Ethanol and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (9.8 mg, 55%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.45 - 8.28 (m, 1H), 7.77 - 7.61 (m, 1H), 7.44 - 6.88 (m, 11H), 5.75 (s, 1H), 5.36 - 5.20 (m, 1H), 4.59 - 4.44 (m, 2H), 4.34 - 4.18 (m, 2H), 3.10 - 3.00 (m, 2H), 2.84 - 2.75 (m, 1H), 2.35 - 2.21 (m, 4H), 1.55 - 1.45 (m, 1H), 1.37 - 1.25 (m, 1H), 1.20 - 1.08 (m, 10H), 1.05 - 0.98 (m, 1H), 0.88 - 0.79 (m, 3H), 0.68 - 0.55 (m, 3H). LCMS (M+1) = 655.4.

Example 98




(S)-2-(tert-Butoxy)-2-(6-((3-(dimethylamino)propyl)(methyl)amino)-4-(4,4-

5 dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol) and N1,N1,N3-trimethylpropane-1,3-diamine (3.15 mg, 0.027 mmol) in NMP (1 mL) was heated at 180 °C for 5 h. Ethanol (mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added and the mixture was heated at 80 °C for 4.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (4.5 mg, 25%). LCMS (M+1) = 663.4.

15

Example 99




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((1-(methylsulfonyl)piperidin-4-yl)amino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol), 1-(methylsulfonyl)piperidin-4-amine (0.019 g, 0.108 mmol), and sodium tert-butoxide (5.20 mg, 0.054 mmol) in NMP (1 mL) was heated at 180 °C for 5 h and cooled to ambient temperature. Ethanol (0.5 mL) and 5 M NaOH

(0.054 mL, 0.271 mmol) were added to the reaction mixture and heated at 80° C for 2 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (2.9 mg, 15%). LCMS (M+1) = 725.29.

5


Example 100



(S)-2-(6-((1-Acetylpiperidin-4-yl)amino)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.02 g, 0.027 mmol), 1-(4-aminopiperidin-1-yl)ethanone (0.015 g, 0.108 mmol) and sodium tert-butoxide (5.20 mg, 0.054 mmol) in NMP (1 mL) was heated at 180 °C for 5 h. The reaction was then cooled to ambient temperature. Ethanol (0.5 mL) and 5 M NaOH (0.054 mL, 0.271 mmol) were added to the reaction mixture and heated at 80° C for 2 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (2.7 mg, 14%). LCMS (M+1) = 689.3.

Example 101




(S)-6-((5-(tert-Butoxy(carboxy)methyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-2-yl)amino)nicotinic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041

mmol), 2-bromo-5-cyanopyridine (9.06 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 3 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of
 5 celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 80 °C for 2.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (9.2 mg, 32%). LCMS (M+1) = 685.2.

10


Example 102



(S)-4-((5-(tert-Butoxy(carboxy)methyl)-4-(4,4-dimethylpiperidin-1-yl)-3-(4-(4-fluorophenethoxy)phenyl)-6-methylpyridin-2-yl)amino)picolinic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.041
 15 mmol), 4-bromo-2-cyanopyridine (9.06 mg, 0.050 mmol), Xantphos (1.433 mg, 2.476 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.756 mg, 0.825 μ mol), and cesium carbonate (0.019 g, 0.058 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 3 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of
 20 celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.083 mL, 0.413 mmol) was added. The mixture was heated at 80 °C for 2.5 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (20.1 mg, 70%). LCMS (M+1) = 685.2.

Example 103




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-(2-hydroxyethoxy)-2-methylpyridin-3-yl)acetic acid:

5 NaH (0.012 g, 0.297 mmol) was added to a solution of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-hydroxy-2-methylpyridin-3-yl)acetate (0.03 g, 0.049 mmol) in DMF (1 mL). The mixture was stirred for 15 min and 2-bromoethanol (0.019 g, 0.148 mmol) was added. Stirring was continued at ambient temperature for 18 h. The reaction mixture was heated at 80 °C for 10 1.5 h and cooled to ambient temperature. Ethanol (1 mL) and 5 M NaOH (0.099 mL, 0.494 mmol) were added and the mixture was heated at 80 °C for 2 h. After cooling to ambient temperature, the reaction was filtered. The crude mixture was purified via preparative HPLC to afford the desired product (5.8 mg, 19%). LCMS (*M*+1) = 609.4.

15

Example 104




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(pyridin-4-ylamino)pyridin-3-yl)acetic acid:

A mixture of (*S*)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (0.025 g, 0.040 mmol), 4-bromopyridine hydrochloride (9.35 mg, 0.048 mmol), Xantphos (1.391 mg, 2.405 μmol), tris(dibenzylideneacetone)dipalladium(0) (0.734 mg, 0.802 μmol), and sodium *tert*-butoxide (9.24 mg, 0.096 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 5 h. The reaction mixture was cooled to ambient temperature,

filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.080 mL, 0.401 mmol) was added. The mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (9.4 mg, 36%). LCMS (M+1) = 659.4.


Example 105



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(pyrimidin-2-ylamino)pyridin-3-yl)acetic acid:

A mixture of (S)-isopropyl 2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.025 g, 0.040 mmol), 2-bromopyrimidine (7.65 mg, 0.048 mmol), Xantphos (1.391 mg, 2.405 μ mol), tris(dibenzylideneacetone)dipalladium(0) (0.734 mg, 0.802 μ mol), and cesium carbonate (0.018 g, 0.056 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 5 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.080 mL, 0.401 mmol) was added. The mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (21.4 mg, 81%). LCMS (M+1) = 660.3.


Example 106



(S)-2-(*tert*-Butoxy)-2-(6-(cyclopropylamino)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

- A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.025 g, 0.034 mmol) and cyclopropanamine (7.73 mg, 0.135 mmol) in NMP (1 mL) was heated at 180 °C for 3 h (LCMS showed the desired product peak as the major peak). Ethanol and 5 M NaOH (0.068 mL, 0.338 mmol) were added. The mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (2.6 mg, 12%).
- LCMS (M+1) = 604.4.


Example 107



- (S)*-2-(*tert*-Butoxy)-2-(6-(cyclopropylamino)-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

- A mixture of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.025 g, 0.033 mmol) and cyclopropanamine (0.038 g, 0.661 mmol) in NMP (1 mL) was heated at 180 °C for 10 h (LCMS showed the desired product peak as the major peak). Ethanol and 5 M NaOH (0.066 mL, 0.330 mmol) were added and the mixture was heated at 80 °C for 3 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (1.1 mg, 5%). LCMS (M+1) = 622.4.


Example 108



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(methylamino)pyridin-3-yl)acetic acid:

- 5 A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methyl-6-(((trifluoromethyl)sulfonyl)oxy)pyridin-3-yl)acetate (0.025 g, 0.033 mmol) and methanamine (0.311 g, 3.30 mmol) in NMP (1 mL) was heated at 180 °C for 22 h (LCMS showed the desired product peak as the major peak). Ethanol and 5 M NaOH (0.066 mL, 10 0.330 mmol) was added and the mixture was heated at 80 °C for 2 h, cooled to ambient temperature, and filtered. The crude mixture was purified via preparative HPLC to afford the desired product (3.6 mg, 18%). LCMS (M+1) = 622.4.

Example 109




- 15 *(S)-2-(tert-Butoxy)-2-(6-((5-cyanopyridin-2-yl)amino)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:*

- A mixture of (S)-2-(6-amino-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid (0.03 g, 0.053 mmol), 2-bromo-5-cyanopyridine (0.012 g, 0.064 mmol), Xantphos (1.848 mg, 3.19 μmol), tris(dibenzylideneacetone)dipalladium(0) (0.975 mg, 1.064 μmol), and cesium carbonate (0.024 g, 0.075 mmol) in dioxane (1 mL) was degassed and heated at 100 °C for 3 h. The reaction mixture was cooled to ambient temperature, filtered through a pad of celite, and concentrated *in vacuo*. The residue was taken up in methanol and the crude
- 20

mixture was purified via preparative HPLC to afford the desired product (20.2 mg, 57%).
LCMS (M+1) = 666.3.

Example 110




5

(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-((4-fluorophenethyl)amino)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

A solution of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (33 mg, 0.070 mmol, 1 equiv) and 2-(4-fluorophenyl)ethanamine (29 mg, 0.21 mmol, 3 equiv) in acetonitrile (2.3 mL) was heated at 120 °C for 18 h. Upon cooling to ambient temperature, the reaction was concentrated. The residue was taken up in 9:1 EtOH: 10 N NaOH and heated at 80 °C for 1 h. After cooling to ambient temperature, the reaction was filtered. The crude mixture was purified by preparative LC/MS to provide the product (13.7 mg, 34%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.03 - 7.96 (m, 1H), 7.90 (s, 1H), 7.35 - 7.24 (m, 3H), 7.12 - 7.05 (m, 2H), 6.61 - 6.48 (m, 2H), 5.82 (s, 1H), 3.58 - 3.32 (m, 2H), 2.94 - 2.81 (m, 2H), 2.49 (s, 3H), 1.60 - 1.16 (m, 4H), 1.13 (s, 9H), 0.84 (br s, 6H) [note: piperidine protons are broad and not all visible]. LCMS (M+1) = 549.3.

20

Example 111




(S)-2-(*tert*-Butoxy)-2-(6'-(dimethylamino)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

A solution of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (31 mg, 0.066 mmol, 1 equiv) in DMF (2 mL), EtOH (2 mL), and 10 N NaOH (0.2 mL) was heated at 90 °C for 2 h. After cooling

25

to ambient temperature, the reaction was filtered. The crude mixture was purified by preparative LC/MS to provide the product (7.6 mg, 25%) and (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-ethoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (8.7 mg, 28%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.10 - 7.90 (m, 2H), 7.44 (dd, *J* = 8.6, 2.4 Hz, 1H), 6.72 (d, *J* = 8.8 Hz, 1H), 5.87 (s, 1H), 3.07 (s, 6H), 2.50 (br s, 3H), 1.33 (br s, 4H), 1.14 (s, 9H), 0.84 (br s, 6H) [note: piperidine protons are broad and not all visible]. LCMS (M+1) = 455.2.


Example 112



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-ethoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

Isolated in the same reaction as (S)-2-(tert-butoxy)-2-(6'-(dimethylamino)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid in 28% yield. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.09 (d, *J* = 1.5 Hz, 1H), 8.06 (s, 1H), 7.65 (dd, *J* = 8.4, 2.2 Hz, 1H), 6.89 (d, *J* = 8.4 Hz, 1H), 5.85 (s, 1H), 4.38 (t, *J* = 7.0 Hz, 2H), 2.51 (s, 3H), 1.40 - 1.22 (m, 4H), 1.14 (s, 9H), 0.82 (br s, 6H) [note: piperidine protons are broad and not all visible]. LCMS (M+1) = 456.2.

Example 113



(S)-2-(2-Amino-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-((4-fluorophenethyl)amino)-6-methyl-[3,3'-bipyridin]-5-yl)-2-(tert-butoxy)acetic acid:


A solution of (S)-isopropyl 2-(2-amino-4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)-2-(tert-butoxy)acetate (0.031 g, 0.061 mmol, 1 equiv) and 2-(4-fluorophenyl)ethanamine (0.043 g, 0.307 mmol, 5 equiv) in DMF (1.5 mL) was heated at 100 °C for 3 h. Upon cooling to ambient temperature, the reaction was

partitioned between EtOAc and brine. The EtOAc layer was dried (Na₂SO₄) and concentrated *in vacuo*. The crude intermediate was taken up in EtOH (0.9 mL) and 10 N NaOH (0.1 mL) and heated at 80 °C for 4 h. After cooling to ambient temperature, the reaction was filtered. The crude mixture was purified by preparative LC/MS to provide

5 the product (5.5 mg, 15%) and (S)-2-(tert-butoxy)-2-(6'-(dimethylamino)-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (12.1 mg, 39%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.75 - 7.60 (m, 1H), 7.26 (br d, *J* = 7.3 Hz, 2H), 7.13 - 7.06 (m, 2H), 6.61 (br s, 1H), 5.72 (s, 1H), 4.99 (br s, 1H), 3.75 - 3.49 (m, 2H), 2.90 (br t, *J* = 7.0 Hz, 2H), 2.84 - 2.76 (m, 1H), 2.32 (s, 3H), 2.29 - 2.23 (m, 1H), 1.57 -

10 1.45 (m, 1H), 1.39 - 1.28 (m, 1H), 1.21 - 1.18 (m, 1H), 1.16 (s, 9H), 1.13 - 1.07 (m, 1H), 0.87 (br s, 3H), 0.66 (br s, 3H) [note: piperidine protons are broad and not all visible]. LCMS (M+1) = 582.3.

Example 114



15


(S)-2-(tert-Butoxy)-2-(6'-(dimethylamino)-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

Isolated as a byproduct from same reaction as (S)-2-(2-amino-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-((4-fluorophenethyl)amino)-6-methyl-[3,3'-

20 bipyridin]-5-yl)-2-(tert-butoxy)acetic acid in 39% yield. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.73 (br s, 1H), 7.42 - 7.17 (m, 1H), 5.72 (s, 1H), 5.01 (s, 1H), 3.07 (d, *J* = 1.5 Hz, 3H), 2.85 - 2.71 (m, 1H), 2.32 (s, 3H), 2.31 - 2.25 (m, 1H), 1.58 - 1.42 (m, 1H), 1.40 - 1.28 (m, 1H), 1.21 - 1.18 (m, 1H), 1.16 (s, 9H), 1.13 - 1.11 (m, 1H), 0.87 (br d, *J* = 0.7 Hz, 3H), 0.65 (br d, *J* = 1.5 Hz, 3H) [note: piperidine protons are broad and not all visible; some

25 integrations may be off from water solvent suppression]. LCMS (M+1) = 488.3.


Example 115



(S)-2-(2-Amino-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-(4-fluorophenethoxy)-6-methyl-[3,3'-bipyridin]-5-yl)-2-(tert-butoxy)acetic acid:

- 5 To a solution of (S)-isopropyl 2-(2-amino-4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)-2-(tert-butoxy)acetate (0.055 g, 0.109 mmol, 1 equiv) and 2-(4-fluorophenyl)ethanol (0.076 g, 0.545 mmol, 5 equiv) in THF (2.7 mL) was added 60% NaH (0.022 g, 0.545 mmol, 5 equiv). The reaction was heated at 60 °C for 1 h. EtOH (0.9 mL) and 10 N NaOH (0.1 mL) were added and the temperature was
- 10 raised to 80 °C for 4 h. After cooling to ambient temperature, the reaction was filtered. The crude mixture was purified by preparative LC/MS to provide the product (15 mg, 24%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.74 (br s, 1H), 7.67 - 7.44 (m, 1H), 7.38 - 7.30 (m, 2H), 7.12 (br t, *J* = 8.4 Hz, 2H), 5.70 (br s, 1H), 5.09 (br s, 1H), 4.70 - 4.56 (m, 2H), 3.12 - 3.04 (m, 2H), 2.84 - 2.62 (m, 1H), 2.33 (s, 3H), 1.55 - 1.44 (m, 1H), 1.40 - 1.30 (m,
- 15 1H), 1.22 - 1.17 (m, 1H), 1.16 (s, 9H), 1.10 - 1.02 (m, 1H), 0.87 (br s, 3H), 0.62 (br s, 3H) [note: piperidine protons are broad and not all visible]. LCMS (M+1) = 583.3.

Example 116




- 20 *(S)-2-(2-Amino-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-(3-fluorophenethoxy)-6-methyl-[3,3'-bipyridin]-5-yl)-2-(tert-butoxy)acetic acid:*

- To a solution of (S)-isopropyl 2-(2-amino-4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)-2-(tert-butoxy)acetate (0.042 g, 0.059 mmol, 1 equiv) and 2-(3-fluorophenyl)ethanol (0.042 g, 0.297 mmol, 5 equiv) in THF (1.5 mL)
- 25 was added 60% NaH (0.012 g, 0.297 mmol, 5 equiv). The reaction was heated at 60 °C for 1 h. EtOH (0.9 mL) and 10 N NaOH (0.1 mL) were added and the temperature was

raised to 80 °C for 4 h. After cooling to ambient temperature, the reaction was filtered. The crude mixture was purified by preparative LC/MS to provide the product (9 mg, 26%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.89 - 7.44 (m, 2H), 7.38 - 7.32 (m, 1H), 7.17 - 7.10 (m, 2H), 7.07 - 7.00 (m, 1H), 5.70 (s, 1H), 5.09 (br s, 1H), 4.75 - 4.53 (m, 2H), 3.18 - 3.02 (m, 2H), 2.91 - 2.64 (m, 1H), 2.32 (s, 3H), 1.60 - 1.43 (m, 1H), 1.26 (s, 2H), 1.16 (s, 9H), 1.09 - 0.98 (m, 1H), 0.86 (br s, 3H), 0.62 (br s, 3H) [note: appears to be a 60:40 mixture of rotamers around pyridine pyridine biaryl bond, piperidine protons are broad and not all visible]. LCMS (M+1) = 583.3.

10


Example 117



(S)-2-(2-Amino-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-(2-fluorophenethoxy)-6-methyl-[3,3'-bipyridin]-5-yl)-2-(tert-butoxy)acetic acid:

To a solution of (S)-isopropyl 2-(2-amino-4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)-2-(tert-butoxy)acetate (0.057 g, 0.081 mmol, 1 equiv) and 2-(2-fluorophenyl)ethanol (0.057 g, 0.406 mmol, 5 equiv) in THF (1.5 mL) was added 60% NaH (0.016 g, 0.406 mmol, 5 equiv). The reaction was heated at 60 °C for 1 h. EtOH (0.9 mL) and 10 N NaOH (0.1 mL) were added and the temperature was raised to 80 °C for 4 h. After cooling to ambient temperature, the reaction was filtered. The crude mixture was purified by preparative LC/MS to provide the product (25 mg, 52%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.89 - 7.46 (m, 2H), 7.39 (br t, *J* = 7.5 Hz, 1H), 7.30 (q, *J* = 7.2 Hz, 1H), 7.16 (br t, *J* = 8.4 Hz, 2H), 5.70 (s, 1H), 4.75 - 4.56 (m, 2H), 3.18 - 3.10 (m, 1H), 2.82 - 2.70 (m, 1H), 2.33 (s, 3H), 1.56 - 1.42 (m, 1H), 1.26 (br s, 2H), 1.16 (s, 9H), 1.10 - 1.01 (m, 1H), 0.86 (br s, 3H), 0.63 (br s, 3H) [note: appears to be a 60:40 mixture of rotamers around pyridine pyridine biaryl bond, piperidine protons are broad and not all visible]. LCMS (M+1) = 583.2.


Example 118



(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-(4-fluorophenethoxy)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

- 5 A mixture of 2-(4-fluorophenyl)ethanol (0.052 mL, 0.419 mmol), NaH (0.017 g, 0.419 mmol), and (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.041 g, 0.084 mmol) in THF was stirred at ambient temperature for 1 h. Upon completion, 5 M NaOH (0.167 mL, 0.837 mmol) was added and the mixture was heated at 80 °C for 2 h. After cooling to ambient
- 10 temperature, the reaction was filtered. The crude mixture was purified by preparative LC/MS to provide the product (23.5 mg, 49%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.13 - 8.04 (m, 1H), 7.93 (d, *J* = 2.2 Hz, 1H), 7.70 (dd, *J* = 11.0, 1.8 Hz, 1H), 7.41 - 7.27 (m, 2H), 7.17 - 7.05 (m, 2H), 5.82 (s, 1H), 4.72 - 4.54 (m, 2H), 3.10 (t, *J* = 6.6 Hz, 1H), 1.36 - 1.28 (m, 3H), 1.14 (s, 10H), 0.90 - 0.76 (m, 6H) [note: piperidine protons not all visible].
- 15 LCMS (M+1) = 568.3.

Example 119




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-(3-fluorophenethoxy)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

- 20 A mixture of 2-(3-fluorophenyl)ethanol (0.052 mL, 0.419 mmol), NaH (0.017 g, 0.419 mmol), and (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.041 g, 0.084 mmol) in THF was stirred at ambient temperature for 1 h. Then, 5 M NaOH (0.167 mL, 0.837 mmol) was added and
- 25 the mixture was heated at 80 °C for 2 h. After cooling to ambient temperature, the reaction was filtered. The crude mixture was purified by preparative LC/MS to provide

the product (23.4 mg, 49%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.14 - 8.03 (m, 1H), 7.93 (d, *J* = 1.8 Hz, 1H), 7.70 (dd, *J* = 11.0, 1.8 Hz, 1H), 7.42 - 7.24 (m, 1H), 7.21 - 6.97 (m, 3H), 5.83 (s, 1H), 4.67 (t, *J* = 6.6 Hz, 2H), 3.18 - 3.00 (m, 1H), 1.32 (br s, 3H), 1.14 (s, 10H), 0.89 - 0.76 (m, 6H) [note: piperidine protons not all visible]. LCMS (M+1) = 568.3.


Example 120



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-(2-fluorophenethoxy)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

- 10 A mixture of 2-(2-fluorophenyl)ethanol (0.056 mL, 0.419 mmol), NaH (0.017 g, 0.419 mmol), and (*S*)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.041 g, 0.084 mmol) in THF was stirred at ambient temperature for 1 h. Then, 5 M NaOH (0.167 mL, 0.837 mmol) was added and the mixture was heated at 80 °C for 2 h. After cooling to ambient temperature, the
- 15 reaction was filtered. The crude mixture was purified by preparative LC/MS to provide the product (25 mg, 52%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.09 (s, 1H), 7.92 (d, *J* = 2.2 Hz, 1H), 7.70 (dd, *J* = 11.2, 2.0 Hz, 1H), 7.43 - 7.35 (m, 1H), 7.34 - 7.26 (m, 1H), 7.33 - 7.24 (m, 1H), 7.20 - 7.07 (m, 2H), 5.83 (s, 1H), 4.74 - 4.57 (m, 2H), 3.19 - 3.10 (m, 2H), 2.52 (s, 3H), 1.37 - 1.25 (m, 4H), 1.15 (s, 9H), 0.83 (br s, 6H) [note: piperidine protons
- 20 not all visible]. LCMS (M+1) = 568.3.

Example 121




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-((4-fluorophenethyl)amino)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

- 25 A mixture of 2-(4-fluorophenyl)ethanamine (0.055 mL, 0.419 mmol) and (*S*)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-

bipyridin]-5-yl)acetate (0.041 g, 0.084 mmol) in NMP was heated at 100 °C for 2 h and cooled to rt. Then, 5M NaOH (0.167 mL, 0.837 mmol) was added and the mixture was heated at 80 °C for 2 h cooled to rt, filtered and purified by preparative LC/MS to give the product (25.0 mg, 50%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.11 - 8.01 (m, 1H), 7.84 -

5 7.76 (m, 1H), 7.38 - 7.19 (m, 3H), 7.16 - 7.02 (m, 2H), 6.67 (br t, *J* = 6.2 Hz, 1H), 5.85 (s, 1H), 3.72 - 3.54 (m, 2H), 2.91 (t, *J* = 7.2 Hz, 2H), 1.34 (br s, 2H), 1.18 - 1.07 (m, 10H), 0.95 - 0.73 (m, 6H) [note: piperidine protons not all visible]. LCMS (M+H) = 567.32

Example 122




10 (S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

To a 7 mL vial charged with the entirety of isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetate prepared above was added ethanol (4 mL) and a stir bar. To the solution was added aq. sodium hydroxide (5M, 0.511 mL, 2.56 mmol). The vial was sealed, then placed in a 90 °C heating block with stirring for 6 h. The reaction mixture was cooled to room temperature, then filtered through a 4 micron syringe filter. The filtrate was subjected to HPLC purification to afford (S)-2-(tert-butoxy)-2-(4-(4,4-

20 dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid as a white solid, 82 mg (66% over two steps). LCMS = 567.30 (M + H). ¹H NMR (500 MHz, methanol-*d*₄) δ 8.05 (s, 1H), 7.38 - 7.31 (m, 2H), 7.20 (t, *J* = 8.5 Hz, 1H), 7.13 (br d, *J* = 11.8 Hz, 1H), 7.07 - 6.99 (m, 3H), 5.72 (s, 1H), 4.31 (t, *J* = 6.6 Hz, 2H), 3.12 (t, *J* = 6.5 Hz, 2H), 3.12 (br s, 2H), 2.73 (br s, 2H), 2.63 (s, 3H), 1.52 - 1.34 (m, 4H), 1.18 (s, 9H), 0.89 (s, 6H).


Example 123



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

- 5 To a 7 mL vial charged with the entirety of isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetate prepared above was added ethanol (4 mL) and a stir bar. To the solution was added aq. sodium hydroxide (5M, 0.511 mL, 2.56 mmol). The vial was sealed, then placed in a 90 °C heating block with stirring for 4.5h. The reaction mixture
- 10 was cooled to room temperature, then was filtered through a 4 micron syringe filter. The filtrate was subjected to HPLC purification to afford (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid as a white solid, 65 mg (52% over two steps). LCMS = 567.30 (M + H). ¹H NMR (500 MHz, methanol-d₄, two atropisomers exist in a 60:40 ratio, the major isomer is reported) δ 7.98 - 7.93 (m, 1H), 7.37 - 7.29 (m, 2H), 7.16 (br t, *J*=8.5 Hz, 1H), 7.07 - 6.98 (m, 1H), 6.89 - 6.83 (m, 1H), 6.83 - 6.79 (m, 1H), 5.74 (s, 1H), 4.25 (t, *J*=6.6 Hz, 2H), 3.10 (t, *J*=6.6 Hz, 2H), 2.61 (s, 3H), 1.49 - 1.31 (m, 4H), 1.17 (s, 9H), 0.84 (br s, 6H)
- 15

Example 124



(S)-2-(tert-Butoxy)-2-(5-(2,3-difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid:


- To a 7 mL vial charged with the entirety of (S)-isopropyl 2-(tert-butoxy)-2-(5-(2,3-difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetate prepared above was added ethanol (4 mL) and a stir bar. To the solution was added aq. sodium hydroxide (5M, 0.511 mL, 2.56 mmol). The vial was sealed, then placed in a 90 °C heating block with stirring for 4.5h. The reaction mixture
- 20
- 25

was cooled to room temperature, then was filtered through a 4 micron syringe filter. The filtrate was subjected to HPLC purification to afford (S)-2-(tert-butoxy)-2-(5-(2,3-difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid as a white solid, 53 mg (41% over two steps). LCMS = 585.25 (M + H).

- 5 ¹H NMR (500 MHz, methanol-d₄, two atropisomers exist in a 69:31 ratio, the major isomer is reported) δ 8.00 - 7.95 (m, 1H), 7.35 (dd, *J*=8.4, 5.4 Hz, 2H), 7.07 - 6.93 (m, 4H), 5.74 (br s, 1H), 4.33 (t, *J*=6.5 Hz, 2H), 3.13 (br t, *J*=6.4 Hz, 2H), 2.61 (s, 3H), 1.39 (br s, 4H), 1.17 (s, 9H), 0.84 (br s, 6H)

10

Example 125




(2*S*)-2-(tert-Butoxy)-2-(5-{2,5-difluoro-4-[2-(4-fluorophenyl)ethoxy]phenyl}-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid:

- To a 14 mL test tube equipped with a stir was added tribasic potassium phosphate (105 mg, 0.494 mmol), 2-(2,5-difluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (26.8 mg, 0.066 mmol), (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (25 mg, 0.055 mmol), and SPhos-Pd-G3 (2.1 mg, 2.7 μmol). The test tube was sealed with a rubber septum and then placed under N₂ atmosphere. To the flask was added a degassed solution (N₂ sparging for 5 min.) of dioxane (0.563 mL) and water (0.188 mL). The test tube was placed in a 60 °C heating block with stirring for 24h. The reaction mixture was cooled to r.t., then was diluted with Et₂O (5 mL) and then washed with water (5 mL). The organic phase was dried over MgSO₄, then filtered, then transferred to a 7 mL vial and evaporated under a N₂ stream. To the vial was added Ethanol (1.0 mL) and a stir bar. To the solution was added aq. sodium hydroxide (5M, 0.15 mL, 0.750 mmol). The vial was sealed, then placed in a 90 °C heating block with stirring for 3h. The reaction mixture was cooled to r.t., then was filtered through a syringe filter. The crude material (filtrate) was purified via preparative LC/MS to afford (2*S*)-2-(tert-butoxy)-2-(5-{2,5-difluoro-4-[2-(4-fluorophenyl)ethoxy]phenyl}-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid (11.9 mg, 37%). LCMS (M+H) : 585.26. Ratio of atropisomers is 63 : 37 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 5.76 (br s, 1H), 5.70 (br s, 0.6H).

^1H NMR (500 MHz, methanol- d_4) δ 8.05 - 7.97 (m, 1H), 7.38 (dd, $J=8.2, 5.8$ Hz, 2H), 7.11 - 7.02 (m, 4H), 5.76 (br s, 0.63H), 5.70 (br s, 0.36H), 4.36 - 4.28 (m, 2H), 3.15 (br t, $J=6.4$ Hz, 2H), 2.95 - 2.69 (m, 2H), 2.68 (s, 3H), 2.00 (s, 3H), 1.43 (br s, 4H), 1.19 (s, 9H), 0.89 (br s, 6H).

5



(2S)-2-(tert-Butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(4-fluorophenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid:

- 10 To a 14 mL test tube equipped with a stir bar was added 2-(5-(4-fluorophenethoxy)pyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (31 mg, 0.082 mmol), (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (25 mg, 0.055 mmol), SPhos-Pd-G3 (2 mg, 3 μ mol), diacetoxycopper (5 mg, 0.03 mmol) and anhydrous tribasic potassium phosphate (finely
- 15 ground, 58.3 mg, 0.274 mmol). The test tube was sealed with a rubber septum, then placed under N_2 atmosphere. To the test tube was added a degassed (N_2 sparging for 5 min) solution of DMF and diethanolamine (5.8 mg, 0.055 mmol). The test tube was placed in a 100 $^\circ\text{C}$ heating block with stirring for 4 days (time not optimized). The reaction solution was cooled to r.t., then diluted with EtOAc (5 mL) and water (5 mL).
- 20 The phases were mixed, then the aq. phase was discarded. The organic phase was dried over MgSO_4 , then filtered into a 7 mL vial, then the volatiles were evaporated under a N_2 stream. To the vial was added a stir bar and ethanol (1 mL), then aq. sodium hydroxide (5M, 0.11 mL, 0.55 mmol). The vial was placed in a 90 $^\circ\text{C}$ heating block with stirring for 3h. The reaction was filtered through a syringe filter and to afford a solution of the crude
- 25 product. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(4-fluorophenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (3 mg, 10%). LCMS ($\text{M}+\text{H}$) = 550.24. ^1H NMR (500 MHz, methanol- d_4) δ 8.33 (d, $J=2.4$ Hz, 1H), 8.12 (s, 1H), 7.50 (dd, $J=8.5, 2.7$ Hz, 1H), 7.41 (d, $J=8.5$ Hz, 1H), 7.35 - 7.29 (m, 2H), 7.02 (br t, $J=8.7$ Hz, 2H), 5.88 (s, 1H), 4.35 (br t,

J=6.6 Hz, 2H), 3.12 (br t, J=6.6 Hz, 2H), 2.93 (br s, 2H), 2.80 (br s, 2H), 2.63 (s, 3H), 1.41 (br s, 4H), 1.19 (s, 9H), 0.87 (s, 6H).

Examples 127 to 199 were synthesized by following one the general methods A-D described below.

5

General methods:

Method A: To a 7 mL vial equipped with a stir bar was added the amine (0.091 mmol), then a solution of aldehyde (0.046 mmol) and acetic acid (6.55 μ l, 0.114 mmol) in dichloromethane (0.5 mL). To the solution was added methanol (0.25 mL), then sodium triacetoxymethylborohydride (19.4 mg, 0.091 mmol). The vial was capped and the solution was stirred at room temperature for 5-18h. The reaction solution was concentrated under a nitrogen gas stream, and the resulting residue was dissolved in a EtOAc (4 mL) and was transferred to a 14 mL test tube. The mixture was washed with aq. NaOH (1M, 2 mL). The aq. phase was back-extracted with EtOAc (1 mL). The combined organics were washed with brine (2 mL), then dried over MgSO₄, then filtered into a 7 mL vial. The volatiles were removed under a nitrogen stream. To the vial was added a stir bar and ethanol (1 mL), then aq. NaOH (5M, 0.091 mL, 0.457 mmol). The vial was capped, then placed in a 80 °C heating block with stirring for 24h. Reaction progress was monitored by LCMS. If conversion was less than 50%, to the reaction solution was added aq. NaOH (5M, 0.091 mL, 0.457 mmol) and the resulting mixture was stirred at 80 °C for 24h. The mixture was filtered through a syringe filter to afford a solution of the crude product.


Method B: To a 14 mL test tube equipped with a stir bar was added (S)-isopropyl 2-(6-(7-azaspiro[3.5]nonan-7-ylmethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (28.9 mg, 0.049 mmol), the boronic acid (0.098 mmol), bis(di-*tert*-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (3.45 mg, 4.88 μ mol) and tribasic potassium phosphate (62.1 mg, 0.293 mmol). The test tube was sealed with a rubber septum, then placed under nitrogen atmosphere. To the test tube was added a degassed (nitrogen sparging for 5 min) dioxane (0.75 mL) + water (0.25 mL). The test tube was placed in a 90 °C heating block with stirring for 3-18h. The reaction mixture was diluted with Et₂O (5 mL) and then was washed with water (5 mL). The organic phase was dried over MgSO₄, then filtered, then was concentrated in a 7 mL vial under a nitrogen stream. To the vial was added a stir bar and EtOH (1.0 mL), then aq.

sodium hydroxide (5M, 0.098 mL, 0.488 mmol). The vial was capped, then placed in a 90 °C heating block with stirring for 5-18h. The reaction mixture was filtered through a syringe filter to afford a solution of the crude product.

Method C: To a 14 mL test tube equipped with a stir and charged with the bromide
5 (0.055 mmol) and (2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl) [2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate ("SPhos-Pd-G3", 2.1 mg, 2.7 µmol) was added tribasic potassium phosphate (105 mg, 0.494 mmol) and the boronic acid (0.082 mmol). The flask was sealed with a rubber septum, then was placed under nitrogen atmosphere. To the test tube was added a degassed (nitrogen sparging for 5 min) solution of dioxane
10 (0.563 mL) and water (0.188 mL). The test tube was placed in a 80 °C heating block with stirring for 2-18h. The reaction mixture was diluted with diethyl ether (5 mL) and then washed with water (5 mL). The organic phase was dried over MgSO₄, then filtered, then transferred to a 7 mL vial where the volatiles were evaporated under a nitrogen gas stream. To the vial was added ethanol (1.0 mL) and a stir bar. To the solution was added
15 aq. sodium hydroxide (5M, 0.15 mL, 0.75 mmol). The vial was sealed, then placed in a 90 °C heating block with stirring for 2-18h. The reaction mixture was filtered to afford a solution of the crude product.

Method D: To a 14 mL test tube equipped with a stir bar was added the boronate (0.082 mmol), the bromide (0.055 mmol), Pd(PPh₃)₄ (13 mg, 11 µmol), Cu(OAc)₂ (5 mg, 0.03
20 mmol) and anhydrous tribasic potassium phosphate (finely ground, 58.3 mg, 0.274 mmol). The test tube was sealed with a rubber septum, then placed under N₂ atmosphere. To the test tube was added a degassed (N₂ sparging for 5 min) solution of DMF (0.5 mL) and diethanolamine (6 mg, 0.06 mmol). The test tube was placed in a 85 °C heating block with stirring for 18h. The reaction mixture was cooled to r.t., then was diluted with
25 EtOAc (5 mL) and water (5 mL). The isolated organic phase was dried over MgSO₄, then filtered, then concentrated in a 7 mL vial under a N₂ stream. To the vial was added a stir bar and ethanol (1.0 mL), then aq. sodium hydroxide (5M, 1.1 mL, 0.55 mmol). The vial was sealed with a cap, then placed in a 90 °C heating block with stirring for 3-18h. The mixture reaction mixture was cooled to room temperature, then filtered through a syringe
30 filter to afford a solution of the crude product.

Example 127




(S)-2-(tert-Butoxy)-2-(5-(3,5-difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid:

- 5 General method C was followed on a 55 μ mol reaction scale using 2-(3,5-difluoro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (S)-2-(tert-butoxy)-2-(5-(3,5-difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid (9.6 mg, 30%). LCMS (M+H) = 585.2. ^1H NMR (500 MHz, methanol- d_4) δ 8.04 (s, 1H), 7.30 (dd, $J=8.5$, 5.5 Hz, 2H), 7.04 - 6.94 (m, 4H), 5.86 (s, 1H), 4.40 (t, $J=6.7$ Hz, 2H), 3.08 (t, $J=6.7$ Hz, 2H), 3.03 (br s, 1H), 2.74 (br s, 2H), 2.61 (s, 3H), 1.48 - 1.36 (m, 4H), 1.19 (s, 9H), 0.89 (s, 6H).

15

Example 128




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(2-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

- General method C was followed on a 55 μ mol reaction scale (3-fluoro-4-(2-fluorophenethoxy)phenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(2-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid (12.9 mg, 42%). LCMS (M+H) = 567.2. ^1H NMR (500 MHz, methanol- d_4) δ 8.05 (s, 1H), 7.42 - 7.36 (m, 1H), 7.31 - 7.24 (m, 1H), 7.20 (t, $J=8.5$ Hz, 1H), 7.15 - 7.09 (m, 2H), 7.06 (dd, $J=8.1$, 6.0 Hz, 2H), 5.85 (s, 1H), 4.37 (t, $J=6.9$ Hz,
- 20
- 25

2H), 3.19 (t, $J=6.7$ Hz, 2H), 3.14 - 3.03 (m, 2H), 2.75 (br dd, $J=11.0, 6.1$ Hz, 2H), 2.64 (s, 3H), 1.50 - 1.37 (m, 4H), 1.21 (s, 9H), 0.89 (s, 6H).

Example 129




5

(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(3,4,5-trifluorophenyl)pyridin-3-yl]acetic acid:

General method C was followed where the coupling was performed at 60 deg C for 3h. The reaction scale was 55 μ mol and the coupling partners were (3,4,5-trifluorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(3,4,5-trifluorophenyl)pyridin-3-yl]acetic acid (11.5 mg, 45%). LCMS (M+H) + 465.21. ^1H NMR (500 MHz, methanol- d_4) δ 8.13 (s, 1H), 7.26 - 7.21 (m, 2H), 5.80 (s, 1H), 2.88 - 2.70 (m, 2H), 2.64 (s, 3H), 1.47 (br s, 4H), 1.21 (s, 9H), 0.94 (s, 6H).

15

Example 130



(2S)-2-(tert-Butoxy)-2-[5-(2,5-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:

20


General method C was followed where the coupling was performed at 60 deg C for 3h. The reaction scale was 55 μ mol and the coupling partners were (2,5-difluorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(2,5-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (11.7 mg, 48%). LCMS (M+H)

25

= 447.2. Ratio of atropisomers is 54 : 46 as determined by ^1H NMR (500 MHz, methanol- d_4) δ 5.85 (br s, 1.00H), 5.76 (br s, 0.84H).

^1H NMR (500 MHz, methanol- d_4) δ 8.12 (br s, 0.6H), 8.07 (br s, 0.4H), 7.37 - 7.22 (m, 2.8H), 7.16 - 7.09 (m, 0.6H), 5.85 (br s, 0.5H), 5.76 (br s, 0.4H), 3.10 (br s, 1.6H), 2.91 (br s, 1H), 2.78 (br s, 1.2H), 2.65 (s, 3H), 1.44 (br s, 4H), 1.22 (s, 9H), 0.90 (br d, $J=12.8$ Hz, 6H).

Example 131



10 (2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluorophenyl)-2-methylpyridin-3-yl]acetic acid:


General method C, where the coupling was performed at 60 deg C for 3h, was followed on a 55 μmol reaction scale using (2-fluorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-

15 butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluorophenyl)-2-methylpyridin-3-yl]acetic acid (13.5 mg, 57%). LCMS ($M+H$) = 429.2. Ratio of atropisomers is 58 : 42 as determined by ^1H NMR (500 MHz, methanol- d_4) δ 5.82 (s, 1H), 5.73 (s, 0.72H).

20 ^1H NMR (500 MHz, methanol- d_4) δ 8.11 (s, 0.6H), 8.05 (s, 0.4H), 7.54 (br d, $J=4.9$ Hz, 1H), 7.46 - 7.39 (m, 0.4H), 7.38 - 7.24 (m, 2.8H), 5.82 (s, 0.6H), 5.73 (s, 0.4H), 3.27 - 2.97 (m, 1.6H), 2.96 - 2.83 (m, 1H), 2.82 - 2.69 (m, 1.2H), 2.67 (s, 3H), 1.42 (br s, 4H), 1.22 (br d, $J=5.8$ Hz, 9H), 0.91 (s, 2.4H), 0.88 - 0.84 (m, 3.5H).

25


Example 132



(2S)-2-(tert-Butoxy)-2-[5-(2,3-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:

General method C, where the coupling was performed at 60 deg C for 3h, was followed on a 55 μ mol reaction scale using (2,3-difluorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(2,3-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (4.7 mg, 15%). LCMS (M+H) = 447.2. Ratio of atropisomers is 61 : 39 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 5.84 (s, 1H), 5.77 (s, 0.62H). ¹H NMR (500 MHz, methanol-d₄) δ 8.11 (s, 0.61H), 8.05 (s, 0.39H), 7.46 - 7.38 (m, 1H), 7.36 - 7.29 (m, 1H), 7.22 (br t, J=6.6 Hz, 0.39H), 7.13 (br t, J=6.6 Hz, 0.61H), 5.84 (s, 0.61H), 5.77 (s, 0.39H), 3.09 (br s, 1.56H), 2.87 (br s, 1H), 2.75 (br s, 1.24H), 2.65 (s, 3H), 2.01 (s, 0.21H), 1.43 (br s, 4H), 1.22 - 1.20 (m, 9H), 0.94 - 0.89 (m, 2.3H), 0.89 - 0.85 (m, 3.6H).


Example 133



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluorophenyl)-2-methylpyridin-3-yl]acetic acid:

General method C, where the coupling was performed at 60 deg C for 3h, was followed on a 55 μ mol reaction scale using (3-fluorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluorophenyl)-2-methylpyridin-3-yl]acetic acid (11 mg, 47%). LCMS (M+H) = 429.2. ¹H NMR (500 MHz, methanol-d₄) δ 8.09 (s, 1H), 7.56 - 7.50 (m, 1H), 7.26 - 7.13 (m, 3H), 5.74 (s, 1H), 2.75 (br s, 2H), 2.65 (s, 3H), 1.42 (br s, 4H), 1.19 (s, 9H), 0.88 (s, 6H).


Example 134



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-phenylpyridin-3-yl]acetic acid:

- 5 General method C was followed on a 55 μ mol reaction scale using phenylboronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-phenylpyridin-3-yl]acetic acid (11.3 mg, 50%). LCMS (M+H) = 411.13. ^1H NMR (500
- 10 MHz, DMSO- d_6) δ 8.04 (s, 1H), 7.51 - 7.45 (m, 2H), 7.45 - 7.40 (m, 1H), 7.32 (d, J=7.3 Hz, 2H), 5.87 (s, 1H), 2.51 (s, 3H), 1.30 (br d, J=2.1 Hz, 2H), 1.14 (s, 9H), 0.87 - 0.70 (m, 6H).


Example 135



- 15 (2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenyl)-2-methylpyridin-3-yl]acetic acid:

- General method C was followed on a 55 μ mol reaction scale using (4-fluorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was
- 20 purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenyl)-2-methylpyridin-3-yl]acetic acid (10.1 mg, 43%). LCMS (M+H) = 429.12. ^1H NMR (500 MHz, methanol- d_4) δ 8.06 (s, 1H), 7.41 - 7.34 (m, 2H), 7.24 (t, J=8.7 Hz, 2H), 5.88 (s, 1H), 3.13 - 2.98 (m, 2H), 2.74 (br d, J=7.0
- 25 Hz, 2H), 2.65 (s, 3H), 1.48 - 1.36 (m, 4H), 1.22 (s, 9H), 0.89 (s, 6H).


Example 136



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(4-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid:

- 5 General method C was followed on a 55 μ mol reaction scale using (4-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(4-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid (11.3 mg, 47%). LCMS (M+H) = 441.14. ^1H NMR (500 MHz, methanol- d_4) δ 8.06 (s, 1H), 7.27 (d, J=8.5 Hz, 2H), 7.08 (d, J=8.5 Hz, 2H), 5.81 (s, 1H), 3.88 (s, 3H), 3.18 - 3.05 (m, 2H), 2.84 - 2.73 (m, 2H), 2.68 (s, 3H), 1.52 - 1.36 (m, 4H), 1.22 (s, 9H), 0.90 (s, 6H).
- 10

Example 137




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(2-methylphenyl)pyridin-3-yl]acetic acid:

- 15 General method C was followed on a 55 μ mol reaction scale using 6-methyl-2-(o-tolyl)-1,3,6,2-dioxazaborocane-4,8-dione and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(2-methylphenyl)pyridin-3-yl]acetic acid (3.3 mg, 14%). LCMS (M+H) = 425.15. Ratio of atropisomers is 80 : 20 by ^1H NMR (500 MHz, methanol- d_4) δ 6.71 (s, 1H), 6.66 (s, 0.24H); Ratio of atropisomers is 77 : 23 by HPLC.
- 20
- 25

¹H NMR (500 MHz, methanol-d₄) δ 8.77 (s, 0.8H), 8.68 (s, 0.2H), 8.19 - 8.12 (m, 2.35H), 8.11 - 8.00 (m, 1H), 7.93 (d, J=7.3 Hz, 0.8H), 6.71 (s, 0.8H), 6.66 (s, 0.2H), 2.92 (s, 2.4H), 2.81 (s, 0.6H), 2.14 - 2.02 (m, 2.6H), 1.98 - 1.96 (m, 1.8H), 1.95 (s, 8.5H), 1.54 (br s, 6H)

5

Example 138




(2S)-2-(5-([1,1'-Biphenyl]-2-yl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

General method C was followed on a 55 μmol reaction scale using [1,1'-biphenyl]-2-ylboronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(5-([1,1'-biphenyl]-2-yl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid (14.3 mg, 53%). LCMS (M+H) = 487.19, 487.19. Ratio of atropisomers is 75 : 25 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 6.66 (s, 1H), 6.27 (s, 0.34H); Ratio of atropisomers is 60 : 40 as determined by HPLC.

¹H NMR (500 MHz, methanol-d₄) δ 8.91 (s, 0.25H), 8.46 (s, 0.75H), 8.37 - 8.28 (m, 3H), 8.13 (br d, J=7.3 Hz, 1H), 8.07 - 8.00 (m, 3H), 7.99 - 7.91 (m, 2.25H), 6.66 (s, 0.75H), 6.27 (s, 0.25H), 3.29 (br s, 0.75H), 3.19 (s, 2.25H), 2.21 - 2.05 (m, 2H), 1.89 (s, 6.75H), 1.87 (s, 2.3H), 1.73 - 1.52 (m, 6H).

20


Example 139



(S)-2-(tert-Butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetic acid:

To a 7 mL vial equipped with a stir bar and charged with (S)-isopropyl 2-(tert-butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate (10 mg, 0.018 mmol) was added ethanol (0.50 mL) and aq. sodium hydroxide (5M, 0.050 mL, 0.250 mmol). The vial was placed in a 90 °C heating block with stirring for 7h. The reaction mixture was filtered through a syringe filter to afford a solution of the crude product. The crude material was purified via preparative LC/MS to afford (S)-2-(tert-butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetic acid (7.0 mg, 0.014 mmol, 76 % yield). LCMS (M+H) = 507.21. ¹H NMR (500 MHz, methanol-d₄) δ 7.12 (br d, J=10.6 Hz, 1H), 6.92 (br d, J=10.6 Hz, 1H), 5.84 (s, 1H), 4.47 - 4.41 (m, 1H), 4.29 (d, J=13.9 Hz, 1H), 4.06 (s, 3H), 3.03 - 2.84 (m, 2H), 2.83 - 2.73 (m, 2H), 2.70 (s, 3H), 2.67 (s, 1H), 1.39 (br s, 4H), 1.22 (s, 9H), 0.87 (s, 6H).

Example 140




(2S)-2-(tert-Butoxy)-2-[5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl]acetic acid:

To a 7 mL vial equipped with a stir bar and charged with (S)-isopropyl 2-(tert-butoxy)-2-(5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate (10 mg, 0.019 mmol) was added ethanol (0.50 mL) and aq. sodium hydroxide (5M, 0.050 mL, 0.250 mmol). The vial was placed in a 90 °C heating block with stirring for 7h. The reaction mixture was filtered through a syringe filter to afford a solution of the crude product. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)-2-methylpyridin-3-yl]acetic acid (6 mg, 66%). LCMS (M+H) = 477.15. Ratio of atropisomers is 1.0 : 1.0 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 7.26 - 7.22 (m, 1H), 7.08 - 7.02 (m, 1H).

¹H NMR (500 MHz, methanol-d₄) δ 7.50 - 7.36 (m, 1.5H), 7.24 (br dd, J=8.1, 2.6 Hz, 0.5H), 7.22 - 7.17 (m, 0.5H), 7.05 (dt, J=3.9, 2.1 Hz, 0.5H), 5.83 (s, 1H), 4.46 - 4.40 (m, 0.5H), 4.26 (d, J=14.3 Hz, 1H), 3.02 - 2.84 (m, 1.5H), 2.83 - 2.74 (m, 2H), 2.72 (s, 3H), 2.67 (s, 0.5H), 1.42 - 1.34 (m, 4H), 1.23 (s, 9H), 0.85 (d, J=4.0 Hz, 6H).

5


Example 141



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,4'-bipyridine]-5-yl]acetic acid:

10 General method C was followed on a 55 μmol reaction scale using pyridin-4-ylboronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,4'-bipyridine]-5-yl]acetic acid (0.7 mg, 3%). LCMS
15 (M+H) = 412.22. ¹H NMR (500 MHz, DMSO-d₆) δ 7.85 (br s, 2H), 7.25 (br s, 1H), 6.65 (br s, 2H), 5.04 (br s, 1H), 2.28 (br s, 2H), 1.93 (br s, 2H), 1.84 (br s, 3H), 0.62 (br s, 4H), 0.40 (br s, 9H), 0.08 (br s, 6H).

Example 142



20


(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2',6-dimethyl-[3,4'-bipyridine]-5-yl]acetic acid:

General method C was followed on a 55 μmol reaction scale using (2-methylpyridin-4-yl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2',6-dimethyl-[3,4'-bipyridine]-5-yl]acetic acid (4.4 mg, 19%).
25


LCMS (M+H) = 426.15. ¹H NMR (500 MHz, methanol-d₄) δ 8.53 (d, J=5.1 Hz, 1H), 8.07 (s, 1H), 7.33 (s, 1H), 7.26 (d, J=4.8 Hz, 1H), 5.89 (s, 1H), 3.08 (br s, 2H), 2.75 (br s, 2H), 2.64 (s, 3H), 2.63 (s, 3H), 1.44 (br s, 4H), 1.21 (s, 9H), 0.90 (s, 6H).

5

Example 143



Example 144



(2S)-2-(tert-Butoxy)-2-[5-(3-chlorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid and (2S)-2-(tert-butoxy)-2-(5-{3'-chloro-[1,1'-biphenyl]-3-yl}-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid:

- 10 The Suzuki cross-coupling procedure of general method C was followed on a 55 μmol reaction scale using (3-chlorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. Following the Suzuki cross-coupling reaction, the crude intermediate ester was further purified as follows: The crude material was dissolved in a min of acetone, then
- 15 concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (24g column, hexanes:EtOAc 100:0→60:40). Fractions were selected based on mass purity of the desired ester intermediate. Concentration of the pooled sample afforded a colorless solid, a mixture of isopropyl (S)-2-(tert-butoxy)-2-(5-(3-chlorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetate and isopropyl
- 20 (S)-2-(tert-butoxy)-2-(5-(3'-chloro-[1,1'-biphenyl]-3-yl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetate. This material was transferred to a 7 mL vial. The saponification procedure of general method C was followed. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(3-chlorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (4.9 mg, 20%) and (2S)-2-
- 25 (tert-butoxy)-2-(5-{3'-chloro-[1,1'-biphenyl]-3-yl}-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid (2.1 mg, 7%).

Analysis of Example 143:


LCMS (M+H) = 445.11. ¹H NMR (500 MHz, DMSO-d₆) δ 8.06 (s, 1H), 7.52 - 7.47 (m, 2H), 7.39 (s, 1H), 7.30 (br d, J=5.9 Hz, 1H), 5.77 (s, 1H), 2.48 (br s, 3H), 1.34 - 1.28 (br s, 2H), 1.15 - 1.12 (br s, 2H), 1.13 (s, 9H), 0.83 (br s, 6H).

Analysis of Example 144:

- 5 LCMS (M+H) = 521.16. ¹H NMR (500 MHz, DMSO-d₆) δ 8.11 (s, 1H), 7.79 (s, 1H), 7.75 (br d, J=7.7 Hz, 1H), 7.73 - 7.69 (m, 1H), 7.63 - 7.61 (m, 1H), 7.59 (t, J=7.7 Hz, 1H), 7.53 - 7.48 (m, 1H), 7.46 - 7.41 (m, 1H), 7.36 (br d, J=7.3 Hz, 1H), 5.77 (s, 1H), 2.55 (s, 3H), 1.92 (s, 0.65H), 1.29 (br dd, J=5.1, 1.5 Hz, 2H), 1.14 (s, 9H), 0.76 (br s, 6H).

10

Example 145




(2S)-2-(tert-Butoxy)-2-[5-(3-chloro-2-fluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:


- The Suzuki cross-coupling procedure of general method C was followed on a 55
 15 μmol reaction scale using (3-chloro-2-fluorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. Following the Suzuki cross-coupling reaction, the crude intermediate ester was further purified as follows: The crude material was dissolved in a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to
 20 SiO₂ purification (24g column, hexanes:EtOAc 100:0→60:40). Fractions were selected based on mass purity of the desired ester intermediate. Concentration of the pooled sample afforded a colorless solid, isopropyl (S)-2-(tert-butoxy)-2-(5-(3-chloro-2-fluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetate. This material was transferred to a 7 mL vial. The saponification procedure of general method C was
 25 followed. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(3-chloro-2-fluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (5.7 mg, 22%). LCMS (M+H) = 463.11. Ratio of atropisomers is 1 : 1 as determined by ¹H NMR (500 MHz, DMSO-d₆) δ 5.80 (s, 1H), 5.74 (s, 1H).

^1H NMR (500 MHz, DMSO- d_6) δ 8.15 - 8.01 (m, 1H), 7.71 - 7.63 (m, 1H), 7.45 - 7.26 (m, 2H), 5.80 (s, 0.5H), 5.74 (s, 0.5H), 2.52 (br s, 3H), 1.47 - 1.20 (m, 4H), 1.14 (s, 9H), 0.81 (br s, 6H).

Example 146



Example 147



(2S)-2-(tert-butoxy)-2-[5-(3-carbamoylphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid and 3-{5-[(S)-(tert-butoxy)(carboxy)methyl]-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl}benzoic acid:

General method C was followed on a 55 μmol reaction scale using 3-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborocan-2-yl)benzonitrile and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(3-carbamoylphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (4.9 mg, 20%) and 3-{5-[(S)-(tert-butoxy)(carboxy)methyl]-4-(4,4-dimethylpiperidin-1-yl)-6-methylpyridin-3-yl}benzoic acid (10.2 mg, 41%).


Analysis of Example 146:

LCMS (M+H) = 454.15. ^1H NMR (500 MHz, DMSO- d_6) δ 8.08 (s, 1H), 7.96 - 7.91 (br s, 1H), 7.93 (br d, J=7.7 Hz, 1H), 7.85 (s, 1H), 7.59 - 7.52 (m, 1H), 7.48 (br d, J=7.7 Hz, 1H), 7.23 (s, 1H), 5.82 (s, 1H), 2.53 (s, 3H), 1.30 (br s, 2H), 1.15 (br s, 2H), 1.15 (s, 9H), 0.79 (br s, 6H).

Analysis of Example 147:

LCMS (M+H) = 455.13. ^1H NMR (500 MHz, DMSO- d_6) δ 8.08 (s, 1H), 7.99 (br d, J=7.3 Hz, 1H), 7.86 (s, 1H), 7.62 - 7.53 (m, 2H), 5.82 (s, 1H), 2.53 (s, 3H), 1.30 (br d, J=5.1 Hz, 2H), 1.14 (s, 9H), 0.79 (br s, 6H).


Example 148



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using (5-fluoropyridin-3-yl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (7.4 mg, 31 %). LCMS (M+H) = 430.1. ^1H NMR (500 MHz, DMSO- d_6) δ 8.64 (d, J=2.6 Hz, 1H), 8.43 (s, 1H), 8.12 (s, 1H), 7.79 (br d, J=9.2 Hz, 1H), 5.81 (s, 1H), 2.54 (s, 3H), 1.32 (br s, 2H), 1.15 (s, 9H), 0.82 (br s, 6H).


Example 149



(2S)-2-(tert-Butoxy)-2-[5-(2,3-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using (2,3-difluoro-4-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(2,3-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (13 mg, 50%). LCMS (M+H) = 477.13. ^1H NMR (500 MHz, DMSO- d_6) δ 8.04 (br s, 1H), 7.17 - 7.08 (m, 2H), 5.82 (br s, 1H), 3.94 (s, 3H), 2.50 (s, 3H), 1.92 (s, 0.6H), 1.38 - 1.23 (m, 4H), 1.14 (s, 9H), 0.82 (br s, 6H).


Example 150



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-5-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using (2-fluoro-5-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-5-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid (10 mg, 40%). LCMS (M+H) = 459.15. ^1H NMR (500 MHz, DMSO- d_6) δ 8.04 (br s, 1H), 7.27 - 7.20 (m, 1H), 7.07 - 6.98 (m, 1H), 6.94 - 6.79 (m, 1H), 5.83 (br d, J=3.7 Hz, 1H), 3.79 (s, 3H), 2.50 (s, 3H), 1.37 - 1.27 (m, 4H), 1.15 (s, 9H), 0.81 (br d, J=1.5 Hz, 6H).

Example 151




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(5-fluoro-2-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using (5-fluoro-2-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(5-fluoro-2-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid (7.9 mg, 33%). LCMS (M+H) = 459.15. Ratio of atropisomers is 55 : 45 as determined by ^1H NMR (500 MHz, DMSO- d_6) δ 5.84 (br s, 1H), 5.78 (br d, J=0.7 Hz, 0.8H). ^1H NMR (500 MHz, DMSO- d_6) δ 7.95 (br s, 0.55H), 7.89 (br s, 0.45H), 7.29 - 7.19 (m, 1H), 7.17 - 7.10 (m, 0.55H), 7.07 (br d, J=4.8 Hz, 1H), 7.00 - 6.94 (m, 0.45H), 5.84 (br s,

0.55H), 5.78 (br d, J=0.7 Hz, 0.45H), 3.71 (br d, J=6.6 Hz, 3H), 2.50 (br s, 3H), 1.29 (br d, J=4.4 Hz, 2H), 1.15 (br d, J=8.4 Hz, 9H), 0.81 (br s, 6H).

Example 152




(2S)-2-(tert-butoxy)-2-[5-(3-chloro-2-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:

The Suzuki cross-coupling procedure of general method C was followed on a 55 μmol reaction scale using (3-chloro-2-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude ester product was purified as follows: The crude material was dissolved in a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ (24g column, hexanes:EtOAc 100:0→60:40). Fractions were selected based on mass purity of the desired ester intermediate. Concentration of the pooled sample afforded isopropyl (S)-2-(tert-butoxy)-2-(5-(3-chloro-2-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetate as a colorless solid. The material was transferred to a 7 mL vial and the saponification procedure of general method C was followed. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(3-chloro-2-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (4.7 mg, 18%). LCMS (M+H) = 475.1. Ratio of atropisomers is 60 : 40 as determined by ¹H NMR (500 MHz, DMSO-d₆) δ 8.05 - 8.02 (m, 1H), 7.99 (s, 0.7H).

¹H NMR (500 MHz, DMSO-d₆) δ 8.04 (s, 0.6H), 7.99 (s, 0.4H), 7.54 (br d, J=8.1 Hz, 1H), 7.27 - 7.20 (m, 1.5H), 7.18 - 7.13 (m, 0.8H), 5.70 - 5.62 (m, 1H), 3.64 (s, 1H), 3.26 (br s, 1.8H), 2.49 - 2.46 (m, 3H), 1.91 (s, 0.7H), 1.34 - 1.19 (m, 3H), 1.11 (s, 9H), 0.80 (br s, 6H).

Example 153

Example 154



(2S)-2-(tert-Butoxy)-2-[5-(2-cyanophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid and (2S)-2-(tert-butoxy)-2-[5-(2-carbamoylphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:

- 5 General method C was followed on a 55 μ mol reaction scale using 2-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborocan-2-yl)benzonitrile and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(2-cyanophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (1.7 mg, 7%) and (2S)-2-(tert-butoxy)-2-[5-(2-carbamoylphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (1 mg, 4%).

Analysis of Example 153:

LCMS (M+H) = 436.13. Ratio of atropisomers is 75 : 25 as determined by ^1H NMR (500 MHz, DMSO-d₆) δ 5.80 (s, 1H), 5.73 (s, 0.33H).


- 15 ^1H NMR (500 MHz, DMSO-d₆) δ 8.07 (s, 0.75H), 8.01 - 7.91 (m, 1.25H), 7.85 - 7.76 (m, 1.25H), 7.64 (br t, J=7.5 Hz, 1.25H), 7.59 (br d, J=8.1 Hz, 0.25H), 7.50 (d, J=7.7 Hz, 0.75H), 5.80 (s, 0.75H), 5.73 (s, 0.25H), 2.54 (s, 3H), 1.91 (s, 0.6H), 1.33 - 1.22 (m, 3H), 1.15 - 1.12 (m, 9H), 0.76 (br s, 6H).

Analysis of Example 154:

- 20 LCMS (M+H) = 454.15. Ratio of atropisomers is 66 : 34 as determined by ^1H NMR (500 MHz, DMSO-d₆) δ 5.73 (s, 1H), 5.37 (s, 0.5H).

- ^1H NMR (500 MHz, DMSO-d₆) δ 8.09 (s, 0.25H), 8.05 (s, 0.75H), 7.65 (br d, J=7.3 Hz, 0.8H), 7.59 - 7.50 (m, 2.2H), 7.26 (br d, J=7.3 Hz, 1.2H), 7.23 - 7.15 (m, 0.8H), 5.73 (s, 0.66H), 5.37 (s, 0.34H), 3.51 - 3.36 (m, 0.5H), 3.05 (br dd, J=6.4, 5.3 Hz, 0.5H), 2.98 - 2.90 (m, 0.8H), 2.67 - 2.62 (m, 0.6H), 2.55 - 2.52 (m, 3H), 1.53 - 1.43 (m, 2H), 1.35 - 1.25 (m, 2H), 1.14 (s, 6H), 1.12 (s, 3H), 1.03 (s, 2H), 0.99 (s, 1H), 0.85 (s, 1H), 0.81 (s, 4H).


Example 155



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using pyridin-3-ylboronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (14.4 mg, 64%). LCMS (M+H) = 412.12. ¹H NMR (500 MHz, DMSO-d₆) δ 8.66 - 8.60 (m, 1H), 8.54 (d, J=1.5 Hz, 1H), 8.08 (s, 1H), 7.80 - 7.72 (m, 1H), 7.50 (dd, J=7.7, 4.8 Hz, 1H), 5.83 (s, 1H), 2.52 (s, 3H), 1.35 - 1.24 (m, 4H), 1.14 (s, 9H), 0.79 (br s, 6H).

Example 156



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-3-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid:


General method C was followed on a 55 μ mol reaction scale using (2-fluoro-3-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-3-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid (10.3 mg, 41%).

LCMS (M+H) = 459.22. Ratio of atropisomers is 57 : 43 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 5.90 (br s, 1H), 5.83 (br s, 0.75H).

¹H NMR (500 MHz, methanol-d₄) δ 8.07 - 7.95 (m, 1H), 7.25 - 7.13 (m, 2H), 6.94 - 6.78 (m, 1H), 5.90 (br s, 0.6H), 5.83 (br s, 0.4H), 5.83 (br d, J=1.5 Hz, 1H), 3.93 (s, 3H), 3.12 -

2.92 (m, 2H), 2.90 - 2.68 (m, 2H), 2.62 (s, 3H), 1.39 (br s, 4H), 1.20 (s, 9H), 0.84 (br s, 6H).

Example 157




5 (2S)-2-(tert-Butoxy)-2-[5-(2,3-difluoro-5-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using (2,3-difluoro-5-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material
 10 was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(2,3-difluoro-5-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (11.2 mg, 43%). LCMS (M+H) = 477.24. ¹H NMR (500 MHz, methanol-d₄) δ 8.05 (br s, 1H), 7.01 - 6.93 (m, 1H), 6.74 - 6.59 (m, 1H), 5.96 - 5.81 (m, 1H), 3.82 (s, 3H), 3.12 - 2.92 (m, 2H), 2.90 - 2.68 (m, 2H), 2.62 (s, 3H), 1.41 (br s, 4H), 1.20 (s, 9H), 0.87 (br s, 6H)

15

Example 158




(2S)-2-(tert-Butoxy)-2-[5-(2,3-dimethoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:

20 General method C was followed on a 55 μ mol reaction scale using (2,3-dimethoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(2,3-dimethoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (14.5
 25 mg, 56%). LCMS (M+H) = 471.15 and 471.15. Ratio of atropisomers is 65 : 35 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 5.82 (s, 1H), 5.73 (s, 0.56H).

¹H NMR (500 MHz, methanol-d₄) δ 8.01 (s, 0.65H), 7.97 (s, 0.35H), 7.20 - 7.10 (m, 2H), 6.84 (dd, J=7.0, 2.4 Hz, 0.35H), 6.80 (dd, J=7.0, 1.8 Hz, 0.65H), 5.82 (s, 0.65H), 5.73 (s, 0.35H), 3.94 (s, 3H), 3.77 (s, 1.8H), 3.53 (s, 1H), 3.11 (br s, 2H), 2.94 (br s, 0.70H), 2.84 - 2.76 (m, 1.4H), 2.66 (s, 3H), 2.65 (s, 3H), 2.00 (s, 1.5H), 1.40 (br s, 4H), 1.22 - 1.19 (m, 9H), 0.88 (s, 2H), 0.85 (s, 4H).


Example 159



(2S)-2-(tert-Butoxy)-2-[5-(2,3-difluoro-4-methylphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:

General method C was followed on a 55 μmol reaction scale using (2,3-difluoro-4-methylphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(2,3-difluoro-4-methylphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (17.6 mg, 70%). LCMS (M+H) = 461.22. ¹H NMR (500 MHz, methanol-d₄) δ 8.08 - 7.97 (m, 1H), 7.15 (br t, J=7.6 Hz, 1H), 6.98 (br s, 1H), 5.89 (br s, 1H), 3.00 (br s, 2H), 2.75 (br s, 2H), 2.62 (s, 3H), 2.38 (d, J=1.8 Hz, 3H), 1.46 - 1.34 (m, 4H), 1.20 (s, 9H), 0.86 (br s, 6H).

Example 160



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-2-methylphenyl)-2-methylpyridin-3-yl]acetic acid:


General method C was followed on a 55 μmol reaction scale using (3-fluoro-2-methylphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-

dimethylpiperidin-1-yl)-5-(3-fluoro-2-methylphenyl)-2-methylpyridin-3-yl]acetic acid (8.6 mg, 35%). LCMS (M+H) = 443.25 and 443.25. Ratio of atropisomers is 75 : 25 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 5.92 (s, 1H), 5.81 (s, 0.33H).

¹H NMR (500 MHz, methanol-d₄) δ 7.98 (s, 0.75H), 7.91 (s, 0.25H), 7.36 - 7.29 (m, 1H),
 5 7.17 (t, J=8.9 Hz, 1H), 7.08 (d, J=7.3 Hz, 0.25H), 7.01 (d, J=7.6 Hz, 0.75H), 5.92 (s, 0.75H),
 5.81 (s, 0.25H), 3.10 - 2.84 (m, 2.5H), 2.76 - 2.68 (m, 1.5H), 2.68 - 2.64 (m, 3H), 2.11 (d,
 J=2.1 Hz, 2.25H), 2.01 (d, J=2.4 Hz, 0.75H), 1.43 - 1.34 (m, 4H), 1.23 (s, 9H), 0.86 - 0.83
 (m, 6H).

10

Example 161




(2S)-2-(tert-Butoxy)-2-[5-(2-chloro-3-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:

The Suzuki cross-coupling procedure of general method C was followed on a 55
 15 μmol reaction scale using (2-chloro-3-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude ester intermediate was purified as follows: The crude sample was dissolved in a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (24g column, hexanes:EtOAc 100:0 → 60:40).
 20 The product fractions were selected based on mass purity, then were pooled and concentrated in vacuo. The resulting residue was transferred to a 7 mL vial using acetone, then was concentrated under a N₂ stream. The saponification procedure of general method C was followed. The crude material was purified via preparative LC/MS to afford
 25 (2S)-2-(tert-butoxy)-2-[5-(2-chloro-3-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (13.1 mg, 50%). LCMS (M+H) = 475.23 and 475.23. Ratio of atropisomers is 75 : 25 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 5.88 (s, 1H), 5.77 - 5.72 (m, 0.32H).

¹H NMR (500 MHz, methanol-d₄) δ 7.97 (s, 0.75H), 7.87 (s, 0.25H), 7.43 - 7.33 (m, 1.25H), 7.18 (d, J=8.5 Hz, 1H), 6.97 (d, J=7.3 Hz, 0.25H), 6.91 (d, J=7.6 Hz, 1H), 5.88 (s,

0.75H), 5.74 (s, 0.25H), 3.95 (s, 3H), 3.15 - 3.02 (m, 0.5H), 3.02 - 2.87 (m, 1.75H), 2.83 - 2.72 (m, 1.75H), 2.66 - 2.58 (m, 3H), 1.43 - 1.31 (m, 4H), 1.23 - 1.16 (m, 9H), 0.85 - 0.79 (m, 6H).

Example 162




5

(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(2,3,4-trifluorophenyl)pyridin-3-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using (2,3,4-trifluorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(2,3,4-trifluorophenyl)pyridin-3-yl]acetic acid (11.1 mg, 43%). LCMS (M+H) = 465.21. ^1H NMR (500 MHz, methanol- d_4) δ 8.00 (br s, 1H), 7.27 - 7.19 (m, 1H), 7.12 (br s, 1H), 5.83 (br s, 1H), 3.04 (br s, 2H), 2.71 (br s, 2H), 2.62 (s, 3H), 1.46 - 1.35 (m, 4H), 1.19 (s, 9H), 0.86 (br s, 6H).

15

Example 163



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-3-methylphenyl)-2-methylpyridin-3-yl]acetic acid:

20


General method C was followed on a 55 μ mol reaction scale using (2-fluoro-3-methylphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-3-methylphenyl)-2-methylpyridin-3-yl]acetic acid (9.2 mg, 38%). LCMS (M+H) = 443.27. Ratio of atropisomers is 60 : 40 as determined by ^1H NMR (500 MHz, methanol- d_4) δ 5.94 - 5.88 (m, 1H), 5.83 (br s, 0.7H).

25

¹H NMR (500 MHz, methanol-d₄) δ 8.09 - 7.94 (m, 1H), 7.39 - 7.33 (m, 1H), 7.23 - 7.17 (m, 1H), 7.18 - 7.07 (m, 1H), 5.91 (br s, 0.6H), 5.83 (br s, 0.4H), 3.03 (br s, 1.8H), 2.86 (br s, 0.8H), 2.75 (br s, 1H), 2.65 (s, 3H), 2.35 (s, 3H), 1.40 (br s, 4H), 1.22 (br s, 9H), 0.90 - 0.82 (m, 6H)

5

Example 164




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2'-methoxy-6-methyl-[3,4'-bipyridine]-5-yl]acetic acid:

General method C was followed on a 55 μmol reaction scale using (2-methoxypyridin-4-yl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2'-methoxy-6-methyl-[3,4'-bipyridine]-5-yl]acetic acid (10.4 mg, 49%). LCMS (M+H) = 442.16. ¹H NMR (500 MHz, methanol-d₄) δ 8.22 (d, J=5.2 Hz, 1H), 8.04 (s, 1H), 6.95 (dd, J=5.2, 1.2 Hz, 1H), 6.79 (s, 1H), 5.87 (s, 1H), 3.98 (s, 3H), 3.09 (br s, 2H), 2.74 (br s, 2H), 2.62 (s, 3H), 1.50 - 1.37 (m, 4H), 1.19 (s, 9H), 0.88 (s, 6H).

15

Example 165



20

(2S)-2-(tert-Butoxy)-2-[5-(2-chloro-3-fluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:


The Suzuki cross-coupling procedure of general method C was followed on a 55 μmol reaction scale using (2-chloro-3-fluorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude ester intermediate was purified as follows: The crude sample

25

was dissolved in a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (24g column, hexanes:EtOAc 100:0 → 60:40). The product fractions were selected based on mass purity, then were pooled and concentrated in vacuo. The resulting residue was transferred to a 7 mL vial using acetone, then was concentrated under a N₂ stream. The saponification procedure of general method C was followed. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(2-chloro-3-fluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (3.9 mg, 15%). LCMS (M+H) = 463.17 and 463.17. Ratio of atropisomers is 74:26 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 5.94 (s, 1.0H), 5.82 (s, 0.35H).

¹H NMR (500 MHz, methanol-d₄) δ 8.03 (s, 1H), 7.93 (s, 0.3H), 7.51 - 7.42 (m, 1.3H), 7.41 - 7.34 (m, 1.3H), 7.26 (d, J=8.2 Hz, 0.3H), 7.19 (d, J=7.6 Hz, 1H), 5.94 (s, 1H), 5.82 (s, 0.3H), 3.08 - 2.87 (m, 2.6H), 2.83 - 2.74 (m, 2.6H), 2.65 (s, 1H), 2.64 (s, 3H), 1.43 - 1.36 (m, 5.2H), 1.23 (s, 12H), 0.87 (s, 2H), 0.85 (s, 6H).

Example 166




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-2-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid:

General method C was followed on a 55 μmol reaction scale using (3-fluoro-2-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-2-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid (10.4 mg, 41%). LCMS (M+H) = 459.23. Ratio of atropisomers is 61:39 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 5.88 (s, 1H), 5.78 (s, 1H).

¹H NMR (500 MHz, methanol-d₄) δ 8.04 (s, 1H), 7.99 (s, 0.6H), 7.30 - 7.23 (m, 1.6H), 7.17 (td, J=8.0, 5.0 Hz, 1.6H), 7.07 (br d, J=7.9 Hz, 0.6H), 7.01 (br d, J=7.0 Hz, 1H), 5.88 (s, 1H), 5.78 (s, 0.6H), 3.89 (s, 3H), 3.68 (s, 1.8H), 3.13 - 2.97 (m, 2.8H), 2.97 - 2.87 (m,

1.3H), 2.83 - 2.74 (m, 2H), 2.65 (s, 4.8H), 1.40 (br s, 6.4H), 1.22 (s, 9H), 1.21 (s, 5H), 0.89 (s, 3.6H), 0.85 (s, 6H).


Example 167



5 (2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(2-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using (2-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material
 10 was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(2-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid (11.4 mg, 47%). LCMS (M+H) = 441.25. Ratio of atropisomers is 59:41 ratio as determined by ^1H NMR (500 MHz, DMSO- d_6) δ 5.90 (s, 1H), 5.82 (s, 0.7H).
 ^1H NMR (500 MHz, DMSO- d_6) δ 7.93 (s, 1H), 7.87 (s, 0.6H), 7.46 - 7.38 (m, 2H), 7.18 -
 15 7.12 (m, 2H), 7.11 - 7.00 (m, 3.3H), 5.90 (s, 1H), 5.82 (s, 0.7H), 3.73 (s, 3H), 3.71 (s, 2.1H), 2.49 (s, 5H), 1.28 (br s, 4H), 1.17 - 1.14 (m, 9H), 1.13 (s, 6.5H), 0.82 - 0.68 (m, 10H).

Example 168




20 (2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(3-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using (3-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material
 25 was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(3-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid (12.9 mg, 53%). LCMS (M+H) = 441.24. ^1H NMR (500 MHz, methanol- d_4) δ 8.85 (br d, J=4.9 Hz,

1H), 8.23 - 8.13 (m, 1H), 7.84 - 7.75 (m, 1H), 7.72 - 7.65 (m, 2H), 6.66 (br s, 1H), 4.62 (s, 3H), 3.36 (br s, 3H), 2.16 - 2.05 (m, 4H), 1.95 (br s, 9H), 1.67 - 1.58 (m, 6H).

Example 169




5

(2S)-2-(tert-Butoxy)-2-{5-[2,3-difluoro-4-(propan-2-yloxy)phenyl]-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl}acetic acid:

General method C was followed on a 55 μ mol reaction scale using (2,3-difluoro-4-isopropoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-{5-[2,3-difluoro-4-(propan-2-yloxy)phenyl]-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl}acetic acid (14.5 mg, 52%). LCMS (M+H) = 505.26. ¹H NMR (500 MHz, methanol-d₄) δ 8.06 (br s, 1H), 7.10 - 6.96 (m, 2H), 5.93 (br s, 1H), 4.72 (dt, J=12.2, 6.1 Hz, 2H), 3.02 (br s, 2H), 2.78 (br s, 2H), 2.64 (s, 3H), 1.40 (dd, J=6.1, 3.1 Hz, 4H), 1.45 - 1.37 (m, 4H), 1.22 (s, 9H), 0.88 (br s, 6H).

15

Example 170




(2S)-2-(tert-Butoxy)-2-[5-(2,3-difluoro-5-methylphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using (2,3-difluoro-5-methylphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(2,3-difluoro-5-methylphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (10.4 mg, 41%). LCMS (M+H) = 461.22. ¹H NMR (500 MHz, DMSO-d₆) δ 8.07 (s, 1H), 7.37 -

25

7.30 (m, 1H), 6.99 (s, 1H), 5.80 (br s, 1H), 2.55 (s, 3H), 2.36 (s, 3H), 1.31 (br s, 4H), 1.14 (s, 9H), 0.82 (br s, 6H).

Example 171




(2S)-2-(tert-Butoxy)-2-[5-(2,4-difluoro-3-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:


General method C was followed on a 55 μ mol reaction scale using (2,4-difluoro-3-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[5-(2,4-difluoro-3-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (12.6 mg, 48%). LCMS (M+H) = 477.21. Ratio of atropisomers is 1:1 as determined by ^1H NMR (500 MHz, methanol- d_4) δ 5.95 - 5.89 (m, 1H), 5.89 - 5.82 (m, 1H).

^1H NMR (500 MHz, methanol- d_4) δ 8.13 - 7.91 (m, 1H), 7.14 - 7.07 (m, 1H), 7.07 - 6.91 (m, 1H), 5.98 - 5.79 (m, 1H), 4.01 (s, 3H), 3.11 - 2.88 (m, 2H), 2.86 - 2.67 (m, 2H), 2.62 (s, 3H), 1.40 (br dd, J=6.0, 4.1 Hz, 4H), 1.20 (s, 9H), 0.86 (br s, 6H).

Example 172



Example 173



(2S)-2-(tert-Butoxy)-2-[5-[2,3-difluoro-4-(trifluoromethyl)phenyl]-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid and (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-[3-ethoxy-2-fluoro-4-(trifluoromethyl)phenyl]-2-methylpyridin-3-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using (2,3-difluoro-4-(trifluoromethyl)phenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material.

The crude material was purified via preparative LC/to afford (2S)-2-(tert-butoxy)-2-{5-[2,3-difluoro-4-(trifluoromethyl)phenyl]-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl}acetic acid (4.3 mg, 15%) and (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-[3-ethoxy-2-fluoro-4-(trifluoromethyl)phenyl]-2-methylpyridin-3-yl]acetic acid (6 mg, 20%).

Analysis of Example 172:


LCMS (M+H) = 515.2. ¹H NMR (500 MHz, methanol-d₄) δ 8.15 - 8.00 (m, 1H), 7.62 (br t, J=7.5 Hz, 1H), 7.44 - 7.24 (m, 1H), 5.96 - 5.81 (m, 1H), 2.96 (br s, 2H), 2.77 (br s, 2H), 2.63 (s, 3H), 1.45 - 1.35 (m, 4H), 1.21 (s, 9H), 0.86 (br s, 6H).

Analysis of Example 173:

LCMS (M+H) = 541.26. Ratio of atropisomers is 1:1 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 5.97 - 5.90 (m, 1H), 5.89 - 5.82 (m, 1H).

¹H NMR (500 MHz, Methanol-d₄) δ 8.11 - 7.97 (m, 1H), 7.52 (d, J=8.9 Hz, 1H), 7.29 - 7.06 (m, 1H), 5.98 - 5.80 (m, 1H), 4.32 - 4.19 (m, 2H), 3.08 - 2.88 (m, 2H), 2.87 - 2.68 (m, 2H), 2.63 (s, 3H), 1.45 - 1.35 (m, 7H), 1.20 (s, 9H), 0.86 (br d, J=15.6 Hz, 6H).


Example 174



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(2,3,5-trifluorophenyl)pyridin-3-yl]acetic acid:

General method C was followed on a 55 μmol reaction scale using (2,3,5-trifluorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(2,3,5-trifluorophenyl)pyridin-3-yl]acetic acid (8.5 mg, 33%). LCMS (M+H) = 465.18. ¹H NMR (500 MHz, DMSO-d₆) δ 8.16 - 8.01 (m, 1H), 7.65 - 7.53 (m, 1H), 7.18 (br s, 1H), 5.78 (br s, 1H), 2.52 (s, 3H), 1.31 (br s, 4H), 1.14 (s, 9H), 0.82 (br s, 6H).


Example 175



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(4-ethoxy-2,3-difluorophenyl)-2-methylpyridin-3-yl]acetic acid:

- 5 General method C was followed on a 55 μ mol reaction scale using (4-ethoxy-2,3-difluorophenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(4-ethoxy-2,3-difluorophenyl)-2-methylpyridin-3-yl]acetic acid
- 10 (11.4 mg, 42%). LCMS (M+H) = 491.24. ^1H NMR (500 MHz, DMSO- d_6) δ 8.05 (br s, 1H), 7.18 - 7.03 (m, 2H), 5.88 - 5.76 (m, 1H), 4.23 (q, J=7.0 Hz, 2H), 2.55 (s, 3H), 1.39 (t, J=7.0 Hz, 3H), 1.31 (br s, 4H), 1.15 (s, 9H), 0.90 - 0.73 (m, 6H).

Example 176




- 15 (2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(isoquinolin-7-yl)-2-methylpyridin-3-yl]acetic acid:
- General method C was followed on a 55 μ mol reaction scale using isoquinolin-7-ylboronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was
- 20 purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(isoquinolin-7-yl)-2-methylpyridin-3-yl]acetic acid (5.9 mg, 23%). LCMS (M+H) = 462.2. Ratio of atropisomers is 55 : 45 as determined by ^1H NMR (500 MHz, methanol- d_4) δ 6.00 (br s, 1H), 5.84 - 5.80 (m, 0.85H); Ratio of atropisomers
- 25 is 69 : 31 by HPLC.
- ^1H NMR (500 MHz, methanol- d_4) δ 8.99 - 8.91 (m, 1H), 8.81 (br s, 0.8H), 8.51 (br d, J=4.6 Hz, 2H), 8.18 - 8.10 (m, 2H), 8.07 (br t, J=7.0 Hz, 1.8H), 7.96 - 7.87 (m, 3.7H), 7.65 (d,

J=7.0 Hz, 0.8H), 7.59 (d, J=6.7 Hz, 1H), 6.00 (br s, 1H), 5.82 (s, 0.8H), 2.70 (s, 6H), 1.24 (s, 9H), 1.31 - 1.21 (m, 3.2H), 1.22 (s, 7.2H), 1.18 - 1.12 (m, 3.2H), 0.72 (s, 6H), 0.56 - 0.49 (m, 4.8H).

5

Example 177




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(3-methylphenyl)pyridin-3-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using m-tolylboronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(3-methylphenyl)pyridin-3-yl]acetic acid (9.4 mg, 40%). LCMS (M+H) = 425.24. ¹H NMR (500 MHz, DMSO-d₆) δ 8.04 (s, 1H), 7.36 (t, J=7.5 Hz, 1H), 7.24 (br d, J=8.2 Hz, 1H), 7.14 (s, 1H), 7.11 (d, J=8.5 Hz, 1H), 5.87 - 5.83 (m, 1H), 2.55 (s, 3H), 2.38 (s, 3H), 1.35 - 1.26 (m, 4H), 1.23 (s, 3H), 1.14 (s, 9H), 0.84 - 0.74 (m, 6H).

15

Example 178



(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(4-methoxy-3-methylphenyl)-2-methylpyridin-3-yl]acetic acid:


General method C was followed on a 55 μ mol reaction scale using (4-methoxy-3-methylphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(4-methoxy-3-methylphenyl)-2-methylpyridin-3-yl]acetic acid (19.8 mg, 79%). LCMS (M+H) = 455.24. ¹H NMR (500 MHz, methanol-d₄) δ 8.11 - 7.91

25

(m, 1H), 7.19 - 7.08 (m, 2H), 7.03 (br d, J=7.9 Hz, 1H), 5.97 - 5.52 (br s, 1H), 3.90 (s, 3H), 3.27 - 3.01 (m, 2H), 2.90 - 2.59 (m, 5H), 2.27 (s, 3H), 1.50 - 1.36 (m, 4H), 1.36 - 1.13 (m, 9H), 0.89 (s, 6H).

5

Example 179




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid:

General method C was followed on a 55 μ mol reaction scale using (3-fluoro-4-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid (13.5 mg, 54%). LCMS (M+H) = 459.23. ¹H NMR (500 MHz, methanol-d₄) δ 8.06 (s, 1H), 7.27 - 7.19 (m, 1H), 7.16 - 7.06 (m, 2H), 5.86 (s, 1H), 3.96 (s, 3H), 3.18 - 3.00 (m, 2H), 2.83 - 2.71 (m, 2H), 2.65 (s, 3H), 1.44 (br d, J=4.3 Hz, 4H), 1.22 (s, 9H), 0.90 (s, 6H).

15

Example 180



20

(2S)-2-[5-(2H-1,3-Benzodioxol-5-yl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]-2-(tert-butoxy)acetic acid:


General method C was followed on a 55 μ mol reaction scale using benzo[d][1,3]dioxol-5-ylboronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-[5-(2H-1,3-benzodioxol-5-yl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]-2-(tert-

25

butoxy)acetic acid (12.9 mg, 52%). LCMS (M+H) = 455.34. ¹H NMR (500 MHz, methanol-d₄) δ 8.04 (s, 1H), 6.95 (d, J=7.9 Hz, 1H), 6.84 (d, J=1.5 Hz, 1H), 6.80 (dd, J=8.1, 1.7 Hz, 1H), 6.04 (s, 2H), 5.83 (s, 1H), 3.23 - 3.08 (m, 2H), 2.83 - 2.72 (m, 2H), 2.65 (s, 3H), 1.51 - 1.38 (m, 4H), 1.21 (s, 9H), 0.91 (s, 6H).

5

Example 181




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-(2-fluoro-4-methoxyphenyl)-2-methylpyridin-3-yl]acetic acid:

10 General method C was followed on a 55 μmol reaction scale using (2-fluoro-4-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-

15 (8.3 mg, 33%). LCMS (M+H) = 459.21. ¹H NMR (500 MHz, methanol-d₄) δ 8.08 - 7.94 (m, 1H), 7.30 - 7.13 (m, 1H), 6.90 (dd, J=8.5, 2.1 Hz, 1H), 6.88 - 6.82 (m, 1H), 5.97 - 5.80 (m, 1H), 3.89 (s, 3H), 3.14 - 2.96 (m, 2H), 2.89 - 2.71 (m, 2H), 2.64 (s, 3H), 1.42 (br s, 4H), 1.22 (s, 9H), 0.88 (br s, 6H).

20

Example 182




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(naphthalen-1-yl)pyridin-3-yl]acetic acid:

25 General method C was followed on a 55 μmol reaction scale using naphthalen-1-ylboronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-

dimethylpiperidin-1-yl)-2-methyl-5-(naphthalen-1-yl)pyridin-3-yl]acetic acid (13.5 mg, 48%). LCMS (M+H) = 461.23, 461.23. Ratio of atropisomers is 53 : 47 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 8.19 (s, 0.9H), 8.16 (s, 1H).

¹H NMR (500 MHz, methanol-d₄) δ 8.19 (s, 1H), 8.16 (s, 1H), 8.06 (br d, J=10.1 Hz, 2H), 8.02 (br d, J=8.5 Hz, 2H), 7.67 - 7.62 (m, 2H), 7.61 - 7.51 (m, 6H), 7.47 - 7.41 (m, 2H), 5.83 (s, 1H), 5.65 (s, 1H), 2.97 - 2.86 (m, 4H), 2.80 (s, 3H), 2.79 - 2.78 (m, 3H), 1.41 - 1.28 (m, 10H), 1.27 (s, 9H), 1.24 (s, 8H), 1.21 - 1.10 (m, 4H), 0.78 (s, 6H), 0.58 (s, 5H).

Example 183




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(naphthalen-2-yl)pyridin-3-yl]acetic acid:

General method C was followed on a 55 μmol reaction scale using naphthalen-2-ylboronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-

methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(naphthalen-2-yl)pyridin-3-yl]acetic acid (14.6 mg, 58%). LCMS (M+H) = 461.24. ¹H NMR (500 MHz, DMSO-d₆) δ 8.15 (s, 1H), 8.05 - 7.96 (m, 3H), 7.88 (s, 1H), 7.61 - 7.53 (m, 2H), 7.48 (d, J=8.5 Hz, 1H), 5.87 (s, 1H), 2.56 - 2.55 (m, 3H), 1.33 - 1.27 (m, 2H), 1.16 (s, 9H), 0.85 - 0.63 (m, 5H).

Example 184




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinolin-8-yl)pyridin-3-yl]acetic acid:

General method C was followed on a 55 μmol reaction scale using quinolin-8-ylboronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-

methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinolin-8-yl)pyridin-3-yl]acetic acid (13.5 mg, 53%). LCMS (M+H) = 462.2. Ratio of atropisomers is 70 : 30 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 5.84 - 5.80 (m, 1H), 5.72 (s, 0.45H).

¹H NMR (500 MHz, methanol-d₄) δ 8.84 (d, J=2.7 Hz, 1H), 8.45 - 8.36 (m, 1.3H), 8.10 - 7.99 (m, 2.4H), 7.74 - 7.65 (m, 2.5H), 7.58 - 7.51 (m, 1.2H), 5.82 (s, 0.7H), 5.72 (s, 0.3H), 3.04 - 2.84 (m, 1H), 2.81 - 2.74 (m, 1H), 2.72 (s, 3H), 2.70 - 2.60 (m, 2H), 1.98 (s, 3H), 1.35 - 1.28 (m, 2H), 1.26 (s, 7.7H), 1.21 (s, 4.5H), 0.75 (s, 4.2H), 0.59 - 0.52 (m, 1.8H).


Example 185



(2S)-2-(tert-Butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5,6'-dimethyl-[2,3'-bipyridine]-5'-yl]acetic acid:

General method D was followed on a 55 μmol reaction scale using 6-methyl-2-(5-methylpyridin-2-yl)-1,3,6,2-dioxazaborocane-4,8-dione and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5,6'-dimethyl-[2,3'-bipyridine]-5'-yl]acetic acid (3.1 mg, 13%). LCMS (M+H) = 426.22. ¹H NMR (500 MHz, methanol-d₄) δ 8.49 (s, 1H), 8.08 (s, 1H), 7.77 (dd, J=8.1, 1.7 Hz, 1H), 7.39 (d, J=7.9 Hz, 1H), 5.79 (s, 1H), 3.00 (br s, 2H), 2.76 (br s, 2H), 2.63 (s, 3H), 2.43 (s, 3H), 1.97 (s, 3H), 1.40 (br t, J=5.2 Hz, 4H), 1.17 (s, 9H), 0.85 (s, 6H).


Example 186



(2S)-2-(tert-Butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid:

General method D was followed on a 55 μ mol reaction scale using 6-methyl-2-(pyridin-2-yl)-1,3,6,2-dioxazaborocane-4,8-dione and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (8.7 mg, 38%). LCMS (M+H) = 412.23. ^1H NMR (500 MHz, methanol- d_4) δ 8.64 (d, J=4.3 Hz, 1H), 8.09 (s, 1H), 7.93 (td, J=7.8, 1.5 Hz, 1H), 7.50 (d, J=7.9 Hz, 1H), 7.45 (dd, J=7.2, 5.0 Hz, 1H), 5.80 (s, 1H), 3.00 (br s, 2H), 2.76 (br s, 2H), 2.65 - 2.63 (m, 3H), 1.96 (s, 3H), 1.39 (br s, 4H), 1.18 (s, 9H), 0.85 (s, 6H).

Example 187




(2S)-2-(tert-Butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(pyrimidin-2-yl)pyridin-3-yl]acetic acid:

To a 14 mL test tube equipped with a stir bar was added (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (75 mg, 0.165 mmol), cesium fluoride (25 mg, 0.165 mmol), and $\text{Pd}(\text{PPh}_3)_4$ (19 mg, 16.5 μ mol). The test tube was sealed with a rubber septum, then placed under N_2 atmosphere. To the test tube was added a degassed (5 min sparging with N_2) solution of 2-(tributylstannyl)pyrimidine in dioxane (1.5 mL). The test tube was placed in a 80 $^\circ\text{C}$ heating block with stirring for 24h. The reaction mixture was cooled to r.t., then was diluted with Et_2O (5 mL) and water (5 mL). The organic phase was isolated and dried over MgSO_4 , then filtered, then concentrated in a 7 mL vial under a N_2 stream. To the vial was added a stir bar and EtOH (1.5 mL), then aq. sodium hydroxide (0.330 mL, 1.650 mmol). The vial was capped, then placed in a 90 $^\circ\text{C}$ heating block with stirring for 2h. The mixture was cooled to r.t., then was filtered through a syringe filter to afford a solution of the crude product. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(pyrimidin-2-

yl)pyridin-3-yl]acetic acid (6 mg, 7%). LCMS (M+H) = 413.07. ¹H NMR (500 MHz, methanol-d₄) δ 9.00 (d, J=4.9 Hz, 2H), 8.49 (s, 1H), 7.57 (t, J=5.0 Hz, 1H), 5.83 (s, 1H), 3.03 (br d, J=18.9 Hz, 4H), 2.77 (s, 3H), 1.56 - 1.44 (m, 4H), 1.25 (s, 9H), 0.97 (s, 6H).

5

Example 188




(2S)-2-(tert-Butoxy)-2-(5-(2,3-difluoro-6-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid:

General method C was followed on a 55 μmol reaction scale using (2,3-difluoro-6-methoxyphenyl)boronic acid and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-(tert-butoxy)-2-(5-(2,3-difluoro-6-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid (0.7 mg, 3%). LCMS (M+H) = 477.2. ¹H NMR (500 MHz, methanol-d₄) δ 7.98 - 7.87 (m, 1H), 7.36 (q, J=9.6 Hz, 1H), 6.94 - 6.86 (m, 1H), 5.83 (s, 1H), 3.78 (s, 3H), 3.05 (br s, 2H), 2.84 (br s, 2H), 2.65 (s, 3H), 1.47 - 1.35 (m, 4H), 1.21 (s, 9H), 0.87 (s, 6H).

15

Example 189



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:


General method D was followed on a 55 μmol reaction scale using 2-(6-methoxypyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione and (S)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (4.9 mg, 17%). LCMS (M+H) = 442.3. ¹H NMR (500 MHz, methanol-d₄) δ

25

8.28 (s, 1H), 7.86 - 7.81 (m, 1H), 7.12 (d, J=7.0 Hz, 1H), 6.91 (d, J=8.2 Hz, 1H), 5.74 (s, 1H), 3.96 (s, 3H), 3.12 - 3.03 (m, 2H), 3.02 - 2.94 (m, 2H), 2.76 (s, 3H), 1.55 - 1.42 (m, 4H), 1.23 (s, 9H), 0.94 (s, 6H).

5

Example 190




(2S)-2-[6-({7-Azaspiro[3.5]nonan-7-yl}methyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-phenylpyridin-3-yl]-2-(tert-butoxy)acetic acid:

General method B was followed on a 49 μ mol reaction scale using phenylboronic acid and (S)-isopropyl 2-(6-(7-azaspiro[3.5]nonan-7-ylmethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-[6-({7-azaspiro[3.5]nonan-7-yl}methyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-phenylpyridin-3-yl]-2-(tert-butoxy)acetic acid (0.9 mg, 3%). LCMS (M+H) = 548.38. ^1H NMR (500 MHz, methanol- d_4) δ 7.60 - 7.50 (m, 2H), 7.37 (br d, J=6.7 Hz, 1H), 7.25 (br d, J=7.3 Hz, 1H), 6.07 (br s, 1H), 4.16 (br d, J=15.3 Hz, 1H), 3.83 (br d, J=15.3 Hz, 1H), 3.17 (br s, 4H) 2.68 (s, 3H), 2.01 - 1.91 (m, 2H), 1.91 - 1.81 (m, 10H), 1.42 - 1.27 (m, 4H), 1.23 (s, 9H), 0.78 (br s, 6H).

20

Example 191




(2S)-2-[6-({7-Azaspiro[3.5]nonan-7-yl}methyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenyl)-2-methylpyridin-3-yl]-2-(tert-butoxy)acetic acid:

General method B was followed on a 49 μ mol reaction scale using (4-fluorophenyl)boronic acid and (S)-isopropyl 2-(6-(7-azaspiro[3.5]nonan-7-ylmethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-[6-({7-azaspiro[3.5]nonan-7-yl}methyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenyl)-2-methylpyridin-3-yl]-2-(tert-butoxy)acetic acid (1.4 mg, 5%). LCMS (M+H) = 566.38.

10

Example 192




(2S)-2-[6-({7-Azaspiro[3.5]nonan-7-yl}methyl)-4-(4-methoxyphenyl)-2-methylpyridin-3-yl]-2-(tert-butoxy)acetic acid:

General method B was followed on a 49 μ mol reaction scale using (4-methoxyphenyl)boronic acid and (S)-isopropyl 2-(6-(7-azaspiro[3.5]nonan-7-ylmethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-[6-({7-azaspiro[3.5]nonan-7-yl}methyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-methoxyphenyl)-2-methylpyridin-3-yl]-2-(tert-butoxy)acetic acid (4.3 mg, 15%). LCMS (M+H) = 578.39. ^1H NMR (500 MHz, methanol- d_4) δ 7.25 - 7.19 (m, 1H), 7.17 - 7.12 (m, 1H), 7.10 - 7.03 (m, 2H), 5.72 (s, 1H), 4.04 (d, J=15.3 Hz, 1H), 3.87 (s, 3H), 3.72 (d, J=15.0 Hz, 1H), 3.08 - 2.98 (m, 4H), 2.65 (d, J=2.1 Hz, 7H), 1.99 - 1.87 (m, 6H), 1.86 - 1.80 (m, 8H), 1.33 (br s, 4H), 1.17 (s, 9H), 0.79 (s, 6H).

20


Example 193



(2S)-2-[6-({7-Azaspiro[3.5]nonan-7-yl}methyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(3,4,5-trifluorophenyl)pyridin-3-yl]-2-(tert-butoxy)acetic acid:

- 5 To a 14 mL test tube equipped with a stir bar was added (3,4,5-trifluorophenyl)boronic acid (19 mg, 0.111 mmol), (S)-isopropyl 2-(6-(7-azaspiro[3.5]nonan-7-ylmethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (43.5 mg, 0.072 mmol), tribasic potassium phosphate (46.7 mg, 0.219 mmol), and bis(di-*tert*-butyl(4-
- 10 dimethylaminophenyl)phosphine)dichloropalladium(II) (5.2 mg, 7.2 μ mol). The test tube was capped with a rubber septum, then was placed under N₂ atmosphere. To the vial was added a degassed (N₂ bubbling for 5 minutes) solution of dioxane (1.125 mL) and water (0.375 mL). The vial was placed in a 60 °C heating block with stirring. After 3h the temperature was increased to 90 °C. After 3h the reaction mixture was cooled to r.t. and
- 15 was then diluted with Et₂O (5 mL). The solution was washed with water (5 mL). The isolated organic phase was dried over MgSO₄, then filtered into a 7 mL vial. The volatiles were removed under a N₂ stream. To the vial was added a stir bar and ethanol (1.5 mL), then aq. sodium hydroxide in water (5M, 0.200 mL, 1.00 mmol). The vial was capped, then placed in a 90 °C heating block with stirring for 18h. The reaction mixture was
- 20 cooled to r.t., then was filtered through a syringe filter to afford a solution of the crude product. The crude material was purified via preparative LC/MS to afford (2S)-2-[6-({7-azaspiro[3.5]nonan-7-yl}methyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(3,4,5-trifluorophenyl)pyridin-3-yl]-2-(tert-butoxy)acetic acid (8.2 mg, 19%). LCMS (M+H) =
- 25 602.16. ¹H NMR (500 MHz, methanol-d₄) δ 7.32 - 7.23 (m, 1H), 7.14 - 7.04 (m, 1H), 5.66 (s, 1H), 4.20 (d, J=15.3 Hz, 1H), 3.79 (d, J=15.3 Hz, 1H), 3.23 - 2.99 (m, 4H), 2.64 (s, 3H), 2.00 - 1.80 (m, 11H), 1.76 - 1.22 (m, 4H), 1.16 (s, 9H), 1.01 - 0.68 (m, 6H).

Example 194




(2S)-2-[6-({7-Azaspiro[3.5]nonan-7-yl}methyl)-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]-2-(tert-butoxy)acetic acid:

- 5 General method B was followed on a 49 μ mol reaction scale using (3,5-difluoro-4-methoxyphenyl)boronic acid and (S)-isopropyl 2-(6-(7-azaspiro[3.5]nonan-7-ylmethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-[6-({7-azaspiro[3.5]nonan-7-yl}methyl)-5-(3,5-difluoro-4-
- 10 methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]-2-(tert-butoxy)acetic acid (3 mg, 10%). LCMS (M+H) = 614.15. ^1H NMR (500 MHz, methanol- d_4) δ 7.12 (br d, J=10.7 Hz, 1H), 6.96 (br d, J=11.0 Hz, 1H), 5.69 (s, 1H), 4.23 (d, J=15.3 Hz, 1H), 4.06 (s, 3H), 3.83 (d, J=15.3 Hz, 1H), 3.24 - 3.01 (m, 4H), 2.66 (s, 3H), 2.01 - 1.83 (m, 10H), 1.53 - 1.28 (m, 2H), 1.18 (s, 9H), 0.98 - 0.72 (m, 6H).

15

Example 195



(2S)-2-[6-({7-Azaspiro[3.5]nonan-7-yl}methyl)-5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]-2-(tert-butoxy)acetic acid:

- 20 General method B was followed on a 49 μ mol reaction scale using (3,4-difluorophenyl)boronic acid and (S)-isopropyl 2-(6-(7-azaspiro[3.5]nonan-7-ylmethyl)-5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-


2-[6-({7-azaspiro[3.5]nonan-7-yl)methyl}-5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]-2-(tert-butoxy)acetic acid (2.5 mg, 9%).

LCMS (M+H) = 584.17. Ratio of atropisomers is 1.0:1.0 as determined by ¹H NMR (500 MHz, methanol-d₄) δ 3.79 (d, J=8.5 Hz, 1H), 3.78 - 3.74 (m, 1H).

- 5 ¹H NMR (500 MHz, methanol-d₄) δ 7.53 - 7.38 (m, 1.5H), 7.29 - 7.18 (m, 1H), 7.11 - 7.05 (m, 0.5H), 5.70 (d, J=2.4 Hz, 1H), 4.19 (dd, J=15.3, 11.6 Hz, 1H), 3.81 - 3.73 (m, 1H), 3.23 - 3.02 (m, 4H), 2.68 (s, 2H), 2.66 (s, 3H), 1.99 - 1.81 (m, 12H), 1.48 - 1.29 (m, 2H), 1.19 (d, J=1.2 Hz, 9H), 0.96 - 0.68 (m, 6H).

10

Example 196




(2S)-2-{6-[(Azetidin-1-yl)methyl]-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl}-2-(tert-butoxy)acetic acid:

General method A was followed on a 46 μmol reaction scale using azetidine and

- 15 (S)-isopropyl 2-(tert-butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formyl-2-methylpyridin-3-yl)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-{6-[(azetidin-1-yl)methyl]-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl}-2-(tert-butoxy)acetic acid (6 mg, 24%). LCMS (M+H) = 546.31. ¹H
- 20 NMR (500 MHz, methanol-d₄) δ 7.11 - 7.05 (m, 1H), 6.93 (br d, J=11.0 Hz, 1H), 5.69 (s, 1H), 4.22 - 4.12 (m, 4H), 4.06 (s, 3H), 2.66 (s, 3H), 2.55 - 2.47 (m, 2H), 1.50 - 1.24 (m, 4H), 1.18 (s, 9H), 0.85 (br s, 6H).

Example 197




25

(2*S*)-2-(*tert*-Butoxy)-2-[5-(3,5-difluoro-4-methoxyphenyl)-6-[(dimethylamino)methyl]-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid:

General method A was followed on a 46 μ mol reaction scale using dimethylamine in MeOH (2M) and (S)-isopropyl 2-(*tert*-butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formyl-2-methylpyridin-3-yl)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2*S*)-2-(*tert*-butoxy)-2-[5-(3,5-difluoro-4-methoxyphenyl)-6-[(dimethylamino)methyl]-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl]acetic acid (10.7 mg, 44%). LCMS (M+H) = 534.29. ¹H NMR (500 MHz, methanol-d₄) δ 7.11 - 7.04 (m, 1H), 6.95 (br d, J=11.3 Hz, 1H), 5.71 (s, 1H), 4.22 (d, J=14.6 Hz, 1H), 4.06 (s, 3H), 3.84 (d, J=14.6 Hz, 1H), 2.82 (s, 6H), 2.68 (s, 3H), 1.38 (br d, J=2.7 Hz, 4H), 1.19 (s, 9H), 0.85 (s, 6H).


Example 198



(2*S*)-2-(*tert*-Butoxy)-2-[5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methyl-6-[(pyrrolidin-1-yl)methyl]pyridin-3-yl]acetic acid:

General method A was followed on a 46 μ mol reaction scale using pyrrolidine and (S)-isopropyl 2-(*tert*-butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formyl-2-methylpyridin-3-yl)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2*S*)-2-(*tert*-butoxy)-2-[5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methyl-6-[(pyrrolidin-1-yl)methyl]pyridin-3-yl]acetic acid (8.6 mg, 33%). LCMS (M+H) = 560.29. ¹H NMR (500 MHz, methanol-d₄) δ 7.09 (br d, J=10.7 Hz, 1H), 6.95 (br d, J=11.3 Hz, 1H), 5.72 (s, 1H), 4.37 (d, J=15.3 Hz, 1H), 4.06 (s, 3H), 3.94 (d, J=15.0 Hz, 1H), 2.67 (s, 3H), 2.07 (dt, J=6.9, 3.4 Hz, 4H), 1.43 - 1.30 (m, 4H), 1.19 (s, 9H), 0.85 (br s, 6H).

Example 199




(2S)-2-{6-[(Azocan-1-yl)methyl]-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl}-2-(tert-butoxy)acetic acid:

- 5 General method A was followed on a 46 μ mol reaction scale using azocane and (S)-isopropyl 2-(tert-butoxy)-2-(5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formyl-2-methylpyridin-3-yl)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2S)-2-{6-[(azocan-1-yl)methyl]-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl}-2-(tert-butoxy)acetic acid (9.6 mg, 35%). LCMS (M+H) = 602.33. ^1H NMR (500 MHz, methanol- d_4) δ 7.11 (br d, J=10.7 Hz, 1H), 6.96 (br d, J=11.0 Hz, 1H), 5.69 (s, 1H), 4.24 (br d, J=14.3 Hz, 1H), 4.06 (s, 3H), 3.91 (d, J=15.3 Hz, 1H), 3.30 - 3.22 (m, 4H), 2.68 (s, 3H), 1.91 (br s, 4H), 1.77 (br s, 6H), 1.44 - 1.33 (m, 4H), 1.19 (s, 9H), 0.86 (s, 6H).

15

Example 200




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetic acid:

- 20 To a solution of ethyl-(S)-2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate (14.7 mg, 0.025 mmol) in MeOH (5 mL) in reaction vial was added palladium hydroxide on carbon (8.0 mg, 0.011 mmol). The reaction was flushed with nitrogen, capped, purged with H_2 and stirred at room temp for 3h under an atmosphere (balloon) of H_2 . The reaction was then treated with acetic acid (33.4 μ L, 0.583 mmol), purged with H_2 and heated at 50 $^\circ\text{C}$ for 18 h. The
- 25

catalyst was filtered off through a 45m frit and the resulting solution was transferred to a pressure bottle. The reaction was charged with a mixture of palladium hydroxide (9 mg) and Pd/C (6 mg), purged with H₂ gas, capped and heated at in a 65 °C for 18 h. The catalyst was filtered off through a 45m frit and the solvent was removed under a gentle stream of nitrogen. The residue was dissolved in EtOH (3 mL), treated with 10 M sodium hydroxide (100 µL, 1.000 mmol) and heated at 105 °C for 4.5h. The crude material was purified via preparative LC/MS to afford (S)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetic acid, 5.0 mg), (38%). LCMS (M+1) = 535.3.


Example 201



(S)-2-(5-(4-((Benzofuro[3,2-d]pyrimidin-4-ylamino)methyl)phenyl)-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(tert-butoxy)acetic acid:

To a dry reaction vial under NITROGEN was added ethyl-(S)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate (32.6 mg, 0.071 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-d]pyrimidin-4-amine (34 mg, 0.085 mmol) and THF (4 mL). The reaction was flushed with argon, treated with 0.5 M potassium phosphate tribasic (490 µL, 0.245 mmol), followed by 2nd generation X-phos precatalyst (4 mg, 5.08 µmol), capped and stirred at room temp for 18 h. The solvent was removed under a gentle stream of air and the crude product was dissolved in dichloromethane (4 mL). The resulting solution was treated with QuadraSil AP, loading 1.5-2 mmol/gram (36 mg), stirred at room temp for 10 min, filtered through a 45µ frit and the solvent was removed under a gentle stream of air. The residue was dissolved in EtOH (4 mL), treated with 10 M sodium hydroxide (110 µL, 1.100 mmol) and heated at 105 °C for 3.5 h. The crude material was purified via preparative LC/MS to afford (S)-2-(5-(4-((benzofuro[3,2-d]pyrimidin-4-ylamino)methyl)phenyl)-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetic acid, 8.4 mg (19%). LCMS (M+1) = 628.2.


Example 202



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-(pyrrolidin-1-yl)pyridin-3-yl)acetic acid:

- 5 To a dry microwave vial under nitrogen was added ethyl-(S)-2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate (9.1 mg, 0.015 mmol), NMP (1.0 mL), pyrrolidine (20 μ L, 0.242 mmol) and N,N-diisopropylethylamine (40 μ L, 0.229 mmol). The reaction was capped and heated in a microwave reactor at 140 – 200 $^{\circ}$ C for 14h. The solvent was removed under a gentle
- 10 stream of nitrogen and the residue was redissolved in EtOH (3 mL). The resulting solution was treated with 10 M sodium hydroxide in water (85 μ L, 0.850 mmol) and heated at 105 $^{\circ}$ C for 18 h. The crude material was purified via preparative LC/MS to afford (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-(pyrrolidin-1-yl)pyridin-3-yl)acetic acid, 7.0 mg (72%).
- 15 LCMS (M+1) = 604.3.

Example 203




- (S)-2-(tert-Butoxy)-2-(2-chloro-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(((tetrahydro-2H-pyran-4-yl)methyl)amino)methyl)pyridin-3-yl)acetic acid:*
- 20

- To a dry vial under nitrogen was added ethyl-(S)-2-(tert-butoxy)-2-(2-chloro-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)acetate (30 mg, 0.054 mmol), 4-aminomethyltetrahydropyran (20.25 mg, 0.176 mmol),
- 25 $\text{ClCH}_2\text{CH}_2\text{Cl}$ (1.25 mL), acetic acid (11.5 μ L, 0.201 mmol) and several pieces of 4A mol sieves. The reaction was stirred at room temp for 10 min, treated with ethanol (0.625 mL)

and stirred at room temp for 3h. The reaction was then treated (slowly) with sodium cyanoborohydride, 1.0M in THF (217 μ L, 0.217 mmol). After the addition was complete, the reaction was stirred at room temp for 5 min, then the solvent was removed under a gentle stream of nitrogen. The residue was dissolved in EtOH (2.5 mL), treated with 10 M sodium hydroxide (115 μ L, 1.15 mmol) and heated at 105 $^{\circ}$ C for 2.5h. The crude material was purified via preparative LC/MS to afford (S)-2-(*tert*-butoxy)-2-(2-chloro-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(((tetrahydro-2H-pyran-4-yl)methyl)amino)methyl)pyridin-3-yl)acetic acid, 20 mg (58%). LCMS (M+1) = 624.2.

10

Example 204




(S)-2-(6-((7-Azaspiro[3.5]nonan-7-yl)methyl)-2-chloro-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetic acid:

To a dry vial under nitrogen was added ethyl-(S)-2-(*tert*-butoxy)-2-(2-chloro-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)acetate (30 mg, 0.054 mmol), 7-azaspiro[3.5]nonane (22 mg, 0.176 mmol), $\text{ClCH}_2\text{CH}_2\text{Cl}$ (1.25 mL), acetic acid (11.5 μ L, 0.201 mmol) and several pieces of 4A mol sieves. The reaction was stirred at room temp for 10 min, treated with ethanol (0.625 mL) and stirred at room temp for 70 min. The reaction was then treated (slowly) with sodium cyanoborohydride, 1.0M in THF (217 μ L, 0.217 mmol). After the addition was complete, the reaction was stirred at room temp for 5 min, then the solvent was removed under a gentle stream of nitrogen. The residue was dissolved in EtOH (2.5 mL), treated with 10 M sodium hydroxide (70 μ L, 0.70 mmol) and heated at 105 $^{\circ}$ C for 7h. The crude material was purified via preparative LC/MS to afford (S)-2-(6-((7-azaspiro[3.5]nonan-7-yl)methyl)-2-chloro-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetic acid, 8.2 mg (23%). LCMS (M+1) = 634.2.

Also isolated from this reaction was


Example 205



(*S*)-2-(*tert*-Butoxy)-2-(2-chloro-5-(3,5-difluoro-4-methoxyphenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-(hydroxymethyl)pyridin-3-yl)acetic acid, 2.5 mg (8%). LCMS

(*M*+1) = 527.1.


Example 206



(*S*)-2-(6-Amino-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)-2-(*tert*-butoxy)acetic acid:

To a reaction vial under nitrogen was added ethyl (*S*)-2-(6-amino-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)-2-(*tert*-butoxy)acetate (34.9 mg, 0.057 mmol) and ethanol (4 mL). The reaction was treated with 10 M sodium hydroxide (70 μ L, 0.700 mmol) and heated at 105 $^{\circ}$ C for 3.5h. The crude material was purified via preparative LC/MS to afford (*S*)-2-(6-amino-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)-2-(*tert*-butoxy)acetic acid, 15.3 mg (46%). LCMS (*M*+1) = 584.2.


Example 207



(S)-2-(6-((7-Azaspiro[3.5]nonan-7-yl)methyl)-2-chloro-5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(tert-butoxy)acetic acid:

- To a solution of ethyl-(S)-2-(tert-butoxy)-2-(2-chloro-5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-6-formylpyridin-3-yl)acetate (60.8 mg, 0.116 mmol) in a mixture of ClCH₂CH₂Cl (3.0 mL) and EtOH (2.0 mL) was added 7-azaspiro[3.5]nonane (55 mg, 0.439 mmol), acetic acid (28 μ L, 0.489 mmol), and several pieces of 4A mol sieves. The reaction was stirred at room temp, for 2 h, then treated (slowly) with sodium cyanoborohydride, 1.0M in THF (410 μ L, 0.410 mmol). After the addition was complete, the reaction was stirred at room temp for 5 min, then the solvent was removed under a gentle stream of nitrogen. The residue was dissolved in EtOH (4.5 mL), treated with 10 M sodium hydroxide (180 μ L, 1.80 mmol) and heated at 105 °C for 3.5 h. The crude material was purified via preparative LC/MS to afford (S)-2-(6-((7-azaspiro[3.5]nonan-7-yl)methyl)-2-chloro-5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(tert-butoxy)acetic acid, 9.7 mg, (12%). LCMS (M+1) = 604.3.
- Also isolated from this reaction is


Example 208



(S)-2-(tert-Butoxy)-2-(2-chloro-5-(3,4-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)acetic acid (1.7 mg, 3%). LCMS (M+1) = 467.2.

20

Example 209




(S)-2-(6-Amino-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)-2-(tert-butoxy)acetic acid:

- To a dry reaction vial under nitrogen was added ethyl-(S)-2-(6-amino-5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(tert-butoxy)acetate (34 mg, 0.071 mmol), 2-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-

dioxaborolane (50 mg, 0.139 mmol) and THF (4 mL). The reaction was flushed with argon, treated with 0.5 M potassium phosphate tribasic (0.6 mL, 0.300 mmol), followed by 2nd generation X-phos precatalyst (5.2 mg, 6.61 μ mol), capped and stirred at room temp for 18 h. The reaction was dissolved in EtOAc, extracted with water, brine, dried over Na₂SO₄ and concentrated. The crude material was purified via silica gel chromatography (12g SiO₂ column, dichloromethane:EtOAc 100:0 -> 65:35) to afford desired ester 35.2 mg (78%). This intermediate was dissolved in ethanol (4.5 mL), treated with 10 M sodium hydroxide (75 μ L, 0.750 mmol) and heated at 105 °C for 3.5h. The crude material was purified via preparative LC/MS to afford (S)-2-(6-amino-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)-2-(tert-butoxy)acetic acid, 29.8 mg (88%). LCMS (M+1) = 602.2.

Example 210




(S)-2-(6-((7-Azaspiro[3.5]nonan-7-yl)methyl)-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)-2-(tert-butoxy)acetic acid:

To a dry reaction vial under nitrogen was added ethyl-(S)-2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-formylpyridin-3-yl)acetate (67.8 mg, 0.105 mmol), ClCH₂CH₂Cl (2.0 mL), 7-azaspiro[3.5]nonane (51 mg, 0.407 mmol), acetic acid (24 μ L, 0.419 mmol) and 4A mol sieves. The reaction was stirred at room temp for 15 min, then treated with EtOH (1.0 mL). The reaction was stirred at room temp for 90 min, treated (slowly, over 2.5h) sodium cyanoborohydride, 1.0M in THF (420 μ L, 0.420 mmol). After the addition was complete, the reaction was allowed to stirred at room temp for 20 min, then the solvent was removed under a gentle stream of nitrogen overnight. The residue was dissolved in EtOH (4 mL), treated with 10 M sodium hydroxide (160 μ L, 1.600 mmol) and heated at 105 °C for 4.5h. The crude material was purified via preparative LC/MS to afford (S)-2-(6-((7-azaspiro[3.5]nonan-7-yl)methyl)-2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-

fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)-2-(*tert*-butoxy)acetic acid, 17.3 mg (23%). LCMS (M+1) = 724.3.

Example 211




(*S*)-2-(*tert*-Butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetic acid:

To a dry reaction vial under nitrogen was added ethyl-(*S*)-2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate (36.2 mg, 0.078 mmol), (4-(4-fluorophenethoxy)phenyl)boronic acid (25.3 mg, 0.097 mmol) and THF (4 mL).

The reaction was flushed with argon, treated with 0.5 M potassium phosphate tribasic (450 μ L, 0.225 mmol), followed by 2nd generation X-phos precatalyst (5 mg, 6.35 μ mol), capped and stirred at room temp for 18 h. The solvent was removed under a gentle stream of air and the crude product was dissolved in dichloromethane (4 mL) and the solvent removed under a gentle stream of air. The residue was dissolved in EtOH (2 mL), stirred at room temp for 1 h, treated with 10 M sodium hydroxide (115 μ L, 1.150 mmol) and heated at 105 $^{\circ}$ C for 35 min. The crude material was purified via preparative LC/MS to afford (*S*)-2-(*tert*-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetic acid, 34.1 mg (76%). LCMS (M+1) = 569.1.

Example 212




(*S*)-2-(*tert*-Butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)pyridin-3-yl)acetic acid:

To a dry reaction vial under nitrogen was added ethyl-(*S*)-2-(*tert*-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-formylpyridin-3-yl)acetate (40 mg, 0.064 mmol) and EtOH (2 mL). The reaction was treated with sodium borohydride (11 mg, 0.291 mmol), stirred at room temp for 5 min,

then then treated with 10 M sodium hydroxide (55 μ l, 0.550 mmol) and and heated at 105 °C for 20 min. The reaction was treated with additional 10 M sodium hydroxide (40 μ l, 0.400 mmol) and heated at 105 °C for 2h. The crude material was purified via preparative LC/MS to afford (S)-2-(*tert*-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)pyridin-3-yl)acetic acid, 20.5 mg (52%).
 LCMS (M+1) = 599.2.


Example 213



(S)-2-(*tert*-Butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-((methyl((tetrahydro-2H-pyran-4-yl)methyl)amino)methyl)pyridin-3-yl)acetic acid:

To a dry reaction vial under nitrogen was added N-methyl-1-(tetrahydro-2H-pyran-4-yl)methanamine (30 mg, 0.232 mmol), (S)-ethyl 2-(*tert*-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-formylpyridin-3-yl)acetate (40 mg, 0.064 mmol), $\text{ClCH}_2\text{CH}_2\text{Cl}$ (1.5 mL), acetic acid (14 μ l, 0.245 mmol) and 4 pieces of activated 4 A sieves. The reaction was flushed with argon, stirred at room temp for 1 min, treated with ethanol (0.5 mL) and stirred at room temp for 1h. The reaction was then treated (slowly) with sodium cyanoborohydride 1 M in THF (250 μ l, 0.250 mmol). After the addition was complete, the solvent was removed under a gentle stream of nitrogen. The residue was dissolved in ethanol (3 mL), treated with 10 M sodium hydroxide (80 μ l, 0.800 mmol) and heated at 60C for 18 h. The reaction was treated with additional 10 M sodium hydroxide (175 μ l, 1.75 mmol) and heated at 105 °C for 44h. The crude material was purified via preparative LC/MS to afford (S)-2-(*tert*-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-6-((methyl((tetrahydro-2H-pyran-4-yl)methyl)amino)methyl)pyridin-3-yl)acetic acid, 16.1 mg (34%). LCMS (M+1) = 710.3.


Example 214



(S)-2-(tert-Butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetic acid:

- 5 To a dry reaction vial under nitrogen was added (S)-ethyl 2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate (56 mg, 0.091 mmol), ethanol (4 mL) and sodium hydroxide 10 N (90 μ L, 0.900 mmol). The reaction was capped and heated at 105°C for 5h. The crude material was purified via preparative LC/MS to afford (S)-2-(tert-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetic acid, 26.8 mg (50%). LCMS (M+1) = 587.2.

Example 215




- 15 *(S)-2-(2-((7-Azaspiro[3.5]nonan-7-yl)methyl)-6-chloro-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-[3,3'-bipyridin]-5-yl)-2-(tert-butoxy)acetic acid:*

- To a dry reaction vial under nitrogen was added (S)-ethyl 2-(tert-butoxy)-2-(6-chloro-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-2-formyl-[3,3'-bipyridin]-5-yl)acetate and ethyl (S)-2-(tert-butoxy)-2-(6-chloro-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-[3,3'-bipyridin]-5-yl)acetate (14 mg, 0.028 mmol) $\text{ClCH}_2\text{CH}_2\text{Cl}$ (1.5 mL), 7-azaspiro[3.5]nonane (50 mg, 0.399 mmol), acetic acid (14 μ L, 0.245 mmol) and 2 pieces of 4 Å mol sieves. The reaction was stirred at room temp for 2 min, treated with ethanol (0.5 mL) and stirred at room temp for 20 min. The reaction was treated (slowly) with sodium cyanoborohydride 1 M in THF (330 μ L, 0.330 mmol). After the addition was complete, the solvent was removed under a gentle stream of nitrogen. The residue was

dissolved in ethanol 92 mL), treated 10 M sodium hydroxide (110 μ L, 1.100 mmol) and heated at 105 °C for 6 h. The reaction was then treated with additional 10 M sodium hydroxide (60 μ L, 0.600 mmol) and heated at 105 °C for 5h. The crude material was purified via preparative LC/MS to afford (S)-2-(2-((7-azaspiro[3.5]nonan-7-yl)methyl)-6-chloro-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-[3,3'-bipyridin]-5-yl)-2-(*tert*-butoxy)acetic acid, 0.6 mg (1.1%). LCMS (M+1) = 587.3.


Also isolated from this reaction is

Example 216



- 10 (S)-2-(*tert*-butoxy)-2-(6-chloro-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-[3,3'-bipyridin]-5-yl)acetic acid, 0.3 mg (0.7%). LCMS (M+1) = 450.1.


Example 217



- 15 (S)-2-(*tert*-Butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetic acid:

To a dry reaction vial under nitrogen was added (S)-ethyl 2-(*tert*-butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate (29.1 mg, 0.048 mmol), ethanol (2 mL) and lithium hydroxide 2 M (50.5 μ L, 0.101 mmol). The reaction was flushed with nitrogen and heated at 100 °C for 35 min. The crude material was purified via preparative LC/MS to afford (S)-2-(*tert*-butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetic acid, 16.2 mg (56%). LCMS (M+1) = 578.2.


Example 218



(S)-2-(5-(4-((Benzofuro[3,2-d]pyrimidin-4-ylamino)methyl)-3-fluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

- 5 In a pressure vial equipped with a magnetic stirring bar was added (*S*)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (66 mg, 0.145 mmol) and *N*-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-d]pyrimidin-4-amine (91 mg, 0.217 mmol). The solids were suspended in distilled THF (5 mL). The mixture was treated with 0.5M K₃PO₄ (1.014 mL, 0.507 mmol) and X-Phos precatalyst G2 (9.69 mg, 0.012 mmol). Argon was streamed over and bubbled into the mixture for 5 minutes with sonication. The vial was capped and stirred at RT for 16 hours. LC/MS showed the desired ester intermediate. Removed water layer and then removed solvent under vacuum. The solids were suspended in ethanol (2 mL) within a pressure. 10 M sodium hydroxide (0.130 mL, 1.299 mmol) was added to the mixture, and the vial capped and heated to 80 °C for 16 hours. LC/MS showed some of the hydrolysis product. The reaction mixture was cooled, then filtered and was purified via preparative LC/MS to give 9.1 mg (10%) of the desired compound. LCMS (M+1) = 626.3. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.57 (br t, *J*=6.1 Hz, 1H), 8.49 (s, 1H), 8.10 (d, *J*=7.7 Hz, 1H), 8.05 (s, 1H), 7.80 (d, *J*=8.4 Hz, 1H), 7.71 (t, *J*=7.5 Hz, 1H), 7.52 (td, *J*=7.6, 2.8 Hz, 2H), 7.18 (br d, *J*=10.6 Hz, 1H), 7.09 (d, *J*=8.1 Hz, 1H), 5.82 (s, 1H), 4.94 - 4.78 (m, 2H), 2.58 - 2.52 (m, 2H), 1.92 (s, 2H), 1.37 - 1.20 (m, 5H), 1.20 - 0.98 (m, 12H), 0.87 - 0.63 (m, 6H).

Example 219




25

(S)-2-(5-(4-((Benzofuro[3,2-*d*]pyrimidin-4-ylamino)methyl)-3,5-difluorophenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetic acid:

In a pressure vial equipped with a magnetic stirring bar was added (*S*)-isopropyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (50 mg, 0.110 mmol) and *N*-(2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-*d*]pyrimidin-4-amine (72.0 mg, 0.165 mmol). The solids were suspended in distilled THF (5 mL). The mixture was treated with 0.5M K₃PO₄ (0.769 mL, 0.384 mmol) and X-Phos precatalyst G2 (7.34 mg, 9.33 μmol). Argon was streamed over and bubbled into the mixture for 5 minutes with sonication. The vial was capped and stirred at RT for 48 hours. LC/MS showed the desired ester intermediate. Removed water layer and then removed solvent under vacuum. The remaining residue was taken up in Ethanol (2 mL). 10M sodium hydroxide (0.110 mL, 1.098 mmol) was added to the mixture, and the vial capped and heated to 80 °C for 16 hours. LC/MS showed the hydrolysis product. The reaction mixture was purified via preparative LC/MS to give 36.6 mg (51%) of the desired compound. LCMS (M+1) = 644.2. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.51 - 8.42 (m, 2H), 8.09 (d, *J*=7.6 Hz, 1H), 8.07 (s, 1H), 7.77 (d, *J*=8.1 Hz, 1H), 7.69 (t, *J*=7.7 Hz, 1H), 7.50 (t, *J*=7.2 Hz, 1H), 7.06 (d, *J*=8.8 Hz, 2H), 5.79 (s, 1H), 4.88 (d, *J*=5.5 Hz, 2H), 2.55 (s, 3H), 1.26 (br d, *J*=13.9 Hz, 4H), 1.12 (s, 12H), 0.76 (br s, 3H), 0.72 (br s, 5H).

Example 220




(S)-2-(5-(4-((Benzofuro[3,2-*d*]pyrimidin-4-yl(methyl)amino)methyl)phenyl)-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetic acid:

In a vial equipped with a magnetic stirring bar was added (*S*)-ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate (31 mg, 0.067 mmol) and *N*-methyl-*N*-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-*d*]pyrimidin-4-amine (34.8 mg, 0.084 mmol). The solids were suspended in THF (5 mL). The mixture was treated with 0.5M K₃PO₄ (0.537 mL, 0.269 mmol) and X-Phos precatalyst G2 (3.96 mg, 5.03 μmol). Argon was streamed over the

mixture for 5 minutes. The flask was capped and stirred at RT for 16 hours. LC/MS showed some desired product. After cooling to RT, removed solvent under a stream of air and took up residue in 3 mL of DCM and added 30 mg of Quadrasil AP to help remove active palladium remaining in the reaction mixture. After stirring 45 minutes under air, the mixture was filtered and concentrated down under a stream of air to give a residue. 10M sodium hydroxide (0.101 mL, 1.007 mmol) was added and the vial capped and heated to 80 °C for 16 hours. LC/MS showed that the hydrolysis was complete. The reaction mixture was cooled, then filtered and was purified via preparative LC/MS to give 4.1 mg (9%) of the desired compound. LCMS (M+1) = 642.3. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.55 (s, 1H), 8.11 (d, *J*=7.7 Hz, 1H), 7.97 (s, 1H), 7.78 - 7.72 (m, 1H), 7.69 (t, *J*=7.7 Hz, 1H), 7.50 (t, *J*=7.5 Hz, 1H), 7.45 (d, *J*=7.7 Hz, 2H), 7.32 (d, *J*=8.1 Hz, 2H), 5.49 (s, 1H), 5.31 - 5.08 (m, 2H), 2.55 (s, 2H), 1.91 (s, 6H), 1.14 (s, 13H), 0.66 (br s, 6H).

Example 221




(S)-2-(5-(4-((Benzofuro[3,2-d]pyrimidin-4-ylamino)methyl)-3-fluorophenyl)-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(tert-butoxy)acetic acid:

In a pressure vial equipped with a magnetic stirring bar was added (S)-ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate (60 mg, 0.130 mmol) and *N*-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)benzofuro[3,2-d]pyrimidin-4-amine (82 mg, 0.195 mmol). The solids were suspended in distilled THF (5 mL). The mixture was treated with 0.5M K₃PO₄ (0.909 mL, 0.455 mmol) and X-Phos precatalyst G2 (8.69 mg, 0.011 mmol). Argon was streamed over and bubbled into the mixture for 5 minutes with sonication. The vial was capped and stirred at RT for 16 hours. LC/MS showed the desired ester intermediate. Removed water layer and then removed solvent under vacuum. The solids were suspend in ethanol (8 mL) and transferred into a pressure vial. 10M sodium hydroxide (0.130 mL, 1.299 mmol) was added, and the vial capped and heated to 80 °C for 16 hours. LC/MS showed some of the hydrolysis product. The reaction mixture was cooled, then filtered and was purified via preparative LC/MS to give 5.6 mg (7%) of the desired compound. LCMS (M+1) = 646.2 .

¹H NMR (500 MHz, DMSO-*d*₆) δ 8.61 - 8.52 (m, 1H), 8.48 (s, 1H), 8.10 (d, *J*=7.7 Hz, 1H), 8.01 (s, 1H), 7.79 (d, *J*=8.4 Hz, 1H), 7.75 - 7.64 (m, 1H), 7.59 - 7.46 (m, 2H), 7.24 (br d, *J*=11.0 Hz, 1H), 7.12 (d, *J*=7.3 Hz, 1H), 5.55 (s, 1H), 4.93 - 4.84 (m, 2H), 2.55 (s, 2H), 1.34 - 1.11 (m, 16H), 0.78 - 0.64 (m, 6H).

5

Example 222




(S)-2-(*tert*-Butoxy)-2-(2-cyano-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetic acid:

- 10 In a microwave pressure vessel equipped with a magnetic stirring bar was added purified (*S*)-ethyl 2-(*tert*-butoxy)-2-(2-chloro-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)pyridin-3-yl)acetate (30 mg, 0.050 mmol), tetrakis(triphenylphosphine)palladium(0) (14.51 mg, 0.013 mmol) in degassed with argon, DMF (2 mL). Dicyanozinc (20.64 mg, 0.176 mmol) was then added and the vial
- 15 was purged with argon, capped and heated to 160 °C within a microwave reactor for 2 hours. LC/MS showed the desired M+1 product after 2h of heating at 160 °C within the microwave reactor as a minor product. The reaction mixture was purified by TFA buffer HPLC. Like fractions were dried down under a stream of nitrogen overnight. LC/MS showed a peak for the desired compound. The reaction mixture was purified via
- 20 preparative LC/MS to give 2.5 mg (9%) of the desired compound. LCMS (M+1) = 559.8. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.19 (s, 1H), 7.38 (t, *J*=6.7 Hz, 2H), 7.25 (d, *J*=8.4 Hz, 2H), 7.20 - 7.10 (m, 2H), 7.07 (d, *J*=8.8 Hz, 2H), 5.31 (s, 1H), 4.33 - 4.16 (m, 2H), 3.06 (t, *J*=6.8 Hz, 1H), 1.88 (s, 3H), 1.43 - 1.30 (m, 1H), 1.30 - 1.19 (m, 2H), 1.11 (s, 9H), 0.83 (s, 6H), 0.44 (s, 1H), 0.37 (s, 2H), 0.30 (s, 1H).

25


Example 223



(2*S*)-2-(*tert*-Butoxy)-2-[6'-chloro-4'-(4,4-dimethylpiperidin-1-yl)-[2,3'-bipyridine]-5'-yl]acetic acid:

General method D was followed on a 54 μ mol reaction scale using 6-methyl-2-(pyridin-2-yl)-1,3,6,2-dioxazaborocane-4,8-dione and (S)-ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2*S*)-2-(*tert*-butoxy)-2-[6'-chloro-4'-(4,4-dimethylpiperidin-1-yl)-[2,3'-bipyridine]-5'-yl]acetic acid (7.3 mg, 31%). LCMS (M+H) = 432.11. ¹H NMR (500 MHz, methanol-d₄) δ 8.66 (br d, J=4.6 Hz, 1H), 8.07 (s, 1H), 7.94 (td, J=7.7, 1.7 Hz, 1H), 7.54 (d, J=7.6 Hz, 1H), 7.47 (dd, J=7.6, 4.9 Hz, 1H), 5.74 (s, 1H), 3.00 - 2.69 (m, 4H), 1.30 - 1.28 (m, 4H), 1.23 (s, 9H), 0.83 (s, 6H).


Example 224



(*S*)-2-(*tert*-Butoxy)-2-(6'-chloro-4'-(4,4-dimethylpiperidin-1-yl)-5-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

General method D was followed on a 54 μ mol reaction scale using 6-methyl-2-(5-methylpyridin-2-yl)-1,3,6,2-dioxazaborocane-4,8-dione and (S)-ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (S)-2-(*tert*-butoxy)-2-(6'-chloro-4'-(4,4-dimethylpiperidin-1-yl)-5-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (1.2 mg, 4%). LCMS (M+H) = 446.1. ¹H NMR (500 MHz, methanol-d₄) δ 8.54 (s, 1H), 8.11 (s, 1H), 7.86 - 7.78 (m, 1H), 7.46 (d, J=7.6 Hz, 1H), 5.82 (s, 1H), 2.46 (s, 3H), 1.46 - 1.34 (m, 4H), 1.28 (s, 9H), 0.85 (s, 6H).


Example 225



(2*S*)-2-(*tert*-Butoxy)-2-[6'-chloro-4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(4-fluorophenyl)ethoxy]-[2,3'-bipyridine]-5'-yl]acetic acid:

General method D was followed on a 54 μ mol reaction scale using 2-(5-(4-fluorophenethoxy)pyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione and (S)-ethyl 2-(5-bromo-2-chloro-4-(4,4-dimethylpiperidin-1-yl)pyridin-3-yl)-2-(*tert*-butoxy)acetate as starting material. The crude material was purified via preparative LC/MS to afford (2*S*)-2-(*tert*-butoxy)-2-[6'-chloro-4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(4-fluorophenyl)ethoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (0.9 mg, 2%). LCMS (M+H) = 570.3. ¹H NMR (500 MHz, methanol-d₄) δ 8.35 (d, J=2.7 Hz, 1H), 8.10 (s, 1H), 7.53 - 7.49 (m, 1H), 7.47 - 7.43 (m, 1H), 7.37 - 7.32 (m, 2H), 7.04 (t, J=8.9 Hz, 2H), 5.81 (s, 1H), 4.36 (td, J=6.6, 1.8 Hz, 2H), 3.14 (t, J=6.6 Hz, 2H), 2.79 (br s, 4H), 1.37 - 1.32 (m, 4H), 1.27 (s, 9H), 0.85 (s, 6H).

Example 226



(*S*)-2-(4-(4,4-Dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(*tert*-pentyloxy)acetic acid:


To a 14 mL test tube equipped with a stir was added tribasic potassium phosphate (407 mg, 1.917 mmol), 2-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (92 mg, 0.256 mmol), isopropyl (*S*)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(*tert*-pentyloxy)acetate (100 mg, 0.213 mmol), and SPhos-Pd-G3 (8.30 mg, 10.65 μ mol). The test tube was sealed with a rubber septum and then placed under N₂ atm (vac/fill x 3). To the flask was added dioxane (1.5 mL) + water (0.5 mL) (degassed for 5 minutes via N₂ bubbling). The test tube was placed in a 60 °C heating block with stirring for 18 h. The reaction solution was diluted with Et₂O (5 mL), then washed with water (5 mL). The organic phase was dried over MgSO₄; filtered into a 7 mL vial; then concentrated under a N₂ stream. To the vial was added a stir bar and Ethanol (4 mL), then sodium hydroxide (0.4 mL, 2.000 mmol). The vial was capped, then placed in a 80 °C hot plate with stirring for t=20h. The reaction solution was filtered; and the filtrate was purified via HPLC purification on the InterChim system. The

first pass was in water:MeCN w/ 0.1% TFA modified. The second pass was in water:MeCN w 10 mM NH₄OAc. Fractions were selected based on mass purity, and purity as measured by LCMS. The combined samples were concentrated in vacuo and the aqueous solution was frozen with dry ice, then lyophilized. The experiment afforded the

5 desired product (S)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetic acid (36.0 mg, 0.061 mmol, 28 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.05 (s, 1H), 7.35 (dd, J=8.5, 5.5 Hz, 2H), 7.19 (t, J=8.5 Hz, 1H), 7.11 (dd, J=11.7, 2.0 Hz, 1H), 7.07 - 6.99 (m, 3H), 5.85 (s, 1H), 4.34 (t, J=6.7 Hz, 2H), 3.13 (t, J=6.6 Hz, 2H), 3.10 - 3.00 (m, 2H), 2.82

10 - 2.69 (m, 2H), 2.65 (s, 3H), 1.64 - 1.47 (m, 2H), 1.46 - 1.37 (m, 4H), 1.19 (s, 3H), 1.13 (s, 3H), 0.89 (s, 6H), 0.79 (t, J=7.5 Hz, 3H). ESI-MS(+) *m/z* = 581.3 (M+1).

Example 227



15 (S)-2-(5-(2,3-Difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetic acid:

To a 14 mL test tube equipped with a stir was added tribasic potassium phosphate (407 mg, 1.917 mmol), 2-(2,3-difluoro-4-(4-fluorophenethoxy)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (104 mg, 0.256 mmol), isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetate (100 mg, 0.213


20 mmol), and SPhos-Pd-G3 (8.30 mg, 10.65 μmol). The test tube was sealed with a rubber septum and then placed under N₂ atm (vac/fill x 3). To the flask was added dioxane (1.5 mL) + water (0.5 mL) (degassed for 5 minutes via N₂ bubbling). The test tube was placed in a 60 °C heating block with stirring for t=18 hrs. The reaction solution was diluted with

25 Et₂O (5 mL), then washed with water (5 mL). The organic phase was dried over MgSO₄; filtered into a 7 mL vial; then concentrated under a N₂ stream. To the vial was added a stir bar and Ethanol (4 mL), then aq. 5 N sodium hydroxide (0.15 mL, 0.750 mmol). The vial was capped, then placed in a 80 °C heating block with stirring. LCMS analysis at 20 h found a major peak corresponding to the desired product. The reaction solution filtered;

30 the filtrate was subjected to HPLC purification on the InterChim system with ESI

detection. The eluent was water:MeCN with 0.1% TFA as modifier. The product fractions were identified by mass, then concentrated overnight in the Genevac. The resulting residue was dissolved in MeOH and then subjected to a second round of HPLC purification on the InterChim system. The eluent was water:MeCN w/ 10 mM NH₄OAc as modifier. The product fractions were selected based on LCMS analysis. The combined sample was frozen, then lyophilized to afford a low density white solid. (S)-2-(5-(2,3-difluoro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetic acid (12.3 mg, 0.021 mmol, 9.64 % yield). ESI-MS(+) *m/z* (TFA buffer) = 599.2 (M+1) retention time = 1.33 min. ESI-MS(+) *m/z* (AA buffer) = 599.3 (M+1) retention time = 2.31 min.


Example 228



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-methoxypyrimidin-2-yl)-2-methylpyridin-3-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-methoxypyrimidin-2-yl)-2-methylpyridin-3-yl)acetate (26 mg, 0.054 mmol) in EtOH (1 mL) and Water (0.100 mL) was added lithium hydroxide monohydrate (22.51 mg, 0.536 mmol) and heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-methoxypyrimidin-2-yl)-2-methylpyridin-3-yl)acetic acid (12.8 mg, 0.029 mmol, 53.9 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.65 (s, 2H), 8.32 (s, 1H), 5.98 (s, 1H), 4.04 (s, 3H), 3.04 - 2.79 (m, 4H), 2.65 (s, 3H), 1.45 (br s, 4H), 1.22 (s, 9H), 0.93 (s, 6H). ESI-MS(+) *m/z* = 443.2 (M+1).


Example 229



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

- 5 To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (22 mg, 0.045 mmol) in EtOH (1 mL) and water (0.100 mL) was added lithium hydroxide monohydrate (19.09 mg, 0.455 mmol) and heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the
- 10 desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (13.4 mg, 0.030 mmol, 66.7 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.37 (d, J=2.9 Hz, 1H), 8.14 (s, 1H), 7.54 (dd, J=8.6, 2.8 Hz, 1H), 7.45 (d, J=8.8 Hz, 1H), 5.91 (s, 1H), 3.96 (s, 3H), 3.06 - 2.75 (m, 4H), 2.65 (s, 3H), 1.47 - 1.37
- 15 (m, 4H), 1.21 (s, 9H), 0.89 (s, 6H). ESI-MS(+) m/z = 442.3 (M+1).

Example 230




- (S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetic acid:*
- 20

- To a 20 mL pressure vial under N₂ was added isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetate (62.7 mg, 0.098 mmol), ethanol (4.5 mL) and 10 M sodium hydroxide (140 μ L, 1.400 mmol). The reaction was flushed briefly with
- 25 N₂, capped and heated at 105 °C for 7.5 h, followed by room temp for 18 h. The reaction was treated with MeOH (100 μ L) and additional 10 M NaOH (15 μ L, 150 mmol) and heated at 105 °C for 8 h. The crude material was purified via preparative LCMS to afford

(S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(hydroxymethyl)-2-methylpyridin-3-yl)acetic acid, 37.3 mg (64 %). LCMS = 597.3 (M+H).

5

Example 231




(S)-2-(6-((7-Azaspiro[3.5]nonan-7-yl)methyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid:

To a dry reaction vial under nitrogen was added isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-formyl-2-methylpyridin-3-yl)acetate (50 mg, 0.079 mmol), 7-azaspiro[3.5]nonane (37.2 mg, 0.297 mmol), $\text{ClCH}_2\text{CH}_2\text{Cl}$ (2.0 mL), acetic acid (18 μL , 0.314 mmol) and several pieces of 4 $\text{\AA}$ molecular sieves. The reaction was stirred at room temp for 10 min, then treated with EtOH (1.0 mL) (previously dried over 4 $\text{\AA}$ molecular sieves). The reaction was stirred at room temp for 25 min, then treated (very slowly, dropwise, over several hours) with sodium cyanoborohydride, 1.0 M in THF (300 μL , 0.300 mmol). After the addition was complete, the solvent was evaporated under a gentle stream of N_2 . The resulting residue was redissolved in a mixture of ethanol (4 mL) and methanol (400 μL), treated with 10 M sodium hydroxide (115 μL , 1.150 mmol) and heated at 105 $^\circ\text{C}$ for 20 h. The crude material was purified via preparative LCMS to afford (S)-2-(6-((7-azaspiro[3.5]nonan-7-yl)methyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid, 31.6 mg (56%). LCMS = 704.3 (M+H).

25


Example 232



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6,6'-dimethyl-[2,3'-bipyridin]-5'-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6,6'-dimethyl-[2,3'-bipyridin]-5'-yl)acetate (20 mg, 0.033 mmol) in EtOH (1 mL) and Water (0.100 mL) was added lithium hydroxide monohydrate (13.85 mg, 0.330 mmol) and heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LCMS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6,6'-dimethyl-[2,3'-bipyridin]-5'-yl)acetic acid (6.9 mg, 0.012 mmol, 36.7 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.12 (s, 1H), 7.43 (d, J=8.4 Hz, 1H), 7.38 - 7.31 (m, 2H), 7.27 (d, J=8.4 Hz, 1H), 7.04 (t, J=8.8 Hz, 2H), 5.90 (s, 1H), 4.33 (t, J=6.4 Hz, 2H), 3.16 (t, J=6.4 Hz, 2H), 3.02 - 2.72 (m, 4H), 2.64 (s, 3H), 2.43 (s, 3H), 1.46 - 1.37 (m, 4H), 1.21 (s, 9H), 0.88 (s, 6H). ESI-MS(+) *m/z* = 564.2 (M+1).


15



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-3-fluoro-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

To a solution of (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-3-fluoro-5-(4-fluorophenoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (24 mg, 0.039 mmol) in EtOH (1 mL) and water (0.100 mL) was added lithium hydroxide monohydrate (16.52 mg, 0.394 mmol) and heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-3-fluoro-5-(4-fluorophenoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (10.9 mg, 0.019 mmol, 48.3 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.22 (d, J=2.2 Hz, 1H), 8.02 (s, 1H), 7.39 - 7.32 (m, 3H), 7.04 (t, J=8.8 Hz, 2H), 5.80 (s, 1H), 4.40 - 4.30 (m, 2H), 3.14 (t, J=6.4 Hz, 2H), 3.04 - 2.72 (m, 4H), 2.64 (s, 3H), 1.40 (br s, 4H), 1.19 (s, 9H), 0.87 (s, 6H). ESI-MS(+) *m/z* = 568.9 (M+1).


Example 234



5 *(S)*-2-(*tert*-Butoxy)-2-(6'-(2,4-dichlorophenethoxy)-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of 2-(2,4-dichlorophenyl)ethan-1-ol (0.045 g, 0.235 mmol, 5 equiv), 60% NaH (9.39 mg, 0.235 mmol, 5 equiv), and isopropyl (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.023 g, 0.047 mmol, 1 equiv) in THF (1.5 mL) was stirred for 1 h. Upon complete addition, 5
10 NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the mixture was heated at 80 °C for 2 h. After cooling to ambient temperature, the mixture was filtered and purified by reverse phase preparative HPLC to give the product (12.4 mg, 42%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.10 - 8.06 (m, 1H), 7.92 (d, *J* = 1.8 Hz, 1H), 7.73 - 7.67 (m, 1H), 7.57 (d, *J* = 2.2 Hz, 1H), 7.47 (d, *J* = 8.4 Hz, 1H), 7.39 (dd, *J* = 8.1, 2.2 Hz, 1H), 5.81 (s, 1H), 4.73 -
15 4.65 (m, 2H), 2.52 (s, 2H), 1.36 - 1.28 (m, 3H), 1.14 (s, 10H), 0.88 - 0.78 (m, 6H). [note: some piperidine protons not seen]. LCMS (*M*+1): 618.2.

Example 235




20 *(S)*-2-(*tert*-Butoxy)-2-(5-(3-chloro-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid:

A solution of isopropyl (*S*)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (0.10 g, 0.220 mmol, 1 equiv), 2-(3-chloro-4-(4-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.124 g, 0.329
25 mmol, 1.5 equiv), Pd(dppf)Cl₂ (16 mg, 0.022 mmol, 0.1 equiv), and 2 M K₃PO₄ (0.66 mL, 1.32 mmol, 6 equiv) in dioxane (2.2 mL) was heated at 80 °C for 2 h. After cooling to ambient temperature, the reaction mixture was diluted with ethyl acetate and washed with brine. The organic layer was dried (Na₂SO₄) and concentrated in vacuo. The residue was

taken up in ethanol (2 mL) and 10 M NaOH (0.2 mL) was added. The mixture was heated at 80 °C for 4 h. After cooling to ambient temperature, the mixture was filtered and purified by reverse phase preparative HPLC to provide the product (40 mg, 32%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.05 (s, 1H), 7.41 (dd, *J* = 8.4, 5.5 Hz, 2H), 7.36 (d, *J* = 1.8 Hz, 1H), 7.27 - 7.21 (m, 2H), 7.16 - 7.10 (m, 2H), 5.83 (s, 1H), 4.37 - 4.29 (m, 2H), 3.10 (t, *J* = 6.4 Hz, 2H), 2.50 (s, 3H), 1.65 - 1.38 (m, 1H), 1.32 (br d, *J* = 2.2 Hz, 3H), 1.14 (s, 9H), 0.83 (br s, 6H) [note: some piperidine protons not visible]. LCMS (M+1): 583.2.

10

Example 236




(2*S*)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(1-hydroxyethyl)-2-methylpyridin-3-yl)acetic acid:

To a dry reaction vial under N₂ was added isopropyl (2*S*)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(1-hydroxyethyl)-2-methylpyridin-3-yl)acetate (15.3 mg, 0.023 mmol, diastereomer 1), EtOH (3 mL), methanol (500 μL) and 10 M sodium hydroxide (35 μL, 0.350 mmol). The reaction is flushed briefly with N₂, capped and heated at 105 °C for 6 h. The reaction was treated with additional sodium hydroxide, 10M in water (10 mlit, 0.100 mmol) and heated at 105 °C for 18 h. The crude material was purified via preparative LCMS to afford (2*S*)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(1-hydroxyethyl)-2-methylpyridin-3-yl)acetic acid (**diastereomer 1**), 13.4 mg (82%). LCMS = 611.3 (M+H).


25

Example 237




(2*S*)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(1-hydroxyethyl)-2-methylpyridin-3-yl)acetic acid:

To a dry reaction vial under N₂ was added isopropyl (2*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(1-hydroxyethyl)-2-methylpyridin-3-yl)acetate (9.7 mg, 0.015 mmol, diastereomer 2), EtOH (3 mL), methanol (500 μ L) and 10 M sodium hydroxide (23 μ L, 0.230 mmol). The reaction is flushed briefly with N₂, capped and heated at 105 °C for 6 h. The reaction was treated with additional 10 M sodium hydroxide (23 μ lit, 0.230 mmol) and heated at 105 °C for 18 h. The crude material was purified via preparative LCMS to afford (2*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(1-hydroxyethyl)-2-methylpyridin-3-yl)acetic acid (**diastereomer 2**), 13.4 mg (82%). LCMS = 611.3 (M+H).




(*S*)-2-(*tert*-Butoxy)-2-(6'-(2-chlorophenethoxy)-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid.

A mixture of 2-(2-chlorophenyl)ethan-1-ol (0.037 g, 0.235 mmol, 5 equiv), 60% NaH (9.39 mg, 0.235 mmol, 5 equiv) and isopropyl (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.023 g, 0.047 mmol, 1 equiv) in THF (1.5 mL) was stirred for 1 h. Upon completion, 5 N NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the mixture was heated at 80 °C for 2 h. After cooling to ambient temperature, the mixture was filtered and purified by reverse phase preparative HPLC to deliver the product (11.1 mg, 40%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.12 - 8.03 (m, 1H), 7.98 - 7.89 (m, 1H), 7.73 - 7.64 (m, 1H), 7.49 - 7.38 (m, 2H), 7.34 - 7.23 (m, 2H), 5.77 (br d, *J* = 2.6 Hz, 1H), 4.76 - 4.64 (m, 2H), 2.52 (s, 2H), 1.38 - 1.27 (m, 3H), 1.21 - 1.05 (m, 10H), 0.96 - 0.75 (m, 6H) [note: some piperidine protons not seen]. LCMS (M+1): 584.2.



(S)-2-(tert-Butoxy)-2-(6'-(2-chloro-6-fluorophenethoxy)-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

- 5 A mixture of 2-(2-chloro-6-fluorophenyl)ethan-1-ol (0.041 g, 0.235 mmol, 5 equiv), 60% NaH (9.39 mg, 0.235 mmol, 5 equiv) and isopropyl *(S)*-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.023 g, 0.047 mmol, 1 equiv) in THF (1.5 mL) was stirred for 1 h. After complete addition, 5 N NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the mixture was heated at 80 °C
- 10 for 2 h. Upon cooling to ambient temperature, the mixture was filtered and purified by reverse phase preparative HPLC to provide the product (15 mg, 53%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.09 - 8.01 (m, 1H), 7.95 - 7.88 (m, 1H), 7.68 (dd, *J* = 11.0, 1.8 Hz, 1H), 7.38 - 7.28 (m, 2H), 7.25 - 7.17 (m, 1H), 5.79 (s, 1H), 4.77 - 4.64 (m, 2H), 1.41 - 1.28 (m, 3H), 1.14 (s, 10H), 0.91 - 0.76 (m, 6H) [note: some piperidine protons not seen].
- 15 LCMS (M+1): 602.2.




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-phenethoxy-[3,3'-bipyridin]-5-yl)acetic acid:

- 20 A mixture of 2-phenylethan-1-ol (0.029 g, 0.235 mmol, 5 equiv), 60% NaH (9.39 mg, 0.235 mmol, 5 equiv), and isopropyl *(S)*-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.023 g, 0.047 mmol, 1 equiv) in THF (1.5 mL) was stirred at ambient temperature for 1 h. Upon complete addition, 5 N NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the mixture was heated at 80 °C
- 25 for 2 h. After cooling to ambient temperature, the mixture was filtered and then purified by reverse phase preparative HPLC to give the product (18 mg, 71%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.14 - 8.06 (m, 1H), 7.98 - 7.89 (m, 1H), 7.70 (dd, *J* = 11.2, 1.7 Hz,

1H), 7.35 - 7.16 (m, 5H), 5.82 (s, 1H), 4.72 - 4.58 (m, 2H), 3.14 - 3.06 (m, 1H), 2.52 (s, 2H), 1.39 - 1.27 (m, 3H), 1.19 - 1.09 (m, 10H), 0.94 - 0.78 (m, 6H) [note: some piperidine protons not observed]. LCMS (M+1): 550.3.

5

Example 241




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)-3-(trifluoromethyl)phenyl)-2-methylpyridin-3-yl)acetic acid:

A mixture of isopropyl isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.04 g, 0.088 mmol, 1 equiv), 2-(4-(4-fluorophenethoxy)-3-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.054 g, 0.132 mmol, 1.5 equiv), SPhos (7.21 mg, 0.018 mmol, 0.2 equiv), palladium(II) acetate (1.972 mg, 8.78 μ mol, 0.1 equiv), and 2 M K₃PO₄ (0.132 ml, 0.263 mmol, 3 equiv) in dioxane was heated at 90 °C for 4 h. The reaction mixture was filtered through celite/Na₂SO₄ eluting with ethyl acetate and concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.176 ml, 0.878 mmol, 10 equiv) was added. The mixture was heated at 90 °C for 4 h. After cooling to ambient temperature, the mixture was filtered and purified by reverse phase preparative HPLC to give the product (8 mg, 14%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.09 - 8.03 (m, 1H), 7.57 (br d, *J* = 8.8 Hz, 1H), 7.47 (d, *J* = 1.8 Hz, 1H), 7.42 - 7.33 (m, 3H), 7.16 - 7.07 (m, 2H), 5.80 (s, 1H), 4.45 - 4.33 (m, 2H), 3.09 (t, *J* = 6.4 Hz, 1H), 1.35 - 1.26 (m, 3H), 1.19 - 1.09 (m, 10H), 0.92 - 0.73 (m, 6H) [note: piperidine protons not all observed]. LCMS (M+1): 617.3.

25

Example 242




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(2-hydroxypropan-2-yl)-2-methylpyridin-3-yl)acetic acid (Locked Atrop Isomer 1):

To a dry reaction vial under N₂ was added isopropyl (S)-2-(6-acetyl-4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (16.5 mg, 0.025 mmol) and THF (700 µL). The reaction was flushed very well with argon, then cooled to 0 °C in ice/water bath. The reaction was then treated with 3 M methylmagnesium chloride in THF (13 µL, 0.039 mmol) over 30 sec. The reaction was allowed to stir at 0 °C while slowly warming to room temp over 40 min.

The reaction was quenched by the addition of ethanol (1.0 mL) and the solvent was removed under a gentle stream of N₂. The residue was redissolved in ethanol (4 mL), treated with 10 M sodium hydroxide (45 µL, 0.450 mmol) and heated at 105 °C for 6 h. The reaction was treated with methanol (500 µlit), additional 10 M sodium hydroxide (25 µlit, 0.250 mmol) and heated at 105 °C for 10.5 h. The crude material was purified via preparative LCMS to afford (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(2-hydroxypropan-2-yl)-2-methylpyridin-3-yl)acetic acid (Atropisomer 1), 3.9 mg (9 %). LCMS = 625.3 (M+H).


Also isolated from this reaction was Atropisomer 2

Example 243



(S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(4-fluorophenethoxy)phenyl)-6-(2-hydroxypropan-2-yl)-2-methylpyridin-3-yl)acetic acid, 6.1 mg (24%). LCMS = 625.3 (M+H).


Example 244



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-4-(trifluoromethyl)-[2,3'-bipyridin]-5'-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-4-(trifluoromethyl)-[2,3'-bipyridin]-5'-yl)acetate (36 mg, 0.055 mmol) in EtOH (1.5 mL) was added sodium hydroxide (0.109 mL, 0.546 mmol) and heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-4-(trifluoromethyl)-[2,3'-bipyridin]-5'-yl)acetic acid (24.4 mg, 0.040 mmol, 72.4 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.62 (s, 1H), 8.08 (s, 1H), 7.63 (s, 1H), 7.36 (dd, *J*=8.4, 5.5 Hz, 2H), 7.03 (t, *J*=8.8 Hz, 2H), 5.66 (s, 1H), 3.18 (t, *J*=6.2 Hz, 2H), 2.65 (s, 3H), 1.48 - 1.20 (m, 4H), 1.16 (s, 9H), 0.87 (br s, 6H). 4 Protons (4 protons from methylenes closest to piperidine nitrogen) and 2 protons (benzylic protons) were not observed in HNMR. ESI-MS(+) *m/z* = 618.2 (M+1).

Example 245




(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)-4-methylpyrimidin-2-yl)-2-methylpyridin-3-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)-4-methylpyrimidin-2-yl)-2-methylpyridin-3-yl)acetate (26 mg, 0.043 mmol) in EtOH (1 mL) was added 1M sodium hydroxide (0.086 mL, 0.428 mmol) then heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LCMS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)-4-methylpyrimidin-2-yl)-2-methylpyridin-3-yl)acetic acid (19.4 mg, 0.034 mmol, 80 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.44 (s, 1H), 8.23 (s, 1H), 7.40 - 7.31 (m, 2H), 7.05 (t, *J*=8.8 Hz, 2H), 5.85 (s, 1H), 4.44 (td, *J*=6.4, 1.5 Hz, 2H), 3.18 (t, *J*=6.2 Hz,

2H), 3.02 - 2.79 (m, 2H), 2.64 (s, 3H), 2.46 (s, 3H), 1.43 (br s, 4H), 1.18 (s, 9H), 0.91 (s, 6H). ESI-MS(+) m/z = 565.3 (M+1).

Example 246




(S)-2-(4'-(4,4-Dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetic acid:

To a 14 mL test tube equipped with a stir bar was added 2-(5-(4-fluorophenethoxy)pyridin-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (59.5 mg, 0.160 mmol), isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetate (50 mg, 0.107 mmol), palladium tetrakis (24.62 mg, 0.021 mmol), diacetoxycopper (9.67 mg, 0.053 mmol) and anhydrous tribasic potassium phosphate (finely ground, 113 mg, 0.533 mmol). The test tube was sealed with a rubber septum, then placed under N₂ atm. To the test tube was added a degassed (N₂ sparging for 5 min) solution of diethanolamine (11.2 mg, 0.107 mmol) in DMF (1.0 mL). The test tube was placed in a 100 °C heating block with stirring for 18h. To the test tube was added water (4 mL). The mixture was extracted with EtOAc (2 x 5 mL). The organic phase was dried over MgSO₄; filtered; then concentrated in vacuo. The resulting residue was dissolved in a min of acetone, then concentrated onto Celite in vacuo. The resulting powder was subjected to SiO₂ purification (hexanes:EtOAc) to afford the desired intermediate, isopropyl (S)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetate. This material was transferred to a 1 dram vial. To the vial was added a stir bar and ethanol (2 mL), then aq. sodium hydroxide (5.0 M, 0.213 mL, 1.065 mmol). The vial was capped, then placed in a 90 °C heating block with stirring for 3.5h. The reaction mixture was cooled to r.t., then filtered through a 0.4 micron syringe filter. The filtrate was directly subjected to HPLC purification with the following conditions: Column: XBridge C18, 19 x 200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 35-75% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. This

purification afforded the desired compound, (S)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetic acid (15.6 mg, 27% yield, 563.71% purity). LCMS Method 2: retention time = 2.04 min.; observed ion = 564.4. ¹H NMR (500 MHz, METHANOL-d₄) Shift 8.34 (d, J=2.7 Hz, 1H), 8.14 (s, 1H), 7.51 (dd, J=8.5, 3.1 Hz, 1H), 7.42 (d, J=8.5 Hz, 1H), 7.35 (dd, J=8.4, 5.3 Hz, 2H), 7.04 (t, J=8.3 Hz, 2H), 5.92 (s, 1H), 4.36 (t, J=6.6 Hz, 2H), 3.14 (t, J=6.6 Hz, 2H), 2.93 (br s, 2H), 2.81 (br s, 2H), 2.65 (s, 3H), 1.63 - 1.47 (m, 2H), 1.45 - 1.39 (m, 4H), 1.20 (s, 3H), 1.13 (s, 3H), 0.89 (s, 6H), 0.79 (t, J=7.5 Hz, 3H).

10


Example 247



(S)-2-(4-(4,4-Dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetic acid:

To a solution of isopropyl (S)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetate (21 mg, 0.035 mmol) in EtOH (1.5 mL) and Water (0.150 mL) was added lithium hydroxide monohydrate (14.52 mg, 0.346 mmol) and heated at 75°C for 24 hrs. After 24 hrs, sodium hydroxide (0.069 mL, 0.346 mmol) was added and stirred for 3 more hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrimidin-2-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetic acid (12.4 mg, 0.022 mmol, 63.4 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.61 (s, 2H), 8.38 - 8.22 (m, 1H), 7.36 (dd, J=8.4, 5.5 Hz, 2H), 7.09 - 6.98 (m, 2H), 6.03 - 5.88 (m, 1H), 4.59 - 4.36 (m, 2H), 3.16 (t, J=6.4 Hz, 2H), 3.02 - 2.74 (m, 4H), 2.65 (s, 3H), 1.63 - 1.49 (m, 2H), 1.44 (br s, 4H), 1.20 (s, 3H), 1.14 (s, 3H), 0.92 (s, 6H), 0.78 (t, J=7.5 Hz, 3H). ESI-MS(+) *m/z* = 565.3 (M+1).


Example 248



(S)-2-(*tert*-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-4,6'-dimethyl-[2,3'-bipyridin]-5'-yl)acetic acid:

- 5 To a solution of isopropyl (*S*)-2-(*tert*-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-4,6'-dimethyl-[2,3'-bipyridin]-5'-yl)acetate (12 mg, 0.020 mmol) in EtOH (1 mL) and added sodium hydroxide (0.040 mL, 0.198 mmol) then heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were
- 10 combined and dried via centrifugal evaporation to afford the product (*S*)-2-(*tert*-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-4,6'-dimethyl-[2,3'-bipyridin]-5'-yl)acetic acid (8.5 mg, 0.015 mmol, 76 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.23 (s, 1H), 8.07 (s, 1H), 7.35 (dd, J=8.4, 5.5 Hz, 2H), 7.28 (s, 1H), 7.07 - 6.99 (m, 2H), 5.83 - 5.74 (m, 1H), 4.45 - 4.31 (m, 2H), 3.16 (t, J=6.4 Hz, 2H), 3.10 - 2.65 (m, 4H), 2.64
- 15 (s, 3H), 2.26 (s, 3H), 1.40 (br s, 4H), 1.18 (s, 9H), 0.87 (s, 6H). ESI-MS(+) m/z = 564.4 (M+1).

Example 249




- 20 (*S*)-2-(*tert*-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

- To a solution of isopropyl (*S*)-2-(*tert*-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (77 mg, 0.124 mmol) in EtOH (1 mL) was added sodium hydroxide (0.248 mL, 1.238 mmol) then
- 25 heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation. Purification afforded the product

(S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (15.8 mg, 0.027 mmol, 21.79 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.12 (s, 1H), 7.39 - 7.30 (m, 3H), 7.02 (t, J=8.8 Hz, 2H), 6.96 (d, J=8.1 Hz, 1H), 5.88 (s, 1H), 4.30 (t, J=6.6 Hz, 2H), 4.00 (s, 3H),
 5 3.12 (t, J=6.6 Hz, 2H), 3.09 - 2.76 (m, 4H), 2.68 - 2.61 (m, 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.91 (s, 6H). ESI-MS(+) *m/z* = 580.4 (M+1).


Example 250



10 (S)-2-(tert-Butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-(4-fluorophenethoxy)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of 2-(4-fluorophenyl)ethan-1-ol (0.032 g, 0.227 mmol, 5 equiv), 60% NaH (9.09 mg, 0.227 mmol, 5 equiv), and isopropyl (S)-2-(tert-butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.023 g,
 15 0.045 mmol, 1 equiv) in THF (1.5 mL) was stirred for 1 h. After complete addition, 5 M NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the mixture was heated at 80 °C for 2 h. Upon cooling to ambient temperature, the reaction was filtered and purified by reverse phase preparative HPLC to afford the product (9.5 mg, 36%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.12 - 8.03 (m, 2H), 7.87 (d, *J* = 2.2 Hz, 1H), 7.41 - 7.31 (m, 2H),
 20 7.15 - 7.06 (m, 2H), 5.75 (s, 1H), 4.62 (t, *J* = 6.8 Hz, 2H), 3.09 (t, *J* = 6.6 Hz, 2H), 1.37 - 1.25 (m, 3H), 1.14 (s, 10H), 0.94 - 0.75 (m, 6H) [note: some piperidine protons not seen]. LCMS (M+1): 584.1.

Example 251




25

(S)-2-(*tert*-Butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-(3-fluorophenethoxy))-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of 2-(3-fluorophenyl)ethan-1-ol (0.032 g, 0.227 mmol, 5 equiv), 60% NaH (9.09 mg, 0.227 mmol, 5 equiv), and isopropyl (*S*)-2-(*tert*-butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.023 g, 0.045 mmol, 1 equiv) in THF (1.5 mL) was stirred for 1 h. After complete addition, 5 M NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the mixture was heated at 80 °C for 2 h. Upon cooling to ambient temperature, the reaction was filtered and purified by reverse phase preparative HPLC to give the product (17.2 mg, 64%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.15 - 7.99 (m, 2H), 7.87 (d, *J* = 2.2 Hz, 1H), 7.41 - 6.92 (m, 4H), 5.74 (s, 1H), 4.65 (t, *J* = 6.6 Hz, 2H), 2.52 (br s, 2H), 1.32 (br s, 3H), 1.13 (s, 9H), 1.00 - 0.74 (m, 6H), 0.80 - 0.72 (m, 1H). LCMS (M+1): 584.2.


Example 252



(S)-2-(*tert*-Butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-(2-fluorophenethoxy))-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of 2-(2-fluorophenyl)ethan-1-ol (0.032 g, 0.227 mmol, 5 equiv), 60% NaH (9.09 mg, 0.227 mmol, 5 equiv), and isopropyl (*S*)-2-(*tert*-butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.023 g, 0.045 mmol, 1 equiv) in THF (1.5 mL) was stirred for 1 h. After addition, 5 M NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the mixture was heated at 80 °C for 2 h. Upon cooling to ambient temperature, the reaction was filtered and purified by reverse phase preparative HPLC to afford the product (1.9 mg, 7%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.12 - 8.01 (m, 2H), 7.88 (s, 1H), 7.44 - 7.08 (m, 4H), 5.72 (s, 1H), 4.72 - 4.60 (m, 2H), 2.52 (br s, 2H), 1.36 - 1.24 (m, 3H), 1.13 (s, 9H), 0.92 - 0.74 (m, 6H). LCMS (M+1): 584.2.

Example 253




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(4-fluorophenethoxy)-5',6-dimethyl-[3,3'-bipyridin]-5-yl)acetic acid:

- 5 A mixture of 2-(4-fluorophenyl)ethan-1-ol (0.033 g, 0.237 mmol, 5 equiv), 60% NaH (9.47 mg, 0.237 mmol, 5 equiv), and isopropyl *(S)*-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-5',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate (0.023 g, 0.047 mmol, 1 equiv) in THF (1.5 mL) was stirred for 1 h. After complete addition, 5 M NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the mixture was heated at 80 °C
- 10 for 2 h. After cooling to ambient temperature, the reaction was filtered and purified by reverse phase preparative HPLC to provide the product (8.8. mg, 33%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.06 - 8.00 (m, 1H), 7.92 (d, *J* = 2.2 Hz, 1H), 7.49 (d, *J* = 1.5 Hz, 1H), 7.39 - 7.29 (m, 2H), 7.11 (t, *J* = 9.0 Hz, 2H), 5.78 (s, 1H), 4.55 (t, *J* = 6.6 Hz, 2H), 2.16 (s, 3H), 1.40 - 1.25 (m, 3H), 1.13 (s, 10H), 0.91 - 0.73 (m, 6H). LCMS (M+1): 564.3.

15

Example 254




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(4-fluorophenethoxy)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

- 20 A mixture of 2-(4-fluorophenyl)ethan-1-ol (0.031 g, 0.223 mmol, 5 equiv), 60% NaH (8.90 mg, 0.223 mmol, 5 equiv) and isopropyl *(S)*-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.021 g, 0.045 mmol, 1 equiv) in THF (1.5 mL) was stirred at ambient temperature for 1 h. Upon complete addition, 5 M NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the
- 25 mixture was heated at 80 °C for 2 h. The reaction was allowed to cool to ambient temperature, filtered, and purified by preparative reverse phase HPLC to provide the product (6.9 mg, 28%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.14 - 7.96 (m, 2H), 7.65 (dd, *J*

= 8.3, 2.4 Hz, 1H), 7.34 (dd, J = 8.4, 5.5 Hz, 2H), 7.18 - 7.07 (m, 2H), 6.88 (d, J = 8.4 Hz, 1H), 5.79 (s, 1H), 4.60 - 4.46 (m, 2H), 1.39 - 1.25 (m, 3H), 1.20 - 1.09 (m, 10H), 0.94 - 0.74 (m, 6H) [note: some piperidine protons not observed]. LCMS (M+1): 550.2.

5

Example 255




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(3-fluorophenethoxy)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of 2-(3-fluorophenyl)ethan-1-ol (0.031 g, 0.223 mmol, 5 equiv), 60% NaH (8.90 mg, 0.223 mmol, 5 equiv), and isopropyl *(S)*-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.021 g, 0.045 mmol, 1 equiv) in THF (1.5 mL) was stirred at ambient temperature for 1 h. Upon complete addition, 5 M NaOH (0.089 mL, 0.445 mmol, 10 equiv) was added and the mixture was heated at 80 °C for 2 h. The reaction was allowed to cool to ambient temperature, filtered, and purified by preparative reverse phase HPLC to provide the product (10 mg, 40%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.18 - 7.97 (m, 2H), 7.73 - 7.60 (m, 1H), 7.40 - 7.29 (m, 1H), 7.21 - 6.94 (m, 3H), 6.93 - 6.83 (m, 1H), 5.86 - 5.75 (m, 1H), 4.62 - 4.50 (m, 2H), 3.14 - 3.02 (m, 1H), 1.38 - 1.24 (m, 3H), 1.18 - 1.02 (m, 10H), 0.91 - 0.70 (m, 6H). LCMS (M+1): 550.3.

20

Example 256




(S)-2-(tert-Butoxy)-2-(5-(3-cyano-4-(4-fluorophenethoxy)phenyl)-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid:

A mixture of *(S)*-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetic acid (0.04 g, 0.097 mmol, 1 equiv), 2-(4-fluorophenethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.053 g, 0.145 mmol, 1.5

equiv), SPhos (7.95 mg, 0.019 mmol, 0.2 equiv), palladium(II) acetate (2.173 mg, 9.68 μ mol, 0.1 equiv), and 2 M K_3PO_4 (0.145 mL, 0.290 mmol, 3 equiv) in dioxane (1 mL) was heated at 90°C for 4 h. After cooling to ambient temperature, the reaction mixture was filtered through celite/ Na_2SO_4 eluting with ethyl acetate and concentrated *in vacuo*. The crude product was purified by reverse phase preparative HPLC to provide the product (4 mg, 7%). ^1H NMR (500 MHz, $DMSO-d_6$) δ 8.06 - 7.99 (m, 1H), 7.65 (d, J = 1.8 Hz, 1H), 7.59 - 7.55 (m, 1H), 7.45 - 7.32 (m, 3H), 7.12 (t, J = 8.8 Hz, 2H), 5.79 - 5.69 (m, 1H), 4.48 (br d, J = 4.4 Hz, 2H), 1.40 - 1.25 (m, 3H), 1.17 - 1.08 (m, 10H), 0.91 - 0.75 (m, 6H). LCMS (M+1): 574.4.

10

Example 257




(*S*)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-(3-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid:

15 A mixture of isopropyl (*S*)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (0.065 g, 0.143 mmol, 1 equiv), 2-(3-fluoro-4-(3-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.077 g, 0.214 mmol, 1.5 equiv), $Pd(dppf)Cl_2$ (10 mg, 0.014 mmol, 0.1 equiv), and 2 M K_3PO_4 (0.43 mL, 0.856 mmol, 6 equiv) in dioxane (1.4 mL) was heated at 80 °C for 2 h. After cooling to ambient temperature, the reaction mixture was diluted with ethyl acetate and washed with brine. The organic layer was dried (Na_2SO_4) and concentrated *in vacuo*. The residue was taken up in ethanol (2 mL) and 10 M NaOH (0.2 mL) was added. The mixture was heated at 80 °C for 18 h. After cooling to ambient temperature, the mixture was filtered and purified by reverse phase preparative HPLC to provide the product (20 mg, 23%). ^1H NMR (500 MHz, $DMSO-d_6$) δ 8.07 (s, 1H), 7.39 - 7.33 (m, 1H), 7.29 (t, J = 8.8 Hz, 1H), 7.23 - 7.15 (m, 3H), 7.09 - 7.00 (m, 2H), 5.82 (s, 1H), 4.37 (td, J = 6.7, 3.9 Hz, 2H), 3.12 (t, J = 6.6 Hz, 2H), 2.52 (br s, 3H), 1.33 (br d, J = 5.5 Hz, 4H), 1.14 (s, 9H), 0.83 (s, 6H) [note: some piperidine protons not visible]. LCMS (M+1): 567.3.

25

Example 258




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(3-fluoro-4-phenethoxyphenyl)-2-methylpyridin-3-yl)acetic acid:

- 5 A solution of isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.064 g, 0.141 mmol, 1 equiv), 2-(3-fluoro-4-phenethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.072 g, 0.211 mmol, 1.5 equiv), Pd(dppf)Cl₂ (10 mg, 0.014 mmol, 0.1 equiv), and 2 M K₃PO₄ (0.42 ml, 0.843 mmol, 6 equiv) in dioxane (1.4 mL) was heated at 80 °C for 2 h. After cooling to ambient
- 10 temperature, the reaction mixture was diluted with ethyl acetate and washed with brine. The organic layer was dried (Na₂SO₄) and concentrated in vacuo. The residue was taken up in ethanol (2 mL) and 10 M NaOH (0.2 mL) was added. The mixture was heated at 80 °C for 18 h. After cooling to ambient temperature, the mixture was filtered and purified
- 15 by reverse phase preparative HPLC to provide the product (27 mg, 34%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.06 (s, 1H), 7.38 - 7.22 (m, 6H), 7.18 (dd, *J* = 12.1, 2.2 Hz, 1H), 7.06 (br d, *J* = 7.7 Hz, 1H), 5.83 (s, 1H), 4.35 (td, *J* = 6.7, 4.6 Hz, 2H), 3.09 (t, *J* = 6.8 Hz, 2H), 2.51 (s, 3H), 1.32 (br d, *J* = 2.6 Hz, 4H), 1.14 (s, 9H), 0.83 (s, 6H) [note: some piperidine protons not visible]. LCMS (M+1): 549.2.

20

Example 259




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(2-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid.

- A mixture of isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetate (0.04 g, 0.088 mmol, 1 equiv), 2-(4-(3-fluorophenethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.045 g, 0.132 mmol, 1.5 equiv), Sphos (7.21 mg, 0.018 mmol, 0.2 equiv), palladium(II) acetate (1.972 mg,
- 25

8.78 μmol , 0.1 equiv), and 2 M K_3PO_4 (0.132 ml, 0.263 mmol, 3 equiv) in dioxane was heated at 90 °C for 4 h. After cooling to ambient temperature, the reaction mixture was filtered through celite/ Na_2SO_4 eluting with ethyl acetate. The filtrate was concentrated *in vacuo*. The residue was taken up in ethanol (1 mL) and 5 M NaOH (0.176 ml, 0.878 mmol, 10 equiv) was added. The mixture was heated at 90 °C for 4 h. After cooling to ambient temperature, the mixture was filtered and purified by reverse phase preparative HPLC to provide the product (23 mg, 46%). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.12 – 8.04 (m, 1H), 7.42 – 7.32 (m, 1H), 7.27 – 7.14 (m, 4H), 7.09 – 7.01 (m, 3H), 5.86 – 5.80 (m, 1H), 4.36 – 4.23 (m, 2H), 3.13 – 3.07 (m, 1H), 1.32 (br d, $J = 4.8$ Hz, 3H), 1.14 (s, 10H), 0.82 (s, 6H). LCMS (M+1): 549.4.


Example 260



(*S*)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(4-fluorophenethoxy)-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of 2-(4-fluorophenyl)ethan-1-ol (0.033 g, 0.237 mmol, 5 equiv), 60% NaH (9.47 mg, 0.237 mmol, 5 equiv), and isopropyl (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate (0.023 g, 0.047 mmol, 1 equiv) in THF (1.5 mL) was stirred for 1 h. After complete addition, 5 M NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the mixture was heated at 80 °C for 2 h. Upon cooling to ambient temperature, the reaction was filtered and purified by reverse phase preparative HPLC to provide the product (6 mg, 22%). NMR shows a 2:1 mixture of atropisomers, major isomer transcribed. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.98 (s, 1H), 7.40 (d, $J = 8.1$ Hz, 1H), 7.35 (dd, $J = 8.4, 5.5$ Hz, 2H), 7.16 - 7.06 (m, 2H), 6.70 (d, $J = 8.4$ Hz, 1H), 5.84 (s, 1H), 4.56 - 4.47 (m, 2H), 3.10 - 3.00 (m, 2H), 2.50 (s, 3H), 2.21 (s, 3H), 1.35 - 1.19 (m, 4H), 1.14 (s, 9H), 0.76 (br s, 6H) [note: some piperidine protons not observed]. LCMS (M+1): 564.4.


Example 261




(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(3-fluorophenethoxy)-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetic acid:

- 5 A mixture of 2-(3-fluorophenyl)ethan-1-ol (0.033 g, 0.237 mmol, 5 equiv), 60% NaH (9.47 mg, 0.237 mmol, 5 equiv), and isopropyl (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate (0.023 g, 0.047 mmol, 1 equiv) in THF (1.5 mL) was stirred for 1 h. Upon completion, 5 N NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the mixture was heated at 80 °C for 2
- 10 h. After cooling to ambient temperature, the reaction was filtered and purified by reverse phase preparative HPLC to give the product (6.6 mg, 24%). NMR shows a mixture of atropisomers, major isomer transcribed. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.98 (s, 1H), 7.41 (d, *J* = 8.4 Hz, 1H), 7.21 - 7.14 (m, *J* = 4.8 Hz, 2H), 7.04 (td, *J* = 8.7, 2.8 Hz, 1H), 6.71 (d, *J* = 8.1 Hz, 1H), 5.84 (s, 1H), 4.61 - 4.52 (m, 2H), 3.09 (td, *J* = 6.5, 3.1 Hz, 2H),
- 15 2.51 (s, 3H), 2.21 (s, 3H), 1.38 - 1.21 (m, 4H), 1.14 (s, 9H), 0.77 (br s, 6H) [note: some piperidine protons not observed]. LCMS (M+1): 564.4.

Example 262



Example 263




- 20 (*S*)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-2'-(4-fluorophenethoxy)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid and (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2'-fluoro-6'-(4-fluorophenethoxy)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

- A mixture of 2-(4-fluorophenyl)ethan-1-ol (0.031 g, 0.225 mmol, 5 equiv), 60% NaH (8.99 mg, 0.225 mmol, 5 equiv), and isopropyl (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-
- 25

dimethylpiperidin-1-yl)-2',6'-difluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (0.022 g, 0.045 mmol, 1 equiv) in THF (1.5 mL) was stirred for 1 h. Upon completion, 5 M NaOH (0.167 mL, 0.837 mmol, 10 equiv) was added and the mixture was heated at 80 °C for 2 h. After cooling to ambient temperature, the reaction was filtered and purified by reverse
 5 phase preparative HPLC to give two regioisomers of product (4.6 mg, 17%) and (3.4 mg, 13%). Isomer 1 (assigned as displacement of 2-F): LCMS (M+1): 568.2. Isomer 2 (assigned as displacement of 6-F): ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.21 (br s, 1H), 7.92 - 7.81 (m, *J* = 9.5, 4.8 Hz, 1H), 7.35 (dd, *J* = 8.4, 5.5 Hz, 2H), 7.12 (t, *J* = 9.0 Hz, 2H), 6.88 (d, *J* = 8.4 Hz, 1H), 5.70 (br d, *J* = 1.5 Hz, 1H), 4.51 (t, *J* = 6.6 Hz, 2H), 3.07 (t, *J* =
 10 6.6 Hz, 2H), 2.58 (s, 3H), 1.44 - 1.25 (m, 4H), 1.15 (s, 9H), 0.84 (s, 6H) [*note: some piperidine protons not observed*]. LCMS (M+1): 568.3.

Example 264




15 *(S)*-2-(4-(4,4-Dimethylpiperidin-1-yl)-2-methyl-5-(4-phenethoxyphenyl)pyridin-3-yl)-2-(tert-pentyloxy)acetic acid:

A mixture of isopropyl *(S)*-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetate (20 mg, 0.043 mmol), 4,4,5,5-tetramethyl-2-(4-phenethoxyphenyl)-1,3,2-dioxaborolane (21 mg, 0.064 mmol), Sphos Pd G3 (3.3
 20 mg, 4.3 μmol), and potassium phosphate tribasic (27 mg, 0.13 mmol) in 1,4-Dioxane (0.7 ml) and Water (0.1 ml) the reaction vessel capped under positive pressure of N₂. The reaction was heated at 80°C for 1 h. The reaction was concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs) to afford the ester intermediate which was taken up in EtOH (1.5 ml) and 5N NaOH (10
 25 equiv) was added and the reaction was stirred at 100°C for 3 hrs and then the mixture was then cooled and purified on C18 Prep HPLC to afford the expected carboxylic acid: *(S)*-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(4-phenethoxyphenyl)pyridin-3-yl)-2-(tert-pentyloxy)acetic acid (14.9 mg, 64% yield). LCMS Method 2: retention time = 2.29 min.; observed ion = 545.4. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.00 (s, 1H), 7.36 - 7.30 (m, 5H),
 30 7.26 - 7.18 (m, 4H), 7.03 (d, *J* = 7.4 Hz, 2H), 5.81 (s, 1H), 4.31 - 4.23 (m, 2H), 3.07 (t,

$J=6.8$ Hz, 2H), 1.56 - 1.36 (m, 4H), 1.31 (br s, 3H), 1.12 (s, 4H), 1.04 (s, 4H), 0.82 (br s, 7H), 0.72 (t, $J=7.5$ Hz, 4H).


Example 265



(*S*)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(4-phenethoxyphenyl)pyridin-3-yl)acetic acid:

A mixture of isopropyl (*S*)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-(*tert*-butoxy)acetate (30 mg, 0.066 mmol), 4,4,5,5-tetramethyl-2-(4-phenethoxyphenyl)-1,3,2-dioxaborolane (32.0 mg, 0.099 mmol), Sphos Pd G3 (5.13 mg, 6.59 μ mol), and potassium phosphate tribasic (41.9 mg, 0.198 mmol) in 1,4-Dioxane (1 ml) and Water (0.2 ml) the reaction vessel capped under positive pressure of N₂. The reaction was heated at 80°C for 1 h. The reaction was concentrated, adsorbed onto celite and was purified on silica gel (Biotage, EtOAc/hexanes gradient, 0-100% over 10 CVs) to give the ester intermediate which was subjected to hydrolysis conditions (1.5 mL EtOH, .1 mL of 5N NaOH, 100C for 3 hrs.) The resulting carboxylic acid was purified on C18 to afford (*S*)-2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(4-phenethoxyphenyl)pyridin-3-yl)acetic acid (9.5 mg, 27% yield) LCMS Method 1: retention time = 2.27 min.; observed ion = 531.3. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.18 (s, 1H), 6.50 - 6.30 (m, 5H), 6.21 (br d, $J=8.4$ Hz, 2H), 5.89 (br dd, $J=17.2$, 8.1 Hz, 3H), 4.33 (br d, $J=6.6$ Hz, 1H), 3.46 (br d, $J=17.2$ Hz, 2H), 2.19 (s, 3H), 2.11 - 2.03 (m, 6H), 2.00 (br s, 3H), 1.95 (br s, 3H), 0.22 - 0.06 (m, 12H).


Example 266



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinolin-2-yl)pyridin-3-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinolin-2-yl)pyridin-3-yl)acetate (74 mg, 0.147 mmol) in EtOH (1.5 mL) was added sodium hydroxide (0.294 mL, 1.469 mmol) then heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinolin-2-yl)pyridin-3-yl)acetic acid (14.5 mg, 0.031 mmol, 21.38 % yield). ¹H NMR (500 MHz, DMSO-d₆) δ 8.49 (d, J=8.4 Hz, 1H), 8.30 (s, 1H), 8.05 (d, J=8.8 Hz, 2H), 7.82 (ddd, J=8.3, 6.9, 1.3 Hz, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.67 - 7.62 (m, 1H), 5.91 (s, 1H), 2.55 (s, 3H), 1.41 - 1.20 (m, 4H), 1.16 (s, 9H), 0.84 - 0.62 (m, 6H) 4 protons (4 from 2 methylenes closest to piperidine nitrogen) were not observed in the HNMR spectrum. ESI-MS(+) m/z = 462.2 (M+1).

Example 267




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinazolin-2-yl)pyridin-3-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinazolin-2-yl)pyridin-3-yl)acetate (13 mg, 0.026 mmol) in EtOH (1.5 mL) was added sodium hydroxide (0.052 mL, 0.258 mmol) and heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(quinazolin-2-yl)pyridin-3-yl)acetic acid (8.6 mg, 0.019 mmol, 72.2 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 9.67 (s, 1H), 8.50 (s, 1H), 8.20 (d, J=8.1 Hz, 1H), 8.14 - 8.07 (m, 2H), 7.83 (ddd, J=8.2, 6.1, 1.8 Hz, 1H), 6.03 (s, 1H), 3.12 - 2.95 (m, 2H), 2.68 (s, 3H), 1.49 - 1.35 (m, 4H), 1.24 (s, 9H), 0.85 (s, 6H) 2

protons on methylenes closest to piperidine nitrogen were not observed in HNMR. ESI-MS(+) $m/z = 463.2$ (M+1).


Example 268



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)-5-methylpyridazin-3-yl)-2-methylpyridin-3-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)-5-methylpyridazin-3-yl)-2-methylpyridin-3-yl)acetate (56 mg, 0.092 mmol) in EtOH (1 mL) was added sodium hydroxide (0.185 mL, 0.923 mmol) then heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)-5-methylpyridazin-3-yl)-2-methylpyridin-3-yl)acetic acid (36.5 mg, 0.065 mmol, 70.0 % yield). ¹H NMR (500 MHz, METHANOL-d₄) δ 8.07 (s, 1H), 7.39 (d, J=1.1 Hz, 1H), 7.25 - 7.18 (m, 2H), 7.01 - 6.89 (m, 2H), 5.87 (s, 1H), 4.41 - 4.29 (m, 2H), 3.20 - 3.04 (m, 4H), 2.87 - 2.73 (m, 2H), 2.63 (s, 3H), 2.26 (d, J=1.1 Hz, 3H), 1.54 - 1.39 (m, 4H), 1.21 (s, 9H), 0.94 (s, 6H). ESI-MS(+) $m/z = 565.3$ (M+1).

Example 269




(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-(hydroxymethyl)-[2,3'-bipyridin]-5'-yl)acetic acid:

To a solution of (S)-5-(tert-butoxy)-4-(4,4-dimethylpiperidin-1-yl)-3-(5-(4-fluorophenethoxy)pyridin-2-yl)-5,8-dihydro-6H-pyrano[3,4-b]pyridin-6-one (17 mg, 0.031 mmol) in EtOH (1 mL) was added sodium hydroxide (0.062 mL, 0.310 mmol) then

heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-(hydroxymethyl)-[2,3'-bipyridin]-5'-yl)acetic acid (5.1 mg, 29% yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.35 (d, *J*=2.4 Hz, 1H), 8.22 (s, 1H), 7.57 - 7.51 (m, 1H), 7.50 - 7.44 (m, 1H), 7.40 - 7.33 (m, 2H), 7.06 (br t, *J*=8.7 Hz, 2H), 5.91 (d, *J*=13.7 Hz, 1H), 5.70 (s, 1H), 5.10 - 4.71 (m, 1H), 4.36 (br t, *J*=6.6 Hz, 2H), 3.15 (br t, *J*=6.4 Hz, 2H), 2.87 - 2.68 (m, 2H), 1.43 (br s, 4H), 1.20 (s, 9H), 0.93 - 0.87 (m, 6H) 2 protons (2 closest to N on piperidine) were not observed in the HNMR spectrum. ESI-MS(+) *m/z* = 566.3 (M+1).


Example 270



Isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-isopropoxyacetate:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-5-(4-fluorophenethoxy)-[2,3'-bipyridin]-5'-yl)acetate (63 mg, 0.104 mmol) in EtOH (2 mL) was added 5 N aq. sodium hydroxide (0.208 mL, 1.040 mmol) then heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via prep HPLC. The desired fractions were collected and lyophilized to afford the product isopropyl (S)-2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)-2-isopropoxyacetate (50.4 mg, 0.089 mmol, 86 % yield) as a white fluffy solid. ¹H NMR (500 MHz, methanol-d₄) δ 8.34 (d, *J*=2.8 Hz, 1H), 8.17 (s, 1H), 7.54 (dd, *J*=8.6, 2.9 Hz, 1H), 7.45 (d, *J*=8.7 Hz, 1H), 7.40 - 7.34 (m, 2H), 7.06 (t, *J*=8.7 Hz, 2H), 5.84 (s, 1H), 4.36 (td, *J*=6.7, 1.2 Hz, 2H), 3.15 (t, *J*=6.6 Hz, 2H), 3.04 - 2.67 (m, 4H), 1.43 (br s, 4H), 1.31 (t, *J*=7.4 Hz, 3H), 1.21 (s, 9H), 0.89 (s, 6H) 2 protons on methylenes closest to piperidine nitrogen were not observed in HNMR spectrum. ESI-MS(+) *m/z* = 564.2 (M+1).

Example 271




(S)-2-(4'-(4,4-Dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-isopropoxyacetic acid:

- 5 To a solution of isopropyl (S)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-isopropoxyacetate (15 mg, 0.026 mmol) in EtOH (1 mL) was added sodium hydroxide (0.052 mL, 0.260 mmol) then heated at 75°C for 3 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product
- 10 were combined and dried via centrifugal evaporation to afford the product (S)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-isopropoxyacetic acid (11 mg, 0.021 mmol, 79 % yield). ^1H NMR (500 MHz, methanol- d_4) δ 8.33 (d, $J=2.4$ Hz, 1H), 8.10 (s, 1H), 7.53 (dd, $J=8.5$, 2.7 Hz, 1H), 7.44 (d, $J=8.5$ Hz, 1H), 7.37 (dd, $J=8.1$, 5.6 Hz, 2H), 7.06 (t, $J=8.7$ Hz, 2H), 5.67 (s, 1H), 4.35 (t, $J=6.6$ Hz, 2H), 3.49 - 3.41 (m, 1H), 3.15 (t, $J=6.4$ Hz, 2H), 2.76 (br s, 3H), 2.63 (s, 3H), 1.37 (br s, 4H), 1.26 (d, $J=5.8$ Hz, 3H), 1.02 (d, $J=6.1$ Hz, 3H), 0.87 (s, 6H). 1 proton (broadened peak of a methylene proton closest to piperine nitrogen) was not observed in the HNMR spectrum. ESI-MS(+) m/z = 536.3 (M+1).
- 15

20

Example 272




(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(phenoxymethyl)-[2,3'-bipyridin]-5'-yl)acetic acid:

- To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(phenoxymethyl)-[2,3'-bipyridin]-5'-yl)acetate (39 mg, 0.070 mmol) in EtOH (464 μ l) was added sodium hydroxide (139 μ l, 0.697 mmol) then heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified
- 25

via preparative LC/MS. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(phenoxymethyl)-[2,3'-bipyridin]-5'-yl)acetic acid (20 mg, 0.039 mmol, 55.5 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.80 (s, 1H), 8.23 (s, 1H), 8.10 (br d, *J*=7.6 Hz, 1H), 7.60 (br d, *J*=7.9 Hz, 1H), 7.36 - 7.25 (m, 2H), 7.05 (br d, *J*=7.9 Hz, 1H), 6.98 (br t, *J*=7.2 Hz, 1H), 7.07 - 6.84 (m, 1H), 5.82 (s, 1H), 5.28 (s, 2H), 3.18 - 2.74 (m, 3H), 2.68 (s, 3H), 1.43 (br s, 4H), 1.21 (s, 9H), 0.88 (s, 6H). 1 proton on one of the methylenes closest to the piperidine N was not observed in the HNMR spectrum. ESI-MS(+) *m/z* = 518.3 (M+1).

Example 273




(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isopentyl-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

To an N₂ sparged solution (N₂ sparge for 5 minutes) of isopropyl (S,Z)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(3-methylbut-1-en-1-yl)-[2,3'-bipyridin]-5'-yl)acetate (164 mg, 0.314 mmol) in Ethanol (3 mL) was added Pd-C (33.5 mg, 0.031 mmol). The vessel was sealed and the solution bubbled with H₂ for 5 minutes. The reaction was then left under positive pressure of H₂ for 2 hrs. The reaction solution was sparged with N₂ and the solution filtered through a 0.45 μ nylon frit filter into a 7 mL vial. To the vial was added 5 N sodium hydroxide (0.629 mL, 3.14 mmol) and the solution stirred for 18 hrs at 75 °C. The reaction was then cooled to rt and filtered through a 0.45 μ nylon frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isopentyl-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (27.2 mg, 18% yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.56 (s, 1H), 8.23 (s, 1H), 7.87 (br d, *J*=7.9 Hz, 1H), 7.50 (br d, *J*=7.9 Hz, 1H), 5.82 (s, 1H), 3.09 - 2.83 (m, 2H), 2.79 (br t, *J*=6.9 Hz, 2H), 2.68 (s, 3H), 1.61 (br s, 2H), 1.43 (br

s, 4H), 1.36 - 1.29 (m, 1H), 1.22 (s, 9H), 1.00 (br d, $J=4.0$ Hz, 6H), 0.90 (s, 6H). 2 protons on the methylenes closest to piperidine N were not observed in the HNMR. ESI-MS(+) $m/z = 482.3$ (M+1).

5

Example 274




(S)-2-(tert-Butoxy)-2-(5-(1,1-difluoro-3-methylbutyl)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(5-(1,1-difluoro-3-methylbutyl)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (152 mg, 0.272 mmol) in EtOH (1810 μ l) was added sodium hydroxide (543 μ l, 2.72 mmol) then heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(5-(1,1-difluoro-3-methylbutyl)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (24.8 mg, 0.046 mmol, 16.87 % yield). ^1H NMR (500 MHz, methanol- d_4) δ 8.86 (br s, 1H), 8.27 (br s, 1H), 8.15 (br d, $J=7.6$ Hz, 1H), 7.71 (br d, $J=7.9$ Hz, 1H), 5.80 (br s, 1H), 3.01 (br s, 1H), 2.84 (br s, 2H), 2.69 (br s, 3H), 2.22 (td, $J=17.2, 6.3$ Hz, 2H), 1.81 (dt, $J=13.0, 6.4$ Hz, 1H), 1.44 (br s, 3H), 1.22 (s, 9H), 1.00 (br s, 6H), 0.90 (s, 7H). 1 proton on one of the methylenes closest to the piperidine N was not observed in the HNMR spectrum. ESI-MS(+) $m/z = 518.3$ (M+1).

25


Example 275



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-6'-methyl-6-(trifluoromethyl)-[2,3'-bipyridin]-5'-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-6'-methyl-6-(trifluoromethyl)-[2,3'-bipyridin]-5'-yl)acetate (99 mg, 0.167 mmol) in EtOH (1112 μ l) was added sodium hydroxide (333 μ l, 1.667 mmol) then heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-6'-methyl-6-(trifluoromethyl)-[2,3'-bipyridin]-5'-yl)acetic acid (22.6 mg, 0.041 mmol, 24.57 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.26 (s, 1H), 7.86 - 7.77 (m, 2H), 5.84 (br s, 1H), 4.02 (br d, *J*=6.1 Hz, 2H), 3.20 - 2.71 (m, 3H), 2.68 (s, 3H), 2.19 (dt, *J*=12.9, 6.5 Hz, 1H), 1.46 (br s, 4H), 1.22 (s, 9H), 1.11 (br d, *J*=6.4 Hz, 6H), 0.93 (s, 6H). 1 proton on one of the methylenes closest to piperidine N was not observed in the HNMR spectrum. ESI-MS(+) *m/z* = 552.3 (M+1).

Example 276




(S)-2-(tert-Butoxy)-2-(5-(1,1-difluoropentyl)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(5-(1,1-difluoropentyl)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (130 mg, 0.232 mmol) in EtOH (1548 μ l) was added aq. 5 N sodium hydroxide (464 μ l, 2.322 mmol) then heated at 75°C for 24 hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(5-(1,1-difluoropentyl)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (29.8 mg, 0.056 mmol, 24.12 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.85 (s, 1H), 8.26 (br s, 1H), 8.14 (br d, *J*=7.9 Hz, 1H), 7.71 (br d, *J*=8.2 Hz, 1H), 5.79 (br s, 1H), 2.84 (br s, 3H), 2.69 (br s, 3H), 2.30 (br s, 2H), 1.47 - 1.37 (m, 8H), 1.21 (s, 9H), 0.96 - 0.86 (m, 10H). 1

proton on one of the methylenes closest to the piperidine N was not observed in the HNMR spectrum. ESI-MS(+) m/z = 518.3 (M+1).

Example 277




(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-5-isobutoxy-[2,3'-bipyridin]-5'-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-5-isobutoxy-[2,3'-bipyridin]-5'-yl)acetate (16 mg, 0.030 mmol) in EtOH (1 mL) was added sodium hydroxide (0.059 mL, 0.296 mmol) then heated at 75°C for 48 hrs.

The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-5-isobutoxy-[2,3'-bipyridin]-5'-yl)acetic acid (5.4 mg, 10.85 μ mol, 36.6 % yield). ^1H NMR (500 MHz, methanol- d_4) δ 8.38 (br s, 1H), 8.24 (s, 1H), 7.60 - 7.53 (m, 1H), 7.51 - 7.46 (m, 1H), 5.87 (br s, 1H), 3.93 (br d, J =6.4 Hz, 2H), 3.05 - 2.97 (m, 2H), 2.92 - 2.69 (m, 2H), 2.16 (dt, J =13.2, 6.7 Hz, 1H), 1.49 - 1.39 (m, 4H), 1.32 (br d, J =7.3 Hz, 3H), 1.23 (s, 9H), 1.10 (br d, J =6.4 Hz, 6H), 0.92 (s, 6H). 2 protons on the methylenes closest to the piperidine N were not observed in the HNMR spectrum. ESI-MS(+) m/z = 498.3 (M+1).

Example 278



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-(fluoromethyl)-5-isobutoxy-[2,3'-bipyridin]-5'-yl)acetic acid:


To an N_2 sparged solution of benzyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-(fluoromethyl)-5-isobutoxy-[2,3'-bipyridin]-5'-yl)acetate (23

mg, 0.039 mmol) in MeOH (2 mL) was added Pd-C (4.14 mg, 3.89 μ mol) and capped with a rubber septum. H₂ was then bubbled through the solution for 10 minutes. The reaction was left under positive pressure of H₂ for 3 days. The LCMS indicated the reaction was complete. The reaction was filtered through a 0.45 μ nylon frit filter and

5 purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-(fluoromethyl)-5-isobutoxy-[2,3'-bipyridin]-5'-yl)acetic acid (9.3 mg, 0.018 mmol, 46.8 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.37 (d, *J*=2.4 Hz, 1H), 8.31 (s, 1H), 7.60 - 7.53 (m, 1H), 7.52 - 7.43 (m, 1H), 5.87 (s, 1H), 5.74 - 5.55

10 (m, 2H), 3.93 (br d, *J*=6.4 Hz, 2H), 2.21 - 2.09 (m, 1H), 1.52 - 1.34 (m, 4H), 1.18 (s, 9H), 1.10 (d, *J*=6.7 Hz, 6H), 0.90 (s, 6H). 4 protons on the methylenes closest to the piperidine N were not observed in the HNMR spectrum. ESI-MS(+) *m/z* = 502.3 (M+1).

Example 279



15

(S)-2-(tert-Butoxy)-2-(5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-[2,3'-bipyridin]-5'-yl)acetic acid:

To a 1 dram vial equipped with a stir bar and charged with isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-5-hydroxy-[2,3'-bipyridin]-5'-yl)acetate (25 mg, 0.052 mmol) was added butan-1-ol (7.10 μ l, 0.078 mmol). To the vial

20 was added triphenylphosphane (20.34 mg, 0.078 mmol) as a solution in THF (0.25 mL). To the solution was added DIAD (0.015 mL, 0.078 mmol) as a solution in THF (0.25 mL). The solution was stirred at r.t. LCMS analysis at t=5 hr found clean and complete conversion to the desired ester intermediate. The reaction solution was concentrated under


25 an N₂ stream. The residue was dissolved in EtOH (1.0 mL). To the solution was added NaOH (0.207 mL, 1.034 mmol). The solution was stirred at 75 °C for 18 hrs. LCMS analysis after 18 hrs found disappearance of the ester peak and a large expected product peak (acid). The mixture was filtered through a syringe filter, neutralized with acetic acid (0.059 mL, 1.034 mmol) and the filtrate was purified via preparative LC/MS. Fractions

30 containing the desired product were combined and dried via centrifugal evaporation to

afford the product (S)-2-(tert-butoxy)-2-(5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-ethyl-[2,3'-bipyridin]-5'-yl)acetic acid (10.6 mg, 0.021 mmol, 41.2 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.37 (br s, 1H), 8.24 (s, 1H), 7.60 - 7.53 (m, 1H), 7.52 - 7.46 (m, 1H), 5.85 (br s, 1H), 4.16 (br t, *J*=6.3 Hz, 2H), 3.00 (q, *J*=7.2 Hz, 2H), 2.93 - 2.70 (m, 2H), 1.90 - 1.79 (m, 2H), 1.57 (sxt, *J*=7.4 Hz, 2H), 1.45 (br s, 4H), 1.32 (br d, *J*=7.6 Hz, 3H), 1.23 (s, 9H), 1.03 (t, *J*=7.3 Hz, 3H), 0.91 (s, 6H). 2 protons on the methylenes closest to the piperidine N were not observed in the HNMR spectrum. ESI-MS(+) *m/z* = 498.3 (M+1).

10


Example 280




(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

To a solution of isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (132 mg, 0.223 mmol) in EtOH (1.5 mL) was added sodium hydroxide (0.446 mL, 2.231 mmol) then heated at 75°C for -- hrs. The reaction was cooled to RT, filtered through a nylon 0.45 μ frit filter and purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (20.5 mg, 17% yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.16 (s, 1H), 7.81 (br t, *J*=7.6 Hz, 1H), 7.28 (br t, *J*=6.6 Hz, 2H), 7.08 (br d, *J*=7.0 Hz, 1H), 6.99 (br t, *J*=8.5 Hz, 2H), 6.85 (br d, *J*=8.2 Hz, 1H), 5.78 (s, 1H), 4.63 - 4.44 (m, 2H), 3.23 - 3.09 (m, 1H), 3.06 (br t, *J*=6.4 Hz, 2H), 2.98 - 2.75 (m, 2H), 2.67 (s, 3H), 1.44 (br s, 4H), 1.21 (s, 9H), 0.88 (s, 6H). 1 proton on the methylenes closest to the piperidine N were not observed in the HNMR spectrum. ESI-MS(+) *m/z* = 550.3 (M+1).

Example 281



Example 282



(S)-2-(tert-Butoxy)-2-(5-((S)-1-(2-chloro-6-methylphenyl)ethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid and (S)-2-(tert-butoxy)-2-(5-((R)-1-(2-chloro-6-methylphenyl)ethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:


To a 1 dram vial equipped with a stir bar and charged with isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (50 mg, 0.106 mmol) was added 1-(2-chloro-6-methylphenyl)ethan-1-ol (27.3 mg, 0.160 mmol). To the vial was added triphenylphosphane (41.9 mg, 0.160 mmol) as a solution in THF (0.25 mL). To the solution was added DIAD (0.031 mL, 0.160 mmol) as a solution in THF (0.25 mL). The solution was stirred at r.t. LCMS analysis at t=5 hr found clean and complete conversion to the desired ester intermediate. The reaction solution was concentrated under a N₂ stream. The residue was dissolved in EtOH (1.5 mL). To the solution was added NaOH (0.426 mL, 2.129 mmol). The solution was stirred at 75 °C for 18 hrs. The mixture was filtered through a syringe filter, neutralized with acetic acid (0.122 mL, 2.129 mmol) and the filtrate was purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the products:

(First eluting): (S)-2-(tert-butoxy)-2-(5-((S)-1-(2-chloro-6-methylphenyl)ethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (20.4 mg, 0.034 mmol, 31.7 % yield): ¹H NMR (500 MHz, methanol-d₄) δ 8.25 (s, 1H), 8.07 (s, 1H), 7.36 (s, 2H), 7.29 (br d, J=7.6 Hz, 1H), 7.17 (br t, J=7.6 Hz, 1H), 7.13 - 7.08 (m, 1H), 6.19 (br d, J=6.7 Hz, 1H), 5.73 (br s, 1H), 2.68 (br s, 2H), 2.62 (s, 3H), 2.52 (s, 3H), 1.80 (br d, J=6.4 Hz, 3H), 1.37 (br s, 4H), 1.16 (s, 9H), 0.88 (s, 6H). 2 protons on the methylenes closest to the piperidine N were not observed in the HNMR spectrum. ESI-MS(+) m/z = 580.3 (M+1).

Second eluting: (S)-2-(tert-butoxy)-2-(5-((R)-1-(2-chloro-6-methylphenyl)ethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (15.1 mg, 0.026 mmol, 24.45 % yield): ¹H NMR (500 MHz, methanol-d₄) δ

8.28 (br s, 1H), 8.14 (s, 1H), 7.43 - 7.35 (m, 2H), 7.30 (br d, $J=7.9$ Hz, 1H), 7.18 (br t, $J=7.8$ Hz, 1H), 7.11 (br d, $J=7.3$ Hz, 1H), 6.20 (br d, $J=6.7$ Hz, 1H), 5.78 (br s, 1H), 3.09 - 2.67 (m, 3H), 2.64 (s, 3H), 2.50 (s, 3H), 1.80 (br d, $J=6.4$ Hz, 3H), 1.36 (br s, 4H), 1.19 (s, 9H), 0.78 (br s, 6H). 1 proton on the methylenes closest to the piperidine N were not
 5 observed in the HNMR spectrum. ESI-MS(+) m/z = 580.3 (M+1).


Example 283



(S)-2-(tert-Butoxy)-2-(5-((2-chloro-6-methylbenzyl)oxy)-4'-(4,4-dimethylpiperidin-1-yl)-
 10 6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

To a 1 dram vial equipped with a stir bar and charged with isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (25 mg, 0.053 mmol) was added (2-chloro-6-methylphenyl)methanol (12.51 mg, 0.080 mmol). To the vial was added triphenylphosphane (20.94 mg, 0.080 mmol) as a solution in THF (0.25 mL). To the solution was added DIAD (0.016 mL, 0.080 mmol)
 15 as a solution in THF (0.25 mL). The solution was stirred at r.t. LCMS analysis at t=5 hr found clean and complete conversion to the desired ester intermediate. The reaction solution was concentrated under a N₂ stream. The residue was dissolved in EtOH (1.0 mL). To the solution was added aq. 5 N NaOH (0.213 mL, 1.065 mmol). The solution
 20 was stirred at 75 °C for 18 hrs. LCMS analysis after 18 hrs found disappearance of the ester peak and a large expected product peak (acid). The mixture was filtered through a syringe filter, neutralized with acetic acid (0.061 mL, 1.065 mmol) and the filtrate was purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (S)-2-(tert-butoxy)-2-(5-((2-chloro-6-methylbenzyl)oxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (19 mg, 63% yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.47 (br s, 1H), 8.21 (s, 1H), 7.72 (br d, $J=8.9$ Hz, 1H), 7.53 (br d, $J=8.5$ Hz, 1H), 7.37 - 7.21 (m, 3H), 5.82 (br s, 1H), 5.43 (s, 2H), 3.16 - 2.70 (m, 3H), 2.67 (s, 3H), 2.50 (s, 3H), 1.45 (br s, 4H), 1.22 (s, 9H), 0.92 (s, 6H). 1 proton on the methylenes closest to the piperidine N
 30 were not observed in the HNMR spectrum. ESI-MS(+) m/z = 566.3 (M+1).


Example 284



5 *(S)*-2-(*tert*-Butoxy)-2-(5-(2-chloro-6-methylphenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

To a 1 dram vial equipped with a stir bar and charged with isopropyl (*S*)-2-(*tert*-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (25 mg, 0.053 mmol) was added 2-(2-chloro-6-methylphenyl)ethan-1-ol (13.63 mg, 0.080 mmol). To the vial was added triphenylphosphane (20.94 mg, 0.080 mmol) as a solution in THF (0.25 mL). To the solution was added DIAD (0.016 mL, 0.080 mmol) as a solution in THF (0.25 mL). The solution was stirred at r.t. LCMS analysis at t=5 hr found clean and complete conversion to the desired ester intermediate. The reaction solution was concentrated under a N₂ stream. The residue was dissolved in EtOH (1.0 mL). To the solution was added NaOH (0.213 mL, 1.065 mmol). The solution was stirred at 75 °C for 18 hrs. LCMS analysis after 18 hrs found disappearance of the ester peak and a large expected product peak (acid). The mixture was filtered through a syringe filter, neutralized with acetic acid (0.061 mL, 1.065 mmol) and the filtrate was purified via preparative LC/MS. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the product (*S*)-2-(*tert*-butoxy)-2-(5-(2-chloro-6-methylphenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (16 mg, 0.028 mmol, 51.8 % yield). ¹H NMR (500 MHz, methanol-d₄) δ 8.33 (br s, 1H), 8.08 (s, 1H), 7.53 (br d, *J*=8.5 Hz, 1H), 7.43 (br d, *J*=8.5 Hz, 1H), 7.27 (br d, *J*=7.3 Hz, 1H), 7.19 - 7.12 (m, 2H), 5.74 (br s, 1H), 4.36 (br t, *J*=6.9 Hz, 2H), 3.39 (br t, *J*=7.0 Hz, 2H), 2.90 - 2.68 (m, 2H), 2.64 (s, 3H), 2.49 (s, 3H), 1.50 - 1.37 (m, 4H), 1.18 (s, 9H), 0.89 (s, 6H). 2 protons on the methylenes closest to the piperidine N were not observed in the HNMR spectrum. ESI-MS(+) *m/z* = 580.3 (M+1).


Example 285



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-phenethoxy-[2,3'-bipyridin]-5'-yl)acetic acid:

- 5 To a 1 dram vial equipped with a stir bar and charged with isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (20 mg, 0.043 mmol) was added triphenylphosphane (16.76 mg, 0.064 mmol). To the vial was added 2-phenylethan-1-ol (7.80 mg, 0.064 mmol) as a solution in THF (0.25 mL). To the solution was added DIAD (0.012 mL, 0.064 mmol) as a solution in
- 10 THF (0.25 mL). The solution was stirred at r.t. After 20 min. the reaction solution was concentrated under a N₂ stream. The residue was dissolved in EtOH (1.0 mL). To the solution was added aq. NaOH (5.0 M, 0.100 mL, 0.500 mmol). The vial was placed in a 85 deg C heating block with stirring for 5 h. The mixture was filtered through a 0.4 micron syringe filter and the filtrate was subjected to Prep-HPLC purification. Fractions
- 15 containing the desired product were combined and dried via centrifugal evaporation to afford (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-phenethoxy-[2,3'-bipyridin]-5'-yl)acetic acid (13.4 mg, 59% yield, 100% purity). ¹H NMR (500 MHz, METHANOL-d₄) δ 8.32 (d, *J*=2.7 Hz, 1H), 8.08 (s, 1H), 7.50 (dd, *J*=8.2, 2.7 Hz, 1H), 7.41 (d, *J*=8.5 Hz, 1H), 7.35 - 7.29 (m, 4H), 7.26 - 7.21 (m, 1H), 5.81 (s, 1H), 4.38 (br t, *J*=6.6 Hz, 2H), 3.15 (t, *J*=6.7 Hz, 2H), 3.02 (br s, 2H), 2.77 (br s, 2H), 2.64 (s, 3H), 1.41 (br s, 4H), 1.19 (s, 9H), 0.88 (s, 6H).
- 20


Example 286



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluoro-2-methylphenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

To a 1 dram vial equipped with a stir bar and charged with isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (20 mg, 0.043 mmol) was added triphenylphosphane (16.76 mg, 0.064 mmol). To the vial was added 2-(4-fluoro-2-methylphenyl)ethan-1-ol (9.85 mg, 0.064 mmol) as a solution in THF (0.25 mL). To the solution was added DIAD (0.012 mL, 0.064 mmol) as a solution in THF (0.25 mL). The solution was stirred at r.t. After 20 min the reaction solution was concentrated under a N₂ stream. The resulting residue was dissolved in ethanol (1.0 mL). To the solution was added aq. NaOH (5.0 M, 0.100 mL, 0.500 mmol). The vial was placed in a 85 deg C heating block with stirring for 5 h. The mixture was filtered through a 0.4 micron syringe filter and the filtrate was subjected to Prep-HPLC purification. Fractions containing the desired product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS and fractions containing the desired product were combined and dried via centrifugal evaporation to afford (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluoro-2-methylphenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (9.1 mg, 37% yield, 97.6% purity). ¹H NMR (500 MHz, METHANOL-d₄) δ 8.40 (d, *J*=2.4 Hz, 1H), 8.28 (s, 1H), 7.56 - 7.49 (m, 2H), 7.27 (dd, *J*=8.2, 5.8 Hz, 1H), 6.95 - 6.91 (m, 1H), 6.87 (t, *J*=8.1 Hz, 1H), 5.74 (s, 1H), 4.36 (t, *J*=6.7 Hz, 2H), 3.16 (t, *J*=6.6 Hz, 2H), 3.00 (br s, 2H), 2.94 (br s, 2H), 2.78 (s, 3H), 2.41 (s, 3H), 1.52 - 1.42 (m, 4H), 1.24 (s, 9H), 0.95 (s, 6H). *Alternative procedure:* To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-phenethoxy-[2,3'-bipyridin]-5'-yl)acetate (210 mg, 0.366 mmol) in ethanol (3 mL) was added a solution of sodium hydroxide (146 mg, 3.66 mmol) dissolved in water (0.3 mL) and heated at 90 °C for 16 hr. Then, the pH was adjusted to about 7 with acetic acid, filtered and the filtrate was directly subjected to HPLC purification to afford (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-phenethoxy-[2,3'-bipyridin]-5'-yl)acetic acid (66 mg, 0.121 mmol, 33.1 % yield). LCMS (M + H) = 532.


Example 287



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:

- 5 To a 1 dram vial charged with isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (25 mg, 0.053 mmol) and equipped with a stir bar was added ethanol (1.0 mL), then aq. NaOH (0.106 mL, 0.532 mmol). The vial was placed in a 85 deg C heating block with stirring for 18 h. The mixture was filtered through a 0.4 micron syringe filter and the filtrate was subjected
- 10 to Prep-HPLC purification. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (17.7 mg, 74 % yield, 95% purity). ¹H NMR (500 MHz, METHANOL-d₄) δ 8.25 (s, 1H), 8.18 - 8.16 (m, 1H), 7.39 (s, 2H), 5.84 (br s, 1H), 3.03 (br s, 1H), 2.83 (br s, 2H), 2.68 - 2.64 (m,
- 15 1H), 2.66 (s, 3H), 2.66 (br s, 1H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

Example 288



- (S)-2-(5-(Benzyloxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-butoxy)acetic acid:*
- 20


- To a 1 dram vial equipped with a stir bar was added isopropyl (S)-2-(5-(benzyloxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-butoxy)acetate (30 mg, 0.054 mmol), then ethanol (1.0 mL), then aq. sodium hydroxide (5.0 M, 0.11 mL, 0.54 mmol). The vial was capped, then placed in a 100 deg C heating
- 25 block with stirring for 2h. The mixture was cooled to r.t and then filtered through a 0.4 micron syringe filter. The filtrate was subjected to Prep-HPLC purification. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford (S)-2-(5-(benzyloxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-

yl)-2-(tert-butoxy)acetic acid (18.3 mg, 65 % yield, 99% purity). ¹H NMR (500 MHz, METHANOL-d₄) δ 8.49 (d, *J*=2.7 Hz, 1H), 8.31 (s, 1H), 7.65 (dd, *J*=8.4, 2.9 Hz, 1H), 7.55 - 7.48 (m, 3H), 7.44 - 7.34 (m, 3H), 5.74 (s, 1H), 5.30 (s, 2H), 2.99 (br s, 2H), 2.90 (br s, 2H), 2.75 (s, 3H), 1.46 (br s, 4H), 1.23 (s, 9H), 0.93 (s, 6H).

5

Examples 289 to 417 were prepared by one of the general methods described below.

General Procedure E




10 To a 1 dram vial equipped with a stir bar was added the alcohol (0.080 mmol), isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (25 mg, 0.053 mmol), and triphenylphosphine (20.9 mg, 0.080 mmol) as a solution in THF (0.25 mL). To the solution was added DIAD (0.016 mL, 0.080 mmol) as a solution in THF (0.25 mL). The solution was stirred at r.t. for 30

15 min to 18 h. The reaction solution was concentrated under a N₂ stream. The residue was dissolved in EtOH (1.0 mL). To the solution was added aq. NaOH (5.0 M, 0.110 mL, 0.532 mmol). The vial was capped, then placed in a 85 °C heating block with stirring for 4 h to 18 h. The mixture was cooled to r.t., then was filtered through a 0.4 micron syringe filter and the filtrate was directly subjected to HPLC purification to afford the purified

20 product.

General Procedure F




To a 1 dram vial equipped with a stir bar was added the alcohol (0.080 mmol), isopropyl (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-hydroxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate as a solution in THF (0.355 M, 0.150 mL, 0.053 mmol), and

25


triphenylphosphine as a solution in THF (0.535 M, 0.150 mL, 0.080 mmol). To the stirred solution was added diisopropyl diazene-1,2-dicarboxylate ("DIAD") as a solution in THF (0.535 M, 0.150 mL, 0.080 mmol). The solution was stirred at r.t. for 30 min to 18 h. The reaction solution was concentrated under a N₂ stream. The residue was dissolved in EtOH (1.0 mL). To the solution was added aq. sodium hydroxide (5.0 M, 0.160 mL, 0.795 mmol). The vial was capped, then placed in a 85 °C heating block with stirring for 4h to 18h. The mixture was cooled to r.t. and to the mixture was added AcOH (0.050 mL). The mixture was filtered through a 0.4 micron syringe filter and the filtrate was directly subjected to HPLC purification to afford the purified product.

General Procedure G




To a 1 dram vial equipped with a stir bar was added the alcohol (0.080 mmol), a solution of isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-hydroxyphenyl)-2-methylpyridin-3-yl)acetate (0.355 M, 0.150 ml, 0.053 mmol) in THF, a solution of triphenylphosphane (0.535 M, 0.150 ml, 0.080 mmol) in THF, then a solution of diisopropyl (E)-diazene-1,2-dicarboxylate (0.535 M, 0.150 ml, 0.080 mmol) in THF. Alternately, to a 1 dram vial equipped with a stir bar was added the alcohol (0.080 mmol), then a solution of isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-hydroxyphenyl)-2-methylpyridin-3-yl)acetate (0.355 M, 0.053 mmol), triphenylphosphane (0.535 M, 0.080 mmol) and diisopropyl (E)-diazene-1,2-dicarboxylate (0.535 M, 0.080 mmol) in THF (0.450 mL). In either preparation, the reaction solution was then stirred at r.t. for 18 h. The reaction solution was concentrated under a N₂ gas stream. To each vial was added EtOH (1.0 mL), then sodium hydroxide (aq.) (5.0 M, 0.160 ml, 0.795 mmol). The vial was capped, then placed in a 85 °C heating block for 4 h. The reaction mixture was cooled to r.t. and then filtered through a 0.4 micron syringe filter. The filtrate was subjected to HPLC purification to afford the purified product.

General Procedure H



To a 1 dram vial equipped with a stir bar was added the alcohol (0.080 mmol), and isopropyl (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5',6'-difluoro-6-methyl-
 5 [3,3'-bipyridin]-5-yl)acetate as a solution in THF (0.105 M, 0.500 mL, 0.053 mmol), then potassium tert-butoxide in THF (1.00 M, 0.077 mL, 0.077 mmol). The solution was stirred at r.t. for 15 min, then the volatiles were evaporated under a N₂ gas stream. The residue was dissolved in EtOH (1.0 mL). To the solution was added aq. sodium hydroxide (5.0 M, 0.160 mL, 0.795 mmol). The vial was capped, then placed in a 85 °C heating
 10 block with stirring for 1 h. The mixture was cooled to r.t. To the mixture was added acetic acid (0.050 mL). The mixture was filtered through a 0.4 micron syringe filter. The filtrate directly subjected to HPLC purification to afford the purified product.

Example 289




15

General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[2-(2-methylphenyl)ethoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (8.7 mg, 30% yield, 98.8% purity). LCMS observed ion = 546.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.42 (d, J=2.7 Hz, 1H), 8.34 (s, 1H), 7.59 - 7.52 (m, 2H), 7.27 (d, J=6.3 Hz, 1H), 7.20 - 7.13 (m, 3H), 5.71 (s, 1H), 4.37 (t, J=6.9 Hz, 2H), 3.20 (t, J=6.9 Hz, 2H), 2.96 (br s, 4H), 2.79 (s, 3H), 2.41 (s, 3H), 1.56 - 1.44 (m, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

20


Example 290



General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[2-(3-methylphenyl)ethoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (11.4 mg, 39% yield, 98.5% purity). LCMS observed ion = 546.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.42 (d, J=2.7 Hz, 1H), 8.35 (s, 1H), 7.59 - 7.53 (m, 2H), 7.22 - 7.19 (m, 1H), 7.17 (s, 1H), 7.13 (d, J=7.3 Hz, 1H), 7.07 (d, J=7.6 Hz, 1H), 5.71 (s, 1H), 4.37 (t, J=6.9 Hz, 2H), 3.12 (t, J=6.7 Hz, 2H), 3.08 - 2.88 (m, 4H), 2.79 (s, 3H), 2.35 (s, 3H), 1.54 - 1.44 (m, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Alternative procedure: To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(3-methylphenethoxy)-[2,3'-bipyridin]-5'-yl)acetate (280 mg, 0.476 mmol) in methanol (8 mL) was added sodium hydroxide (381 mg, 9.53 mmol) in water (3 mL) and stirred at 80°C overnight. Then, the mixture was acidified with aq. HCl to pH = 7 and concentrated. The crude was purified by Prep-HPLC to afford (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(3-methylphenethoxy)-[2,3'-bipyridin]-5'-yl)acetic acid (210 mg, 0.381 mmol, 80 % yield) as a white solid. LCMS [M + H] 546.


Example 291



General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(4-methoxy-3-methylphenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (11.1 mg, 36% yield, 100% purity). LCMS observed ion = 576.4. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.42 (s, 1H), 8.36 (d, J=1.5 Hz, 1H), 7.56 (q, J=9.0 Hz, 2H), 7.14 - 7.09 (m, 2H), 6.85 (d, J=8.2 Hz, 1H), 5.71 (s, 1H), 4.35 - 4.31 (m, 2H), 3.82 (d, J=1.8 Hz, 3H), 3.06 (br t, J=6.7

Hz, 2H), 2.96 (br s, 4H), 2.79 (d, J=1.5 Hz, 3H), 2.19 (s, 3H), 1.56 - 1.43 (m, 4H), 1.25 (d, J=1.5 Hz, 9H), 0.98 - 0.94 (m, 6H).

Example 292




5

General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(4-methoxy-2-methylphenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (12.2 mg, 40% yield, 100% purity). LCMS observed ion = 576.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.32 (d, J=2.7 Hz, 1H), 8.08 (s, 1H), 7.52 (dd, J=8.5, 2.7 Hz, 1H), 7.42 (d, J=8.5 Hz, 1H), 7.18 (d, J=8.5 Hz, 1H), 6.77 (s, 1H), 6.73 (d, J=8.1 Hz, 1H), 5.76 (s, 1H), 4.30 (t, J=7.0 Hz, 2H), 3.77 (s, 3H), 3.12 (t, J=6.9 Hz, 2H), 2.74 (br s, 2H), 2.64 (s, 3H), 2.38 (s, 3H), 1.42 (br s, 4H), 1.18 (s, 9H), 0.89 (s, 6H).

10

15

Example 293



General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(4-methoxyphenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (16.1 mg, 54% yield, 100% purity). LCMS observed ion = 562.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.32 (d, J=3.1 Hz, 1H), 8.09 (s, 1H), 7.52 (dd, J=8.5, 2.7 Hz, 1H), 7.43 (d, J=8.5 Hz, 1H), 7.27 - 7.24 (m, J=8.5 Hz, 2H), 6.91 - 6.87 (m, J=8.5 Hz, 2H), 5.76 (s, 1H), 4.32 (t, J=6.7 Hz, 2H), 3.79 (s, 3H), 3.09 (t, J=6.7 Hz, 2H), 2.74 (br s, 2H), 2.64 (s, 3H), 1.42 (br s, 4H), 1.19 (s, 9H), 0.89 (s, 6H).


20

25

Alternative procedure: To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-methoxyphenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (0.290 g, 0.480 mmol) in ethanol (5 mL) and water (1.0 mL)) was added NaOH (0.192 g,


4.80 mmol) at once. The resulting mixture was stirred at 90 °C for 10 hours. Then, the reaction was cooled, diluted with EtOAc (10ml), washed with 1N HCl and brine (10 ml each), dried by Na₂SO₄, filtered and concentrated to give crude product. The crude product was purified by prep-HPLC to give the desired product (S)-2-(tert-butoxy)-2-(4'-
 5 (4,4-dimethylpiperidin-1-yl)-5-(4-methoxyphenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (140 mg, 0.243 mmol, 50.6 % yield) as white solid. LCMS (M + H) = 562.3.

Example 294




General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(4-fluoro-3-methylphenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (10.4 mg, 34% yield, 98.5% purity). LCMS observed ion = 564.2. ¹H NMR (500 MHz, METHANOL-d₄) δ
 15 8.42 (d, J=2.4 Hz, 1H), 8.35 (s, 1H), 7.59 - 7.53 (m, 2H), 7.22 (br d, J=7.0 Hz, 1H), 7.18 - 7.14 (m, 1H), 6.97 (t, J=8.7 Hz, 1H), 5.70 (s, 1H), 4.36 (t, J=6.6 Hz, 2H), 3.11 (t, J=6.6 Hz, 2H), 2.96 (br s, 4H), 2.79 (s, 3H), 2.27 (s, 3H), 1.54 - 1.42 (m, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Example 295




General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(5-fluoro-2-methylphenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (9.7 mg, 32% yield, 97.6% purity). LCMS observed ion = 564.2. ¹H NMR (500 MHz, METHANOL-d₄) δ
 25 8.33 (d, J=3.1 Hz, 1H), 8.08 (s, 1H), 7.54 (dd, J=8.5, 2.7 Hz, 1H), 7.43 (d, J=8.5 Hz, 1H), 7.19 (t, J=7.2 Hz, 1H), 7.05 (dd, J=9.9, 2.6 Hz, 1H), 6.88 (td, J=8.5, 2.7 Hz, 1H), 5.75 (s, 1H), 4.37 (t, J=6.7 Hz, 2H), 3.18 (t, J=6.7 Hz, 2H), 2.74 (br s, 2H), 2.64 (s, 3H), 2.38 (s, 3H), 1.42 (br s, 4H), 1.18 (s, 9H), 0.89 (s, 6H).

Example 296



General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(2-methoxyphenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (10 mg, 33% yield, 99% purity). LCMS observed ion = 562.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.43 (d, J=2.7 Hz, 1H), 8.36 (s, 1H), 7.59 - 7.53 (m, 2H), 7.27 - 7.23 (m, 2H), 6.99 (d, J=8.5 Hz, 1H), 6.91 (t, J=7.3 Hz, 1H), 5.71 (s, 1H), 4.35 (t, J=7.2 Hz, 2H), 3.89 (s, 3H), 3.16 (t, J=7.2 Hz, 2H), 2.97 (br s, 4H), 2.79 (s, 3H), 1.55 - 1.44 (m, 4H), 1.24 (s, 9H), 0.97 (s, 6H).

Example 297




General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(2,6-dichlorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (10.9 mg, 34% yield, 100% purity). LCMS observed ion = 600.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.43 (d, J=2.4 Hz, 1H), 8.35 (s, 1H), 7.61 (dd, J=8.5, 2.4 Hz, 1H), 7.55 (d, J=8.9 Hz, 1H), 7.43 (d, J=7.9 Hz, 2H), 7.27 (t, J=8.1 Hz, 1H), 5.70 (s, 1H), 4.44 (t, J=7.0 Hz, 2H), 3.59 - 3.52 (m, 2H), 2.96 (br s, 4H), 2.79 (s, 3H), 1.49 (br d, J=4.0 Hz, 4H), 1.24 (s, 9H), 0.97 (s, 6H).

Alternative Procedure: To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(5-(2,6-dichlorophenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (300 mg, 0.467 mmol) in methanol (10 mL) and water (2.00 mL) was added sodium hydroxide (373 mg, 9.34 mmol) and stirred for 20 hours at 100 °C. Then, neutralized and purified by Prep-HPLC to give desired product (S)-2-(tert-butoxy)-2-(5-

(2,6-dichlorophenoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (110 mg, 0.180 mmol, 38.6 % yield) as white solid. LCMS (M + H) = 600.2.

5


Example 298



General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[2-(2,4,6-trifluorophenyl)ethoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (10.5 mg, 33% yield, 97.6% purity). LCMS observed ion = 586.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.40 (s, 1H), 7.59 - 7.52 (m, 2H), 6.89 (t, J=8.4 Hz, 2H), 5.58 (br s, 1H), 4.37 (t, J=6.4 Hz, 2H), 3.21 (t, J=6.4 Hz, 2H), 2.92 (br s, 4H), 2.78 (br s, 3H), 1.47 (br s, 4H), 1.23 (s, 9H), 0.95 (s, 6H).


15

Example 299




General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(3,4-difluorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (11.3 mg, 37% yield, 97% purity). LCMS observed ion = 568.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.42 (br s, 1H), 8.35 (br s, 1H), 7.60 - 7.53 (m, 2H), 7.29 (t, J=9.5 Hz, 1H), 7.24 - 7.18 (m, 1H), 7.18 - 7.13 (m, 1H), 5.67 (br s, 1H), 4.38 (t, J=6.4 Hz, 2H), 3.16 (t, J=6.3 Hz, 2H), 2.95 (br s, 4H), 2.78 (s, 3H), 1.48 (br s, 4H), 1.24 (s, 9H), 0.95 (s, 6H).

Example 300




General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[2-(4-methylphenyl)ethoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (13.3 mg, 45% yield, 98% purity). LCMS observed ion = 546.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.41 (d, J=2.7 Hz, 1H), 8.35 (s, 1H), 7.59 - 7.52 (m, 2H), 7.24 - 7.21 (m, J=7.9 Hz, 2H), 7.16 - 7.13 (m, J=7.9 Hz, 2H), 5.71 (s, 1H), 4.36 (t, J=6.7 Hz, 2H), 3.12 (t, J=6.7 Hz, 2H), 2.95 (br s, 4H), 2.79 (s, 3H), 2.33 (s, 3H), 1.53 - 1.44 (m, 4H), 1.24 (s, 9H), 0.98 - 0.92 (m, 6H).

Example 301




General Procedure E was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(3-methoxyphenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (11.7 mg, 39% yield, 98% purity). LCMS observed ion = 562.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.42 (d, J=2.7 Hz, 1H), 8.35 (s, 1H), 7.59 - 7.52 (m, 2H), 7.24 (t, J=8.1 Hz, 1H), 6.92 (s, 1H), 6.92 (d, J=6.7 Hz, 1H), 6.82 (d, J=8.2 Hz, 1H), 5.71 (s, 1H), 4.39 (t, J=6.7 Hz, 2H), 3.81 (s, 3H), 3.14 (t, J=6.6 Hz, 2H), 2.99 (br s, 2H), 2.95 (br s, 2H), 2.78 (s, 3H), 1.54 - 1.43 (m, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Example 302



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(2-chlorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (22.4 mg, 74% yield, 98.6% purity). LCMS observed ion = 566.2. ¹H NMR (500 MHz, METHANOL-d4) δ 8.43 (d, J=2.7 Hz, 1H), 8.35 (s, 1H), 7.60 - 7.53 (m, 2H), 7.47 - 7.41 (m, 2H), 7.32 - 7.25 (m, 2H), 5.70 (s, 1H), 4.43 (t, J=6.9 Hz, 2H), 3.35 - 3.31 (m, 2H), 2.95 (br s, 4H), 2.79 (s, 3H), 1.54 - 1.43 (m, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Example 303




10

General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(2-fluorophenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (20 mg, 68% yield, 100% purity). LCMS observed ion = 550.3. ¹H NMR (500 MHz, METHANOL-d4) δ 8.42 (d, J=2.4 Hz, 1H), 8.35 (s, 1H), 7.58 (d, J=8.3 Hz, 1H), 7.54 (d, J=8.5 Hz, 1H), 7.41 (t, J=7.6 Hz, 1H), 7.32 - 7.27 (m, 1H), 7.16 (t, J=7.4 Hz, 1H), 7.10 (t, J=9.3 Hz, 1H), 5.71 (s, 1H), 4.40 (t, J=6.7 Hz, 2H), 3.22 (t, J=6.7 Hz, 2H), 2.95 (br s, 4H), 2.78 (s, 3H), 1.54 - 1.43 (m, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Alternative procedure: To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(2-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (210 mg, 0.355 mmol) in methanol (15 mL) was added a solution of sodium hydroxide (142 mg, 3.55 mmol) in water (3 mL). The mixture was stirred at reflux for 6 h. Then, the pH was adjusted to 8 and purified by Pre-HPLC to give desired product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(2-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (110 mg, 0.194 mmol, 54.7 % yield). LCMS [M + H] = 550.2.


25

Example 304




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(3-fluorophenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (19.9 mg, 68% yield, 96.4% purity). LCMS observed ion = 550.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.43 (d, J=2.7 Hz, 1H), 8.35 (s, 1H), 7.60 - 7.57 (m, 1H), 7.56 - 7.53 (m, 1H), 7.37 - 7.32 (m, 1H), 7.17 (d, J=7.6 Hz, 1H), 7.11 (br d, J=10.1 Hz, 1H), 6.98 (t, J=8.2 Hz, 1H), 5.71 (s, 1H), 4.40 (t, J=6.4 Hz, 2H), 3.19 (t, J=6.4 Hz, 2H), 2.96 (br s, 4H), 2.78 (s, 3H), 1.54 - 1.42 (m, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Example 305



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(2-chloro-6-fluorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (19.9 mg, 64% yield, 98.7% purity). LCMS observed ion = 584.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.42 (d, J=2.4 Hz, 1H), 8.36 (s, 1H), 7.60 - 7.57 (m, 1H), 7.56 - 7.53 (m, 1H), 7.33 - 7.28 (m, 2H), 7.15 - 7.10 (m, 1H), 5.70 (s, 1H), 4.42 (t, J=6.9 Hz, 2H), 3.41 - 3.36 (m, 2H), 2.96 (br s, 4H), 2.79 (s, 3H), 1.54 - 1.44 (m, 4H), 1.24 (s, 9H), 0.97 (s, 6H).


Example 306



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(2,4-difluorophenyl)ethoxy]-4'-(4,4-


dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (21.6 mg, 71% yield, 98.6% purity). LCMS observed ion = 568.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.42 (d, J=2.7 Hz, 1H), 8.35 (s, 1H), 7.59 - 7.56 (m, 1H), 7.56 - 7.52 (m, 1H), 7.47 - 7.41 (m, 1H), 6.98 - 6.93 (m, 2H), 5.71 (s, 1H), 4.38 (t, J=6.6 Hz, 2H), 3.20 (t, J=6.6 Hz, 2H), 2.95 (br s, 4H), 2.78 (s, 3H), 1.54 - 1.44 (m, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Example 307



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(3-chloro-4-fluorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (18.5 mg, 59% yield, 100% purity). LCMS observed ion = 584.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.34 (d, J=2.7 Hz, 1H), 8.10 (s, 1H), 7.53 (dd, J=8.5, 2.7 Hz, 1H), 7.49 (dd, J=7.0, 2.1 Hz, 1H), 7.44 (d, J=8.5 Hz, 1H), 7.32 (t, J=6.6 Hz, 1H), 7.19 (t, J=8.9 Hz, 1H), 5.77 (s, 1H), 4.36 (t, J=6.4 Hz, 2H), 3.15 (t, J=6.3 Hz, 2H), 3.23 - 2.85 (m, 2H), 2.77 (br s, 2H), 2.64 (s, 3H), 1.42 (br s, 4H), 1.19 (s, 9H), 0.89 (s, 6H).

Example 308




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(3-chlorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (25.7 mg, 85% yield, 98.7% purity). LCMS observed ion = 566.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.43 (d, J=2.7 Hz, 1H), 8.36 (s, 1H), 7.60 - 7.57 (m, 1H), 7.57 - 7.54 (m, 1H), 7.39 (s, 1H), 7.34 - 7.25 (m, 3H), 5.70 (s, 1H), 4.40 (t, J=6.6 Hz, 2H), 3.17 (t, J=6.4 Hz, 2H), 2.96 (br s, 4H), 2.79 (s, 3H), 1.49 (br d, J=4.0 Hz, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Alternative procedure: To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(5-(3-chlorophenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate


(300 mg, 0.493 mmol) in methanol (1 mL) and trifluoroethanol (1.000 mL) was added sodium hydroxide (4.93 mL, 4.93 mmol) and stirred for 20 hours at 100 °C. Then, the reaction mixture was neutralized with HCl (1N, 0.5ml) and purified by HPLC to give desired product (S)-2-(tert-butoxy)-2-(5-(3-chlorophenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (95.7 mg, 0.165 mmol, 33.4 % yield) as white solid. LCMS [M + H] = 566.2.

Example 309




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(4-chlorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (26.7 mg, 89% yield, 98.7% purity). LCMS observed ion = 566.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.42 (d, J=2.7 Hz, 1H), 8.35 (s, 1H), 7.59 - 7.56 (m, 1H), 7.56 - 7.53 (m, 1H), 7.36 - 7.31 (m, 4H), 5.70 (s, 1H), 4.38 (t, J=6.6 Hz, 2H), 3.16 (t, J=6.4 Hz, 2H), 2.96 (br s, 4H), 2.79 (s, 3H), 1.49 (br d, J=4.3 Hz, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Example 310




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(2-chloro-4-fluorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (23.7 mg, 76% yield, 98.5% purity). LCMS observed ion = 584.1. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.43 (d, J=2.7 Hz, 1H), 8.36 (s, 1H), 7.60 - 7.57 (m, 1H), 7.55 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.5, 6.1 Hz, 1H), 7.26 (dd, J=8.7, 2.6 Hz, 1H), 7.08 (td, J=8.4, 2.7 Hz, 1H), 5.70 (s, 1H), 4.41 (t, J=6.6 Hz, 2H), 3.31 - 3.29 (m, 2H), 2.96 (br s, 4H), 2.79 (s, 3H), 1.55 - 1.43 (m, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Example 311



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[(2S)-3-methylbutan-2-yl]oxy]-[2,3'-bipyridine]-5'-yl]acetic acid (13.1 mg, 49% yield, 96.4% purity). LCMS observed ion = 498.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.41 (d, J=2.7 Hz, 1H), 8.39 - 8.35 (m, 1H), 7.59 (dd, J=8.5, 3.1 Hz, 1H), 7.55 (d, J=8.9 Hz, 1H), 5.73 (s, 1H), 4.44 (quin, J=6.1 Hz, 1H), 2.97 (br s, 4H), 2.79 (s, 3H), 2.04 - 1.95 (m, 1H), 1.53 - 1.44 (m, 4H), 1.32 (d, J=6.4 Hz, 3H), 1.27 - 1.23 (m, 9H), 1.07 (d, J=6.7 Hz, 3H), 1.04 (d, J=6.7 Hz, 3H), 0.96 (s, 6H).

Example 312




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(2-methylpropoxy)]-[2,3'-bipyridine]-5'-yl]acetic acid (17.6 mg, 68% yield, 100% purity). LCMS observed ion = 484.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.37 (d, J=2.7 Hz, 1H), 8.17 (s, 1H), 7.55 (dd, J=8.7, 2.9 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H), 5.84 (s, 1H), 3.92 (d, J=6.4 Hz, 2H), 2.83 (br s, 4H), 2.66 (s, 3H), 2.15 (dt, J=13.3, 6.8 Hz, 1H), 1.44 (br s, 4H), 1.21 (s, 9H), 1.10 (d, J=6.7 Hz, 6H), 0.91 (s, 6H).

Alternative procedure: To a stirred solution of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (100 mg, 0.190 mmol) in methanol (5 mL) was added NaOH (152 mg, 3.80 mmol) in water (1.00 mL) and stirred at 90 °C for 18 hours. The mixture was concentrated and residue was diluted with EtOAc (50 mL), water (20 mL) and adjusted the pH to 7 with acetic acid. Then, the organic layer was separated and washed with brine (20 mL x3), dried over MgSO₄ and concentrated to afford (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-isobutoxy-

6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (80 mg, 0.163 mmol, 86 % yield) as a white foam. LCMS (M + H) = 484.

Example 313




5

General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (20.1 mg, 78% yield, 100% purity). LCMS observed ion = 484.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.37 (d, J=2.7 Hz, 1H), 8.18 (s, 1H), 7.55 (dd, J=8.5, 3.1 Hz, 1H), 7.47 (d, J=8.9 Hz, 1H), 5.84 (s, 1H), 4.16 (t, J=6.4 Hz, 2H), 2.84 (br s, 4H), 2.66 (s, 3H), 1.88 - 1.82 (m, 2H), 1.57 (sxt, J=7.4 Hz, 2H), 1.44 (br s, 4H), 1.21 (s, 9H), 1.03 (t, J=7.5 Hz, 3H), 0.91 (s, 6H).

Alternative procedure: To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (250 mg, 0.476 mmol) in methanol (5 mL) was added a solution of NaOH (285 mg, 7.13 mmol) in water (1 mL). The resulting mixture was stirred at 70 °C for 16 h. Then, the reaction solution was purified by Pre-HPLC to afford the desired product (S)-2-(tert-butoxy)-2-(5-butoxy-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (180 mg, 0.361 mmol, 76 % yield) as white solid. LCMS (M + H) = 484.3.

20


Example 314



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(propan-2-yloxy)-[2,3'-bipyridine]-5'-yl]acetic acid (17.3 mg, 69% yield, 100% purity). LCMS observed ion = 470.1. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.40 (d, J=2.7 Hz, 1H), 8.38 (s, 1H), 7.58 (dd, J=8.9, 2.7 Hz, 1H), 7.55 (d, J=8.5 Hz, 1H), 5.72 (s, 1H), 4.81 -

4.78 (m, 1H), 2.98 (br s, 4H), 2.79 (s, 3H), 1.53 - 1.45 (m, 4H), 1.41 (dd, J=6.0, 3.5 Hz, 6H), 1.25 (s, 9H), 0.97 (s, 5H), 0.96 - 0.95 (m, 1H).

Example 315




5

General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(3-methylbutoxy)-[2,3'-bipyridine]-5'-yl]acetic acid (14.4 mg, 54% yield, 98.8% purity). LCMS Method 2: retention time = 2.06 min.; observed ion = 498.2. ¹H NMR (500 MHz, 10 METHANOL-d₄) δ 8.37 (d, J=2.7 Hz, 1H), 8.17 (s, 1H), 7.56 (dd, J=8.5, 2.7 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H), 5.84 (s, 1H), 4.19 (t, J=6.6 Hz, 2H), 2.83 (br s, 1H), 3.15 - 2.75 (m, 4H), 2.66 (s, 3H), 1.90 (spt, J=6.6 Hz, 1H), 1.76 (q, J=6.7 Hz, 2H), 1.44 (br s, 4H), 1.21 (s, 9H), 1.02 (d, J=6.7 Hz, 6H), 0.91 (s, 6H).

Alternative procedure: To a stirred solution of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(isopentyloxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (240 mg, 0.445 mmol) in methanol (10 mL) was added a solution of sodium hydroxide (534 mg, 13.34 mmol) in water (3.00 mL). The mixture was stirred overnight at 75 °C, cooled, pH was adjusted to 8 and concentrated. The residue was purified by Pre-HPLC to afford the desired product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(isopentyloxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (153 mg, 0.307 mmol, 69.1 % 20 yield) as a white solid. LCMS [M + H] = 498.4.

Example 316




25

General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[5-(3,3-dimethylbutoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (13.1 mg, 48% yield, 98.8% purity).

LCMS observed ion = 512.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.36 (d, J=2.7 Hz, 1H), 8.17 (s, 1H), 7.56 (dd, J=8.5, 2.7 Hz, 1H), 7.48 (d, J=8.9 Hz, 1H), 5.85 (s, 1H), 4.23 (t, J=7.0 Hz, 2H), 3.14 - 2.72 (m, 4H), 2.66 (s, 3H), 1.81 (t, J=7.0 Hz, 2H), 1.44 (br s, 4H), 1.21 (s, 9H), 1.05 (s, 9H), 0.91 (s, 6H).

5


Example 317



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(pentyloxy)-[2,3'-bipyridine]-5'-yl]acetic acid (11.6 mg, 44% yield, 100% purity). LCMS observed ion = 498.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.37 (d, J=2.7 Hz, 1H), 8.17 (s, 1H), 7.55 (dd, J=8.5, 2.7 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H), 5.84 (s, 1H), 4.15 (t, J=6.4 Hz, 2H), 3.15 - 2.72 (m, 4H), 2.66 (s, 3H), 1.90 - 1.84 (m, 2H), 1.56 - 1.41 (m, 8H), 1.21 (s, 9H), 0.99 (t, J=7.2 Hz, 3H), 0.91 (s, 6H).

Alternative procedure: To a stirred solution of (S)-isopropyl 2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(pentyloxy)-[2,3'-bipyridin]-5'-yl)acetate (220 mg, 0.408 mmol) in methanol (10 mL) was added a solution of sodium hydroxide (489 mg, 12.23 mmol) in water (3.00 mL). The mixture was stirred overnight at 75 °C and cooled, pH was adjusted to 8 and concentrated. The residue was purified by Pre-HPLC to afford the desired product (S)-2-(tert-butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(pentyloxy)-[2,3'-bipyridin]-5'-yl)acetic acid (121 mg, 0.238 mmol, 58.5 % yield) as a white solid. LCMS [M + H] = 498.4.

Example 318




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-propoxy-[2,3'-bipyridine]-5'-yl]acetic acid (5.2 mg, 20% yield, 97.5% purity). LCMS observed ion = 470.1. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.37 (d, J=2.7 Hz, 1H), 8.18 (s,

1H), 7.56 (dd, J=8.5, 2.7 Hz, 1H), 7.48 (d, J=8.5 Hz, 1H), 5.84 (s, 1H), 4.12 (t, J=6.4 Hz, 2H), 3.13 - 2.72 (m, 4H), 2.67 (s, 3H), 1.92 - 1.85 (m, 2H), 1.45 (br s, 4H), 1.22 (s, 9H), 1.11 (t, J=7.5 Hz, 3H), 0.92 (s, 6H).

5


Example 319



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-{[(2R)-3-methylbutan-2-yl]oxy}-[2,3'-bipyridine]-5'-yl]acetic acid (9.3 mg, 35% yield, 98.6%
 10 purity). LCMS observed ion = 498.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.35 (d, J=2.4 Hz, 1H), 8.19 (s, 1H), 7.57 (dd, J=8.7, 2.9 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H), 5.82 (s, 1H), 4.43 (quin, J=6.1 Hz, 1H), 2.83 (br s, 4H), 2.67 (s, 3H), 2.01 (sxt, J=7.0 Hz, 1H), 1.44 (br s, 4H), 1.32 (d, J=6.4 Hz, 3H), 1.21 (s, 9H), 1.06 (d, J=7.0 Hz, 3H), 1.03 (d, J=7.0 Hz, 3H), 0.91 (s, 6H).


15

Example 320




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(4-ethoxyphenyl)ethoxy]-6'-methyl-2,3'-bipyridine]-5'-yl]acetic acid (18.3 mg, 60% yield,
 20 100% purity). LCMS observed ion = 576.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.32 (d, J=2.7 Hz, 1H), 8.09 (s, 1H), 7.52 (dd, J=8.7, 2.9 Hz, 1H), 7.43 (d, J=8.5 Hz, 1H), 7.26 - 7.23 (m, J=8.5 Hz, 2H), 6.89 - 6.86 (m, J=8.5 Hz, 2H), 5.74 (s, 1H), 4.32 (t, J=6.6 Hz, 2H), 4.03 (q, J=6.8 Hz, 2H), 3.08 (t, J=6.9 Hz, 2H), 2.84 - 2.67 (m, 2H), 2.64 (s, 3H),
 25 1.49 - 1.32 (m, 7H), 1.18 (s, 9H), 0.89 (s, 6H).

Example 321




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(3-phenylpropoxy)-[2,3'-bipyridine]-5'-yl]acetic acid (10.1 mg, 34% yield, 100% purity). LCMS observed ion = 546.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.38 (d, J=2.7 Hz, 1H), 8.22 (s, 1H), 7.55 (dd, J=8.5, 2.7 Hz, 1H), 7.49 (d, J=8.9 Hz, 1H), 7.31 - 7.27 (m, 2H), 7.25 (d, J=6.7 Hz, 2H), 7.21 - 7.18 (m, 1H), 5.80 (s, 1H), 4.14 (t, J=6.3 Hz, 2H), 2.86 (br t, J=7.6 Hz, 2H), 3.16 - 2.77 (m, 4H), 2.68 (s, 3H), 2.20 - 2.14 (m, 2H), 1.45 (br s, 4H), 1.22 (s, 9H), 0.92 (s, 6H).

Example 322



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(4-ethylphenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (14.1 mg, 48% yield, 98.1% purity). LCMS observed ion = 560.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.38 (d, J=2.4 Hz, 1H), 8.13 (s, 1H), 7.52 (dd, J=8.7, 2.6 Hz, 1H), 7.44 (d, J=8.9 Hz, 1H), 7.24 (d, J=7.6 Hz, 2H), 7.16 (d, J=7.9 Hz, 2H), 5.88 (s, 1H), 4.36 - 4.25 (m, 2H), 3.30 (br s, 4H), 3.04 (t, J=6.9 Hz, 2H), 2.57 (q, J=7.9 Hz, 2H), 2.49 - 2.47 (m, 3H), 2.07 (br s, 1H), 1.62 - 1.45 (m, 1H), 1.30 (br s, 2H), 1.16 (t, J=7.6 Hz, 3H), 1.12 (s, 9H), 0.88 (br s, 3H), 0.77 (br s, 3H).

Example 323




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(3,5-difluorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (5.2 mg, 17% yield, 99.3% purity). LCMS observed ion = 568.2. ¹H NMR (500 MHz, METHANOL-d₄) δ

8.34 (d, J=2.4 Hz, 1H), 8.09 (s, 1H), 7.55 (dd, J=8.9, 2.7 Hz, 1H), 7.44 (d, J=8.5 Hz, 1H), 7.00 (br d, J=7.0 Hz, 2H), 6.83 (br t, J=8.5 Hz, 1H), 5.75 (s, 1H), 4.39 (t, J=6.4 Hz, 2H), 3.19 (t, J=6.3 Hz, 2H), 2.71 (br s, 2H), 2.64 (s, 3H), 1.42 (br s, 4H), 1.18 (s, 9H), 0.89 (s, 6H).

Alternative procedure: To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(5-(3,5-difluorophenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (200 mg, 0.328 mmol) in methanol (10 mL) was added a solution of sodium hydroxide (394 mg, 9.84 mmol) in water (3.00 mL). The mixture was stirred overnight at 75 °C and pH was adjusted to 8. The mixture was purified by Pre-HPLC to afford the desired product (S)-2-(tert-butoxy)-2-(5-(3,5-difluorophenethoxy)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (60 mg, 0.106 mmol, 32.2 % yield) as a white solid. LCMS [M + H] = 568.2.


Example 324



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(3,5-dichlorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (1.3 mg, 4% yield, 98.5% purity). LCMS observed ion = 600.2. ¹H NMR (500 MHz, METHANOL-d₄) δ


8.37 (d, J=2.4 Hz, 1H), 8.17 (s, 1H), 7.56 (dd, J=8.7, 2.9 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H), 7.37 - 7.33 (m, 3H), 5.81 (s, 1H), 4.39 (t, J=6.3 Hz, 2H), 3.17 (t, J=6.3 Hz, 2H), 2.80 (br s, 4H), 2.66 (s, 3H), 1.44 (br s, 4H), 1.21 (s, 9H), 0.90 (s, 6H).

Example 325




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[2-(4-propoxyphenyl)ethoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (16.5 mg, 53% yield, 100% purity). LCMS observed ion = 590.4. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.35 (d, J=2.7 Hz, 1H), 8.17 (s, 1H), 7.54 (dd, J=8.5, 2.7 Hz, 1H), 7.46 (d, J=8.5 Hz, 1H), 7.26 - 7.23 (m, J=8.5 Hz, 2H), 6.89 - 6.86 (m, J=8.5 Hz, 2H), 5.81 (s, 1H), 4.32 (t, J=6.6 Hz, 2H), 3.93 (t, J=6.6 Hz, 2H), 3.09 (t, J=6.7 Hz, 2H), 2.81 (br s, 2H), 2.66 (s, 3H), 1.83 - 1.76 (m, 2H), 1.44 (br s, 4H), 1.21 (s, 9H), 1.05 (t, J=7.5 Hz, 3H), 0.91 (s, 6H).

Example 326



General procedure B was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-(heptyloxy)-6'-methyl-2,3'-bipyridine]-5'-yl]acetic acid (11.1 mg, 39% yield, 100% purity). LCMS observed ion = 526.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.37 (d, J=2.4 Hz, 1H), 8.20 (s, 1H), 7.56 (dd, J=8.7, 2.6 Hz, 1H), 7.48 (d, J=8.5 Hz, 1H), 5.82 (s, 1H), 4.15 (t, J=6.3 Hz, 2H), 2.84 (br s, 4H), 2.67 (s, 3H), 1.89 - 1.83 (m, 2H), 1.54 (quin, J=7.6 Hz, 2H), 1.49 - 1.40 (m, 6H), 1.37 (br s, 4H), 1.21 (s, 9H), 0.96 - 0.91 (m, 9H).


Example 327



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(2,6-difluorophenyl)ethoxy]-4'-(4,4-


dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (16.7 mg, 55% yield, 98.6% purity). LCMS observed ion = 568.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.30 (d, J=2.1 Hz, 1H), 8.08 (s, 1H), 7.53 (dd, J=8.5, 2.7 Hz, 1H), 7.43 (d, J=8.5 Hz, 1H), 7.35 - 7.29 (m, 1H), 7.00 (t, J=7.8 Hz, 2H), 5.74 (s, 1H), 4.37 (t, J=6.7 Hz, 2H), 3.25 (br t, J=6.6 Hz, 2H), 2.75 (br s, 2H), 2.64 (s, 3H), 1.42 (br s, 4H), 1.18 (s, 9H), 0.89 (s, 6H).

Example 328




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(2,3-dichlorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (6.7 mg, 21% yield, 99.3% purity). LCMS observed ion = 600.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.33 (s, 1H), 8.08 (s, 1H), 7.55 (br d, J=8.2 Hz, 1H), 7.48 - 7.41 (m, 3H), 7.29 (t, J=7.8 Hz, 1H), 5.74 (s, 1H), 4.42 (br t, J=6.4 Hz, 2H), 3.39 - 3.35 (m, 2H), 2.73 (br s, 2H), 2.64 (s, 3H), 1.42 (br s, 4H), 1.18 (s, 9H), 0.89 (s, 6H).

Example 329



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(2,3-difluorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (11.9 mg, 39% yield, 99.4% purity). LCMS observed ion = 568.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.31 (d, J=2.4 Hz, 1H), 8.08 (s, 1H), 7.52 (d, J=7.7 Hz, 1H), 7.43 (d, J=8.3 Hz, 1H), 7.22 - 7.10 (m, 3H), 5.74 (s, 1H), 4.39 (br t, J=6.7 Hz, 2H), 3.23 (br t, J=6.4 Hz, 2H), 2.75 (br s, 2H), 2.62 (s, 3H), 1.40 (br s, 4H), 1.17 (s, 9H), 0.87 (s, 6H).


Example 330



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(3-fluoro-4-methoxyphenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (21.1 mg, 68% yield, 98.6% purity). LCMS observed ion = 580.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.32 (s, 1H), 8.08 (s, 1H), 7.53 (d, J=8.1 Hz, 1H), 7.43 (br d, J=8.5 Hz, 1H), 7.13 - 7.03 (m, 3H), 5.74 (s, 1H), 4.33 (br t, J=6.4 Hz, 2H), 3.87 (s, 3H), 3.09 (br t, J=6.6 Hz, 2H), 2.74 (br s, 2H), 2.64 (s, 3H), 1.41 (br s, 4H), 1.18 (s, 9H), 0.88 (s, 6H).

10


Example 331



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(3-chloro-4-methylphenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (14.8 mg, 48% yield, 99.4% purity). LCMS observed ion = 580.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.33 (s, 1H), 8.11 (br s, 1H), 7.54 (dd, J=8.7, 2.6 Hz, 1H), 7.44 (d, J=8.5 Hz, 1H), 7.36 (s, 1H), 7.25 (d, J=7.9 Hz, 1H), 7.19 (br d, J=7.6 Hz, 1H), 5.76 (br s, 1H), 4.35 (t, J=6.4 Hz, 2H), 3.12 (br t, J=6.4 Hz, 2H), 2.76 (br s, 2H), 2.64 (s, 3H), 2.35 (s, 3H), 1.42 (br s, 4H), 1.19 (s, 9H), 0.89 (s, 6H).

20

Example 332




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[2-(3-fluoro-4-

25


methylphenyl)ethoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (10 mg, 33% yield, 100% purity). LCMS observed ion = 564.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.36 (d, J=2.1 Hz, 1H), 8.17 (s, 1H), 7.55 (dd, J=8.4, 2.6 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H), 7.18 (t, J=7.7 Hz, 1H), 7.07 - 7.02 (m, 2H), 5.81 (br s, 1H), 4.36 (t, J=6.6 Hz, 2H), 3.13 (br t, J=6.4 Hz, 2H), 2.82 (br s, 2H), 2.66 (s, 3H), 2.25 (s, 3H), 1.44 (br s, 4H), 1.21 (s, 9H), 0.91 (s, 6H).

Example 333




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(3-chloro-5-fluorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (2.5 mg, 8% yield, 95.9% purity). LCMS observed ion = 584.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.43 (s, 1H), 8.36 (s, 1H), 7.61 - 7.54 (m, 2H), 7.25 (s, 1H), 7.10 (br t, J=8.2 Hz, 2H), 5.70 (s, 1H), 4.41 (t, J=6.3 Hz, 2H), 3.19 (br t, J=6.1 Hz, 2H), 2.96 (br s, 4H), 2.78 (s, 3H), 1.48 (br s, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Example 334




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-(hexyloxy)-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (10.9 mg, 40% yield, 97.3% purity). LCMS observed ion = 512.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.37 (d, J=2.1 Hz, 1H), 8.19 (s, 1H), 7.56 (dd, J=8.4, 2.3 Hz, 1H), 7.48 (d, J=8.2 Hz, 1H), 5.82 (s, 1H), 4.15 (t, J=6.4 Hz, 2H), 2.84 (br s, 2H), 3.15 - 2.76 (m, 2H), 2.67 (s, 3H), 1.90 - 1.82 (m, 2H), 1.54 (br s, 2H), 1.49 - 1.38 (m, 8H), 1.21 (s, 9H), 0.98 - 0.94 (m, 3H), 0.92 (s, 6H).

Example 335




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[2-(3,4-dichlorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (8 mg, 25% yield, 98.8% purity). LCMS observed ion = 600.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.36 (s, 1H), 8.15 (s, 1H), 7.55 (s, 2H), 7.50 - 7.45 (m, 2H), 7.31 (br d, J=8.9 Hz, 1H), 5.81 (br s, 1H), 4.65 (br s, 4H), 4.38 (t, J=6.3 Hz, 2H), 3.16 (t, J=6.1 Hz, 2H), 2.65 (s, 3H), 1.43 (br s, 4H), 1.20 (s, 9H), 0.90 (s, 6H).

Example 336



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[(2-chlorophenyl)methoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (13.5 mg, 46% yield, 98.5% purity). LCMS observed ion = 552.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.47 (d, J=2.7 Hz, 1H), 8.19 (s, 1H), 7.67 - 7.60 (m, 2H), 7.53 - 7.48 (m, 2H), 7.39 (d, J=6.2 Hz, 2H), 5.82 (s, 1H), 5.37 (s, 2H), 2.82 (br s, 2H), 2.91 (br s, 2H), 2.66 (s, 3H), 1.44 (br s, 4H), 1.21 (s, 9H), 0.90 (s, 6H).


Example 337



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[(3-chlorophenyl)methoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (15 mg, 51% yield,


100% purity). LCMS observed ion = 552.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.46 (d, J=2.4 Hz, 1H), 8.18 (s, 1H), 7.63 (dd, J=8.7, 2.9 Hz, 1H), 7.53 (s, 1H), 7.49 (d, J=8.9 Hz, 1H), 7.45 (br d, J=7.6 Hz, 1H), 7.41 (t, J=7.6 Hz, 1H), 7.37 (d, J=7.9 Hz, 1H), 5.81 (s, 1H), 5.30 (s, 2H), 2.94 (br s, 2H), 2.81 (br s, 2H), 2.66 (s, 3H), 1.43 (br s, 4H),
5 1.21 (s, 9H), 0.89 (s, 6H).

Example 338




General Procedure F was followed. The experiment afforded the desired
10 compound, (2S)-2-(tert-butoxy)-2-{5-[(4-chlorophenyl)methoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (12.1 mg, 41% yield, 98% purity). LCMS observed ion = 552.2. ¹H NMR (500 MHz, DMSO-d₆) δ 8.45 (d, J=3.1 Hz, 1H), 8.13 (s, 1H), 7.59 (dd, J=8.7, 2.9 Hz, 1H), 7.54 - 7.51 (m, 2H), 7.49 - 7.45 (m, 3H), 5.86 (s, 1H), 5.30 - 5.23 (m, 2H), 2.49 - 2.47 (m, 3H), 2.12 - 1.95 (m, 2H),
15 1.53 (br s, 1H), 1.29 (br s, 2H), 1.12 (s, 9H), 1.05 (br s, 1H), 0.89 (br s, 3H), 0.72 (br s, 3H).

Example 339




General Procedure F was followed. The experiment afforded the desired
20 compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[(4-methoxyphenyl)methoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (4.1 mg, 14% yield, 95.7% purity). LCMS observed ion = 548.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.48 (d, J=2.4 Hz, 1H), 8.37 (s, 1H), 7.65 (dd, J=8.5, 2.7 Hz, 1H), 7.55 (d, J=8.5 Hz, 1H), 7.42 (br d, J=8.5 Hz, 2H), 6.96 (br d, J=8.5 Hz, 2H), 5.69 (s, 1H), 5.22 (s, 2H), 3.82
25 (s, 3H), 2.94 (br s, 4H), 2.79 (s, 3H), 1.47 (br s, 4H), 1.24 (s, 9H), 0.95 (s, 6H).

Example 340




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[(3-methoxyphenyl)methoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (16.3 mg, 56% yield, 97.4% purity). LCMS observed ion = 548.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.50 (d, J=2.1 Hz, 1H), 8.36 (s, 1H), 7.65 (dd, J=8.5, 2.7 Hz, 1H), 7.55 (d, J=8.9 Hz, 1H), 7.32 (t, J=8.1 Hz, 1H), 7.05 (s, 1H), 7.06 (d, J=7.5 Hz, 1H), 6.92 (br d, J=8.9 Hz, 1H), 5.70 (s, 1H), 5.29 (s, 2H), 3.82 (s, 3H), 2.93 (br s, 4H), 2.78 (s, 3H), 1.47 (br s, 4H), 1.24 (s, 9H), 0.94 (s, 6H).

Example 341




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(4-phenylbutoxy)-[2,3'-bipyridine]-5'-yl]acetic acid (11.8 mg, 39% yield, 94.5% purity). LCMS observed ion = 560.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.50 (d, J=2.1 Hz, 1H), 8.36 (s, 1H), 7.65 (dd, J=8.5, 2.7 Hz, 1H), 7.55 (d, J=8.9 Hz, 1H), 7.32 (t, J=8.1 Hz, 1H), 7.05 (s, 1H), 7.06 (d, J=7.5 Hz, 1H), 6.92 (br d, J=8.9 Hz, 1H), 5.70 (s, 1H), 5.29 (s, 2H), 3.82 (s, 3H), 2.93 (br s, 4H), 2.78 (s, 3H), 1.47 (br s, 4H), 1.24 (s, 9H), 0.94 (s, 6H).

Example 342




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[(4-methylphenyl)methoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (12.9 mg, 45% yield, 100% purity). LCMS observed ion = 532.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.42 (br s, 1H), 8.17 (br s, 1H), 7.61 (br d, J=8.2 Hz, 1H), 7.46 (d, J=8.9 Hz, 1H), 7.38 (br d, J=7.9 Hz, 2H), 7.23 (br d, J=7.6 Hz, 2H), 5.80 (br s, 1H), 5.24 (s, 2H), 2.79 (br s, 2H), 2.91 (br s, 2H), 2.66 (s, 3H), 2.36 (s, 3H), 1.42 (br s, 4H), 1.21 (s, 9H), 0.89 (s, 6H).

Example 343



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5'-(3-fluorophenyl)methoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (12.8 mg, 45% yield, 100% purity). LCMS observed ion = 536.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.46 (d, J=2.4 Hz, 1H), 8.18 (s, 1H), 7.63 (d, J=8.3 Hz, 1H), 7.50 - 7.41 (m, 2H), 7.33 (br d, J=7.9 Hz, 1H), 7.26 (br d, J=10.1 Hz, 1H), 7.09 (br t, J=8.4 Hz, 1H), 5.81 (s, 1H), 5.31 (s, 2H), 2.81 (br s, 2H), 2.94 (br s, 2H), 2.66 (s, 3H), 1.43 (br s, 4H), 1.21 (s, 9H), 0.89 (s, 6H).


Example 344



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5'-(4-fluorophenyl)methoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (8.6 mg, 30% yield, 100% purity). LCMS observed ion = 536.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.44 (br s, 1H), 8.18 (s, 1H), 7.63 (dd, J=8.5, 2.7 Hz, 1H), 7.54 (t, J=6.4 Hz, 2H), 7.48 (d,

J=8.9 Hz, 1H), 7.17 - 7.13 (m, 2H), 5.81 (br s, 1H), 5.26 (s, 2H), 2.93 (br s, 2H), 2.79 (br s, 2H), 2.66 (s, 3H), 1.43 (br s, 4H), 1.21 (s, 9H), 0.89 (s, 6H).

Example 345




5

General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[(4-methylpentyl)oxy]-[2,3'-bipyridine]-5'-yl]acetic acid (11 mg, 40% yield, 100% purity). LCMS observed ion = 512.4. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.37 (s, 1H), 8.19 (s, 1H), 7.56 (br d, J=8.9 Hz, 1H), 7.48 (d, J=8.5 Hz, 1H), 5.81 (s, 1H), 4.14 (t, J=6.4 Hz, 2H), 2.97 (br s, 2H), 2.84 (br s, 2H), 2.67 (s, 3H), 1.90 - 1.84 (m, 2H), 1.70 - 1.61 (m, 1H), 1.50 - 1.38 (m, 6H), 1.21 (s, 9H), 0.97 (d, J=6.7 Hz, 6H), 0.92 (s, 6H).

10

Example 346




15

General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[(2-methylphenyl)methoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (13.8 mg, 49% yield, 100% purity). LCMS observed ion = 532.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.45 (d, J=2.1 Hz, 1H), 8.19 (s, 1H), 7.65 (d, J=8.2 Hz, 1H), 7.49 (d, J=8.5 Hz, 1H), 7.44 (br d, J=7.3 Hz, 1H), 7.29 - 7.20 (m, 3H), 5.82 (s, 1H), 5.28 (s, 2H), 2.97 (br s, 2H), 2.83 (br s, 2H), 2.66 (s, 3H), 2.43 (s, 3H), 1.44 (br s, 4H), 1.21 (s, 9H), 0.90 (s, 6H).

20


Example 347



25


General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[(3-methylphenyl)methoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (12 mg, 42% yield, 100% purity). LCMS observed ion = 532.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.44 (d, J=2.4 Hz, 1H), 8.18 (br s, 1H), 7.62 (dd, J=8.5, 2.7 Hz, 1H), 7.47 (d, J=8.9 Hz, 1H), 7.33 - 7.27 (m, 3H), 7.18 (br d, J=5.5 Hz, 1H), 5.80 (br s, 1H), 5.25 (s, 2H), 2.94 (br s, 2H), 2.81 (br s, 2H), 2.66 (s, 3H), 2.38 (s, 3H), 1.43 (br s, 4H), 1.21 (s, 9H), 0.89 (s, 6H).

Example 348




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[(2-fluorophenyl)methoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (11.7 mg, 41% yield, 100% purity). LCMS observed ion = 536.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.46 (d, J=2.4 Hz, 1H), 8.19 (s, 1H), 7.66 (dd, J=8.5, 2.7 Hz, 1H), 7.58 (t, J=7.5 Hz, 1H), 7.50 (d, J=8.5 Hz, 1H), 7.45 - 7.40 (m, 1H), 7.24 (t, J=7.5 Hz, 1H), 7.19 (t, J=9.3 Hz, 1H), 5.82 (br s, 1H), 5.34 (s, 2H), 2.93 (br s, 2H), 2.82 (br s, 2H), 2.66 (s, 3H), 1.44 (br s, 4H), 1.21 (s, 9H), 0.90 (s, 6H).

Example 349




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[(1S)-1-phenylethoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (10.3 mg, 36% yield, 100% purity). LCMS observed ion = 532.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.34 (d, J=2.1 Hz, 1H), 8.13 (s, 1H), 7.49 - 7.43 (m, 3H), 7.38 - 7.34 (m, 3H), 7.30 - 7.26 (m, 1H), 5.78 (br s, 1H), 5.61 (q, J=6.3 Hz, 1H), 2.88 (br s, 2H), 2.74 (br s, 2H), 2.64 (s, 3H), 1.71 (d, J=6.4 Hz, 3H), 1.39 (br s, 4H), 1.19 (s, 9H), 0.90 (s, 6H).

Example 350




General Procedure F was followed. The experiment afforded the desired
 5 compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[(1R)-1-phenylethoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (16.8 mg, 59% yield, 100% purity).
 LCMS observed ion = 532.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.29 (br s, 1H),
 8.04 (s, 1H), 7.44 (br d, J=7.0 Hz, 3H), 7.38 - 7.26 (m, 4H), 5.70 (s, 1H), 5.59 (br d, J=5.8
 Hz, 1H), 2.62 (s, 3H), 2.77 - 2.52 (m, 4H), 1.70 (br d, J=6.4 Hz, 3H), 1.33 (br s, 4H), 1.16
 10 (s, 9H), 0.76 (br s, 6H).

Example 351



General procedure B was followed. The experiment afforded the desired
 15 compound, (2S)-2-(tert-butoxy)-2-{5-[(4,4-dimethylpentyl)oxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (12.9 mg, 46%
 yield, 100% purity). LCMS observed ion = 526.4. ¹H NMR (500 MHz, METHANOL-d₄)
 δ 8.38 (br s, 1H), 8.21 (s, 1H), 7.57 (br d, J=8.5 Hz, 1H), 7.49 (d, J=8.5 Hz, 1H), 5.80 (s,
 1H), 4.14 (br t, J=6.3 Hz, 2H), 2.99 (br s, 2H), 2.84 (br s, 2H), 2.68 (s, 3H), 1.88 - 1.81
 20 (m, 2H), 1.48 - 1.38 (m, 6H), 1.22 (s, 9H), 0.98 - 0.96 (m, 9H), 0.92 (s, 6H).


Example 352



General Procedure F was followed. The experiment afforded the desired
 25 compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[2-(3,4,5-


trifluorophenyl)ethoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (5.5 mg, 17% yield, 99.3% purity). LCMS observed ion = 586.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.38 (d, J=2.4 Hz, 1H), 8.19 (s, 1H), 7.57 (d, J=8.3 Hz, 1H), 7.48 (d, J=8.5 Hz, 1H), 7.19 - 7.13 (m, 2H), 5.80 (s, 1H), 4.38 (t, J=6.3 Hz, 2H), 3.16 (br t, J=6.1 Hz, 2H), 2.98 (br s, 2H),
 5 2.83 (br s, 2H), 2.67 (s, 3H), 1.44 (br s, 4H), 1.21 (s, 9H), 0.91 (s, 6H).

Example 353




General Procedure F was followed. The experiment afforded the desired
 10 compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-[2-(2,4,5-trifluorophenyl)ethoxy]-[2,3'-bipyridine]-5'-yl]acetic acid (13.7 mg, 44% yield, 100% purity). LCMS observed ion = 586.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.33 (d, J=2.4 Hz, 1H), 8.10 (s, 1H), 7.54 (d, J=8.3 Hz, 1H), 7.45 (d, J=8.5 Hz, 1H), 7.43 - 7.36 (m, 1H), 7.22 - 7.14 (m, 1H), 5.75 (s, 1H), 4.38 (t, J=6.4 Hz, 2H), 3.18 (br t, J=6.1 Hz,
 15 2H), 2.77 (br s, 2H), 2.64 (s, 3H), 1.42 (br s, 4H), 1.18 (s, 9H), 0.89 (s, 6H).

Example 354




General Procedure F was followed. The experiment afforded the desired
 20 compound, (2S)-2-(tert-butoxy)-2-[5-[2-(3-chloro-2-fluorophenyl)ethoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (12.8 mg, 41% yield, 99.3% purity). LCMS observed ion = 584.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.42 (s, 1H), 8.36 (s, 1H), 7.61 - 7.54 (m, 2H), 7.41 - 7.36 (m, 2H), 7.16 (t, J=7.6 Hz, 1H), 5.70 (s, 1H), 4.42 (t, J=6.3 Hz, 2H), 3.26 (br t, J=6.1 Hz, 2H), 3.11 - 2.87 (m,
 25 4H), 2.79 (s, 3H), 1.48 (br s, 4H), 1.24 (s, 9H), 0.96 (s, 6H).

Example 355




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[(2,6-dichlorophenyl)methoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (16.8 mg, 54% yield, 100% purity). LCMS observed ion = 586.2. ¹H NMR (500 MHz, DMSO-d₆) δ 8.49 (d, J=2.7 Hz, 1H), 8.16 (s, 1H), 7.69 (dd, J=8.5, 2.7 Hz, 1H), 7.58 (d, J=7.6 Hz, 2H), 7.52 - 7.47 (m, 2H), 5.87 (s, 1H), 5.38 (s, 2H), 2.48 (br s, 3H), 2.17 - 1.90 (m, 2H), 1.54 (br s, 1H), 1.30 (br s, 2H), 1.12 (s, 9H), 1.10 - 1.03 (m, 1H), 0.88 (br s, 3H), 0.76 (br s, 3H).

Example 356



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{5-[(2,6-dimethylphenyl)methoxy]-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (6 mg, 20% yield, 99.3% purity). LCMS observed ion = 546.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.47 (s, 1H), 8.21 (br s, 1H), 7.71 (d, J=8.1 Hz, 1H), 7.53 (d, J=8.5 Hz, 1H), 7.21 - 7.17 (m, 1H), 7.11 (d, J=7.3 Hz, 2H), 5.81 (br s, 1H), 5.29 (s, 2H), 3.01 (br s, 2H), 2.85 (br s, 2H), 2.68 (s, 3H), 2.42 (s, 6H), 1.46 (br s, 4H), 1.22 (s, 9H), 0.93 (s, 6H).


Example 357



General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-[(2-methoxyphenyl)methoxy]-6'-methyl-[2,3'-bipyridine]-5'-yl]acetic acid (12.3 mg, 42%


yield, 100% purity). LCMS observed ion = 548.3. ¹H NMR (500 MHz, METHANOL-d₄)
 δ 8.42 (br s, 1H), 8.19 (s, 1H), 7.61 (dd, J=8.5, 2.1 Hz, 1H), 7.48 (d, J=8.1 Hz, 1H), 7.43
 (d, J=7.3 Hz, 1H), 7.36 (t, J=7.6 Hz, 1H), 7.06 (d, J=7.9 Hz, 1H), 6.98 (t, J=7.5 Hz, 1H),
 5.80 (br s, 1H), 5.29 (s, 2H), 3.91 (s, 3H), 3.00 (br s, 2H), 2.82 (br s, 2H), 2.67 (s, 3H),
 5 1.44 (br s, 4H), 1.21 (s, 9H), 0.90 (s, 6H).

Example 358




General Procedure F was followed. The experiment afforded the desired
 10 compound, (2S)-2-(tert-butoxy)-2-{5-[(2,4-dimethoxyphenyl)methoxy]-4'-(4,4-
 dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridine]-5'-yl}acetic acid (7.4 mg, 24% yield,
 98.5% purity). LCMS observed ion = 578.3. ¹H NMR (500 MHz, METHANOL-d₄) δ
 8.40 (d, J=2.7 Hz, 1H), 8.19 (s, 1H), 7.61 (dd, J=8.2, 2.7 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H),
 7.33 (d, J=8.5 Hz, 1H), 6.60 (s, 1H), 6.55 (br d, J=8.5 Hz, 1H), 5.79 (s, 1H), 5.21 - 5.19
 15 (m, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 2.95 (br s, 2H), 2.81 (br s, 2H), 2.67 (s, 3H), 1.44 (br
 s, 4H), 1.21 (s, 9H), 0.90 (s, 6H).

Example 359




General procedure B was followed. The experiment afforded the desired
 20 compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-5-(2-ethylbutoxy)-6'-
 methyl-[2,3'-bipyridine]-5'-yl]acetic acid (14.9 mg, 54% yield, 100% purity). LCMS
 observed ion = 512.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.37 (d, J=2.4 Hz, 1H),
 8.17 (s, 1H), 7.57 (dd, J=8.4, 2.6 Hz, 1H), 7.47 (d, J=8.5 Hz, 1H), 5.80 (s, 1H), 4.07 (d,
 25 J=5.8 Hz, 2H), 2.98 (br s, 2H), 2.82 (br s, 2H), 2.66 (s, 3H), 1.77 - 1.71 (m, 1H), 1.61 -
 1.49 (m, 4H), 1.44 (br s, 4H), 1.21 (s, 9H), 1.00 (t, J=7.3 Hz, 6H), 0.91 (s, 6H).

Example 360




General Procedure F was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-5-(2-methylbutoxy)-[2,3'-bipyridine]-5'-yl]acetic acid (13.3 mg, 50% yield, 100% purity). LCMS observed ion = 498.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.39 (s, 1H), 8.21 (br s, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.49 (d, J=8.1 Hz, 1H), 5.78 (br s, 1H), 4.02 (br d, J=6.1 Hz, 1H), 3.98 - 3.93 (m, 1H), 3.02 (br s, 2H), 2.85 (br s, 2H), 2.69 (s, 3H), 1.97 - 1.90 (m, 1H), 1.69 - 1.60 (m, 1H), 1.46 (br s, 4H), 1.39 - 1.32 (m, 1H), 1.22 (s, 9H), 1.09 (d, J=6.7 Hz, 3H), 1.01 (t, J=7.5 Hz, 3H), 0.92 (s, 6H).

Example 361



General Procedure G was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-[4-(3-methylbutoxy)phenyl]pyridin-3-yl]acetic acid (8.3 mg, 31% yield, 97.7% purity). LCMS observed ion = 497.3.


Example 362



General Procedure G was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(4-{[(2R)-3-methylbutan-2-yl]oxy}phenyl)pyridin-3-yl]acetic acid (4.6 mg, 17% yield, 98.8% purity). LCMS observed ion = 497.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.09 (br s, 1H), 7.26 (br d, J=7.9 Hz, 2H), 7.07 (br d, J=8.5 Hz, 2H), 5.68 (br s, 1H), 4.33 (br t, J=6.0

Hz, 1H), 2.78 (br s, 2H), 2.68 (s, 3H), 2.00 - 1.92 (m, 1H), 1.44 (br s, 4H), 1.28 (d, J=6.4 Hz, 3H), 1.20 (s, 9H), 1.05 (d, J=6.7 Hz, 3H), 1.02 (d, J=6.7 Hz, 3H), 0.91 (s, 6H).

Example 363




5

General Procedure G was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-(4-{[(2S)-3-methylbutan-2-yl]oxy}phenyl)pyridin-3-yl]acetic acid (6.4 mg, 24% yield, 99.4% purity). LCMS observed ion = 497.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.09 (br s, 1H), 7.26 (br d, J=7.9 Hz, 2H), 7.07 (br d, J=8.5 Hz, 2H), 5.68 (br s, 1H), 4.33 (br t, J=6.0 Hz, 1H), 2.78 (br s, 2H), 2.68 (s, 3H), 2.00 - 1.92 (m, 1H), 1.44 (br s, 4H), 1.28 (d, J=6.4 Hz, 3H), 1.20 (s, 9H), 1.05 (d, J=6.7 Hz, 3H), 1.02 (d, J=6.7 Hz, 3H), 0.91 (s, 6H).

10

Example 364




15

General Procedure G was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-(5-{4-[2-(3-chlorophenyl)ethoxy]phenyl}-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid (8.2 mg, 27% yield, 98.3% purity). LCMS observed ion = 565.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.12 (br s, 1H), 7.37 (s, 1H), 7.33 - 7.24 (m, 5H), 7.09 (br d, J=8.2 Hz, 2H), 5.67 (br s, 1H), 4.29 (br t, J=6.4 Hz, 2H), 3.13 (br t, J=6.4 Hz, 2H), 3.17 (br s, 2H), 2.79 (br s, 2H), 2.71 (s, 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

20


Example 365



General Procedure G was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-methyl-5-{4-[2-(3-methylphenyl)ethoxy]phenyl}pyridin-3-yl]acetic acid (9.1 mg, 31% yield, 98.4% purity). LCMS observed ion = 545.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.10 (s, 1H), 7.27 (br d, J=7.6 Hz, 2H), 7.22 - 7.15 (m, 2H), 7.13 - 7.05 (m, 4H), 5.67 (br s, 1H), 4.26 (t, J=6.9 Hz, 2H), 3.19 (br s, 2H), 3.08 (br t, J=6.9 Hz, 2H), 2.80 (br s, 2H), 2.70 (s, 3H), 2.34 (s, 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

10


Example 366



General Procedure G was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-(5-{4-[2-(2,6-dichlorophenyl)ethoxy]phenyl}-4-(4,4-dimethylpiperidin-1-yl)-2-methylpyridin-3-yl)acetic acid (5.7 mg, 17% yield, 97.9% purity). LCMS observed ion = 599.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.06 (s, 1H), 7.43 (d, J=8.2 Hz, 2H), 7.29 - 7.24 (m, 3H), 7.08 (br d, J=8.5 Hz, 2H), 5.67 (s, 1H), 4.30 (t, J=7.2 Hz, 2H), 3.51 (br t, J=7.2 Hz, 2H), 2.75 (br s, 2H), 2.67 (s, 3H), 1.44 (br s, 4H), 1.20 (s, 9H), 0.91 (s, 6H).

20


Example 367



General Procedure G was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5-{4-[2-(4-methoxyphenyl)ethoxy]phenyl}-2-methylpyridin-3-yl]acetic acid.


methoxyphenyl)ethoxy]phenyl}-2-methylpyridin-3-yl]acetic acid (9.7 mg, 32% yield, 100% purity). LCMS observed ion = 561.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.07 (s, 1H), 7.29 - 7.23 (m, 4H), 7.07 (br d, J=8.5 Hz, 2H), 6.88 (br d, J=8.2 Hz, 2H), 5.67 (s, 1H), 4.23 (t, J=6.9 Hz, 2H), 3.79 (s, 3H), 3.06 (br t, J=6.9 Hz, 2H), 2.77 (br s, 2H), 2.68 (s, 3H), 1.44 (br s, 4H), 1.20 (s, 9H), 0.91 (s, 6H).

Example 368




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-(3-methylbutoxy)-[3,3'-bipyridine]-5-yl]acetic acid (26.6 mg, 51% yield, 515.67% purity). LCMS observed ion = 516.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.15 (br s, 1H), 7.92 (s, 1H), 7.57 (br d, J=11.0 Hz, 1H), 5.78 (br s, 1H), 4.56 - 4.48 (m, 2H), 3.11 (br s, 2H), 2.79 (br s, 2H), 2.66 (br s, 3H), 1.90 - 1.82 (m, 1H), 1.75 (q, J=6.5 Hz, 2H), 1.46 (br s, 4H), 1.21 (s, 9H), 1.02 (d, J=6.7 Hz, 6H), 0.93 (s, 6H).

Example 369



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-((2R)-3-methylbutan-2-yl)oxy]-[3,3'-bipyridine]-5-yl]acetic acid (14.8 mg, 28% yield, 515.67% purity). LCMS observed ion = 516.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.15 (s, 1H), 7.91 (s, 1H), 7.56 (br d, J=10.7 Hz, 1H), 5.79 (br s, 1H), 5.24 (br t, J=6.0 Hz, 1H), 3.12 (br s, 2H), 2.79 (br s, 2H), 2.66 (s, 3H), 2.06 - 1.99 (m, 1H), 1.45 (br s, 4H), 1.35 (d, J=6.1 Hz, 3H), 1.21 (s, 9H), 1.03 (t, J=7.2 Hz, 6H), 0.92 (s, 6H).


Example 370



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-{[(2S)-3-methylbutan-2-yl]oxy}-[3,3'-bipyridine]-5-yl]acetic acid (12.4 mg, 23% yield, 515.67% purity). LCMS observed ion = 516.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.15 (s, 1H), 7.91 (s, 1H), 7.56 (br d, J=10.7 Hz, 1H), 5.79 (s, 1H), 5.20 (quin, J=6.1 Hz, 1H), 3.14 (br s, 2H), 2.79 (br s, 2H), 2.66 (s, 3H), 2.06 - 1.98 (m, 1H), 1.45 (br s, 4H), 1.34 (d, J=6.1 Hz, 3H), 1.21 (s, 9H), 1.08 - 1.00 (m, 6H), 0.92 (s, 6H).

10


Example 371



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[6'-[2-(3-chlorophenyl)ethoxy]-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (10.8 mg, 18% yield, 584.13% purity). LCMS observed ion = 584.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.09 (br s, 1H), 7.92 (br s, 1H), 7.56 (br d, J=10.4 Hz, 1H), 7.36 (br s, 1H), 7.33 - 7.23 (m, 3H), 5.75 (br s, 1H), 4.70 - 4.67 (m, 2H), 3.16 (br t, J=6.6 Hz, 2H), 3.12 (br s, 2H), 2.75 (br s, 2H), 2.65 (br s, 3H), 1.45 (br s, 4H), 1.20 (s, 9H), 0.91 (s, 6H).

20


Example 372



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-[2-(3-methylphenyl)ethoxy]-[3,3'-bipyridine]-5-yl]acetic acid (25.3 mg, 44% yield,


563.71% purity). LCMS observed ion = 564.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.12 (s, 1H), 7.92 (s, 1H), 7.56 (br d, J=10.7 Hz, 1H), 7.19 (t, J=7.3 Hz, 1H), 7.15 (s, 1H), 7.11 (br d, J=7.6 Hz, 1H), 7.05 (br d, J=7.6 Hz, 1H), 5.78 (br s, 1H), 4.67 - 4.64 (m, 2H), 3.11 (br t, J=6.9 Hz, 2H), 3.11 (br s, 2H), 2.78 (br s, 2H), 2.65 (s, 3H), 2.34 (s, 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

Example 373




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{6'-[2-(2,6-dichlorophenyl)ethoxy]-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl}acetic acid (7.8 mg, 12% yield, 618.57% purity). LCMS observed ion = 618.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.13 (br s, 1H), 7.91 (s, 1H), 7.56 (br d, J=10.7 Hz, 1H), 7.41 (d, J=7.4 Hz, 2H), 7.27 - 7.23 (m, 1H), 5.78 (br s, 1H), 4.77 (br t, J=6.4 Hz, 2H), 3.53 (br t, J=6.6 Hz, 2H), 2.78 (br s, 2H), 2.65 (s, 3H), 1.46 (br s, 4H), 1.21 (s, 9H), 0.94 (s, 6H).

Example 374




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-[2-(4-methoxyphenyl)ethoxy]-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (26.3 mg, 45% yield, 579.71% purity). LCMS observed ion = 580.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.13 (s, 1H), 7.92 (s, 1H), 7.56 (br d, J=10.1 Hz, 1H), 7.26 - 7.22 (m, J=8.5 Hz, 2H), 6.89 - 6.86 (m, J=8.5 Hz, 2H), 5.79 (br s, 1H), 4.65 - 4.61 (m, 2H), 3.79 (s, 3H), 3.09 (br t, J=6.9 Hz, 2H), 2.78 (br s, 2H), 2.65 (s, 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

Example 375




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-6'-(2,2-dimethylpropoxy)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (15.3 mg, 29% yield, 515.67% purity). LCMS observed ion = 516.3. ¹H NMR (500 MHz, METHANOL-d4) δ 8.13 (s, 1H), 7.91 (s, 1H), 7.58 (br d, J=10.4 Hz, 1H), 5.78 (br s, 1H), 4.21 - 4.11 (m, 2H), 2.78 (br s, 2H), 2.65 (s, 3H), 1.46 (br s, 4H), 1.21 (s, 9H), 1.09 (s, 9H), 0.92 (s, 6H).

Example 376



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[6'-(3,3-dimethylbutoxy)-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (16.3 mg, 30% yield, 529.7% purity). LCMS observed ion = 530.3. ¹H NMR (500 MHz, METHANOL-d4) δ 8.15 (s, 1H), 7.93 (s, 1H), 7.57 (br d, J=10.7 Hz, 1H), 5.78 (br s, 1H), 4.62 - 4.50 (m, 2H), 2.79 (br s, 2H), 2.66 (s, 3H), 1.79 (t, J=7.2 Hz, 2H), 1.46 (br s, 4H), 1.21 (s, 9H), 1.06 - 1.02 (m, 9H), 0.93 (s, 6H).

Example 377




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[6'-butoxy-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (12.7 mg, 25% yield, 501.64% purity). LCMS observed ion = 502.3. ¹H NMR (500 MHz, METHANOL-d4) δ 8.13 (s, 1H), 7.92 (s, 1H),

7.57 (br d, J=10.4 Hz, 1H), 5.78 (br s, 1H), 4.53 - 4.43 (m, 2H), 2.78 (br s, 2H), 2.65 (s, 3H), 1.84 (quin, J=7.1 Hz, 2H), 1.54 (sxt, J=7.3 Hz, 2H), 1.46 (br s, 4H), 1.21 (s, 9H), 1.05 - 1.00 (m, 3H), 0.92 (s, 6H).

5

Example 378




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-[6'-(benzyloxy)-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl]-2-(tert-butoxy)acetic acid (11.9 mg, 22% yield, 535.66% purity).

10 LCMS observed ion = 536.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.14 (s, 1H), 7.94 (s, 1H), 7.60 (br d, J=10.1 Hz, 1H), 7.50 (br d, J=7.0 Hz, 2H), 7.41 - 7.32 (m, 3H), 5.78 (s, 1H), 5.60 (d, J=12.2 Hz, 1H), 5.52 (d, J=12.5 Hz, 1H), 2.78 (br s, 2H), 2.65 (s, 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.90 (s, 6H).

15


Example 379



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-(2-phenylpropan-2-yl)oxy]-[3,3'-bipyridine]-5-yl]acetic acid (13.6 mg, 24% yield, 563.71% purity). LCMS observed ion = 564.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.11 (s, 1H), 7.88 (s, 1H), 7.52 (br d, J=10.1 Hz, 1H), 7.32 - 7.25 (m, 4H), 7.21 - 7.17 (m, 1H), 5.77 (s, 1H), 5.62 - 5.57 (m, 1H), 3.14 (br dd, J=13.7, 7.0 Hz, 1H), 2.97 (br dd, J=13.7, 5.8 Hz, 1H), 2.76 (br s, 2H), 2.65 (s, 3H), 1.45 (br s, 4H), 1.40 (br d, J=6.1 Hz, 3H), 1.20 (s, 9H), 0.92 (s, 6H).


25

Example 380




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-{[(2R)-1-phenylpropan-2-yl]oxy}-[3,3'-bipyridine]-5-yl]acetic acid (12.2 mg, 21% yield, 563.71% purity). LCMS observed ion = 564.3.

Example 381




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-(2-methylpropoxy)-[3,3'-bipyridine]-5-yl]acetic acid (12.8 mg, 25% yield, 501.64% purity). LCMS observed ion = 502.3.

Example 382




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-[2-(2-methoxyphenyl)ethoxy]-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (16.5 mg, 28% yield, 579.71% purity). LCMS observed ion = 580.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.13 (br s, 1H), 7.90 (s, 1H), 7.55 (br d, J=10.4 Hz, 1H), 7.25 - 7.19 (m, 2H), 6.97 (d, J=7.9 Hz, 1H), 6.89 (t, J=7.5 Hz, 1H), 5.76 (br s, 1H), 4.66 - 4.62 (m, 2H), 3.86 (s, 3H), 3.15 (br t, J=6.7 Hz, 2H), 2.79 (br s, 2H), 2.66 (s, 3H), 1.46 (br s, 4H), 1.21 (s, 9H), 0.93 (s, 6H).

Example 383




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-[2-(3-methoxyphenyl)ethoxy]-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (17.5 mg, 30% yield, 579.71% purity). LCMS observed ion = 580.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.14 (s, 1H), 7.92 (s, 1H), 7.57 (br d, J=11.3 Hz, 1H), 7.22 (t, J=7.9 Hz, 1H), 6.91 (br s, 2H), 6.80 (br d, J=8.2 Hz, 1H), 5.76 (br s, 1H), 4.67 (br t, J=6.1 Hz, 2H), 3.80 (s, 3H), 3.13 (br t, J=6.9 Hz, 2H), 2.79 (br s, 2H), 2.66 (s, 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

Example 384




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-methyl-6'-[(4-methylpentan-2-yl)oxy]-[3,3'-bipyridine]-5-yl]acetic acid (11.6 mg, 21% yield, 529.7% purity). LCMS observed ion = 530.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.17 (br s, 1H), 7.92 (br s, 1H), 7.57 (br d, J=9.5 Hz, 1H), 5.77 (br s, 1H), 5.55 - 5.46 (m, 1H), 3.13 (br s, 2H), 2.81 (br s, 2H), 2.67 (s, 3H), 1.84 - 1.76 (m, 2H), 1.52 - 1.42 (m, 5H), 1.41 - 1.36 (m, J=6.4, 6.4 Hz, 3H), 1.21 (s, 9H), 0.98 (br d, J=6.1 Hz, 3H), 0.94 (br d, J=5.8 Hz, 3H), 0.92 (s, 6H).

Example 385




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-[2-(2-methylphenyl)ethoxy]-[3,3'-bipyridine]-5-yl]acetic acid (18.2 mg, 32% yield, 563.71% purity). LCMS observed ion = 564.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.14 (s, 1H), 7.92 (s, 1H), 7.57 (br d, J=10.1 Hz, 1H), 7.24 (br d, J=4.9 Hz, 1H), 7.17 (br d, J=3.7 Hz, 1H), 7.15 - 7.11 (m, 2H), 5.76 (s, 1H), 4.69 - 4.63 (m, 2H), 3.18 (br t, J=7.0 Hz, 2H), 2.79 (br s, 2H), 2.66 (s, 3H), 2.42 (s, 3H), 1.46 (br s, 4H), 1.21 (s, 9H), 0.93 (s, 6H).

Example 386




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-(2-methylbutoxy)-[3,3'-bipyridine]-5-yl]acetic acid (16.9 mg, 32% yield, 515.67% purity). LCMS observed ion = 516.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.16 (br s, 1H), 7.92 (s, 1H), 7.58 (br d, J=10.7 Hz, 1H), 5.74 (br s, 1H), 4.40 - 4.24 (m, 2H), 3.14 (br s, 2H), 2.81 (br s, 2H), 2.67 (br s, 3H), 1.98 - 1.91 (m, 1H), 1.61 (dt, J=13.8, 7.0 Hz, 1H), 1.46 (br s, 4H), 1.40 - 1.31 (m, 1H), 1.21 (s, 9H), 1.07 (d, J=6.7 Hz, 3H), 1.00 (t, J=7.5 Hz, 3H), 0.93 (s, 6H).

Example 387




The desired compound was isolated as a second product during the synthesis of Example EG-195. The isolated material is (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-hydroxy-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (14.3 mg, 32% yield, 445.54% purity). LCMS observed ion = 446.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.00 (s, 1H), 7.48 (br d, J=10.1 Hz, 1H), 7.29 (s, 1H), 5.64 (s, 1H), 2.61 (s, 3H), 1.17 (s, 9H), 0.94 (br s, 6H); the piperidine protons were not observed due to line broadening.

Example 388




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-hydroxy-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (19 mg, 33% yield, 563.71% purity). LCMS observed ion = 564.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.14 (s, 1H), 7.91 (s, 1H), 7.56 (br d, J=11.3 Hz, 1H), 7.35 - 7.31 (m, 4H), 7.25 - 7.21 (m, 1H), 5.78 (br s, 1H), 4.62 (dd, J=10.4, 6.4 Hz, 1H), 4.50 (dd, J=10.4, 7.3 Hz, 1H), 3.37 - 3.34 (m, 1H), 2.79 (br s, 2H), 2.66 (s, 3H), 1.46 (br s, 4H), 1.43 (d, J=7.0 Hz, 3H), 1.21 (s, 9H), 0.93 (s, 6H).

Example 389




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-hydroxy-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (15.7 mg, 32% yield, 487.62% purity). LCMS observed ion = 488.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.15 (s, 1H), 7.92 (s, 1H), 7.58 (br d, J=10.7 Hz, 1H), 5.79 (s, 1H), 4.47 - 4.39 (m, 2H), 2.79 (br s, 2H), 2.66 (s, 3H), 1.92 - 1.85 (m, 2H), 1.46 (br s, 4H), 1.21 (s, 9H), 1.08 (t, J=7.5 Hz, 3H), 0.93 (s, 6H).

Example 390




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{6'-[2-(3,5-difluorophenyl)ethoxy]-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl}acetic acid (6.8 mg, 11% yield, 585.67% purity). LCMS observed ion = 586.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.15 (s, 1H), 7.94 (s, 1H), 7.59 (br d, J=10.4 Hz, 1H), 6.96 (br d, J=7.0 Hz, 2H), 6.82 (br t, J=8.5 Hz, 1H), 5.78 (s, 1H), 4.71 (t, J=6.4 Hz, 2H), 3.19 (t, J=6.4 Hz, 2H), 3.14 (br s, 2H), 2.79 (br s, 2H), 2.66 (s, 3H), 1.46 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

Example 391



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-[2-(4-methoxy-3-methylphenyl)ethoxy]-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (15.5 mg, 26% yield, 593.74% purity). LCMS observed ion = 594.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.10 (s, 1H), 7.91 (s, 1H), 7.55 (br d, J=9.8 Hz, 1H), 7.11 - 7.08 (m, 2H), 6.84 (d, J=7.9 Hz, 1H), 5.77 (s, 1H), 4.64 - 4.59 (m, 2H), 3.82 (s, 3H), 3.05 (t, J=7.0 Hz, 2H), 2.77 (br s, 2H), 2.65 (s, 3H), 2.18 (s, 3H), 1.45 (br s, 4H), 1.20 (s, 9H), 0.91 (s, 6H).


Example 392



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{6'-[2-(3,4-difluorophenyl)ethoxy]-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl}acetic acid (8.1 mg, 13% yield, 585.67% purity). LCMS observed ion = 586.2. ¹H NMR (500 MHz,

- 5 METHANOL-d₄) δ 8.13 (s, 1H), 7.92 (s, 1H), 7.57 (br d, J=10.4 Hz, 1H), 7.28 - 7.22 (m, 1H), 7.22 - 7.17 (m, 1H), 7.14 (br s, 1H), 5.78 (s, 1H), 4.70 - 4.66 (m, 2H), 3.15 (br t, J=6.6 Hz, 2H), 2.78 (br s, 2H), 2.65 (s, 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).


Example 393



10

General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{6'-[2-(2,6-difluorophenyl)ethoxy]-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl}acetic acid (11.6 mg, 19% yield, 585.67% purity). LCMS observed ion = 586.2. ¹H NMR (500 MHz, 15 METHANOL-d₄) δ 8.13 (s, 1H), 7.91 (s, 1H), 7.56 (br d, J=10.4 Hz, 1H), 7.33 - 7.27 (m, 1H), 6.96 (t, J=7.8 Hz, 2H), 5.78 (s, 1H), 4.71 (br t, J=5.8 Hz, 2H), 3.24 (br t, J=6.3 Hz, 2H), 2.78 (br s, 2H), 2.66 (s, 3H), 1.46 (br s, 4H), 1.21 (s, 9H), 0.93 (s, 6H).


Example 394



20


General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-[(4-methylpentyl)oxy]-[3,3'-bipyridine]-5-yl]acetic acid (12 mg, 22% yield, 529.7% 25 purity). LCMS observed ion = 530.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.15 (s, 1H), 7.92 (s, 1H), 7.57 (br d, J=10.7 Hz, 1H), 5.78 (s, 1H), 4.51 - 4.42 (m, 2H), 2.80 (br s, 2H), 2.66 (s, 3H), 1.90 - 1.83 (m, 2H), 1.65 (dt, J=13.2, 6.7 Hz, 1H), 1.46 (br s, 4H), 1.42 - 1.36 (m, 2H), 1.21 (s, 9H), 0.96 (d, J=6.4 Hz, 6H), 0.93 (s, 6H).

Example 395




General Procedure H was followed. The experiment afforded the desired
 5 compound, (2S)-2-(tert-butoxy)-2-{6'-[2-(4-chlorophenyl)ethoxy]-4-(4,4-
 dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl}acetic acid (17.4 mg,
 29% yield, 584.13% purity). LCMS observed ion = 584.2. ¹H NMR (500 MHz,
 METHANOL-d₄) δ 8.14 (s, 1H), 7.92 (s, 1H), 7.57 (br d, J=10.1 Hz, 1H), 7.34 - 7.30 (m,
 4H), 5.77 (s, 1H), 4.70 - 4.66 (m, 2H), 3.15 (t, J=6.7 Hz, 2H), 2.79 (br s, 2H), 2.66 (s,
 10 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

Example 396



General Procedure H was followed. The experiment afforded the desired
 15 compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-
 [(1R)-1-phenylethoxy]-[3,3'-bipyridine]-5-yl]acetic acid (18.3 mg, 33% yield, 549.69%
 purity). LCMS observed ion = 550.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.11 (br s,
 1H), 7.83 (s, 1H), 7.57 (br d, J=10.1 Hz, 1H), 7.45 (d, J=7.6 Hz, 2H), 7.34 (t, J=7.6 Hz,
 2H), 7.29 - 7.23 (m, 1H), 6.34 (q, J=6.2 Hz, 1H), 5.72 (br s, 1H), 2.69 (br s, 2H), 2.64 (br
 20 s, 3H), 1.71 (d, J=6.4 Hz, 3H), 1.39 (br s, 4H), 1.19 (s, 9H), 0.82 (br s, 6H).

Example 397




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-[2-(4-fluoro-3-methylphenyl)ethoxy]-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (20.1 mg, 34% yield, 581.71% purity). LCMS observed ion = 582.2. ¹H NMR (500 MHz,

- 5 METHANOL-d₄) δ 8.13 (br s, 1H), 7.92 (s, 1H), 7.57 (br d, J=10.4 Hz, 1H), 7.20 (br d, J=7.3 Hz, 1H), 7.13 (br t, J=6.8 Hz, 1H), 6.96 (t, J=9.0 Hz, 1H), 5.78 (br s, 1H), 4.67 - 4.62 (m, 2H), 3.10 (t, J=6.7 Hz, 2H), 2.78 (br s, 2H), 2.65 (s, 3H), 2.26 (s, 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

10

Example 398




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-[2-(4-fluoro-2-methylphenyl)ethoxy]-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (21.3 mg,

- 15 36% yield, 581.71% purity). LCMS observed ion = 582.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.13 (br s, 1H), 7.91 (s, 1H), 7.56 (br d, J=10.7 Hz, 1H), 7.26 (t, J=7.0 Hz, 1H), 6.93 (br d, J=10.1 Hz, 1H), 6.86 (t, J=8.2 Hz, 1H), 5.78 (br s, 1H), 4.65 (t, J=6.7 Hz, 2H), 3.16 (br t, J=7.0 Hz, 2H), 2.78 (br s, 2H), 2.65 (s, 3H), 2.43 (s, 3H), 1.46 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

20

Example 399




General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-[2-(4-methoxy-2-methylphenyl)ethoxy]-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (18.4 mg, 30% yield, 593.74% purity). LCMS observed ion = 594.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.13 (s, 1H), 7.91 (s, 1H), 7.56 (br d, J=10.1 Hz, 1H), 7.16 (d, J=8.2

25

Hz, 1H), 6.75 (s, 1H), 6.71 (d, J=8.0 Hz, 1H), 5.78 (br s, 1H), 4.64 - 4.59 (m, 2H), 3.77 (s, 3H), 3.11 (br t, J=7.0 Hz, 2H), 2.78 (br s, 2H), 2.65 (s, 3H), 2.39 (s, 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

5


Example 400



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-[(1S)-1-phenylethoxy]-[3,3'-bipyridine]-5-yl]acetic acid (20 mg, 36% yield, 549.69%
 10 purity). LCMS observed ion = 550.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.11 (s, 1H), 7.86 (s, 1H), 7.56 (br d, J=10.1 Hz, 1H), 7.47 (d, J=7.3 Hz, 2H), 7.35 (t, J=7.5 Hz, 2H), 7.29 - 7.25 (m, 1H), 6.35 (q, J=6.6 Hz, 1H), 5.76 (br s, 1H), 2.74 (br s, 2H), 2.64 (s, 3H), 1.71 (d, J=6.4 Hz, 3H), 1.42 (br s, 4H), 1.20 (s, 9H), 0.91 (s, 6H).


15

Example 401



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-[2-(5-fluoro-2-methylphenyl)ethoxy]-6-methyl-[3,3'-bipyridine]-5-yl]acetic acid (17.9 mg,
 20 30% yield, 581.71% purity). LCMS observed ion = 582.3. ¹H NMR (500 MHz, DMSO-d₆) δ 8.08 (s, 1H), 7.93 (s, 1H), 7.75 (br d, J=10.7 Hz, 1H), 7.20 (br t, J=7.2 Hz, 1H), 7.07 (br d, J=10.1 Hz, 1H), 6.95 (br t, J=8.2 Hz, 1H), 5.78 (br s, 1H), 4.67 - 4.58 (m, 2H), 3.09 (br t, J=6.7 Hz, 2H), 2.49 - 2.47 (m, 3H), 2.29 (s, 3H), 2.22 (br s, 2H), 1.53 (br s, 1H), 1.31 (br s, 3H), 1.11 (s, 9H), 0.89 (br s, 3H), 0.74 (br s, 3H).


Example 402



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-(2-methyl-2-phenylpropoxy)-[3,3'-bipyridine]-5-yl]acetic acid (14.3 mg, 24% yield, 577.74% purity). LCMS observed ion = 578.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.11 (s, 1H), 7.89 (s, 1H), 7.56 - 7.48 (m, 3H), 7.33 (t, J=7.6 Hz, 2H), 7.26 - 7.19 (m, 1H), 5.77 (br s, 1H), 4.52 (s, 2H), 2.75 (br s, 2H), 2.65 (s, 3H), 1.51 (s, 6H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

10


Example 403



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-{6'-[2-(3-chloro-4-fluorophenyl)ethoxy]-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridine]-5-yl}acetic acid (13.4 mg, 22% yield, 602.12% purity). LCMS observed ion = 602.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.13 (s, 1H), 7.92 (s, 1H), 7.57 (br d, J=10.7 Hz, 1H), 7.46 (br d, J=7.0 Hz, 1H), 7.32 - 7.28 (m, 1H), 7.18 (t, J=8.5 Hz, 1H), 5.78 (br s, 1H), 4.70 - 4.66 (m, 2H), 3.15 (br t, J=6.6 Hz, 2H), 2.78 (br s, 2H), 2.65 (s, 3H), 1.45 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).


20

Example 404



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-[2-(2,4,6-trifluorophenyl)ethoxy]-[3,3'-bipyridine]-5-yl]acetic acid (14.4 mg, 23% yield, 603.66% purity). LCMS observed ion = 604.2. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.12 (s, 1H), 7.91 (s, 1H), 7.56 (br d, J=9.8 Hz, 1H), 6.86 (br t, J=8.4 Hz, 2H), 5.78 (br s, 1H), 4.69 (t, J=6.1 Hz, 2H), 3.21 (br t, J=6.3 Hz, 2H), 2.77 (br s, 2H), 2.65 (s, 3H), 1.46 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

Example 405




10

General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-[2-(4-methylphenyl)ethoxy]-[3,3'-bipyridine]-5-yl]acetic acid (17.7 mg, 31% yield, 563.71% purity). LCMS observed ion = 564.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.13 (s, 1H), 7.92 (s, 1H), 7.56 (br d, J=10.1 Hz, 1H), 7.22 - 7.18 (m, J=7.6 Hz, 2H), 7.15 - 7.11 (m, J=7.6 Hz, 2H), 5.78 (s, 1H), 4.66 - 4.62 (m, 2H), 3.10 (t, J=6.9 Hz, 2H), 2.78 (br s, 2H), 2.66 (s, 3H), 2.32 (s, 3H), 1.46 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

15

Example 406




20

General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-(3-phenylpropoxy)-[3,3'-bipyridine]-5-yl]acetic acid (15.6 mg, 27% yield, 563.71% purity). LCMS observed ion = 564.3. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.14 (s, 1H), 7.91 (s, 1H), 7.59 (br d, J=11.0 Hz, 1H), 7.30 - 7.23 (m, 4H), 7.21 - 7.17 (m, 1H), 5.78 (br s, 1H), 4.50 - 4.43 (m, 2H), 2.83 (t, J=7.6 Hz, 2H), 2.83 (br s, 2H), 2.66 (s, 3H), 2.17 (quin, J=6.9 Hz, 2H), 1.46 (br s, 4H), 1.21 (s, 9H), 0.92 (s, 6H).

25


Example 407



General Procedure H was followed. The experiment afforded the desired compound, (2S)-2-(tert-butoxy)-2-[4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-6'-(pentyloxy)-[3,3'-bipyridine]-5-yl]acetic acid (16.9 mg, 32% yield, 515.67% purity).
 observed ion = 516.4. ¹H NMR (500 MHz, METHANOL-d₄) δ 8.13 (s, 1H), 7.92 (s, 1H), 7.57 (br d, J=10.1 Hz, 1H), 5.77 (s, 1H), 4.51 - 4.43 (m, 2H), 2.78 (br s, 2H), 2.66 (s, 3H), 1.89 - 1.83 (m, 2H), 1.53 - 1.41 (m, 8H), 1.21 (s, 9H), 0.98 (t, J=7.0 Hz, 3H), 0.93 (s, 6H).

10

Example 408




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(pentyloxy)-[3,3'-bipyridin]-5-yl)acetic acid:

To a stirred solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(pentyloxy)-[3,3'-bipyridin]-5-yl)acetate (60 mg, 0.111 mmol) in methanol (15 mL) was added a solution of sodium hydroxide (133 mg, 3.33 mmol) in water (3.00 mL). The mixture was stirred overnight at 75 °C and pH was adjusted to 8. The mixture was concentrated and the residue was purified by Prep-HPLC to afford the desired product (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(pentyloxy)-[3,3'-bipyridin]-5-yl)acetic acid (25 mg, 45.2 % yield). LCMS [M + H] = 498.2. ¹H NMR (400 MHz, CD₃OD) δ 8.23 (s, 1H), 8.15 (d, J = 2.0 Hz, 1H), 7.71 (dd, J = 8.5, 2.4 Hz, 1H), 6.96 (d, J = 8.6 Hz, 1H), 5.72 (s, 1H), 4.37 (qd, J = 8.8, 3.9 Hz, 2H), 3.15 (s, 2H), 2.89 (s, 2H), 2.73 (s, 3H), 1.87 - 1.79 (m, 2H), 1.54 - 1.40 (m, 8H), 1.23 (s, 9H), 1.00 - 0.92 (m, 9H).

25


Example 409



To a stirred solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate (75 mg, 0.143 mmol) in
 5 methanol (10 mL) was added a solution of sodium hydroxide (5.71 mg, 0.143 mmol) in water (3.0 mL). The mixture was stirred overnight at 75 °C and pH was adjusted to 8. The mixture was concentrated and the residue purified by Prep-HPLC to afford the desired product (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (40 mg, 58.0 % yield) as a white solid. LCMS [M + H] =
 10 484.2. ¹H NMR (400 MHz, CD₃OD) δ 8.31 (s, 1H), 8.17 (s, 1H), 7.73 (d, *J* = 7.0 Hz, 1H), 7.00 (d, *J* = 8.6 Hz, 1H), 5.68 (s, 1H), 4.20 – 4.13 (m, 2H), 3.13 (d, *J* = 14.7 Hz, 2H), 2.95 (s, 2H), 2.79 (s, 3H), 2.13 (dt, *J* = 13.4, 6.7 Hz, 1H), 1.49 (s, 4H), 1.25 (s, 9H), 1.06 (d, *J* = 6.7 Hz, 6H), 0.97 (s, 6H).

15

Example 410




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-5'-methoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of sodium hydride (71.8 mg, 2.99 mmol) and 2-methylpropan-1-ol (148
 20 mg, 1.993 mmol) in DMF (10 mL) was stirred over 30 mins. Then, (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-5'-methoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate (100 mg, 0.199 mmol) was added and stirred at 25 °C. After 4 h, the pH was of reaction mixture adjusted to 8, concentrated and purified by Prep-HPLC to afford the desired product (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-
 25 isobutoxy-5'-methoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (25 mg, 23.19 % yield) as a white solid. LCMS [M + H] = 514.3. ¹H NMR (400 MHz, CD₃OD) δ 8.13 (s, 1H), 7.64 (s, 1H), 7.24 (s, 1H), 5.77 (s, 1H), 4.21 – 4.14 (m, 2H), 3.92 (s, 3H), 3.15 (s, 2H),

2.82 (s, 2H), 2.66 (s, 3H), 2.19 – 2.13 (m, 1H), 1.47 (s, 4H), 1.21 (s, 9H), 1.06 (d, $J = 6.7$ Hz, 6H), 0.92 (s, 6H).


Example 411



5 (2S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(1-fluoro-3-methylbutyl)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

To a solution of (2S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(1-fluoro-3-methylbutyl)-6-methyl-[3,3'-bipyridin]-5-yl)acetate (410 mg, 0.757 mmol) in methanol (15 mL) was added a solution of sodium hydroxide (908 mg, 22.70 mmol) in water (5.00 mL). The mixture was stirred overnight at 75 °C. Then, the pH was adjusted to 8 and concentrated. The residue was purified by Prep-HPLC to afford the desired product (2S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(1-fluoro-3-methylbutyl)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (27.5 mg, 7.05 % yield) as a white solid. LCMS [M + H] = 500.3. ¹H NMR (400 MHz, CD₃OD) δ 8.16 – 8.11 (m, 2H), 7.72 (dd, $J = 8.5$, 2.4 Hz, 1H), 7.24 (d, $J = 8.0$ Hz, 1H), 7.15 (d, $J = 6.8$ Hz, 1H), 7.01 (t, $J = 8.3$ Hz, 2H), 5.77 (s, 1H), 4.73 (ddd, $J = 15.9$, 10.4, 3.7 Hz, 2H), 4.40 – 4.31 (m, 2H), 3.15 (s, 2H), 2.76 (s, 2H), 2.66 (s, 3H), 2.34 (s, 3H), 1.45 (s, 4H), 1.21 (s, 9H), 0.89 (s, 6H).

Example 412




20 (S)-2-(tert-Butoxy)-2-(6'-(2-chloro-6-methylphenethoxy)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

To a pre-cooled solution of 2-(2-chloro-6-methylphenyl)ethanol (28.9 mg, 0.170 mmol) in DMF (4 mL) was added the NaH (67.8 mg, 1.696 mmol) in portions. Then, (S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-hydroxy-6-methyl-3,3'-bipyridin-5-yl)acetate (80 mg, 0.170 mmol) in DMF (1 mL) was added quickly. The mixture was stirred at rt for 16 h and the pH of the reaction mixture was to 7 with acetic

acid. The mixture was filtered and the filtrate was purified by Prep-HPLC (NH₄HCO₃ as buffer) to give (S)-2-(tert-butoxy)-2-(6'-(2-chloro-6-methylphenethoxy)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (21.8 mg, 0.038 mmol, 22.15 % yield). LCMS [M + H] = 580.0. ¹H NMR (400 MHz, CD₃OD) δ 8.30 (s, 1H), 8.17 (s, 1H), 7.71 (d, *J* = 8.1 Hz, 1H), 7.25 (d, *J* = 7.6 Hz, 1H), 7.19 – 7.07 (m, 2H), 6.96 (d, *J* = 8.6 Hz, 1H), 5.68 (s, 1H), 4.60 (t, *J* = 7.1 Hz, 2H), 3.36 (d, *J* = 7.2 Hz, 2H), 3.11 (s, 2H), 2.94 (s, 2H), 2.78 (s, 3H), 2.48 (s, 3H), 1.49 (s, 4H), 1.24 (s, 9H), 0.97 (s, 6H).


Example 413



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2'-methoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2'-methoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate (69 mg, 0.124 mmol) in methanol (3 mL) and H₂O (0.5 mL) was added sodium hydroxide (149 mg, 3.72 mmol). The mixture was stirred at 70 °C for 36 h, cooled, the pH of the mixture was adjusted to ~7 and purified by Prep-HPLC to give (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2'-methoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (20 mg, 0.039 mmol, 31.4 % yield). LCMS [M + H] = 514.0. ¹H NMR (400 MHz, CD₃OD) δ 7.99 (d, *J* = 42.3 Hz, 1H), 7.48 (dd, *J* = 44.4, 8.0 Hz, 1H), 6.50 (t, *J* = 8.0 Hz, 1H), 5.62 (d, *J* = 51.5 Hz, 1H), 4.25 – 4.10 (m, 2H), 3.92 (d, *J* = 5.3 Hz, 3H), 3.19 (s, 2H), 2.99 (s, 1H), 2.77 (s, 1H), 2.67 (s, 3H), 2.25 – 2.06 (m, 1H), 1.44 (s, 4H), 1.20 (d, *J* = 11.5 Hz, 9H), 1.06 (d, *J* = 6.6 Hz, 6H), 0.92 (d, *J* = 17.6 Hz, 6H).


Example 414



(S)-2-(tert-Butoxy)-2-(6'-(butylamino)-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(6'-(butylamino)-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.129 mmol) in methanol (8 mL) was added sodium hydroxide (103 mg, 2.58 mmol) in H₂O (3 mL). Then, the reaction mixture was stirred at 80 °C overnight. The mixture was acidified with aq. HCl to pH = 7 at rt and concentrated. The crude was purified by Prep-HPLC to afford (S)-2-(tert-butoxy)-2-(6'-(butylamino)-4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (43.3 mg, 0.086 mmol, 67.1 % yield) as a white solid. LCMS = 501[M+H]. ¹H NMR (400MHz, CD₃OD): δ 8.31 (s, 1H), 7.81 (s, 1H), 7.41 (d, J = 11.5 Hz, 1H), 5.67 (s, 1H), 3.60–3.42 (m, 2H), 3.15 (brs, 2H), 2.99 (brs, 2H), 2.78 (s, 3H), 1.69–1.67 (m, 2H), 1.55–1.48 (m, 6H), 1.24 (s, 9H), 1.09 – 0.88 (m, 9H).


Example 415



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-(isobutylamino)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-(isobutylamino)-6-methyl-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.129 mmol) in methanol (8 mL) was added sodium hydroxide (103 mg, 2.58 mmol) in H₂O (3 mL). Then the reaction mixture was stirred at 80 °C overnight, cooled, acidified with aq. HCl to pH = 7 and concentrated. The crude was purified by Prep-HPLC to afford (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-(isobutylamino)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (45.5 mg, 0.091 mmol, 70.5 % yield) as a white solid. LCMS = 501.2 [M+H]. ¹H NMR (400 MHz, CD₃OD): δ 8.31 (s, 1H), 7.80 (s, 1H), 7.41 (d, J = 11.6 Hz, 1H), 5.67 (s, 1H), 3.36 (s, 1H), 3.30–3.26 (m, 2H), 3.18 (brs, 2H), 2.98 (brs, 2H), 2.78 (s, 3H), 2.08–1.89 (m, 1H), 1.55–1.48 (m, 4H), 1.24 (s, 9H), 1.00 (d, J = 6.3 Hz, 12H).


Example 416



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-((4-fluorophenethyl)amino)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

- 5 To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-((4-fluorophen-ethyl)amino)-6-methyl-[3,3'-bipyridin]-5-yl)acetate (80 mg, 0.131 mmol) in methanol (8 mL) was added sodium hydroxide (105 mg, 2.63 mmol) in H₂O (3 mL). Then, the reaction mixture was stirred at 80 °C overnight, cooled, acidified with aq. HCl to pH = 7 and concentrated. The crude was purified by Prep-HPLC to afford
- 10 *(S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-fluoro-6'-((4-fluorophenethyl)amino)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid* (42.4 mg, 0.075 mmol, 56.9 % yield) as a white solid. LCMS = 567 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.30 (s, 1H), 7.84 (s, 1H), 7.37 (d, J = 11.5 Hz, 1H), 7.33–7.22 (m, 2H), 7.10–6.93 (m, 2H), 5.67 (s, 1H), 3.73 (t, J = 7.3 Hz, 2H), 3.18 (brs, 2H), 3.09–2.85 (m, 4H), 2.78 (s,
- 15 3H), 1.64–1.39 (m, 4H), 1.24 (s, 9H), 0.99 (s, 6H).

Example 417




- (S)-2-(tert-Butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:*
- 20

- A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetate (65 mg, 0.116 mmol) and sodium hydroxide (93 mg, 2.321 mmol) in methanol (6 mL) was heated at 80 °C overnight. The mixture was neutralized with aq. HCl to pH = 7. The solvent was removed
- 25 and the residue was purified by Prep-HPLC to give *(S)-2-(tert-butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid* (45 mg, 0.087 mmol, 74.9 % yield) as a white solid. LCMS = 518 [M+H]. ¹H NMR (400

MHz, CD3OD): δ 8.34 (s, 1H), 8.11 (d, J = 1.4 Hz, 1H), 7.90 (s, 1H), 5.67 (s, 1H), 4.26 (dd, J = 6.5, 4.6 Hz, 2H), 3.14 (brs, 2H), 2.98 (brs, 2H), 2.78 (s, 3H), 2.27–2.12 (m, 1H), 1.55–1.48 (s, 4H), 1.24 (s, 9H), 1.09 (d, J = 6.7 Hz, 6H), 0.98 (s, 6H).

5

Example 418




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate (37 mg, 0.069 mmol) and sodium hydroxide (54.8 mg, 1.371 mmol) in methanol (3 mL) was heated at 80 °C overnight. The mixture was neutralized with aq. HCl to pH = 7. The solvent was removed and the residue was purified by Prep-HPLC to give (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetic acid (22 mg, 0.044 mmol, 64.5 % yield) as a white solid. LCMS = 498 [M+H]. ¹H NMR (400 MHz, CD3OD): δ 8.31 (s, 0.7H), 8.14 (s, 0.4H), 7.53 (d, J = 8.4 Hz, 1H), 6.81 (t, J = 8.4 Hz, 1H), 5.68 (s, 0.8H), 5.57 (s, 0.4H), 4.23–4.00 (m, 2H), 3.25–2.84 (m, 4H), 2.77 (d, J = 5.6 Hz, 3H), 2.35 (s, 2H), 2.24 (s, 1H), 2.15–2.10 (m, 1H), 1.55–1.33 (m, 4H), 1.25 (d, J = 3.0 Hz, 9H), 1.06 (dd, J = 6.7, 2.3 Hz, 6H), 0.95 (d, J = 4.8 Hz, 6H).

20

Example 419




(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-isopentyl-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-isopentyl-6-methyl-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.134 mmol) and sodium hydroxide (107 mg, 2.67 mmol) in methanol (3 mL) was heated at 80 °C overnight. The

25

mixture was neutralized with aq. HCl to pH = 7. The solvent was removed and the residue was purified by Prep-HPLC to give (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5'-isopentyl-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (27 mg, 0.056 mmol, 41.8 % yield) as a white solid. LCMS = 482 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD): δ 8.63 (s, 1H),
 5 8.52 (s, 1H), 8.38 (s, 1H), 7.88 (s, 1H), 5.67 (s, 1H), 3.20-3.02 (m, 4H), 2.89-2.68 (m, 5H), 1.81-1.56 (m, 3H), 1.47 (brs, 4H), 1.24 (s, 9H), 1.01 (dd, J = 6.2, 1.1 Hz, 6H), 0.96 (s, 6H).

Example 420




10 (S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isopentyl-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of (S)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isopentyl-6-methyl-[3,3'-bipyridin]-5-yl)acetate (75 mg, 0.143 mmol) and sodium

15 hydroxide (115 mg, 2.86 mmol) in methanol (3 mL) was heated at 80 °C overnight. The mixture was neutralized with aq. HCl to pH = 7. The solvent was removed and the residue was purified by Prep-HPLC to give (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isopentyl-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (34.8 mg, 0.072 mmol, 50.5 %
 20 yield) as a white solid. LCMS = 482 [M+H]. ¹H NMR (400 MHz, CD₃OD): δ 8.63 (s, 1H), 8.40 (s, 1H), 8.02 (s, 1H), 7.70 (s, 1H), 5.66 (s, 1H), 3.12-2.80 (m, 6H), 2.81 (s, 3H), 1.82-1.54 (m, 3H), 1.43 (brs, 4H), 1.24 (s, 9H), 1.10-0.96 (m, 12H).


Example 421



(S,E)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of (S,E)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetate (30 mg, 0.058 mmol) and sodium hydroxide (46.0 mg, 1.150 mmol) in methanol (3 mL) was heated at 80 °C overnight. The mixture was neutralized with aq. HCl to pH = 7. The solvent was removed and the residue was purified by Prep-HPLC to give (S,E)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetic acid (9.6 mg, 0.020 mmol, 34.8 % yield) as a white solid. LCMS = 480 [M+H]. ¹H NMR (400 MHz, CD₃OD): δ 8.56 (s, 1H), 8.38 (s, 1H), 7.92 (s, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.07- 6.80 (m, 1H), 6.61 (d, J = 16.0 Hz, 1H), 5.66 (s, 1H), 3.15(brs, 2H), 3.05 (brs, 2H), 2.80 (s, 3H), 2.63-2.61 (m, 1H), 1.55-1.48 (m, 4H), 1.25 (s, 9H), 1.19 (d, J = 6.8 Hz, 6H), 0.97 (s, 6H).


Example 422



(S,Z)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetic acid:

A mixture of (S,Z)-isopropyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.134 mmol) and sodium hydroxide (107 mg, 2.68 mmol) in methanol (3 mL) was heated at 80 °C overnight. Then, the mixture was neutralized with aq. HCl to pH = 7. The solvent was removed and the residue was purified by Prep-HPLC to give (S,Z)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(3-methylbut-1-en-1-yl)-[3,3'-bipyridin]-5-yl)acetic acid (38.6 mg, 0.079 mmol, 58.9 % yield) as a white solid. LCMS = 480 [M+H]. ¹H NMR (400 MHz, CD₃OD): δ 8.65 (s, 1H), 8.40 (s, 1H), 7.94 (s, 1H), 7.62 (s, 1H), 6.47 (d, J = 11.8 Hz, 1H), 5.93-5.89 (m, 1H), 5.67 (s, 1H), 3.41 (brs, 1H), 3.10-2.95 (m, 4H), 2.81 (s, 3H), 1.48 (brs, 4H), 1.23 (s, 9H), 1.11 (dd, J = 6.5, 4.1 Hz, 6H), 0.97 (s, 6H).


Example 423



(S)-2-(*tert*-Butoxy)-2-(6'-((2-chloro-6-methylbenzyl)oxy)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:

- 5 To a solution of (*S*)-isopropyl 2-(*tert*-butoxy)-2-(6'-((2-chloro-6-methylbenzyl)oxy)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetate (70 mg, 0.115 mmol) in ethanol (3 mL) was added a solution of sodium hydroxide (46.0 mg, 1.151 mmol) in H₂O (0.3 mL) and heated at 90 °C for 16 hr. Then, the pH was adjusted with acetic acid and purified by preparative HPLC (NH₄CO₃ as buffer) to give
- 10 (*S*)-2-(*tert*-butoxy)-2-(6'-((2-chloro-6-methylbenzyl)oxy)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (21.2 mg, 0.037 mmol, 32.4 % yield) as a white solid. LCMS [M + H] = 565.27. ¹H NMR (500MHz, DMSO-*d*₆): ¹H NMR (400 MHz, DMSO) δ 8.18 (s, 1H), 8.10 (s, 1H), 7.71 (d, *J* = 8.4 Hz, 1H), 7.43 – 7.22 (m, 3H), 6.95 (d, *J* = 8.4 Hz, 1H), 5.82 (s, 1H), 5.56 (d, *J* = 11.6 Hz, 1H), 5.46 (d, *J* = 11.6 Hz, 1H),
- 15 3.34 (s, 3H), 2.96 (s, 1H), 2.42 (s, 3H), 2.22 (s, 2H), 1.56 (s, 1H), 1.32 (s, 2H), 1.13 (s, 10H), 0.82 (d, *J* = 62.4 Hz, 6H).

Example 424



- 20 (*2S*)-2-(*tert*-Butoxy)-2-(6'-(1-(2-chloro-6-methylphenyl)ethoxy)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid:


To a pre-cooled solution of 1-(2-chloro-6-methylphenyl)ethanol (145 mg, 0.848 mmol) in DMF (4 mL) was added the NaH (33.9 mg, 0.848 mmol) in portion. Then, (*S*)-isopropyl 2-(*tert*-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-[3,3'-bipyridin]-5-yl)acetate (80 mg, 0.170 mmol) in DMF (1 ML) was added rapidly and stirred

25 at rt. After 16 h, the pH was adjusted to about 7 with acetic acid, the mixture filtered and

purified by Prep-HPLC to provide (2S)-2-(tert-butoxy)-2-(6'-(1-(2-chloro-6-methylphenyl)ethoxy)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetic acid (21.6 mg, 21.6% yield) as white solid. LCMS [M + H] = 580 and 582. ¹H NMR (400 MHz, CD₃OD) δ 8.11 – 7.97 (m, 2H), 7.64 (dt, *J* = 8.5, 2.5 Hz, 1H), 7.20 (dd, *J* = 7.5, 1.5 Hz, 1H), 7.11 – 7.03 (m, 2H), 6.95 (d, *J* = 8.5 Hz, 1H), 6.72 (tt, *J* = 6.8, 3.4 Hz, 1H), 5.73 (d, *J* = 3.4 Hz, 1H), 3.05 (s, 2H), 2.80 (s, 2H), 2.64 (s, 3H), 2.57 (d, *J* = 3.2 Hz, 3H), 1.75 (dd, *J* = 6.9, 1.9 Hz, 3H), 1.36 (d, *J* = 11.3 Hz, 4H), 1.18 (s, 9H), 0.87 (d, *J* = 15.0 Hz, 3H), 0.80 (s, 3H).

10

Example 425




(S)-2-(tert-Butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetic acid:

To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetate (20 mg, 0.035 mmol) in DMF (2 mL) was added a solution of NaOH (13.93 mg, 0.348 mmol) in H₂O (0.5 mL). The mixture was stirred at room temperature for 72 hr. The pH value of the reaction mixture was adjusted to ~7 by with aq. HCl (1 M) and purified by preparative HPLC (NH₄CO₃ as buffer) to (S)-2-(tert-butoxy)-2-(5'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-2',6-dimethyl-[3,3'-bipyridin]-5-yl)acetic acid (2 mg, 3.62 μmol, 10.40 % yield) as a white solid. LCMS [M + H] = 532. ¹H NMR (400 MHz, CD₃OD) δ 8.08 (s, 1H), 7.56 (s, 1H), 5.81 (s, 1H), 4.80 – 4.46 (m, 2H), 4.33 – 4.13 (m, 2H), 2.98 (s, 2H), 2.75 (s, 1H), 2.69 – 2.61 (m, 4H), 2.30 (s, 2H), 2.23 – 2.08 (m, 2H), 1.42 (s, 4H), 1.22 (d, *J* = 1.3 Hz, 9H), 1.08 (dd, *J* = 6.7, 2.9 Hz, 6H), 0.90 (d, *J* = 3.4 Hz, 6H).

25

Example 426




(S)-2-tert-Butoxy-2-(6'-butoxy-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetic acid:

To a solution of (S)-isopropyl 2-tert-butoxy-2-(6'-butoxy-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetate (55 mg, 0.105 mmol) in methanol (3 mL) and water (0.5 mL) was added the sodium hydroxide (42 mg, 1.05 mmol) and heated at 70 °C overnight. Then, the reaction mixture was neutralized with acetic acid and purified by preparative HPLC (TFA as buffer) to give (S)-2-tert-butoxy-2-(6'-butoxy-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetic acid (30 mg, 59%).

LCMS [M + H] = 484.3. ¹H NMR (400 MHz, CD₃OD) δ 8.32 (s, 1H), 8.17 (s, 1H), 7.72 (d, J = 6.8 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 5.68 (s, 1H), 4.47 – 4.29 (m, 2H), 3.11 (s, 2H), 2.95 (s, 2H), 2.79 (s, 3H), 1.81 (dt, J = 14.4, 6.6 Hz, 2H), 1.59 – 1.36 (m, 6H), 1.25 (s, 9H), 1.05 – 0.90 (m, 9H).

Example 427




(S)-2-tert-Butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(isopentyloxy)-6-methyl-3,3'-bipyridin-5-yl)acetic acid:

To an ice-cold solution of 3-methylbutan-1-ol (74.8 mg, 0.848 mmol) in anhydrous DMF (3 mL) was added sodium hydride (33.9 mg, 0.848 mmol). The mixture was stirred at rt for 20 min. Then, (S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-3,3'-bipyridin-5-yl)acetate (80 mg, 0.170 mmol) was added and stirred at 90 °C overnight. Then, cooled, neutralized and purified by preparative HPLC (TFA as buffer) to give (S)-2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(isopentyloxy)-6-methyl-3,3'-bipyridin-5-yl)acetic acid (35 mg, 41%).

LCMS [M + H] = 498.4. ¹H NMR (400 MHz, CD₃OD) δ 8.31 (s, 1H), 8.17 (s, 1H), 7.72 (d, J = 8.4 Hz, 1H), 6.98 (t, J = 7.8 Hz, 1H), 5.68 (s, 1H), 4.42 (dq, J = 6.7, 4.0 Hz, 2H), 3.12 (s, 2H), 2.95 (s, 2H), 2.77 (d, J = 7.1 Hz, 3H), 1.85 (dt, J = 13.4, 6.7 Hz, 1H), 1.72 (q, J = 6.7 Hz, 2H), 1.48 (d, J = 10.7 Hz, 4H), 1.24 (s, 9H), 1.04 – 0.90 (m, 12H).


Example 428



(S)-2-tert-Butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-5',6-dimethyl-3,3'-bipyridin-5-yl)acetic acid:

- 5 To a ice-cold solution of 2-methylpropan-1-ol (198 mg, 2.68 mmol) in anhydrous THF (1 mL) was added the sodium hydride (107 mg, 2.68 mmol). The mixture was stirred at rt for 30 min. Then, (S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-5',6-dimethyl-3,3'-bipyridin-5-yl)acetate (70 mg, 0.148 mmol) was added and stirred at 70 °C overnight. Then, reaction mixture acidified with aq. HCl and purified
- 10 by preparative HPLC (TFA as buffer) to give (S)-2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-5',6-dimethyl-3,3'-bipyridin-5-yl)acetic acid (55 mg, 58%). LCMS [M + H] = 498.3. ¹H NMR (400 MHz, CD₃OD) δ 8.30 (s, 1H), 7.98 (s, 1H), 7.56 (s, 1H), 5.68 (s, 1H), 4.26 – 4.10 (m, 2H), 3.13 (s, 2H), 2.95 (s, 2H), 2.78 (s, 3H), 2.31 (s, 3H), 2.16 (dt, *J* = 13.3, 6.7 Hz, 1H), 1.58 – 1.40 (m, 4H), 1.24 (s, 9H), 1.08
- 15 (d, *J* = 6.7 Hz, 6H), 0.97 (s, 6H).

Example 429




- (2S)-2-tert-Butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-4',6-dimethyl-3,3'-bipyridin-5-yl)acetic acid:*
- 20

To an ice-cold solution of 2-methylpropan-1-ol (275 mg, 3.71 mmol) in anhydrous THF (4 mL) was added sodium hydride (148 mg, 3.71 mmol). The mixture was stirred at rt for 30 min. Then, (2S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-4',6-dimethyl-3,3'-bipyridin-5-yl)acetate (180 mg, 0.371

25 mmol) was added and stirred at 70 °C overnight. Then, the reaction mixture was acidified with aq. HCl and purified by preparative HPLC (TFA as buffer) to give (2S)-2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-4',6-dimethyl-3,3'-bipyridin-5-

yl)acetic acid (50 mg, 27%). LCMS $[M + H] = 498.3$. ^1H NMR (400 MHz, CD_3OD) δ 8.24 (d, $J = 60.7$ Hz, 1H), 7.97 (d, $J = 47.7$ Hz, 1H), 6.88 (d, $J = 13.5$ Hz, 1H), 5.62 (d, $J = 43.4$ Hz, 1H), 4.20 – 4.05 (m, 2H), 3.22 – 2.86 (m, 4H), 2.78 (s, 3H), 2.23 (s, 2H), 2.12 (dd, $J = 8.4, 4.9$ Hz, 2H), 1.43 (s, 4H), 1.25 (d, $J = 1.8$ Hz, 9H), 1.05 (dd, $J = 6.7, 3.3$ Hz, 6H), 0.94 (d, $J = 8.3$ Hz, 6H).


Example 430



(S)-2-tert-Butoxy-2-(6'-(1,1-difluoro-3-methylbutyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetic acid:

To a solution of (S)-isopropyl 2-tert-butoxy-2-(6'-(1,1-difluoro-3-methylbutyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetate (70 mg, 0.125 mmol) in methanol (3 mL) and water (0.5 mL) was added the sodium hydroxide (50 mg, 1.25 mmol) and heated at 70 °C overnight. Then, the pH was adjusted to neutral and purified by preparative HPLC (TFA as buffer) to give (S)-2-tert-butoxy-2-(6'-(1,1-difluoro-3-methylbutyl)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetic acid (50 mg, 77%). LCMS $[M + H] = 518.3$. ^1H NMR (400 MHz, CD_3OD) δ 8.66 (s, 1H), 8.17 (s, 1H), 7.99 (dd, $J = 8.0, 2.0$ Hz, 1H), 7.92 – 7.80 (m, 1H), 5.84 (s, 1H), 3.01 (s, 2H), 2.76 (t, $J = 26.6$ Hz, 2H), 2.66 (s, 3H), 2.30 (tdd, $J = 17.1, 6.4, 4.2$ Hz, 2H), 1.81 (dt, $J = 13.3, 6.7$ Hz, 1H), 1.40 (d, $J = 21.1$ Hz, 4H), 1.26 – 1.16 (m, 9H), 0.97 (dd, $J = 6.7, 2.3$ Hz, 6H), 0.89 (s, 6H).

Example 431




(2S)-2-tert-Butoxy-2-(2'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetic acid:


To a solution of (2S)-isopropyl 2-tert-butoxy-2-(2'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetate (100 mg, 0.179 mmol) in methanol (3 mL) and water (0.5 mL) was added the sodium hydroxide (72 mg, 1.79 mmol) and heated at 70 °C overnight. Then, cooled, adjusted pH to neutral with acetic acid and purified by preparative HPLC (TFA as buffer) to give (2S)-2-tert-butoxy-2-(2'-chloro-4-(4,4-dimethylpiperidin-1-yl)-6'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetic acid (20 mg, 21%). LCMS [M + H] = 518.2. ¹H NMR (400 MHz, CD₃OD) δ 7.99 (d, *J* = 38.6 Hz, 1H), 7.59 (dd, *J* = 40.7, 8.3 Hz, 1H), 6.82 (dd, *J* = 8.3, 7.1 Hz, 1H), 5.59 (d, *J* = 65.0 Hz, 1H), 4.08 – 3.97 (m, 2H), 3.06 – 2.89 (m, 2H), 2.75 (s, 2H), 2.63 – 2.52 (m, 3H), 2.07 – 1.94 (m, 1H), 1.32 (d, *J* = 6.1 Hz, 3H), 1.20 (d, *J* = 9.1 Hz, 1H), 1.14 – 1.04 (m, 9H), 0.94 (dd, *J* = 6.7, 2.8 Hz, 6H), 0.85 – 0.74 (m, 6H).

15

Example 432



Example 433



(S)-2-tert-Butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-((S)-1-hydroxy-3-methylbutyl)-6-methyl-3,3'-bipyridin-5-yl)acetic acid:


To a solution of (2S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(1-hydroxy-3-methylbutyl)-6-methyl-3,3'-bipyridin-5-yl)acetate (250 mg, 0.463 mmol) in methanol (3 mL) and water (0.5 mL) was added the sodium hydroxide (185 mg, 4.63 mmol). Then, the solution was heated at 70 °C overnight, cooled, adjusted pH to neutral with acetic acid and purified by preparative HPLC (TFA as buffer) to give (S)-2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(S)-1-hydroxy-3-methylbutyl)-6-methyl-3,3'-bipyridin-5-yl)acetic acid (5 mg, 2%). LCMS [M + H] = 498.4. ¹H NMR (400 MHz, CD₃OD) δ 8.48 (s, 1H), 8.13 (s, 1H), 7.87 (dd, *J* = 8.1, 1.7 Hz, 1H), 7.72 (d, *J* = 8.1 Hz, 1H), 5.81 (s, 1H), 4.87 (d, *J* = 5.6 Hz, 2H), 3.06 (d, *J* = 7.3 Hz, 2H), 2.73 (d, *J* = 10.9 Hz, 2H), 2.66 (s, 3H), 1.87 – 1.73 (m, 1H), 1.72 – 1.60 (m, 2H), 1.40 (d, *J* = 22.5 Hz, 4H), 1.21 (s, 9H), 1.00 (dd, *J* = 8.1, 6.7 Hz, 6H), 0.88 (s, 6H).

30

Also isolated

(S)-2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-((R)-1-hydroxy-3-methylbutyl)-6-methyl-3,3'-bipyridin-5-yl)acetic acid (5 mg, 2%). LCMS [M + H] = 498.4. ¹H NMR (400 MHz, CD₃OD) δ 8.48 (d, *J* = 1.6 Hz, 1H), 8.13 (s, 1H), 7.86 (dd, *J* = 8.1, 2.0 Hz, 1H), 7.72 (d, *J* = 8.1 Hz, 1H), 5.82 (s, 1H), 4.89 – 4.85 (m, 2H), 3.18 – 2.90 (m, 2H), 2.74 (dd, *J* = 33.7, 15.7 Hz, 2H), 2.66 (s, 3H), 1.90 – 1.74 (m, 1H), 1.74 – 1.58 (m, 2H), 1.40 (d, *J* = 22.3 Hz, 4H), 1.21 (s, 9H), 1.00 (dd, *J* = 11.3, 6.6 Hz, 6H), 0.89 (s, 6H).

Example 434




10 (2S)-2-tert-Butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-2'-fluoro-6'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetic acid:

To a solution of (2S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-2'-fluoro-6'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetate (51 mg, 0.094 mmol) in methanol (2 mL) and water (0.5 mL) was added sodium hydroxide (38 mg, 0.94 mmol).

15 Then, the solution was heated at 70 °C overnight cooled, adjusted to neutral with acidic acid and purified by preparative HPLC (TFA as buffer) to give (2S)-2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-2'-fluoro-6'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetic acid (14 mg, 30%). LCMS [M + H] = 502.1. ¹H NMR (400 MHz, CD₃OD) δ 8.09 (d, *J* = 26.9 Hz, 1H), 7.74 (d, *J* = 40.1 Hz, 1H), 6.86 (d, *J* = 8.1 Hz, 1H), 5.79 (d, *J* = 36.1 Hz, 1H), 4.19 – 4.03 (m, 2H), 3.06 (d, *J* = 38.1 Hz, 2H), 2.91 (d, *J* = 19.5 Hz, 1H), 2.79 (d, *J* = 14.2 Hz, 1H), 2.65 (s, 3H), 2.13 (dt, *J* = 13.4, 6.7 Hz, 1H), 1.45 (d, *J* = 3.5 Hz, 4H), 1.21 (s, 9H), 1.06 (d, *J* = 6.7 Hz, 6H), 0.91 (s, 6H).

Example 435



25


(2S)-2-tert-Butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-2'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetic acid: To a solution of (2S)-isopropyl 2-tert-butoxy-2-(4-(4,4-

dimethylpiperidin-1-yl)-6'-fluoro-2'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetate (30 mg, 0.055 mmol) in methanol (2 mL) and water (0.5 mL) was added sodium hydroxide (22 mg, 0.55 mmol) and heated at 70 °C overnight. The solution was then acidified and purified by preparative HPLC (TFA as buffer) to give (2S)-2-tert-butoxy-2-(4-(4,4-

5 dimethylpiperidin-1-yl)-6'-fluoro-2'-isobutoxy-6-methyl-3,3'-bipyridin-5-yl)acetic acid (4 mg, 12%). LCMS [M + H] = 502.1. ¹H NMR (400 MHz, CD₃OD) δ 7.89 (d, *J* = 41.2 Hz, 1H), 7.68 – 7.53 (m, 1H), 6.62 (dt, *J* = 9.8, 4.9 Hz, 1H), 5.69 (s, 1H), 4.03 – 3.90 (m, 2H), 2.81 (s, 2H), 2.65 (s, 2H), 2.53 (s, 3H), 1.81 (dt, *J* = 13.1, 6.7 Hz, 1H), 1.30 (s, 4H), 1.08 (s, 9H), 0.84 – 0.67 (m, 12H).

10


Example 436



(S)-2-tert-Butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(isobutylamino)-6-methyl-3,3'-bipyridin-5-yl)acetic acid:

To a solution of (S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(isobutylamino)-6-methyl-3,3'-bipyridin-5-yl)acetate (55 mg, 0.105 mmol) in methanol (5 ml) and water (1 ml) was added NaOH (62.9 mg, 1.572 mmol). The mixture was stirred at 100 °C for 16 hours. The mixture was then acidified with acetic acid (adjust solution to pH = 7), concentrated and purified by preparative HPLC (TFA as buffer) to give (S)-2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-(isobutylamino)-6-methyl-3,3'-bipyridin-5-yl)acetic acid (25 mg, 49.4%). LCMS [M + H] = 483.3. ¹H NMR (400 MHz, CD₃OD) δ 8.19 (s, 1H), 7.84 (s, 1H), 7.67 (d, *J* = 9.2 Hz, 1H), 7.02 (d, *J* = 9.2 Hz, 1H), 5.50 (s, 1H), 4.74 (s, 2H), 3.10 (dd, *J* = 11.1, 9.2 Hz, 4H), 3.01 – 2.77 (m, 2H), 2.62 (s, 3H), 1.88 (dp, *J* = 13.5, 6.8 Hz, 1H), 1.51 – 1.27 (m, 4H), 1.09 (s, 9H), 0.91 (t, *J* = 8.4 Hz, 6H), 0.85 (s, 6H).


Example 437



(S)-2-tert-Butoxy-2-(6'-(butylamino)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetic acid:

To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(6'-(butylamino)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-[3,3'-bipyridin]-5-yl)acetate (55 mg, 0.105 mmol) in methanol (5 ml) and water (1 ml) was added NaOH (41.9 mg, 1.048 mmol) and stirred at 100 °C for 16 hours. Then, the reaction mixture was acidified with acetic acid (adjusted solution to pH = 7), concentrated and purified by preparative HPLC (TFA as buffer) to give (S)-2-tert-butoxy-2-(6'-(butylamino)-4-(4,4-dimethylpiperidin-1-yl)-6-methyl-3,3'-bipyridin-5-yl)acetic acid (25 mg, 49.4%). LCMS [M + H] = 483.2. ¹H NMR (400 MHz, CD₃OD) δ 8.32 (s, 1H), 7.98 (s, 1H), 7.80 (s, 1H), 7.11 (s, 1H), 5.67 (s, 1H), 3.45 (dd, *J* = 22.1, 14.9 Hz, 4H), 3.15 (s, 3H), 3.04 (s, 3H), 2.76 (s, 4H), 1.83 – 1.66 (m, 2H), 1.52 (dd, *J* = 14.9, 7.6 Hz, 6H), 1.24 (s, 10H), 1.03 (dd, *J* = 13.4, 5.9 Hz, 10H).

Example 438




(2S)-2-tert-Butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(3-methylbutan-2-yloxy)-3,3'-bipyridin-5-yl)acetic acid:

- 5 To a solution of 3-methylbutan-2-ol (187 mg, 2.120 mmol) in anhydrous DMF (5 ml) was added NaH (127 mg, 3.18 mmol) and the resulting mixture was stirred at 100 °C for 30 min. Then, (S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-3,3'-bipyridin-5-yl)acetate (100 mg, 0.212 mmol) was added to the mixture and stirred at 100 °C for 16 hours. The reaction mixture was diluted with water (20 mL),
- 10 extracted with EtOAc (2 x 40 mL) and the combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and concentrated to afford crude product. The crude product was dissolved in MeOH and purified by Prep-HPLC to afford (2S)-2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(3-methylbutan-2-yloxy)-3,3'-bipyridin-5-yl)acetic acid (25 mg, 23.69%). LCMS [M + H] = 497.3. ¹H NMR (400 MHz, CD₃OD)
- 15 δ 8.33 (d, *J* = 2.7 Hz, 1H), 8.16 (s, 1H), 7.71 (d, *J* = 8.2 Hz, 1H), 6.94 (d, *J* = 8.6 Hz, 1H), 5.68 (s, 1H), 5.12 (tt, *J* = 12.1, 6.1 Hz, 1H), 3.12 (s, 2H), 2.91 (d, *J* = 46.5 Hz, 2H), 2.79 (s, 3H), 2.13 – 1.87 (m, 1H), 1.46 (t, *J* = 17.1 Hz, 4H), 1.30 (dt, *J* = 8.9, 4.5 Hz, 3H), 1.25 (s, 8H), 1.13 – 0.85 (m, 11H).

20

Example 439




(2S)-2-tert-Butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(4-methylpentan-2-yloxy)-3,3'-bipyridin-5-yl)acetic acid:

- To a solution of 4-methylpentan-2-ol (217 mg, 2.120 mmol) in anhydrous DMF (5 ml) was added NaH (127 mg, 3.18 mmol) and the resulting mixture was stirred at 100 °C for 30 min. Then, (S)-isopropyl 2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6'-fluoro-6-methyl-3,3'-bipyridin-5-yl)acetate (100 mg, 0.212 mmol) added and stirred at 100 °C
- 25

for 16 hours. To the reaction mixture was added water (20 ml), extracted with EtOAc (2 x 40 mL) and the combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and concentrated to afford crude product. The crude product was dissolved in MeOH, and the solution was purified by Prep-HPLC to afford (2S)-2-tert-butoxy-2-(4-(4,4-dimethylpiperidin-1-yl)-6-methyl-6'-(4-methylpentan-2-yloxy)-3,3'-bipyridin-5-yl)acetic acid (40 mg, 36.9%) . LCMS [M + H] = 511.3. ¹H NMR (400 MHz, CD₃OD) δ 8.33 (s, 1H), 8.17 (s, 1H), 7.71 (d, *J* = 8.5 Hz, 1H), 6.92 (d, *J* = 8.5 Hz, 1H), 5.68 (s, 1H), 5.42 (dt, *J* = 13.1, 8.2 Hz, 1H), 3.11 (s, 2H), 2.92 (d, *J* = 32.9 Hz, 2H), 2.79 (s, 3H), 1.87 – 1.68 (m, 2H), 1.45 (dd, *J* = 12.3, 6.3 Hz, 4H), 1.41 (d, *J* = 5.6 Hz, 1H), 1.34 (dd, *J* = 6.0, 4.7 Hz, 3H), 1.25 (s, 7H), 1.06 – 0.84 (m, 10H).


Example 440



(S)-2-tert-Butoxy-2-(4'-(4,4-dimethylpiperidin-1-yl)-6-iodo-5-isobutoxy-6'-methyl-2,3'-bipyridin-5'-yl)acetic acid:

To a solution of (S)-isopropyl 2-tert-butoxy-2-(4'-(4,4-dimethylpiperidin-1-yl)-6-iodo-5-isobutoxy-6'-methyl-2,3'-bipyridin-5'-yl)acetate (150 mg, 0.230 mmol) in MeOH (10 mL) and water (2 mL) was added NaOH (27.6 mg, 0.691 mmol) and stirred for 20 hours at 100 °C. The mixture was concentrated under vacuo, then, HCl (1N, 0.5mL) was added . The mixture was extracted by EtOAc (5ml) and concentrated to give crude product. The crude product was purified by HPLC to give (S)-2-tert-butoxy-2-(4'-(4,4-dimethylpiperidin-1-yl)-6-iodo-5-isobutoxy-6'-methyl-2,3'-bipyridin-5'-yl)acetic acid (53 mg, 37.8% yield). ESI-MS (EI⁺, *m/z*)⁺ [M + H]⁺ 610.2. ¹H NMR (400 MHz, MeOD) δ 8.20 (s, 1H), 7.48 (d, *J* = 8.3 Hz, 1H), 7.37 (d, *J* = 8.3 Hz, 1H), 5.87 (s, 1H), 4.02–3.89 (m, 2H), 2.93–2.86 (m, 4H), 2.65 (s, 3H), 2.19 (td, *J* = 13.0, 6.4 Hz, 1H), 1.48–1.42 (m, 4H), 1.21 (s, 9H), 1.16 (d, *J* = 6.7 Hz, 6H), 0.96 (d, *J* = 17.1 Hz, 6H).


Example 441



(S)-2-(tert-Butoxy)-2-(5-(butylamino)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:


- 5 To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(5-(butylamino)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (65 mg, 0.124 mmol) in methanol (8 mL) was added sodium hydroxide (99 mg, 2.477 mmol) in H₂O (3 mL). Then, the reaction mixture was stirred at 80 °C overnight. The mixture was acidified with HCl to pH = 7. The crude was purified by Prep-HPLC to afford (S)-2-(tert-butoxy)-2-(5-(butylamino)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid
- 10 (28 mg, 0.057 mmol, 46.2 % yield) as a white solid. LCMS [M + H] = 483.

Example 442



- 15 *(S)-2-(tert-Butoxy)-2-(5-(butyl(methyl)amino)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid:*
- To a solution of (S)-isopropyl 2-(tert-butoxy)-2-(5-(butyl(methyl)amino)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetate (50 mg, 0.093 mmol) in methanol (8 mL) was added sodium hydroxide (74.2 mg, 1.856 mmol) in H₂O (3 mL).
- 20 Then, the reaction mixture was stirred at 80 °C overnight. The mixture was acidified with HCl to pH = 7. The crude was purified by Prep-HPLC to afford (S)-2-(tert-butoxy)-2-(5-(butyl(methyl)amino)-4'-(4,4-dimethylpiperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid (24.1 mg, 0.049 mmol, 52.3 % yield) as a white solid. LCMS [M + H] = 497.
- 25 The following compounds could be prepared by procedures similar to those described in this specification for the Examples above.


Example 443



(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-methoxypyrazin-2-yl)-2-methylpyridin-3-yl)acetic acid


5

Example 444



(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(2-(4-fluorophenethoxy)pyrimidin-5-yl)-2-methylpyridin-3-yl)acetic acid


Example 445



10

(S)-2-(*tert*-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-4-fluoro-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid


Example 446



15

(S)-2-(*tert*-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)-1,2,4,5-tetrazin-3-yl)-2-methylpyridin-3-yl)acetic acid


Example 447



(S)-2-(tert-Butoxy)-2-(4-chloro-4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid


5

Example 448



(S)-2-(tert-Butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)-6-methylpyrazin-2-yl)-2-methylpyridin-3-yl)acetic acid


Example 449



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-4-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid

10


Example 450



(S)-2-(4-(4,4-Dimethylpiperidin-1-yl)-5-(2-fluoro-4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetic acid

15


Example 451



(S)-2-(4'-(4,4-Dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6,6'-dimethyl-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetic acid


5

Example 452



(S)-2-(4'-(4,4-Dimethylpiperidin-1-yl)-3-fluoro-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetic acid


Example 453



10

(S)-2-(4'-(4,4-Dimethylpiperidin-1-yl)-4-fluoro-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetic acid


Example 454



15

(S)-2-(4-Chloro-4'-(4,4-dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetic acid


Example 455



(S)-2-(4'-(4,4-Dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6'-methyl-4-(trifluoromethyl)-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetic acid


5

Example 456



(S)-2-(4'-(4,4-Dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-4-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetic acid


Example 457



10

(S)-2-(4-(4,4-Dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)-4-methylpyrimidin-2-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetic acid


Example 458



15


(S)-2-(4-(4,4-Dimethylpiperidin-1-yl)-5-(2-(4-fluorophenethoxy)pyrimidin-5-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetic acid

Example 459




(S)-2-(4-(4,4-Dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)pyrazin-2-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetic acid

Example 460




5 (S)-2-(4-(4,4-Dimethylpiperidin-1-yl)-5-(5-(4-fluorophenethoxy)-6-methylpyrazin-2-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetic acid

Example 461



10 (S)-2-(4-(4,4-Dimethylpiperidin-1-yl)-5-(6-(4-fluorophenethoxy)-1,2,4,5-tetrazin-3-yl)-2-methylpyridin-3-yl)-2-(tert-pentyloxy)acetic acid


Example 462



(S)-2-(4'-(4,4-Dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-4,6'-dimethyl-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetic acid


15

Example 463



(S)-2-(4'-(4,4-Dimethylpiperidin-1-yl)-5-(4-fluorophenethoxy)-6-methoxy-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetic acid


Example 464



(S)-2-(tert-Butoxy)-2-(4'-(4,4-dimethylpiperidin-1-yl)-6-fluoro-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)acetic acid

5

Example 465



(S)-2-(4'-(4,4-Dimethylpiperidin-1-yl)-6-fluoro-5-(4-fluorophenethoxy)-6'-methyl-[2,3'-bipyridin]-5'-yl)-2-(tert-pentyloxy)acetic acid

10

Biological Methods

Inhibition of HIV replication: A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the *Renilla* Luciferase gene. This virus is fully infectious and can undergo multiple cycles of replication in cell culture. In addition, the luciferous reporter provides a simple and easy method for quantitating the extent of virus growth and consequently, the antiviral activity of test compounds. The plasmid pNLRLuc contains the proviral NL-RLuc DNA cloned into pUC18 at the *PvuII* site. The NL-RLuc virus was prepared by transfection of 293T cells with the plasmid pNLRLuc. Transfections were performed using the LipofectAMINE PLUS kit from Invitrogen (Carlsbad, CA) according to the manufacturer and the virus generated was titered in MT-2 cells. For susceptibility analyses, the titrated virus was used to infect MT-2 cells in the presence of compound, and after 5 days of incubation, cells were processed and quantitated for virus growth by the amount of expressed luciferase. Assay media was RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum (FBS), 100 units/ml penicillin G/100 units/ml streptomycin, 10 mM HEPES buffer pH 7.55 and 2 mM L-glutamine. The results form at

least 2 experiments were used to calculate the EC₅₀ values. Luciferase was quantitated using the Dual Luciferase kit from Promega (Madison, WI). Susceptibility of viruses to compounds was determined by incubation in the presence of serial dilutions of the compound. The 50% effective concentration (EC₅₀) was calculated by using the

- 5 exponential form of the median effect equation where $(Fa) = 1/[1 + (ED_{50}/\text{drug conc.})^m]$ (Johnson VA, Byington RT. Infectivity Assay. In *Techniques in HIV Research*. ed. Aldovini A, Walker BD. 71-76. New York: Stockton Press. 1990). Results are summarized in Table 1.

10

Table 1.

Example	EC ₅₀ μM
1	0.020
2	0.005
3	0.008
4	0.008
5	0.007
6	0.014
7	0.002
8	0.003
9	0.38
10	0.031
11	0.004
12	0.004
13	0.010
14	0.002
15	0.016
16	0.002
17	0.085
18	0.004
19	0.004
20	0.002

Example	EC ₅₀ μ M
21	0.002
22	0.003
23	0.002
24	0.002
25	0.0008
26	0.0005
27	0.0007
28	0.0007
29	0.0002
30	0.002
31	0.0008
32	0.005
33	0.002
34	0.0007
35	0.001
36	0.004
37	0.002
38	0.008
39	0.003
40	0.002
41	0.004
42	0.003
43	0.0006
44	0.003
45	0.004
46	0.004
47	0.004
48	0.003
49	0.0007
50	0.002

Example	EC ₅₀ μM
51	0.005
52	0.001
53	0.003
54	0.002
55	0.003
56	0.002
57	0.013
58	0.018
59	0.003
60	0.025
61	0.011
62	0.003
63	0.006
64	0.005
65	0.002
66	0.002
67	0.027
68	0.002
69	0.003
70	0.002
71	0.002
72	0.002
73	0.001
74	0.002
75	0.003
76	0.004
77	0.0006
78	0.006
79	0.006
80	0.002

Example	EC ₅₀ μ M
81	0.011
82	0.002
83	0.005
84	0.005
85	0.003
86	0.003
87	0.002
88	0.0005
89	0.013
90	0.005
91	0.072
92	0.004
93	0.012
94	0.006
95	0.008
96	0.021
97	0.005
98	0.002
99	0.0006
100	0.0005
101	0.010
102	0.050
103	0.002
104	0.0007
105	0.004
106	0.001
107	nd
108	0.003
109	0.013
110	0.002

Example	EC ₅₀ μ M
111	0.002
112	0.005
113	0.003
114	0.024
115	0.001
116	0.001
117	0.001
118	0.001
119	0.001
120	0.002
121	0.002
122	0.001
123	0.002
124	0.002
125	0.003
126	0.0004
127	0.004
128	0.002
129	0.003
130	0.013
131	0.010
132	0.007
133	0.004
134	0.007
135	0.003
136	0.002
137	0.053
138	0.071
139	0.027
140	0.053

Example	EC ₅₀ μ M
141	0.008
142	0.006
143	0.004
144	0.078
145	0.005
146	0.142
147	0.328
148	0.007
149	0.006
150	0.012
151	0.006
152	0.060
153	0.029
154	0.052
155	0.011
156	0.001
157	0.022
158	0.016
159	0.002
160	0.013
161	0.009
162	0.007
163	0.006
164	0.004
165	0.008
166	0.011
167	0.005
168	0.004
169	0.007
170	0.019

Example	EC ₅₀ μ M
171	0.005
172	0.014
173	0.021
174	0.011
175	0.006
176	0.005
177	0.012
178	0.002
179	0.005
180	0.003
181	0.006
182	0.027
183	0.006
184	0.008
185	0.011
186	0.037
187	0.107
188	nd
189	0.041
190	0.003
191	0.002
192	0.001
193	0.004
194	0.0006
195	0.001
196	0.019
197	0.011
198	0.012
199	0.004
200	0.002

Example	EC ₅₀ μ M
201	0.001
202	0.075
203	0.007
204	0.001
205	0.006
206	0.002
207	0.036
208	0.035
209	0.004
210	0.002
211	0.003
212	0.0003
213	0.0006
214	0.009
215	nd
216	nd
217	0.010
218	0.0002
219	0.002
220	0.002
221	0.0003
222	0.008
223	0.015
224	nd
225	0.001
226	0.005
227	nd
228	0.052
229	0.013
230	0.003

Example	EC ₅₀ μ M
231	0.0006
232	0.006
233	0.002
234	0.004
235	0.002
236	0.002
237	0.003
238	0.002
239	0.003
240	0.001
241	0.007
242	0.005
243	0.007
244	0.003
245	0.002
246	0.0004
247	0.0008
248	0.001
249	0.002
250	0.002
251	0.002
252	0.001
253	0.001
254	0.0006
255	0.0008
256	0.0008
257	0.001
258	0.001
259	0.001
260	0.011

Example	EC ₅₀ μ M
261	0.028
262	1.126
263	0.003
264	0.003
265	0.001
266	0.011
267	0.009
268	0.05
269	0.009
270	0.0006
271	0.003
272	0.002
273	0.004
274	0.016
275	0.008
276	0.014
277	0.006
278	0.004
279	0.006
280	0.02
281	nd
282	nd
283	0.003
284	0.003
285	0.0006
286	0.001
287	0.379
288	0.001
289	0.001
290	0.001

Example	EC ₅₀ μ M
291	0.002
292	0.002
293	0.001
294	0.002
295	0.002
296	0.002
297	0.001
298	0.001
299	0.001
300	0.001
301	0.001
302	0.0006
303	0.0006
304	0.0005
305	0.001
306	0.0006
307	0.001
308	0.0007
309	0.0004
310	0.0005
311	0.001
312	0.001
313	0.001
314	0.005
315	0.002
316	0.002
317	0.001
318	0.003
319	0.007
320	0.002

Example	EC ₅₀ μ M
321	0.0005
322	0.0007
323	0.001
324	nd
325	0.003
326	0.003
327	0.005
328	nd
329	0.0005
330	0.0004
331	0.0005
332	0.0005
333	nd
334	0.004
335	nd
336	0.002
337	0.002
338	0.001
339	0.002
340	0.002
341	0.003
342	0.002
343	0.002
344	0.002
345	0.002
346	0.005
347	0.001
348	0.0006
349	0.001
350	0.003

Example	EC ₅₀ μM
351	0.0008
352	nd
353	0.0008
354	0.0005
355	0.001
356	nd
357	0.0008
358	0.0012
359	0.002
360	0.0008
361	0.004
362	0.008
363	0.013
364	0.002
365	0.002
366	0.005
367	0.001
368	0.001
369	0.002
370	0.001
371	0.001
372	0.001
373	0.003
374	0.0003
375	0.008
376	0.005
377	0.004
378	0.002
379	0.002
380	0.002

Example	EC ₅₀ μ M
381	0.003
382	0.005
383	0.003
384	0.009
385	0.003
386	0.006
387	4.000
388	0.003
389	0.003
390	0.002
391	0.004
392	0.001
393	0.002
394	0.003
395	0.002
396	0.002
397	0.002
398	0.002
399	0.002
400	0.006
401	0.002
402	0.003
403	0.002
404	0.003
405	0.004
406	0.004
407	0.004
408	0.002
409	0.001
410	0.006

Example	EC ₅₀ μ M
411	0.020
412	0.004
413	0.016
414	0.003
415	0.002
416	0.0006
417	0.012
418	0.107
419	0.031
420	0.013
421	0.008
422	0.01
423	0.008
424	0.016
425	0.126
426	0.0003
427	0.002
428	0.007
429	0.219
430	0.016
431	0.032
432	0.032
433	0.025
434	0.013
435	0.501
436	0.007
437	0.009
438	0.014
439	0.015
440	nd

Example	EC ₅₀ μ M
441	0.007
442	0.005


nd: Not determined

5 It will be evident to one skilled in the art that the present disclosure is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

CLAIMS

We claim:

1. A compound of Formula I,



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is hydrogen, halo, cyano, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, -C₁₋₁₀alkyl-OH, HO-C₁₋₁₀alkyl-O-, Ar¹, -N(R⁵)(R⁶), -C(O)N(R⁷)(R⁸), or (R⁹)(R¹⁰)NC₁₋₁₀alkyl-;

provided R¹ and R⁴ are not both alkyl;

R² is benzodioxolyl, naphthalenyl, phenyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, tetrazinyl, or triazinyl, and is optionally substituted with 1-4 substituents selected from cyano, carbamoyl, carboxyl, halo, hydroxy, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, -N(R⁵)(R⁷), C₁₋₁₀alkyl-O-, Ar⁴, Ar⁴-C₁₋₁₀alkyl-O-, (R⁵)(Ar⁴-C₁₋₁₀alkyl)N-, Ar⁴-O-C₁₋₁₀alkyl-, or (Ar⁴)(R⁵)N-C₁₋₁₀alkyl-;

R³ is C₁₋₁₀alkyl;

R⁴ is hydrogen, cyano, halo, C₁₋₁₀haloalkyl, C₁₋₁₀alkyl, C₁₋₁₀alkyl-O-, C₁₋₁₀alkenyl, NH₂, hydroxy, -C₁₋₁₀alkyl-OH, carbamoyl, azetidiny, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl; provided R¹ and R⁴ are not both alkyl;

R⁵ is hydrogen, or C₁₋₁₀alkyl;

R⁶ is hydrogen, C₁₋₁₀alkyl, C₁₋₁₀alkyl-O-C₁₋₁₀alkyl-, C₁₋₁₀alkyl-O-C(O)-, C₃₋₉cycloalkyl, (C₃₋₉cycloalkyl)C₁₋₁₀alkyl-, 1-(C₁₋₁₀alkyl)piperidinyl-, tetrahydropyranyl, (tetrahydropyranyl)C₁₋₁₀alkyl-, morpholinoC₁₋₁₀alkyl-, (C₁₋₁₀alkyl)₂N-C₁₋₁₀alkyl-, piperidinylC₁₋₁₀alkyl-, 1-(C₁₋₁₀alkyl)piperidinylC₁₋₁₀alkyl-, 1-(C₁₋₁₀alkyl)piperazinylC₁₋₁₀alkyl-, Ar²-C₁₋₁₀alkyl-, Ar³, 1-(C₁₋₁₀alkylsulfonyl)piperidinyl-, or 1-(C₁₋₁₀alkylcarbonyl)piperidinyl-;

R⁷ is hydrogen, or C₁₋₁₀alkyl;

R⁸ is hydrogen, C₁₋₁₀alkyl, C₃₋₉cycloalkyl, (C₁₋₁₀alkyl)C₃₋₉cycloalkyl-, -SO₂(C₁₋₁₀alkyl), or -SO₂(C₃₋₉cycloalkyl);

R⁹ is hydrogen, or C₁₋₁₀alkyl;

R¹⁰ is hydrogen, C₁₋₁₀alkyl, (tetrahydropyranyl)C₁₋₁₀alkyl-, or C₁₋₁₀alkyl-O-C(O)-;

(R⁷)(R⁸)N taken together form an azetidiny, pyrrolidiny, piperidiny, 1,1-dioxidothiomorpholiny, or morpholiny ring;

(R⁹)(R¹⁰)N taken together form an azetidiny, azocany, pyrrolidiny, piperidiny, or azaspirononany ring, and is optionally substituted with 1-3 C₁₋₁₀alkyl substituents;

Ar¹ is imidazolyl, pyrazolyl, pyridiny, pyrimidiny, pyrroly, or dihydrocyclopentapyrazolyl and is optionally substituted with 1-3 substituents selected from amino, C₁₋₁₀alkyl, or C₃₋₉cycloalkyl;

Ar² is imidazolyl, pyrazolyl, or pyridiny, and is optionally substituted with 1-3 substituents selected from C₁₋₁₀alkyl and halo substituents;

Ar³ is phenyl, pyridiny, pyrazolyl, pyridaziny, or pyrimidiny, and is optionally substituted with 1-3 substituents selected from C₁₋₆alkyl, halo, carboxy, and cyano; and

Ar⁴ is phenyl, benzofuopyrimidiny, or pyridofuopyrimidiny and is optionally substituted with 1-3 substituents selected from cyano, halo, C₁₋₁₀alkyl, and C₁₋₁₀alkyl-O-; and wherein each reference to "haloalkyl" includes all halogenated isomers from monohalo to perhalo.

2. A compound or salt according to Claim 1 wherein R¹ is hydrogen, halo, cyano, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, -C₁₋₁₀alkyl-OH, Ar¹, -N(R⁵)(R⁶), or (R⁹)(R¹⁰)NC₁₋₁₀alkyl-; provided R¹ and R⁴ are not both alkyl.

3. A compound or salt according to Claim 2 wherein R¹ is hydrogen or (R⁹)(R¹⁰)NC₁₋₁₀alkyl-.


4. A compound or salt according to any of Claims 1-3 wherein R² is phenyl, pyraziny, pyridaziny, pyridiny, pyrimidiny, quinoliny, or isoquinoliny, and is optionally substituted with 1-4 substituents selected from cyano, carbamoyl, carboxyl, halo, hydroxy, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, -N(R⁵)(R⁷), C₁₋₁₀alkyl-O-, Ar⁴, Ar⁴-C₁₋₁₀alkyl-O-, (R⁵)(Ar⁴-C₁₋₁₀alkyl)N-, Ar⁴-O-C₁₋₁₀alkyl-, or (Ar⁴)(R⁵)N-C₁₋₁₀alkyl-.

5. A compound or salt according to Claim 4 wherein R² is phenyl, pyrazinyl, pyridazinyl, pyridinyl, or pyrimidinyl, and is optionally substituted with 1-4 substituents selected from cyano, carbamoyl, carboxyl, halo, hydroxy, C₁₋₁₀alkyl, C₁₋₁₀haloalkyl, -N(R⁵)(R⁷), C₁₋₁₀alkyl-O-, Ar⁴, Ar⁴-C₁₋₁₀alkyl-O-, (R⁵)(Ar⁴-C₁₋₁₀alkyl)N-, Ar⁴-O-C₁₋₁₀alkyl-, or (Ar⁴)(R⁵)N-C₁₋₁₀alkyl-.

6. A compound or salt according to any of Claims 1-5 wherein R⁴ is hydrogen, cyano, halo, C₁₋₁₀haloalkyl, C₁₋₁₀alkyl, C₁₋₁₀alkyl-O-, C₁₋₁₀alkenyl, hydroxy, or -C₁₋₁₀alkyl-OH; provided R¹ and R⁴ are not both alkyl. More preferably, R⁴ is C₁₋₁₀alkyl, cyano, halo, or C₁₋₁₀haloalkyl; provided R¹ and R⁴ are not both alkyl.


7. A compound or salt according to Claim 1 wherein R¹ is hydrogen, R² is pyridinyl and is optionally substituted with a C₄alkyl-O-, R³ is C₄alkyl, and R⁴ is methyl.

8. The compound



or a pharmaceutically acceptable salt thereof.

9. The compound



or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a compound or salt according to any of Claims 1-9.

11. The composition of claim 10 further comprising at least one other agent used for treatment of AIDS or HIV infection selected from nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors,

CAPSID inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors, and a pharmaceutically acceptable carrier.

12. A method for treating HIV infection comprising administering a composition according to Claim 10 to a patient in need thereof.

13. The method of claim 12 further comprising administering at least one other agent used for treatment of AIDS or HIV infection selected from nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, CAPSID inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.

14. A compound or pharmaceutically acceptable salt thereof according to any of Claims 1-9 for use in therapy

15. A compound or pharmaceutically acceptable salt thereof according to any of Claims 1-9 for use in treating HIV infection.

16. A compound or pharmaceutically acceptable salt thereof according to any of Claims 1-9 for use in the manufacture of a medicament for the treatment of HIV infection.

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2018/050021

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D401/14 C07D405/14 C07D401/04 C07D491/048 A61P31/18
A61K31/4545

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2017/025915 A1 (VIIV HEALTHCARE UK LTD [GB]) 16 February 2017 (2017-02-16) cited in the application claims 1,24; examples 1-185 -----	1-16
X,P	WO 2017/195113 A1 (VIIV HEALTHCARE UK LTD [GB]) 16 November 2017 (2017-11-16) claims 1,23; examples 33,36,37,43,45 -----	1-16
X,P	WO 2017/025917 A1 (VIIV HEALTHCARE UK LTD [GB]) 16 February 2017 (2017-02-16) claims 1,11; examples 164,165 -----	1-16
X,P	WO 2017/006280 A1 (VIIV HEALTHCARE UK LTD [GB]) 12 January 2017 (2017-01-12) claims 1,10; example 32 ----- -/-	1-16



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

2 March 2018

Date of mailing of the international search report

14/03/2018

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Johnson, Claire

INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2018/050021

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2015/126726 A1 (SQUIBB BRISTOL MYERS CO [US]) 27 August 2015 (2015-08-27) cited in the application page 3, line 9 - line 12; claims 1,11,12 -----	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2018/050021

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2017025915 A1	16-02-2017	AR 105665 A1 TW 201718537 A WO 2017025915 A1	25-10-2017 01-06-2017 16-02-2017
WO 2017195113 A1	16-11-2017	NONE	
WO 2017025917 A1	16-02-2017	AR 105653 A1 TW 201718549 A WO 2017025917 A1	25-10-2017 01-06-2017 16-02-2017
WO 2017006280 A1	12-01-2017	AU 2016290205 A1 WO 2017006280 A1	18-01-2018 12-01-2017
WO 2015126726 A1	27-08-2015	AR 099511 A1 EP 3107908 A1 TW 201613885 A US 2015232463 A1 WO 2015126726 A1	27-07-2016 28-12-2016 16-04-2016 20-08-2015 27-08-2015